FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Bradley, KA Williams, EC Greiner, G Achtmeyer, CE Volpp, B Frey, MS Hawkins, E Harris, A Kivlahan, DR AF Bradley, K. A. Williams, E. C. Greiner, G. Achtmeyer, C. E. Volpp, B. Frey, M. S. Hawkins, E. Harris, A. Kivlahan, D. R. TI Use of electronic reminders and a performance measure to increase brief alcohol counseling by primary care providers in VA SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Bradley, K. A.; Williams, E. C.; Greiner, G.; Achtmeyer, C. E.; Volpp, B.; Frey, M. S.; Hawkins, E.; Harris, A.; Kivlahan, D. R.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 337A EP 337A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497201298 ER PT J AU Lieber, CS Weiss, DG Paronetto, F AF Lieber, Charles S. Weiss, David G. Paronetto, Fiorenzo CA Vet Affairs Cooperative Study 391 TI Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE alcoholic liver disease; fibrosis markers; fibrosis score ID CHRONIC HEPATITIS-C; SERUM MARKERS; PERIVENULAR FIBROSIS; TISSUE INHIBITOR; HYALURONIC-ACID; BIOPSY; PROGRESSION; CIRRHOSIS; POLYENYLPHOSPHATIDYLCHOLINE; METALLOPROTEINASE AB Background: Our aim was to identify markers predictive of fibrosis in alcoholic liver disease (ALD). Percutaneous liver biopsy is the recommended standard for histologic assessment of liver fibrosis. Seven serum markers (tissue inhibitor of matrix metalloproteinase 1 {TIMP1}, tenascin, collagen VI, amino-terminal propeptide of type III collagen {PIIINP}, matrix metalloproteinases {MMP2}, laminin, and hyaluronic acid {HA}) representing various aspects of collagen and extracellular matrix deposition and degradation, have been proposed as noninvasive surrogates for liver biopsy. Moreover, a diagnostic algorithm including 3 serum markers (TIMP1, PIIINP, HA) and age has been proposed to accurately detect fibrosis with acceptable levels of sensitivity/specificity in a chronic hepatitis C subgroup. Methods: To determine variability of these markers in liver fibrosis with different etiologies, we conducted an evaluation of their correlative properties in a subgroup of patients (n = 247) with biopsy confirmed liver fibrosis resulting from long-term heavy alcohol consumption. Patients were participants in a recently completed VA multicenter clinical trial followed over 2 years with liver biopsy at baseline and 24 months, and with markers assessed every 3 months. Results: Among the markers measured in this alcoholic subgroup all except collagen VI displayed significant correlation with degrees of fibrosis. Three markers, TIMP1, PIIINP and HA adjusted for age, emerged as the most promising predictors of the degree of fibrosis in a population of alcoholics. However, there was little change over time as related to change in fibrosis. The lower than expected accuracy of these markers based on receiver operating curves (ROC) also showed their limited use in this etiologic subgroup. Conclusion: In alcoholic patients, various markers have limited value in predicting and diagnosing the stages of fibrosis compared to liver biopsy. Thus, further prospective studies are required to better define the usefulness of each marker or their combination which are possibly affected by alcohol metabolism. C1 [Lieber, Charles S.; Paronetto, Fiorenzo] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Weiss, David G.] Vet Affairs Med Ctr, Perry Point, MD USA. RP Lieber, CS (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd 151-2, Bronx, NY 10468 USA. EM liebercs@aol.com FU NIAAA NIH HHS [AA014326] NR 48 TC 28 Z9 33 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 BP 1031 EP 1039 DI 10.1111/j.1530-0277.2008.00664.x PG 9 WC Substance Abuse SC Substance Abuse GA 304NQ UT WOS:000256116600015 PM 18422837 ER PT J AU Groeneveld, PW Matta, MA Greenhut, AP Yang, FF AF Groeneveld, Peter W. Matta, Mary Anne Greenhut, Alexis P. Yang, Feifei TI The costs of drug-eluting coronary stents among Medicare beneficiaries SO AMERICAN HEART JOURNAL LA English DT Article ID TRIAL; LESIONS; SIRIUS; MODELS; ARTERY; RISK; LOG AB Background Clinical trials predict the higher initial costs of drug-eluting coronary stents (DES) compared to bare metal stents (BMS) would be partially offset by decreased costs during the first year after percutaneous coronary intervention (PCI). However, the costs of DES in nonexperimental settings are not well understood. Methods We used a random, nationwide sample of Medicare beneficiaries who had received either DES from April through December 2003 or BMS from July 2002 through December 2003. Propensity score methods separately matched DES recipients (n = 4,375) to historical and contemporary BMS controls. Costs were estimated for each patient based on all physician and institutional claims beginning with the PCI hospitalization through the subsequent year, with institutional charges converted to costs via cost center-specific cost-to-charge ratios, as reported to Medicare by each institution. Results Drug-eluting stent patients had higher 30-day costs compared to both historical controls (mean difference $2,131, 95% CI $1,726 to $2,516) and contemporary controls ($1,882, 95% CI $1,480 to $2,322), but at 1 year, the DES-BMS mean cost differences had diminished substantially ($647, 95% CI $-385 to $1,664 compared to historical controls; $-84, 95% CI $-1,202 to $1,018 compared to contemporary controls) and were no longer statistically significant. Conclusions Despite higher initial costs of DES, the lower follow-up costs during the first year resulted in relatively small cumulative cost differences between DES and BMS recipients. These differences are comparable to those modeled in economic studies predicting acceptable cost-effectiveness for drug-eluting stents. C1 [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Groeneveld, Peter W.; Matta, Mary Anne; Greenhut, Alexis P.; Yang, Feifei] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Groeneveld, PW (reprint author), VA Med Ctr, 9 E 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM pefer.groeneveld@va.gov NR 22 TC 8 Z9 8 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD JUN PY 2008 VL 155 IS 6 BP 1097 EP 1105 DI 10.1016/j.ahj.2008.01.012 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 309WM UT WOS:000256490900021 PM 18513525 ER PT J AU Mendez, MF Licht, EA Shapira, JS AF Mendez, Mario F. Licht, Eliot A. Shapira, Jill S. TI Changes in dietary or eating behavior in frontotemporal dementia versus Alzheimer's disease SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE dietary or eating behaviors; frontotemporal dementia ID FRONTAL-LOBE DEGENERATION; KLUVER-BUCY-SYNDROME; VASCULAR DEMENTIA; TEMPORAL VARIANTS; SEMANTIC DEMENTIA; DISORDERS; ATROPHY; COMPULSIONS; DIAGNOSIS; CONSENSUS AB Background: Changes in dietary or eating behavior are common in dementia and may help distinguish between different dementing illnesses. Objective: To evaluate and characterize differences in dietary and eating behavior among patients with early frontotemporal dementia (FTD) versus Alzheimer's disease (AD). Methods: This study administered the Food-Related Problems Questionnaire (FRPQ) to caregivers of 16 patients with FTD and 16 comparable patients with AD. The FRPQ was evaluated at initial presentation when patients presented for a diagnostic evaluation. Results: Compared with the AD patients, the FTD patients had significantly more changes on the FRPQ. Subscale analysis indicated that the FTD patients showed impairment of observed satiety, improper taking of food, and inappropriate responses when food was not available. Conclusions: The use of food-related questionnaires, such as the FRPQ, can help distinguish FTD patients, early in their course, from those with AD and can further characterize the altered dietary and eating behavior. C1 [Mendez, Mario F.; Licht, Eliot A.; Shapira, Jill S.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Psychiat & Biobehavicating Sci, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles, Neurobehav Unit AF116, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Mmendez@UCLA.edu NR 38 TC 15 Z9 15 U1 0 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD JUN-JUL PY 2008 VL 23 IS 3 BP 280 EP 285 DI 10.1177/1533317507313140 PG 6 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA 344WE UT WOS:000258957200010 PM 18198236 ER PT J AU Leung, FW AF Leung, Felix W. TI Unsedated colonoscopy for paradoxical agitation: An unusual practice for an uncommon complication in US veterans SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Los Angeles, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Los Angeles, CA USA. NR 5 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUN PY 2008 VL 103 IS 6 BP 1578 EP 1579 DI 10.1111/j.1572-0241.2008.01880_12.x PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 311OY UT WOS:000256610700049 PM 18494833 ER PT J AU Sriwattanakomen, R Ford, AF Thomas, SB Miller, MD Stack, JA Morse, JQ Kasckow, J Brown, C Reynolds, CF AF Sriwattanakomen, Roy Ford, Angela F. Thomas, Stephen B. Miller, Mark D. Stack, Jacqueline A. Morse, Jennifer Q. Kasckow, John Brown, Charlotte Reynolds, Charles F., III TI Preventing depression in later life: Translation from concept to experimental design and implementation SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE depression prevention; indicated preventive intervention; elderly; African American; translation ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PATIENTS; MENTAL-HEALTH; MEDICAL ILLNESS; RATING-SCALE; OLDER-ADULTS; EPIDEMIOLOGY; DISORDERS; INVENTORY; DIAGNOSIS AB Objective: The authors detail the public health need for depression prevention research and the decisions made in designing an experiment testing problem solving therapy as "indicated" preventive intervention for high-risk older adults with sub-syndromal depression. Special attention is given to the recruitment of African Americans because of well-documented inequalities in mental health services and depression treatment outcomes between races. Methods: A total of 306 subjects (half white, half African American) with scores of 16 or higher on the Center for Epidemiological Studies of Depression Scale, but with no history of major depressive disorder in the past 12 months, are being recruited and randomly assigned to either problem solving therapy-primary care or to a dietary education control condition. Time to, and rate of, incident episodes of major depressive disorder are to be modeled using survival analysis. Level of depressive symptoms will be analyzed via a mixed models approach. Results: Twenty-two subjects have been recruited into the study, and to date eight have completed the randomly assigned intervention and postintervention assessment. Four of 22 have exited after developing major depressive episodes. None have complained about study procedures or demands. Implementation in a variety of community settings is going well. Conclusion: The data collected to date support the feasibility of translating from epidemiology to RCT design and implementation of empirical depression prevention research in later life. C1 [Sriwattanakomen, Roy; Miller, Mark D.; Stack, Jacqueline A.; Kasckow, John; Brown, Charlotte; Reynolds, Charles F., III] Univ Pittsburgh, Sch Med, Adv Ctr Intervent, Pittsburgh, PA USA. [Sriwattanakomen, Roy; Miller, Mark D.; Stack, Jacqueline A.; Kasckow, John; Brown, Charlotte; Reynolds, Charles F., III] Univ Pittsburgh, Sch Med, Serv Res Late Life Mood Disorders, Pittsburgh, PA USA. [Reynolds, Charles F., III] Univ Pittsburgh, Sch Med, John A Hartford Ctr Excellence Geriat Psychiat, Pittsburgh, PA USA. [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. [Ford, Angela F.; Thomas, Stephen B.] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Minor Hlth, Pittsburgh, PA USA. [Ford, Angela F.; Thomas, Stephen B.] Univ Pittsburgh, Grad Sch Publ Hlth, Res Ctr Excellence Minor Hlth Dispar, Pittsburgh, PA USA. RP Reynolds, CF (reprint author), Western Psychiat Inst & Clin, 3811 OHara St,E-1135, Pittsburgh, PA 15213 USA. EM reynoldscf@upmc.edu FU NIMH NIH HHS [T32 MH019986, P30 MH071944-05, P30 MH071944, T32 MH19986]; NIMHD NIH HHS [P60 MD000207, P60 MD000-207] NR 37 TC 13 Z9 13 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUN PY 2008 VL 16 IS 6 BP 460 EP 468 DI 10.1097/JGP.0b013e318165db95 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 307GJ UT WOS:000256307100005 PM 18515690 ER PT J AU Teng, E Ringman, JM Ross, LK Mulnard, RA Dick, MB Bartzokis, G Davies, HD Galasko, D Hewett, L Mungas, D Reed, BR Schneider, LS Segal-Gidan, F Yaffe, K Cummings, JL AF Teng, Edmond Ringman, John M. Ross, Leslie K. Mulnard, Ruth A. Dick, Malcolm B. Bartzokis, George Davies, Helen D. Galasko, Douglas Hewett, Linda Mungas, Dan Reed, Bruce R. Schneider, Lon S. Segal-Gidan, Freddi Yaffe, Kristine Cummings, Jeffrey L. CA Alzheimer's Dis Res Ctr Californi Depression Alzheimer's Dis Investi TI Diagnosing depression in Alzheimer disease with the National Institute of Mental Health provisional criteria SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID CORNELL SCALE; NEUROPSYCHIATRIC INVENTORY; RATING-SCALE; DEMENTIA; SYMPTOMS; VALIDITY; VALIDATION AB Objective: To compare the rates of depression in Alzheimer Disease (AD) determined using National Institute of Mental Health (NIMH) provisional criteria for depression in AD (NIMH-dAD) to those determined using other established depression assessment tools. Design: Descriptive longitudinal cohort study. Setting: The Alzheimer's Disease Research Centers of California. Participants: A cohort of 101 patients meeting NINDS-ADRDA criteria for possible/probable AD, intentionally selected to increase the frequency of depression at baseline. Measurements: Depression was diagnosed at baseline and after 3 months using NIMH-dAD criteria and the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I Disorders. Depressive symptoms also were assessed with the Cornell Scale for Depression in Dementia (CSDD), the Geriatric Depression Scale (GDS), and the Neuropsychiatric Inventory Questionnaire. Results: The baseline frequency of depression using NIMH-dAD criteria (44%) was higher than that obtained using DSM-IV criteria for major depression (14%; Z = -5.50, df = 101, p < 0.001) and major or minor depression (36%; Z = -2.86, df = 101, p = 0.021) or using established cut-offs for the CSDD (30%; Z = -2.86, df = 101, p = 0.004) or GDS (33%; Z = -2.04, df = 101, p = 0.041). The NIMH-dAD criteria correctly identified all patients meeting DSM-IV criteria for major depression, and correlated well with DSM-IV criteria for major or minor depression (kappa = 0.753, p < 0.001), exhibiting 94% sensitivity and 85% specificity. The higher rates of depression found with NIMH-dAD criteria derived primarily from its less stringent requirements for the frequency and duration of symptoms. Remission rates at 3 months were similar across instruments. Conclusions: The NIMH-dAD criteria identify a greater proportion of AD patients as depressed than several other established tools. C1 [Teng, Edmond; Ringman, John M.; Bartzokis, George; Cummings, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA. [Cummings, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA USA. [Ross, Leslie K.] Univ Calif San Francisco, Sch Nursing, Inst Hlth & Aging, San Francisco, CA 94143 USA. [Mulnard, Ruth A.] Univ Calif Irvine, Program Nursing Sci, Irvine, CA USA. [Dick, Malcolm B.] Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA USA. [Davies, Helen D.] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA USA. [Galasko, Douglas] VA Med Ctr, San Diego, CA USA. [Hewett, Linda] Calif State Univ Fresno, Alzheimers & Memory Ctr, Fresno, CA 93740 USA. [Mungas, Dan] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA. [Reed, Bruce R.] Univ Calif Davis, Rush Alzheimers Dis Ctr, Davis, CA 95616 USA. [Schneider, Lon S.] USC, Keck Sch Med, Dept Psychiat, Los Angeles, CA USA. [Schneider, Lon S.] USC, Keck Sch Med, Dept Neurol, Los Angeles, CA USA. [Schneider, Lon S.] USC, Keck Sch Med, Dept Gerontol, Los Angeles, CA USA. [Segal-Gidan, Freddi] USC, Keck Sch Med, Rancho Los Amigos Natl Rehabil Ctr, Downey, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Teng, E (reprint author), W Los Angeles VA Healthcare Ctr, Neurobehav Unit 116AF, Bldg 500,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu RI Mungas, Dan/E-6810-2011; Bartzokis, George/K-2409-2013 FU NIA NIH HHS [P30 AG010129, P30 AG010129-129001, P50 AG 16570, P50 AG016570] NR 37 TC 42 Z9 44 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUN PY 2008 VL 16 IS 6 BP 469 EP 477 DI 10.1097/JGP.0b013e318165dbae PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 307GJ UT WOS:000256307100006 PM 18515691 ER PT J AU Aspinall, SL Glassman, PA AF Aspinall, Sherrie L. Glassman, Peter A. TI Cost-effectiveness of blood glucose monitoring is controversial SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Letter ID RANDOMIZED-TRIAL; INSULIN C1 [Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Aspinall, Sherrie L.] Hines VA, VA Ctr Medicat Safety, Hines, IL USA. [Aspinall, Sherrie L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA. [Glassman, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Glassman, Peter A.] VA Greater Los Angeles Healthcare System, Los Angeles, CA USA. RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot 151CH, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM sherrie.aspinall@med.va.gov NR 4 TC 2 Z9 2 U1 0 U2 1 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JUN PY 2008 VL 14 IS 6 BP 398 EP 399 PG 2 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 316RL UT WOS:000256967300008 PM 18554079 ER PT J AU Rajan, S Hammond, MC Goldstein, B AF Rajan, Suparna Hammond, Margaret C. Goldstein, Barry TI Trends in diabetes mellitus indicators in veterans with spinal cord injury SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE spinal cord injury; diabetes mellitus; chronic disease; veteran ID AFFAIRS HEALTH-CARE; QUALITY IMPROVEMENT; MANAGED CARE; RETINOPATHY; GUIDELINES; DISORDERS; CENTERS; SYSTEM; MODEL AB Objective: Persons with spinal cord injury (SCI) are at increased risk for developing diabetes mellitus (M). However, published data on the care provided to this population are minimal. The purpose of this study was to examine a set of measures of quality of DM care in veterans with SCI. Design: Retrospective analysis of the External Peer Review Program data for veterans with SCI and DM from 2002 to 2004 in the Veterans Healthcare System. Trends in DM measures were examined using generalized estimation equation models. Results: The percentage of veterans who received testing for lipids, retinal, and renal exams significantly increased during this period. This was accompanied by significant improvements in intermediate outcomes, glycemic, lipid, and blood pressure (BP) control. The percentage of veterans with glycosylated hemoglobin (HbA1c) (levels <= 9%; P < 0.001) and those with poorly controlled levels (HbA1c >9.5%; P = 0.022) improved. BP (140/90) rates increased from 59% in fiscal year (FY) 2002 to nearly 70% in 2004 (P < 0.001). The percentage of veterans who received renal screening (anatomical tests, physiologic test, and urine microalbumin) increased significantly (P < 0.001). Retinopathy exam rates also increased from 55.1% in FY 2002 to 70.8% in IFY 2004 (P < 0.001). Conclusions: Significant improvements were made in a set of DM measures used to evaluate care provided to veterans with SCI. The positive trends in DM care seen in the general veteran population were also evident in the SCI population. C1 [Rajan, Suparna; Hammond, Margaret C.; Goldstein, Barry] VA Puget Sound Hlth Care Syst, Spinal Cord Injury Qual Enhancement Res Initiat S, Seattle, WA 98108 USA. [Hammond, Margaret C.; Goldstein, Barry] VA Puget Sound Hlth Care Syst, Spinal Cord Injury Disorders Serv, Seattle, WA 98108 USA. RP Rajan, S (reprint author), VA Puget Sound Hlth Care Syst, Spinal Cord Injury Qual Enhancement Res Initiat S, 1660 S Columbian Way,S-152, Seattle, WA 98108 USA. NR 29 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD JUN PY 2008 VL 87 IS 6 BP 468 EP 474 DI 10.1097/PHM.0b013e318174e66e PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 305EP UT WOS:000256160900007 PM 18496249 ER PT J AU Lin, AL Zhu, B Zhang, WK Dang, H Zhang, BX Katz, MS Yeh, CK AF Lin, Alan L. Zhu, Bing Zhang, WanKe Dang, Howard Zhang, Bin-Xian Katz, Michael S. Yeh, Chih-Ko TI Distinct pathways of ERK activation by the muscarinic agonists pilocarpine and carbachol in a human salivary cell line SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE muscarinic receptor; epidermal growth factor receptor; protein kinase C ID GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; SIGNAL-REGULATED KINASE; ACETYLCHOLINE-RECEPTORS; EPITHELIAL-CELLS; PAROTID-GLAND; ADENYLYL-CYCLASE; CANCER CELLS; MAP KINASE; T-84 CELLS AB Cholinergic-muscarinic receptor agonists are used to alleviate mouth dryness, although the cellular signals mediating the actions of these agents on salivary glands have not been identified. We examined the activation of ERK1/2 by two muscarinic agonists, pilocarpine and carbachol, in a human salivary cell line (HSY). Immunoblot analysis revealed that both agonists induced transient activation of ERK1/2. Whereas pilocarpine induced phosphorylation of the epidermal growth factor (EGF) receptor, carbachol did not. Moreover, ERK activation by pilocarpine, but not carbachol, was abolished by the EGF receptor inhibitor AG-1478. Downregulation of PKC by prolonged treatment of cells with the phorbol ester PMA diminished carbachol-induced ERK phosphorylation but had no effect on pilocarpine responsiveness. Depletion of intracellular Ca2+ ([Ca2+](i)) by EGTA did not affect ERK activation by either agent. In contrast to carbachol, pilocarpine did not elicit [Ca2+](i) mobilization in HSY cells. Treatment of cells with the muscarinic receptor subtype 3 (M-3) antagonist N-(3-chloropropyl)-4-piperidnyl diphenylacetate decreased ERK responsiveness to both agents, whereas the subtype 1 (M-1) antagonist pirenzepine reduced only the carbachol response. Stimulation of ERKs by pilocarpine was also decreased by M-3, but not M-1, receptor small interfering RNA. The Src inhibitor PP2 blocked pilocarpine-induced ERK activation and EGF receptor phosphorylation, without affecting ERK activation by carbachol. Our results demonstrate that the actions of pilocarpine and carbachol in salivary cells are mediated through two distinct signaling mechanisms-pilocarpine acting via M-3 receptors and Src-dependent transactivation of EGF receptors, and carbachol via M-1/M-3 receptors and PKC- converging on the ERK pathway. C1 [Zhang, Bin-Xian; Katz, Michael S.; Yeh, Chih-Ko] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Audie L Murphy Div, San Antonio, TX 78229 USA. [Lin, Alan L.; Zhu, Bing; Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. [Dang, Howard; Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Community Dent, San Antonio, TX 78229 USA. [Zhang, WanKe; Zhang, Bin-Xian; Katz, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Yeh, CK (reprint author), S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Audie L Murphy Div, San Antonio, TX 78229 USA. EM yeh@uthscsa.edu FU NHLBI NIH HHS [R01-HL-075011]; NIDCR NIH HHS [R21 DE-15381] NR 47 TC 17 Z9 18 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD JUN PY 2008 VL 294 IS 6 BP C1454 EP C1464 DI 10.1152/ajpcell.00151.2007 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 311BL UT WOS:000256574900020 PM 18385290 ER PT J AU Mizumori, M Choi, Y Guth, PH Engel, E Kaunitz, JD Akiba, Y AF Mizumori, Misa Choi, Yuri Guth, Paul H. Engel, Eli Kaunitz, Jonathan D. Akiba, Yasutada TI CFTR inhibition augments NHE3 activity during luminal high CO2 exposure in rat duodenal mucosa SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE CO2 absorption; bicarbonate secretion; portal venous PCO2 ID APICAL CL-/HCO3-EXCHANGER; ACID-BASE-BALANCE; BICARBONATE ABSORPTION; CARBONIC-ANHYDRASES; NA+/H+ EXCHANGERS; PROXIMAL TUBULE; FLUID SECRETION; HCO3-SECRETION; EPITHELIUM; MICE AB We hypothesized that the function of duodenocyte apical membrane acid-base transporters are essential for H+ absorption from the lumen. We thus examined the effect of inhibition of Na+/H+ exchanger-3 (NHE3), cystic fibrosis transmembrane regulator (CFTR), or apical anion exchangers on transmucosal CO2 diffusion and HCO3- secretion in rat duodenum. Duodena were perfused with a pH 6.4 high CO2 solution or pH 2.2 low CO2 solution with the NHE3 inhibitor, S3226, the anion transport inhibitor, DIDS, or pretreatment with the potent CFTR inhibitor, CFTRinh-172, with simultaneous measurements of luminal and portal venous (PV) pH and carbon dioxide concentration ([CO2]). Luminal high CO2 solution increased CO2 absorption and HCO3- secretion, accompanied by PV acidification and PV PCO2 increase. During CO2 challenge, CFTRinh-172 induced HCO3- absorption, while inhibiting PV acidification. S3226 reversed CFTRinh-associated HCO3- absorption. Luminal pH 2.2 challenge increased H+ and CO2 absorption and acidified the PV, inhibited by CFTRinh-172 and DIDS, but not by S3226. CFTR inhibition and DIDS reversed HCO3- secretion to absorption and inhibited PV acidification during CO2 challenge, suggesting that HCO3- secretion helps facilitate CO2/H+ absorption. Furthermore, CFTR inhibition prevented CO2-induced cellular acidification reversed by S3226. Reversal of increased HCO3- loss by NHE3 inhibition and reduced intracellular acidification during CFTR inhibition is consistent with activation or unmasking of NHE3 activity by CFTR inhibition, increasing cell surface H+ available to neutralize luminal HCO3- with consequent CO2 absorption. NHE3, by secreting H+ into the luminal microclimate, facilitates net transmucosal HCO3- absorption with a mechanism similar to proximal tubular HCO3- absorption. C1 [Guth, Paul H.; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Mizumori, Misa; Kaunitz, Jonathan D.; Akiba, Yasutada] Sch Med, Dept Med, Los Angeles, CA USA. [Engel, Eli] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA USA. [Mizumori, Misa; Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA USA. [Choi, Yuri] Harvard Westlake Sch, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 114,Ste 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK54221, R01 DK054221, P30 DK0413] NR 41 TC 10 Z9 10 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JUN PY 2008 VL 294 IS 6 BP G1318 EP G1327 DI 10.1152/ajpgi.00025.2008 PG 10 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 310YU UT WOS:000256567800003 PM 18420826 ER PT J AU Thrower, EC Osgood, S Shugrue, CA Kolodecik, TR Chaudhuri, AM Reeve, JR Pandol, SJ Gorelick, FS AF Thrower, Edwin C. Osgood, Sara Shugrue, Christine A. Kolodecik, Thomas R. Chaudhuri, Anamika M. Reeve, Joseph R., Jr. Pandol, Stephen J. Gorelick, Fred S. TI The novel protein kinase C isoforms -delta and -epsilon modulate caerulein-induced zymogen activation in pancreatic acinar cells SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE translocation; PKC activator phorbol ester; PKC inhibitor ID MURINE PERITONEAL-MACROPHAGES; KAPPA-B ACTIVATION; INOSITOL 1,4,5-TRISPHOSPHATE; PKC-DELTA; TRYPSINOGEN ACTIVATION; CATHEPSIN-B; CHOLECYSTOKININ RECEPTOR; PHOSPHORYLATION; CA2+; RELEASE AB Isoforms of protein kinase C (PKC) have been shown to modulate some cellular responses such as pathological secretion and generation of inflammatory mediators during acute pancreatitis (AP). We propose that PKC also participates in premature zymogen activation within the pancreatic acinar cell, a key event in the initiation of AP. This hypothesis was examined in in vivo and cellular models of caerulein-induced AP using PKC activators and inhibitors. Phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA, 200 nM), a known activator of PKC, enhanced zymogen activation at both 0.1 nM and 100 nM caerulein, concentrations which mimic physiological and supraphysiological effects of the hormone cholecystokinin, respectively, in preparations of pancreatic acinar cells. Isoform-specific PKC inhibitors for PKC-delta and PKC-epsilon reduced supraphysiological caerulein-induced zymogen activation. Using a cell-free reconstitution system, we showed that inhibition of PKC-delta and -epsilon, reduced zymogen activation in both zymogen granule-enriched and microsomal fractions. In dispersed acinar cells, 100 nM caerulein stimulation caused PKC-delta and -epsilon isoform translocation to microsomal membranes using cell fractionation and immunoblot analysis. PKC translocation was confirmed with in vivo studies and immunofluorescence microscopy in pancreatic tissues from rats treated with or without 100 nM caerulein. PKC-epsilon redistributed from an apical to a supranuclear region following caerulein administration. The signal for PKC-epsilon overlapped with granule membrane protein, GRAMP-92, an endosomal/lysosomal marker, in a supranuclear region where zymogen activation takes place. These results indicate that PKC-delta and -epsilon isoforms translocate to specific acinar cell compartments and modulate zymogen activation. C1 [Thrower, Edwin C.; Osgood, Sara; Shugrue, Christine A.; Kolodecik, Thomas R.; Chaudhuri, Anamika M.; Gorelick, Fred S.] Dept Internal Med, Sect Digest Dis, New Haven, CT USA. [Gorelick, Fred S.] Vet Affairs Connecticut Healthcare W Haven, Dept Cell Biol, New Haven, CT USA. [Gorelick, Fred S.] Yale Univ, Sch Med, New Haven, CT USA. [Reeve, Joseph R., Jr.; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Hlth Care Syst, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. [Reeve, Joseph R., Jr.; Pandol, Stephen J.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Thrower, EC (reprint author), Vet Adm Med Ctr, 950 Campbell Ave,Bldg 4, West Haven, CT 06516 USA. EM edwin.thrower@yale.edu FU NIAAA NIH HHS [5 P60 AA-11999, P50 AA011999]; NIDDK NIH HHS [R01 DK033850, R01 DK054021-02, R01 DK054021, DK-54021, R21 DK069702-01, R01 DK-33850, R21 DK-69702, R21 DK069702] NR 35 TC 20 Z9 20 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JUN PY 2008 VL 294 IS 6 BP G1344 EP G1353 DI 10.1152/ajpgi.00020.2008 PG 10 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 310YU UT WOS:000256567800006 PM 18388183 ER PT J AU Au, DH Chien, JW Bryson, CL AF Au, David H. Chien, Jason W. Bryson, Chris L. TI Inhaled corticosteroids might not protect against lung cancer - Reply SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID OBSTRUCTIVE PULMONARY-DISEASE C1 [Au, David H.; Bryson, Chris L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Au, David H.; Chien, Jason W.; Bryson, Chris L.] Univ Washington, Seattle, WA 98195 USA. [Chien, Jason W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUN 1 PY 2008 VL 177 IS 11 BP 1290 EP 1291 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 306QM UT WOS:000256262900019 ER PT J AU Yaffe, K Lindquist, K Shlipak, MG Simonsick, E Fried, L Rosano, C Satterfield, S Atkinson, H Windham, BG Kurella-Tamura, M AF Yaffe, Kristine Lindquist, Karla Shlipak, Michael G. Simonsick, Eleanor Fried, Linda Rosano, Caterina Satterfield, Suzanne Atkinson, Hal Windham, B. Gwen Kurella-Tamura, Manjula CA Hlth ABC Study TI Cystatin C as a marker of cognitive function in elders: Findings from the Health ABC study SO ANNALS OF NEUROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; ONSET ALZHEIMER-DISEASE; OLDER-ADULTS; FOLLOW-UP; IMPAIRMENT; RISK; ASSOCIATION; HEART AB We determined whether serum cystatin C, a novel measure of kidney function that colocalizes with brain P-amyloid, is associated with cognition among 3,030 elders. Those with high cystatin C (n = 445; 15%) had worse baseline scores on Modified Mini-Mental State Examination or Digit Symbol Substitution Test (p <= 0.02) compared with those with intermediate/low level and 7 years greater decline (p <= 0.04). Incident cognitive impairment (decline >= 1.0 standard deviation) was greatest among those with high cystatin C (Modified Mini-Mental State Examination: 38 vs 25%; adjusted odds ratio, 1.92; 95% confidence interval, 1.37-2.69; Digit Symbol Substitution: 38 vs 26%; odds ratio, 1.54; 95% confidence interval, 1.10-2.15). C1 [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, San Francisco, CA 94121 USA. [Lindquist, Karla; Shlipak, Michael G.; Kurella-Tamura, Manjula] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA. [Simonsick, Eleanor; Windham, B. Gwen] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Fried, Linda] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Rosano, Caterina] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Atkinson, Hal] Wake Forest Univ, Sch Med, Dept Internal Med, Sect Gerontol & Geriatr Med, Winston Salem, NC 27109 USA. [Yaffe, Kristine; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu RI Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479; Rosano, Caterina/0000-0002-0909-1506; Rosano, Caterina/0000-0002-4271-6010 FU Intramural NIH HHS; NIA NIH HHS [AG-6-2101, AG-6-2103, AG-6-2106, AG021918, N01 AG062101, N01 AG062103, N01 AG062106, R01 AG021918, R01 AG021918-01A1]; NIDDK NIH HHS [DK069406, R01 DK069406, R01 DK069406-01A1] NR 20 TC 41 Z9 48 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD JUN PY 2008 VL 63 IS 6 BP 798 EP 802 DI 10.1002/ana.21383 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 321HA UT WOS:000257294100014 PM 18496846 ER PT J AU Bilimoria, KY Balch, CM Bentrem, DJ Talamonti, MS Ko, CY Lange, JR Winchester, DP Wayne, JD AF Bilimoria, Karl Y. Balch, Charles M. Bentrem, David J. Talamonti, Mark S. Ko, Clifford Y. Lange, Julie R. Winchester, David P. Wayne, Jeffrey D. TI Complete lymph node dissection for sentinel node-positive melanoma: Assessment of practice patterns in the United States SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 61st Annual Cancer Symposium of the Society-of-Surgical-Oncology CY MAR 13-16, 2008 CL Chicago, IL SP Soc Surg Oncol DE melanoma; skin neoplasm; sentinel lymph node biopsy; completion lymph node dissection; lymph node; surgery ID STAGE-III MELANOMA; CANCER DATA-BASE; MALIGNANT-MELANOMA; BREAST-CANCER; BIOPSY; MORBIDITY; SURVIVAL; QUALITY; TERM; CARE AB Background: Currently, complete lymph node dissection (CLND) is recommended after identification of a metastatic lymph node by sentinel lymph node biopsy (SLNB). Guidelines suggest that CLND should be performed as a separate procedure, and a sufficient number of nodes should be examined. Our objective was to examine the utilization, timing, and adequacy of CLND for melanoma in the United States. Methods: From the National Cancer Data Base, patients diagnosed with stage I to III melanoma during 2004-2005 were identified. Multiple logistic regression was used to assess factors associated with CLND utilization, timing (separate operation from SLNB), and adequacy (examination of >= 10 nodes). Results: Of the 44,548 patients identified, 47.5% were pathologic stage IA, 23.8% stage IB, 14.1% stage II, and 14.6% stage III. Of the 17% (2942 of 17,524) with nodal metastases on SLNB, only 50% underwent a CLND. Patients were significantly less likely to undergo a CLND after SLNB if > 75 years old or had lower extremity melanomas. Of the patients who underwent a CLND, only 42% underwent the CLND at a separate procedure after the SLNB. Of those who underwent a CLND, 69.2% had >= 10 nodes examined. Patients were significantly less likely to have >= 10 nodes examined if they were > 75 years old or had lower extremity melanomas. Patients treated at NCCN/NCI-designated centers were significantly more likely to undergo nodal evaluation in concordance with established guidelines. Conclusions: Only half of patients with sentinel node-positive melanoma underwent CLND. Quality surveillance measures are needed to monitor, standardize, and improve the care of patients with malignant melanoma. C1 [Bilimoria, Karl Y.; Ko, Clifford Y.; Winchester, David P.] Amer Coll Surg, Canc Programs, Chicago, IL USA. [Bilimoria, Karl Y.; Bentrem, David J.; Talamonti, Mark S.; Winchester, David P.; Wayne, Jeffrey D.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Balch, Charles M.; Lange, Julie R.] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA. [Talamonti, Mark S.; Winchester, David P.] Evanston NW Healthcare, Dept Surg, Evanston, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Canc Programs, Chicago, IL USA. EM k-bilimoria@northwestern.edu NR 45 TC 75 Z9 75 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD JUN PY 2008 VL 15 IS 6 BP 1566 EP 1576 DI 10.1245/s10434-008-9885-2 PG 11 WC Oncology; Surgery SC Oncology; Surgery GA 299FM UT WOS:000255741500005 PM 18414952 ER PT J AU Azor, M Gene, J Cano, J Sutton, DA Fothergill, AW Rinaldi, MG Guarrol, J AF Azor, Monica Gene, Josepa Cano, Josep Sutton, Deanna A. Fothergill, Annette W. Rinaldi, Michael G. Guarrol, Josep TI In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F-moniliforme) and Fusarium thapsinum SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID FUJIKUROI SPECIES COMPLEX; INFECTIONS AB A microdilution method was used to test 11 antifungal drugs against clinical isolates of Fusarium thapsinum and three different phylogenetic clades of Fusarium verticillioides that were characterized by sequencing a region of the P-tubulin gene. Terbinafine was the most-active drug against both species, followed by posaconazole against F. verticillioides. C1 [Azor, Monica; Gene, Josepa; Cano, Josep; Guarrol, Josep] Univ Rovira & Virgili, Unitat Microbiol, Fac Med & Ciencies Salut, Tarragona 43201, Spain. [Sutton, Deanna A.; Fothergill, Annette W.; Rinaldi, Michael G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. [Rinaldi, Michael G.] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Guarrol, J (reprint author), Univ Rovira & Virgili, Unitat Microbiol, Fac Med & Ciencies Salut, C St Llorenc 21, Tarragona 43201, Spain. EM josep.guarro@urv.cat OI Cano-Lira, Jose F./0000-0003-4495-4394; Guarro, Josep/0000-0002-7839-7568 NR 22 TC 27 Z9 27 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JUN PY 2008 VL 52 IS 6 BP 2228 EP 2231 DI 10.1128/AAC.00176-08 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 306UG UT WOS:000256272700044 PM 18391027 ER PT J AU Chan, L Ciol, MA Shumway-Cook, A Yorkston, KM Dudgeon, BJ Asch, SM Hoffman, JM AF Chan, Leighton Ciol, Marcia A. Shumway-Cook, Anne Yorkston, Kathryn M. Dudgeon, Brian J. Asch, Steven M. Hoffman, Jeanne M. TI A longitudinal evaluation of persons with disabilities: Does a longitudinal definition help define who receives necessary care? SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE disability evaluation; medicare; rehabilitation ID MEDICARE BENEFICIARIES; HEALTH-CARE; POPULATION; SERVICES; SATISFACTION; PEOPLE; COSTS AB Objective: To assess, using a longitudinal definition, the impact of disability on a broad range of objective health care quality indicators. Design: Longitudinal cohort study following up with patients over several years. The first 2 interviews, 1 year apart, were used to determine each patient's disability status in activities of daily living (ADLs). Assessment of the health care indicators commenced after the second interview and continued throughout the survey period (an additional 1-3y). Setting: National survey. Participants: Participants (N = 29,074) of the Medicare Current Beneficiary Survey (1992-2001) with no, increasing, decreasing, and stable ADL disability. Interventions: Not applicable. Main Outcome Measure: The incidence of 5 avoidable outcomes, receipt of 3 preventive care measures, and adherence to 32 diagnostically based indicators assessing the quality of treatment for acute myocardial infarction [AMI], angina, breast cancer, cerebrovascular accident, transient ischemic attack, cholelithiasis, chronic obstructive pulmonary disease [COPD], congestive heart failure, depression, gastrointestinal bleeding, diabetes, and hypertension. Results: For most indicators, less than 75% of eligible patients received necessary care, regardless of disability status. For 5 indicators, less than 50% of patients received appropriate treatment. In a logistic regression analysis that controlled for patient age, sex, race, and income, disability status was a significant factor in 7 quality measures (AMI, breast cancer, COPD, diabetes, angina, pneumonia, annual visits). Conclusions: Using a longitudinal definition of disability and objective health quality indicators, we found that disability status can be an important factor in determining receipt of quality health care in a broad range of diagnostic categories. However, the impact of disability status varies depending on the indicator measured. In this cohort of patients, the changing nature of a person's disability seems to have less impact than whether they ever have had any functional deficits. C1 [Chan, Leighton] NIH, Dept Rehabil Med, Clin Res Ctr, Bethesda, MD 20892 USA. [Ciol, Marcia A.; Shumway-Cook, Anne; Yorkston, Kathryn M.; Dudgeon, Brian J.; Asch, Steven M.] Univ Washington, Sch Med, Seattle, WA USA. [Hoffman, Jeanne M.] W Los Angeles Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Los Angeles, CA 90073 USA. RP Chan, L (reprint author), NIH, Dept Rehabil Med, Clin Res Ctr, Bldg 10,Room 1-1469,10 Ctr Dr,MSC 1604, Bethesda, MD 20892 USA. EM chanle@cc.nih.gov FU Intramural NIH HHS [ZIA CL060072-04]; PHS HHS [MM-0625-04/04] NR 20 TC 16 Z9 16 U1 2 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUN PY 2008 VL 89 IS 6 BP 1023 EP 1030 DI 10.1016/j.apmr.2007.10.045 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 310TN UT WOS:000256553400003 PM 18503795 ER PT J AU Karmarkar, A Cooper, RA Liu, HY Connor, S Puhlman, J AF Karmarkar, Amol Cooper, Rory A. Liu, Hsin-yi Connor, Sam Puhlman, Jeremy TI Evaluation of pushrim-activated power-assisted wheelchairs using ANSI/RESNA standards SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT Annual Meeting of RESNA CY JUN 15-19, 2007 CL Phoenix, AZ SP RESNA DE quality assurance; health care; rehabilitation; wheelchairs ID MANUAL WHEELCHAIR; PERFORMANCE; TETRAPLEGIA; DURABILITY; INJURIES AB Objective: To determine and compare performance of pushrim-activated power-assisted wheelchairs (PAPAW) (iGLIDE, e-motion, Xtender) on national standards. Design: Engineering performance and safety evaluation. Setting: A Veteran Affairs and university-based research center. Specimens: Nine PAPAWs. Interventions: Not applicable. Main Outcome Measures: Static, dynamic stability, brake effectiveness, maximum speed, acceleration, retardation, energy consumption, static, impact, and fatigue strength. Results: There was no significant difference among the 3 models in forward stability. The iGLIDE was the most stable, whereas the e-motion was the least stable model in the rearward stability tests. All PAPAWs performed equally on the slopes of 3 degrees and 6 degrees in the forward and rearward directions. Braking distance was the highest for e-motion (5.64 +/- 0.28m) and the lowest (1.13 +/- 0.03m) for the iGLIDE in forward direction. The average equivalent cycles of all PAPAWs were 318,292 +/- 112,776.6 cycles (n=8) on the fatigue tests. All PAPAWs passed the impact and static strength tests. Conclusions: The standards of the American National Standards Institute and the Rehabilitation Engineering and Assistive Technology Society of North America could act as quality assurance tool for wheelchairs. The standards for wheelchairs were first approved in 1990; after 17 years, exceeding the minimum values in the standards would be a reasonable expectation. C1 [Karmarkar, Amol; Cooper, Rory A.; Liu, Hsin-yi; Connor, Sam; Puhlman, Jeremy] VA Pittsburgh Healthcare Syst, VA Rehabil Res & Dev Serv, Human Engn Res Labs, Pittsburgh, PA 15260 USA. [Karmarkar, Amol; Liu, Hsin-yi] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Cooper, Rory A.; Puhlman, Jeremy] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151 R1 HD, 7180 Highland Dr, Pittsburgh, PA 15260 USA. EM rcooper@pitt.edu RI Karmarkar, Amol/E-6030-2011 OI Karmarkar, Amol/0000-0001-8355-1585 NR 18 TC 6 Z9 6 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUN PY 2008 VL 89 IS 6 BP 1191 EP 1198 DI 10.1016/j.apmr.2007.10.029 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 310TN UT WOS:000256553400027 PM 18503819 ER PT J AU Gray, SH Vick, CC Graham, LA Finan, KR Neumayer, LA Hawn, MT AF Gray, Stephen H. Vick, Catherine C. Graham, Laura A. Finan, Kelly R. Neumayer, Leigh A. Hawn, Mary T. TI Risk of complications from enterotomy or unplanned bowel resection during elective hernia repair SO ARCHIVES OF SURGERY LA English DT Article ID OF-VETERANS-AFFAIRS; INCISIONAL HERNIA; POLYPROPYLENE MESH; ABDOMINAL-WALL; ADHESION FORMATION; SURGICAL CARE; SURGERY; PREVENTION; INFECTION; OUTCOMES AB Hypothesis: Enterotomy or unplanned bowel resection (EBR) may occur during elective incisional hernia repair (IHR) and significantly affects surgical outcomes and hospital resource use. Design: Retrospective review of patients undergoing IHR between January 1998 and December 2002. Setting: Sixteen tertiary care Veterans Affairs medical centers. Patients: A total of 1124 elective incisional hernia repairs identified in the National Surgical Quality Improvement Program data set. Intervention: Elective IHR. Main Outcome Measures: Thirty-day postoperative complication rate, return to operating room, length of stay, and operative time. Results: Of the 1124 elective procedures, 74.1% were primary IHR, 13.3% were recurrent prior mesh IHR, and 12.6% were recurrent prior suture. Overall, 7.3% had an EBR. The incidence of EBR was increased in patients with prior repair: 5.3% for primary repair, 5.7% for recurrent prior suture, and 20.3% for prior mesh repair (P <.001). The occurrence of EBR was associated with increased postoperative complications (31.7% vs 9.5%; P <.001), rate of reoperation within 30 days (14.6% vs 3.6%; P <.001), and development of enterocutaneous fistula (7.3% vs 0.7%; P <.001). After adjusting for procedure type, age, and American Society of Anesthesiologists class, EBR was associated with an increase in median operative time (1.7 to 3.5 hours; P <.001) and mean length of stay (4.0 to 6.0 days; P <.001). Conclusions: Enterotomy or unplanned bowel resection is more likely to complicate recurrent IHR with prior mesh. The occurrence of EBR is associated with increased postoperative complications, return to the operating room, risk of enterocutaneous fistula, length of hospitalization, and operative time. C1 [Gray, Stephen H.; Vick, Catherine C.; Graham, Laura A.; Finan, Kelly R.; Hawn, Mary T.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL 35294 USA. [Gray, Stephen H.; Vick, Catherine C.; Graham, Laura A.; Finan, Kelly R.; Hawn, Mary T.] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. [Gray, Stephen H.] Univ Alabama, Hlth Serv & Outcomes Res Traininng Program, Dept Med, Birmingham, AL 35294 USA. [Neumayer, Leigh A.] Univ Utah, Dept Surg, Salt Lake City, UT USA. [Neumayer, Leigh A.] Univ Utah, Vet Affairs Med Ctr, Salt Lake City, UT USA. RP Hawn, MT (reprint author), Univ Alabama, Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness Res, 1530 3rd Ave S,KB 429, Birmingham, AL 35294 USA. EM mhawn@uab.edu OI Gray, Stephen/0000-0002-5702-7226 FU AHRQ HHS [5 T32 HS013852, HS013852]; None [HS013852] NR 30 TC 43 Z9 43 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD JUN PY 2008 VL 143 IS 6 BP 582 EP 586 DI 10.1001/archsurg.143.6.582 PG 5 WC Surgery SC Surgery GA 314FP UT WOS:000256795200015 PM 18559752 ER PT J AU Sundararaj, KP Li, YC Samuvel, DJ Nareika, A Lopes-Virella, MF Huang, Y AF Sundararaj, Kamala P. Li, Yanchun Samuvel, Devadoss J. Nareika, Alena Lopes-Virella, Maria F. Huang, Yan TI Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting Ras and Rac protein isoprenylation-mediated ERK activation SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Meeting Abstract CT 9th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology CY APR 16-18, 2008 CL Atlanta, GA C1 [Sundararaj, Kamala P.; Nareika, Alena; Huang, Yan] Med Univ S Carolina, Charleston, SC 29425 USA. [Li, Yanchun; Huang, Yan] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD JUN PY 2008 VL 28 IS 6 MA P117 BP E55 EP E55 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 303PS UT WOS:000256053400143 ER PT J AU Cooper, RA Cooper, R Boninger, ML AF Cooper, Rory A. Cooper, Rosemarie Boninger, Michael L. TI Trends and issues in wheelchair technologies SO ASSISTIVE TECHNOLOGY LA English DT Article DE manual wheelchair; power wheelchair; bariatric wheelchair; pushrim-activated power-assist wheelchairs (PA-PAW); independence 3000 IBOT transporter; wheelchair usage; wheelchair transportation; wheelchair marketplace; emerging trends ID POWER-ASSISTED WHEELCHAIR; WHOLE-BODY VIBRATION; MULTIPLE-SCLEROSIS; MANUAL WHEELCHAIRS; PEOPLE; DEVICES; SYSTEM; ADULTS; LIFE; HOME AB There is an overwhelming need for wheelchairs and the research and development required to make them safer, more effective, and widely available. The following areas are of particular importance: practitioner credentials, accreditation, device evaluation, device user training, patient education, clinical prescribing criteria, national contracts, and access to new technology. There are over 170 U.S. wheelchair manufacturers with a total reported income of $1.33 billion. However, of these companies, only five had sales in excess of $100 million. Wheelchairs account for about 1% of Medicare spending. Use of assistive technology is an increasingly common way of adapting to a disability. The emergence of advanced mobility devices shows promise for the contribution of engineering to the amelioration of mobility impairments for millions of people who have disabilities or who are elderly. Some of the trends in wheelchairs are going to require new service delivery mechanisms, changes to public policy, and certainly greater coordination between consumers, policy makers, manufacturers, researchers, and service providers. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr Excellence Wheel Chairs, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151 R1, 7180 Highland Dr, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X NR 76 TC 26 Z9 26 U1 1 U2 13 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD SUM PY 2008 VL 20 IS 2 BP 61 EP 72 PG 12 WC Rehabilitation SC Rehabilitation GA 318IC UT WOS:000257083800001 PM 18646429 ER PT J AU Morinelli, TA Walker, LP Ullian, ME AF Morinelli, Thomas A. Walker, Linda P. Ullian, Michael E. TI COX-2 expression stimulated by Angiotensin II depends upon AT(1) receptor internalization in vascular smooth muscle cells SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH LA English DT Article DE Angiotensin; G protein-coupled receptor; cyclooxygenase 2; signal transduction; endocytosis ID PROXIMAL TUBULE CELLS; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; MEDIATED ENDOCYTOSIS; NUCLEAR-LOCALIZATION; TYPE-1 RECEPTOR; MESSENGER-RNA; ANG-II; CYCLOOXYGENASE-2; TRANSACTIVATION AB Previously, we demonstrated that nuclear localization of the Angiotensin II AT(1A) receptor was associated with the activation of transcription for the COX-2 gene, PTGS-2. The hypothesis of the present study is that AT(1A)R internalization from the plasma membrane is a first step in the nuclear localization of the endogenous AT(1A)R of rat aortic vascular smooth muscle cells and the resultant increase of COX-2 protein expression. Angiotensin II produced both a time- and concentration-dependent increase in COX-2 protein expression in these cells. Treatment with sucrose or phenylarsine oxide, inhibitors of receptor internalization, significantly inhibited AT(1A)R internalization and abolished the increase in COX-2 protein produced by Angiotensin II without affecting COX-2 expression on its own. Sucrose pre-treatment of rat aortic vascular smooth muscle cells resulted in an increase in p42/44 and p38 activation, while phenylarsine oxide pre-treatment activated only p38 kinase without inhibiting activation of p42/44 produced by Angiotensin II. These results demonstrate that inhibiting the internalization of the AT(1A)R results in a loss of ability of Angiotensin II to increase the protein expression of COX-2, thus supporting previous work showing a relationship between AT(1A)R nuclear localization and activation of COX-2 gene expression. Surprisingly, in contrast to other studies, the data also indicates that activation of p42/44 and/or p38 does not correlate with the increased expression of COX-2. (C) 2008 Elsevier B.V. All rights reserved. C1 [Morinelli, Thomas A.; Walker, Linda P.; Ullian, Michael E.] Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA. [Morinelli, Thomas A.; Ullian, Michael E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Morinelli, TA (reprint author), Med Univ S Carolina, Div Nephrol, Dept Med, Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA. EM morinelt@musc.edu NR 35 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-4889 J9 BBA-MOL CELL RES JI Biochim. Biophys. Acta-Mol. Cell Res. PD JUN PY 2008 VL 1783 IS 6 BP 1048 EP 1054 DI 10.1016/j.bbamcr.2008.01.012 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 312FX UT WOS:000256655600010 PM 18267125 ER PT J AU Wittrant, Y Gorin, Y Woodruff, K Horn, D Abboud, HE Mohan, S Abboud-Werner, SL AF Wittrant, Y. Gorin, Y. Woodruff, K. Horn, D. Abboud, H. E. Mohan, S. Abboud-Werner, S. L. TI High D(+)glucose concentration inhibits RANKL-induced osteoclastogenesis SO BONE LA English DT Article DE oteoclast; glucose; RANKL; reactive oxygen species; differentiation ID KAPPA-B LIGAND; REACTIVE OXYGEN; BONE-RESORPTION; OSTEOPROTEGERIN LIGAND; MATRIX METALLOPROTEINASES; FIBRONECTIN EXPRESSION; RECEPTOR ACTIVATOR; DIABETES-MELLITUS; OXIDATIVE STRESS; DIFFERENTIATION AB Diabetes is a chronic disease associated with hyperglycemia and altered bone metabolism that may lead to complications including osteopenia, increased risk of fracture and osteoporosis. Hyperglycemia has been implicated in the pathogenesis of diabetic bone disease; however, the biologic effect of glucose on osteoclastogenesis is unclear. In the present study, we examined the effect of high D(+)glucose (D-Glc) and L(-)glucose (L-Glc; osmotic control) on RANKL-induced osteoclastogenesis using RAW264.7 cells and Bone Marrow Macrophages (BMM) as models. Cells were exposed to sustained high glucose levels to mimic diabetic conditions. Osteoclast formation was analyzed using tartrate resistant acid phosphatase (TRACP) assay, expression of calcitonin receptor (CrR) and cathepsin K mRNAs, and Cultures were examined for reactive oxygen species (ROS) using dichlorodihydrofluorescein diacetate (DCF-DA) fluorescence, caspase-3 and Nuclear Factor kappaB (NF-kappa B) activity. Cellular function was assessed using a migration assay. Results show, for the first time, that high D-Glc inhibits osteoclast formation, ROS production, caspase-3 activity and migration in response to RANKL through a metabolic pathway. Our findings also suggest that high D-Glc may alter RANKL-incluced osteoclast formation by inhibiting redox-sensitive NF-kappa B activity through an anti-oxidative mechanism. This study increases our understanding of the role of glucose in diabetes-associated bone disease. Our data suggest that high glucose levels may alter bone turnover by decreasing osteoclast differentiation and function in diabetes and provide new insight into the biologic effects of glucose on osteoclastogenesis. (C) 2008 Elsevier Inc. All rights reserved. C1 [Gorin, Y.; Abboud, H. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Nephrol, San Antonio, TX 78229 USA. [Wittrant, Y.; Woodruff, K.; Horn, D.; Mohan, S.; Abboud-Werner, S. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Wittrant, Y.; Gorin, Y.; Woodruff, K.; Horn, D.; Abboud, H. E.; Mohan, S.; Abboud-Werner, S. L.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. RP Wittrant, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wittrant@uthscsa.edu; gorin@uthscsa.edu; woodruff@uthscsa.edu; hornd@uthscsa.edu; abboud@uthscsa.edu; mohan@uthscsa.edu; AbboudWerner@uthscsa.edu FU NIAMS NIH HHS [AR-42306, R01 AR042306, R01 AR042306-05A1]; NIDCR NIH HHS [R01 DE015857] NR 45 TC 61 Z9 69 U1 2 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD JUN PY 2008 VL 42 IS 6 BP 1122 EP 1130 DI 10.1016/j.bone.2008.02.006 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 307PE UT WOS:000256330000014 PM 18378205 ER PT J AU Weisbord, SD Hartwig, KC Sonel, AF Fine, MJ Palevsky, P AF Weisbord, Steven D. Hartwig, Kathryn C. Sonel, Ali F. Fine, Michael J. Palevsky, Paul TI The incidence of clinically significant contrast-induced nephropathy following non-emergent coronary angiography SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE contrast-induced nephropathy; outcomes; mortality; contrast media; angiography; coronary; complications ID ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; CHRONIC KIDNEY-DISEASE; CARDIAC ANGIOGRAPHY; N-ACETYLCYSTEINE; SERUM CREATININE; PREVENTION; AGENT; MEDIA; NEPHROTOXICITY AB Objectives: The primary aim of this study was to assess the incidence of clinically significant contrast-induced nephropathy (CIN) among patients undergoing non-emergent coronary angiography. Background: Although retrospective analyses have emphasized the association of CIN with adverse patient outcomes, the actual incidence of clinically significant CIN following non-emergent coronary angiography is not clear. Methods: We prospectively identified patients with baseline estimated glomerular filtration rates (eGFR) < 60 ml/min/1.73 m(2) undergoing non-emergent coronary angiography. We measured serum creatinine 48-96 hr following angiography and assessed the incidence of CIN using two definitions, a rise in Scr >= 25% and >= 0.5 mg/dl. We tracked the need for dialysis, hospitalization related to kidney injury, and 30-day mortality to examine the association of CIN with these outcomes. Results: We enrolled 181 patients with a median eGFR of 52 ml/min/1.73 m(2). Of the 165 patients (91%) with post-procedure Scr data, the incidence of CIN was 6.1-8.5%. One patient required dialysis (0.55%) and one (0.55%) died within 30 days. Although 38 patients required hospital admission, CIN was not associated with the need for hospitalization. Patients with an increase in Scr >= 25% demonstrated a trend toward increased risk for 30-day mortality (P = 0.09), whereas those with increments in Scr >= 0.5 mg/dl had a marginally higher risk for dialysis (P = 0.06) and 30-day mortality (P = 0.06), although these associations failed to meet the level of statistical significance. Conclusions: Biochemically defined CIN occurs in a small, but notable proportion of patients undergoing non-emergent coronary angiography. However, clinically significant CIN is very uncommon. (C) 2008 Wiley-Liss, Inc. C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15214 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Mailstop 111 F-U,7E Room 120, Pittsburgh, PA 15214 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU NIAID NIH HHS [K24 AI001769] NR 42 TC 11 Z9 11 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD JUN 1 PY 2008 VL 71 IS 7 BP 879 EP 885 DI 10.1002/ccd.21565 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 308SD UT WOS:000256409400004 PM 18412255 ER PT J AU Sobel, M Verhaeghe, R AF Sobel, Michael Verhaeghe, Raymond TI Antithrombotic therapy for peripheral artery occlusive disease SO CHEST LA English DT Review DE anticoagulation; antiplatelet therapy; aspirin; atherosclerosis; carotid artery; haparin; intermittent claudication; peripheral vascular disease; randomized controlled trial; review; thrombolysis; vascular surgery ID DOUBLE-BLIND TRIAL; RANDOMIZED CONTROLLED-TRIAL; MOLECULAR-WEIGHT HEPARIN; LOWER-EXTREMITY BYPASS; LOW-DOSE ASPIRIN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; KNEE FEMOROPOPLITEAL BYPASS; PROSTAGLANDIN I-2 ANALOG; FEMORO-POPLITEAL GRAFTS; HUMAN UMBILICAL VEIN AB This chapter is devoted to antithrombotic therapy for peripheral artery occlusive disease as part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see the "Grades of Recommendation" chapter by Guyatt et al, CHEST 2008; 133:123S-131S). Among the key recommendations in this chapter are the following: We recommend lifelong antiplatelet therapy in comparison to no antiplatelet therapy in pulmonary artery disease (PAD) patients with clinically manifest coronary or cerebrovascular disease (Grade 1A), and also in those without clinically manifest coronary or cerebrovascular disease (Grade 1B). In patients with PAD and intermittent claudication, we recommend against the use of anticoagulants (Grade 1A). For patients with moderate to severe disabling intermittent claudication who do not respond to exercise therapy, and who are not candidates for surgical or catheter-based intervention, we recommend cilostazol (Grade 1A). We suggest that clinicians not use cilostazol in those with less-disabling claudication (Grade 2A). In patients with short-term (< 14 days) arterial thrombosis or embolism, we suggest intraarterial thrombolytic therapy (Grade 2B), provided they are at low risk of myonecrosis and ischemic nerve damage developing during the time to achieve revascularization. For patients undergoing major vascular reconstructive procedures, we recommend IV unfractionated heparin (UFH) prior to the application of vascular cross clamps (Grade 1A). For all patients undergoing infrainguinal arterial reconstruction, we recommend aspirin (75-100 mg, begun preoperatively) [Grade 1A]. For routine autogenous vein infrainguinal bypass, we recommend aspirin (75-100 mg, begun preoperatively) [Grade 1A]. For routine prosthetic infrainguinal bypass, we recommend aspirin (75-100 mg, begun preoperatively) [Grade 1A]. In patients undergoing carotid endarterectomy, we recommend that aspirin, 75-100 mg, be administered preoperatively and continued indefinitely (75-100 mg/d) [Grade 1A]. In nonoperative patients with asymptomatic carotid stenosis (primary or recurrent), we suggest that dual antiplatelet therapy with aspirin and clopidogrel be avoided (Grade 1B). For all patients undergoing lower-extremity balloon angioplasty (with or without stenting), we recommend long-term aspirin, 75-100 mg/d (Grade 1C). C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Sobel, Michael] Univ Washington, Sch Med, Seattle, WA USA. [Verhaeghe, Raymond] Katholieke Univ Leuven, Louvain, Belgium. RP Sobel, M (reprint author), Mailstop S-112,1660 S Columbian Way, Seattle, WA 98108 USA. EM michael.sobel@va.gov NR 203 TC 83 Z9 89 U1 1 U2 11 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JUN PY 2008 VL 133 IS 6 SU S BP 815S EP 843S DI 10.1378/chest.08-0686 PG 29 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 319GJ UT WOS:000257151800021 PM 18574279 ER PT J AU Lee, DBN Roberts, M AF Lee, David B. N. Roberts, Martin TI A peritoneal-based automated wearable artificial kidney SO CLINICAL AND EXPERIMENTAL NEPHROLOGY LA English DT Review DE automated wearable artificial kidney; AWAK; peritoneal dialysis ID SALICYLATE INTOXICATION; DIALYSIS BAGS; ZIRCONIA; INTERMITTENT; REMOVAL; SYSTEM; ERYTHROPOIETIN; REGENERATION; HEMODIALYSIS; REPLACEMENT AB Work on wearable kidneys has evolved around the technology of hemodialysis or hemofiltration, which call for continuous anticoagulation of the extracoporeal circulation and are encumbered with potential immunologic and non-immunologic complications of continuous blood-artificial membrane interactions. A peritoneal-based automated wearable artificial kidney (AWAK) requires no extracorporeal circulation and is therefore "bloodless.'' Because AWAK is designed to continuously regenerate and reuse the spent dialysate in perpetuity, it is also "waterless.'' A sorbent-based assembly regenerates both the aqueous and the protein components (AqC and PrC) of the spent dialysate, producing a novel, autologous protein-containing dialysate. The regenerated AqC has the same composition as the commercially available peritoneal dialysate, but contains bicarbonate instead of lactate and has a more physiological pH. The regenerated PrC is recycled back into the peritoneal cavity, thereby ameliorating or eliminating protein loss. Depending on the steady-state protein concentrations that can be achieved ( under the condition of continuous dialysate regeneration and recycling), the PrC also has the potential of both augmenting ultrafiltration and mediating the removal of protein-bound toxins. Additional sorbents can be incorporated into AWAK for the removal of middle molecular weight uremic toxins. At a regeneration rate of 4 l/h, AWAK provides a dialysate flow of 96 l/day (8-12 times the current rate). Round-the-clock dialysis and ultrafiltration provide steady-state metabolic-biochemical and fluid balance regulation, thereby eliminating "shocks'' of abrupt changes in these parameters that characterize the current dialytic modalities. Dialysis-on-the-go, made possible by AWAK's "wearability'' and automation, frees end-stage renal failure patients from the servitude that is demanded by the current dialytic regimentations. C1 [Lee, David B. N.; Roberts, Martin] VA Greater LA Healthcare Syst, Sepulveda Ambulatory Care Ctr & Nursing Home, LAKID, Los Angeles, CA USA. [Lee, David B. N.; Roberts, Martin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Lee, DBN (reprint author), 16016 Jeanne Lane, Encino, CA 91436 USA. EM dbnlee@ucla.edu NR 58 TC 22 Z9 23 U1 3 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1342-1751 J9 CLIN EXP NEPHROL JI Clin. Exp. Nephrol. PD JUN PY 2008 VL 12 IS 3 BP 171 EP 180 DI 10.1007/s10157-008-0050-9 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 343IM UT WOS:000258846800002 PM 18386116 ER PT J AU Sharma, S Nemeth, E Chen, YH Goodnough, J Huston, A Roodman, GD Ganz, T Lichtenstein, A AF Sharma, Sanjai Nemeth, Elizabeta Chen, Yi-Hsiang Goodnough, Julia Huston, Alissa Roodman, G. D. Ganz, Tomas Lichtenstein, Alan TI Involvement of hepcidin in the anemia of multiple myeloma SO CLINICAL CANCER RESEARCH LA English DT Article ID ERYTHROID COLONY FORMATION; MONOCLONAL GAMMOPATHY; CHRONIC DISEASE; IRON; EXPRESSION; CELLS; ERYTHROPOIETIN; INFLAMMATION; IL-6; IDENTIFICATION AB Purpose: Hepcidin is a liver-produced peptide implicated in the anemia of inflammation. Because interleukin (IL)-6 is a potent inducer of hepcidin expression and its levels are elevated in multiple myeloma, we studied the role of hepcidin in the anemia of multiple myeloma. Experimental Design: Urinary hepcidin and serum levels of IL-6, ferritin, C-reactive protein, tumor necrosis factor-alpha, and IL-1 beta were studied in newly diagnosed myeloma patients. In vitro hepcidin induction assay was assessed by real-time PCR assay. Results: Pretreatment urinary hepcidin levels in 44 patients with stage III multiple myeloma were 3-fold greater than normal controls. In the subset of multiple myeloma patients without renal insufficiency (n = 27), a marked inverse correlation was seen between hemoglobin at diagnosis and urinary hepcidin level (P = 0.014) strongly supporting a causal relationship between up-regulated hepcidin expression and anemia. The urinary hepcidin also significantly (P < 0.05) correlated with serum ferritin and C-reactive protein, whereas its correlation with serum IL-6 levels was of borderline significance (P = 0.06). Sera from 14 multiple myeloma patients, with known elevated urinary hepcidin, significantly induced hepcidin mRNA in the Hep3B cells, whereas normal sera had no effect. For 10 patients, the ability of anti-IL-6 and anti-IL-6 receptor antibodies to prevent the serum-induced hepcidin RNA was tested. In 6 of these patients, hepcidin induction was abrogated by the anti-IL-6 antibodies, but in the other 4 patients, the neutralizing antibodies had no effect. Conclusions: These results indicate hepcidin is up-regulated in multiple myeloma patients by both IL-6-dependent and IL-6-independent mechanisms and may play a role in the anemia of multiple myeloma. C1 [Sharma, Sanjai; Lichtenstein, Alan] Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Huston, Alissa; Roodman, G. D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Huston, Alissa; Roodman, G. D.] Univ Pittsburgh, Pittsburgh VA Med Ctr, Pittsburgh, PA USA. [Chen, Yi-Hsiang] Univ Illinois, Chicago, IL USA. [Chen, Yi-Hsiang] Jesse Brown VA Med Ctr, Chicago, IL USA. [Nemeth, Elizabeta; Goodnough, Julia; Ganz, Tomas] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,Blvd 304,Room E1-115, Los Angeles, CA 90073 USA. EM sasharma@mednet.ucia.edu FU NCI NIH HHS [R01CA96920, R01CA111448]; NIDDK NIH HHS [KO1 DK07538, R01 DK065029] NR 33 TC 54 Z9 63 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2008 VL 14 IS 11 BP 3262 EP 3267 DI 10.1158/1078-0432.CCR-07-4153 PG 6 WC Oncology SC Oncology GA 308RY UT WOS:000256408900005 PM 18519751 ER PT J AU Kambugu, A Meya, DB Rhein, J O'Brien, M Janoff, EN Ronald, AR Kamya, MR Mayanja-Kizza, H Sande, MA Bohjanen, PR Boulware, DR AF Kambugu, Andrew Meya, David B. Rhein, Joshua O'Brien, Meagan Janoff, Edward N. Ronald, Allan R. Kamya, Moses R. Mayanja-Kizza, Harriet Sande, Merle A. Bohjanen, Paul R. Boulware, David R. TI Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID HIV-INFECTED PATIENTS; RECONSTITUTION INFLAMMATORY SYNDROME; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EARLY MORTALITY; AMPHOTERICIN-B; AIDS; DISEASE; FLUCONAZOLE; IMPACT; DETERMINANTS AB Background. Cryptococcal meningitis (CM) is the proximate cause of death in 20%-30% of persons with acquired immunodeficiency syndrome in Africa. Methods. Two prospective, observational cohorts enrolled human immunodeficiency virus (HIV)-infected, antiretroviral-naive persons with CM in Kampala, Uganda. The first cohort was enrolled in 2001-2002 (n = 92), prior to the availability of highly active antiretroviral therapy (HAART), and the second was enrolled in 2006 2007 (n = 44), when HAART was available. Results. Ugandans presented with prolonged CM symptoms (median duration, 14 days; interquartile range, 7-21 days). The 14-day survival rates were 49% in 2001-2002 and 80% in 2006 (P < .001). HAART was started 35 +/- 13 days after CM diagnosis and does not explain the improved 14-day survival rate in 2006. In 2006-2007, the survival rate continued to decrease after hospitalization, with only 55% surviving to initiate HAART as an outpatient. Probable cryptococcal-related immune reconstitution inflammatory syndrome occurred in 42% of patients, with 4 deaths. At 6 months after CM diagnosis, 18 persons (41%) were alive and receiving HAART in 2007. The median cerebral spinal fluid (CSF) opening pressure was 330 mm H2O; 81% of patients had elevated pressure (1200 mm H2O). Only 5 patients consented to therapeutic lumbar puncture. There was a trend for higher mortality for pressures 1250 mm H2O (odds ratio [OR], 2.1; 95% confidence interval [CI], 0.9-5.2; P = .09). Initial CSF WBC counts of <5 cells/mL were associated with failure of CSF sterilization (OR, 17.3; 95% CI, 3.1-94.3; P < .001), and protein levels <35 mg/dL were associated with higher mortality (OR, 2.0; 95% CI, 1.2-3.3; P = .007). Conclusions. Significant CM-associated mortality persists, despite the administration of amphotericin B and HIV therapy, because of the high mortality rate before receipt of HAART and because of immune reconstitution inflammatory syndrome-related complications after HAART initiation. Approaches to increase acceptance of therapeutic lumbar punctures are needed. C1 [Kamya, Moses R.; Mayanja-Kizza, Harriet] Makerere Univ, Sch Med, Dept Med, Kampala, Uganda. [Kambugu, Andrew; Meya, David B.; Ronald, Allan R.; Kamya, Moses R.; Mayanja-Kizza, Harriet; Sande, Merle A.] Makerere Univ, Infect Dis Inst, Kampala, Uganda. [Rhein, Joshua; Bohjanen, Paul R.; Boulware, David R.] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA. [Bohjanen, Paul R.] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA. [Bohjanen, Paul R.; Boulware, David R.] Univ Minnesota, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA. [O'Brien, Meagan] NYU, Sch Med, Div Infect Dis, Dept Med, New York, NY USA. [Janoff, Edward N.] Univ Colorado, Sch Med,Div Infect Dis, Denver Vet Affairs Med Ctr,Colorado Ctr AIDS Res, Mucosal & Vaccine Res Program Colorado MAVRC, Denver, CO USA. [Ronald, Allan R.] Univ Manitoba, Winnipeg, MB, Canada. RP Boulware, DR (reprint author), MMC 250,420 Delaware St SE, Minneapolis, MN 55455 USA. EM boulw001@umn.edu RI Boulware, David/B-5516-2011; Boulware, David/I-4533-2013; Bohjanen, Paul/B-2329-2015 OI Bohjanen, Paul/0000-0002-2772-3597; Meya, David/0000-0002-4138-240X; Mayanja-Kizza, Harriet/0000-0002-9297-6208; Ronald, Allan/0000-0002-5746-3490; Boulware, David/0000-0002-4715-0060 FU FIC NIH HHS [D43 TW000011, TW000011]; NCRR NIH HHS [K12 RR023247, K12 RR023247-01, K12RR023247]; NIAID NIH HHS [L30 AI066779, L30 AI066779-02, L30AI066779, P30 AI054907, P30AI054907, T32 AI055433, T32AI055433] NR 31 TC 136 Z9 142 U1 1 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2008 VL 46 IS 11 BP 1694 EP 1701 DI 10.1086/587667 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 297HC UT WOS:000255606700008 PM 18433339 ER PT J AU Tobia, CC Aspinall, SL Good, CB Fine, MJ Hanlon, JT AF Tobia, Colleen Cook Aspinall, Sherrie L. Good, Chester B. Fine, Michael J. Hanlon, Joseph T. TI Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: A cross-sectional study SO CLINICAL THERAPEUTICS LA English DT Article DE antibiotic; Medication Appropriateness Index; respiratory tract infections ID OBSTRUCTIVE PULMONARY-DISEASE; ANTIMICROBIAL THERAPY; MANAGEMENT; ADULTS; RELIABILITY; PREVENTION; GUIDELINES; RESISTANCE; DIAGNOSIS; OUTCOMES AB Background: Studies that have assessed antibiotic appropriateness in acute respiratory tract infections (RTIs) with a likely bacterial etiology have focused only on antibiotic choice and ignored other important aspects of prescribing, such as dosing, drug-drug interactions, and duration of treatment. Objective: The aim of this study was to determine the prevalence and predictors of inappropriate antibiotic prescribing practices in outpatients with acute bacterial RTIs (community-acquired pneumonia [CAP], sinusitis, or acute exacerbations of chronic bronchitis [AECB]). Methods: This retrospective, cross-sectional study enrolled outpatients with CAP, sinusitis, or AECB who were evaluated in a Veterans Affairs emergency department over a 1-year period. Using electronic medical records, trained research assistants completed data-collection forms that included patient characteristics (eg, marital status, history of alcohol abuse), diagnosis, comorbidities, concurrent medications, and antibiotics prescribed. To assess antimicrobial appropriateness, a trained clinical pharmacist reviewed the data-collection forms and applied a Medication Appropriateness Index (MAI), which rated the appropriateness of a medication using 10 criteria: indication, effectiveness, dosage, directions, practicality (defined as capability of being used or being put into practice), drug-drug interactions, drug-disease interactions, unnecessary duplication, duration, and expensiveness (defined as the cost of the drug compared with other agents of similar efficacy and tolerability). Previous studies have found good inter- and intrarater reliabilities between a clinical pharmacist's and an internal medicine physician's MAI ratings (kappa = 0.83 and 0.92, respectively). Results: One hundred fifty-three patients were included (mean age, 58 years; 92% male; and 65% white). Overall, 99 of 153 patients (65%) had inappropriate antibiotic prescribing as assessed using the MAI. Expensiveness (60 patients [39%]), impracticality (32 [21%]), and incorrect dosage (15 [10%]) were the most frequently rated problem. Penicillins, quinolones, and macrolides were the most common antibiotic classes prescribed inappropriately. A history of alcohol abuse was associated with a lower likelihood of inappropriate prescribing compared with no history of alcohol abuse (adjusted odds ratio [AOR], 0.32; 95% CI, 0.10-0.98), while patients who were married were more likely to receive inappropriately prescribed antibiotics than those who were not married (AOR, 2.64; 95% CI, 1.25-5.59). Conclusions: Inappropriate antibiotic prescribing based on the MAI criteria was common (65%) in this selected patient population with acute bacterial RTIs, and often involved problems with expensiveness (39%), impracticality (21%), and incorrect dosage (10%). Future interventions to improve antibiotic prescribing should consider aspects beyond choice of agent. C1 [Tobia, Colleen Cook] Vet Affairs Pittsburgh Healthcare Syst, Dept Pharm, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Good, Chester B.; Fine, Michael J.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Good, Chester B.; Fine, Michael J.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Good, Chester B.; Fine, Michael J.] Hines Vet Affairs Med Ctr, Vet Affairs Ctr Medicat Safety, Hines, IL USA. [Good, Chester B.; Fine, Michael J.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Tobia, CC (reprint author), VA Pittsburgh Healthcare Syst, Dept Pharm, Pittsburgh, PA 15240 USA. EM colleen.tobla@va.gov FU NIA NIH HHS [R01AG027017, P30AG024827, R01 AG027017, P30 AG024827] NR 31 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD JUN PY 2008 VL 30 IS 6 BP 1135 EP 1144 DI 10.1016/j.clinthera.2008.06.009 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 326ZS UT WOS:000257698900007 PM 18640469 ER PT J AU Avins, AL Bent, S Staccone, S Badua, E Padula, A Goldberg, H Neuhaus, J Hudes, E Shinohara, K Kane, C AF Avins, Andrew L. Bent, Stephen Staccone, Suzanne Badua, Evelyn Padula, Amy Goldberg, Harley Neuhaus, John Hudes, Esther Shinohara, Katusto Kane, Christopher TI A detailed safety assessment of a saw palmetto extract SO COMPLEMENTARY THERAPIES IN MEDICINE LA English DT Article DE saw palmetto; drug toxicity; benign prostatic; hyperplasia ID BENIGN PROSTATIC HYPERPLASIA; SERENOA-REPENS; COMPLEMENTARY; PERMIXON(R); CANCER; CARE AB Background: Saw palmetto is commonly used by men for tower-urinary tract symptoms. Despite its widespread use, very little is known about the potential toxicity of this dietary supplement. Methods: The Saw palmetto for Treatment of Enlarged Prostates (STEP) study was a randomized clinical trial performed among 225 men with mode rate-to-severe symptoms of benign prostatic hyperplasia, comparing a standardized extract of the saw palmetto berry (160 mg twice daily) with a placebo over a 1-year period. As part of this study, detailed data were collected on serious and non-serious adverse events, sexual functioning, and laboratory tests of blood and urine. Between-group differences were assessed with mixed-effects regression models. Results: There were no significant differences observed between the saw palmetto and placebo-allocated participants in the risk of suffering at least one serious adverse event (5.4% vs. 9.7%, respectively; p = 0.31) or non-serious symptomatic adverse event (34.8% vs. 30.1%, p = 0.48). There were few significant between-group differences in sexual functioning or for most laboratory analyses, with only small differences observed in changes over time in total bilirubin (p = 0.001), potassium (p = 0.03), and the incidence of glycosuria (0% in the saw palmetto group vs. 3.7% in the placebo group, p = 0.05). Conclusions: Despite careful assessment, no evidence for serious toxicity of saw palmetto was observed in this clinical trial. Given the sample size and length of this study, however, these data do not rule out potential rare adverse effects associated with the use of saw palmetto. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Avins, Andrew L.; Goldberg, Harley] No Calif Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Avins, Andrew L.; Bent, Stephen; Staccone, Suzanne; Padula, Amy] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Bent, Stephen] Univ Calif San Francisco, Dept Med, Osher Ctr Integrat Med, San Francisco, CA USA. [Avins, Andrew L.; Neuhaus, John; Hudes, Esther] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Badua, Evelyn; Shinohara, Katusto; Kane, Christopher] Son Francisco VA Med Ctr, Urol Sect, San Francisco, CA USA. [Shinohara, Katusto; Kane, Christopher] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Avins, AL (reprint author), No Calif Kaiser Permanente, Div Res, 2000 Broadway,3rd Floor, Oakland, CA 94612 USA. EM andrew.avins@ucsf.edu FU NCCIH NIH HHS [K08 AT001338]; NIDDK NIH HHS [R01 DK056199, R01 DK56199, R01 DK056199-01] NR 28 TC 26 Z9 27 U1 0 U2 11 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0965-2299 J9 COMPLEMENT THER MED JI Complement. Ther. Med. PD JUN PY 2008 VL 16 IS 3 BP 147 EP 154 DI 10.1016/j.ctim.2007.10.005 PG 8 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 322MG UT WOS:000257378700005 PM 18534327 ER PT J AU Patterson, M Maurer, S Adler, SR Avins, AL AF Patterson, Michael Maurer, Stephanie Adler, Shelley R. Avins, Andrew L. TI A novel clinical-trial design for the study of massage therapy SO COMPLEMENTARY THERAPIES IN MEDICINE LA English DT Article DE massage therapy; cancer; clinical trials; methodology ID ONSET MUSCLE SORENESS; LOW-BACK-PAIN; MULTIPLE-SCLEROSIS; BENEFIT; MOTHERS; QUALITY AB Objectives: To develop and test the feasibility and acceptability of a structured design for a massage therapy clinical trial that included a treatment arm designed to control for the non-specific effects of a massage therapy intervention. Design: Pilot randomized controlled clinical trial. Setting: University-integrated medicine research clinic. Interventions: Participants were randomized to a structured Swedish-style massage therapy intervention, a light-touch bodywork control intervention, or usual medical care. Details of the interventions are provided. Main outcome measures: The primary outcome measures were the adherence of the participants to the study protocol and the perception of the intervention experience. Results: Forty-four participants were randomized. Participants often found adherence to the twice-weekly outpatient bodywork interventions to be somewhat difficult; white, overall, 84% of participants completed the study, only 76% of those in an intervention arm successfully completed the trial. Participants randomized to the massage arm expressed uniformly positive attitudes both before and after the intervention. White some participants randomized to the light-touch bodywork arm initially expressed some reservations about their randomization assignment, all participants available for interview were pleased with their experience after the intervention period. Conclusions: The proposed design was found to be relatively straightforward to implement and acceptable to participants. Early disappointment with not receiving massage therapy expressed by the tight-touch intervention participants dissipated quickly. Twice-weekly outpatient intervention appointments were found to be highly burdensome for many patients actively undergoing chemotherapy, thus reducing adherence. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Avins, Andrew L.] No Calif Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Patterson, Michael; Maurer, Stephanie; Adler, Shelley R.; Avins, Andrew L.] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. [Patterson, Michael; Maurer, Stephanie] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Adler, Shelley R.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Avins, Andrew L.] San Francisco VA Med Ctr, Dept Med, Gen Internal Med Sect, San Francisco, CA USA. [Avins, Andrew L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Avins, AL (reprint author), No Calif Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM andrew.avins@ucsf.edu FU NCCIH NIH HHS [R21 AT000348-01, R21 AT000348] NR 34 TC 6 Z9 6 U1 0 U2 3 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0965-2299 J9 COMPLEMENT THER MED JI Complement. Ther. Med. PD JUN PY 2008 VL 16 IS 3 BP 169 EP 176 DI 10.1016/j.ctim.2007.08.001 PG 8 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 322MG UT WOS:000257378700008 PM 18534330 ER PT J AU Zhou, XH Cheng, H AF Zhou, Xiao-Hua Cheng, Hao TI A computer program for estimating the re-transformed mean in heteroscedastic two-part models SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE LA English DT Article DE computer programs; nonparametric; confidence intervals; skewed data; costs AB The population of health care costs is typically skewed, heteroscedastic, and may include zero costs. Without proper accounting for these special distributional features, resulting prediction may be biased, and wrong inferences about the distribution of patients' health care costs may be made. Welsh and Zhou [A.H. Welsh, X.H. Zhou, Estimating the retransformed mean in a heteroscedastic two-part model, J. Stat. Plan. inference 136 (2006) 860-881] proposed a semi-parametric regression model, which addressed these special features. In this paper we developed a software program to implement this statistical method, which would provide better prediction of health care costs for clinical researchers. Our program computed two mean estimators, their asymptotical standard deviation, confidence interval, and optional bootstrap confidence interval. Our program included user-friendly interactive mode and more efficient and flexible batch mode. It was written in free statistical computing language R and could be run on a wide variety of platforms. (c) 2008 Published by Elsevier Ireland Ltd. C1 [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98108 USA. [Cheng, Hao] SAS Inst Inc, Dept Operat Res, Cary, NC 27513 USA. RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, 1100 Olive Way 1400, Seattle, WA 98108 USA. EM azhou@u.washington.edu; hao.cheng@sas.com FU AHRQ HHS [R01HS013105] NR 5 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-2607 J9 COMPUT METH PROG BIO JI Comput. Meth. Programs Biomed. PD JUN PY 2008 VL 90 IS 3 BP 210 EP 216 DI 10.1016/j.cmpb.2008.01.004 PG 7 WC Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics SC Computer Science; Engineering; Medical Informatics GA 304VW UT WOS:000256138200003 PM 18355938 ER PT J AU Lee, JM Yanagawa, J Peebles, KA Sharma, S Mao, JT Dubinett, SM AF Lee, Jay M. Yanagawa, Jane Peebles, Katherine A. Sharma, Sherven Mao, Jenny T. Dubinett, Steven M. TI Inflammation in lung carcinogenesis: New targets for lung cancer chemoprevention and treatment SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY LA English DT Review DE inflammation; lung cancer; cyclooxygenase 2; COX-2; NSCLC; chemoprevention; targeted therapy; bronchogenic carcinoma ID GROWTH-FACTOR RECEPTOR; REGULATORY T-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; OBSTRUCTIVE PULMONARY-DISEASE; MYELOID SUPPRESSOR-CELLS; ACUTE MYOCARDIAL-INFARCTION; TYROSINE KINASE; SELF-TOLERANCE; CYCLOOXYGENASE-2-DEPENDENT REGULATION; PROGNOSTIC-SIGNIFICANCE AB Lung carcinogenesis is a complex process involving the acquisition of genetic mutations that confer cancer development and the malignant phenotype, and is critically linked to apoptosis resistance, unregulated proliferation, invasion, metastasis, and angiogenesis. Epithelial mesenchymal transition (EMT) in cancer is an unregulated process in a host environment with deregulated inflammatory response that impairs cell-mediated immunity and permits cancer progression. Given the immunosuppressive tumor environment, strategies to reverse these events by stimulating host immune responses are an important area of investigation. Cyclooxygenase 2 (COX-2) and its downstream signaling pathways are potential targets for lung cancer chemoprevention and therapy. Clinical trials are underway to evaluate COX-2 inhibitors as adjuvants to chemotherapy in patients with lung cancer and to determine efficacy in prevention of bronchogenic carcinoma. The understanding of molecular mechanisms involved in inflammation and lung carcinogenesis provide insight for new drug development that target reversible, non-mutational events in the chemoprevention and treatment of lung cancer. Published by Elsevier Ireland Ltd. C1 [Lee, Jay M.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, UCLA Lung Canc Res Program,Dept Surg,Div Cardioth, Los Angeles, CA 90095 USA. [Yanagawa, Jane; Peebles, Katherine A.; Mao, Jenny T.; Dubinett, Steven M.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, UCLA Lung Canc Res Program,Dept Med,Div Pulm & Cr, Los Angeles, CA 90095 USA. [Sharma, Sherven] Univ Calif Los Angeles, W Los Angeles VA, David Geffen Sch Med,Jonsson Comprehens Canc Ctr, UCLA Lung Canc Res Program,Dept Med,Div Pulm & Cr, Los Angeles, CA 90073 USA. RP Lee, JM (reprint author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, UCLA Lung Canc Res Program,Dept Surg,Div Cardioth, Los Angeles, CA 90095 USA. EM jaymoonlee@mednet.ucla.edu; jyanagawa@mednet.ucla.edu; Katherine.peebles@gmail.com; sharmasp@ucla.edu; jmao@mednet.ucla.edu; sdubinett@mednet.ucla.edu FU NCI NIH HHS [K12 CA076905, K12 CA076905-10, K23 CA131577, P50 CA090388, P50 CA090388-05S3] NR 114 TC 82 Z9 84 U1 3 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1040-8428 J9 CRIT REV ONCOL HEMAT JI Crit. Rev. Oncol./Hematol. PD JUN PY 2008 VL 66 IS 3 BP 208 EP 217 DI 10.1016/j.critrevonc.2008.01.004 PG 10 WC Oncology; Hematology SC Oncology; Hematology GA 305SZ UT WOS:000256199400004 PM 18304833 ER PT J AU Muntoni, S Muntoni, S Draznin, B AF Muntoni, Sergio Muntoni, Sandro Draznin, Boris TI Effects of Chronic Hyperinsulinemia in Insulin-Resistant Patients SO CURRENT DIABETES REPORTS LA English DT Article ID TYPE-2 DIABETES-MELLITUS; CORONARY-HEART-DISEASE; ACTIVATED PROTEIN-KINASE; MACROVASCULAR DISEASE; MOLECULAR-MECHANISMS; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; GLYCEMIC CONTROL; MORTALITY; THERAPY AB Selective insulin resistance influences pathogenesis and treatment of type 2 diabetes and metabolic syndrome. Downregulation of the antiatherogenic pathway and maintained activity of the proatherogenic and cancerogenic pathways lead to atherosclerosis and cancer. Exogenous insulin added to "compensatory" hyperinsulinemia might worsen the primary end points, resulting in potential increase in cardiovascular and cancer events in spite of improvement of surrogate metabolic end points. Conversely, metformin can improve primary and surrogate end points. C1 [Draznin, Boris] Univ Colorado, Hlth Sci Ctr, ACOS R&D, Denver VA Med Ctr, Denver, CO 80220 USA. RP Draznin, B (reprint author), Univ Colorado, Hlth Sci Ctr, ACOS R&D, Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM boris.draznin@va.gov NR 49 TC 12 Z9 14 U1 0 U2 2 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD JUN PY 2008 VL 8 IS 3 BP 233 EP 238 DI 10.1007/s11892-008-0040-z PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 375FV UT WOS:000261100400010 PM 18625122 ER PT J AU Goodfriend, TL AF Goodfriend, Theodore L. TI Obesity, sleep apnea, aldosterone, and hypertension SO CURRENT HYPERTENSION REPORTS LA English DT Article ID AMBULATORY BLOOD-PRESSURE; POSITIVE AIRWAY PRESSURE; RESISTANT HYPERTENSION; METABOLIC SYNDROME; ADIPOSE-TISSUE; CARDIOVASCULAR-DISEASE; PLASMA-ALDOSTERONE; RISK-FACTORS; WEIGHT-LOSS; INSULIN AB The pathogenesis of hypertension associated with obesity is unclear. This review provides evidence supporting excess visceral fat as an early aspect, and obstructive sleep apnea and elevated levels of aldosterone as factors closer to hypertension in the mechanistic chain. Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here. Possible therapeutic interventions addressing the hypertension associated with obesity are briefly mentioned. C1 William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI 53705 USA. RP Goodfriend, TL (reprint author), William S Middleton Mem Vet Adm Med Ctr, Res Serv, 2500 Overlook Terrace, Madison, WI 53705 USA. EM theodore.goodfriend@med.va.gov NR 44 TC 17 Z9 18 U1 0 U2 7 PU CURRENT SCIENCE INC PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1522-6417 J9 CURR HYPERTENS REP JI Curr. Hypertens. Rep. PD JUN PY 2008 VL 10 IS 3 BP 222 EP 226 DI 10.1007/s11906-008-0042-x PG 5 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 310MC UT WOS:000256532700013 PM 18765094 ER PT J AU Watnick, S Rueda, J AF Watnick, Suzanne Rueda, Jose TI Reproduction and contraception after kidney transplantation SO CURRENT OPINION IN OBSTETRICS & GYNECOLOGY LA English DT Article DE contraception; kidney transplantation; reproduction ID RENAL-TRANSPLANTATION; ORGAN TRANSPLANT; PREGNANCY; DISEASE; ISSUES; WOMEN; RECIPIENTS AB Purpose of review In this manuscript we review the most recent data regarding birth rates and complications in the kidney transplant population. Despite improved fertility, contraceptive counseling is infrequent and contraceptive use engenders many problems not frequently seen in women of childbearing age. Recent findings Pregnancy outcomes in this population are improving, but these patients are still considered 'high risk'. With improved fertility after transplantation, contraception should be viewed as essential in those who wish to avoid pregnancy. Many forms of contraception are viable for women with a kidney transplant. Summary Given increased rates of preeclampsia, preterm delivery, low birth weight, and increased risk of cesarean section, a multidisciplinary team must be involved, which will tend to everything from general fetal and maternal monitoring, serial measurement of kidney function, and medication adjustment. For all these reasons, contraceptive counseling is necessary for all women of childbearing age, both pre and posttransplantation. Specific methods of contraception can be individualized to a patient's needs and should be discussed between patient and provider. Future study of both reproduction and contraception use in kidney transplant recipients is sorely needed. C1 [Watnick, Suzanne] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97239 USA. [Watnick, Suzanne; Rueda, Jose] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. RP Watnick, S (reprint author), Portland VA Med Ctr, Div Hosp & Specialty Med, PP262,3710 SW US Vet Hosp Dr, Portland, OR 97239 USA. EM watnicks@ohsu.edu NR 30 TC 25 Z9 26 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-872X J9 CURR OPIN OBSTET GYN JI Curr. Opin. Obstet. Gynecol. PD JUN PY 2008 VL 20 IS 3 BP 308 EP 312 DI 10.1097/GCO.0b013e3282f8b009 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 304XP UT WOS:000256142700017 PM 18460947 ER PT J AU Egede, LE Ellis, C AF Egede, Leonard E. Ellis, Charles TI The effects of depression on diabetes knowledge, diabetes self-management, and perceived control in indigent patients with type 2 diabetes SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Article ID MEDICATION ADHERENCE; AFRICAN-AMERICANS; HEALTH LITERACY; CARE PROFILE; SYMPTOMS; SCALE; DISEASE; LIFE; HYPERTENSION; RELIABILITY AB Background: This study was designed to assess differences in diabetes knowledge, diabetes self-management, and perceived control among depressed and nondepressed individuals in an indigent population with type 2 diabetes. Research Design and Methods: Depressed and nondepressed patients with the clinical diagnosis of type 2 diabetes were recruited from an indigent care clinic. Subjects completed validated surveys to assess diabetes knowledge, diabetes self-management, and perceived control of diabetes. We compared demographic characteristics and diabetes knowledge, diabetes self-management, and perceived control of diabetes by depression status. Statistical analysis was performed with SPSS version 14.0 (SPSS, Inc., Chicago, IL). Results: Of the 201 subjects with diagnosed type 2 diabetes enrolled in the study, approximately 20% (n = 40) of the sample was depressed. Subjects with depression were more likely to report self-care control problems (mean = 2.2 +/- 1.0 vs. 1.5 +/- 0.6, P < 0.001) and less likely to report positive attitude (mean = 2.9 +/- 0.7 vs. 3.7 +/- 0.5, P < 0.001), self-care ability (mean = 3.2 +/- 3.6 vs. 3.7 +/- 0.5, P < 0.001), and self-care adherence (mean = 3.3 +/- 0.9 vs. 4.1 +/- 0.6, P < 0.001). Depressed patients were less likely to report perceived control of diabetes (mean = 47.7 +/- 8.5 vs. 57.8 +/- 7.4, P < 0.001). There were no significant differences in diabetes knowledge, self-care understanding, and Perceived importance of self-care between depressed and nondepressed patients. Conclusions: In this indigent population with type 2 diabetes, diabetes knowledge did not differ significantly by depression status, but diabetes self-management practices and perceived control of diabetes differed significantly by depression status. Patients who were depressed had poorer diabetes self-care and felt they had less control over their disease. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA Targeted Res Enhancement Program, Charleston, SC USA. [Ellis, Charles] Med Univ S Carolina, Dept Rehabil Sci, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU AHRQ HHS [5K08HS114418, K08 HS011418] NR 39 TC 39 Z9 40 U1 4 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD JUN PY 2008 VL 10 IS 3 BP 213 EP 219 DI 10.1089/dia.2007.0278 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 311PD UT WOS:000256611200009 PM 18473696 ER PT J AU Dang, H Elliott, JJ Lin, AL Zhu, B Katz, MS Yeh, CK AF Dang, Howard Elliott, James J. Lin, Alan L. Zhu, Bing Katz, Michael S. Yeh, Chih-Ko TI Mitogen-activated protein kinase up-regulation and activation during rat parotid gland atrophy and regeneration: role of epidermal growth factor and beta 2-adrenergic receptors SO DIFFERENTIATION LA English DT Article DE salivary gland; extracellular signal-regulated kinase; p38; tissue regeneration ID ELECTRON MICROSCOPIC ALTERATIONS; SUBMANDIBULAR-GLANDS; MYOEPITHELIAL CELLS; SIGNALING PATHWAY; SALIVARY-GLANDS; DUCT LIGATION; ACINAR-CELLS; OBSTRUCTION; RECOVERY; ISOPROTERENOL AB The rat secretory ductal obstruction model has been widely used to assess salivary gland injury, growth, and differentiation. In this study, a novel ductal obstruction and release procedure was used to explore the signaling pathways leading to salivary gland regeneration. Rats underwent bilateral parotid ductal obstruction in which the duct was occluded against a plastic disk subcutaneously and released by external ligature removal. This ductal obstruction/release procedure was validated to produce glandular atrophy and regeneration with histological analysis and periodic acid-Schiff staining. Immunoblot analysis indicated that during ductal obstruction and the early post-release period (day 7), expression of immunoreactive proliferating cell nuclear antigen and vimentin was increased in the parotid glands compared with sham-operated animals. Immunohistochemical staining and immunoblots revealed up-regulation of the mitogen-activated protein kinases (MAPKs), extracellular signal-regulated receptor kinase (ERK)1/2, and p38 during the atrophic and regeneration phases of ductal obstruction/release. Similarly, increases in activated, i.e., phosphorylated, ERK1/2 (pERK1/2) and p38 (phospho-p38) were demonstrable in both ductal and recovering acinar cells, with pERKs expressed predominantly in the nuclei and phospho-p38 distributed throughout the cells. Furthermore, levels of epidermal growth factor (EGF) receptor and beta 2-adrenergic receptor (beta 2-AR) were elevated in the ligated glands and at day 7 post-release; beta 1-AR levels did not change over the same time period. These results support the view that cell proliferation is involved in duct ligation-induced atrophy of the rat parotid gland and gland recovery upon ligature removal. Up-regulation of ERKs and p38, and the activation of these MAPKs by up-regulated EGF and beta 2-ARs, may be important signaling components underlying glandular atrophy and subsequent regeneration. C1 [Lin, Alan L.; Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78249 USA. [Dang, Howard] Univ Texas Hlth Sci Ctr San Antonio, Dept Community Dent, San Antonio, TX USA. [Elliott, James J.] Univ Texas Hlth Sci Ctr San Antonio, Lab Anim Resource, San Antonio, TX USA. [Lin, Alan L.; Zhu, Bing; Katz, Michael S.; Yeh, Chih-Ko] Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Audie L Murphy Div, San Antonio, TX 78229 USA. [Katz, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78284 USA. RP Yeh, CK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78249 USA. EM Yeh@uthscsa.edu FU NIDCR NIH HHS [R21DE15381] NR 42 TC 10 Z9 11 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0301-4681 J9 DIFFERENTIATION JI Differentiation PD JUN PY 2008 VL 76 IS 5 BP 546 EP 557 DI 10.1111/j.1432-0436.2007.00251.x PG 12 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 304NZ UT WOS:000256117500010 PM 18177419 ER PT J AU Leung, FW AF Leung, Felix W. TI Methods of reducing discomfort during colonoscopy SO DIGESTIVE DISEASES AND SCIENCES LA English DT Review DE colonoscopy; sedated; unsedated; as-needed; on-demand ID RANDOMIZED CONTROLLED-TRIAL; PATIENT-CONTROLLED SEDATION; VARIABLE-STIFFNESS COLONOSCOPE; CARBON-DIOXIDE INSUFFLATION; COLORECTAL-CANCER; NITROUS-OXIDE; INCOMPLETE COLONOSCOPY; UNSEDATED ENDOSCOPY; CONSCIOUS SEDATION; SELECTIVE SEDATION AB In the United States sedation for colonoscopy is usual practice. Unsedated colonoscopy is limited to a small proportion of unescorted patients and those with a personal preference for no sedation. Over 80% of patients who accept the option of as-needed sedation can complete colonoscopy without sedation. Colonoscopy in these unsedated patients is performed with techniques similar to those used in the sedated patients. Uncontrolled observations indicate willingness to repeat colonoscopy amongst these patients was correlated significantly with low discomfort score during the examination. Methods reported to minimize patient discomfort or enhance cecal intubation during sedated or unsedated colonoscopy included use of pediatric colonoscope, variable stiffness colonoscope, gastroscope, and inhalation of nitrous oxide or insufflation of carbon dioxide, hypnosis, music, audio distraction, or simply allowing the patients to participate in administration of the medication. Research focusing on confirming the efficacy of a simple inexpensive nonmedication dependent method for minimizing discomfort will likely improve the outcome of care and more importantly will ensure compliance with future surveillance in patients accepting the unsedated option. C1 [Leung, Felix W.] Sepulveda Ambulatory Care Ctr, Div Gastroenterol 111G, Sepulveda, CA 91343 USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Leung, Felix W.] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Res & Med Serv, Los Angeles, CA USA. RP Leung, FW (reprint author), Sepulveda Ambulatory Care Ctr, Div Gastroenterol 111G, 16111 Plummer St, Sepulveda, CA 91343 USA. EM felix.leung@va.gov NR 66 TC 42 Z9 43 U1 1 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JUN PY 2008 VL 53 IS 6 BP 1462 EP 1467 DI 10.1007/s10620-007-0025-9 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 302GB UT WOS:000255955700004 PM 17999189 ER PT J AU Leung, FW AF Leung, Felix W. TI Endoscopic reflectance spectrophotometry and visible light spectroscopy in clinical gastrointestinal studies SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE mucosal blood flow; reflectance spectrophotometry; visible light spectroscopy ID PORTAL-HYPERTENSIVE GASTROPATHY; GASTRIC-MUCOSAL HEMODYNAMICS; BLOOD-FLOW; CIRRHOTIC-PATIENTS; OXYGEN-SATURATION; DUODENAL-ULCERS; PERFUSION; VASOPRESSIN; ISCHEMIA; COLON AB The use of reflectance spectrophotometry (RS) for mucosal hemodynamic measurement relies on the recognition of changes in indexes of mucosal hemoglobin concentration and oxygen saturation. Endoscopic application in clinical studies has confirmed important observations demonstrated in animal experiments. The vasoconstriction induced by propranolol, vasopressin, glypressin, or somatostatin in the portal hypertensive gastric mucosa and the reduction of gastroduodenal mucosal perfusion by nonsteroidal anti-inflammatory drugs (NSAIDs) or smoking, mesenteric venoconstriction associated with systemic hypoxia, and acid-induced duodenal hyperemia are important examples. Prognostic predictions include the development of stress-induced gastric ulcerations in patients with significant reductions in gastric perfusion after thermal or head injury, or the demonstration of delayed gastric or duodenal ulcer healing when the hyperemia at the ulcer margin fails to materialize. In mechanical-ventilator-dependent patients with sepsis, a significantly reduced gastric mucosal RS measurement portends a grave prognosis (mortality >80%). Recent advances in technology resulted in the construction and validation of instruments for visible light spectroscopy. Measurements focused on tissue oxygen saturation demonstrated epinephrine and vessel-ligation-induced vasoconstriction, the absence of ischemia in radiation-induced rectal telangiectasias, and gut ischemia responsive to revascularization treatment. Endoscopic RS and visible light spectroscopy are suitable for assessing the role of blood flow in conditions with a lesser degree of ischemia and for testing the hypothesis that functional dyspepsia and dysmotility syndromes may be due to gut ischemia. C1 [Leung, Felix W.] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol 111G, Res & Med Serv, Sepulveda Ambulatory Care Ctr, Sepulveda, CA 91343 USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Leung, FW (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gastroenterol 111G, Res & Med Serv, Sepulveda Ambulatory Care Ctr, 16111 Plummer St,North Hills, Sepulveda, CA 91343 USA. EM felix.leung@va.gov NR 43 TC 6 Z9 6 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JUN PY 2008 VL 53 IS 6 BP 1669 EP 1677 DI 10.1007/s10620-007-0026-8 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 302GB UT WOS:000255955700031 PM 17932761 ER PT J AU Tabibian, JH Wirshing, DA Pierre, JM Guzik, LH Kisicki, MD Danovitch, I Mena, SJ Wirshing, WC AF Tabibian, James H. Wirshing, Donna A. Pierre, Joseph M. Guzik, Lisa H. Kisicki, Michael D. Danovitch, Itai Mena, Shirley J. Wirshing, William C. TI Hepatitis B and C among veterans on a psychiatric ward SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE hepatitis; epidemiology; psychiatric; veterans; risk factors ID VIRUS-INFECTION; MENTAL-DISORDERS; SUBSTANCE-ABUSE; SEXUAL-BEHAVIOR; RISK BEHAVIOR; PREVALENCE; HIV; SCHIZOPHRENIA; INPATIENTS; THERAPY AB Hepatitis B and C are public health problems. Psychiatric patients may be at risk of hepatitis B and C exposure due to lifestyle and inadequate health care. We aimed to determine prevalence of hepatitis B and C virus exposure and associated risk factors in acutely hospitalized psychiatric veterans. A total of 234 individuals consecutively admitted to the psychiatric wards at the West Los Angeles Veterans Affairs Hospital were asked to participate. A total of 129 patients consented and were screened for viral hepatitis risk factors, hepatitis B surface antigen, hepatitis B surface and core antibodies, and hepatitis C antibodies. About 31 and 38% of the patients had been exposed to hepatitis B and C viruses, respectively. Several risk factors were associated with exposure. Inpatient psychiatric veterans seem to have increased rates of hepatitis B and C exposure. This highlights the need for prevention of risk behavior in this vulnerable population. C1 [Tabibian, James H.; Wirshing, Donna A.; Pierre, Joseph M.; Guzik, Lisa H.; Kisicki, Michael D.; Danovitch, Itai; Mena, Shirley J.; Wirshing, William C.] Univ Calif Los Angeles, Dept Psychiat, W Los Angeles Vet Affairs Hosp, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Tabibian, JH (reprint author), Univ Calif Los Angeles, Dept Psychiat, W Los Angeles Vet Affairs Hosp, David Geffen Sch Med, 1440 Vet Ave 601, Los Angeles, CA 90024 USA. EM jhtabib@ucla.edu NR 30 TC 8 Z9 9 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JUN PY 2008 VL 53 IS 6 BP 1693 EP 1698 DI 10.1007/s10620-007-0045-5 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 302GB UT WOS:000255955700034 PM 17932751 ER PT J AU Nagai, H Russell, JA Jackson, MA Connor, NP AF Nagai, Hiromi Russell, John A. Jackson, Michelle A. Connor, Nadine P. TI Effect of aging on tongue protrusion forces in rats SO DYSPHAGIA LA English DT Article DE dysphagia; tongue force; aging; deglutition; deglutition disorders ID CONTRACTILE PROPERTIES; RETRACTOR MUSCLES; SWALLOWING DISORDERS; MOTOR UNITS; AGE; PHARYNGEAL; PROTRUDOR; FATIGUABILITY; COACTIVATION; STIMULATION AB The purpose of this study was to ascertain the effect of aging on muscle contractile properties associated with tongue protrusion in a rat model. Fischer 344/Brown Norway hybrid rats, ten young (9 months old) and ten old (32 months old), were used to measure protrusive contractile properties. Results showed a significant reduction in tetanic forces in the old animals. The following measures of muscle contraction were not different between age groups: mean twitch contraction force, twitch contraction time, twitch contraction half-decay time, and a calculated measure of fatigability. In conclusion, aging influenced protrusive tongue muscle contractions in a rat model such that tetanic forces were reduced. The reduction of tetanus force may parallel findings in human subjects relative to isometric tongue force generation and may be associated with age-related disorders of swallowing. C1 [Nagai, Hiromi; Jackson, Michelle A.; Connor, Nadine P.] Univ Wisconsin, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53792 USA. [Nagai, Hiromi] Kitasato Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Kanagawa, Japan. [Russell, John A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53792 USA. [Connor, Nadine P.] Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53792 USA. RP Connor, NP (reprint author), 600 Highland Ave,Room K4-711, Madison, WI 53792 USA. EM Connor@surgery.wisc.edu FU NIDCD NIH HHS [R01 DC008149-01A1, R01 DC005935, R01 DC005935-03, R01 DC008149, R01DC008149, R01DC005935] NR 30 TC 12 Z9 12 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X J9 DYSPHAGIA JI Dysphagia PD JUN PY 2008 VL 23 IS 2 BP 116 EP 121 DI 10.1007/s00455-007-9103-6 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 307LH UT WOS:000256319900004 PM 17694408 ER PT J AU Gross, RD Atwood, CW Ross, SB Eichhorn, KA Olszewski, JW Doyle, PJ AF Gross, Roxann Diez Atwood, Charles W., Jr. Ross, Sheryl B. Eichhorn, Kimberly A. Olszewski, Joan W. Doyle, Patrick J. TI The coordination of breathing and swallowing in Parkinson's disease SO DYSPHAGIA LA English DT Article DE Parkinson's disease; oropharyngeal dysphagia; swallowing; respiratory control; deglutition; deglutition disorders; subglottic air pressure ID TRACHEOSTOMY SPEAKING VALVE; INTENSIVE SPEECH TREATMENT; PASSY-MUIR VALVE; SUBTHALAMIC NUCLEUS; PULMONARY DYSFUNCTIONS; RESPIRATORY PATTERNS; ELDERLY-PATIENTS; FOLLOW-UP; ASPIRATION; DYSPHAGIA AB Multiple investigations have determined that healthy adults swallow most often during exhalation and that exhalation regularly follows the swallow, even when a swallow occurs during inhalation. We hypothesized that persons with idiopathic Parkinson's disease would demonstrate impaired breathing and swallowing coordination during spontaneous eating. Twenty-five healthy volunteers and 25 Parkinson's disease patients spontaneously swallowed calibrated pudding and cookie portions while simultaneous nasal airflow and respiratory inductance plethysmography were used to track spontaneous breathing. Surface EMG was used to record the timing of each swallow within the respiratory cycle. When compared to the healthy control group, those with Parkinson's disease swallowed significantly more often during inhalation and at low tidal volumes. The Parkinson's participants also exhibited significantly more postswallow inhalation for both consistencies. Only the healthy subjects exhibited significantly longer deglutitive apnea when swallows that occurred during inhalation were compared with those that occurred during exhalation. The high incidence of oropharyngeal dysphagia and risk of aspiration pneumonia found in Parkinson's disease patients may be partially attributable to impaired coordination of breathing and swallowing. C1 [Gross, Roxann Diez; Ross, Sheryl B.] Univ Pittsburgh, Inst Eye & Ear, Div Otolaryngol, Pittsburgh, PA 15213 USA. [Atwood, Charles W., Jr.; Eichhorn, Kimberly A.; Doyle, Patrick J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Olszewski, Joan W.] Henry Ford Hosp, Detroit, MI 48202 USA. RP Gross, RD (reprint author), Univ Pittsburgh, Inst Eye & Ear, Div Otolaryngol, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM Grossrd@upmc.edu NR 68 TC 35 Z9 42 U1 2 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X J9 DYSPHAGIA JI Dysphagia PD JUN PY 2008 VL 23 IS 2 BP 136 EP 145 DI 10.1007/s00455-007-9113-4 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA 307LH UT WOS:000256319900007 PM 18027027 ER PT J AU Huang, ST Boulos, MNK Dellavalle, RP AF Huang, Stephen T. Boulos, Maged N. Kamel Dellavalle, Robert P. TI Scientific discourse 2.0 - Will your next poster session be in Second Life (R)? SO EMBO REPORTS LA English DT Editorial Material ID VIRTUAL WORLDS; EDUCATION; HEALTH C1 [Huang, Stephen T.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Boulos, Maged N. Kamel] Univ Plymouth, Plymouth PL4 8AA, Devon, England. [Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Dellavalle, Robert P.] Univ Colorado, Denver, CO 80202 USA. RP Huang, ST (reprint author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. EM robert.dellavalle@uchsc.edu RI Dellavalle, Robert/L-2020-2013; Kamel Boulos, Maged/B-3728-2013 OI Dellavalle, Robert/0000-0001-8132-088X; Kamel Boulos, Maged/0000-0003-2400-6303 NR 28 TC 16 Z9 16 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1469-221X J9 EMBO REP JI EMBO Rep. PD JUN PY 2008 VL 9 IS 6 BP 496 EP 499 DI 10.1038/embor.2008.86 PG 4 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 307GW UT WOS:000256308400003 PM 18516082 ER PT J AU Ellis, C Breland, HL Egede, LE AF Ellis, Charles Breland, Hazel L. Egede, Leonard E. TI RACIAL/ETHNIC DIFFERENCES IN UTILIZATION OF POST-STROKE REHABILITATION SERVICES: A SYSTEMATIC REVIEW SO ETHNICITY & DISEASE LA English DT Review DE Stroke; Rehabilitation; Race/Ethnicity ID HEALTH-CARE SYSTEM; INPATIENT STROKE REHABILITATION; ISCHEMIC-STROKE; RACIAL DISPARITIES; UNITED-STATES; ETHNIC-DIFFERENCES; VETERANS AFFAIRS; HIP FRACTURE; MORTALITY; OUTCOMES AB Objective: To examine racial/ethnic differences in utilization of stroke-related rehabilitation. Methods: We searched Medline (from 1966-2007), CINAHL (from 1982-2007), PsycINFO (1966-2007), REHABDATA (1966-2007), the Cochrane Library, and reference lists of published articles. We identified 82 studies in our initial search, including randomized and quasi-randomized controlled trials, working papers, technical reports, and conference presentations of stroke patients that reported utilization of rehabilitation services including physical therapy (PT), occupational therapy (OT), speech-language pathology (SLP), and at least two groups that differed by race/ethnicity. Because of limited information on outcomes and heterogeneity of the studies, a formal meta-analysis was not conducted. A qualitative aggregation of study findings was performed instead. Results: Ten studies involving 214,229 patients met the final criteria for review. Racial/ethnic minorities were more likely to receive rehabilitation and have longer lengths of stays in studies that reported use of rehabilitation services. In contrast, when studies reported discipline-specific (PT, OT, SLP) utilization of services, the results were mixed. Conclusions: Racial/ethnic differences in the utilization of rehabilitation services primarily reflected the manner in which service utilization was reported. Future studies should be designed to ensure an accurate comparison of service utilization by race/ethnicity. (Ethn Dis. 2008; 18:365-372) C1 [Ellis, Charles; Breland, Hazel L.] Med Univ S Carolina, Dept Rehabil Sci, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA TREP, Charleston, SC USA. RP Ellis, C (reprint author), Med Univ S Carolina, Dept Rehabil Sci, 151-B Rutledge Ave, Charleston, SC 29425 USA. EM ellisc@musc.edu NR 40 TC 9 Z9 9 U1 0 U2 1 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SUM PY 2008 VL 18 IS 3 BP 365 EP 372 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 489MC UT WOS:000269423200016 PM 18785453 ER PT J AU Sawalha, AH Jeffries, M Webb, R Lu, Q Gorelik, G Ray, D Osban, J Knowlton, N Johnson, K Richardson, B AF Sawalha, A. H. Jeffries, M. Webb, R. Lu, Q. Gorelik, G. Ray, D. Osban, J. Knowlton, N. Johnson, K. Richardson, B. TI Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients SO GENES AND IMMUNITY LA English DT Article DE epigenetics; T cell; autoimmunity; interferon; methylation; lupus ID DRUG-INDUCED LUPUS; PERIPHERAL-BLOOD CELLS; DNA METHYLATION; INDUCIBLE EXPRESSION; SYNGENEIC MICE; IN-VITRO; ERYTHEMATOSUS; PROCAINAMIDE; DEMETHYLATION; HYDRALAZINE AB Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies against a host of nuclear antigens. The pathogenesis of lupus is incompletely understood. Environmental factors may play a role via altering DNA methylation, a mechanism regulating gene expression. In lupus, genes including CD11a and CD70 are overexpressed in T cells as a result of promoter hypomethylation. T-cell DNA methyltransferase expression is regulated in part by the extracellular signal-regulated kinase (ERK) signaling pathway. In this study, we investigate the effects of decreased ERK pathway signaling in T cells using transgenic animals. We generated a transgenic mouse that inducibly expresses a dominant-negative MEK in T cells in the presence of doxycycline. We show that decreased ERK pathway signaling in T cells results in decreased expression of DNA methyltransferase 1 and overexpression of the methylation-sensitive genes CD11a and CD70, similar to T cells in human lupus. Our transgenic animal model also develops anti-dsDNA antibodies. Interestingly, microarray expression assays revealed overexpression of several interferon-regulated genes in the spleen similar to peripheral blood cells of lupus patients. This model supports the contention that ERK pathway signaling defects in T cells contribute to the development of autoimmunity. C1 [Sawalha, A. H.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Dept Med, Oklahoma City, OK 73104 USA. [Sawalha, A. H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Sawalha, A. H.; Jeffries, M.; Webb, R.; Osban, J.; Knowlton, N.] Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. [Lu, Q.] Cent S Univ, Xiangya Hosp 2, Changsha 410083, Peoples R China. [Gorelik, G.; Ray, D.; Richardson, B.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Johnson, K.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Richardson, B.] US Dept Vet Affairs, Med Ctr, Ann Arbor, MI USA. RP Sawalha, AH (reprint author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Dept Med, 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu FU NCRR NIH HHS [P20 RR015577, P20 RR016478, P20 RR017703, P20 RR020143, P20-RR015577, P20RR016478, P20RR017703, P20RR020143, P20RR15577]; NIA NIH HHS [AG25877, R01 AG025877, R01 AG025877-04]; NIAID NIH HHS [U19 AI062629, U19AI062629]; NIAMS NIH HHS [AR42525, P30 AR053483, R01 AR042525, R01 AR042525-09, R01 AR042525-14, R21 AR056370, R21 AR056370-01]; NIEHS NIH HHS [ES015214, R01 ES015214, R01 ES015214-04, T32 ES007062] NR 46 TC 78 Z9 82 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD JUN PY 2008 VL 9 IS 4 BP 368 EP 378 DI 10.1038/gene.2008.29 PG 11 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 308KJ UT WOS:000256388500013 PM 18523434 ER PT J AU De Gasperi, R Rocher, AB Sosa, MAG Wearne, SL Perez, GM Friedrich, VL Hof, PR Elder, GA AF De Gasperi, Rita Rocher, Anne B. Sosa, Miguel A. Gama Wearne, Susan L. Perez, Gissel M. Friedrich, Victor L., Jr. Hof, Patrick R. Elder, Gregory A. TI The IRG mouse: A two-color fluorescent reporter for assessing Cre-mediated recombination and imaging complex cellular relationships in situ SO GENESIS LA English DT Article DE Cre recombinase; loxP; conditional gene activation; DsRed-express; red fluorescent protein; enhanced green fluorescent protein; transgenic mice ID EXPRESSION; STRAIN; CELLS; MICE; PROTEIN; GENE; INSULATORS; ACTIVATION; EXCISION; LINEAGE AB The Cre-loxP system is widely used for making conditional alterations to the mouse genome. Cre-mediated recombination is frequently monitored using reporter lines in which Cre expression activates a reporter gene driven by a ubiquitous promoter. Given the distinct advantages of fluorescent reporters, we developed a transgenic reporter line, termed IRG, in which DsRed-Express, a red fluorescent protein (RFP) is expressed ubiquitously prior to Cre-mediated recombination and an enhanced green fluorescent protein (EGFP) following recombination. Besides their utility for monitoring Cre-mediated recombination, we show that in IRG mice red and green native fluorescence can be imaged simultaneously in thick tissue sections by confocal microscopy allowing for complex reconstructions to be created that are suitable for analysis of neuronal morphologies as well as neurovascular interactions in brain. IRG mice should provide a versatile tool for analyzing complex cellular relationships in both neural and nonneural tissues. C1 [De Gasperi, Rita; Sosa, Miguel A. Gama; Perez, Gissel M.; Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Res & Dev, Bronx, NY USA. [De Gasperi, Rita; Sosa, Miguel A. Gama; Perez, Gissel M.; Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Rocher, Anne B.; Wearne, Susan L.; Friedrich, Victor L., Jr.; Hof, Patrick R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Wearne, Susan L.] Mt Sinai Sch Med, Ctr Biomath Sci, New York, NY USA. [Wearne, Susan L.; Hof, Patrick R.] Mt Sinai Sch Med, Computat Neurobiol & Imaging Ctr, New York, NY USA. [Friedrich, Victor L., Jr.] Mt Sinai Sch Med, Microscopy Shared Res Facil, New York, NY USA. [Hof, Patrick R.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Rehabil Med Serv, Bronx, NY USA. RP Elder, GA (reprint author), James J Peters VA Med Ctr Res & Dev 3F22, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu FU NCI NIH HHS [5R24 CA095823-04, R24 CA095823-04, R24 CA095823]; NIA NIH HHS [AG021305, P01 AG002219-28, P50 AG005138-24, R03 AG021305, R03 AG021305-01, AG05138, P01 AG002219, R21 AG023599, AG02219, AG023599, P50 AG005138-25, P50 AG005138, R21 AG023599-02]; NIMH NIH HHS [P50 MH058911-10, MH070603, MH58911, R03 MH070603-02, P50 MH058911, R03 MH070603] NR 27 TC 24 Z9 24 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-954X J9 GENESIS JI Genesis PD JUN PY 2008 VL 46 IS 6 BP 308 EP 317 DI 10.1002/dvg.20400 PG 10 WC Developmental Biology; Genetics & Heredity SC Developmental Biology; Genetics & Heredity GA 323XE UT WOS:000257480900005 PM 18543298 ER PT J AU Braun, UK Pham, C Kunik, ME AF Braun, Ursula K. Pham, Catherine Kunik, Mark E. TI Recognizing and managing depression at end of life SO GERIATRICS LA English DT Article DE depression; end of life; terminal illness ID PRIMARY-CARE; ANXIETY; MANAGEMENT AB The dying process is characterized by feelings of sadness and fear. It is normal for patients at the end of life to worry and grieve the loss of their health. However, when these feelings become excessive and interfere with all aspects of the patient's life, they are abnormal responses to the stress of terminal illness. Screening for depression in terminally ill patients can optimize their physical comfort at the end of life and provide them the opportunity to confront and prepare for death. C1 [Braun, Ursula K.] Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Sect Geriatr & Hlth Serv Res, Houston, TX 77030 USA. [Braun, Ursula K.] Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Sect Dev Serv, Houston, TX 77030 USA. [Braun, Ursula K.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Kunik, Mark E.] Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Little Rock, AR USA. [Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Little Rock, AR USA. [Kunik, Mark E.] Baylor Coll Med, Dept Med, Little Rock, AR USA. [Kunik, Mark E.] VA S Cent MIRECC, Little Rock, AR USA. [Pham, Catherine] Texas A&M Univ, College Stn, TX USA. RP Braun, UK (reprint author), Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Sect Geriatr & Hlth Serv Res, Houston, TX 77030 USA. NR 13 TC 3 Z9 3 U1 0 U2 0 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 USA SN 0016-867X J9 GERIATRICS JI Geriatrics PD JUN PY 2008 VL 63 IS 6 BP 25 EP 27 PG 3 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 314AG UT WOS:000256780500004 PM 18512998 ER PT J AU Naik, AD Burnett, J Pickens-Pace, S Dyer, CB AF Naik, Aanand D. Burnett, Jason Pickens-Pace, Sabrina Dyer, Carmel B. TI Impairment in instrumental activities of daily living and the geriatric syndrome of self-neglect SO GERONTOLOGIST LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 02-06, 2007 CL Seattle, WA SP Amer Geriatr Soc DE elder mistreatment; functional assessment; geriatric self-neglect; geriatric syndrome ID COMMUNITY-DWELLING ELDERS; OLDER-ADULTS; PHYSICAL-PERFORMANCE; DEPENDENCE; DISABILITY; MORTALITY; UTILITY; RISK AB Purpose: We sought to characterize self-neglect definitively as a geriatric syndrome by identifying an association with functional impairment. Design and Methods: We performed a cross-sectional home evaluation of 100 community-living older adults referred by Adult Protective Services for geriatric self-neglect and 100 matched adults from a community geriatrics clinic. We made our assessments by using two manual muscle tests, a timed-gait test, a modified Physical Performance Test (mPPT), and the Kohlman Evaluation of Living Skills (KELS). Results: Participants in the self-neglect group had impaired mPPT (p <.077) and KELS (p <.001) scores compared with community-controls. Using analysis of covariance models, we found that self-neglect referral explained a significant proportion of the variance in KELS scores (32%; p <.001) but not in mPPT scores (22%; p =.49). Implications: The geriatric syndrome of self-neglect is associated with increased morbidity and mortality and appears to be independently associated with impairments in instrumental activities of daily living. The evaluation and treatment of geriatric self-neglect should be consistent with that of other geriatric syndromes. C1 [Naik, Aanand D.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Burnett, Jason; Pickens-Pace, Sabrina; Dyer, Carmel B.] CREST, Houston, TX USA. [Burnett, Jason; Pickens-Pace, Sabrina; Dyer, Carmel B.] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA. RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. FU NCRR NIH HHS [P20 RR020626, P20 RR020626-01, P20-RR020626]; NIA NIH HHS [K23 AG027144, K23 AG027144-03, K23AG027144] NR 24 TC 23 Z9 25 U1 3 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD JUN PY 2008 VL 48 IS 3 BP 388 EP 393 PG 6 WC Gerontology SC Geriatrics & Gerontology GA 322ZZ UT WOS:000257415100012 PM 18591364 ER PT J AU Scobie, J Keyhani, S Hebert, PL McLaughlin, MA AF Scobie, Janice Keyhani, Salomeh Hebert, Paul L. McLaughlin, Mary Ann TI Gender and blood pressure control - Response SO HYPERTENSION LA English DT Letter ID HYPERTENSION TREATMENT; UNITED-STATES C1 [Scobie, Janice; McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Keyhani, Salomeh] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Keyhani, Salomeh; Hebert, Paul L.; McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA. [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Gen Internal Med, New York, NY USA. [McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. RP Scobie, J (reprint author), Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD JUN PY 2008 VL 51 IS 6 BP E49 EP E49 DI 10.1161/HYPERTENSIONAHA.108.112623 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 303PT UT WOS:000256053500048 ER PT J AU Scalapino, KJ Daikh, DI AF Scalapino, Kenneth J. Daikh, David I. TI CTLA-4: a key regulatory point in the control of autoimmune disease SO IMMUNOLOGICAL REVIEWS LA English DT Review DE Tcells; regulatory T cells; suppression; autoimmunity ID CYTOTOXIC-T-LYMPHOCYTE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; IMMUNOLOGICAL SELF-TOLERANCE; B-CELL ACTIVATION; A-G POLYMORPHISM; ANTIGEN-4 MONOCLONAL-ANTIBODY; COLONY-STIMULATING FACTOR; PHASE-I TRIAL; GRAVES-DISEASE; RHEUMATOID-ARTHRITIS AB Chronic autoimmune disease in humans is the result of a failure to control autoreactive immune cells in the periphery. This control is largely achieved by inhibition of newly activated and memory cells. A number of negative immune regulatory pathways have been characterized. The cell surface coreceptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) has emerged as a critical attenuator of T-cell activation and an essential component of the regulatory systems that serve to maintain peripheral tolerance. CTLA-4 expression is induced on the surface of T cells after they have received a costimulatory signal from antigen-presenting cells (APCs) via engagement of CD28 on the T-cell surface. CTLA-4 attenuates this costimulation by competing for CD28 ligands and through direct effects on APCs via the same ligands utilized by CD28. A large number of genetic association studies suggest that the CTLA-4 gene is a locus of susceptibility to autoimmune disease. However, specific functional defects in the CTLA-4 gene in patients have not been identified to date. Elucidating the role of CTLA-4 in immune tolerance has also led to a number of therapeutic applications, particularly in the treatment of malignancy and autoimmune disease. C1 [Scalapino, Kenneth J.] Univ Calif San Francisco, Div Rheumatol, Dept Med, San Francisco, CA 94143 USA. [Daikh, David I.] San Francisco VA Med Ctr, Arthrit Immunol Sect, San Francisco, CA USA. RP Daikh, DI (reprint author), Arthrit Immunology 111R,4150 Clement St, San Francisco, CA 94121 USA. EM david.daikh@ucsf.edu NR 164 TC 94 Z9 102 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-2896 EI 1600-065X J9 IMMUNOL REV JI Immunol. Rev. PD JUN PY 2008 VL 223 BP 143 EP 155 DI 10.1111/j.1600-065X.2008.00639.x PG 13 WC Immunology SC Immunology GA 325CG UT WOS:000257565200009 PM 18613834 ER PT J AU Patel, M Weinheimer, JD Waites, KB Baddley, JW AF Patel, Mukesh Weinheimer, Jeffrey D. Waites, Ken B. Baddley, John W. TI Active surveillance to determine the impact of methicillin-resistant Staphylococcus aureus colonization on patients in intensive care units of a Veterans Affairs Medical Center SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT 47th Interscience Conference on Antimicrobial Agents and Chemotherapy CY SEP 17-20, 2007 CL Chicago, IL ID RISK-FACTORS; NASAL COLONIZATION; HOSPITAL ADMISSION; INFECTION; MRSA; BACTEREMIA; PREVALENCE; MORTALITY; CULTURES AB OBJECTIVE. The impact of methicillin-resistant Staphylococcus aureus (MRSA) colonization on mortality has not been well characterized. We sought to describe the impact of MRSA colonization on patients admitted to intensive care units (ICUs) in the Birmingham Veterans Affairs Medical Center (VAMC). METHODS. We conducted a retrospective cohort study of ICU patients at the Birmingham VAMC during 2005 to evaluate the predictors of MRSA colonization and determine its effect on clinical outcomes. Surveillance cultures for MRSA were performed on admission to the ICU and weekly thereafter. Clinical findings, the incidence of MRSA infection, and mortality within 3 months after ICU admission were recorded. Predictors of mortality and S. aureus colonization were determined using multivariable models. RESULTS. S. aureus colonization was present in 97 (23.3%) of 416 patients screened, of whom 67 (16.1%) were colonized with methicillin-susceptible S. aureus (MSSA) and 30 (7.2%) with MRSA. All-cause mortality at 3 months among MRSA-colonized patients was significantly greater than that among MSSA-colonized patients (46.7% vs 19.4%; P = .009). MRSA colonization was an independent predictor of death (adjusted odds ratio [OR], 3.7 [95% confidence interval {CI}, 1.5-8.9]; P = .003) and onset of MRSA infection after hospital discharge (adjusted OR, 7.6 [95% CI, 2.48-23.2]; P < .001). Risk factors for MRSA colonization included recent antibiotic use (adjusted OR, 4.8 [ 95% CI, 1.9-12.2]; P = .001) and dialysis (adjusted OR, 18.9 [95% CI, 2.1-167.8]; P = .008). CONCLUSIONS. Among ICU patients, MRSA colonization is associated with subsequent MRSA infection and an all-cause mortality that is greater than that for MSSA colonization. Active surveillance for MRSA colonization may identify individuals at risk for these adverse outcomes. Prospective studies of outcomes in MRSA-colonized patients may better define the role of programs for active MRSA surveillance. C1 [Patel, Mukesh; Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Patel, Mukesh] Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Weinheimer, Jeffrey D.] Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA. [Waites, Ken B.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. RP Patel, M (reprint author), Univ Alabama, Dept Med, Div Infect Dis, Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM mukesh@uab.edu NR 22 TC 25 Z9 29 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2008 VL 29 IS 6 BP 503 EP 509 DI 10.1086/588161 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 307JI UT WOS:000256314800005 PM 18510459 ER PT J AU Treiber, KA Lyketsos, CG Corcoran, C Steinberg, M Norton, M Green, RC Rabins, P Stein, DM Welsh-Bohmer, KA Breitner, JCS Tschanz, JT AF Treiber, Katherine A. Lyketsos, Constantine G. Corcoran, Chris Steinberg, Martin Norton, Maria Green, Robert C. Rabins, Peter Stein, David M. Welsh-Bohmer, Kathleen A. Breitner, John C. S. Tschanz, JoAnn T. TI Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE dementia; Alzheimer's disease; neuropsychiatric; disturbance; risk factors; vascular ID APOLIPOPROTEIN-E GENOTYPE; CEREBRAL-BLOOD-FLOW; E E4 ALLELE; BEHAVIORAL DISTURBANCES; PSYCHIATRIC-SYMPTOMS; PSYCHOLOGICAL SYMPTOMS; NONCOGNITIVE SYMPTOMS; COGNITIVE IMPAIRMENT; AGGRESSIVE-BEHAVIOR; MEDICAL COMORBIDITY AB Objective: To examine, in an exploratory analysis, the association between vascular conditions and the occurrence of neuropsychiatric symptoms (NPS) in a population-based sample of incident Alzheimer's disease (AD). Methods: The sample consisted of 254 participants, identified through two waves of assessment. NPS were assessed using the Neuropsychiatric Inventory. Prior to the onset of AD, data regarding a history of stroke, hypertension, hyperlipidemia, heart attack or coronary artery bypass graft (CABG), and diabetes were recorded. Logistic regression procedures were used to examine the relationship of each vascular condition to individual neuropsychiatric symptoms. Covariates considered were age, gender, education, APOE genotype, dementia severity, and overall health status. Results: One or more NPS were observed in 51 % of participants. Depression was most common (25.8%), followed by apathy (18.6%), and irritability (17.7%). Least common were elation (0.8%), hallucinations (5.6%), and disinhibition (6.0%). Stroke prior to the onset of AD was associated with increased risk of delusions (OR=4.76, p=0.02), depression (OR=3.87, p=0.03), and apathy (OR=4.48, p=0.02). Hypertension was associated with increased risk of delusions (OR= 2.34, p =0.02), anxiety (OR= 4.10, p=0.002), and agitation/aggression (OR= 2.82, p=0.01). No associations were observed between NPS and diabetes, hyperlipidemia, heart attack or CABG, or overall health. Conclusions: Results suggest that a history of stroke and hypertension increase the risk of specific NPS in patients with AD. These conditions may disrupt neural circuitry in brain areas involved in NPS. Findings may provide an avenue for reduction in occurrence of NPS through the treatment or prevention of vascular risk conditions. C1 [Tschanz, JoAnn T.] Utah State Univ, Ctr Epidemiol Studies, UMC 4440, Dept Psychol, Logan, UT 84322 USA. [Lyketsos, Constantine G.; Steinberg, Martin; Rabins, Peter] Johns Hopkins Univ, Johns Hopkins Bayview, Dept Psychiat, Baltimore, MD USA. [Lyketsos, Constantine G.; Steinberg, Martin; Rabins, Peter] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Corcoran, Chris] Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA. [Norton, Maria] Utah State Univ, Dept Family & Human Dev, Logan, UT 84322 USA. [Green, Robert C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Welsh-Bohmer, Kathleen A.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. [Breitner, John C. S.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Breitner, John C. S.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Green, Robert C.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. RP Tschanz, JT (reprint author), Utah State Univ, Ctr Epidemiol Studies, UMC 4440, Dept Psychol, Logan, UT 84322 USA. EM joannt@cc.usu.edu RI Corcoran, Chris/F-2155-2010; Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013 FU National Institute on Aging [R01AG21136, R01AG1183, R01AG18712] FX This research was supported by National Institute on Aging grants R01AG21136, R01AG1183 and R01AG18712. We wish to thank Dr. Truls Ostbye for his thoughtful review of this manuscript. We are grateful to the neurogenetics laboratory of the Bryan Alzheimer's Disease Research Center at Duke University for the APOE genotyping, and to Cara Brewer, Tony Calvert, Michelle McCart, Tiffany Newman, Roxane Pfister, Dr. Nancy Sassano and Joslin Werstack for expert technical assistance. Other Cache County Study of Memory, Health, and Aging Investigators include: Dr. James Anthony, Dr. Erin Bigler, Dr. Ron Brookmeyer, Dr. James Burke, Dr. Eric Christopher, Dr. Jane Gagliardi, Michael Helms, Dr. Christine Hulette, Liz Klein, Carol Leslie, Dr. Lawrence Mayer, Dr. John Morris, Dr. Ronald G. Munger, Dr. Chiadi Onyike, Dr. Truls Ostbye, Dr. Ron Petersen, Dr. Kathy Piercy, Dr. Carl Pieper, Dr. Brenda Plassman, Dr. Pritham Raj, Russell Ray, Linda Sanders, Dr. Ingmar Skoog, Dr. David Steffens, Dr. Marty Toohill, Leslie Toone, Dr. Jeannette Townsend, Lauren Warren, Dr. Michael Williams and Dr. Bonita Wyse.; The board-certified or board-eligible geriatric psychiatrists or neurologists who examined the study members included Drs Steinberg, Breitner, Steffens, Lyketsos, and Green. Dr. Williams also examined several subjects and provided expert neurologic consultation. Autopsy examinations were conducted by Dr. Townsend. Ms. Leslie coordinated the autopsy enrollment program. Diagnosticians at the expert consensus conferences included Drs Breitner, Burke, Lyketsos, Plassman, Steffens, Steinberg, Tschanz and Welsh-Bohmer. NR 58 TC 39 Z9 40 U1 1 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD JUN PY 2008 VL 20 IS 3 BP 538 EP 553 DI 10.1017/S1041610208006704 PG 16 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 352SZ UT WOS:000259519000009 PM 18289451 ER PT J AU Reddy, VS Harskamp, RE Van Ginkel, MW Calhoon, J Baisden, CE Kim, IS Valente, AJ Chandrasekar, B AF Reddy, Venkatapuram Seenu Harskamp, Ralf Egan Van Ginkel, Margreet Willie Calhoon, John Baisden, Clinton Eugene Kim, In-San Valente, Anthony J. Chandrasekar, Bysani TI Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappa B activation SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; GENE-EXPRESSION; MYOCARDIAL-INFARCTION; MATRIX-METALLOPROTEINASE-9 EXPRESSION; SIGNALING PATHWAY; POTENTIAL ROLE; HYPERTROPHY; MICE; FIBROSIS AB Fibronectin (FN), a key component of the extracellular matrix, is upregulated in cardiac tissue during myocardial hypertrophy and failure. Here we show that interleukin (IL)-18, a proinflammatory and pro-hypertrophic cytokine, stimulates FN expression in adult human cardiac fibroblasts (HCF), an effect blocked by either the IL-18BP:Fc chimera or IL-18 neutralizing antibodies. IL-18 stimulated FN promoter-reporter activity in HCF, a response attenuated by mutation of an NF-kappa B binding site in the FN promoter. Overexpression of p65 stimulated FN transcription. IL-18 stimulated in vitro (p65, p50) and in vivo NF-kappa B DNA binding activities, and induced kappa B-dependent reporter gene activity. These effects were inhibited by adenoviral transduction of dominant negative (dn) p65 (Ad.dnp65) and dn1KK2 (Ad.dn1KK2). Investigation of signaling intermediates revealed that IL-18 stimulated P13 kinase activity (blocked by wortmannin, LY294002, or Ad.dnP13Kp85), and Akt phosphorylation and kinase activity (blocked by SH-5 or Ad.dnAkt). Furthermore, targeting MyD88, IRAK 1, TRAF6, PI3K, Akt, and NF-kappa B by RNA interference or dn expression vectors blunted IL-18 mediated FN transcription and mRNA expression. Conversely, FIN stimulated IL-18 expression. These data provide the first evidence that IL-18 and FIN stimulate each other's expression in HCF, and suggest a role for IL-18, FN and their crosstalk in myocardial hypertrophy and remodeling, disease states characterized by enhanced FIN expression and fibrosis. C1 [Valente, Anthony J.; Chandrasekar, Bysani] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Chandrasekar, Bysani] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Kim, In-San] Kyungpook Natl Univ, Sch Med, Dept Cell, Taegu 702701, South Korea. [Kim, In-San] Kyungpook Natl Univ, Sch Med, Matrix Biol Lab, Taegu 702701, South Korea. [Reddy, Venkatapuram Seenu; Harskamp, Ralf Egan; Van Ginkel, Margreet Willie; Calhoon, John; Baisden, Clinton Eugene] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. RP Chandrasekar, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chandraseka@uthscsa.edu RI Harskamp, Ralf/A-9816-2009; 김, 인산/I-8988-2014; Kim, In-San/D-3956-2017 OI Harskamp, Ralf/0000-0001-9041-0350; NR 50 TC 38 Z9 38 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JUN PY 2008 VL 215 IS 3 BP 697 EP 707 DI 10.1002/jcp.21348 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 298PL UT WOS:000255699500015 PM 18064631 ER PT J AU Leonard, CE Haynes, K Localio, AR Hennessy, S Tjia, J Cohen, A Kimmel, SE Feldman, HI Metlay, JP AF Leonard, Charles E. Haynes, Kevin Localio, A. Russell Hennessy, Sean Tjia, Jennifer Cohen, Abigail Kimmel, Stephen E. Feldman, Harold I. Metlay, Joshua P. TI Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT 21st International Conference on Pharmacoepidemiology and Therapeutic Risk Management CY AUG 21-24, 2005 CL Nashville, TN DE adverse drug events; patient safety; ICD-9 CM codes; E-codes; diagnostic coding; validation study ID HOSPITAL ADMISSIONS; RISK-FACTORS; OUTPATIENTS; PREVENTABILITY; POPULATION; FREQUENCY; ADULTS; COSTS AB Objective: We sought to examine the validity of specific hospital discharge codes in identifying drug toxicity precipitating hospitalization, among elderly users of high-risk medications. Study Design and Setting: We conducted a cross-sectional evaluation assessing the diagnostic test characteristics of International Classification of Diseases-9 External-Cause-of-Injury codes (E-codes) compared with a reference standard of medical record review. This study was nested within a prospective cohort of elders using warfarin, digoxin, or phenytoin as identified in the Pharmaceutical Assistance Contract for the Elderly benefit program. Results: We identified 4,803 subjects contributing 11,409 person-years of exposure to at least one of three drug groups. Subjects experienced 8,756 hospitalizations, of which 304 were deemed, by expert review, to be a result of an adverse event of warfarin, digoxin, or phenytoin. The sensitivity, specificity, and positive (PPVs) and negative predictive values for drug-specific E-codes were warfarin-25.5%, 98.3%, 46.6%, and 95.7%; digoxin-84.0%, 99.1%, 56.8%, and 99.8%; and phenytoin-86.7%, 98.7%, 59.1%, and 99.7%. Conclusions: E-codes for digoxin and phenytoin have a high sensitivity, but E-codes for all three medications have poor PPVs, a result that might produce misclassification in studies based solely on discharge coding. Investigators should confirm such rare events via medical record review. (c) 2008 Elsevier Inc. All rights reserved. C1 [Leonard, Charles E.] Univ Penn, Ctr Clin Epidemiol & Biostat, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Leonard, Charles E.; Localio, A. Russell; Hennessy, Sean; Cohen, Abigail; Kimmel, Stephen E.; Feldman, Harold I.; Metlay, Joshua P.] Univ Penn, Program Reduct Medicat Errors, Philadelphia, PA 19104 USA. [Tjia, Jennifer] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. [Kimmel, Stephen E.; Feldman, Harold I.; Metlay, Joshua P.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Leonard, CE (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Sch Med, Dept Biostat & Epidemiol, 423 Guardian Dr,826 Blockley Hall, Philadelphia, PA 19104 USA. EM celeonar@mail.med.upenn.edu RI Leonard, Charles/K-3447-2012; Cohen, Abigail/K-9180-2013 OI Cohen, Abigail/0000-0002-7425-7218 FU AHRQ HHS [P01-HS11530]; NIA NIH HHS [5-F32-AG-026180, K08-AG-021527, K23-AG-000987]; NIDDK NIH HHS [K24-DK-002651] NR 21 TC 14 Z9 14 U1 4 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD JUN PY 2008 VL 61 IS 6 BP 561 EP 571 DI 10.1016/j.jclinepi.2007.08.003 PG 11 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 305GB UT WOS:000256164700008 PM 18471660 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI New Insights Into Hypertension Management in Acute Stroke: Let the CHHIPS Fall Where They May SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID ISCHEMIC-STROKE; BLOOD-PRESSURE; TRIAL; OUTCOMES C1 [Rosendorff, Clive] James J Peters VA Med Ctr, Dept Med, Bronx, NY 10468 USA. [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Dept Med, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@ua.gov NR 7 TC 1 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JUN PY 2008 VL 10 IS 6 BP 425 EP 426 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 375FP UT WOS:000261099800001 PM 18550930 ER PT J AU Marangell, LB Dennehy, EB Wisniewski, SR Bauer, MS Miyahara, S Allen, MH Martinez, M Al Jurdi, RK Thase, ME AF Marangell, Lauren B. Dennehy, Ellen B. Wisniewski, Stephen R. Bauer, Mark S. Miyahara, Sachiko Allen, Michael H. Martinez, Melissa Al Jurdi, Rayan K. Thase, Michael E. TI Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: Findings from STEP-BD SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID TREATMENT ENHANCEMENT PROGRAM; SEROTONIN REUPTAKE INHIBITORS; RANDOMIZED CONTROLLED-TRIALS; MOOD DISORDERS; LITHIUM; RISK; BEHAVIOR; ANTIDEPRESSANTS; PARTICIPANTS; METAANALYSIS AB Objective: Given high rates of suicide and suicide attempts in bipolar disorder and the data suggesting a suicide-protective effect of lithium, we evaluated the impact of pharmacotherapy on prospectively observed suicides and suicide attempts in subjects in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Method: The STEP-BD study enrolled 4360 participants with DSM-IV bipolar disorder diagnoses from September 1998 through November 2004. There were 270 suicide events in STEP-BD (8 completed suicides, 262 attempts). These occurred in 182 of STEP-1313 participants (cases). Inclusion criteria required cases to be white or Caucasian, have at least 1 postbaseline visit, and have prescription information within 30 days of the suicide event. This reduced the available cohort to 106 cases. Matching included age, gender, history of previous suicide attempt, and a propensity score that considered bipolar subtype, marital status, age at onset, and history of psychosis, resulting in 93 matched pairs. A secondary analysis added mood state status within 30 days of the suicide event to the propensity score (N = 54 pairs). The association of drug prescriptions with suicide attempts/completions was assessed using a conditional logistic regression model. Results: The results do not indicate a relationship between lithium use and suicide attempts or completions (p = .41). Similar findings were found for exposure to valproate, carbamazepine, lamotrigine, and the atypical antipsychotic medications. An association between selective serotonin reuptake inhibitor (SSRI) prescription and suicide events was observed (p < .0001). Findings were similar in a secondary analysis that controlled for mood state. Conclusion: Our data are not consistent with a suicide-protective effect of lithium. The association between suicide events and SSRI prescriptions requires cautious interpretation due to complex relationships between treatment, severity, and suicidality. Trial Registration: clinicaltrials.gov Identifier: NCT00012558. C1 [Marangell, Lauren B.; Martinez, Melissa; Al Jurdi, Rayan K.] Baylor Coll Med, Dept Psychiat, Mood Disorders Ctr, Houston, TX 77030 USA. [Marangell, Lauren B.; Martinez, Melissa; Al Jurdi, Rayan K.] S Cent Mental Illness Res & Educ Core, Dept Vet Affairs, Houston, TX 77030 USA. [Dennehy, Ellen B.] Purdue Univ, Dept Psychol Sci, W Lafayette, IN 47907 USA. [Wisniewski, Stephen R.; Miyahara, Sachiko] Univ Pittsburgh, Epidemiol Data Ctr, Pittsburgh, PA USA. [Miyahara, Sachiko] Univ Pittsburgh, Western Psychiat Inst, Dept Psychiat, Pittsburgh, PA USA. [Bauer, Mark S.] Harvard Univ, Sch Med, Boston, MA USA. [Bauer, Mark S.] Vet Affairs Boston Healthcare Syst, Boston, MA USA. [Allen, Michael H.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Marangell, LB (reprint author), Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA. EM drlauren@lilly.com RI Allen, Michael/A-8776-2011 OI Wisniewski, Stephen/0000-0002-3877-9860 FU NIMH NIH HHS [N01MH80001] NR 21 TC 38 Z9 38 U1 2 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUN PY 2008 VL 69 IS 6 BP 916 EP 922 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 318LI UT WOS:000257092800005 PM 18399724 ER PT J AU Coombes, JM Steiner, JF Bekelman, DB Prochazka, AV Denberg, TD AF Coombes, John M. Steiner, John F. Bekelman, David B. Prochazka, Allan V. Denberg, Thomas D. TI Clinical outcomes associated with attempts to educate patients about lower endoscopy: A narrative review SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE colonoscopy; flexible sigmoidoscopy; lower endoscopy; patient knowledge; colorectal cancer screening ID OPEN-ACCESS ENDOSCOPY; INFORMED-CONSENT; GASTROINTESTINAL ENDOSCOPY; RANDOMIZED-TRIAL; FLEXIBLE SIGMOIDOSCOPY; MALPRACTICE CLAIMS; INFORMATION; COLONOSCOPY; ANXIETY; GASTROSCOPY AB Patient knowledge about lower endoscopy might have beneficial effects on satisfaction outcomes, pre-procedure anxiety, and adherence, although this is poorly understood. Methods Searching the national and international literature, we reviewed 20 years of observational studies and randomized trials that examine possible relationships between educating patients about lower endoscopy and clinical outcomes. Twenty-three publications were included but their heterogeneity precluded meta-analyses. Standard and modified informed consent procedures and enhanced educational interventions were associated most often with levels of patient knowledge, satisfaction, anxiety, and adherence. Regardless of the approach, a large proportion of patients have poor comprehension of lower endoscopy's risks, benefits, and alternatives; patient satisfaction with information and procedures manifests ceiling effects; only a subset of patients have clinically significant pre-procedure anxiety; and providing written information and reminders may improve procedure adherence. Future work should focus on strategies for improving patient knowledge in the setting of initial screening colonoscopy within open access systems. Patient knowledge of lower endoscopy is often inadequate even though greater knowledge might be associated with better clinical outcomes for certain patient subgroups. Professional societies have an important role to play in endorsing educational strategies and in clarifying and assessing the adequacy of patient knowledge. C1 [Bekelman, David B.; Denberg, Thomas D.] Univ Colorado, Dept Med, Denver, CO 80262 USA. [Bekelman, David B.; Denberg, Thomas D.] Hlth Sci Ctr, Denver, CO 80262 USA. [Coombes, John M.] Gastroenterol Associates No New York PC, Irongate Ctr 5, Glens Falls, NY 12801 USA. [Steiner, John F.] Univ Colorado Denver, Colorado Hlth Outcomes Program, Aurora, CO 80045 USA. [Steiner, John F.] Hlth Sci Ctr, Aurora, CO 80045 USA. [Prochazka, Allan V.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Denberg, TD (reprint author), Univ Colorado, Dept Med, 4200 E 9th Ave,B180, Denver, CO 80262 USA. EM tom.denberg@uchsc.edu RI Coombes, Jeff/F-1764-2010 NR 35 TC 9 Z9 10 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD JUN PY 2008 VL 33 IS 3 BP 149 EP 157 DI 10.1007/s10900-007-9081-5 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 285DI UT WOS:000254757100006 PM 18165928 ER PT J AU Varra, AA Hayes, SC Roget, N Fisher, G AF Varra, Alethea A. Hayes, Steven C. Roget, Nancy Fisher, Gary TI A randomized control trial examining the effect of acceptance and commitment training on clinician willingness to use evidence-based pharmacotherapy SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article; Proceedings Paper CT 40th Annual Meeting of the Association-for-Behavioral-and-Cognitive-Therapies CY NOV, 2006 CL Chicago, IL SP Assoc Behav & Cognit Therapies DE dissemination; pharmacotherapy; substance abuse; acceptance and commitment therapy ID PSYCHOLOGICAL-RESEARCH; MENTAL-HEALTH; THERAPY; DISSEMINATION; BUPRENORPHINE; ATTITUDES; CARE; PSYCHOTHERAPY; METAANALYSIS; COUNSELORS AB This study evaluated the effectiveness of acceptance and commitment training (ACT) for increasing drug and alcohol counselors' willingness to use evidence-based agonist and antagonist pharmacotherapy. Fifty-nine drug and alcohol counselors were randomly assigned to either a 1-day ACT workshop or a 1-day educational control workshop. Both groups then attended a 2-day workshop on empirically supported treatments for substance abuse. Measures were taken at pre- and posttraining and 3-month follow-up on reported use of pharmacotherapy, willingness to use pharmacotherapy, perceived barriers to implementing new treatments, and general acceptance. As compared with those in the education alone condition, participants in the ACT condition showed significantly higher rates of referrals to pharmacotherapy at follow-up, rated barriers to learning new treatments as less believable at posttraining and follow-up, and showed greater psychological flexibility at posttraining and follow-up. Mediational analyses indicated that reduced believability of barriers and greater psychological flexibility mediated the impact of the intervention. Results support the idea that acceptance-based interventions may be helpful in addressing the psychological factors related to poor adoption of evidence-based treatments. C1 [Varra, Alethea A.] Mental Hlth Serv 116, Vet Affairs Puget Sound Healthcare Syst, Seattle, WA 98108 USA. [Hayes, Steven C.; Roget, Nancy; Fisher, Gary] Univ Nevada, Dept Psychol, Reno, NV 89557 USA. RP Varra, AA (reprint author), Mental Hlth Serv 116, Vet Affairs Puget Sound Healthcare Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM alethea.varra@va.gov RI Hayes, Steven/F-9306-2012 OI Hayes, Steven/0000-0003-4399-6859 NR 57 TC 37 Z9 40 U1 2 U2 12 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD JUN PY 2008 VL 76 IS 3 BP 449 EP 458 DI 10.1037/0022-006X.76.3.449 PG 10 WC Psychology, Clinical SC Psychology GA 307NX UT WOS:000256326700009 PM 18540738 ER PT J AU Frank, D DeBenedetti, AF Volk, RJ Williams, EC Kivlahan, DR Bradley, KA AF Frank, Danielle DeBenedetti, Anna F. Volk, Robert J. Williams, Emily C. Kivlahan, Daniel R. Bradley, Katharine A. TI Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race/ethnic groups SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE alcohol; alcohol misuse; race; ethnicity; screening; diagnostic test ID IDENTIFICATION TEST AUDIT; PRIMARY-CARE PATIENTS; BEHAVIORAL-COUNSELING INTERVENTIONS; RANDOMIZED CONTROLLED TRIAL; US GENERAL-POPULATION; AT-RISK DRINKING; USE DISORDERS; EMERGENCY-ROOM; CONSUMPTION QUESTIONS; UNITED-STATES AB BACKGROUND: The Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) is a brief validated screen for risky drinking and alcohol abuse and dependence (alcohol misuse). However, the AUDIT-C was validated in predominantly White populations, and its performance in different racial/ethnic groups is unclear. OBJECTIVE: To evaluate the validity of the AUDIT-C among primary care patients from the predominant racial/ethnic subgroups within the United States: White, African American, and Hispanic. DESIGN: Cross-sectional interview validation study. PARTICIPANTS: 1,292 outpatients from an academic family practice clinic in Texas (90% of randomly sampled eligible). MEASUREMENTS AND MAIN RESULTS: Race/ethnicity was self-reported. Areas under the receiver operating curve (AuROCs) evaluated overall AUDIT-C performance in the 3 racial/ethnic groups compared to diagnostic interviews for alcohol misuse. AUDIT-C sensitivities and specificities at recommended screening thresholds were compared across racial/ethnic groups. AuROCs were greater than 0.85 in all 3 groups, with no significant differences across racial/ethnic groups in men (P=.43) or women (P=.12). At previously recommended cut points, there were statistically significant differences by race in AUDIT-C sensitivities but not specificities. In women, the sensitivity was higher in Hispanic (85%) than in African-American (67%; P=.03) or White (70%; P=.04) women. In men, the sensitivity was higher in White (95%) than in African-American men (76%; P=.01), with no significant difference from Hispanic men (85%; P=.11). CONCLUSIONS: The overall performance of the AUDIT-C was excellent in all 3 racial/ethnic groups as reflected by high AuROCs. At recommended cut points, there were significant differences in the AUDIT-C's sensitivity but not in specificity across the 3 racial/ethnic groups. C1 [Frank, Danielle; DeBenedetti, Anna F.; Williams, Emily C.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Biobehav Sci, Seattle, WA 98195 USA. [Volk, Robert J.] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA. [Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Frank, D (reprint author), VA Puget Sound Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM diegop@u.washington.edu OI Volk, Robert/0000-0001-8811-5854 FU NIAAA NIH HHS [R21 AA014672, R21AA14672] NR 42 TC 84 Z9 85 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2008 VL 23 IS 6 BP 781 EP 787 DI 10.1007/s11606-008-0594-0 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 303FX UT WOS:000256027500012 PM 18421511 ER PT J AU Fung, CH Setodji, CM Kung, FY Keesey, J Asch, SM Adams, J McGlynn, EA AF Fung, Constance H. Setodji, Claude M. Kung, Fuan-Yue Keesey, Joan Asch, Steven M. Adams, John McGlynn, Elizabeth A. TI The relationship between multimorbidity and patients' ratings of communication SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE multimorbidity; pay-for-performance; patient-physician communication ID QUALITY-OF-CARE; NEW-YORK-STATE; HEALTH-CARE; PERFORMANCE; COMORBIDITY; PREFERENCES; PREVALENCE; PHYSICIANS; OUTCOMES; ADULTS AB BACKGROUND: The growing interest in pay-for-performance and other quality improvement programs has generated concerns about potential performance measurement penalties for providers who care for more complex patients, such as patients with more chronic conditions. Few data are available on how multimorbidity affects common performance metrics. OBJECTIVE: To examine the relationship between multimorbidity and patients' ratings of communication, a common performance metric. DESIGN: Cross-sectional study SETTING: Nationally representative sample of U.S. residents PARTICIPANTS: A total of 15,709 noninstitutionalized adults living in the United States participated in a telephone interview. MEASUREMENTS: We used 2 different measures of multimorbidity: 1) "individual conditions" approach disregards similarities/concordance among chronic conditions and 2) "condition-groups" approach considers similarities/concordance among conditions. We used a composite measure of patients' ratings of patient-physician communication. RESULTS: A higher number of individual conditions is associated with lower ratings of communication, although the magnitude of the relationship is small (adjusted average communication scores: 0 conditions, 12.20; 1-2 conditions, 12.06; 3+ conditions, 11.90; scale range 5 = worst, 15 = best). This relationship remains statistically significant when concordant relationships among conditions are considered (0 condition groups 12.19; 1-2 condition groups 12.03; 3+ condition groups 11.94). CONCLUSIONS: In our nationally representative sample, patients with more chronic conditions gave their doctors modestly lower patient-doctor communication scores than their healthier counterparts. Accounting for concordance among conditions does not widen the difference in communication scores. Concerns about performance measurement penalty related to patient complexity cannot be entirely addressed by adjusting for multimorbidity. Future studies should focus on other aspects of clinical complexity (e.g., severity, specific combinations of conditions). C1 [Fung, Constance H.] Zynx Hlth Inc, Los Angeles, CA USA. [Setodji, Claude M.; Kung, Fuan-Yue; Keesey, Joan; Asch, Steven M.; Adams, John; McGlynn, Elizabeth A.] RAND Corp, Santa Monica, CA USA. [Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Fung, CH (reprint author), 10880 Wilshire Blvd,Suite 300, Los Angeles, CA 90024 USA. EM cfung@zynx.com NR 47 TC 25 Z9 25 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2008 VL 23 IS 6 BP 788 EP 793 DI 10.1007/s11606-008-0602-4 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 303FX UT WOS:000256027500013 PM 18427902 ER PT J AU Anaya, HD Hoang, TY Golden, JF Goetz, MB Gifford, A Bowman, C Osborn, T Owens, DK Sanders, GD Asch, SM AF Anaya, Henry D. Hoang, Tuyen Golden, Joya F. Goetz, Matthew Bidwell Gifford, Allen Bowman, Candice Osborn, Teresa Owens, Douglas K. Sanders, Gillian D. Asch, Steven M. TI Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE nurse-initiated HIV screening; HIV rapid testing; streamlined counseling ID RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; PRIMARY-CARE; RISK; PREFERENCES; PREVENTION; PHYSICIANS; EFFICACY; BARRIERS; DISEASE AB BACKGROUND: HIV testing is cost-effective in unselected general medical populations, yet testing rates among those at risk remain low, even among those with regular primary care. HIV rapid testing is effective in many healthcare settings, but scant research has been done within primary care settings or within the US Department of Veteran's Affairs Healthcare System. OBJECTIVES: We evaluated three methods proven effective in other diseases/settings: nurse standing orders for testing, streamlined counseling, and HIV rapid testing. DESIGN: Randomized, controlled trial with three intervention models: model A (traditional counseling/testing); model B (nurse-initiated screening, traditional counseling/testing); model C (nurse-initiated screening, streamlined counseling/rapid testing). PARTICIPANTS: Two hundred fifty-one patients with primary/urgent care appointments in two VA clinics in the same city (one large urban hospital, one freestanding outpatient clinic in a high HIV prevalence area). MEASUREMENTS: Rates of HIV testing and receipt of results; sexual risk reduction; HIV knowledge improvement. RESULTS: Testing rates were 40.2% (model A), 84.5% (model B), and 89.3% (model C; p=<.01). Test result receipt rates were 14.6% (model A), 31.0% (model B), 79.8% (model C; all p=<.01). Sexual risk reduction and knowledge improvement did not differ significantly between counseling methods. CONCLUSIONS: Streamlined counseling with rapid testing significantly increased testing and receipt rates over current practice without changes in risk behavior or posttest knowledge. Increased testing and receipt of results could lead to earlier disease identification, increased treatment, and reduced morbidity/mortality. Policymakers should consider streamlined counseling/rapid testing when implementing routine HIV testing into primary/urgent care. C1 [Anaya, Henry D.; Hoang, Tuyen; Golden, Joya F.; Goetz, Matthew Bidwell; Gifford, Allen; Bowman, Candice; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, VA Qual Enhancement Res Initiat HIV & Hepatitis Q, Los Angeles, CA 90073 USA. [Anaya, Henry D.; Hoang, Tuyen; Golden, Joya F.; Goetz, Matthew Bidwell; Gifford, Allen; Bowman, Candice; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles Hlth Serv Res & Dev HSRD C, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90073 USA. [Bowman, Candice] VA San Diego Healthcare Syst, Ctr Res Patient Oriented Care, La Jolla, CA USA. [Asch, Steven M.] Univ Calif Los Angeles, Sch Med, Div Gen Internal Med & Hlth, Serv Res GIM & HSR, Los Angeles, CA USA. [Asch, Steven M.] RAND Hlth, Santa Monica, CA USA. [Gifford, Allen] VA New England Healthcare Syst, Bedford, England. [Osborn, Teresa] VA VISN22, Long Beach, CA USA. [Owens, Douglas K.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Sanders, Gillian D.] Duke Univ, Sch Med, Durham, NC USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA. RP Anaya, HD (reprint author), VA Greater Los Angeles Healthcare Syst, VA Qual Enhancement Res Initiat HIV & Hepatitis Q, 11301 Wilshire Blvd 111G, Los Angeles, CA 90073 USA. EM henry.anaya@va.gov OI Goetz, Matthew/0000-0003-4542-992X NR 39 TC 52 Z9 53 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2008 VL 23 IS 6 BP 800 EP 807 DI 10.1007/s11606-008-0617-x PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 303FX UT WOS:000256027500015 PM 18421508 ER PT J AU Bent, S AF Bent, Stephen TI Herbal medicine in the United States: Review of efficacy, safety, and regulation - Grand rounds at University of California, San Francisco Medical Center SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE herbal medicine; efficacy; safety; regulation ID RANDOMIZED CLINICAL-TRIALS; ST-JOHNS-WORT; GINKGO-BILOBA; WEIGHT-LOSS; ECHINACEA-ANGUSTIFOLIA; RHINOVIRUS INFECTIONS; DIETARY-SUPPLEMENTS; CITRUS-AURANTIUM; METAANALYSIS; PRODUCTS AB INTRODUCTION: Herbal products have gained increasing popularity in the last decade, and are now used by approximately 20% of the population. Herbal products are complex mixtures of organic chemicals that may come from any raw or processed part of a plant, including leaves, stems, flowers, roots, and seeds. Under the current law, herbs are defined as dietary supplements, and manufacturers can therefore produce, sell, and market herbs without first demonstrating safety and efficacy, as is required for pharmaceutical drugs. Although herbs are often perceived as "natural" and therefore safe, many different side effects have been reported owing to active ingredients, contaminants, or interactions with drugs. RESULTS: Unfortunately, there is limited scientific evidence to establish the safety and efficacy of most herbal products. Of the top 10 herbs, 5 (ginkgo, garlic, St. John's wort, soy, and kava) have scientific evidence suggesting efficacy, but concerns over safety and a consideration of other medical therapies may temper the decision to use these products. CONCLUSIONS: Herbal products are not likely to become an important alternative to standard medical therapies unless there are changes to the regulation, standardization, and funding for research of these products. C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Bent, Stephen] Univ Calif San Francisco, Osher Ctr Intergrat Med, San Francisco, CA 94143 USA. [Bent, Stephen] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Bent, Stephen] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Bent, S (reprint author), San Francisco VA Med Ctr, 111-A1,4150 Clement St, San Francisco, CA 94121 USA. EM Stephen.Bent@ucsf.edu FU NCCIH NIH HHS [K08 AT001338]; PHS HHS [1 K08 ATO1338-01] NR 57 TC 169 Z9 176 U1 5 U2 27 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2008 VL 23 IS 6 BP 854 EP 859 DI 10.1007/s11606-008-0632-y PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 303FX UT WOS:000256027500024 PM 18415652 ER PT J AU Whittle, J Good, CB AF Whittle, Jeff Good, Chester B. TI Prescription drug samples: Making decisions with imperfect data SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID COSTS C1 [Whittle, Jeff] Clement J Zablocki VA Med Ctr, Milwaukee, WI 53295 USA. [Whittle, Jeff] Med Coll Wisconsin, Dept Med, Div Gen Internal Med, Milwaukee, WI 53226 USA. [Good, Chester B.] VA Pittsburgh Healthcare Syst, Gen Internal Med Sect, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Whittle, J (reprint author), Clement J Zablocki VA Med Ctr, Mailstop 00 PC,5000 W Natl Ave, Milwaukee, WI 53295 USA. EM jeffrey.whittle@va.gov NR 13 TC 3 Z9 3 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2008 VL 23 IS 6 BP 890 EP 892 DI 10.1007/s11606-008-0642-9 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 303FX UT WOS:000256027500031 PM 18461406 ER PT J AU Oehlberg, K Barg, FK Brown, GK Taraborelli, D Stern, MB Weintraub, D AF Oehlberg, Katherine Barg, Frances K. Brown, Gregory K. Taraborelli, Donna Stern, Matthew B. Weintraub, Daniel TI Attitudes regarding the etiology and treatment of depression in Parkinson's disease: A qualitative study SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE Parkinson's disease; depression; antidepressant; psychotherapy; qualitative interview ID ANTIDEPRESSANT; PREDICTORS; SYMPTOMS; LIFE AB Depression in Parkinson's disease (dPD) remains under recognized and under treated. As patients' beliefs may impact the reporting and treatment of depression, this study assessed the opinions of 38 dPD patients, approximately half with a self-reported poor response to antidepressant treatment, regarding the etiology and treatment of their depression using a semi-structured, audio-taped, qualitative interview. About half of the participants listed PD itself as a primary cause for their depressive symptoms, with most in this group citing psychosocial factors rather than PD-related neurobiological factors. Antidepressant therapy, psychotherapy, and self-initiated approaches were noted as preferred treatments for dPD. Many had concerns about antidepressant therapy, listing side-effects and medication dependency most frequently. About half raised concerns about psychotherapy with trust/discomfort, stigma, and transportation issues most frequently mentioned. This preliminary study suggests that many PD patients with clinically significant depressive symptoms attribute their depression to psychosocial factors and endorse nonpharmacologic treatment approaches. C1 [Oehlberg, Katherine; Brown, Gregory K.; Taraborelli, Donna; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Barg, Frances K.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Barg, Frances K.] Univ Penn, Sch Arts & Sci, Dept Anthropol, Philadelphia, PA 19104 USA. [Stern, Matthew B.; Weintraub, Daniel] Philadelphia VA Med Ctr, PADRECC, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia VA Med Ctr, MIRECC, Philadelphia, PA USA. RP Weintraub, D (reprint author), Univ Penn, Sect Geriatr Psychiat, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu FU NIMH NIH HHS [K23 MH067894, K23 MH067894-01A1, K23 MH067894-05, K23MH067894] NR 20 TC 22 Z9 22 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD JUN PY 2008 VL 21 IS 2 BP 123 EP 132 DI 10.1177/0891988708316862 PG 10 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 303YS UT WOS:000256077800005 PM 18474721 ER PT J AU Spira, AP Friedman, L Aulakh, JS Lee, T Sheikh, JI Yesavage, JA AF Spira, Adam P. Friedman, Leah Aulakh, Jasdeep S. Lee, Tina Sheikh, Javaid I. Yesavage, Jerome A. TI Subclinical anxiety symptoms, sleep, and daytime dysfunction in older adults with primary insomnia SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE anxiety; depression; insomnia; actigraphy ID DSM-IV; PREVALENCE; DISORDERS AB Both insomnia complaints and anxiety disorders are common in older adults, and are associated with poor daytime functioning. The present study investigated whether subclinical levels of anxiety were associated with sleep disturbance and daytime functioning in older adults who met diagnostic criteria for primary insomnia, and therefore did not meet criteria for depression or an anxiety disorder. After adjustment for depressive symptoms, elevated state anxiety was associated with higher levels of wake after sleep onset (measured by both actigraphy and sleep log) and shorter sleep onset latency (measured by sleep log). Higher levels of trait anxiety were associated with greater wake after sleep onset (measured by sleep log). Elevated state and trait anxiety were associated with worse social functioning, and higher levels of trait anxiety were associated with worse role functioning. Thus, subclinical anxiety symptoms may be an important target for clinical intervention to improve sleep and functioning in older adults with primary insomnia. C1 [Spira, Adam P.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA. [Spira, Adam P.] San Francisco VA Med Ctr, San Francisco, CA USA. [Friedman, Leah; Aulakh, Jasdeep S.; Sheikh, Javaid I.; Yesavage, Jerome A.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Aulakh, Jasdeep S.; Lee, Tina; Sheikh, Javaid I.; Yesavage, Jerome A.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Spira, AP (reprint author), 4150 Clement St,181-G, San Francisco, CA USA. EM adam.spira@ucsf.edu FU NIA NIH HHS [AG 12914] NR 19 TC 12 Z9 13 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD JUN PY 2008 VL 21 IS 2 BP 149 EP 153 DI 10.1177/0891988707317120 PG 5 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 303YS UT WOS:000256077800008 PM 18474724 ER PT J AU Kaplan, DE Ikeda, F Li, Y Nakamoto, N Ganesan, S Valiga, ME Nunes, FA Reddy, KR Chang, KM AF Kaplan, David E. Ikeda, Fusao Li, Yun Nakamoto, Nobuhiro Ganesan, Sutharsan Valiga, Mary E. Nunes, Frederick A. Reddy, K. Rajender Chang, Kyong-Mi TI Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis SO JOURNAL OF HEPATOLOGY LA English DT Article DE hepatitis C; interleukin-10; interferon-gamma; regulatory T-cells; CD8(+) T-cells; IL-10; HCV ID INTERFERON-ALPHA; IL-10 PRODUCTION; DENDRITIC CELLS; RIBAVIRIN TREATMENT; IMMUNE-RESPONSES; VIRAL CLEARANCE; IFN-ALPHA; IN-VIVO; CD4(+); LYMPHOCYTES AB Background/Aims: Interleukin-10 (IL-10) has been ascribed pro-viral but anti-fibrotic properties in chronic hepatitis C virus (HCV) infection. In this study, we examined the role of HCV-specific T-cell IL-10 response in patients with acute and chronic HCV infection. Methods: Peripheral HCV-specific T-cell IL-10 and IFN gamma responses were measured in cytokine Elispot assay using overlapping HCV-derived peptides in patients with chronic (n = 61), resolved (n = 15) and acute (n = 8) hepatitis C, looking for their onset, quantity, breadth and durability relative to clinical and virological outcomes. The source and effect of HCV-specific IL-10 response were determined in depletion and IL-10 neutralization experiments. Results: Both HCV-specific IL-10 and IFN gamma responses were detected early within 1-2 months of acute clinical hepatitis C. However, only HCV-specific IL-10 response correlated with elevated liver enzymes, increased viremia and suppressed HCV-specific CD4(+) T-cell proliferation in acute infection. While these associations were lost in established chronic infection, HCV-specific IL-10 responses were increased in patients without cirrhosis while IL-10 blockade enhanced antiviral effector IFN gamma responses. Conclusions:HCV-specific IL-10 Tr1 responses may play a dual role in HCV infection, dampening effector T-cells to promote viral persistence in acute infection but also protecting against progressive fibrosis in chronic infection. (c) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 [Kaplan, David E.; Chang, Kyong-Mi] Philadelphia VA Med Ctr, Res Sect, Philadelphia, PA 19104 USA. [Kaplan, David E.; Ikeda, Fusao; Li, Yun; Nakamoto, Nobuhiro; Ganesan, Sutharsan; Valiga, Mary E.; Reddy, K. Rajender; Chang, Kyong-Mi] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. [Nunes, Frederick A.] Penn Hosp, Philadelphia, PA 19106 USA. RP Kaplan, DE (reprint author), Philadelphia VA Med Ctr, Res Sect, Res A216,Woodland Ave, Philadelphia, PA 19104 USA. EM dakaplan@mail.med.upenn.edu OI Kaplan, David E./0000-0002-3839-336X FU NCRR NIH HHS [K12 RR017625, K12 RR017625-01, K12-RR-017625, M01 RR000040, M01-RR00040]; NIAAA NIH HHS [R01 AA012849-01, R01 AA012849, R01 AA012849-02, R01 AA012849-03, R01 AA012849-04, R01 AA012849-05, R01-AA-12849]; NIAID NIH HHS [R01 AI047519, R01 AI047519-01, R01 AI047519-02, R01 AI047519-03, R01 AI047519-04, R01 AI047519-05, R01 AI047519-06, R01 AI047519-07, R01 AI047519-08, R01 AI047519-09, R01 AI047519-10, R01-AI-47519]; NIDDK NIH HHS [L30 DK069063, L30 DK069063-01, P30 DK050306, P30 DK050306-06, P30DK50306, T32 DK 07066, T32 DK007066, T32 DK007066-25] NR 61 TC 55 Z9 56 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD JUN PY 2008 VL 48 IS 6 BP 903 EP 913 DI 10.1016/j.jhep.2008.01.030 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 312PK UT WOS:000256683100004 PM 18384906 ER PT J AU Oberley, TD Swanlund, JM Zhang, HJ Kregel, KC AF Oberley, Terry D. Swanlund, Jamie M. Zhang, Hannah J. Kregel, Kevin C. TI Aging results in increased autophagy of mitochondria and protein nitration in rat hepatocytes following heat stress SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE mitochondria; 3-nitrotyrosine; autophagy; heat stress; oxidative stress ID OXIDATIVE STRESS; NITRIC-OXIDE; TYROSINE NITRATION; SHOCK PROTEINS; LIVER-INJURY; CELL-DEATH; EXPRESSION; OXIDANTS; DISEASES; DAMAGE AB The natural breakdown of cells, tissues, and organ systems is a significant consequence of aging and is at least partially caused by a decreased ability to tolerate environmental stressors. Based on quantitative ultrastructural analysis using transmission electron microscopy and computer imaging, we show significant differences in hepatocyte morphology between young and old rats during a 48-hr recovery period following a 2-day heat stress protocol. Mitochondrial injury was greater overall in old compared with young rats. Autophagy was observed in both young and old rats, with autophagy greater overall in old compared with young hepatocytes. Lipid peroxidation and protein nitration were evaluated by localization and quantification of 4-hydroxy-2-nonenal (4-HNE)-modified protein adducts and 3-nitrotyrosine (3-NT) levels, respectively. Levels of 3-NT but not 4-HNE-protein adducts were significantly elevated in hepatocytes of old rats in comparison with young at 90 min after heat stress, suggesting a major role for reactive nitrogen species in the pathology observed at this time point. These results show a differential response of hepatocyte mitochondria to heat stress with aging, as well as greater levels of both autophagic and nitrative damage in old vs young hepatocytes. This manuscript contains online supplemental material at http://www.jhc.org. Please visit this article online to view these materials. C1 [Oberley, Terry D.; Swanlund, Jamie M.] William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Madison, WI 53705 USA. [Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. [Zhang, Hannah J.; Kregel, Kevin C.] Univ Iowa, Dept Radiat Oncol, Radiat Biol Program, Iowa City, IA USA. [Zhang, Hannah J.; Kregel, Kevin C.] Univ Iowa, Dept Integrat Physiol & Free Rad, Iowa City, IA USA. RP Oberley, TD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Room A-35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@wisc.edu; kevin-kregel@uiowa.edu FU NIA NIH HHS [R01 AG012350, AG012350] NR 51 TC 30 Z9 31 U1 0 U2 4 PU HISTOCHEMICAL SOC INC PI SEATTLE PA UNIV WASHINGTON, DEPT BIOSTRUCTURE, BOX 357420, SEATTLE, WA 98195 USA SN 0022-1554 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD JUN PY 2008 VL 56 IS 6 BP 615 EP 627 DI 10.1369/jhc.2008.950873 PG 13 WC Cell Biology SC Cell Biology GA 301IT UT WOS:000255890300010 PM 18379016 ER PT J AU Eggena, P AF Eggena, P. TI Is hepatic intracellular angiotensin II of physiological significance? SO JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension CY JUN 14-19, 2008 CL Berlin, GERMANY SP Euorpean Soc Hyperten, Deutsch Hochdruckliga C1 [Eggena, P.] Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD JUN PY 2008 VL 26 SU 1 BP S511 EP S511 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 319WZ UT WOS:000257197003486 ER PT J AU Nyby, M Abedi, K Smutko, V Ibrahim, E Wijesuriya, J Tuck, M AF Nyby, M. Abedi, K. Smutko, V. Ibrahim, E. Wijesuriya, J. Tuck, M. TI Rosiglitazone increases expression of oxidative stress and inflammation associated genes in hearts from fructose-fed rats SO JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension CY JUN 14-19, 2008 CL Berlin, GERMANY SP Euorpean Soc Hyperten, Deutsch Hochdruckliga C1 [Nyby, M.; Tuck, M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD JUN PY 2008 VL 26 SU 1 BP S317 EP S317 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 319WZ UT WOS:000257197002211 ER PT J AU Aqel, RA Zoghbi, GJ Hage, FG Dell'Italia, L AF Aqel, Raed A. Zoghbi, Gilbert J. Hage, Fadi G. Dell'Italia, Louis TI Three-Dimensional Balloon Catheter Sizing Identifies Significant Underdeployed Stents Using Conventional Methods in Renal Artery Interventions SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Article AB Background. Renal artery stent restenosis remains a significant impediment that in part is attributed to suboptimal stent deployment. We tested the hypothesis that optimal stent deployment during renal artery interventions can be achieved using the Metricath (MC) system, a balloon-catheter sizing device. Methods. The MC low-pressure balloon derives accurate vessel lumen dimensions from the three-dimensional reconstruction of volume of fluid and pressure within the inflated balloon. We systematically compared the Anal visual assessment of renal artery intervention with a subsequent MC minimal lumen diameter (MLD) in patients undergoing renal artery stenting. Results. Sixteen patients underwent angioplasry and stenting of 20 renal artery lesions. MC guidance resulted in adjunctive intervention in 90% of lesions, increasing MLD from 4.40 +/- 0.77 mm before to 5.17 +/- 0.82 mm (p < 0.001) after adjunctive intervention. The MC MLD to the angiographic reference vessel diameter improved from 77.4 +/- 15.2% to 91.2 +/- 17.5% (p < 0.001), and the MC MLD to the nominal stent diameter improved from 76.2 +/- 7.1% to 90.0 +/- 9.4% (p < 0.001) after adjunctive intervention. Stent expansion was more pronounced at its distal site compared to the lesion site where the postinterventional distal stent MLD was 5.52 +/- 0.93 mm (p = 0.23), and the lesion MLD was 5.17 0.82 (p = 0.001) compared to a nominal stent diameter of 5.78 +/- 0.88 mm. An MC MLD-to-nominal scent diameter ratio >= 85% occurred in 10% of lesions before adjunctive dilatation and in 65% of lesions after adjunctive balloon post dilatation. Conclusions. MC guidance during renal interventions revealed a large proportion of underdeployed stents that were further optimized by adjunctive intervention. C1 [Aqel, Raed A.; Zoghbi, Gilbert J.; Dell'Italia, Louis] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Aqel, Raed A.; Zoghbi, Gilbert J.; Hage, Fadi G.; Dell'Italia, Louis] Univ Alabama, Birmingham, AL USA. RP Aqel, RA (reprint author), BDB 383,1530 3rd Ave S, Birmingham, AL 35294 USA. EM raed.aqel@med.va.gov OI Hage, Fadi/0000-0002-1397-4942 FU Angiometrx Inc FX This study was funded by a grant from Angiometrx Inc. NR 26 TC 1 Z9 1 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD JUN PY 2008 VL 20 IS 6 BP 270 EP 276 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V14MQ UT WOS:000207738900005 PM 18523318 ER PT J AU Ebrahimi, R Saleh, J Toggart, E Shah, AP Azmoon, S Babaei, H Lee, J Smith, R Movahed, MR Rubin, SA AF Ebrahimi, Ramin Saleh, Jahandar Toggart, Edward Shah, Atman P. Azmoon, Shahdad Babaei, Hormoz Lee, James Smith, Ryan Movahed, M. Reza Rubin, Stanley A. TI Effect of Preprocedural Statin Use on Procedural Myocardial Infarction and Major Cardiac Adverse Events in Percutaneous Coronary Intervention: A Meta-Analysis SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Review ID AVERAGE CHOLESTEROL LEVELS; HEART-DISEASE; PRIMARY PREVENTION; RANDOMIZED-TRIAL; PRAVASTATIN; THERAPY; ATORVASTATIN; INFLAMMATION; INHIBITORS; SURVIVAL AB Background. Multiple primary and secondary prevention trials demonstrate significant reduction in adverse cardiovascular outcomes in patients with, or at risk of, coronary artery disease as a result of swirl therapy. This study was conducted to determine whether statin use prior to elective percutaneous coronary intervention (PCI) is associated with lower procedural myocardial infarction (MI) and major adverse cardiovascular events (MACE) in the form of a meta-analysis. Methods. Trials were eligible for inclusion if they included patients who received a statin prior to PCI and if appropriate documentation of procedural MI was performed. Studies that included acute coronary syndrome patients were excluded. For each trial, the results immediately post intervention and at the longest follow up (up to 12 months) were extracted and analyzed based on an intention-to-treat principle. Six trials involving 2,996 subjects met the inclusion criteria for periprocedural MI and were included in the analysis. Three trials involving 6,723 subjects had appropriate follow up and were analyzed for MACE (the combined endpoint of death, nonfatal MI or target vessel revascularization) up to 12 months after PCI. Results. When the 6 trials included in the main analysis were combined, the summary effect of statins on reducing procedural MI was -5.44% (95% CI -8.2% to -2.7% [p < 0.0001]). There was no evidence of heterogeneity between trials (p = 0.66). The relative risk reduction was 59.3% (9.17% vs. 3.73%; p < 0.001). Sensitivity analysis did not alter this finding. The MACE rates were 19.5% and 15.5% in the control and statin groups, respectively. The overall MACE risk difference was -4.0%, (95% CI -11.4% to +3.4% [p = 0.2900]). The corresponding overall relative risk reduction was 20.5%. C1 [Ebrahimi, Ramin; Saleh, Jahandar; Toggart, Edward; Babaei, Hormoz; Rubin, Stanley A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. [Ebrahimi, Ramin; Toggart, Edward; Shah, Atman P.; Azmoon, Shahdad; Lee, James; Smith, Ryan; Rubin, Stanley A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Movahed, M. Reza] Univ Arizona, Coll Med, Tucson, AZ USA. RP Ebrahimi, R (reprint author), VA Med Ctr Greater Los Angeles Healthcare Syst, Div Cardiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ebrahimi@ucla.edu NR 20 TC 14 Z9 15 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 EI 1557-2501 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD JUN PY 2008 VL 20 IS 6 BP 292 EP 295 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V14MQ UT WOS:000207738900010 PM 18523323 ER PT J AU Moghadam-Kia, S Gaines, E Costner, M Rose, M Okawa, J Werth, V AF Moghadam-Kia, S. Gaines, E. Costner, M. Rose, M. Okawa, J. Werth, V. TI Initial analysis of a collaborative web-based database for skin manifestations of lupus erythematosus: 102 prospectively enrolled patients SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Academy-of-Dermatology CY FEB 01-05, 2008 CL San Antonio, TX SP Amer Acad Dermatol C1 [Moghadam-Kia, S.; Gaines, E.; Rose, M.; Okawa, J.; Werth, V.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Costner, M.] Univ Texas SW Med Ctr Dallas, Dallas, TX USA. [Werth, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JUN PY 2008 VL 128 IS 6 MA 2 BP 1606 EP 1606 PG 1 WC Dermatology SC Dermatology GA 302FG UT WOS:000255953600047 ER PT J AU Osorio, Y Bonilla, DL Peniche, AG Melby, PC Travi, BL AF Osorio, Yaneth Bonilla, Diana L. Peniche, Alex G. Melby, Peter C. Travi, Bruno L. TI Pregnancy enhances the innate immune response in experimental cutaneous leishmaniasis through hormone-modulated nitric oxide production SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE leishmania; hamster; estrogen ID SYNTHASE GENE-EXPRESSION; VISCERAL LEISHMANIASIS; NEUTROPHIL GRANULOCYTES; MACROPHAGE FUNCTION; MAJOR INFECTION; MESSENGER-RNA; CUTTING EDGE; ESTROGEN; HAMSTER; GAMMA AB The maintenance of host defense during pregnancy may depend on heightened innate immunity. We evaluated the immune response of pregnant hamsters during early infection with Leishmania (Viannia) panamensis, a cause of American cutaneous leishmaniasis. At 7 days post-infection, pregnant animals showed a lower parasite burden compared with nonpregnant controls at the cutaneous infection site (P = 0.0098) and draining lymph node (P = 0.02). Resident peritoneal macrophages and neutrophils from pregnant animals had enhanced Leishmania killing capacity compared with nonpregnant controls (P = 0.018 each). This enhanced resistance during pregnancy was associated with increased expression of inducible NO synthase (iNOS) mRNA in lymph node cells (P = 0.02) and higher NO production by neutrophils (P = 0.0001). Macrophages from nonpregnant hamsters infected with L. panamensis released high amounts of NO upon estrogen exposure (P = 0.05), and addition of the iNOS inhibitor L-N6-(1-iminoethyl) lysine blocked the induction of NO production (P = 0.02). Infected, nonpregnant females treated with estrogen showed a higher percentage of cells producing NO at the infection site than controls (P = 0.001), which correlated with lower parasite burdens (P = 0.036). Cultured macrophages or neutrophils from estrogen-treated hamsters showed significantly increased NO production and Leishmania killing compared with untreated controls. iNOS was identified as the likely source of estrogen-induced NO in primed and naive macrophages, as increased transcription was evident by real-time PCR. Thus, the innate defense against Leishmania infection is heightened during pregnancy, at least in part as a result of estrogen-mediated up-regulation of iNOS expression and NO production. C1 [Osorio, Yaneth; Melby, Peter C.; Travi, Bruno L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Osorio, Yaneth; Bonilla, Diana L.; Peniche, Alex G.; Travi, Bruno L.] Ctr Int Entrenamiento & Invest Med CIDEIM, Cali, Colombia. [Osorio, Yaneth; Melby, Peter C.; Travi, Bruno L.] S Texas Vet Hlth Care System, Res Serv, Dept Vet Affairs Med Ctr, San Antonio, TX USA. RP Travi, BL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,Mailcode 7881, San Antonio, TX 78229 USA. EM travi@uthscsa.edu FU NIAID NIH HHS [AI 061624, R01 AI061624] NR 51 TC 22 Z9 23 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD JUN 1 PY 2008 VL 83 IS 6 BP 1413 EP 1422 DI 10.1189/jlb.0207130 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 331NV UT WOS:000258019800014 PM 18347075 ER PT J AU Ordway, D Henao-Tamayo, M Smith, E Shanley, C Harton, M Troudt, J Bai, XY Basaraba, RJ Orme, IM Chan, ED AF Ordway, Diane Henao-Tamayo, Marcela Smith, Erin Shanley, Crystal Harton, Marisa Troudt, JoLynn Bai, Xiyuan Basaraba, Randall J. Orme, Ian M. Chan, Edward D. TI Animal model of Mycobacterium abscessus lung infection SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE T cells; dendritic cells; macrophages; cytokines ID RAPIDLY GROWING MYCOBACTERIA; DENDRITIC CELLS; IMMUNE-RESPONSE; TUBERCULOSIS INFECTION; GAMMA-INTERFERON; HOST-DEFENSE; T-CELLS; LEPTIN; MICE; PNEUMONIA AB Chronic lung disease as a result of Mycobacterium abscessus is an emerging infection in the United States. We characterized the lung immune responses in mice and guinea pigs infected with M. abscessus. C57BL/6 and leptin-deficient ob/ob mice challenged with a low-dose aerosol (LDA) of M. abscessus did not develop an infection. However, when challenged with a high-dose aerosol (HDA), C57BL/6 and ob/ob mice developed an established infection and a pulmonary immune response consisting of an early influx of IFN-gamma+ CD4+ T cells; this immune response preceded the successful clearance of M. abscessus in both strains of mice, although mycobacterial elimination was delayed in the ob/ob mice. Infected guinea pigs showed an increased influx of lymphocytes into the lungs with bacterial clearance by Day 60. In contrast to the C57BL/6 and ob/ob mice and guinea pigs, IFN-gamma knockout (GKO) mice challenged with a LDA or HDA of M. abscessus showed a progressive lung infection despite a robust influx of T cells, macrophages, and dendritic cells, culminating in extensive lung consolidation. Furthermore, with HDA challenge of the GKO mice, emergence of IL-4- and IL-10-producing CD4+ and CD8+ T cells was seen in the lungs. In conclusion, IFN-gamma is critically important in the host defense against M. abscessus. As the number of effective drugs against M. abscessus is limited, the GKO mice provide a model for in vivo testing of novel drugs. C1 [Ordway, Diane; Henao-Tamayo, Marcela; Smith, Erin; Shanley, Crystal; Harton, Marisa; Troudt, JoLynn; Basaraba, Randall J.; Orme, Ian M.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA. [Chan, Edward D.] Univ Colorado, Sch Med, Div Pulm Sci & Crit Care Med, Denver, CO USA. [Bai, Xiyuan; Chan, Edward D.] Natl Jewish Med & Res Ctr, Denver, CO USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Ordway, D (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA. EM D.Ordway-Rodriguez@colostate.edu RI Henao-Tamayo, Marcela/D-8189-2017 OI Henao-Tamayo, Marcela/0000-0002-4249-9650 FU NIAID NIH HHS [AI 040091, AI 44072] NR 45 TC 52 Z9 52 U1 0 U2 4 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD JUN 1 PY 2008 VL 83 IS 6 BP 1502 EP 1511 DI 10.1189/jlb.1007696 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 331NV UT WOS:000258019800024 PM 18310351 ER PT J AU Smith, J AF Smith, Jason TI Therapy analysis and evidenced-based treatment guidelines (including review of antiviral medications) SO JOURNAL OF MANAGED CARE PHARMACY LA English DT Article ID CHRONIC HEPATITIS-B; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTION; LAMIVUDINE TREATMENT; TREATMENT ALGORITHM; UNITED-STATES; TENOFOVIR; ADEFOVIR; EFFICACY; SAFETY AB OBJECTIVE: To summarize current treatment options and guidelines for treatment of HBV infection and HIV-HBV co-infection, including a review of the relevant antiviral agents. SUMMARY. Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection have caused large global epidemics, which may overlap because they are transmitted by similar routes, including sex and injection drug use. About 30% of individuals with chronic HBV infection develop cirrhosis, and 5% to 10% develop hepatocellular cancer (HCC). In HBV-HIV co-infection, HIV decreases the rate at which hepatitis B "E" antigen (HBeAg) is lost, increases levels of HBV DNA, and increases the progression to cirrhosis, the number of liver-related complications, and mortality. Three classes of oral antiviral agents for HBV are approved in the United States. L-nucleoside analogs include lamivudine, emtricitabine, and telbivudine. Acyclic adenine phosphonates are adefovir and tenofovir, which is not yet approved for HBV infection. Entecavir is a guanine nucleoside analog. HBV resistance to antiviral agents arises because of HBV's rapid viral production and the high rate of spontaneous mutations. Anti-HBV therapy is also effective in patients with HIV-HBV co-infection. The decision to treat HBV in a patient with HIV-HBV co-infection depends on whether highly active antiretroviral therapy (HAART) for HIV is indicated, the severity of the liver disease, the likelihood of response, and the potential for adverse events. CONCLUSION: Effective treatment of HBV infection is important to reduce risk of cirrhosis, HCC, and death. Treatment of HBV infection in HIV-infected persons should consider the activity of the antiviral agents used against both viruses. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Smith, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111C, Los Angeles, CA 90073 USA. EM jason.smith2@va.gov NR 38 TC 0 Z9 0 U1 0 U2 1 PU ACAD MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 1083-4087 J9 J MANAGE CARE PHARM JI J. Manag. Care Pharm. PD JUN PY 2008 VL 14 IS 5 SU A BP S7 EP S11 PG 5 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA 326TP UT WOS:000257682100002 ER PT J AU Giri, S Khan, M Nath, N Singh, I Singh, AK AF Giri, Shailendra Khan, Mushfiquddin Nath, Narender Singh, Inderjit Singh, Avtar K. TI The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: Implication for Krabbe Disease SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE AMP-activated protein kinase; astrocytes; inflammation; Krabbe disease; oligodendrocyte; psychosine ID ACTIVATED PROTEIN-KINASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GLOBOID-CELL LEUKODYSTROPHY; CENTRAL-NERVOUS-SYSTEM; C6 GLIAL-CELLS; ADIPOCYTE DIFFERENTIATION; TWITCHER MICE; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; INHIBITION; EXPRESSION AB Krabbe disease (KD) is an inherited neurological disorder caused by the deficiency of galactocerebrosidase activity resulting in accumulation of psychosine, which leads to energy depletion, loss of oligodendrocytes, induction of gliosis, and inflammation by astrocytes in CNS. In this study, for the first time, we report the regulation of 'cellular energy switch,'AMP-activated protein kinase (AMPK), by psychosine in oligodendrocytes and astrocytes. Psychosine treatment significantly down-regulated AMPK activity, resulting in increased biosynthesis of lipids including cholesterol and free fatty acid in oligodendrocytes cell line (MO3.13) and primary astrocytes. Pharmacological activator of AMPK, 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuated the psychosine-mediated down-regulation of AMPK and restored altered biosynthesis of lipids. AICAR treatment also down-regulated psychosine induced expression of proinflammatory cytokines and inducible nitric oxide synthase in primary astrocytes. However, AICAR treatment had no effect on psychosine incluced-reactive oxygen species generation, arachidonic acid release, and death of oligodendrocytes; suggesting the specific role of AMPK in regulation of psychosine-mediated inflammatory response of astrocytes but not in cell death of oligodendrocytes. This study delineates an explicit role for AMPK in psychosine induced inflammation in astrocytes without directly affecting the cell death of oligodendrocytes. It also suggests that AMPK activating agents act as anti-inflammatory agents and can hold a therapeutic potential in Krabbe disease/twitcher disease, particularly when used in combination with drugs, which protect oligodendrocyte cell loss, such as sPLA2 inhibitor C1 [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. [Giri, Shailendra; Khan, Mushfiquddin; Nath, Narender; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 516 Darby Childrens Res Inst, Charleston, SC 29425 USA. EM singhi@musc.edu FU NCRR NIH HHS [C06 RR018823]; NINDS NIH HHS [NS-37766, R01 NS040810, NS-22576, R01 NS034741, R01 NS040810-05, R01 NS034741-12, R01 NS037766-10, NS-40810, R37 NS022576, R01 NS037766, NS-34741, R01 NS022576-17, R01 NS022576] NR 56 TC 47 Z9 48 U1 2 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD JUN PY 2008 VL 105 IS 5 BP 1820 EP 1833 DI 10.1111/j.1471-4159.2008.05279.x PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 300OQ UT WOS:000255835000022 PM 18248608 ER PT J AU Sintuu, C Murray, SS Behnam, K Simon, R Jawien, J Silva, JD Duarte, ME Brochmann, EJ AF Sintuu, Chananit Murray, Samuel S. Behnam, Keyvan Simon, Robert Jawien, Janusz Prado Silva, Jose Denison Leite Duarte, Maria Eugenia Brochmann, Elsa J. TI Full-length bovine spp24 [spp24 (24-203)] inhibits BMP-2 induced bone formation SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE bone formation; spp24; bone morphogenetic protein ID MORPHOGENETIC PROTEIN; TRANSGENIC MICE; II RECEPTOR; OSTEOCALCIN; SEQUENCE; BINDING AB Secreted phosphoprotein 24 kDa (spp24) is a bone matrix protein. It contains a TGF-beta receptor II homology 1(TRH1) domain. A cyclic, synthetic 19 amino acid peptide (bone morphogenetic protein binding peptide or BBP) based on the sequence of the TRH1 domain enhances BMP-2 induced osteogenesis. Many observations suggest that different size forms of this protein have very different effects (inhibiting or enhancing) on BMP-2 induced osteogenesis. Using the stable recombinant Met(His)(6)-tagged secretory form of full-length (fl) bovine spp24 [Met(His)(6)-spp24 (residues 24-203)] and transgenic (TG) mice expressing fl bovine spp24 (residues 1-203), we have demonstrated that spp24 inhibits BMP-2 induced bone formation. The effects of Met(His)(6)-spp24 (24-203) were determined in the ectopic bone-forming bioassay in male mice. Implantation of 5 mu g of BMP-2 stimulated bone formation, assessed densitometrically as bone area and mineral content. When Met(His)(6)-spp24 (24-203) was implanted with BMP-2, it elicited a dose-dependent decrease in BMP-2-medicated ectopic bone formation. When added at a 50-fold excess (w/w), Met(His)(6)-spp24 (24-203) completely ablated the effects of BMP-2, while addition of a 10-fold excess had no effect. Constitutive expression of fl bovine spp24 (1-203) under the control of the osteocalcin promoter in TG female mice reduced femoral and vertebral bone mineral density at 3 months of age and reduced femoral BMD at 8 months of age, but had no effects in male mice, which can exhibit less osteocalcin-promoter driven gene transcription than females. Histomorphometric analysis demonstrated that bone volume and trabecular thickness were lower in TG female mice at 3 months of age than in sex- and age-matched wild type (WT) controls. Thus, fl spp24 and its secretory isoform (Met(His)(6)-spp24 [24-203]), which contain a BMP-binding or TRH1 motif, inhibit ectopic bone formation in male mice and adversely affects BMD and histological parameters related to bone mass and formation in female mice expressing the human transgene. Under these conditions, fl spp24 acts as a BMP antagonist in vivo. 2008 Orthopaedic Research Society.* Published by Wiley Periodicals, Inc. C1 [Murray, Samuel S.; Simon, Robert; Jawien, Janusz; Brochmann, Elsa J.] VA Greater Los Angeles Hlthcare Syst, Geriatr Res Educ & Clin Ctr 11 E, Sepulveda, CA 91343 USA. [Sintuu, Chananit] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90024 USA. [Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Behnam, Keyvan] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90024 USA. [Prado Silva, Jose Denison] Univ Fed Alagoas, Dept Histol, BR-29222222 Maceio, AL, Brazil. [Leite Duarte, Maria Eugenia] Natl Inst Traumatol & Orthopaed, BR-20230020 Rio De Janeiro, Brazil. RP Murray, SS (reprint author), VA Greater Los Angeles Hlthcare Syst, Geriatr Res Educ & Clin Ctr 11 E, 16111 Plummer St, Sepulveda, CA 91343 USA. EM samuel.murray@med.va.gov FU NIAMS NIH HHS [5R21AR53259] NR 13 TC 19 Z9 20 U1 0 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD JUN PY 2008 VL 26 IS 6 BP 753 EP 758 DI 10.1002/jor.20580 PG 6 WC Orthopedics SC Orthopedics GA 304FJ UT WOS:000256095100003 PM 18253966 ER PT J AU Hu, HM Zielinska-Kwiatkowska, A Munro, K Wilcox, J Wu, DY Yang, L Chansky, HA AF Hu, Hsien-Ming Zielinska-Kwiatkowska, Anna Munro, Karen Wilcox, Jason Wu, Daniel Y. Yang, Liu Chansky, Howard A. TI EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE Ewing's sarcoma; EWS/FLI1; retinoblastoma; senescence; cyclin D1 ID ONCOGENIC FUSION PROTEIN; DNA-BINDING; CYCLIN D1; GROWTH; GENE; EWS-FLI1; TRANSLOCATION; TRANSFORMATION; SUFFICIENT; FIBROBLAST AB Ewing's Family Tumors (EFTs) most commonly harbor a specific t(11;22) translocation that generates the EWS/FLI1 fusion protein responsible for malignant transformation. Many potential downstream targets of EWS/FLI1 have been identified but a detailed mechanism by which the fusion protein brings about transformation remains unknown. In this report, we show that depletion of EWS/FLI1 in Ewing's cell lines results in a senescence phenotype, a marked increase in expression of the G1/S regulatory proteins p27(kip1) and p57(kip2), and a significant decrease in cyclin D1 and CDK2. We also demonstrate for the first time, to our knowledge, that knockdown of EWS/FLI1 leads to hypophosphorylation and functional activation of the retinoblastoma (pRb) family of proteins. Consistent with activation of the pRb proteins, E2F-responsive genes such as cyclin A are repressed in EWS/FLI1-depleted cells. Together, these results support the role of EWS/LI1 as an inhibitor of cellular senescence and implicate the retinoblastoma family of proteins as key mediators of this inhibition. (C) 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. C1 [Hu, Hsien-Ming; Zielinska-Kwiatkowska, Anna; Munro, Karen; Wilcox, Jason; Yang, Liu; Chansky, Howard A.] Univ Washington, Dept Orthopaed & Sports Med, Sch Med, Seattle, WA 98108 USA. [Wu, Daniel Y.] Univ Washington, Dept Med Oncol, Sch Med, Seattle, WA 98195 USA. [Wu, Daniel Y.; Chansky, Howard A.] VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. RP Chansky, HA (reprint author), Univ Washington, Dept Orthopaed & Sports Med, Sch Med, 1660 S Columbian Way,ORT112, Seattle, WA 98108 USA. EM chansky@u.washington.edu FU NCI NIH HHS [R01 CA90941] NR 26 TC 18 Z9 20 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD JUN PY 2008 VL 26 IS 6 BP 886 EP 893 DI 10.1002/jor.20597 PG 8 WC Orthopedics SC Orthopedics GA 304FJ UT WOS:000256095100022 PM 18271016 ER PT J AU Goy, ER Carter, JH Ganzini, L AF Goy, Elizabeth R. Carter, Julie H. Ganzini, Linda TI Needs and experiences of caregivers for family members dying with Parkinson disease SO JOURNAL OF PALLIATIVE CARE LA English DT Article ID COMPLICATED GRIEF; SYMPTOMS; PREDICTORS; BURDEN; SCALE; CARE AB The caregiver burdens and unmet needs of patients with Parkinson disease (PD) in the final months of life are poorly documented. We surveyed 47 family caregivers of PD patients a median of 18 months after death. We measured caregiver preparedness for their role, assistance provided the patient, and types and settings of care received by the patient. Typical caregivers were older female spouses. Though 66% of patients resided in a care facility during the last month, over half received care from hospice, 36% from a home health agency, and 43% by privately paid aide in the months before death. Caregivers rated tasks involving physical effort as most difficult. While most caregivers felt prepared for their role, one-third or more were unprepared for the stress and physical strain encountered. These data suggest that increasing education and assistance with physical tasks may address unmet needs of PID caregivers. C1 [Goy, Elizabeth R.; Ganzini, Linda] Portland VA Med Ctr, HSR&D, Res Career Dev Award Program, Portland, OR USA. [Goy, Elizabeth R.; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Goy, Elizabeth R.; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Div Geriatr Psychiat, Portland, OR 97201 USA. RP Goy, ER (reprint author), Portland VA Med Ctr, HSR&D, Res Career Dev Award Program, 66 POB 1034, Portland, OR USA. NR 13 TC 13 Z9 13 U1 0 U2 5 PU CENTER BIOETHICS CLIN RES INST MONTREAL PI MONTREAL PA 110 PINE AVE W, MONTREAL, QUEBEC H2W 1R7, CANADA SN 0825-8597 J9 J PALLIAT CARE JI J. Palliative Care PD SUM PY 2008 VL 24 IS 2 BP 69 EP 75 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 322UP UT WOS:000257401100002 PM 18681242 ER PT J AU Lorenz, K AF Lorenz, Karl TI Progress in measuring and improving palliative and end-of-life quality SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Editorial Material ID CANCER CARE; INDICATORS C1 VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Los Angeles, CA 90073 USA. RP Lorenz, K (reprint author), VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM Karl.Lorenz@va.gov NR 16 TC 2 Z9 2 U1 0 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD JUN PY 2008 VL 11 IS 5 BP 682 EP 684 DI 10.1089/jpm.2008.9906 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 324RG UT WOS:000257535100007 PM 18588397 ER PT J AU Nery, FG Hatch, JP Glahn, DC NiColetti, MA Monkul, ES Najt, P Fonseca, M Bowden, CL Cloninger, CR Soares, JC AF Nery, Fabiano G. Hatch, John P. Glahn, David C. NiColetti, Mark A. Monkul, E. Serap Najt, Pablo Fonseca, Manoela Bowden, Charles L. Cloninger, C. Robert Soares, Jair C. TI Temperament and character traits in patients with bipolar disorder and associations with comorbid alcoholism or anxiety disorders SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article; Proceedings Paper CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat DE bipolar disorder; personality; comorbidity; alcoholism; anxiety disorders; psychopathology ID TRIDIMENSIONAL PERSONALITY QUESTIONNAIRE; MANIC-DEPRESSIVE PATIENTS; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; HARM AVOIDANCE; DIMENSIONS; INVENTORY; PROFILE; STATE; TCI AB Temperament and character traits may determine differences in clinical presentations and outcome of bipolar disorder. We compared personality traits in bipolar patients and healthy individuals using the Temperament and Character Inventory (TCI) and sought to verify whether comorbidity with alcoholism or anxiety disorders is associated with specific personality traits. Seventy-three DSM-IV bipolar patients were compared to 63 healthy individuals using the TCI. In a second step, the bipolar sample was subgrouped according to the presence of psychiatric comorbidity (alcoholism, n = 10; anxiety disorders; n = 23; alcoholism plus anxiety disorders, n = 21; no comorbidity, n = 19). Bipolar patients scored statistically higher than the healthy individuals on novelty seeking, harm avoidance and self-transcendence and lower on self-directedness and cooperativeness. Bipolar patients with only comorbid alcoholism scored statistically lower than bipolar patients without any comorbidity on persistence. Bipolar patients with only comorbid anxiety disorders scored statistically higher on harm avoidance and lower on self-directedness than bipolar patients without any comorbidity. Limitations of this study include the cross-sectional design and the small sample size, specifically in the analysis of the subgroups. However, our results suggest that bipolar patients exhibit a different personality structure than healthy individuals and that presence of psychiatric comorbidity in bipolar disorder is associated with specific personality traits. These findings suggest that personality, at least to some extent, mediates the comorbidity phenomena in bipolar disorder. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Soares, Jair C.] Univ N Carolina, Sch Med, Dept Psychiat, CERT BD, Chapel Hill, NC 27599 USA. [Nery, Fabiano G.; Hatch, John P.; Glahn, David C.; NiColetti, Mark A.; Monkul, E. Serap; Najt, Pablo; Fonseca, Manoela; Bowden, Charles L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Nery, Fabiano G.; NiColetti, Mark A.; Monkul, E. Serap; Najt, Pablo; Fonseca, Manoela] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Nery, Fabiano G.] Univ Sao Paulo, Sch Med, Dept Psychiat, Bipolar Disorder Res Program, Sao Paulo, Brazil. [Hatch, John P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA. [Monkul, E. Serap] Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. [Cloninger, C. Robert] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. RP Soares, JC (reprint author), Univ N Carolina, Sch Med, Dept Psychiat, CERT BD, 10616 Neurosci Hosp CB 7160, Chapel Hill, NC 27599 USA. EM jsoares@med.unc.edu RI Cloninger, Claude/F-5357-2012 OI Cloninger, Claude/0000-0003-3096-4807 FU NCRR NIH HHS [RR020571, K24 RR020571, K24 RR020571-01A1, K24 RR020571-02, K24 RR020571-03, K24 RR020571-04, K24 RR020571-05, M01 RR001346, M01-RR-01346]; NIMH NIH HHS [K23 MH001736, K23 MH001736-05, MH 01736, MH 068662, MH 068766, P20 MH068662, R01 MH068766, R01 MH068766-01A2, R01 MH068766-02, R01 MH068766-03, R01 MH068766-04, R01 MH068766-05] NR 42 TC 43 Z9 44 U1 3 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JUN PY 2008 VL 42 IS 7 BP 569 EP 577 DI 10.1016/j.jpsychires.2007.06.004 PG 9 WC Psychiatry SC Psychiatry GA 294RU UT WOS:000255424000008 PM 17675066 ER PT J AU Hall, DE Meador, KG Koenig, HG AF Hall, Daniel E. Meador, Keith G. Koenig, Harold G. TI Measuring religiousness in health research: Review and critique SO JOURNAL OF RELIGION & HEALTH LA English DT Review DE religiousness; spirituality; measurement; philosophy; worldview ID WELL-BEING SCALE; SPIRITUAL EXPERIENCE; NONDISABLED PERSONS; INITIAL DEVELOPMENT; CONSTRUCT-VALIDITY; CANCER-PATIENTS; UNITED-STATES; MENTAL-HEALTH; ITEM SCALES; ORIENTATION AB Although existing measures of religiousness are sophisticated, no single approach has yet emerged as a standard. We review the measures of religiousness most commonly used in the religion and health literature with particular attention to their limitations, suggesting that vigilance is required to avoid over-generalization. After placing the development of these scales in historical context, we discuss measures of religious attendance, private religious practice, and intrinsic/extrinsic religious motivation. We also discuss measures of religious coping, wellbeing, belief, affiliation, maturity, history, and experience. We also address the current trend in favor of multi-dimensional and functional measures of religiousness. We conclude with a critique of the standard, "context-free" approach aimed at measuring "religiousness-in-general", suggesting that future work might more fruitfully focus on developing ways to measure religiousness in specific, theologically relevant contexts. C1 [Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hall, Daniel E.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Meador, Keith G.; Koenig, Harold G.] Duke Univ, Med Ctr, Durham, NC USA. [Koenig, Harold G.] Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA. RP Hall, DE (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. EM hallde@upmc.edu RI Koenig, Harold/F-7379-2011; Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 NR 140 TC 75 Z9 76 U1 4 U2 35 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 J9 J RELIG HEALTH JI J. Relig. Health PD JUN PY 2008 VL 47 IS 2 BP 134 EP 163 DI 10.1007/s10943-008-9165-2 PG 30 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA 299HQ UT WOS:000255747100002 PM 19105008 ER PT J AU Lyamin, OI Lapierre, JL Kosenko, PO Mukhametov, LM Siegel, JM AF Lyamin, Oleg I. Lapierre, Jennifer L. Kosenko, Peter O. Mukhametov, Lev M. Siegel, Jerome M. TI Electroencephalogram asymmetry and spectral power during sleep in the northern fur seal SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE asymmetry index; eeg asymmetry; northern fur seal; pinnipedia; spectral analysis; unihemispheric sleep ID SLOW-WAVE SLEEP; UNILATERAL CORTICAL APPLICATION; INTERHEMISPHERIC EEG ASYMMETRY; UNIHEMISPHERIC SLEEP; WAKING; RAT; DEPRIVATION; STIMULATION; WAKEFULNESS; PATTERNS AB The fur seal (Callorhinus ursinus), a member of the Pinniped family, displays a highly expressed electroencephalogram (EEG) asymmetry during slow wave sleep (SWS), which is comparable with the unihemispheric sleep in cetaceans. In this study, we investigated the EEG asymmetry in the fur seal using spectral analysis. Four young (2-3 years old) seals were implanted with EEG electrodes for polygraphic sleep recording. In each animal, EEG spectral power in the frequency range of 1.2-16 Hz was computed in symmetrical cortical recordings over two consecutive nights. The degree of EEG asymmetry was measured by using the asymmetry index [AI = (L - R)/(L + R), where L and R are the spectral powers in the left and right hemispheres, respectively]. In fur seals, EEG asymmetry, as measured by the percent of 20-s epochs with absolute AI > 0.3 and > 0.6, was expressed in the entire frequency range (1.2-16 Hz). The asymmetry was significantly greater during SWS (25.6-44.2% of all SWS epochs had an absolute AI > 0.3 and 2.1-12.2% of all epochs had AI > 0.6) than during quiet waking (11.0-20.3% and 0-1.9% of all waking epochs, respectively) and REM sleep (4.2-8.9% of all REM sleep epochs and no epochs, respectively). EEG asymmetry was recorded during both low- and high-voltage SWS, and was maximal in the range of 1.2-4 and 12-16 Hz. As shown in this study, the degree of EEG asymmetry and the frequency range in which it is expressed during SWS in fur seals are profoundly different from those of terrestrial mammals and birds. C1 Univ Calif Los Angeles, Sepulveda, CA USA. VA GLAHS, Sepulveda, CA USA. [Lyamin, Oleg I.; Kosenko, Peter O.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow, Russia. RP Lyamin, OI (reprint author), VA GLAHS Sepulveda, Neurobiol Res 151A3,16111 Plummer St, North Hills, CA USA. EM olyamin@ucla.edu NR 40 TC 21 Z9 21 U1 2 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0962-1105 J9 J SLEEP RES JI J. Sleep Res. PD JUN PY 2008 VL 17 IS 2 BP 154 EP 165 DI 10.1111/j.1365-2869.2008.00639.x PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 300OR UT WOS:000255835300005 PM 18482104 ER PT J AU Ishizuka, S Kurihara, N Hiruma, Y Miura, D Namekawa, JI Tamura, A Kato-Nakamura, Y Nakano, Y Takenouchi, K Hashimoto, Y Nagasawa, K Roodman, GD AF Ishizuka, Seiichi Kurihara, Noriyoshi Hiruma, Yuko Miura, Daishiro Namekawa, Jun-ichi Tamura, Azusa Kato-Nakamura, Yuko Nakano, Yusuke Takenouchi, Kazuya Hashimoto, Yuichi Nagasawa, Kazuo Roodman, G. David TI 1 alpha,25-dihydroxyvitamin D(3)-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article DE vitamin D receptor antagonist; 1 alpha,25-dihydroxyvitamin D(3)-26,23-lactam analogues; HL-60 cell differentiation; osteoclast formation; gene expression ID PROMYELOCYTIC LEUKEMIA-CELLS; INHIBITS OSTEOCLAST FORMATION; CARBOXYLIC ESTER ANTAGONISTS; BONE-MARROW CULTURES; PAGETS-DISEASE; D-3-26,23-LACTONE ANALOGS; 1,25-DIHYDROXYVITAMIN D-3; MOLECULAR-MECHANISM; HL-60 CELLS; DIFFERENTIATION AB (23S,25S)-N-Benzyl-1 alpha,25-dihydroxyvitamin D(3)-26,23-lactam ((23S,25S)-N-benzyl-1 alpha,25-(OH)(2)D(3)-26,23-lactam, (23S,25S)-DLAM-1P) antagonizes nuclear vitamin D receptor (VDR)-mediated differentiation of human promyelocytic leukemia (HL-60) cells [Y. Kato, Y. Nakano, H. Sano, A. Tanatani, H. Kobayashi, R. Shimazawa, H. Koshino, Y. Hashimoto, K. Nagasawa, Synthesis of 1 alpha,25-dihydroxy vitamin D(3)-26,23-lactams (DLAMs), a novel series of 1 alpha,25-dihydroxy vitamin D(3) antagonist, Bioorg. Med. Chem. Lett. 14 (2004) 2579-2583]. To enhance its VDR antagonistic actions, we synthesized multiple analogues of 1 alpha,25-(OH)(2)D(3)-26,23-lactam. Among these analogues, (23S,25S)-N-phenetyl-1 alpha,25-(OH)(2)D(3)-26,23-lactam, ((23S,25S)-DLAM-2P) had the strongest VDR binding affinity, which was 3 times higher than that of (23S,25S)-DLAM-1P. The 1 alpha,25-(OH)(2)D(3)-26,23-lactam analogues never induced HL-60 cell differentiation even at 10(-6) M, but (23S,25S)-DLAM-1P and (23S,25S)-DLAM-2P significantly and dose-dependently inhibited HL-60 differentiation induced by 10(-8) M 1 alpha,25-dihydroxyvitamin D(3) (1 alpha,25-(OH)(2)D(3)). These compounds also inhibited human and mouse cultures of osteoclast formation by marrow cells treated with 1 alpha,25-(CH)(2)D(3)- Moreover, the 1 alpha,25-(OH)(2)D(3)-26,23-lactam analogues minimally induced 25-hydroxyvitamin D(3)-24-hydroxylase gene expression in HL-60 cells and human and mouse osteoblastic cells, but 10(-6) M (23S,25S)-DLAM-1P or (23S,25S)-DLAM-2P significantly blocked 24-hydroxylase gene expression induced by 10(-8) M 1 alpha,25-(OH)(2)D(3). (23S,25S)-DIAM-2P was 5-12 times more potent as a vitamin D antagonist than (23S,25S)-DLAM-1P in HL-60 cells, human and mouse bone marrow cultures. These results demonstrate that (23S,25S)-DLAM-1P and (23S,25S)-DLAM-2P antagonize HL-60 cell differentiation and osteoclast formation by human and mouse osteoclast precursors induced by 1 alpha,25-(OH)(2)D(3) through blocking VDR-mediated gene transcription. In contrast, (23S)-25-deoxy-1 alpha-thydroxyvitamin D(3)-26,23-lactone, which only blocks human VDR, these vitamin D antagonists can block VDR in human cells and rodent cells. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Ishizuka, Seiichi; Miura, Daishiro; Namekawa, Jun-ichi; Tamura, Azusa; Kato-Nakamura, Yuko; Takenouchi, Kazuya] Teijin Inst Biomed Res, Hino, Tokyo 1918512, Japan. [Ishizuka, Seiichi; Kurihara, Noriyoshi; Hiruma, Yuko; Roodman, G. David] Univ Pittsburgh, Sch Med, Div Hematol Oncol, Pittsburgh, PA 15261 USA. [Nakano, Yusuke; Hashimoto, Yuichi] Univ Tokyo, Inst Mol & Cell Biosci, Bunkyo Ku, Tokyo 110031, Japan. [Nagasawa, Kazuo] Tokyo Univ Agr & Technol, Fac Technol, Dept Biotechnol & Life Sci, Koganei, Tokyo 1848588, Japan. [Roodman, G. David] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu RI Nagasawa, Kazuo/B-9959-2013 FU NIAMS NIH HHS [P01 AR049363, P01 AR 049363, P01 AR049363-05] NR 30 TC 7 Z9 7 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD JUN PY 2008 VL 110 IS 3-5 BP 269 EP 277 DI 10.1016/j.jsbmb.2007.11.007 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 326DY UT WOS:000257639600010 PM 18501591 ER PT J AU Pettinati, HM Kampman, KM Lynch, KG Suh, JJ Dackis, CA Oslin, DW O'Brien, CP AF Pettinati, Helen M. Kampman, Kyle M. Lynch, Kevin G. Suh, Jesse J. Dackis, Charles A. Oslin, David W. O'Brien, Charles P. TI Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the College-on-Problems-of-Drug-Dependence CY JUN 14-19, 2003 CL Bal Harbour, FL SP Coll Problems Drug Dependence DE naltrexone; cocaine dependence; alcohol dependence; CBT; BRENDA; adverse events ID RELAPSE PREVENTION TREATMENT; RANDOMIZED CONTROLLED-TRIAL; ADDICTION SEVERITY INDEX; PLACEBO-CONTROLLED TRIAL; SEX-DIFFERENCES; SELF-REPORTS; BEHAVIORAL PHARMACOLOGY; ETHANOL INGESTION; DRINKING BEHAVIOR; CONCURRENT USE AB This is a randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy of a higher-than-typical daily dose of naltrexone (150 mg/day), taken for 12 weeks, in 164 patients (n = 116 men and n = 48 women) with co-occurring cocaine and alcohol dependence. Patients were stratified by gender and then randomly assigned to either naltrexone or placebo, and to either cognitive-behavioral therapy or a type of medical management. The two primary outcomes were cocaine use and alcohol use. Significant Gender x Medication interactions were found for cocaine use via urine drug screens (three way, with time) and self-reports (two way) for drug severity (two way) and alcohol use (two way). The type of psychosocial treatment did not affect outcomes. Thus, 150 mg/day naltrexone added to a psychosocial treatment resulted in reductions in cocaine and alcohol use and drug severity in men, compared to higher rates of cocaine and alcohol use and drug severity in women. (C) 2008 Elsevier Inc. All rights reserved. C1 [Pettinati, Helen M.; Kampman, Kyle M.; Lynch, Kevin G.; Suh, Jesse J.; Dackis, Charles A.; Oslin, David W.; O'Brien, Charles P.] Univ Penn, Sch Med, Dept Psychiat, Ctr Study Addict, Philadelphia, PA 19104 USA. [Oslin, David W.; O'Brien, Charles P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Pettinati, HM (reprint author), Univ Penn, Dept Psychiat, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM pettinati_h@mail.trc.upenn.edu FU NIDA NIH HHS [P60 DA005186-14S10014, P50 DA012756, P50 DA012756-02, P50 DA012756-03, P50 DA012756-09, P50 DA012756-099001, P50 DA12756, P60 DA005186, P60 DA005186-110014, P60 DA005186-120014, P60 DA005186-130014, P60 DA005186-13S10014, P60 DA005186-140014, P60 DA005186-150014, P60 DA05186] NR 74 TC 40 Z9 41 U1 4 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUN PY 2008 VL 34 IS 4 BP 378 EP 390 DI 10.1016/j.jsat.2007.05.011 PG 13 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 301JO UT WOS:000255892400002 PM 17664051 ER PT J AU Fowler, CG King, JL AF Fowler, Cynthia G. King, Jennifer L. TI Sudden Bilateral Sensorineural Hearing Loss Following Speedballing SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE Autoimmune; bilateral hearing loss; cocaine; cochlear pathology; drug abuse; heroin; otoacoustic emissions; recreational drugs; sensorineural hearing loss; sudden hearing loss ID HEROIN; COCAINE; ADDICTS AB Background: Hearing loss is an infrequently-reported consequence of recreational drug abuse. Although there are sporadic reports of hearing loss from heroin and cocaine ingested separately, there are no reports of hearing loss resulting from the combination of both drugs ingested simultaneously in the form of speedballing. Purpose: The purpose of this report is to document a case of bilateral sensorineural hearing loss associated with an episode of speedballing. Research Design: Case Report Data Collection and Analysis: The subject of this report was a 40-year-old man with a 20-year history of substance abuse. Data collected included a case history, pure tone audiometry, tympanometry and acoustic reflexes, and transient evoked otoacoustic emissions. Results: The audiologic evaluation indicated a mild to moderate, relatively flat, bilateral sensorineural hearing loss that was worse in the right ear. Conclusions: A bilateral sensorineural hearing loss involving both cochlear and neural pathology may be a rare complication of cocaine, heroin, or the combination of the two drugs. C1 [Fowler, Cynthia G.] Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53706 USA. [King, Jennifer L.] Vet Affairs Greater Los Angeles Healthcare Syst, San Luis Obispo Community Based Outpatient Ctr, San Luis Obispo, CA USA. RP Fowler, CG (reprint author), Univ Wisconsin, Dept Communicat Disorders, 1975 Willow Dr, Madison, WI 53706 USA. EM cgfowler@wisc.edu NR 18 TC 8 Z9 10 U1 0 U2 2 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD JUN PY 2008 VL 19 IS 6 BP 461 EP 464 DI 10.3766/jaaa.19.6.2 PG 4 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 386IF UT WOS:000261876200002 PM 19253779 ER PT J AU Murrell, DE Dick, S Ahmed, AR Amagai, M Barnadas, MA Borradori, L Bystryn, JC Cianchini, G Diaz, L Fivenson, D Hall, R Harman, KE Hashimoto, T Hertl, M Hunzelmann, N Iranzo, P Joly, P Jonkman, ME Kitajima, Y Korman, NJ Martin, LK Mimouni, D Pandya, AG Payne, AS Rubenstein, D Shimizu, H Sinha, AA Sirois, D Zillikens, D Werth, VP AF Murrell, Dedee E. Dick, Sarah Ahmed, A. R. Amagai, Masayuki Barnadas, Maria A. Borradori, Luca Bystryn, Jean-Claude Cianchini, Giuseppe Diaz, Luis Fivenson, David Hall, Russell Harman, Karen E. Hashimoto, Takashi Hertl, Michael Hunzelmann, Nico Iranzo, Pilar Joly, Pascal Jonkman, Marcel E. Kitajima, Yasuo Korman, Neil J. Martin, Linda K. Mimouni, Daniel Pandya, Amit G. Payne, Aimee S. Rubenstein, David Shimizu, Hiroshi Sinha, Animesh A. Sirois, David Zillikens, Detlef Werth, Victoria P. TI Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article AB Our scientific knowledge of pemphigus has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in pemphigus. A major obstacle in comparing therapeutic outcomes between centers is the lack of generally accepted definitions and measurements for the clinical evaluation of patients with pemphigus. Common terms and end points of pemphigus are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. This consensus statement from the International Pemphigus Committee represents 2 years of collaborative efforts to attain mutually acceptable common definitions for pemphigus. These should assist in development of consistent reporting of outcomes in future studies. C1 [Dick, Sarah; Payne, Aimee S.; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19119 USA. [Murrell, Dedee E.; Martin, Linda K.] Univ New S Wales, St Georges Hosp, Dept Dermatol, Sydney, NSW, Australia. [Amagai, Masayuki] Keio Univ, Sch Med, Tokyo, Japan. [Barnadas, Maria A.] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Borradori, Luca] Univ Geneva, Hop Cantonal, CH-1211 Geneva, Switzerland. [Bystryn, Jean-Claude] NYU, Med Ctr, New York, NY 10016 USA. [Diaz, Luis] Univ N Carolina, Chapel Hill, NC USA. [Hall, Russell] Duke Univ, Med Ctr, Div Dermatol, Durham, NC 27710 USA. [Harman, Karen E.] Univ Hosp Leicester, Leicester, Leics, England. [Hashimoto, Takashi] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan. [Hashimoto, Takashi] Univ Giessen Klinikum, Giessen, Germany. [Hashimoto, Takashi] Marburg GmbH, Marburg, Germany. [Hunzelmann, Nico] Univ Klin Koln, Cologne, Germany. [Iranzo, Pilar] Univ Barcelona, Hosp Clin, E-08007 Barcelona, Spain. [Jonkman, Marcel E.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands. [Kitajima, Yasuo] Gifu Univ, Sch Med, Gifu, Japan. [Korman, Neil J.] Univ Hosp, Case Med Ctr Cleveland, Cleveland, OH USA. [Mimouni, Daniel] Rabin Med Ctr, Petah Tiqwa, Israel. [Pandya, Amit G.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Shimizu, Hiroshi] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan. [Zillikens, Detlef] Med Univ Lubeck, D-23538 Lubeck, Germany. [Werth, Victoria P.] Vet Affairs Med Ctr, Philadelphia Dept, Philadelphia, PA USA. [Ahmed, A. R.] New England Baptist Hosp, Ctr Blistering Dis, Dept Med, Boston, MA USA. [Cianchini, Giuseppe] IRCCS, Inst Dermopact Immacolata, Immunodermatol Dept, Rome, Italy. [Joly, Pascal] Hop Charles Nicolle, Dermatol Clin, Rouen, France. [Sinha, Animesh A.] Michigan State Univ, Ctr Invest Dermatol, Div Dermatol & Cutaneous Sci, E Lansing, MI 48824 USA. [Sirois, David] NYU, Dept Oral Med, New York, NY 10003 USA. RP Werth, VP (reprint author), Univ Penn, Dept Dermatol, 2 Rhodes Pavill,3600 Spruce St, Philadelphia, PA 19119 USA. EM werth@mail.med.upenn.edu RI Zillikens, Detlef/C-8572-2011; Cianchini, Giuseppe/I-8877-2012; Amagai, Masayuki/K-5325-2013 OI Amagai, Masayuki/0000-0003-3314-7052 FU NIAMS NIH HHS [K08 AR053505, K24 AR002207, K24 AR002207-06A2, K24-AR 02207] NR 1 TC 194 Z9 203 U1 0 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JUN PY 2008 VL 58 IS 6 BP 1043 EP 1046 DI 10.1016/j.jaad.2008.01.012 PG 4 WC Dermatology SC Dermatology GA 303QO UT WOS:000256055800016 PM 18339444 ER PT J AU Billingsley, KG Morris, AM Green, P Dominitz, JA Matthews, B Dobie, SA Barlow, W Baldwin, LM AF Billingsley, Kevin G. Morris, Arden M. Green, Pamela Dominitz, Jason A. Matthews, Barbara Dobie, Sharon A. Barlow, William Baldwin, Laura-Mae TI Does surgeon case volume influence nonfatal adverse outcomes after rectal cancer resection? SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID ACHIEVING EXCELLENT OUTCOMES; HOSPITAL VOLUME; ADMINISTRATIVE DATA; COLON-CANCER; COLORECTAL RESECTION; QUALITY INDICATOR; MORBIDITY; MORTALITY; SURVIVAL; POPULATION AB BACKGROUND: The aim of this study was to assess the relationship between surgeon and hospital volume and major postoperative complications after rectal cancer surgery, and to define other surgeon and hospital characteristics that may explain observed volume-complication relationships. STUDY DESIGN: This was a retrospective cohort design using data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry program for individuals with stage I to III rectal cancer diagnosed between 1992 and 1999 and treated with resection. The patients' Surveillance, Epidemiology, and End Results data were linked with Medicare claims data from 1991 to 2000. The primary outcomes were 30-day postoperative procedural interventions (PPI) to treat surgical complications, such as reoperation. The association between surgeon volume and PPI was examined using logistic regression modeling with adjustment for covariates. RESULTS: The odds of a rectal cancer patient requiring a PPI is notably less if the operation is performed by one of a small subset of very high volume surgeons (unadjusted odds ratio 0.53; 95% CI 0.31 to 0.92). Board certification in colorectal surgery did not alter the relationship between surgeon volume and PPI, although surgeon age did, with mid-career surgeons having the lowest rates of PPI, regardless of practice volume. When adjusted for surgeon age, surgeon volume is no longer a marked predictor of complications (adjusted odds ratio 0.57; 95% CI 0.30 to 1.09). CONCLUSIONS: Over-all, rectal cancer operations are safe, with a low frequency of severe complications. A subset of very high volume rectal surgeons performs these operations with fewer complications that require procedural intervention or reoperation. Surgeon age, as an indicator of experience, also contributes modestly to outcomes. These data do not justify regionalizing rectal cancer care based on safety concerns. C1 Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA. Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI USA. Univ Washington, Sch Med Canc Res & Biostat, Dept Family Med, Seattle, WA 98195 USA. Univ Washington, Sch Med Canc Res & Biostat, VA Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA 98195 USA. RP Billingsley, KG (reprint author), Oregon Hlth & Sci Univ, Dept Surg L223A, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. OI Dominitz, Jason/0000-0002-8070-7086 FU NCI NIH HHS [R01 CA089544-01S1, R01 CA089544] NR 27 TC 25 Z9 25 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD JUN PY 2008 VL 206 IS 6 BP 1167 EP 1177 DI 10.1016/j.jamcollsurg.2007.12.042 PG 11 WC Surgery SC Surgery GA 310EO UT WOS:000256511900011 PM 18501815 ER PT J AU Mader, SL AF Mader, Scott L. TI In memoriam - Amasa Ford SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Biographical-Item C1 Portland VA Med Ctr, Vancouver Div, Vancouver Long Term Care Div, Portland, OR USA. RP Mader, SL (reprint author), Portland VA Med Ctr, Vancouver Div, Vancouver Long Term Care Div, Portland, OR USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2008 VL 56 IS 6 BP 1164 EP 1164 DI 10.1111/j.1532-5415.2008.01735.x PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 308SU UT WOS:000256411100040 ER PT J AU Thomas, DR Cote, TR Lawhorne, L Levenson, SA Rubenstein, LZ Smith, DA Stefanacci, RG Tangalos, EG Morley, JE AF Thomas, David R. Cote, Todd R. Lawhorne, Larry Levenson, Steven A. Rubenstein, Laurence Z. Smith, David A. Stefanacci, Richard G. Tangalos, Eric G. Morley, John E. CA Dehydration Council TI Understanding clinical dehydration and its treatment SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Review DE dehydration; long-term care; hyperosmolar dehydration; hyponatremia dehydration; education; prevention; recombinant hyaluronidase; subcutaneous infusion of fluid; hypodermoclysis ID NURSING-HOME RESIDENTS; DWELLING OLDER-ADULTS; HEALTHY ELDERLY MEN; HYDRATION STATUS; FLUID BALANCE; THIRST; REHYDRATION; HYPERNATREMIA; PREVALENCE; HYPODERMOCLYSIS AB Dehydration in clinical practice, as opposed to a physiological definition, refers to the loss of body water, with or without salt, at a rate greater than the body can replace it. We argue that the clinical definition for dehydration, ie, loss of total body water, addresses the medical needs of the patient most effectively. There are 2 types of dehydration, namely water loss dehydration (hyperosmolar, due either to increased sodium or glucose) and salt and water loss dehydration (hyponatremia). The diagnosis requires an appraisal of the patient and laboratory testing, clinical assessment, and knowledge of the patient's history. Long-term care facilities are reluctant to have practitioners make a diagnosis, in part because dehydration is a sentinel event thought to reflect poor care. Facilities should have an interdisciplinary educational focus on the prevention of dehydration in view of the poor outcomes associated with its development. We also argue that dehydration is rarely due to neglect from formal or informal caregivers, but rather results from a combination of physiological and disease processes. With the availability of recombinant hyaluronidase, subcutaneous infusion of fluids (hypodermoclysis) provides a better opportunity to treat mild to moderate dehydration in the nursing home and at home. C1 [Thomas, David R.] St Louis Univ, Sch Med, Div Geriatr Med, St Louis, MO 63104 USA. [Cote, Todd R.] Hosp Bluegrass, Palliat Care Ctr Bluegrass, Lexington, KY USA. [Lawhorne, Larry] Wright State Univ, Boonshoft Sch Med, Dayton, OH 45435 USA. [Levenson, Steven A.] Genesis Elder Care, Baltimore, MD USA. [Rubenstein, Laurence Z.] VA Greater Los Angeles, Los Angeles, CA USA. [Rubenstein, Laurence Z.] Univ Calif Los Angeles, Los Angeles, CA USA. [Smith, David A.] Texas A&M Univ, Brownwood, TX USA. [Stefanacci, Richard G.] Allegheny Univ Hlth Sci, Ctr Medicare Medicat Management, Philadelphia, PA 19102 USA. [Tangalos, Eric G.] Mayo Clin, Rochester, MN USA. [Morley, John E.] VA Med Ctr, GRECC, St Louis, MO USA. RP Thomas, DR (reprint author), St Louis Univ, Sch Med, Div Geriatr Med, 1402 S Grand Blvd,M238, St Louis, MO 63104 USA. EM ThomasDR@slu.edu RI morley, john/F-9177-2011 OI morley, john/0000-0001-6444-2965 NR 73 TC 97 Z9 98 U1 3 U2 39 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD JUN PY 2008 VL 9 IS 5 BP 292 EP 301 DI 10.1016/j.jamda.2008.03.006 PG 10 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 315PD UT WOS:000256891000004 PM 18519109 ER PT J AU Huang, CM AF Huang, Christine M. TI Human papillomavirus and vaccination SO MAYO CLINIC PROCEEDINGS LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; YOUNG-WOMEN; PARTICLE VACCINE; QUADRIVALENT VACCINE; SUSTAINED EFFICACY; UNITED-STATES; DOUBLE-BLIND; FOLLOW-UP; INFECTION; TYPE-16 AB Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the United States. Modeling estimates Suggest that more than 80% of sexually active women will have acquired genital HPV by age 50 years. Although most infections are transient and asymptomatic, persistent infection with high-risk types of HPV can lead to precancerous lesions and progress to cancer. In June 2006, the US Food and Drug Administration licensed the first vaccine to prevent cervical cancers and other diseases in women. This quadrivalent vaccine protects against HPV-6, HPV-11, HPV-16, and HPV-18, which are responsible for 70% of cervical cancers and 90% of genital warts. Several studies have been published examining the vaccine's efficacy, duration, immunogenicity, and safety. Questions and controversy remain regarding mandatory vaccination, need for booster doses, and cost-effectiveness. C1 [Huang, Christine M.] Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Internal Med, Los Angeles, CA USA. RP Huang, CM (reprint author), 11301 Wilshire Blvd PACC, Los Angeles, CA 90073 USA. NR 25 TC 13 Z9 18 U1 0 U2 3 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JUN PY 2008 VL 83 IS 6 BP 701 EP 707 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 307PY UT WOS:000256332000013 PM 18533087 ER PT J AU Sochalski, J Konetzka, RT Zhu, JS Volpp, K AF Sochalski, Julie Konetzka, R. Tamara Zhu, Jingsan Volpp, Kevin TI Will mandated minimum nurse staffing ratios lead to better patient outcomes? SO MEDICAL CARE LA English DT Article DE nurse staffing; staffing ratios; quality of care ID ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; ADMINISTRATIVE DATA; ADVERSE EVENTS; HOSPITAL MORTALITY; MEDICARE PATIENTS; ICD-9-CM; FAILURE; RESCUE; DEATH AB Background: Mandatory hospital nurse staffing ratios are under consideration in a number of states without strong empirical evidence of the optimal ratio. Objective: To determine whether increases in medical-surgical licensed nurse staffing levels are associated with improvements in patient outcomes for hospitals having different baseline staffing levels. Research Design: Cross-sectional and fixed-effects regression analyses using a 1993-2001 panel of patient and hospital data from California. Splines define 4 staffing ratios. Subjects: Adult acute myocardial infarction (AMI) (n = 348,720) and surgical failure to rescue (FTR) (n = 109,066) patients discharged between 1993 and 2001 from 343 California acute care general hospitals. Measures: Patient outcomes are 30-day AMI mortality and surgical FTR; 4 baseline staffing levels-4 to 7 patients per licensed nurse [registered nurses (RN) and licensed vocational nurses (LVN)]. Results: Significant cross-sectional associations between higher nurse staffing and AMI mortality are reduced in the fixed-effects analyses. Improvements in outcomes were smaller in hospitals with higher baseline staffing: for each RN and RN + LVN increase, respectively, AMI mortality declined by 0.71 (P < 0.05) and by 2.75 percentage points for hospitals with more than 7 patients per nurse compared with 0.19 (P = NS) and 0.28 percentage points (P < 0.05) in hospitals with more than 4 patients per nurse. Significant cross-sectional associations between higher nurse staffing and FTR were not found in the fixed-effects analyses. Conclusions: Strong diminishing returns to nurse staffing improvements and lack of significant evidence that staffing uniformly increases improve outcomes raise questions about the likely cost-effectiveness of implementing state-wide mandatory nurse staffing ratios. C1 [Sochalski, Julie] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Zhu, Jingsan; Volpp, Kevin] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Volpp, Kevin] Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. RP Sochalski, J (reprint author), Univ Penn, Sch Nursing, Claire M Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA. EM julieas@nursing.upenn.edu NR 50 TC 28 Z9 28 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JUN PY 2008 VL 46 IS 6 BP 606 EP 613 DI 10.1097/MLR.0b013e3181648e5c PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 310CR UT WOS:000256507000008 PM 18520315 ER PT J AU Mishra, AK Alderwick, LJ Rittmann, D Wang, C Bhatt, A Jacobs, WR Takayama, K Eggeling, L Besra, GS AF Mishra, Arun K. Alderwick, Luke J. Rittmann, Doris Wang, Cindy Bhatt, Apoorva Jacobs, William R., Jr. Takayama, Kuni Eggeling, Lothar Besra, Gurdyal S. TI Identification of a novel alpha(1 -> 6) mannopyranosyltransferase MptB from Corynebacterium glutamicum by deletion of a conserved gene, NCgl1505, affords a lipomannan- and lipoarabinomannan-deficient mutant SO MOLECULAR MICROBIOLOGY LA English DT Article ID WALL ARABINAN BIOSYNTHESIS; BOMBARDMENT MASS-SPECTROMETRY; MYCOBACTERIUM-TUBERCULOSIS; CELL-WALL; PHOSPHATIDYLINOSITOL MANNOSIDES; MONOPHOSPHOMANNOSE SYNTHASE; STRUCTURAL DEFINITION; CORYNEFORM BACTERIA; NONREDUCING TERMINI; BOVIS BCG AB Mycobacterium tuberculosis and Corynebacterium glutamicum share a similar cell wall structure and orthologous enzymes involved in cell wall assembly. Herein, we have studied C. glutamicum NCgl1505, the orthologue of putative glycosyltransferases Rv1459c from M. tuberculosis and MSMEG3120 from Mycobacterium smegmatis. Deletion of NCgl1505 resulted in the absence of lipomannan (Cg-LM-A), lipoarabinomannan (Cg-LAM) and a multi-mannosylated polymer (Cg-LM-B) based on a 1,2-di-O-C(16)/C(18:1)-(alpha-D-glucopyranosyluronic acid)-(1 -> 3)-glycerol (GlcAGroAc(2)) anchor, while syntheses of triacylated-phosphatidyl-myo-inositol dimannoside (Ac(1)PIM(2)) and Man(1)GlcAGroAc(2) were still abundant in whole cells. Cell-free incubation of C. glutamicum membranes with GDP-[(14)C]Man established that C. glutamicum synthesized a novel alpha(1 -> 6)-linked linear form of Cg-LM-A and Cg-LM-B from Ac(1)PIM(2) and Man(1)GlcAGroAc(2) respectively. Furthermore, deletion of NCgl1505 also led to the absence of in vitro synthesized linear Cg-LM-A and Cg-LM-B, demonstrating that NCgl1505 was involved in core alpha(1 -> 6) mannan biosynthesis of Cg-LM-A and Cg-LM-B, extending Ac(1)PI[(14)C]M(2) and [(14)C]Man(1)GlcAGroAc(2) primers respectively. Use of the acceptor alpha-D-Manp-(1 -> 6)-alpha-D-Manp-O-C(8) in an in vitro cell-free assay confirmed NCgl1505 as an alpha(1 -> 6) mannopyranosyltransferase, now termed MptB. While Rv1459c and MSMEG3120 demonstrated similar in vitro alpha(1 -> 6) mannopyranosyltransferase activity, deletion of the Rv1459c homologue in M. smegmatis did not result in loss of mycobacterial LM/LAM, indicating a functional redundancy for this enzyme in mycobacteria. C1 [Mishra, Arun K.; Alderwick, Luke J.; Bhatt, Apoorva; Besra, Gurdyal S.] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England. [Rittmann, Doris; Eggeling, Lothar] Res Ctr, Inst Biotechnol 1, D-52425 Julich, Germany. [Wang, Cindy; Takayama, Kuni] William S Middleton Mem Vet Adm Med Ctr, Mycobacteriol Res Lab, Madison, WI 53705 USA. [Jacobs, William R., Jr.] Albert Einstein Coll Med, Howard Hughes Med Inst, Dept Microbiol & Immunol, Bronx, NY 10461 USA. RP Besra, GS (reprint author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England. EM g.besra@bham.ac.uk FU Medical Research Council [G0600105, G9901077]; Wellcome Trust [081569/Z/06/Z] NR 77 TC 33 Z9 37 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0950-382X J9 MOL MICROBIOL JI Mol. Microbiol. PD JUN PY 2008 VL 68 IS 6 BP 1595 EP 1613 DI 10.1111/j.1365-2958.2008.06265.x PG 19 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 304LJ UT WOS:000256110700021 PM 18452585 ER PT J AU Katiyar, SK AF Katiyar, Santosh K. TI Grape seed proanthocyanidines and skin cancer prevention: Inhibition of oxidative stress and protection of immune system SO MOLECULAR NUTRITION & FOOD RESEARCH LA English DT Review DE Grape seed proanthocyanidins; Immunosuppression; Oxidative stress; Photocarcinogenesis; Ultraviolet radiation ID SKH-1 HAIRLESS MICE; NF-KAPPA-B; ULTRAVIOLET-RADIATION; LIPID-PEROXIDATION; MOUSE SKIN; CONTACT HYPERSENSITIVITY; TRANSPLANT RECIPIENTS; PROTEIN-KINASES; RICH EXTRACT; RISK-FACTOR AB Overexposure of the skin to UV radiation has a variety of adverse effects on human health, including the development of skin cancers. There is a need to develop nutrition-based efficient chemopreventive strategies. The proanthocyanidins present in grape seeds (Vitis vinifera) have been shown to have some biological effects, including prevention of photocarcinogenesis. The present communication discusses the in vitro and in vivo studies of the possible protective effect of grape seed proanthocyanidins (GSPs) and the molecular mechanism for these effects. In SKH-1 hairless mice, dietary supplementation with GSPs is associated with a decrease of UVB-induced skin tumor development in terms of tumor incidence, tumor multiplicity, and a decrease in the malignant transformation of papillomas to carcinomas. It is suggested that the chemopreventive effects of dietary GSPs are mediated through the attenuation of UV-induced: (i) oxidative stress; (ii) activation of mitogen-activated protein kinases and nuclear factor-kappa B (NF-kappa B) signaling pathways; and (iii) immunosuppression through alterations in immunoregulatory cytokines. Collectively, these studies indicate protective potential of GSPs against experimental photocarcinogenesis in SKH-1 hairless mice, and the possible mechanisms of action of GSPs, and suggest that dietary GSPs could be useful in the attenuation of the adverse UV-induced health effects in human skin. C1 [Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Cancer Institute/NIH [CA104428]; Veterans Affairs Merit Review Award FX The work reported from the author's laboratory was supported from the funds from National Cancer Institute/NIH (CA104428) and Veterans Affairs Merit Review Award. The content of this publication does not necessarily reflect the views or policies of the funding sources. Grateful thanks are due to our former and current postdoctoral fellows for their outstanding contributions. NR 57 TC 34 Z9 36 U1 2 U2 17 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1613-4125 J9 MOL NUTR FOOD RES JI Mol. Nutr. Food Res. PD JUN PY 2008 VL 52 SU 1 BP S71 EP S76 DI 10.1002/mnfr.200700198 PG 6 WC Food Science & Technology SC Food Science & Technology GA 472CC UT WOS:000268105800008 PM 18384090 ER PT J AU Graham, DY Shiotani, A AF Graham, David Y. Shiotani, Akiko TI New concepts of resistance in the treatment of Helicobacter pylori infections SO NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY LA English DT Review DE antibiotics; cytochrome P450; Helicobacter pylori; phenotypic drug resistance; therapy ID PROTON-PUMP INHIBITOR; TRIPLE THERAPY; QUADRUPLE THERAPY; ERADICATION THERAPY; DUAL THERAPY; ANTIBIOTIC-RESISTANCE; CURE RATES; PHARMACOKINETIC CONSIDERATIONS; CYP2C19 POLYMORPHISM; SEQUENTIAL THERAPY AB The prevalence of antimicrobial drug resistance is now so high that all patients infected with Helicobacter pylori should be considered as having resistant infections. Ideally, therapy should be based on pretreatment antibiotic-susceptibility testing but this strategy is not currently practical. At present, clarithromycin-containing triple therapies do not reliably produce a >= 80% cure rate on an intention-to-treat basis and are, therefore, no longer acceptable as empiric therapy. In this Review, we discuss concepts of resistance that have become part of mainstream thinking for other infectious diseases but have not yet become so with regard to H. pylori. We also put data on the pharmacokinetics and pharmacodynamics of the drugs used in H. pylori therapy and the effect of host cytochrome P450 genotypes in context with treatment outcomes. Our primary focus is to address the problem of H. pylori resistance from a novel perspective, which also attempts to anticipate the direction that research will need to take to provide clinicians with reliable approaches to this serious infection. We also discuss current therapies that provide acceptable cure rates when used empirically (i.e. sequential therapy; four-drug, three-antibiotic, non-bismuth-containing 'concomitant' therapy; and bismuth-containing quadruple therapy) and how they might be further improved. C1 [Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. [Shiotani, Akiko] Kawasaki Med Univ, Dept Internal Med, Okayama, Japan. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU NIDDK NIH HHS [P30 DK056338, DK56338, P30 DK056338-07] NR 73 TC 156 Z9 166 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1743-4378 J9 NAT CLIN PRACT GASTR JI Nat. Clin. Pract. Gastroenterol. Hepatol. PD JUN PY 2008 VL 5 IS 6 BP 321 EP 331 DI 10.1038/ncpgasthep1138 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 307XG UT WOS:000256352300010 PM 18446147 ER PT J AU Kondo, Y Shen, L Cheng, AS Ahmed, S Boumber, Y Charo, C Yamochi, T Urano, T Furukawa, K Kwabi-Addo, B Gold, DL Sekido, Y Huang, THM Issa, JPJ AF Kondo, Yutaka Shen, Lanlan Cheng, Alfred S. Ahmed, Saira Boumber, Yanis Charo, Chantale Yamochi, Tadanori Urano, Takeshi Furukawa, Koichi Kwabi-Addo, Bernard Gold, David L. Sekido, Yoshitaka Huang, Tim Hui-Ming Issa, Jean-Pierre J. TI Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation SO NATURE GENETICS LA English DT Article ID HISTONE LYSINE METHYLATION; CPG ISLAND MICROARRAY; EMBRYONIC STEM-CELLS; GROUP PROTEIN EZH2; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL-CANCER; PROSTATE-CANCER; SUPPRESSOR GENE; H3; HYPERMETHYLATION AB Epigenetic silencing in cancer cells is mediated by at least two distinct histone modifications, polycomb-based histone H3 lysine 27 trimethylation (H3K27triM) and H3K9 dimethylation. The relationship between DNA hypermethylation and these histone modifications is not completely understood. Using chromatin immunoprecipitation microarrays (ChIP-chip) in prostate cancer cells compared to normal prostate, we found that up to 5% of promoters (16% CpG islands and 84% non-CpG islands) were enriched with H3K27triM. These genes were silenced specifically in prostate cancer, and those CpG islands affected showed low levels of DNA methylation. Downregulation of the EZH2 histone methyltransferase restored expression of the H3K27triM target genes alone or in synergy with histone deacetylase inhibition, without affecting promoter DNA methylation, and with no effect on the expression of genes silenced by DNA hypermethylation. These data establish EZH2-mediated H3K27triM as a mechanism of tumor-suppressor gene silencing in cancer that is potentially independent of promoter DNA methylation. C1 [Kondo, Yutaka; Shen, Lanlan; Ahmed, Saira; Boumber, Yanis; Charo, Chantale; Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kondo, Yutaka; Sekido, Yoshitaka] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan. [Cheng, Alfred S.; Huang, Tim Hui-Ming] Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Yamochi, Tadanori] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA. [Urano, Takeshi; Furukawa, Koichi] Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4668550, Japan. [Kwabi-Addo, Bernard] Baylor Coll Med & Michael E DeBakey, Dept Pathol, Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. [Gold, David L.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA. RP Issa, JPJ (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM jpissa@mdanderson.org RI Cheng, Alfred/C-3327-2014; Sekido, Yoshitaka/P-9756-2015; Kwabi-Addo, Bernard/A-6993-2016 OI Cheng, Alfred/0000-0003-2345-6951; Urano, Takeshi/0000-0003-3383-3554; Kwabi-Addo, Bernard/0000-0003-3692-6350 FU NCI NIH HHS [P50CA058204, P50CA100632, R01CA098006, R33CA89837] NR 37 TC 379 Z9 393 U1 2 U2 35 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JUN PY 2008 VL 40 IS 6 BP 741 EP 750 DI 10.1038/ng.159 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 305XV UT WOS:000256212000016 PM 18488029 ER PT J AU Gourcerol, G Adelson, D Million, M Wang, LX Tache, Y AF Gourcerol, Guillaume Adelson, David Million, Mulugeta Wang, Lixin Tache, Yvette TI A novel non-invasive method to monitor gastric motility in mice: role of CRF during cold stress SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Meeting Abstract C1 [Gourcerol, Guillaume; Adelson, David; Million, Mulugeta; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Dept Med, Div Digest Dis,VA Greater Los Angeles Healthcare, Los Angeles, CA USA. [Gourcerol, Guillaume; Adelson, David; Million, Mulugeta; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Div Digest Dis,VA Greater Los Angeles Healthcare, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD JUN PY 2008 VL 20 IS 6 MA 16 BP V EP VI PG 2 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 300OT UT WOS:000255835500035 ER PT J AU Nemec, J Swerdlow, SH Bazaz, R Saba, SF Shalaby, AA AF Nemec, Jan Swerdlow, Steven H. Bazaz, Raveen Saba, Samir F. Shalaby, Ala A. TI B-cell lymphoproliferative disorder of an ICD pocket: A diagnostic puzzle in an immunosuppressed patient SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE implantable cardioverter defibrillator; lymphoma; immune suppression ID PACEMAKER POCKET; ONCOTAXIS; LYMPHOMA AB We present a case of a patient with lymphoma in an ICD pocket in the setting of posttransplant immune suppression. Infection of the ICD system was suspected and the correct diagnosis was established by biopsy. C1 [Shalaby, Ala A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Nemec, Jan; Bazaz, Raveen; Saba, Samir F.; Shalaby, Ala A.] Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA USA. [Swerdlow, Steven H.] Univ Pittsburgh, Dept Pathol, Div Hematopathol, Pittsburgh, PA USA. RP Shalaby, AA (reprint author), VA Pittsburgh Healthcare Syst, 111 Univ Dr C, Pittsburgh, PA 15240 USA. EM Alaa.Shalaby@med.va.gov NR 8 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD JUN PY 2008 VL 31 IS 6 BP 769 EP 771 DI 10.1111/j.1540-8159.2008.01084.x PG 3 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 306JH UT WOS:000256243600019 PM 18507553 ER PT J AU Kobelt, P Wisser, AS Stengel, A Goebel, M Bannert, N Gourcerol, G Inhoff, T Noetzel, S Wiedenmann, B Klapp, BF Tache, Y Monnikes, H AF Kobelt, Peter Wisser, Anna-Sophia Stengel, Andreas Goebel, Miriam Bannert, Norbert Gourcerol, Guillaume Inhoff, Tobias Noetzel, Steffen Wiedenmann, Bertram Klapp, Burghard F. Tache, Yvette Moennikes, Hubert TI Peripheral obestatin has no effect on feeding behavior and brain Fos expression in rodents SO PEPTIDES LA English DT Article DE obestatin; food intake; CCK; urocortin 1; rats; mice; dark phase; light phase ID GROWTH-HORMONE-SECRETION; HYPOTHALAMIC ARCUATE NUCLEUS; GHRELIN-ASSOCIATED PEPTIDE; DORSAL VAGAL COMPLEX; REDUCES FOOD-INTAKE; RAT-BRAIN; PARAVENTRICULAR NUCLEUS; ACYLATED PEPTIDE; NEUROPEPTIDE-Y; WEIGHT-GAIN AB Obestatin is produced in the stomach from proghrelin by post-translational cleavage. The initial report claimed anorexigenic effects of obestatin in mice. Contrasting studies indicated no effect of obestatin on food intake (FI). We investigated influences of metabolic state (fed/fasted), environmental factors (dark/light phase) and brain Fos response to intraperitoneal (ip) obestatin in rats, and used the protocol from the original study assessing obestatin effects in mice. FI was determined in male rats injected ip before onset of dark or light phase, with obestatin (1 or 5 mu mol/kg), CCK8S (3.5 nmol/kg) or 0.15 M NaCl, after fasting (16 h, n = 8/group) or ad libitum (n =10-14/group) food intake. Fos expression in hypothalamic and brainstem nuclei was examined in freely fed rats 90 min after obestatin (5 mu mol/kg), CCK8S (1.75 nmol/kg) or 0.15 M NaCl (n = 4/group). Additionally, fasted mice were injected ip with obestatin (1 mu mol/kg) or urocortin 1 (2 nmol/kg) 15 min before food presentation. No effect on FI was observed after obestatin administration during the light and dark phase under both metabolic conditions while CCK8S reduced FI irrespectively of the conditions. The number of Fos positive neurons was not modified by obestatin while CCK8S increased Fos expression in selective brain nuclei. Obestatin did not influence the refeeding response to a fast in mice, while urocortin was effective. Therefore, peripheral obestatin has no effect on FI under various experimental conditions and did not induce Fos in relevant central neuronal circuitries modulating feeding in rodents. (C) 2008 Elsevier Inc. All rights reserved. C1 [Moennikes, Hubert] Charite Univ Med Berlin, Acad Teaching Inst, Martin Luther Hosp, Dept Med, D-14133 Berlin, Germany. [Moennikes, Hubert] Charite Univ Med Berlin, Acad Teaching Inst, Martin Luther Hosp, Inst Neurogastroenterol, D-14133 Berlin, Germany. [Kobelt, Peter; Klapp, Burghard F.] Charite Univ Med Berlin, Dept Med, Div Psychosomat Med & Psychotherapy, D-14133 Berlin, Germany. [Kobelt, Peter; Wisser, Anna-Sophia; Stengel, Andreas; Goebel, Miriam; Inhoff, Tobias; Noetzel, Steffen; Wiedenmann, Bertram; Moennikes, Hubert] Humboldt Univ, Charite, Div Hepatol Gastroenterol & Endocrinol, Dept Med, D-1086 Berlin, Germany. [Bannert, Norbert] Robert Koch Inst, D-1000 Berlin, Germany. [Gourcerol, Guillaume; Tache, Yvette] Univ Calif Los Angeles, Digest Dis Div, Ctr Neurobiol Stress, CURE Digest Dis Res Ctr,Dept Med, Los Angeles, CA USA. [Gourcerol, Guillaume; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Monnikes, H (reprint author), Charite Univ Med Berlin, Acad Teaching Inst, Martin Luther Hosp, Dept Med, Caspar Theyss Str 27-31, D-14133 Berlin, Germany. EM moennikes@web.de FU NIDDK NIH HHS [R01 DK033061-23, R01 DK033061]; PHS HHS [R01 33061] NR 54 TC 31 Z9 32 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JUN PY 2008 VL 29 IS 6 BP 1018 EP 1027 DI 10.1016/j.peptides.2008.01.020 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 310HE UT WOS:000256518700018 PM 18342400 ER PT J AU Khalil, P Murty, P Palevsky, PM AF Khalil, Patricia Murty, Preethi Palevsky, Paul M. TI The patient with acute kidney injury SO PRIMARY CARE LA English DT Review ID ACUTE-RENAL-FAILURE; CONTRAST-INDUCED NEPHROPATHY; RANDOMIZED CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; GELATINASE-ASSOCIATED LIPOCALIN; INTENSIVE-CARE-UNIT; LOW-DOSE DOPAMINE; CARDIAC-SURGERY; REPLACEMENT THERAPY; RIFLE CRITERIA AB During the past half decade there has been a paradigm shift in the view of acute kidney disease that has resulted in a change in nomenclature from the older term, "acute renal failure," to "acute kidney injury" (AKI). This article reviews the new criteria for diagnosis and staging of AKI and summarizes the current understanding of the many causes of AKI and the approach to diagnosis and management. C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Univ Drive Div, Renal Sect, Pittsburgh, PA 15240 USA. [Khalil, Patricia; Murty, Preethi; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Univ Drive Div, Renal Sect, Room 7E123,111F-U, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 106 TC 7 Z9 7 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0095-4543 J9 PRIMARY CARE JI Primary Care PD JUN PY 2008 VL 35 IS 2 BP 239 EP + DI 10.1016/j.pop.2008.01.003 PG 27 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 316OR UT WOS:000256960100005 PM 18486715 ER PT J AU Lee, K Fox, PT Lancaster, JL Jerabek, PA AF Lee, Kihak Fox, Peter T. Lancaster, Jack L. Jerabek, Paul A. TI A positron-probe system for arterial input function quantification for positron emission tomography in humans SO REVIEW OF SCIENTIFIC INSTRUMENTS LA English DT Article ID CEREBRAL-BLOOD-FLOW; INTRACEREBRAL RADIOSENSITIVE PROBE; VIVO NEUROPHARMACOLOGY INVESTIGATIONS; SMALL LABORATORY-ANIMALS; INTRAVENOUS (H2O)-O-15; BETA-MICROPROBE; ERROR ANALYSIS; PET; OXYGEN; INHALATION AB We developed an intra-arterial positron-probe (beta(+)-probe) system to measure the arterial time-activity concentration in humans for quantitative compartmental modeling of positron emission tomography studies. Performance was characterized in vitro, by using a uniform phantom to calculate dead time, linearity, and absolute detector sensitivity. In vitro evaluations in a uniform phantom showed a system dead time of 2.5 mu s, linear regression between measured and true count rates with R(2)=0.999, and detector sensitivity of 6.9-7.0 counts/s kBq(-1) ml. These met or exceeded values of previously reported systems. (c) 2008 American Institute of Physics. C1 [Lee, Kihak; Fox, Peter T.; Lancaster, Jack L.; Jerabek, Paul A.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Lee, Kihak; Fox, Peter T.; Lancaster, Jack L.] Univ Texas San Antonio, Joint Grad Program Biomed Engn, San Antonio, TX 78249 USA. [Fox, Peter T.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA. RP Fox, PT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. EM fox@uthscsa.edu RI Lancaster, Jack/F-2994-2010; Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU NINDS NIH HHS [R21 NS050486, R21 NS 050486] NR 35 TC 3 Z9 3 U1 0 U2 0 PU AMER INST PHYSICS PI MELVILLE PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1, MELVILLE, NY 11747-4501 USA SN 0034-6748 J9 REV SCI INSTRUM JI Rev. Sci. Instrum. PD JUN PY 2008 VL 79 IS 6 AR 064301 DI 10.1063/1.2936880 PG 7 WC Instruments & Instrumentation; Physics, Applied SC Instruments & Instrumentation; Physics GA 321DA UT WOS:000257283700031 PM 18601420 ER PT J AU Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S Ragan, SL AF Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra Ragan, Sandra L. TI Communicating a terminal prognosis in a palliative care setting: Deficiencies in current communication training protocols SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE USA; end-of-life; medical education; communication; palliative care; terminal prognosis ID BREAKING BAD-NEWS; OF-LIFE CARE; CANCER; END; PERSPECTIVE; GUIDELINES AB The goal of this study was to understand the use and effectiveness of current communication protocols in terminal prognosis disclosures. Data were gathered from an interdisciplinary palliative care consultation service team at a Veterans Hospital in Texas, USA. Medical communication guidelines, a consistent component in United States palliative care education, propose models for delivery of bad news. However, there is little empirical evidence that demonstrates the effectiveness of these guidelines in disclosures of a terminal prognosis. Based on ethnographic observations of terminal prognosis meetings with dying patients, palliative care team meetings, and semi-structured interviews with palliative care team practitioners, this study notes the contradictory conceptualizations of current bad news communication guidelines and highlights that communicating a terminal prognosis also includes (1) adaptive communication based on the patient's acceptability, (2) team based/family communication as opposed to physician-patient dyadic communication, and (3) diffusion of topic through repetition and definition as opposed to singularity of topic. We conclude that environmentally based revision to communication protocol and practice in medical school training is imperative. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. RP Wittenberg-Lyles, EM (reprint author), Univ N Texas, POB 305268, Denton, TX 76203 USA. EM lyles@unt.edu; jgoldsmith@yhc.edu; sanchezreill@uthscsa.edu; sragan@ou.edu NR 24 TC 18 Z9 20 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD JUN PY 2008 VL 66 IS 11 BP 2356 EP 2365 DI 10.1016/j.socscimed.2008.01.042 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 307QW UT WOS:000256334400015 PM 18321625 ER PT J AU Glasheen, JJ Prochazka, AV AF Glasheen, Jeffrey J. Prochazka, Allan V. TI Further evidence of a clinically significant levofloxacin-warfarin interaction SO SOUTHERN MEDICAL JOURNAL LA English DT Letter ID INTERNATIONAL NORMALIZED RATIOS; THERAPY C1 [Glasheen, Jeffrey J.; Prochazka, Allan V.] Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver VA Med Ctr, Denver, CO 80262 USA. RP Glasheen, JJ (reprint author), Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver VA Med Ctr, Denver, CO 80262 USA. NR 4 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD JUN PY 2008 VL 101 IS 6 BP 660 EP 660 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 310UC UT WOS:000256554900035 PM 18475216 ER PT J AU Ullrich, PM Jensen, MP Loeser, JD Cardenas, DD AF Ullrich, P. M. Jensen, M. P. Loeser, J. D. Cardenas, D. D. TI Pain intensity, pain interference and characteristics of spinal cord injury SO SPINAL CORD LA English DT Article DE pain site; spinal cord injury; pain; pain interference; functioning AB Study Design: Postal survey. Objectives: To examine if the intensity of pain in persons with spinal cord injury (SCI) varied as a function of pain site, and to identify the patient and SCI characteristics associated with pain location, pain intensity and pain interference in a sample of persons with SCI. Setting: Community sample, United States. Methods: A postal survey including measures of pain intensity, pain interference, other pain, demographic and medical characteristics was completed by 238 adults with SCI. Results: Average pain intensity was moderate and pain was common across the body. Demographic and medical variables, including SCI level, were generally not associated with pain prevalence, intensity and interference. However, persons with higher level injuries were more likely to report upper extremity pain than persons with paraplegic injuries. The lower body was the location of the highest pain ratings. Conclusion: Persons with SCI tend to experience high pain intensity over multiple body locations. Lower body pain was as common as upper extremity pain, but tended to be more intense. C1 [Ullrich, P. M.; Jensen, M. P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98101 USA. [Ullrich, P. M.] VA Puget Sound Healthcare Syst, Spinal Cord Injury Qual Enhancement Res Initiat, Dept Vet Affairs, Seattle, WA USA. [Loeser, J. D.] Univ Washington, Dept Neurol Surg, Seattle, WA 98101 USA. [Cardenas, D. D.] Univ Miami, Miller Sch Med, Dept Rehabil Med, Miami, FL 33136 USA. RP Ullrich, PM (reprint author), Univ Washington, Dept Rehabil Med, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM philip.ullrich@va.gov FU NICHD NIH HHS [P01 HD33988, P01 HD033988-04, P01 HD033988] NR 20 TC 26 Z9 29 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD JUN PY 2008 VL 46 IS 6 BP 451 EP 455 DI 10.1038/sc.2008.5 PG 5 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 309NX UT WOS:000256468600011 PM 18283293 ER PT J AU Liu, YY Brent, GA AF Liu, Yan-Yun Brent, Gregory A. TI Stealth sequences in reporter gene vectors confound studies of T3-regulated negative gene expression SO THYROID LA English DT Editorial Material ID THYROID-HORMONE RECEPTOR; LUCIFERASE; PROMOTER; CELLS C1 [Liu, Yan-Yun; Brent, Gregory A.] VA Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Los Angeles, CA 90073 USA. RP Liu, YY (reprint author), VA Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [NIH R01 DK67233] NR 11 TC 2 Z9 2 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD JUN PY 2008 VL 18 IS 6 BP 593 EP 595 DI 10.1089/thy.2008.0138 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 327WS UT WOS:000257759800001 PM 18578606 ER PT J AU Salem, AK Fenton, MS Marion, KM Hershman, JM AF Salem, Andrew K. Fenton, Mike S. Marion, Kenneth M. Hershman, Jerome M. TI Effect of sunitinib on growth and function of FRTL-5 thyroid cells SO THYROID LA English DT Article ID SYMPORTER GENE-EXPRESSION; HYPOTHYROIDISM AB Background: Sunitinib, a multitargeted vascular endothelial growth factor and receptor tyrosine kinase inhibitor, causes hypothyroidism in patients who take it for treatment of cancer. Although the pathophysiologic mechanism of the hypothyroidism is unclear, it has been claimed that it is due to inhibition of iodide uptake. Methods: To evaluate the pathologic mechanism of induction of the hypothyroidism, we studied the effect of sunitinib on FRTL-5 rat thyroid cells. We measured the effect of sunitinib on cell growth, I-125-iodide uptake and efflux, TSH receptor (TSH-R), and sodium-iodide symporter (NIS) message. Results: At 48 hours, sunitinib caused a dose-related inhibition of growth with LC50 of 14.6 mu M, but there was no apparent inhibition of growth at 24 hours at concentrations of 0.1-25 mu M. Preincubation with sunitinib did not impair the response to TSH, indicating that it did not affect the TSH-R. Incubation with sunitinib for 24 hours caused a dose-related increase of I-125-iodide uptake and did not reduce iodide efflux or NIS mRNA expression. Conclusion: The data indicate that sunitinib is unlikely to cause hypothyroidism by inhibition of iodide uptake. C1 [Hershman, Jerome M.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare System, Endocrinol & Diabet Div, Endocrine Res Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Hershman, JM (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare System, Endocrinol & Diabet Div, Endocrine Res Lab, Endocrinol 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu RI Salem, Aliasger /J-3674-2012 OI Salem, Aliasger /0000-0002-1923-6633 NR 13 TC 32 Z9 34 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD JUN PY 2008 VL 18 IS 6 BP 631 EP 635 DI 10.1089/thy.2007.0336 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 327WS UT WOS:000257759800007 PM 18578612 ER PT J AU Rawat, A Huynh, TT Peden, EK Kougias, P Lin, PH AF Rawat, Anish Huynh, Taro T. Peden, Eric K. Kougias, Panagiotis Lin, Peter H. TI Primary Prophylaxis of Venous Thromboembolism in Surgical Patients SO VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE venous thromboembolism; deep-venous thrombosis; pulmonary embolism; complication; heparin; inferior vena cava filter; LMWH; warfarin; mechanical prophylaxis; pharmacological prophylaxis ID DEEP-VEIN THROMBOSIS; INTERMITTENT PNEUMATIC COMPRESSION; MOLECULAR-WEIGHT HEPARINS; RISK TRAUMA PATIENTS; PULMONARY-EMBOLISM; UNFRACTIONATED HEPARIN; INDUCED THROMBOCYTOPENIA; ANTICOAGULANT-THERAPY; BYPASS-SURGERY; PREVENTION AB Venous thromboembolism is a major risk for surgical patients during the perioperative period. Prevention of perioperative venous thromboembolism remains a critical component of surgical patient care. The risk for venous thromboembolism in Surgical patients can he stratified by their risk factors and by the type of operation. Pharmacological prophylaxis for venous thromboembolism includes unfractionated heparin, low-molecular weight heparin, fondaparinux, warfarin, antiplatelet therapy, and direct thrombin inhibitors. Mechanical devices such Lis graduated compression stockings, intermittent pneumatic compressions, and venous foot pumps are also effective modalities for venous thromboembolism prophylaxis. The optimal preventive measure of venous thromboembolism should he based on the degree of risk for venous thromboembolism with the intensity of prophylaxis while balancing potential treatment benefits and risks in each individual patient. The epidemiology of venous thromboembolism, the methods for achieving venous thromboembolism prophylaxis, and the approach to institute venous thromboembolism prophylaxis in surgical patients undergoing various operative interventions are reviewed in this article. C1 [Lin, Peter H.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston VA Med Ctr, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. [Peden, Eric K.] Methodist Hosp, Houston, TX 77030 USA. [Rawat, Anish; Huynh, Taro T.; Kougias, Panagiotis; Lin, Peter H.] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Lin, PH (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Houston VA Med Ctr, Div Vasc Surg & Endovasc Therapy, 2002 Holcomh Blvd 112, Houston, TX 77030 USA. EM plin@bcm.edu NR 71 TC 9 Z9 10 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1538-5744 EI 1938-9116 J9 VASC ENDOVASC SURG JI Vasc. Endovasc. Surg. PD JUN-JUL PY 2008 VL 42 IS 3 BP 205 EP 216 DI 10.1177/1538574408315208 PG 12 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 394QY UT WOS:000262463600001 PM 18375602 ER PT J AU Barshes, NR Annambhotla, S Bechara, C Kougias, P Huynh, TT Dardik, A Silva, MB Lin, PH AF Barshes, Neal R. Annambhotla, Suman Bechara, Carlos Kougias, Panagiotis Huynh, Tam T. Dardik, Alan Silva, Michael B., Jr. Lin, Peter H. TI Endovascular Repair of Hemodialysis Graft-Related Pseudoaneurysm: An Alternative Treatment Strategy in Salvaging Failing Dialysis Access SO VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE arteriovenous grafts; endograft exclusion; endovascular repair; hemodialysis; hemodialysis complication pseudoaneurysm; stent graft repair ID STAGE RENAL-DISEASE; COVERED STENTS; ARTERIOVENOUS-FISTULAS; COMPLICATIONS; WALLGRAFT; ANEURYSMS AB Introduction Hemodialysis access-related pseudoaneurysm is a known complication in patients requiring hemodialysis via prosthetic arteriovenous grafts (AVGs). The traditional treatment strategy of AVG-related pseudoaneurysms is either AVG ligation or interposition replacement with another prosthetic graft segment or autogenous veins. Patients and methods From June 2002 to August 2007, 32 self-expanding stent grafts were implanted in 26 patients with AVG pseudoaneurysms. Indications for treatment consisted of large AVG pseudoaneurysm sire, localized pain at pseudoaneurysm site, enlarging pseudoaneurysm, and skin site breakdown. AVG pseudoaneurysm exclusion was accomplished with Wallgrafts, Viabahn endoprosthesis, and Fluency endograft. Technical success was achieved in all patients. Nineteen patients experienced a marked decrease in the size of their pseudoaneurysm following endograft exclusion. Successful hemodialysis was resumed through endograft-excluded AVG in all patients within 48 hours. Conclusions Endoluminal exclusion of AVG pseudoaneurysms using endografts is a safe and effective treatment strategy in patients with hemodialysis-related pseudoaneurysm. C1 [Lin, Peter H.] Baylor Coll Med, Houston VAMC, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. [Barshes, Neal R.; Annambhotla, Suman; Bechara, Carlos; Kougias, Panagiotis; Huynh, Tam T.; Lin, Peter H.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Dardik, Alan] Yale Univ, Sch Med, Dept Surg, Div Vasc Surg, New Haven, CT 06510 USA. [Dardik, Alan] VA Connecticut Healthcare Syst, New Haven, CT USA. [Silva, Michael B., Jr.] Univ Texas Galveston, Med Branch, Vasc Surg Sect, Dept Surg, Galveston, TX 77550 USA. RP Lin, PH (reprint author), Baylor Coll Med, Houston VAMC, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcomb Blvd 112, Houston, TX 77030 USA. EM plin@bcm.tmc.edu NR 21 TC 25 Z9 27 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1538-5744 J9 VASC ENDOVASC SURG JI Vasc. Endovasc. Surg. PD JUN-JUL PY 2008 VL 42 IS 3 BP 228 EP 234 DI 10.1177/1538574408314443 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 394QY UT WOS:000262463600004 PM 18375603 ER PT J AU Chen, WL Song, BB Zhang, GH Marvizon, JCG AF Chen, Wenling Song, Bingbing Zhang, Guohua Marvizon, Juan Carlos G. TI Effects of veratridine and high potassium on mu-opioid receptor internalization in the rat spinal cord: Stimulation of opioid release versus inhibition of internalization SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE depolarization; dynorphin; enkephalin; internalization; Na+ channels; potassium; substance P; veratridine ID ENKEPHALIN-LIKE MATERIAL; DORSAL-HORN NEURONS; MEDIAL PREOPTIC NUCLEUS; NOXIOUS THERMAL STIMULI; PRIMARY AFFERENT-FIBERS; SUBSTANCE-P RELEASE; METHYL-D-ASPARTATE; GABA(B) RECEPTORS; SEGMENTAL RELEASE; ANESTHETIZED RATS AB Veratridine and high K+-induced mu-opioid receptor (MOR) internalization in rat spinal cord slices by evoking opioid release. Veratridine induced up to 75 % MOR internalization but showed an atypical concentration-response: its effect increased steeply from 5 mu M to 10 mu M, and declined thereafter to disappear at 100 mu M. At 100 mu M, veratridine also inhibited of MOR internalization induced by exogenous endomorphin-2. This inhibition was caused by Na+ entry, since the Ne ionophore monensin (50 mu M) also inhibited endomorphin-induced MOR internalization. In contrast, veratridine induced neurokinin 1 receptor internalization (by evoking substance P release) without any inhibition at high concentrations. KCl evoked up to 80% MOR internalization, which disappeared in the presence of lidocaine or in the absence of peptidase inhibitors, indicating that it involved neuronal firing and peptide release. Unlike veratridine, KCl did not inhibit MOR internalization at high concentrations. However, both KCl and veratridine evoked more MOR internalization when applied for 2 min than for 20 min because of a direct inhibition of MOR internalization with the longer incubation times. These results show that short incubations with 20 mu M veratridine or 30 mM KCl are optimal stimuli to evoke opioid release and MOR internalization in the spinal cord. (C) 2008 Elsevier B.V. All rights reserved. C1 [Chen, Wenling; Zhang, Guohua; Marvizon, Juan Carlos G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Chen, Wenling; Song, Bingbing; Zhang, Guohua; Marvizon, Juan Carlos G.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, CURE Digest Dis Res Ctr,Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. RP Marvizon, JCG (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM marvizon@ucla.edu FU NIDA NIH HHS [R01 DA012609-07, R01 DA012609-08, R01 DA012609, 2-R01-DA012609] NR 52 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 J9 J NEUROSCI METH JI J. Neurosci. Methods PD MAY 30 PY 2008 VL 170 IS 2 BP 285 EP 293 DI 10.1016/j.jneumeth.2008.01.032 PG 9 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 300TX UT WOS:000255849200012 PM 18377995 ER PT J AU Zinzow, HM Grubaugh, AL Frueh, BC Magruder, KM AF Zinzow, Heidi M. Grubaugh, Anouk L. Frueh, Bartley Christopher Magruder, Kathryn M. TI Sexual assault, mental health, and service use among male and female veterans seen in Veterans Affairs primary care clinics: A multi-site study SO PSYCHIATRY RESEARCH LA English DT Article DE trauma; revictimization; sexual abuse; child sexual abuse; assault characteristics; psychiatric functioning; healthcare; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; WOMEN VETERANS; CHILDHOOD ABUSE; RISK-FACTORS; CRIMINAL VICTIMIZATION; PSYCHOLOGICAL IMPACT; GENERAL-POPULATION; GENDER-DIFFERENCES; TRAUMATIC EVENTS; SOMATIC SYMPTOMS AB This study examined the nature and prevalence of sexual assault (SA), as well as its relationship to psychiatric sequelae and service use, among the veteran population. We performed a secondary data analysis of a cross-sectional dataset consisting of 643 male and 173 female veterans seen in four Veterans Affairs (VA) primary care clinics. Original data were obtained through semi-structured clinic assessments, structured telephone interviews, and medical chart reviews. Analyses included descriptive statistics, chi-square, analysis of variance (ANOVA), and logistic regression. The lifetime prevalence of SA was 38% among women and 6% among men. Of veterans reporting a history of SA, most experienced child sexual abuse and sexual revictimization. SA victims also had a more extensive trauma history and demonstrated greater psychological impairment in comparison to veterans reporting other types of trauma. However, only 25% of male SA survivors and 38% of female SA survivors used mental health services in the past year. These findings suggest that VA primary care clinics may benefit from expanding the current mandated screen for military sexual trauma to include lifetime experiences and trauma-related symptoms, thereby connecting more veterans with needed mental health services. (C) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Grubaugh, Anouk L.; Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Zinzow, Heidi M.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA. [Grubaugh, Anouk L.; Magruder, Kathryn M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Frueh, Bartley Christopher] Univ Hawaii, Hilo, HI 96720 USA. RP Grubaugh, AL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, POB 250861, Charleston, SC 29425 USA. EM grubaugh@musc.edu NR 60 TC 24 Z9 26 U1 6 U2 19 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAY 30 PY 2008 VL 159 IS 1-2 BP 226 EP 236 DI 10.1016/j.psychres.2007.04.008 PG 11 WC Psychiatry SC Psychiatry GA 310GU UT WOS:000256517700030 PM 18423615 ER PT J AU Sales, A Helfrich, C Ho, PM Hedeen, A Plomondon, ME Li, YF Connors, A Rumsfeld, JS AF Sales, Anne Helfrich, Christian Ho, P. Michael Hedeen, Ashley Plomondon, Mary E. Li, Yu-Fang Connors, Alison Rumsfeld, John S. TI Implementing electronic clinical reminders for lipid management in patients with ischemic heart disease in the veterans health administration: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID SCANDINAVIAN SIMVASTATIN SURVIVAL; RANDOMIZED-TRIAL; PRIMARY-CARE; DECISION-SUPPORT; CORONARY EVENTS; GUIDELINES; BARRIERS; SYSTEMS; INTERVENTIONS; REDUCTION AB Background: Ischemic heart disease (IHD) affects at least 150,000 veterans annually in the United States. Lowering serum cholesterol has been shown to reduce coronary events, cardiac death, and total mortality among high risk patients. Electronic clinical reminders available at the point of care delivery have been developed to improve lipid measurement and management in the Veterans Health Administration (VHA). Our objective was to report on a hospital-level intervention to implement and encourage use of the electronic clinical reminders. Methods: The implementation used a quasi- experimental design with a comparison group of hospitals. In the intervention hospitals (N = 3), we used a multi-faceted intervention to encourage use of the electronic clinical reminders. We evaluated the degree of reminder use and how patient-level outcomes varied at the intervention and comparison sites (N = 3), with and without adjusting for self-reported reminder use. Results: The national electronic clinical reminders were implemented in all of the intervention sites during the intervention period. A total of 5,438 patients with prior diagnosis of ischemic heart disease received care in the six hospitals (3 intervention and 3 comparison) throughout the 12-month intervention. The process evaluation showed variation in use of reminders at each site. Without controlling for provider self-report of use of the reminders, there appeared to be a significant improvement in lipid measurement in the intervention sites (OR 1.96, 95% CI 1.34, 2.88). Controlling for use of reminders, the amount of improvement in lipid measurement in the intervention sites was even greater (OR 2.35, CI 1.96, 2.81). Adjusting for reminder use demonstrated that only one of the intervention hospitals had a significant effect of the intervention. There was no significant change in management of hyperlipidemia associated with the intervention. Conclusion: There may be some benefit to focused effort to implement electronic clinical reminders, although reminders designed to improve relatively simple tasks, such as ordering tests, may be more beneficial than reminders designed to improve more complex tasks, such as initiating or titrating medications, because of the less complex nature of the task. There is value in monitoring the process, as well as outcome, of an implementation effort. C1 [Sales, Anne; Connors, Alison] Univ Alberta, Edmonton, AB, Canada. [Helfrich, Christian; Hedeen, Ashley; Li, Yu-Fang] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Ho, P. Michael; Plomondon, Mary E.; Rumsfeld, John S.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Ho, P. Michael; Plomondon, Mary E.; Rumsfeld, John S.] Univ Denver, Hlth Sci Ctr, Denver, CO USA. RP Sales, A (reprint author), Univ Alberta, Edmonton, AB, Canada. EM anne.sales@ualberta.ca; christian.helfrich@va.gov; michael.ho@va.gov; ashley.hedeen@va.gov; meg.plomondon@va.gov; yufang.li@va.gov; lucarott@ualberta.ca; john.rumsfeld@va.gov RI Sales, Anne/D-9678-2012; Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768; Sales, Anne/0000-0001-9360-3334 FU Department of Veterans Affairs (VA) Health Services Research and Development Service [IHT 01-040] FX This study was supported by the Department of Veterans Affairs (VA) Health Services Research and Development Service, IHT 01-040. The views expressed in this article are those of the authors and do not necessarily represent the position or policy of the U.S. Department of Veterans Affairs. NR 38 TC 12 Z9 12 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAY 29 PY 2008 VL 3 AR 28 DI 10.1186/1748-5908-3-28 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432RH UT WOS:000265151300001 PM 18510748 ER PT J AU Stetler, CB McQueen, L Demakis, J Mittman, BS AF Stetler, Cheryl B. McQueen, Lynn Demakis, John Mittman, Brian S. TI An organizational framework and strategic implementation for system-level change to enhance research-based practice: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID HEALTH-CARE; QUALITY IMPROVEMENT; UNITED-STATES; VETERANS; INTERVENTIONS; TRANSLATION; PROGRAMS; ADULTS AB Background: The continuing gap between available evidence and current practice in health care reinforces the need for more effective solutions, in particular related to organizational context. Considerable advances have been made within the U.S. Veterans Health Administration (VA) in systematically implementing evidence into practice. These advances have been achieved through a system-level program focused on collaboration and partnerships among policy makers, clinicians, and researchers. The Quality Enhancement Research Initiative (QUERI) was created to generate research-driven initiatives that directly enhance health care quality within the VA and, simultaneously, contribute to the field of implementation science. This paradigm-shifting effort provided a natural laboratory for exploring organizational change processes. This article describes the underlying change framework and implementation strategy used to operationalize QUERI. Strategic approach to organizational change: QUERI used an evidence-based organizational framework focused on three contextual elements: 1) cultural norms and values, in this case related to the role of health services researchers in evidence-based quality improvement; 2) capacity, in this case among researchers and key partners to engage in implementation research; 3) and supportive infrastructures to reinforce expectations for change and to sustain new behaviors as part of the norm. As part of a QUERI Series in Implementation Science, this article describes the framework's application in an innovative integration of health services research, policy, and clinical care delivery. Conclusion: QUERI's experience and success provide a case study in organizational change. It demonstrates that progress requires a strategic, systems-based effort. QUERI's evidence-based initiative involved a deliberate cultural shift, requiring ongoing commitment in multiple forms and at multiple levels. VA's commitment to QUERI came in the form of visionary leadership, targeted allocation of resources, infrastructure refinements, innovative peer review and study methods, and direct involvement of key stakeholders. Stakeholders included both those providing and managing clinical care, as well as those producing relevant evidence within the health care system. The organizational framework and related implementation interventions used to achieve contextual change resulted in engaged investigators and enhanced uptake of research knowledge. QUERI's approach and progress provide working hypotheses for others pursuing similar system-wide efforts to routinely achieve evidence-based care. C1 [Stetler, Cheryl B.] Independent Consultant, Amherst, MA USA. [McQueen, Lynn] US Dept Vet Affairs, Off Qual Performance, Washington, DC USA. [Demakis, John] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Washington, DC USA. [Mittman, Brian S.] Vet Affairs Greater Los Angeles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. RP Stetler, CB (reprint author), Independent Consultant, Amherst, MA USA. EM Cheryl.Stetler@comcast.net; Lynn.McQueen@va.gov; jgd11@erols.com; Brian.Mittman@va.gov NR 45 TC 55 Z9 56 U1 3 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAY 29 PY 2008 VL 3 AR 30 DI 10.1186/1748-5908-3-30 PG 11 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432RH UT WOS:000265151300003 PM 18510750 ER PT J AU Yano, EM AF Yano, Elizabeth M. TI The role of organizational research in implementing evidence-based practice: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID HEALTH-CARE-SYSTEM; PREVENTIVE SERVICE DELIVERY; RANDOMIZED CONTROLLED-TRIAL; AFFAIRS MEDICAL-CENTERS; QUALITY-IMPROVEMENT; VETERANS; INTERVENTIONS; STRATEGIES; MANAGEMENT; PERFORMANCE AB Background: Health care organizations exert significant influence on the manner in which clinicians practice and the processes and outcomes of care that patients experience. A greater understanding of the organizational milieu into which innovations will be introduced, as well as the organizational factors that are likely to foster or hinder the adoption and use of new technologies, care arrangements and quality improvement (QI) strategies are central to the effective implementation of research into practice. Unfortunately, much implementation research seems to not recognize or adequately address the influence and importance of organizations. Using examples from the U. S. Department of Veterans Affairs (VA) Quality Enhancement Research Initiative (QUERI), we describe the role of organizational research in advancing the implementation of evidence-based practice into routine care settings. Methods: Using the six-step QUERI process as a foundation, we present an organizational research framework designed to improve and accelerate the implementation of evidence-based practice into routine care. Specific QUERI-related organizational research applications are reviewed, with discussion of the measures and methods used to apply them. We describe these applications in the context of a continuum of organizational research activities to be conducted before, during and after implementation. Results: Since QUERI's inception, various approaches to organizational research have been employed to foster progress through QUERI's six-step process. We report on how explicit integration of the evaluation of organizational factors into QUERI planning has informed the design of more effective care delivery system interventions and enabled their improved "fit" to individual VA facilities or practices. We examine the value and challenges in conducting organizational research, and briefly describe the contributions of organizational theory and environmental context to the research framework. Conclusion: Understanding the organizational context of delivering evidence-based practice is a critical adjunct to efforts to systematically improve quality. Given the size and diversity of VA practices, coupled with unique organizational data sources, QUERI is well-positioned to make valuable contributions to the field of implementation science. More explicit accommodation of organizational inquiry into implementation research agendas has helped QUERI researchers to better frame and extend their work as they move toward regional and national spread activities. C1 [Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Vet Affairs Hlth Serv Res & Dev, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Yano, EM (reprint author), VA Greater Los Angeles Healthcare Syst, Vet Affairs Hlth Serv Res & Dev, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA. EM elizabeth.yano@va.gov FU Veterans Health Administration, VA Health Services Research & Development (HSR&D) Service through the VA Greater Los Angeles HSR&D Center of Excellence [HFP 94-028, MNT 01-027, RCS 05-195] FX This work was funded by the U.S. Department of Veterans Affairs, Veterans Health Administration, VA Health Services Research & Development (HSR&D) Service through the VA Greater Los Angeles HSR&D Center of Excellence (Project #HFP 94-028), the VA HSR&D and QUERI-funded "Regional Expansion and Testing of Depression Collaborative Care" (ReTIDES) (Project #MNT 01-027), and Dr. Yano's VA HSR&D Research Career Scientist award (Project #RCS 05-195). The author also would like to acknowledge and thank the editors and reviewers for their thoughtful critiques and useful input. NR 99 TC 32 Z9 36 U1 3 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAY 29 PY 2008 VL 3 AR 29 DI 10.1186/1748-5908-3-29 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432RH UT WOS:000265151300002 PM 18510749 ER PT J AU Ho, PM Rumsfeld, JS AF Ho, P. Michael Rumsfeld, John S. TI Adverse events associated with stopping clopidogrel after acute coronary syndrome - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO 80220 USA. RP Ho, PM (reprint author), Denver VA Med Ctr, Denver, CO 80220 USA. EM michael.ho@uchsc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 28 PY 2008 VL 299 IS 20 BP 2389 EP 2390 DI 10.1001/jama.299.20.jlt0528-h PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 305BD UT WOS:000256151900019 ER PT J AU Baruch, L Agarwal, S Gupta, B Haynos, A Eng, C AF Baruch, Lawrence Agarwal, Sanjay Gupta, Bhanu Haynos, Anne Eng, Calvin TI Direct LDL measurement: Friend or foe? SO CIRCULATION LA English DT Meeting Abstract CT 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY APR 30-MAY 02, 2008 CL Baltimore, MD C1 [Baruch, Lawrence; Agarwal, Sanjay; Gupta, Bhanu; Haynos, Anne; Eng, Calvin] James J Peters VA Med Cntr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 27 PY 2008 VL 117 IS 21 MA 84 BP E428 EP E428 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 305EN UT WOS:000256160700102 ER PT J AU Bradley, SM Veenstra, DL AF Bradley, Steven M. Veenstra, David L. TI Cost-effectiveness of ultrafiltration for acute decompensated heart failure: A decision model approach SO CIRCULATION LA English DT Meeting Abstract CT 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY APR 30-MAY 02, 2008 CL Baltimore, MD C1 [Bradley, Steven M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Veenstra, David L.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 27 PY 2008 VL 117 IS 21 MA 130 BP E438 EP E438 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 305EN UT WOS:000256160700147 ER PT J AU Fihn, SD Vaughan-Sarrazin, M Lowy, E Popescu, I Maynard, C Rosenthal, GE Sales, AE Rumsfeld, J Jesse, R Almenoff, P Fleming, B Kussman, M AF Fihn, Stephan D. Vaughan-Sarrazin, Mary Lowy, Elliott Popescu, Ioana Maynard, Charles Rosenthal, Gary E. Sales, Anne E. Rumsfeld, John Jesse, Robert Almenoff, Peter Fleming, Barbara Kussman, Michael TI Trends in mortality following acute myocardial infarction in the veterans health administration and medicare funded hospitals SO CIRCULATION LA English DT Meeting Abstract CT 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY APR 30-MAY 02, 2008 CL Baltimore, MD C1 [Fihn, Stephan D.; Maynard, Charles] Univ Washington, Seattle, WA 98195 USA. [Fihn, Stephan D.; Lowy, Elliott; Maynard, Charles] VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Vaughan-Sarrazin, Mary; Popescu, Ioana; Rosenthal, Gary E.] Univ Iowa, Iowa City, IA USA. [Vaughan-Sarrazin, Mary; Popescu, Ioana; Rosenthal, Gary E.] Iowa City VA Med Cntr, Iowa City, IA USA. [Sales, Anne E.] Univ Alberta, Edmonton, AB, Canada. [Rumsfeld, John] Univ Colorado, Denver, CO 80202 USA. [Rumsfeld, John] Denver VA Med Cntr, Denver, CO 80202 USA. [Jesse, Robert; Almenoff, Peter; Fleming, Barbara; Kussman, Michael] Dept Vet Affairs, Washington, DC USA. RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 27 PY 2008 VL 117 IS 21 MA 129 BP E438 EP E438 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 305EN UT WOS:000256160700146 ER PT J AU Heidenreich, P Sahay, A Shlipak, M Van Osteyerean, D Ansari, M Massie, B AF Heidenreich, Paul Sahay, Anju Shlipak, Michael Van Osteyerean, Denise Ansari, Maria Massie, Barry TI Cost-effectiveness of a nurse based clinic to initate beta-blocker therapy in patients with heart failure SO CIRCULATION LA English DT Meeting Abstract CT 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY APR 30-MAY 02, 2008 CL Baltimore, MD C1 [Heidenreich, Paul] VA Palo Alto HCS, Palo Alto, CA USA. [Shlipak, Michael; Massie, Barry] San Francisco VA Med Ctr, San Francisco, CA USA. [Van Osteyerean, Denise] Portland VA Med Cntr, Portland, OR USA. [Ansari, Maria] Kaiser Permanente, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 27 PY 2008 VL 117 IS 21 MA 112 BP E434 EP E434 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 305EN UT WOS:000256160700130 ER PT J AU Ho, PM Maddox, TM Shetterly, SM Rumsfeld, JS Magid, DJ AF Ho, P. Michael Maddox, Thomas M. Shetterly, Susan M. Rumsfeld, John S. Magid, David J. TI The costs of healthcare associated with medication non-adherence SO CIRCULATION LA English DT Meeting Abstract CT 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY APR 30-MAY 02, 2008 CL Baltimore, MD C1 [Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Shetterly, Susan M.; Magid, David J.] Kaiser Pemanente Colorado, Denver, CO USA. NR 0 TC 4 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 27 PY 2008 VL 117 IS 21 MA 228 BP E460 EP E460 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 305EN UT WOS:000256160700243 ER PT J AU Ho, PM Maddox, TM Ross, C Magid, DJ Rumsfeld, JS AF Ho, P. Michael Maddox, Thomas M. Ross, Colleen Magid, David J. Rumsfeld, John S. TI Medication adherence is associated with lower Framingham 10-year Chd risk score SO CIRCULATION LA English DT Meeting Abstract CT 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY APR 30-MAY 02, 2008 CL Baltimore, MD C1 [Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.] DENVER VA MED CTR, Denver, CO USA. [Ross, Colleen; Magid, David J.] Kaiser Permanente Colorado, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 27 PY 2008 VL 117 IS 21 MA 110 BP E434 EP E434 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 305EN UT WOS:000256160700128 ER PT J AU Maddox, TM Plomondon, ME Ho, PM Rumsfeld, JS AF Maddox, Thomas M. Plomondon, Mary E. Ho, P. M. Rumsfeld, John S. TI Secondary prevention among patients with non-obstructive and obstructive CAD SO CIRCULATION LA English DT Meeting Abstract CT 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY APR 30-MAY 02, 2008 CL Baltimore, MD C1 [Maddox, Thomas M.; Plomondon, Mary E.; Ho, P. M.; Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Denver VAMC, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 27 PY 2008 VL 117 IS 21 MA 251 BP E465 EP E465 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 305EN UT WOS:000256160700266 ER PT J AU Shaw, LJ Berman, DS Maron, DJ Mancini, GBJ Weintraub, WS Spertus, JA Sedlis, SP Hayes, S Hartigan, PM O'Rourke, RA Dada, M Chaitman, BR Friedman, J Slomka, P Heller, GV Germano, G Kostuk, W Schwartz, R Bates, ER Teo, KK Boden, WE AF Shaw, Leslee J. Berman, Daniel S. Maron, David J. Mancini, G. B. John Weintraub, William S. Spertus, John A. Sedlis, Steven P. Hayes, Sean Hartigan, Pamela M. O'Rourke, Robert A. Dada, Marcin Chaitman, Bernard R. Friedman, John Slomka, Piotr Heller, Gary V. Germano, Guido Kostuk, William Schwartz, Ronald Bates, Eric R. Teo, Koon K. Boden, William E. TI Correlation between angina and reduced myocardial ischemia: Results from the courage trial nuclear substudy SO CIRCULATION LA English DT Meeting Abstract CT 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY APR 30-MAY 02, 2008 CL Baltimore, MD C1 [Shaw, Leslee J.] Emory Univ, Sch Med, Atlanta, GA USA. [Berman, Daniel S.; Hayes, Sean; Friedman, John; Slomka, Piotr; Germano, Guido] Cedars Sinai Med Cntr, Los Angeles, CA USA. [Maron, David J.] Vanderbilt Univ, Nashville, TN USA. [Mancini, G. B. John] Vancouver Hosp & Hlth Sci Cntr, Vancouver, BC, Canada. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA. [Sedlis, Steven P.] NYU, Sch Med, NYC, NY USA. [Hartigan, Pamela M.] VA Cooperat Studies Program Coordinating Cntr, West Haven, CT USA. [O'Rourke, Robert A.] S Texas Vet HCS, San Antonio, TX USA. [Dada, Marcin; Heller, Gary V.] Hartford Hosp, Hartford, CT 06115 USA. [Chaitman, Bernard R.] St Louis Univ, St Louis, MO 63103 USA. [Kostuk, William] London Hlth Sci Cntr, Hamilton, ON, Canada. [Schwartz, Ronald] Univ Rochester, Rochester, NY USA. [Bates, Eric R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Teo, Koon K.] McMaster Univ, Hamilton, ON, Canada. [Boden, William E.] Buffalo Gen Hosp, Buffalo, NY 14203 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 27 PY 2008 VL 117 IS 21 MA 87 BP E429 EP E429 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 305EN UT WOS:000256160700105 ER PT J AU Groeneveld, PW Matta, MA Greenhut, AP Yang, FF AF Groeneveld, Peter W. Matta, Mary Anne Greenhut, Alexis P. Yang, Feifei TI Drug-eluting compared with bare-metal coronary stents among elderly patients SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID PROPENSITY SCORE METHODS; CLINICAL-OUTCOMES; STANDARD STENT; THROMBOSIS; TRIAL; RESTENOSIS; SIRIUS; ARTERY; DEATH; RISK AB Objectives We sought to determine whether drug-eluting stents ( DES) were associated with improved clinical outcomes compared with bare-metal stents ( BMS) among a nationally representative, nonexperimental elderly patient cohort. Background Randomized controlled clinical trials comparing DES and BMS for treatment of coronary artery disease indicate that although the use of DES reduces rates of coronary restenosis after percutaneous coronary intervention, it does not reduce the rates of mortality or acute myocardial infarction ( AMI). Nevertheless, clinical outcomes of DES in nonexperimental, routine clinical practice are uncertain. Methods We assembled a retrospective cohort of elderly Medicare beneficiaries ( n = 76,525) who received DES within 9 months after Food and Drug Administration approval of the sirolimus-eluting stent ( April 2003 to December 2003). Using propensity score methods, we assembled 2 matched control cohorts who received BMS from July 2002 to March 2003 ( historical controls) or from April 2003 to December 2003 ( contemporary controls). Patient enrollment and claims records were obtained through December 2005 to ascertain mortality, hospitalization for AMI, and subsequent coronary revascularization. Results Receipt of a DES was associated with a significant survival benefit, with an adjusted mortality hazard ratio of 0.83 ( 95% confidence interval 0.81 to 0.86) compared with contemporary controls, and a hazard ratio of 0.79 ( 95% confidence interval 0.77 to 0.81) compared with historical controls ( control group heterogeneity: p < 0.001). Patients with DES had significantly lower adjusted rates of revascularization procedures within the first 2 years after PCI and lower hospitalization rates for subsequent AMI. Conclusions In contrast to clinical trial results, DES receipt was associated with fewer subsequent revascularization procedures, lower rates of hospitalization for AMI, and improved survival among elderly Medicare beneficiaries. C1 [Groeneveld, Peter W.] Philadelphia Vet Adm Med Ctr, Philadelphia Vet Affairs Hlth Care Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.; Matta, Mary Anne; Greenhut, Alexis P.; Yang, Feifei] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Groeneveld, PW (reprint author), Philadelphia Vet Adm Med Ctr, Philadelphia Vet Affairs Hlth Care Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs, 9 E,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM peter.groeneveld@va.gov NR 24 TC 62 Z9 70 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 27 PY 2008 VL 51 IS 21 BP 2017 EP 2024 DI 10.1016/j.jacc.2008.01.057 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 306FR UT WOS:000256234200003 PM 18498954 ER PT J AU Tyler, KL AF Tyler, Kenneth L. TI Bacterial meningitis: An urgent need for further progress to reduce mortality and morbidity SO NEUROLOGY LA English DT Editorial Material ID CLINICAL-FEATURES; ADULTS C1 [Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. [Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Dept Med & Microbiol, Denver, CO 80262 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Serv Neurol, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, Neurol B-182,4200 E 9th Ave, Denver, CO 80262 USA. EM ken.tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 NR 11 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 27 PY 2008 VL 70 IS 22 BP 2095 EP 2096 DI 10.1212/01.wnl.0000313158.07093.6a PN 2 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 312YG UT WOS:000256707700002 PM 18505990 ER PT J AU Medina, MT Suzuki, T Alonso, ME Duron, RM Martinez-Juarez, IE Bailey, JN Bai, D Inoue, Y Yoshimura, I Kaneko, S Montoya, MC Ochoa, A Prado, AJ Tanaka, M Machado-Salas, J Fujimoto, S Ito, M Hamano, S Sugita, K Ueda, Y Osawa, M Oguni, H Rubio-Donnadieu, F Yamakawa, K Delgado-Escueta, AV AF Medina, M. T. Suzuki, T. Alonso, M. E. Duron, R. M. Martinez-Juarez, I. E. Bailey, J. N. Bai, D. Inoue, Y. Yoshimura, I. Kaneko, S. Montoya, M. C. Ochoa, A. Prado, A. Jara Tanaka, M. Machado-Salas, J. Fujimoto, S. Ito, M. Hamano, S. Sugita, K. Ueda, Y. Osawa, M. Oguni, H. Rubio-Donnadieu, F. Yamakawa, K. Delgado-Escueta, A. V. TI Novel mutations in Myoclonin1/EFHC1 in sporadic and familial juvenile myoclonic epilepsy SO NEUROLOGY LA English DT Article ID IDIOPATHIC GENERALIZED EPILEPSY; EFHC1; GENE; SUSCEPTIBILITY; PHOTOSENSITIVITY; IDENTIFICATION; SEIZURES; CHANNEL; LINKAGE; GABRA1 AB Background: Juvenile myoclonic epilepsy (JME) accounts for 3 to 12% of all epilepsies. In 2004, the GENESS Consortium demonstrated four missense mutations in Myoclonin1/EFHC1 of chromosome 6p12.1 segregating in 20% of Hispanic families with JME. Objective: To examine what percentage of consecutive JME clinic cases have mutations in Myoclonin1/EFHC1. Methods: We screened 44 consecutive patients from Mexico and Honduras and 67 patients from Japan using heteroduplex analysis and direct sequencing. Results: We found five novel mutations in transcripts A and B of Myoclonin1/EFHC1. Two novel heterozygous missense mutations (c. 755C > A and c. 1523C > G) in transcript A occurred in both a singleton from Mexico and another singleton from Japan. A deletion/frameshift (C. 789del. AV264fsx280) in transcript B was present in a mother and daughter from Mexico. A nonsense mutation (c. 829C > T) in transcript B segregated in four clinically and seven epileptiform-EEG affected members of a large Honduran family. The same nonsense mutation (c. 829C > T) occurred as a de novo mutation in a sporadic case. Finally, we found a three-base deletion (-364(boolean AND)- 362del. GAT) in the promoter region in a family from Japan. Conclusion: Nine percent of consecutive juvenile myoclonic epilepsy cases from Mexico and Honduras clinics and 3% of clinic patients from Japan carry mutations in Myoclonin1/EFCH1. These results represent the highest number and percentage of mutations found for a juvenile myoclonic epilepsy causing gene of any population group. C1 [Medina, M. T.; Duron, R. M.; Martinez-Juarez, I. E.; Bailey, J. N.; Bai, D.; Tanaka, M.; Machado-Salas, J.; Delgado-Escueta, A. V.] VA Greater Los Angeles Healthcare Syst W Los Ange, Epilepsy Genet Genom Labs, Epilepsy Ctr Excellence Neurol & Res Serv, Los Angeles, CA 90073 USA. [Bailey, J. N.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci, Los Angeles, CA 90095 USA. [Medina, M. T.; Duron, R. M.; Montoya, M. C.] Natl Autonomous Univ Honduras, Neurol Training Program, Tegucigalpa, Honduras. [Suzuki, T.; Yamakawa, K.] RIKEN, Brain Sci Inst, Saitama, Japan. [Inoue, Y.] Shizuoka Inst Epilepsy Neurol Disorders, Natl Epilepsy Ctr, Shizuoka, Japan. [Yoshimura, I.; Kaneko, S.] Hirosaki Univ, Sch Med, Dept Neuropsychiat, Aomori, Japan. [Fujimoto, S.] Nagoya City Univ, Sch Med, Nagoya, Aichi, Japan. [Ito, M.] Shiga Med Ctr Children, Dept Pediat, Moriyama, Japan. [Hamano, S.] Childrens Med Ctr, Saitama, Japan. [Sugita, K.] Ichikawa Gen Hosp, Tokyo Dent Coll, Dept Paediat, Oral Hlth Sci Ctr, Shiga, Japan. [Ueda, Y.] Miyazaki Univ, Miyazaki Med Coll, Dept Psychiat, Kiyotake, Miyazaki, Japan. [Ito, M.; Oguni, H.] Tokyo Womens Med Univ, Dept Pediat, Tokyo, Japan. RP Delgado-Escueta, AV (reprint author), VA Greater Los Angeles Healthcare Syst W Los Ange, Epilepsy Genet Genom Labs, Epilepsy Ctr Excellence Neurol & Res Serv, Bldg 500,Room 3405,127B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM escueta@ucla.edu RI Yamakawa, Kazuhiro/N-5050-2015 OI Duron, Reyna M./0000-0002-9425-2289; Delgado-Escueta, Antonio V./0000-0002-1581-6999; Martinez-Juarez, Iris E./0000-0001-6512-5312 FU NINDS NIH HHS [R01 NS055057, R01-NS42376] NR 38 TC 38 Z9 39 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 27 PY 2008 VL 70 IS 22 BP 2137 EP 2144 DI 10.1212/01.wnl.0000313149.73035.99 PN 2 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 312YG UT WOS:000256707700009 PM 18505993 ER PT J AU Pugh, MJV Van Cott, AC Cramer, JA Knoefel, JE Amuan, ME Tabares, J Ramsay, RE Berlowitz, DR AF Pugh, M. J. V. Van Cott, A. C. Cramer, J. A. Knoefel, J. E. Amuan, M. E. Tabares, J. Ramsay, R. E. Berlowitz, D. R. CA TIGER Team TI Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004 SO NEUROLOGY LA English DT Article ID NEWLY-DIAGNOSED EPILEPSY; ELDERLY-PATIENTS; DOUBLE-BLIND; SPECIALIST PHYSICIANS; ADULT PATIENTS; HEALTH-CARE; CARBAMAZEPINE; LAMOTRIGINE; SEIZURES; MONOTHERAPY AB Background: Newer antiepileptic drugs (AEDs) have been shown to be equally efficacious as older seizure medications but with fewer neurotoxic and systemic side effects in the elderly. A growing body of clinical recommendations based on systematic literature review and expert opinion advocate the use of the newer agents and avoidance of phenobarbital and phenytoin. This study sought to determine if changes in practice occurred between 2000 and 2004-a time during which evidence and recommendations became increasingly available. Methods: National data from the Veterans Health Administration (VA; inpatient, outpatient, pharmacy) from 1998 to 2004 and Medicare data (1999 - 2004) were used to identify patients 66 years and older with new-onset epilepsy. Initial AED was the first AED received from the VA. AEDs were categorized into four groups: phenobarbital, phenytoin, standard (carbamazepine, valproate), and new (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate). Results: We found a small reduction in use of phenytoin (70.6% to 66.1%) and phenobarbital (3.2% to 1.9%). Use of new AEDs increased significantly from 12.9% to 19.8%, due primarily to use of lamotrigine, levetiracetam, and topiramate. Conclusions: Despite a growing list of clinical recommendations and guidelines, phenytoin was the most commonly used antiepileptic drug, and there was little change in its use for elderly patients over 5 years. Research further exploring physician and health care system factors associated with change (or lack thereof) will provide better insight into the impact of clinical recommendations on practice. C1 [Pugh, M. J. V.] S Texas Vet Hlth Care Syst VERDICT HSR&D, Dept Vet Affairs, San Antonio, TX USA. [Pugh, M. J. V.; Tabares, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Van Cott, A. C.] VA Pittsburgh Healthcare Syst, Dept Internal Med, Pittsburgh, PA USA. [Cramer, J. A.] Yale Univ, Dept Psychiat, West Haven, CT USA. [Knoefel, J. E.] New Mexico Vet Hlth Care Syst, Albuquerque, NM USA. [Amuan, M. E.; Berlowitz, D. R.] Bedford VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Ramsay, R. E.] Univ Miami, Sch Med, Miami, FL USA. RP Pugh, MJV (reprint author), S Texas Vet Hlth Care Syst VERDICT, Audie L Murphy Div 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM PughM@uthscsa.edu RI Ramsay, R. Eugene/D-4491-2011 FU HSRD VA [I01 HX000717] NR 39 TC 54 Z9 54 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 27 PY 2008 VL 70 IS 22 BP 2171 EP 2178 DI 10.1212/01.wnl.0000313157.15089.e6 PN 2 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 312YG UT WOS:000256707700014 PM 18505996 ER PT J AU Singh, H Thomas, EJ Petersen, LA Studdert, DM AF Singh, Hardeep Thomas, Eric J. Petersen, Laura A. Studdert, David M. TI Resident supervision and the electronic medical record - Reply SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter C1 [Singh, Hardeep] Baylor Coll Med, Dept Med, Michael E Debakey VA Med Ctr 152, Houston, TX 77030 USA. RP Singh, H (reprint author), Baylor Coll Med, Dept Med, Michael E Debakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.tmc.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 26 PY 2008 VL 168 IS 10 BP 1118 EP 1118 DI 10.1001/archinte.168.10.1118-b PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 303RA UT WOS:000256057000018 ER PT J AU Guyatt, GH Oxman, AD Kunz, R Jaeschke, R Helfand, M Liberati, A Vist, GE Schunemann, HJ AF Guyatt, Gordon H. Oxman, Andrew D. Kunz, Regina Jaeschke, Roman Helfand, Mark Liberati, Alessandro Vist, Gunn E. Schunemann, Holger J. CA GRADE Working Grp TI GRADE: Incorporating considerations of resources use into grading recommendations SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID COST-EFFECTIVENESS; MAGNESIUM-SULFATE; MAGPIE TRIAL; PREECLAMPSIA; WOMEN C1 [Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Hamilton, ON L8N 3Z5, Canada. [Oxman, Andrew D.; Vist, Gunn E.] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway. [Kunz, Regina] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland. [Jaeschke, Roman] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada. [Helfand, Mark] Portland VA Med Ctr, Portland, OR 97201 USA. [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Liberati, Alessandro] Univ Modena & Reggio Emilia, I-40127 Bologna, Italy. [Liberati, Alessandro] Agenzia Sanit Reg, I-40127 Bologna, Italy. [Schunemann, Holger J.] Italian Natl Canc Inst Regina Elena, Dept Epidemiol, Rome, Italy. RP Guyatt, GH (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Hamilton, ON L8N 3Z5, Canada. EM guyatt@mcmaster.ca RI Whittington, Craig/B-1380-2008; Djulbegovic, Benjamin/I-3661-2012 OI Whittington, Craig/0000-0002-1950-0334; Djulbegovic, Benjamin/0000-0003-0671-1447 NR 11 TC 180 Z9 196 U1 1 U2 11 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD MAY 24 PY 2008 VL 336 IS 7654 BP 1170 EP 1173 DI 10.1136/bmj.39504.506319.80 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 308WJ UT WOS:000256420900039 PM 18497416 ER PT J AU Lieber, CS Leo, MA Wang, XL DeCarli, LM AF Lieber, Charles S. Leo, Maria A. Wang, Xiaolei DeCarli, Leonore M. TI Effect of chronic alcohol consumption on Hepatic SIRT1 and PGC-1 alpha in rats SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE alcohol; CYP2E1; SIRT1; PGC-1 alpha; medium-chain triglycerides ID MEDIUM-CHAIN TRIGLYCERIDES; GENE-EXPRESSION; LIVER; MITOCHONDRIA; METABOLISM; COMPLEX AB The nuclear genes, NAD-dependent deacetylase Sirtuis 1 (SIRT1) and the peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha) are regulators of energy metabolism. Here, we studied the role of alcohol consumption in expression of these sensing molecules. Alcohol significantly reduced hepatic SIRT1 mRNA by 50% and PGC-1 alpha mRNA by 46% and it significantly inhibited the protein expression of SIRT1 and PGC-1 alpha, while the transcription factor PPAR-gamma remained unchanged. However, when the lipid composition of the alcohol diet was changed by replacing long-chain triglycerides (LCT) with medium chain triglycericles (MCT), SIRT1 and PGC-1 alpha mRNA were restored to near control levels. This study demonstrates that alcohol reduces key energy sensing proteins and that replacement of LCT by MCT affects the transcription of these genes. Since there is a pathophysiological link between SIRT1 and PGC-1 alpha and mitochondrial energy, the implication of the study is that mitochondrial dysfunction due to alcohol abuse can be treated by dietary modifications. (c) 2008 Elsevier Inc. All rights reserved. C1 [Lieber, Charles S.; Leo, Maria A.; DeCarli, Leonore M.] James J Peters VA Med Ctr, Liver Dis Sect, Bronx, NY 10468 USA. [Lieber, Charles S.; Leo, Maria A.; Wang, Xiaolei] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Lieber, CS (reprint author), James J Peters VA Med Ctr, Liver Dis Sect, 130 W Kingsbridge Rd 151-2, Bronx, NY 10468 USA. EM liebercs@aol.com NR 29 TC 63 Z9 66 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAY 23 PY 2008 VL 370 IS 1 BP 44 EP 48 DI 10.1016/j.bbrc.2008.03.005 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 294ST UT WOS:000255426700009 PM 18342626 ER PT J AU Misra, S Obeid, LM Hannun, YA Minamisawa, S Berger, FG Markwald, RR Toole, BP Ghatak, S AF Misra, Suniti Obeid, Lina M. Hannun, Yusuf A. Minamisawa, Susumu Berger, Franklin G. Markwald, Roger R. Toole, Bryan P. Ghatak, Shibnath TI Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ANCHORAGE-INDEPENDENT GROWTH; COLORECTAL-CANCER; BETA-CATENIN; MESENCHYMAL-TRANSITION; PROSTATE-CANCER; CYCLOOXYGENASE-2 EXPRESSION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; CD44 EXPRESSION; IN-VITRO AB Hyaluronan is a major component of the pericellular matrix surrounding tumor cells, including colon carcinomas. Elevated cycooxygenase-2 levels have been implicated in several malignant properties of colon cancer. We now show for the first time a strong link between hyaluronan-CD44 interaction and cyclooxygenase-2 in colon cancer cells. First, we have shown that increased expression of hyaluronan synthase-2 induces malignant cell properties, including increased proliferation, anchorage-independent growth, and epithelial-mesenchymal transition in HIEC6 cells. Second, constitutive hyaluronan-CD44 interaction stimulates a signaling pathway involving ErbB2, phosphoinositide 3-kinase/AKT, beta-catenin, and cyclooxygenase-2/prostaglandin E-2 in HCA7 colon carcinoma cells. Third, the HA/CD44-activated ErbB2 --> phosphoinositide 3-kinase/ AKT --> beta-catenin pathway stimulates cell survival/cell proliferation through COX-2 induction in hyaluronan-overexpressing HIEC6 cells and in HCA7 cells. Fourth, perturbation of hyaluronan-CD44 interaction by hyaluronan oligomers or CD44-silencing RNA decreases cyclooxygenase-2 expression and enzyme activity, and inhibition of cyclooxygenase-2 decreases hyaluronan production suggesting the possibility of an amplifying positive feedback loop between hyaluronan and cyclooxygenase-2. We conclude that hyaluronan is an important endogenous regulator of colon cancer cell survival properties and that cyclooxygenase-2 is a major mediator of these hyaluronan-induced effects. Defining hyaluronan-dependent cyclooxygenase-2/prostaglandin E-2-associated signaling pathways will provide a platform for developing novel therapeutic approaches for colon cancer. C1 [Misra, Suniti; Markwald, Roger R.; Toole, Bryan P.; Ghatak, Shibnath] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29401 USA. [Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Berger, Franklin G.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA. [Minamisawa, Susumu] Yokohama City Univ, Dept Physiol, Yokohama, Kanagawa 2360004, Japan. RP Misra, S (reprint author), Med Univ S Carolina, Dept Cell Biol & Anat, 171 Ashley Ave, Charleston, SC 29425 USA. EM misra@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [CA 073839, CA 082867, R01 CA 87584]; NCRR NIH HHS [P20 RR 017698, P20 RR 016434]; NIGMS NIH HHS [GM 062887] NR 73 TC 52 Z9 53 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 23 PY 2008 VL 283 IS 21 BP 14335 EP 14344 DI 10.1074/jbc.M703811200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 302BL UT WOS:000255941400020 PM 18326857 ER PT J AU Volpp, KG AF Volpp, Kevin G. TI A delicate balance - Physician work hours, patient safety, and organizational efficiency SO CIRCULATION LA English DT Editorial Material DE editorials; internship and residency; medical errors; personnel staffing and scheduling ID IN-HOSPITAL MORTALITY; MYOCARDIAL-INFARCTION; OUTCOMES; INTERNS; RISK; REGULATIONS; ADMISSION; REFORM; TIME C1 [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Leonard Davis Inst Hlth Econ, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. RP Volpp, KG (reprint author), 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu FU AHRQ HHS [U18 HS015906]; NHLBI NIH HHS [R01 HL082637]; NIA NIH HHS [P30 AG034546] NR 21 TC 6 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 20 PY 2008 VL 117 IS 20 BP 2580 EP 2582 DI 10.1161/CIRCULATIONAHA.108.777508 PG 3 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 303PQ UT WOS:000256053200004 PM 18490535 ER PT J AU Duvic, M Vanaclocha, F Bernengo, MG Okada, C Breneman, D Zinzani, PL Zhang, L Bopp, K Laird, G Hirawat, S Prince, M AF Duvic, M. Vanaclocha, F. Bernengo, M. G. Okada, C. Breneman, D. Zinzani, P. L. Zhang, L. Bopp, K. Laird, G. Hirawat, S. Prince, M. TI Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Turin, Turin, Italy. Portland VA Med Ctr, Portland, OR USA. Univ Cincinnati, Cincinnati, OH USA. Ist Ematol Oncol Med, Bologna, Italy. Novartis Pharmaceut, Florham Pk, NJ USA. Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. RI Zinzani, Pier Luigi/J-9182-2016 OI Zinzani, Pier Luigi/0000-0002-2112-2651 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2008 VL 26 IS 15 SU S MA 8555 PG 1 WC Oncology SC Oncology GA V25CZ UT WOS:000208457403132 ER PT J AU Hayes, TG Digumarti, R Engelmeyer, J Fodor, M Petrak, K Wang, Y Malik, R Varadhachary, A AF Hayes, T. G. Digumarti, R. Engelmeyer, J. Fodor, M. Petrak, K. Wang, Y. Malik, R. Varadhachary, A. TI Effect of oral talactoferrin (TLF) on levels of cytokines involved in the Th1-mediated immune response in clinical studies SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 VA Med Ctr, Houston, TX USA. Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India. Agennix Inc, Houston, TX USA. Univ Chile, Hosp Clin, Santiago, Chile. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2008 VL 26 IS 15 SU S PG 1 WC Oncology SC Oncology GA V25CZ UT WOS:000208457400718 ER PT J AU Hynes, DM Tarlov, E Lee, T Perrin, R Zhang, Q Ferreira, M Durazo-Arvizu, RA Benson, AB Bentrem, DJ Bennett, CL AF Hynes, D. M. Tarlov, E. Lee, T. Perrin, R. Zhang, Q. Ferreira, M. Durazo-Arvizu, R. A. Benson, A. B., III Bentrem, D. J. Bennett, C. L. TI Examining disparities in colon cancer treatment patterns SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Northwestern Univ, Sch Med, Chicago, IL USA. Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2008 VL 26 IS 15 SU S MA 6534 PG 1 WC Oncology SC Oncology GA V25CZ UT WOS:000208457402411 ER PT J AU Pickard, AS Shaw, JW Lin, H Trask, PC Aaronson, NK Lee, TA Cella, D AF Pickard, A. S. Shaw, J. W. Lin, H. Trask, P. C. Aaronson, N. K. Lee, T. A. Cella, D. TI A patient-based utility measure of health for clinical trials of cancer therapy SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Illinois, Chicago, IL USA. Pfizer Inc, New London, CT USA. Netherlands Canc Inst, Amsterdam, Netherlands. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2008 VL 26 IS 15 SU S MA 6529 PG 1 WC Oncology SC Oncology GA V25CZ UT WOS:000208457402331 ER PT J AU Rettig, MB Heber, D An, J Klatte, T Seeram, N Liu, H Rao, JY Henning, S Belldegrun, AS Pantuck, AJ AF Rettig, M. B. Heber, D. An, J. Klatte, T. Seeram, N. Liu, H. Rao, J. Y. Henning, S. Belldegrun, A. S. Pantuck, A. J. TI Impact of pomegranate extract on NF-kappa B activation and emerge of androgen-independent prostate cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2008 VL 26 IS 15 SU S MA 16099 PG 1 WC Oncology SC Oncology GA V25CZ UT WOS:000208457401837 ER PT J AU Shannon, J Palma, AJ Peters, L Garzotto, M AF Shannon, J. Palma, A. J. Peters, L. Garzotto, M. TI Body mass index, PSA, and prostate cancer risk SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2008 VL 26 IS 15 SU S MA 5159 PG 1 WC Oncology SC Oncology GA V25CZ UT WOS:000208457401741 ER PT J AU Ma, QL Yang, FS Calon, F Ubeda, OJ Hansen, JE Weisbart, RH Beech, W Frautschy, SA Cole, GM AF Ma, Qiu-Lan Yang, Fusheng Calon, Frederic Ubeda, Oliver J. Hansen, James E. Weisbart, Richard H. Beech, Walter Frautschy, Sally A. Cole, Greg M. TI p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TRANSGENIC MOUSE MODEL; AMYLOID-BETA OLIGOMERS; LONG-TERM POTENTIATION; IN-VIVO; A-BETA; MENTAL-RETARDATION; RHO-GTPASES; DENDRITIC SPINES; NMDA RECEPTOR; MICE AB Defects in dendritic spines and synapses contribute to cognitive deficits in mental retardation syndromes and, potentially, Alzheimer disease. p21-activated kinases (PAKs) regulate actin filaments and morphogenesis of dendritic spines regulated by the Rho family GTPases Rac and Cdc42. We previously reported that active PAK was markedly reduced in Alzheimer disease cytosol, accompanied by downstream loss of the spine actin-regulatory protein Drebrin. beta-Amyloid (A beta) oligomer was implicated in PAK defects. Here we demonstrate that PAK is aberrantly activated and translocated from cytosol to membrane in Alzheimer disease brain and in 22-month-old Tg2576 transgenic mice with Alzheimer disease. This active PAK co-immunoprecipitated with the small GTPase Rac and both translocated to granules. A beta(42) oligomer treatment of cultured hippocampal neurons induced similar effects, accompanied by reduction of dendrites that were protected by kinase-active but not kinase-dead PAK. A beta(42) oligomer treatment also significantly reduced N-methyl-D-aspartic acid receptor subunit NR2B phosphotyrosine labeling. The Src family tyrosine kinase inhibitor PP2 significantly blocked the PAK/Rac translocation but not the loss of p-NR2B in A beta(42) oligomer-treated neurons. Src family kinases are known to phosphorylate the Rac activator Tiam1, which has recently been shown to be A beta-responsive. In addition, anti-oligomer curcumin comparatively suppressed PAK translocation in aged Tg2576 transgenic mice with Alzheimer amyloid pathology and in A beta(42) oligomer-treated cultured hippocampal neurons. Our results implicate aberrant PAK in A beta oligomer-induced signaling and synaptic deficits in Alzheimer disease. C1 [Ma, Qiu-Lan; Yang, Fusheng; Ubeda, Oliver J.; Hansen, James E.; Weisbart, Richard H.; Beech, Walter; Frautschy, Sally A.; Cole, Greg M.] Vet Affairs Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res & Clin Ctr, North Hills, CA 91343 USA. [Ma, Qiu-Lan; Yang, Fusheng; Ubeda, Oliver J.; Hansen, James E.; Weisbart, Richard H.; Beech, Walter; Frautschy, Sally A.; Cole, Greg M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Frautschy, Sally A.; Cole, Greg M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Calon, Frederic] Univ Laval, Med Ctr, Mol Endocrinol & Oncol Res Ctr, Quebec City, PQ G1V 4G2, Canada. [Calon, Frederic] Univ Laval, Fac Pharm, Quebec City, PQ G1K 7P4, Canada. RP Cole, GM (reprint author), Vet Affairs Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res & Clin Ctr, Alzheimer Res 151,Bldg 7,Rm A102, North Hills, CA 91343 USA. EM gmcole@ucla.edu FU NCCIH NIH HHS [AT003008, R01 AT003008, R01 AT003008-01, R01 AT003008-02, R01 AT003008-03]; NIA NIH HHS [AG021975, AG13471, AG16570, P50 AG005142, P50 AG016570, P50 AG016570-040001, P50 AG016570-060005, P50 AG016570-070005, P50 AG016570-080005, P50 AG016570-090005, P50 AG016570-100005, R01 AG013741, R01 AG013741-05, R01 AG013741-06, R01 AG013741-07A2, R01 AG013741-08, R01 AG021975, R01 AG021975-01A2, R01 AG021975-02, R01 AG021975-03, R01 AG021975-04, U01 AG028583, U01 AG028583-03]; PHS HHS [U0128583] NR 53 TC 66 Z9 69 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 16 PY 2008 VL 283 IS 20 BP 14132 EP 14143 DI 10.1074/jbc.M708034200 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 299AM UT WOS:000255728200067 PM 18347024 ER PT J AU Aggarwal, A Dai, D Rumsfeld, JS Klein, LW Roe, MT AF Aggarwal, Atul Dai, David Rumsfeld, John S. Klein, Lloyd W. Roe, Matthew T. TI Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ANTIPLATELET THERAPY; RISK AB The periprocedural management, bleeding risks, and outcomes of patients taking warfarin previous to percutancous coronary intervention (PCI) have not been well characterized. All patients undergoing PCI in the National Cardiovascular Data Registry from January 1, 2004 to March 31, 2006 were analyzed (n = 307,443). Multivariable modeling was used to evaluate the association between home warfarin use and in-hospital mortality and bleeding (requiring blood transfusion and/or prolonging hospital stay and/or causing hemoglobin drop >3.0 g/dl). Patients undergoing elective PCI and urgent PCI (primary/rescue/facilitated PCI with symptoms fewer than 24 hours) were analyzed separately. Overall, 11,173 patients (3.6%) were taking warfarin previous to PCI. Compared with patients not taking warfarin, patients taking warfarin were older and had greater burden of comorbidities. Patients taking warfarin were less likely to receive aspirin, theinopyridines, and glycoprotein IIb-IIIa antagonists during PCI. Unadjusted bleeding rates (elective PCI = 3.2% vs 1.9%; urgent PCI = 8.2% vs 4.8%) and in-hospital mortality (elective PCI = 1.4% vs. 0.6%; urgent PCI = 8.6% vs. 4.5%) were higher among patients taking warfarin. After adjustment for clinical characteristics, the risk of in-hospital mortality was similar with and without previous warfarin use. However, the adjusted risk of bleeding was significantly higher in patients receiving warfarin, for both elective (odds ratio = 1.26, 95% confidence interval = 1.09 to 1.46) and urgent PCI (odds ratio = 1.42, 95 % confidence interval = 1.14 to 1.76). In conclusion, while fewer than 5% of patients undergoing PCI are taking previous warfarin, these patients have a higher risk of in-hospital bleeding events but a similar risk of mortality despite lower use of antiplatelet agents. (C) 2008 Elsevier Inc. All rights reserved. C1 [Aggarwal, Atul] Nebraska Heart Inst, Hastings, NE USA. [Klein, Lloyd W.] Rush Med Coll, Chicago, IL 60612 USA. [Rumsfeld, John S.] Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA. [Dai, David; Roe, Matthew T.] Duke Clin Res Inst, Durham, NC USA. RP Aggarwal, A (reprint author), Nebraska Heart Inst, Hastings, NE USA. EM vipulatul7@yahoo.com NR 10 TC 6 Z9 7 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAY 15 PY 2008 VL 101 IS 10 BP 1413 EP 1417 DI 10.1016/j.amjcard.2008.01.018 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 302LO UT WOS:000255970000008 PM 18471451 ER PT J AU Goldberger, ZD Rho, RW Page, RL AF Goldberger, Zachary D. Rho, Robert W. Page, Richard L. TI Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID VENTRICULAR OUTFLOW TRACT; QRS COMPLEX; DIFFERENTIAL-DIAGNOSIS; SUPRAVENTRICULAR TACHYCARDIA; ANTIARRHYTHMIC DRUGS; CLINICAL APPROACH; FIBRILLATION; CONDUCTION; CRITERIA; ORIGIN AB The initial electrocardiographic evaluation of every tachyarrhythmia should begin by addressing the question of whether the QRS complex is wide or narrow. The most important cause of wide complex tachycardia (WCT) is ventricular tachycardia. However, supraventricular tachycardia can also manifest with a wide QRS complex. The ability to differentiate between supraventricular tachycardia with a wide QRS due to aberrancy or preexcitation and ventricular tachycardia often presents a diagnostic challenge. The identification of whether WCT has a ventricular or supraventricular origin is critical because the treatment for each is different, and improper therapy may have potentially lethal consequences. In conclusion, although the diagnosis and treatment of sustained WCT often arise in emergency situations, this report focuses on a stepwise approach to the management of WCT in relatively stable adult patients, particularly the diagnosis and differentiation of ventricular tachycardia from supraventricular tachycardia with a wide QRS complex on standard 12-lead electrocardiography. (C) 2008 Elsevier Inc. All rights reserved. C1 [Goldberger, Zachary D.] Univ Washington, Med Ctr, VA Puget Sound Hlth Care Syst, Dept Internal Med, Seattle, WA 98195 USA. [Rho, Robert W.; Page, Richard L.] Univ Washington, Sch Med, Dept Internal Med, Div Cardiol, Seattle, WA 98195 USA. RP Goldberger, ZD (reprint author), Univ Washington, Med Ctr, VA Puget Sound Hlth Care Syst, Dept Internal Med, Seattle, WA 98195 USA. EM zgoldber@u.washington.edu RI Page, Richard/L-5501-2014 OI Page, Richard/0000-0001-5603-1330 NR 37 TC 11 Z9 11 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAY 15 PY 2008 VL 101 IS 10 BP 1456 EP 1466 DI 10.1016/j.amjcard.2008.01.024 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 302LO UT WOS:000255970000015 PM 18471458 ER PT J AU Chandler, C Gryniewicz, CM Pringle, T Cunningham, F AF Chandler, Chris Gryniewicz, Connie M. Pringle, Tom Cunningham, Fran TI Insulin temperature and stability under simulated transit conditions SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article DE control, quality; insulin human isophane; insulin human; insulins; packaging; stability; storage; temperature; transportation AB Purpose. The transit temperature profiles, mean kinetic temperatures (MKTs), and stability of insulin samples in both insulated and noninsulated containers exposed to summer and winter temperatures were evaluated. Methods. Regular insulin, isophane insulin human (NPH) insulin, and 70% isophane-30% regular (70/30) insulin were packaged in the most commonly dispensed quantity of four vials in noninsulated mailers and insulated containers with frozen gel packs. After packaging, sealed containers and mailers were placed in an environmental chamber for 24-120 hours and exposed to summer and winter transit conditions. Temperatures inside the environmental chamber were recorded every 15 minutes and maintained within 3 degrees C of the specified transit temperature. After exposure to the transit conditions, insulin cartons were removed from their packaging, visually inspected for changes in physical appearance, and stored at 4 degrees C until analysis. The MKT of each package was calculated. High-performance liquid chromatography was performed to determine sample stability, and size-exclusion chromatography was conducted to detect aggregate products of insulin. Results. Regardless of shipping conditions or packaging, all samples met the United States Pharmacopeia's (USP's) specified limits and retained product stability. Visual inspection of the physical appearance of insulin samples before and after temperature exposure revealed results similar to those described in the product inserts. Microscopic analysis of the injectable suspensions confirmed similar crystal morphologies before and after temperature exposure. Conclusion. Regular, NPH, and 70/30 insulin maintained potency within USP limits when stored in programmable environmental chambers simulating summer and winter overnight or three- to five-day ground delivery conditions, regardless of packaging material. C1 [Chandler, Chris] Dept Vet Affairs Great Lakes Consolidated Mail Ou, Hines, IL 60141 USA. [Gryniewicz, Connie M.] US FDA, Div Pharmaceut Anal, St Louis, MO USA. [Pringle, Tom] Tegrant Diversified Brands Inc, ThermoSafe Brands, Phoenix, AZ USA. [Cunningham, Fran] Patient Safety Ctr Inquiry, Ctr Medicat Safety, Hines, IL USA. [Cunningham, Fran] US Dept Vet Affairs, Pharm Benefits Management Strateg Healthcare Grp, Hines, IL 60141 USA. RP Chandler, C (reprint author), Dept Vet Affairs Great Lakes Consolidated Mail Ou, 5th & Roosevelt Rd,Bldg 37 NW, Hines, IL 60141 USA. EM chris.chandler@va.gov NR 6 TC 8 Z9 9 U1 1 U2 5 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD MAY 15 PY 2008 VL 65 IS 10 BP 953 EP 963 DI 10.2146/ajhp070347 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 300RF UT WOS:000255842200016 PM 18463345 ER PT J AU Groeneveld, PW Kwoh, CK Mor, MK Appelt, CJ Geng, M Gutierrez, JC Wessel, DS Ibrahim, SA AF Groeneveld, Peter W. Kwoh, C. Kent Mor, Maria K. Appelt, Cathleen J. Geng, Ming Gutierrez, Jennifer C. Wessel, Damaris S. Ibrahim, Said A. TI Racial differences in expectations of joint replacement surgery outcomes SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article ID TOTAL KNEE REPLACEMENT; TOTAL HIP-ARTHROPLASTY; SURVEY NHANES-I; AFRICAN-AMERICAN; NATIONAL-HEALTH; PHYSICIAN SCALE; OSTEOARTHRITIS; ARTHRITIS; CARE; DISPARITIES AB Objective. Prior studies have indicated racial differences in patients' expectations for joint replacement surgery outcomes. The goal of this study was to measure these differences using a well-validated survey instrument and to determine if the differences could be explained by racial variation in disease severity, socioeconomic factors, literacy, or trust. Methods. Detailed demographic, clinical, psychological, and social data were collected from 909 male patients (450 African American, 459 white) ages 50-79 years with moderate or severe osteoarthritis (OA) of the hip or knee receiving primary care at 2 veterans affairs medical centers. The previously validated Joint Replacement Expectations Survey was used to assess expectations for pain relief, functional improvement, and psychological well-being after joint replacement. Results. Among knee OA patients (n = 627), the unadjusted mean expectation score (scale 0-76) for African American patients was 48.7 versus 53.6 for white patients (mean difference 4.9, P < 0.001). For hip OA patients (n = 282), the unadjusted mean expectation score (scale 0-72) for African Americans was 45.4 versus 51.5 for whites (mean difference 6.1, P < 0.001). Multivariable adjustment for disease severity, socioeconomic factors, education, social support, literacy, and trust reduced these racial differences to 3.8 points (95% confidence interval [95% CI] 1.2, 6.3) among knee OA patients and 4.2, points (95% CI 0.4, 8.0) among hip patients. Conclusion. Among potential candidates for joint replacement, African American patients have significantly lower expectations for surgical outcomes-than white patients. This difference is not entirely explained by racial differences in demographics, disease severity, education, income, social support, or trust. C1 [Groeneveld, Peter W.; Gutierrez, Jennifer C.; Wessel, Damaris S.] Philadelphia VAMC, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kwoh, C. Kent; Mor, Maria K.; Appelt, Cathleen J.; Geng, Ming; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kwoh, C. Kent; Mor, Maria K.; Ibrahim, Said A.] Univ Pittsburgh, Pittsburgh, PA USA. RP Groeneveld, PW (reprint author), Philadelphia VAMC, 9 E,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM peter.groeneveld@va.gov FU NIAMS NIH HHS [K24 AR 055259, K24 AR055259, K24 AR055259-01] NR 29 TC 50 Z9 50 U1 2 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD MAY 15 PY 2008 VL 59 IS 5 BP 730 EP 737 DI 10.1002/art.23565 PG 8 WC Rheumatology SC Rheumatology GA 300TL UT WOS:000255848000018 PM 18438917 ER PT J AU Cai, Y Wang, QD Ling, ZD Pipeleers, D McDermott, P Pende, M Heimberg, H Van de Casteele, M AF Cai, Ying Wang, Qidi Ling, Zhidong Pipeleers, Daniel McDermott, Paul Pende, Mario Heimberg, Harry Van de Casteele, Mark TI Akt activation protects pancreatic beta cells from AMPK-mediated death through stimulation of mTOR SO BIOCHEMICAL PHARMACOLOGY LA English DT Article DE diabetes; beta cell; apoptosis; AMPK; Akt; mTOR ID GENE-EXPRESSION; PHOSPHORYLATION SITES; GLUCOSE-HOMEOSTASIS; INSULIN-SECRETION; ADULT CARDIOCYTES; MAMMALIAN TARGET; MESSENGER-RNA; KINASE; APOPTOSIS; RAPAMYCIN AB Sustained activation of AMP-activated protein kinase (AMPK) induces apoptosis in several cell types. In pancreatic beta cells this occurs under glucose limitation, or in the presence of the pharmacological AMPK activator 5-aminoimidazole-4-carboxamide-riboside (AICAR). It is unknown whether Akt activation can counteract AMPK-mediated apoptosis, nor whether mTOR activation downstream of Akt mediates any survival signal in these conditions. We report that expression of a constitutively active form of Akt increases mTOR activity and prevents apoptosis upon AMPK activation. Akt-mediated survival was inhibited by rapamycin. Expression of a constitutively active form of the mTOR target ribosomal protein S6 kinase (S6K) or of translation factor eIF4E reduced apoptosis by glucose limitation, and co-expression of S6K and eIF4E protected beta cells to the same extent as active Akt. The protective effects of active Akt and S6K were associated with increased cellular protein synthesis activity. It is concluded that Akt stimulation of mTOR and subsequent activation of the targets by which rnTOR affects protein translation are required and sufficient mechanisms for Akt-mediated survival of beta cells undergoing sustained AMPK activation. (C) 2008 Elsevier Inc. All rights reserved. C1 [Cai, Ying; Wang, Qidi; Ling, Zhidong; Heimberg, Harry; Van de Casteele, Mark] Free Univ Brussels, Diabet Res Ctr, VUB, Partner Juvenile Diabet Res Ctr Beta Cell Therapy, B-1090 Brussels, Belgium. [McDermott, Paul] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29425 USA. [McDermott, Paul] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. [Pende, Mario] Univ Paris 05, INSERM, Avenir, U584,Fac Med Necker Enfants Malad, F-75730 Paris, France. RP Van de Casteele, M (reprint author), Free Univ Brussels, Diabet Res Ctr, VUB, Partner Juvenile Diabet Res Ctr Beta Cell Therapy, Laarbeeklaan 103, B-1090 Brussels, Belgium. EM mvdcaste@vub.ac.be RI Ain, Kenneth/A-5179-2012 OI Ain, Kenneth/0000-0002-2668-934X NR 54 TC 25 Z9 25 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0006-2952 J9 BIOCHEM PHARMACOL JI Biochem. Pharmacol. PD MAY 15 PY 2008 VL 75 IS 10 BP 1981 EP 1993 DI 10.1016/j.bcp.2008.02.019 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 304YI UT WOS:000256144600012 PM 18377870 ER PT J AU Yusuf, N Nasti, TH Katiyar, SK Jacobs, MK Seibert, MD Ginsburg, AC Timares, L Xu, H Elmets, CA AF Yusuf, Nabiha Nasti, Tahseen H. Katiyar, Santosh K. Jacobs, Michael K. Seibert, Megan D. Ginsburg, Alexis C. Timares, Laura Xu, Hui Elmets, Craig A. TI Antagonistic roles of CD4(+) and CD8(+) T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis SO CANCER RESEARCH LA English DT Article ID MOUSE SKIN; HA-RAS; CONTACT HYPERSENSITIVITY; POLYAROMATIC HYDROCARBONS; CHEMICAL CARCINOGENESIS; INITIATION STAGE; CANCER; IL-17; CYTOKINE; GROWTH AB The role that cell-mediated immune responses play during cutaneous carcinogenesis has received little attention. In this study, we evaluated the contribution of CD4(+) and CD8(+) T cells in C3H/HeN mice that were subjected to a two-stage 7,12-dimethylbenz(a)anthracene (DMBA) initiation, 12-O-tetradecanoylphorbol-13-acetate (TPA) promotion skin carcinogenesis protocol. In CD8 knockout (CD8(-/-)) mice, allergic contact hypersensitivity to DMBA was reduced compared with wild-type (WT) C3H/HeN mice. On the other hand, CD4 knockout (CD4(-/-)) mice developed an exaggerated contact hypersensitivity response. CD4(+) T cells from DMBA contact-sensitized mice preferentially produced interleukin 4 (IL-4), IL-10, and IL-17; CD8(+) T cells, on the other hand, secreted IFN-gamma. When CD4(-/-), CD8(-/-), and WT mice were subjected to a standard two-stage DMBA/TPA cutaneous carcinogenesis protocol, the percentage of mice with tumors was much greater (P < 0.001) in CD8(-/-) mice than in WT mice. In contrast, the percentage of tumors was significantly less (P < 0.001) in CD4(-/-) mice than in WT mice. Similar results were obtained when the data were evaluated as the number of tumors per mouse. These findings indicate that (a) CD8(+) T cells are the predominant effector cells in allergic contact hypersensitivity to DMBA and that CD4(+) T cells have an inhibitory role and (b) the development of CD8(+) T cells plays a protective role in skin tumor development whereas CD4(+) T cells have the opposite effect. Manipulation of T-cell subpopulations that are induced by carcinogenic chemicals, like DMBA, could be a means of preventing skin cancers caused by these agents. C1 [Yusuf, Nabiha; Nasti, Tahseen H.; Katiyar, Santosh K.; Jacobs, Michael K.; Seibert, Megan D.; Ginsburg, Alexis C.; Timares, Laura; Xu, Hui; Elmets, Craig A.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Yusuf, Nabiha; Nasti, Tahseen H.; Katiyar, Santosh K.; Jacobs, Michael K.; Seibert, Megan D.; Ginsburg, Alexis C.; Timares, Laura; Xu, Hui; Elmets, Craig A.] Univ Alabama, Skin Dis Res Ctr, Birmingham, AL 35294 USA. [Yusuf, Nabiha; Timares, Laura; Xu, Hui; Elmets, Craig A.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Yusuf, N (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,VH 566A,POB 202, Birmingham, AL 35294 USA. EM nabiha@uab.edu RI Xu, Hui/A-8167-2009 FU NCI NIH HHS [P30 CA013148, P30 CA13148, R01 CA079820]; NIAMS NIH HHS [P30 AR050948, P30 AR048311] NR 34 TC 28 Z9 28 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2008 VL 68 IS 10 BP 3924 EP 3930 DI 10.1158/0008-5472.CAN-07-3059 PG 7 WC Oncology SC Oncology GA 301YW UT WOS:000255933600049 PM 18483278 ER PT J AU Krajewska, M Kitada, S Winter, JN Variakojis, D Lichtenstein, A Zhai, DY Cuddy, M Huang, XS Luciano, F Baker, CH Kim, H Shin, E Kennedy, S Olson, AH Badzio, A Jassem, J Meinhold-Heerlein, I Duffy, MJ Schimmer, AD Tsao, M Brown, E Sawyers, A Andreeff, M Mercola, D Krajewski, S Reed, JC AF Krajewska, Maryla Kitada, Shinichi Winter, Jane N. Variakojis, Daina Lichtenstein, Alan Zhai, Dayong Cuddy, Michael Huang, Xianshu Luciano, Frederic Baker, Cheryl H. Kim, Hoguen Shin, Eunah Kennedy, Susan Olson, Allen H. Badzio, Andrzej Jassem, Jacek Meinhold-Heerlein, Ivo Duffy, Michael J. Schimmer, Aaron D. Tsao, Ming Brown, Ewan Sawyers, Anne Andreeff, Michael Mercola, Dan Krajewski, Stan Reed, John C. TI Bcl-B expression in human epithelial and nonepithelial malignancies SO CLINICAL CANCER RESEARCH LA English DT Article ID CELL-DEATH; MULTIPLE-MYELOMA; PLASMA-CELL; FAMILY MEMBER; BONE-MARROW; APOPTOSIS; PROTEIN; CANCER; MITOCHONDRIA; QUANTIFICATION AB Purpose: Apoptosis plays an important role in neoplastic processes. Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in human malignancies has not been reported. Experimental Design: We investigated Bcl-B expression in normal human tissues and several types of human epithelial and nonepithelial malignancy by immunohistochemistry, correlating results with tumor stage, histologic grade, and patient survival. Results: Bcl-B protein was strongly expressed in all normal plasma cells but found in only 18% of multiple myelomas (n = 133). Bcl-B immunostaining was also present in normal germinal center centroblasts and centrocytes and in approximately half of diffuse large B-cell lymphoma (n = 48) specimens, whereas follicular lymphomas (n = 57) did not contain Bcl-B. In breast (n = 119), prostate (n = 66), gastric (n = 180), and colorectal (n = 106) adenocarcinomas, as well as in non - small cell lung cancers (n = 82), tumor-specific overexpression of Bcl-B was observed. Bcl-B expression was associated with variables of poor prognosis, such as high tumor grade in breast cancer (P = 0.009), microsatellite stability (P = 0.0002), and left-sided anatomic location (P = 0.02) of colorectal cancers, as well as with greater incidence of death from prostate cancer (P = 0.005) and shorter survival of patients with small cell lung cancer (P = 0.009). Conversely, although overexpressed in many gastric cancers, Bcl-B tended to correlate with better outcome (P = 0.01) and more differentiated tumor histology (P < 0.0001). Conclusions: Tumor-specific alterations in Bcl-B expression may define subsets of nonepithelial and epithelial neoplasms with distinct clinical behaviors. C1 [Krajewska, Maryla; Kitada, Shinichi; Zhai, Dayong; Cuddy, Michael; Huang, Xianshu; Krajewski, Stan; Reed, John C.] Burnham Inst Med Res, La Jolla, CA 92037 USA. [Winter, Jane N.; Variakojis, Daina] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Lichtenstein, Alan] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Luciano, Frederic] Fac Med, INSERM, U526, Nice, France. [Baker, Cheryl H.] MD Anderson Canc Ctr, Canc Res Inst, Orlando, FL USA. [Kim, Hoguen] Yonsei Univ, Coll Med, Seoul 120749, South Korea. [Shin, Eunah] Inje Univ Sanggyepaik Hosp, Dept Pathol, Seoul, South Korea. [Duffy, Michael J.] St Vincents Univ Hosp, Dublin 4, Ireland. [Duffy, Michael J.] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Sch Med & Med Sci, Dublin 2, Ireland. [Olson, Allen H.] Aperio Technologies Inc, Vista, CA USA. [Badzio, Andrzej; Jassem, Jacek] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland. [Meinhold-Heerlein, Ivo] Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany. [Tsao, Ming] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada. [Sawyers, Anne] Sidney Kimmel Canc Ctr, San Diego, CA USA. [Andreeff, Michael] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Sawyers, Anne; Mercola, Dan] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA. RP Reed, JC (reprint author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM reedoffice@burnham.org OI , dan/0000-0002-0281-9840 FU NCI NIH HHS [P01 CA081534, CA-113318, P30CA06055, U19 CA113318, CA114810, U01 CA114810, CA-81534]; NIGMS NIH HHS [R01 GM060554, GM-60554] NR 36 TC 39 Z9 41 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2008 VL 14 IS 10 BP 3011 EP 3021 DI 10.1158/1078-0432.CCR-07-1955 PG 11 WC Oncology SC Oncology GA 303AW UT WOS:000256012700015 PM 18483366 ER PT J AU Turner, EH Tell, RA AF Turner, Erick H. Tell, Robert A. TI Selective publication of antidepressant trials - Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Turner, Erick H.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Tell, Robert A.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Turner, EH (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97239 USA. EM turnere@ohsu.edu OI Turner, Erick/0000-0002-3522-3357 NR 1 TC 1 Z9 1 U1 3 U2 6 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 15 PY 2008 VL 358 IS 20 BP 2181 EP 2182 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 300TY UT WOS:000255849300026 ER PT J AU Kim, JH Kim, D Marder, SR AF Kim, Jin Hun Kim, Daeho Marder, Stephen R. TI Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Review DE alcohol use disorder; clozapine; community survival; risperidone; schizophrenia ID SUBSTANCE USE DISORDERS; DRUG-USE; ABUSE; OLANZAPINE; OUTCOMES; RELAPSE; COCAINE AB Clozapine is known to be effective in treating schizophrenia patients with comorbid alcohol use disorders (AUD). However, few prospective studies have examined the effect of clozapine on community survival of the patient, which is one of the most important indicators of success for patients with schizophrenia. In this prospective, naturalistic, observational, community-survival-analysis study, we compared the effect of clozapine and risperidone on two-year psychiatric hospitalization rate and time to hospitalization in the treatment of patients with schizophrenia and comorbid AUD. We found that the clozapine treated patients were readmitted to hospital significantly later (mean survival=526.5 days, n=25 patients) than the risperidone treated patients (mean survival=420.4 days, n=36 patients). The survival curve for the clozapine-treated patients was significantly different from that of the risperidone treated patients (log-rank test, df=1, p=.045). At the end of the two-year study period, 75% of the risperidone treated patients had been admitted to the hospital, compared to only 48% of the clozapine treated patients. These findings suggest that clozapine should be considered for the treatment of schizophrenia patients with comorbid AUD. However, due to the limitations of this study, further studies will be required to confirm these findings. (C) 2008 Elsevier Inc. All rights reserved. C1 [Kim, Jin Hun; Marder, Stephen R.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kim, Jin Hun; Marder, Stephen R.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. [Kim, Jin Hun] Seoul Natl Hosp, Dept Psychiat, Schizophrenia Res Grp, Seoul, South Korea. [Kim, Daeho] Hanyang Univ, Dept Neuropsychiat, Seoul 133791, South Korea. RP Kim, JH (reprint author), Mental Illness Res Educ & Clin Ctr, Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM vertex11@ucla.edu NR 31 TC 11 Z9 12 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD MAY 15 PY 2008 VL 32 IS 4 BP 984 EP 988 DI 10.1016/j.pnpbp.2008.01.009 PG 5 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 310ZU UT WOS:000256570400010 PM 18262321 ER PT J AU Meeran, SM Katiyar, S Katiyar, SK AF Meeran, Syed M. Katiyar, Suchitra Katiyar, Santosh K. TI Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE berberine; apoptosis; reactive oxygen species; mitochondrial disruption; xanthine oxidase ID MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C; RAT-LIVER; DEATH; INDUCTION; PORE; CHEMOPREVENTION; PHYTOCHEMICALS; INHIBITION; PATHWAYS AB Phytochemicals show promise as potential chemopreventive or chemotherapeutic agents against various cancers. Here we report the chemotherapeutic effects of berberine, a phytochemical, on human prostate cancer cells. The treatment of human prostate cancer cells (PC-3) with berberine induced dose-dependent apoptosis but this effect of berberine was not seen in non-neoplastic human prostate epithelial cells (PWR-IE). Berberine-induced apoptosis was associated with the disruption of the mitochondrial membrane potential, release of apoptogenic molecules (cytochrome c and Smac/DIABLO) from mitochondria and cleavage of caspase-9,-3 and PARP proteins. This effect of berberine on prostate cancer cells was initiated by the generation of reactive oxygen species (ROS) irrespective of their androgen responsiveness, and the generation of ROS was through the increased induction of xanthine oxidase. Treatment of cells with allopurinol, an inhibitor of xanthine oxidase, inhibited berberine-induced oxidative stress in cancer cells. Berberine-induced apoptosis was blocked in the presence of antioxidant, N-acetylcysteine, through the prevention of disruption of mitochondrial membrane potential and subsequently release of cytochrome c and Smac/DIABLO. In conclusion, the present study reveals that the berberine-mediated cell death of human prostate cancer cells is regulated by reactive oxygen species, and therefore suggests that berberine may be considered for further studies as a promising therapeutic candidate for prostate cancer. (C) 2008 Elsevier Inc. All rights reserved. C1 [Meeran, Syed M.; Katiyar, Suchitra; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Dept Environm Hlth Sci, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu NR 36 TC 83 Z9 86 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD MAY 15 PY 2008 VL 229 IS 1 BP 33 EP 43 DI 10.1016/j.taap.2007.12.027 PG 11 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 299CE UT WOS:000255732600004 PM 18275980 ER PT J AU Werner, RM Goldman, LE Dudley, RA AF Werner, Rachel M. Goldman, L. Elizabeth Dudley, R. Adams TI Comparison of change in quality of care between safety-net and non-safety-net hospitals SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID PAY-FOR-PERFORMANCE; COMMUNITY-HEALTH CENTERS; US HOSPITALS; DISPARITIES; MORTALITY; MEDICAID; WILL AB Context Safety- net hospitals ( ie, those that predominantly treat poor and under-served patients) often have lower quality of care than non - safety- net hospitals. While public reporting and pay for performance have the potential to improve quality of care at poorly performing hospitals, safety- net hospitals may be unable to invest in quality improvement. As such, some have expressed concern that these incentives have the potential to worsen existing disparities among hospitals. Objective To examine trends in disparities of quality of care between hospitals with high and low percentages of Medicaid patients. Design and Setting Longitudinal study of the relationship between hospital performance and percentage Medicaid coverage from 2004 to 2006, using publicly available data on hospital performance. A simulation model was used to estimate payments at hospitals with high and low percentages of Medicaid patients. Main Outcome Measures Changes in hospital performance between 2004 and 2006, estimating whether disparities in hospital quality between hospitals with high and low percentages of Medicaid patients have changed. Results Of the 4464 participating hospitals, 3665 ( 82%) were included in the final analysis. Hospitals with high percentages of Medicaid patients had worse performance in 2004 and had significantly smaller improvement over time than those with low percentages of Medicaid patients. Hospitals with low percentages of Medicaid patients improved composite acute myocardial infarction performance by 3.8 percentage points vs 2.3 percentage points for those with high percentages, an absolute difference of 1.5 ( P=. 03). This resulted in a relative difference in performance gains of 39%. Larger performance gains at hospitals with low percentages of Medicaid patients were also seen for heart failure ( difference of 1.4 percentage points, P= 0.04) and pneumonia ( difference of 1.3 percentage points, P <. 001). Over time, hospitals with high percentages of Medicaid patients had a lower probability of achieving high-performance status. In a simulation model, these hospitals were more likely to incur financial penalties due to low performance and were less likely to receive bonuses. Conclusions Safety- net hospitals tended to have smaller gains in quality performance measures over 3 years and were less likely to be high- performing over time than non - safety- net hospitals. An incentive system based on these measures has the potential to increase disparities among hospitals. C1 [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Goldman, L. Elizabeth; Dudley, R. Adams] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Dudley, R. Adams] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA. RP Werner, RM (reprint author), Univ Penn, Sch Med, Div Gen Internal Med, 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@mail.med.upenn.edu NR 28 TC 138 Z9 138 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 14 PY 2008 VL 299 IS 18 BP 2180 EP 2187 DI 10.1001/jama.299.18.2180 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 299XX UT WOS:000255790000025 PM 18477785 ER PT J AU Ross, JS Keyhani, S Keenan, PS Bernheim, SM Penrod, JD Boockvar, KS Federman, AD Krumholz, HM Siu, AL AF Ross, Joseph S. Keyhani, Salomeh Keenan, Patricia S. Bernheim, Susannah M. Penrod, Joan D. Boockvar, Kenneth S. Federman, Alex D. Krumholz, Harlan M. Siu, Albert L. TI Use of recommended ambulatory care services - Is the Veterans Affairs quality gap narrowing? SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID OF-CARE; HEALTH; PERFORMANCE; SYSTEM; BEHAVIORS; MEDICARE; CANCER; RISK; PAY AB Background: Veterans Affairs medical centers (VAMCs) provide better preventive and chronic disease care when compared with other health care organizations, although recent health care quality improvement initiatives outside the VAMC sector may have narrowed quality differences. Methods: Using the nationally representative 2000 and 2004 surveys of the Behavior Risk Factor Surveillance System, which included 152 310 community-dwelling insured adults in 2000 and 251570 in 2004, we compared self-reported use of 17 recommended ambulatory care services for cancer prevention, cardiovascular risk reduction, diabetes mellitus management, and infectious disease prevention among insured adults receiving and not receiving care at VAMCs. Results: A total of 2852 insured adults (1.9%) received care at VAMCs in 2000 and 7155 (2.4%) received care at VAMCs in 2004. Use of 9 of the 17 services was greater in 2004 when compared with 2000 (P <= .05). In 2000, receiving VAMC care was associated with greater use of 6 of the 17 services; in 2004, receiving VAMC care was associated with greater use of 12 of the 17 services (P <=.05). Conclusion: Despite increasing emphasis on quality of care and improved performance throughout the US health care system, adults receiving VAMC care remain more likely to receive recommended ambulatory care. C1 [Ross, Joseph S.; Penrod, Joan D.; Boockvar, Kenneth S.; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10025 USA. [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10025 USA. [Federman, Alex D.] Mt Sinai Sch Med, Dept Internal Med, New York, NY 10025 USA. [Ross, Joseph S.; Keyhani, Salomeh; Penrod, Joan D.; Boockvar, Kenneth S.; Siu, Albert L.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Ross, Joseph S.; Keyhani, Salomeh; Penrod, Joan D.; Boockvar, Kenneth S.; Siu, Albert L.] James J Peters Vet Adm Med Ctr, HSR&D Targeted Res Enhancement Program, Bronx, NY USA. [Keenan, Patricia S.; Krumholz, Harlan M.] Yale Univ, Sch Med, Div Hlth Policy & Adm, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA. [Bernheim, Susannah M.] Yale Univ, Sch Med, Sect Geriatr, Dept Internal Med, New Haven, CT 06520 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Dept Internal Med, New Haven, CT 06520 USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Ross, JS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10025 USA. EM joseph.ross@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU NIA NIH HHS [T32AG1934] NR 43 TC 33 Z9 33 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 12 PY 2008 VL 168 IS 9 BP 950 EP 958 DI 10.1001/archinte.168.9.950 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 297VJ UT WOS:000255645200008 PM 18474759 ER PT J AU Kilby, JM Lee, HY Hazelwood, JD Bansal, A Bucy, RP Saag, MS Shaw, GM Acosta, EP Johnson, VA Perelson, AS Goepfert, PA AF Kilby, J. Michael Lee, Ha Youn Hazelwood, J. Darren Bansal, Anju Bucy, R. Patterson Saag, Michael S. Shaw, George M. Acosta, Edward P. Johnson, Victoria A. Perelson, Alan S. Goepfert, Paul A. TI Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline SO AIDS LA English DT Article DE acute HIV infection; mathematical modeling; viral clearance; viral dynamics ID VIRUS TYPE-1 INFECTION; DYNAMICS IN-VIVO; ANTIRETROVIRAL THERAPY; IMMUNE-RESPONSES; VIRAL DYNAMICS; PLASMA; CELL; CLEARANCE; INDIVIDUALS; REPLICATION AB Objective: Compare the initial phases of virologic decay when acute/early and advanced HIV-infected adults are administered the same treatment regimen. Design: Mathematical modeling of a previously completed prospective treatment pilot study involving treatment-naive patients with early and advanced immunosuppression. Methods: We analyzed data from a treatment protocol in which 18 individuals with acute or recent HIV-1 seroconversion and six patients with advanced AIDS were administered the same four-drug antiretroviral regimen. Initial treatment responses were compared by fitting a mathematical model to frequent viral load measurements in order to calculate the first and second phase kinetics of viral clearance, and also by comparing viral load suppression over 24 weeks. Patients were also comprehensively compared in terms of protease inhibitor drug levels, HIV-specific immune responses at baseline, and the presence of drug resistance-conferring mutations. Results: There was no statistically meaningful difference in first phase clearance of comparable high-level viremia in the two groups, whether protease inhibitor levels were inserted into the model or 100% antiviral drug effectiveness was assumed. In contrast, acute/early patients had inferior sustained responses than advanced patients, reflecting erratic adherence. Conclusions: Despite many years of intervening immune destruction, the initial virologic decay on therapy appears to be the same at the extremes of the HIV disease spectrum. (C) 2008 Wolters Kluwer Health Lippincott Williams & Wilkins. C1 [Kilby, J. Michael; Hazelwood, J. Darren; Bansal, Anju; Saag, Michael S.; Shaw, George M.; Johnson, Victoria A.; Goepfert, Paul A.] Div Infect Dis, Birmingham, AL USA. [Kilby, J. Michael; Hazelwood, J. Darren; Bansal, Anju; Saag, Michael S.; Shaw, George M.; Johnson, Victoria A.; Goepfert, Paul A.] Univ Alabama, Dept Med, HIV Res Clin, Birmingham, AL 35294 USA. [Bucy, R. Patterson] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Acosta, Edward P.] Univ Alabama, Dept Pharmacol, Birmingham, AL 35294 USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Johnson, Victoria A.] Univ Alabama, Sch Med, Birmingham, AL USA. [Lee, Ha Youn; Perelson, Alan S.] Los Alamos Natl Lab, Theoret Biol & Biophys Grp, Los Alamos, NM USA. [Lee, Ha Youn] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA. RP Kilby, JM (reprint author), Univ Alabama, Pittman Gen Clin Res Ctr, 142 Community Care Bldg,908 20th St S, Birmingham, AL 35294 USA. EM mkilby@uab.edu OI Kilby, J. Michael/0000-0003-3222-1003 FU NCRR NIH HHS [M01 RR000032, MO1 RR00032, RR06555, R01 RR006555]; NIAID NIH HHS [AI49126, U01 AI032775, R01 AI028433, AI32775, R21 AI049126, R01 AI049126, U01 AI041530, R37 AI028433, AI41530, P30 AI27767, U01 AI038858, U01AI38858, AI28433, P30 AI027767]; NIH HHS [R01 OD011095] NR 28 TC 18 Z9 19 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD MAY 11 PY 2008 VL 22 IS 8 BP 957 EP 962 DI 10.1097/QAD.0b013e3282fbd1da PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 307ZO UT WOS:000256358300006 PM 18453855 ER PT J AU Moore, JP Klasse, PJ Dolan, MJ Ahuja, SK AF Moore, John P. Klasse, P. J. Dolan, Matthew J. Ahuja, Sunil K. TI AIDS/HIV - A STEP into darkness or light? SO SCIENCE LA English DT Editorial Material ID HIV-1 TRANSMISSION; PREVENTIVE VACCINE; INFECTION; SUSCEPTIBILITY; MEASLES; RESPONSES; RECEPTOR; ALLELES; DESIGN; TYPE-1 C1 [Moore, John P.; Klasse, P. J.] Cornell Univ, Weill Med Coll, New York, NY 10065 USA. [Dolan, Matthew J.] San Antonio Mil Med Ctr, Infect Dis Clin Res Program, Ft Sam Houston, TX 78234 USA. [Dolan, Matthew J.] San Antonio Mil Med Ctr, Infect Dis Clin Res Program, Lackland AFB, TX USA. [Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV 1 Infect, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Moore, JP (reprint author), Cornell Univ, Weill Med Coll, New York, NY 10065 USA. EM jpm2003@med.cornell.edu; ahujas@uthscsa.edu NR 26 TC 39 Z9 41 U1 0 U2 0 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD MAY 9 PY 2008 VL 320 IS 5877 BP 753 EP 755 DI 10.1126/science.1154258 PG 3 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 297VB UT WOS:000255644400026 PM 18467578 ER PT J AU Houston, TK Richman, JS Coley, HL Ray, MN Allison, JJ Gilbert, GH Gordon, JS Kiefe, CI AF Houston, Thomas K. Richman, Joshua S. Coley, Heather L. Ray, Midge N. Allison, Jeroan J. Gilbert, Gregg H. Gordon, Judith S. Kiefe, Catarina I. CA DPBRN Collaborative Grp TI Does delayed measurement affect patient reports of provider performance? Implications for performance measurement of medical assistance with tobacco cessation: A Dental PBRN study SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID ECOLOGICAL MOMENTARY ASSESSMENT; PAY-FOR-PERFORMANCE; QUALITY-OF-CARE; HEALTH-CARE; SMOKING; RECALL; GUIDELINES; RECORD AB Background: We compared two methods of measuring provider performance of tobacco control activities: immediate "exit cards" versus delayed telephone follow-up surveys. Current standards, e. g. HEDIS, use delayed patient measures that may over or under-estimate overall performance. Methods: Patients completed exit cards in 60 dental practices immediately after a visit to measure whether the provider "asked" about tobacco use, and "advised" the patient to quit. One to six months later patients were asked the same questions by telephone survey. Using the exit cards as the standard, we quantified performance and calculated sensitivity (agreement of those responding yes on telephone surveys compared with exit cards) and specificity (agreement of those responding no) of the delayed measurement. Results: Among 150 patients, 21% reporting being asked about tobacco use on the exit cards and 30% reporting being asked in the delayed surveys. The sensitivity and specificity were 50% and 75%, respectively. Similarly, among 182 tobacco users, 38% reported being advised to quit on the exit cards and this increased to 51% on the delayed surveys. The sensitivity and specificity were 75% and 64%, respectively. Increasing the delay from the visit to the telephone survey resulted in increasing disagreement. Conclusion: Patient reports differed considerably in immediate versus delayed measures. These results have important implications because they suggest that our delayed measures may overestimate performance. The immediate exit cards should be included in the armamentarium of tools for measuring providers' performance of tobacco control, and perhaps other service delivery. C1 [Houston, Thomas K.; Kiefe, Catarina I.] Birmingham VA Med Ctr, VA HSR&D REAP, Deep S Ctr Effectiveness Res, Birmingham, AL USA. [Houston, Thomas K.; Coley, Heather L.; Allison, Jeroan J.] Univ Alabama, Div Gen Internal Med, Birmingham, AL USA. [Houston, Thomas K.; Richman, Joshua S.; Ray, Midge N.; Allison, Jeroan J.; Gilbert, Gregg H.; Kiefe, Catarina I.] Univ Alabama, Ctr Outcomes & Effectiveness Res, Birmingham, AL USA. [Houston, Thomas K.; Richman, Joshua S.; Allison, Jeroan J.; Kiefe, Catarina I.] Univ Alabama, Div Prevent Med, Birmingham, AL USA. [Ray, Midge N.] Univ Alabama, Dept Hlth Serv Adm, Birmingham, AL USA. [Gilbert, Gregg H.] Univ Alabama, Sch Dent, Dept Diagnost Sci, Birmingham, AL 35294 USA. [Gordon, Judith S.] Oregon Res Inst, Eugene, OR 97403 USA. RP Houston, TK (reprint author), Birmingham VA Med Ctr, VA HSR&D REAP, Deep S Ctr Effectiveness Res, Birmingham, AL USA. EM thouston@uab.edu; jrichman@uab.edu; coleyhl@uab.edu; midgeray@uab.edu; jallison@uab.edu; ghg@uab.edu; judith@ori.org; ckiefe@uab.edu RI Houston, Thomas/F-2469-2013 OI Gordon, Judith/0000-0002-5911-4219; Allison, Jeroan/0000-0003-4472-2112 FU NIDA NIH HHS [R01 DA017971, R01-DA-17971]; NIDCR NIH HHS [U01 DE016746, U01 DE016747, U01-DE-16746, U01-DE-16747] NR 25 TC 6 Z9 6 U1 5 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD MAY 8 PY 2008 VL 8 AR 100 DI 10.1186/1472-6963-8-100 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 308NL UT WOS:000256397200001 PM 18466617 ER PT J AU McFarland, LV AF McFarland, Lynne V. TI State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008 SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material DE irritable bowel syndrome; inflammatory bowel disease ID CROHNS-DISEASE; ULCERATIVE-COLITIS; PROBIOTICS; EPIDEMIOLOGY; METAANALYSIS; POPULATION; COMMON; ONSET AB Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are two of the leading causes of chronic intestinal conditions in the world. This issue of World Journal of Gastroenterology (WJG) presents a series of papers from world experts who discuss the current knowledge and opinions on these important conditions. Although great strides have been made in the diagnosis, treatment and pathology of IBS and IBD; much has yet to be explained. The etiologies and risk factors of these multifactorial conditions remain elusive. Specific diagnostic biomarkers need to be developed and safer treatments developed. The burden of IBS and IBD on the healthcare system is felt with repeated medical care visits and high costs. IBS and IBD patients can account for 30%-50% of office visits at gastroenterology services/clinics. Over one million people have IBD in the United States, with 30000 new cases being diagnosed every year. One-quarter million people in the UK are afflicted with IBD. The cost of medical care in the United States for IBD is estimated to be $1.8 billion/year. (C) 2008 WJG. All rights reserved. C1 [McFarland, Lynne V.] VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA 98101 USA. [McFarland, Lynne V.] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98101 USA. RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Metropolitan Pk W, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM lynne.mcfarland@va.gov NR 38 TC 16 Z9 16 U1 0 U2 1 PU W J G PRESS PI BEIJING PA APT 1066, YISHOU GARDEN, NO 58, NORTH LANGXINZHUANG RD, PO BOX 2345, BEIJING 100023, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD MAY 7 PY 2008 VL 14 IS 17 BP 2625 EP 2629 DI 10.3748/wjg.14.2625 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 299ST UT WOS:000255776000001 PM 18461647 ER PT J AU McFarland, LV Dublin, S AF McFarland, Lynne V. Dublin, Sascha TI Meta-analysis of probiotics for the treatment of irritable bowel syndrome SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE probiotics; meta-analysis; irritable bowel syndrome ID ANTIBIOTIC-ASSOCIATED DIARRHEA; LACTOBACILLUS-PLANTARUM 299V; RANDOMIZED CONTROLLED-TRIALS; PLACEBO-CONTROLLED TRIAL; INTENTION-TO-TREAT; QUALITY-OF-LIFE; DOUBLE-BLIND; SYNDROME IBS; INTESTINAL MICROFLORA; THERAPY VSLNUMBER-3 AB Irritable bowel syndrome (IBS) is a chronic condition affecting 3%-25% of the general population. As no curative treatment is available, therapy is aimed at reducing symptoms, often with little success. Because alteration of the normal intestinal microflora has been observed in IBS, probiotics (beneficial microbes taken to improve health) may be useful in reducing symptoms. This paper systematically reviews randomized, controlled, blinded trials of probiotics for the treatment of IBS and synthesizes data on efficacy across trials of adequate quality. PubMed, Medline, Google Scholar, NIH registry of clinical trials, metaRegister, and the Cochrane Central Register of Controlled Trials were searched from 1982-2007. We also conducted secondary searches of reference lists reviews, commentaries, relevant articles on associated diseases, books and meeting abstracts. Twenty trials with 23 probiotic treatment arms and a total of 1404 subjects met inclusion criteria. Probiotic use was associated with improvement in global IBS symptoms compared to placebo [pooled relative risk (RRpooled) 0.77, 95% confidence interval (95% CI) 0.62-0.94]. Probiotics were also associated with less abdominal pain compared to placebo [RRpooled = 0.78 (0.69-0.88)]. Too few studies reported data on other IBS symptoms or on specific probiotic strains to allow estimation of a pooled RR. While our analyses suggest that probiotic use may be associated with improvement in IBS symptoms compared to placebo, these results should be interpreted with caution, given the methodological limitations of contributing studies. Probiotics warrant further study as a potential therapy for IBS. (C) 2008 WJG. All rights reserved. C1 [McFarland, Lynne V.] VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA 98101 USA. [McFarland, Lynne V.] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98101 USA. [Dublin, Sascha] Grp Hlth Ctr Hlth Studies, Seattle, WA 98101 USA. RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Metropolitan Pk W,1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM lynne.mcfarland@va.gov FU NIA NIH HHS [AG028954-01A1, K23 AG028954, K23 AG028954-01A1] NR 74 TC 165 Z9 177 U1 0 U2 15 PU W J G PRESS PI BEIJING PA APT 1066, YISHOU GARDEN, NO 58, NORTH LANGXINZHUANG RD, PO BOX 2345, BEIJING 100023, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD MAY 7 PY 2008 VL 14 IS 17 BP 2650 EP 2661 DI 10.3748/wjg.14.2650 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 299ST UT WOS:000255776000005 PM 18461650 ER PT J AU Qaseem, A Snow, V Shekelle, P Hopkins, R Forciea, MA Owens, DK AF Qaseem, Amir Snow, Vincenza Shekelle, Paul Hopkins, Robert, Jr. Forciea, Mary Ann Owens, Douglas K. CA Clin Efficacy Assessment Subcomm TI Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID ANDROGEN DEPRIVATION THERAPY; BONE-MINERAL DENSITY; X-RAY ABSORPTIOMETRY; PROSTATE-CANCER; QUANTITATIVE ULTRASOUND; RISK-FACTORS; FRACTURE RISK; HORMONE AGONISTS; ELDERLY-MEN; HEEL ULTRASOUND AB Description: The American College of Physicians developed this guideline to present the available evidence on risk factors and screening tests for osteoporosis in men. Methods: Published literature on this topic was identified by using MEDLINE (1990 to July 2007). Reference mining was done on the retrieved articles, references of previous reviews, and solicited articles from experts. The inclusion criteria for the studies were measuring risk factors for low bone mineral density or osteoporotic fracture in men or comparing 2 different methods of assessment for the presence of osteoporosis in men. This guideline grades the evidence and recommendations by using the American College of Physicians' clinical practice guidelines grading system. Recommendation 1: The American College of Physicians recommends that clinicians periodically perform individualized assessment of risk factors for osteoporosis in older men (Grade: strong recommendation; moderate-quality evidence). Recommendation 2: The American College of Physicians recommends that clinicians obtain dual-energy x-ray absorptiometry for men who are at increased risk for osteoporosis and are candidates for drug therapy (Grade: strong recommendation; moderate-quality evidence). Recommendation 3: The American College of Physicians recommends further research to evaluate osteoporosis screening tests in men. C1 Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Arkansas, Little Rock, AR 72204 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA USA. RAND Corp, Santa Monica, CA USA. Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA. Stanford Univ, Stanford, CA 94305 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org NR 49 TC 84 Z9 89 U1 1 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 6 PY 2008 VL 148 IS 9 BP 680 EP 684 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 299BW UT WOS:000255731800006 PM 18458281 ER PT J AU Liu, H Paige, NM Goldzweig, CL Wong, E Zhou, A Suttorp, MJ Munjas, B Orwoll, E Shekelle, P AF Liu, Hau Paige, Nell M. Goldzweig, Caroline L. Wong, Elaine Zhou, Annie Suttorp, Marika J. Munjas, Brett Orwoll, Eric Shekelle, Paul TI Screening for osteoporosis in men: A systematic review for an American College of Physicians guideline SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID BONE-MINERAL DENSITY; ANDROGEN DEPRIVATION THERAPY; X-RAY ABSORPTIOMETRY; SPINAL-CORD-INJURY; EUROPEAN PROSPECTIVE OSTEOPOROSIS; RISK-FACTORS; HIP FRACTURE; PROSTATE-CANCER; QUANTITATIVE ULTRASOUND; ELDERLY-MEN AB Background: Screening for low bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA) is the primary way to identify asymptomatic men who might benefit from osteoporosis treatment. Identifying men at risk for low BMD and fracture can help clinicians determine which men should be tested. Purpose: To identify which asymptomatic men should receive DXA BMD testing, this systematic review evaluates 1) risk factors for osteoporotic fracture in men that may be mediated through low BMD and 2) the performance of non-DXA tests in identifying men with low BMD. Data Sources: Studies identified through the MEDLINE database (1990 to July 2007). Study Selection: Articles that assessed risk factors for osteoporotic fracture in men or evaluated a non-DXA screening test against a gold standard of DXA. Data Extraction: Researchers performed independent dual abstractions for each article, determined performance characteristics of screening tests, and assessed the quality of included articles. Data Synthesis: A published meta-analysis of 167 studies evaluating risk factors for low BMD-related fracture in men and women found high-risk factors to be increased age (>70 years), low body weight (body mass index <20 to 25 kg/m(2)), weight loss (>10%), physical inactivity, prolonged corticosteroid use, and previous osteoporotic fracture. An additional 102 studies assessing 15 other proposed risk factors were reviewed; most had insufficient evidence in men to draw conclusions. Twenty diagnostic study articles were reviewed. At a T-score threshold of -1.0, calcaneal ultrasonography had a sensitivity of 75% and specificity of 66% for identifying DXA-determined osteoporosis (DXA T-score, -2.5). At a risk score threshold of -1, the Osteoporosis Self-Assessment Screening Tool had a sensitivity of 81% and specificity of 68% to identify DXA-determined osteoporosis. Limitation: Data on other screening tests, including radiography, and bone geometry variables, were sparse. Conclusion: Key risk factors for low BMD-mediated fracture include increased age, low body weight, weight loss, physical inactivity, prolonged corticosteroid use, previous osteoporotic fracture, and androgen deprivation therapy. Non-DXA tests either are too insensitive or have insufficient data to reach conclusions. C1 Santa Clara Valley Med Ctr, San Jose, CA 95128 USA. Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Liu, H (reprint author), Santa Clara Valley Med Ctr, 751 S Baascon Ave, San Jose, CA 95128 USA. EM hauliu@stanford.edu OI Orwoll, Eric/0000-0002-8520-7355 FU AHRQ HHS [HS000028-19]; NCRR NIH HHS [RR024140]; NIA NIH HHS [AG027810]; NIAMS NIH HHS [AR45647] NR 137 TC 75 Z9 82 U1 1 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 6 PY 2008 VL 148 IS 9 BP 685 EP 701 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA 299BW UT WOS:000255731800007 PM 18458282 ER PT J AU Lionakis, MS Hamill, RJ AF Lionakis, Michail S. Hamill, Richard J. TI Malaise, weight loss, pleuritic chest pain and productive cough: What is your call? SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Editorial Material ID ACTINOMYCOSIS C1 [Lionakis, Michail S.; Hamill, Richard J.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. RP Lionakis, MS (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. NR 5 TC 3 Z9 3 U1 0 U2 0 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA SN 0820-3946 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD MAY 6 PY 2008 VL 178 IS 10 BP 1289 EP 1291 DI 10.1503/cmaj.070094 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 291WI UT WOS:000255227500015 PM 18458260 ER PT J AU Schultz, MR Lyons, MJ Franz, CE Grant, MD Boake, C Jacobson, KC Xian, H Schellenberg, GD Eisen, SA Kremen, WS AF Schultz, M. R. Lyons, M. J. Franz, C. E. Grant, M. D. Boake, C. Jacobson, K. C. Xian, H. Schellenberg, G. D. Eisen, S. A. Kremen, W. S. TI Apolipoprotein E genotype and memory in the sixth decade of life SO NEUROLOGY LA English DT Article ID VIETNAM ERA TWIN; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; VET REGISTRY; ALLELE; PERFORMANCE; ADULTS; GENE; AGE; IQ AB Background: Virtually all adult studies of APOE genotypes and cognition have included individuals over 60. In older adults, epsilon 4 carriers may manifest greater cognitive asymmetries than non-epsilon 4 carriers even in the absence of overall mean differences. General cognitive ability may also be affected by aging and APOE genotype, but most studies have inadequately addressed this potential confound. The goals of this study were to examine, in middle age, the relationship of APOE genotype with episodic memory and verbal-visuospatial episodic memory asymmetries, after accounting for prior general cognitive ability. Method: We compared epsilon 4+ and epsilon 4-individuals in 626 male twins in their 50s. We examined verbal and visuospatial episodic memory and verbal-visual asymmetry scores after adjusting for cognitive ability at age 20. Analyses corrected for correlations between twin pair members. Results: Compared with epsilon 4-individuals, epsilon 4 carriers performed significantly more poorly on verbal, but not visuospatial memory, manifested significantly greater cognitive asymmetry, and also had significantly more concerns about memory. At age 20, epsilon 4 carriers had higher general cognitive ability than epsilon 4-individuals, and current memory differences were enhanced after adjusting for age 20 cognitive ability. Conclusions: Small, but significant, APOE-epsilon 4-related memory deficits appear in the sixth decade of life in individuals who show no signs of preclinical dementia. The results partially support studies of older adults that suggest that increased cognitive asymmetries reflect risk for dementia and are associated with the APOE-epsilon 4 genotype. The results also highlight the potential problems of not having accurate data on prior cognitive ability. C1 [Schultz, M. R.; Lyons, M. J.; Grant, M. D.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Jacobson, K. C.] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA. [Boake, C.] Inst Rehabil & Res, Houston, TX USA. [Xian, H.; Eisen, S. A.] St Louis VA Med Ctr, Res Serv, St Louis, MO USA. [Eisen, S. A.] St Louis VA Med Ctr, Med Serv, St Louis, MO USA. [Xian, H.; Eisen, S. A.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA. [Eisen, S. A.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Schellenberg, G. D.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Schellenberg, G. D.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. [Schellenberg, G. D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Schellenberg, G. D.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. [Franz, C. E.; Kremen, W. S.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Kremen, W. S.] Univ Calif San Diego, Ctr Behav Genom, San Diego, CA 92103 USA. RP Kremen, WS (reprint author), Univ Calif San Diego, Dept Psychiat, Ctr Behav Genom, 9500 Gilman Dr,MC 0738, La Jolla, CA 92093 USA. EM wkremen@ucsd.edu RI Jacobson, Kristen/D-2064-2009; Lyons, Michael/B-6119-2011 OI Lyons, Michael/0000-0001-6516-9219 FU NIA NIH HHS [P50 AG005136-16, P50 AG005136-25, P50 AG005136, R01 AG018384, R01 AG018384-06A2, R01 AG018386, R01 AG018386-06A2, R01 AG022381, R01 AG022381-01, R01 AG022982, R01 AG022982-01A1] NR 39 TC 27 Z9 29 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 6 PY 2008 VL 70 IS 19 BP 1771 EP 1777 PN 2 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 312YB UT WOS:000256707200008 PM 18235080 ER PT J AU Siddiqa, A Long, LM Li, LX Marciniak, RA Kazhdan, I AF Siddiqa, Aisha Long, Linda M. Li, Liuxia Marciniak, Robert A. Kazhdan, Irene TI Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways SO BMC CANCER LA English DT Article ID REGULATORS; RECEPTOR; DEATH; BAX; ACTIVATION; MECHANISMS; ERBB-2; GENE AB Background: The oncoprotein HER-2 is over-expressed and/ or has undergone gene amplification in between 20 to 30% of breast and ovarian cancers. HER-2 amplified breast cancer is associated with a poor prognosis and increased resistance to chemo-and hormonal therapy. Data supporting the transforming potential of HER-2 are irrefutable but the mechanism by which HER-2 contributes to this process is complex and a unified model of HER2-induced increased cell proliferation and survival has not emerged. To understand the initial event(s) that take place by HER-2 over expression, we studied the effect of short term induction of HER-2 expression in the MCF7 breast cancer cell line. Methods: We examined the modulation of apoptotic pathways by tetracycline-regulated HER-2 expression for 48 hrs in the MCF7 breast cancer cell line. Specific inhibitors were used to determine signalling pathways that are required for HER-2 induced up-regulation of survivin. Results: Tetracycline regulated short term over expression of HER-2 in the MCF7 cell line increased the antiapoptotic proteins Bcl-2 and survivin levels. Significant increase of extracellular signal-related kinase (ERK) activation but not AKT1, AKT2 and STAT3 was observed in HER-2 over-expressing MCF7 cells. Specific inhibitors of ERK, and phosphoinositide-3 kinase (PI3K), inhibited the HER-2 induced upregulation of survivin. We did not observe a change in survivin and NF-kappa B promoter activity in HER-2 expressing MCF7 cells. Conclusion: Our results indicate that short term over expression of HER-2 up regulates antiapoptotic proteins Bcl-2 and survivin in MCF7 cells. We determined that survivin is up-regulated via ERK activation and PI3K signalling. Additionally we show that survivin up-regulation is not at transcriptional level. These data provide insight into the mechanism(s) by which induction of HER-2 over expression up-regulates survivin and Bcl-2 and identifies new targets for therapy of breast cancer. C1 [Siddiqa, Aisha; Long, Linda M.; Li, Liuxia; Marciniak, Robert A.; Kazhdan, Irene] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Marciniak, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Marciniak, Robert A.] S Texas Vet Healthcare Adm, San Antonio, TX 78229 USA. RP Siddiqa, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM siddiqa@uthscsa.edu; LONGL2@UTHSCSA.EDU; llxia698@yahoo.com; marciniak@uthscsa.edu; KAZHDAN@UTHSCSA.EDU NR 32 TC 50 Z9 55 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD MAY 2 PY 2008 VL 8 AR 129 DI 10.1186/1471-2407-8-129 PG 8 WC Oncology SC Oncology GA 302BA UT WOS:000255939800002 PM 18454859 ER PT J AU Kunik, ME Hudson, S Schubert, B Nasrallah, H Kirchner, JE Sullivan, G AF Kunik, Mark E. Hudson, Sonora Schubert, Brenda Nasrallah, Henry Kirchner, JoAnn E. Sullivan, Greer TI Growing our own: A regional approach to encourage psychiatric residents to enter research SO ACADEMIC PSYCHIATRY LA English DT Article ID MEDICAL-SCHOOL; TRENDS AB Objective: This article describes a regional program developed by the Department of Veterans Affairs South Central Mental Illness Research, Education and Clinical Center for training psychiatry residents in research and attracting them to academic careers. Methods: The authors describe a low-cost, innovative program developed to increase the number of psychiatry residents entering postresidency research training fellowships by providing them with mentorship and exposure to seasoned researchers, didactic coursework, and a stipend to cover academic expenses. Results: Over the first 4 years, the program has generated enthusiastic participation among postgraduate year-3 (PGY-3) residents, with a high percentage of underrepresented ethnic minorities and women. Products include publication of four first-authored and two coauthored manuscripts, one first-authored abstract, submission of six additional papers, 28 academic presentations and development of research projects. Half of graduating awardees have gone on to pursue research careers. Conclusion: Our regional approach provides sufficient academic expertise to make residency training feasible in a cost-effective manner. C1 [Kunik, Mark E.] MEDVAMC, Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Kunik, Mark E.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kunik, Mark E.; Hudson, Sonora] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX USA. [Kunik, Mark E.; Schubert, Brenda; Kirchner, JoAnn E.; Sullivan, Greer] VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA. [Nasrallah, Henry] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA. [Nasrallah, Henry] Univ Cincinnati, Coll Med, Neurosci Program, Cincinnati, OH USA. [Kirchner, JoAnn E.; Sullivan, Greer] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. [Sullivan, Greer] RAND Corp, Gulf States Policy Inst, Santa Monica, CA 90406 USA. RP Kunik, ME (reprint author), MEDVAMC, Baylor Coll Med, Dept Psychiat & Behav Sci, 2002 Holcombe 152, Houston, TX 77030 USA. EM mkunik@bcm.tmc.edu NR 15 TC 9 Z9 10 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1042-9670 J9 ACAD PSYCHIATR JI Acad. Psych. PD MAY-JUN PY 2008 VL 32 IS 3 BP 236 EP 240 DI 10.1176/appi.ap.32.3.236 PG 5 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA 299XI UT WOS:000255788500014 PM 18467482 ER PT J AU Pettinati, HM Kampman, KM Lynch, KG Xie, H Dackis, C Rabinowitz, AR O'Brien, CP AF Pettinati, Helen M. Kampman, Kyle M. Lynch, Kevin G. Xie, Hu Dackis, Charles Rabinowitz, Amanda R. O'Brien, Charles P. TI A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence SO ADDICTIVE BEHAVIORS LA English DT Article; Proceedings Paper CT 67th Annual Scientific Meeting of the College-on-Problems-of-Drug-Dependence CY JUN 21-23, 2005 CL Orlando, FL SP Coll Problems Drug Dependence DE combining medications; cocaine; alcohol; disulfiram; naltrexone; clinical trial; medication non-adherence ID PATTERN-MIXTURE MODELS; CONCURRENT USE; RELAPSE PREVENTION; CRACK COCAINE; COPING SKILLS; DRUG-USE; ACAMPROSATE; COMBINATION; EFFICACY; THERAPY AB Background: This is a double blind, placebo-controlled trial that evaluated the efficacy of disulfiram, naltrexone and their combination in patients with co-occurring cocaine and alcohol dependence. Methods: 208 patients were randomized to disulfiram (250 mg/day), naltrexone (100 mg/day), the combination, or placebo for 11 weeks. Outcomes were in-trial abstinence from cocaine and/or alcohol. Results: Few safety concerns were reported, although medication adherence was low in a number of patients for both medications, alone or in combination. In the primary analyses (GEE modeling), abstinence from cocaine as measured by cocaine-negative urines and days of self-reported abstinence from cocaine or alcohol did not differ between placebo and any of the medication groups. However, patients taking disulfiram (alone or in combination) were most likely to achieve combined abstinence from cocaine and alcohol. Secondary analyses revealed that patients taking the disulfiram-naltrexone combination were most likely to achieve 3 consecutive weeks of abstinence from cocaine and alcohol. Conclusion: There was an association between disulfiram treatment and abstinence from cocaine and alcohol. More patients taking the disulfiram-naltrexone combination achieved 3 consecutive weeks of abstinence in treatment than placebo-treated patients. (C) 2007 Elsevier Ltd. All rights reserved. C1 Univ Penn, Treatment Res Ctr, Philadelphia, PA 19104 USA. [Pettinati, Helen M.; Kampman, Kyle M.; Lynch, Kevin G.; Xie, Hu; Dackis, Charles; Rabinowitz, Amanda R.; O'Brien, Charles P.] Univ Penn, Sch Med, Dept Psychiat, Ctr Study Addict, Philadelphia, PA 19104 USA. [O'Brien, Charles P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Pettinati, HM (reprint author), Univ Penn, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM pettinati_h@mail.trc.upenn.edu FU NIDA NIH HHS [P60 DA005186, P50 DA012756, P50 DA012756-010002, P50 DA012756-020002, P50 DA012756-030002, P50 DA012756-040002, P50 DA12756, P60 DA005186-16, P60 DA005186-17, P60 DA005186-17S1, P60 DA005186-18, P60 DA005186-18S1, P60 DA005186-19, P60 DA005186-19S1, P60 DA05186] NR 64 TC 50 Z9 50 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD MAY PY 2008 VL 33 IS 5 BP 651 EP 667 DI 10.1016/j.addbeh.2007.11.011 PG 17 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 289PP UT WOS:000255066700003 PM 18079068 ER PT J AU Fotuhi, M Zandi, PP Hayden, KM Khachaturian, AS Szekely, CA Wengreen, H Munger, RG Norton, MC Tschanz, JT Lyketsos, CG Breitner, JCS Welsh-Bohmer, K AF Fotuhi, Majid Zandi, Peter P. Hayden, Kathleen M. Khachaturian, Ara S. Szekely, Christine A. Wengreen, Heidi Munger, Ronald G. Norton, Maria C. Tschanz, JoAnn T. Lyketsos, Constantine G. Breitner, John C. S. Welsh-Bohmer, Kathleen TI Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: The Cache County Study SO ALZHEIMERS & DEMENTIA LA English DT Article DE antioxidant vitamins; NSAIDs; cognitive performance; random effect model; dementia prevention ID RISK; WOMEN; NSAID; MEN; AD AB Studies have shown less cognitive decline and lower risk of Alzheimer's disease in elderly individuals consuming either antioxidant vitamins or nonsteroidall anti-inflammatory drugs (NSAIDs). The potential of added benefit from their combined use has not been studied. We therefore analyzed data from 3,376 elderly participants of the Cache County Study who were given the Modified Mini-Mental State examination up to three times during a period of 8 years. Those who used a combination of vitamins E and C supplements and NSAIDs at baseline declined by an average 0.96 fewer points every 3 years than nonusers (P <.05). This apparent effect was attributable entirely to participants with the APOE epsilon 4 allele, whose users declined by 2.25 fewer points than nonusers every 3 years (P <.05). These results suggest that among elderly individuals with an APOE epsilon 4 allele, there is an association between using antioxidant supplements in combination with NSAIDs and less cognitive decline over time. (C) 2008 The Alzheimer's Association. All rights reserved . C1 [Fotuhi, Majid] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Fotuhi, Majid] LifeBridge Hlth Brain & Spine Inst, Ctr Memory & Brain Hlth, Baltimore, MD USA. [Zandi, Peter P.; Szekely, Christine A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Hayden, Kathleen M.; Welsh-Bohmer, Kathleen] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Khachaturian, Ara S.] Khachaturian & Associates Inc, Potomac, MD USA. [Wengreen, Heidi; Munger, Ronald G.] Utah State Univ, Dept Nutr & Food Sci, Logan, UT 84322 USA. [Norton, Maria C.; Tschanz, JoAnn T.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Norton, Maria C.; Tschanz, JoAnn T.] Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. [Lyketsos, Constantine G.] Dept Psychiat, Baltimore, MD USA. [Lyketsos, Constantine G.] Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD USA. [Breitner, John C. S.] Univ Washington, Dept Psychiat, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Fotuhi, M (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. EM mfotuhi@lifebridgehealth.org RI Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Fotuhi, Majid/0000-0002-0980-1176; Hayden, Kathleen/0000-0002-7745-3513 FU NIA NIH HHS [R01-AG-11380, R01 AG011380, R01 AG011380-13, T32 AG000029, T32 AG000029-29, T32-AG-00029]; NIMH NIH HHS [T32 MH014592, T32 MH014592-29, T32-MH-14592] NR 12 TC 34 Z9 35 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD MAY PY 2008 VL 4 IS 3 BP 223 EP 227 DI 10.1016/j.jalz.2008.01.004 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 302JX UT WOS:000255965700013 PM 18631971 ER PT J AU Ho, PM Eng, MH Rumsfeld, JS Spertus, JA Peterson, PN Jones, PG Peterson, ED Alexander, KP Havranek, EP Krumholz, HM Masoudi, FA AF Ho, P. Michael Eng, Marvin H. Rumsfeld, John S. Spertus, John A. Peterson, Pamela N. Jones, Philip G. Peterson, Eric D. Alexander, Karen P. Havranek, Edward P. Krumholz, Harlan M. Masoudi, Frederick A. TI The influence of age on health status outcomes after acute myocardial infarction SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE CORONARY SYNDROMES; QUALITY-OF-LIFE; ARTERY-DISEASE; FUNCTIONAL STATUS; ELDERLY-PATIENTS; MANAGEMENT; ASSOCIATION; HEART; CARE; REGISTRY AB Background Older age is a risk factor for higher mortality after acute myocardial infarction (AMI), but the association with health status outcomes is largely unexplored. Methods In a prospective cohort of 2498 patients in the PREMIER study, we compared health-related quality of life (HRQL) and burden of angina symptoms among survivors of AMI by age strata (age groups >= 75, 65-74, 50-64, and 19-49 years) using the Seattle Angina Questionnaire. Multivariable analyses assessed the relationship between age and 1-year HRQL and angina burden, adjusting for differences in clinical characteristics, treatment, and baseline health status. Results Older patients comprised a majority: 20.1% were 75 years of age, 41.7% were 65 to 74 years of age, 20.7% were 50 to 64 years of age, and 17.4% were < 50 years of age. At 12 months, older patients had higher mortality (17.0% vs 8.7% vs 6.1% vs 3.2% for age groups 75, 65-74, 50-64, 19-49; P <.001). Among survivors of AMI, increasing age was associated with less angina and better HRQL. By 12 months, older patients reported less angina (10.9% vs 12.7% vs 19.3% vs 23.4% for age groups 75, 65-74, 50-64, 19-49; P <.0001) and better HRQL (scores 89.1 vs 88.1 vs 82.5 vs 80.0, respectively; P <.0001), which persisted after adjustment for baseline angina, HRQL, and other demographic, clinical, disease severity, and treatment differences. Conclusions Although older patients have higher mortality after AMI, those who survive experience fewer symptoms and better HRQL at 1 year than younger patients. Angina remains present in a number of patients across the spectrum of age, supporting strategies to systematically assess and treat symptoms after AMI. C1 [Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Med Serv, Denver, CO USA. [Ho, P. Michael; Eng, Marvin H.; Rumsfeld, John S.; Peterson, Pamela N.; Havranek, Edward P.; Masoudi, Frederick A.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Spertus, John A.; Jones, Philip G.] Mid Amer Heart Inst, Kansas City, MO USA. [Peterson, Pamela N.; Havranek, Edward P.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Dept Med, Denver, CO USA. [Peterson, Eric D.; Alexander, Karen P.] Duke Clin Res Inst, Durham, NC USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT USA. RP Ho, PM (reprint author), 1055 Clermont St,Cardiol 111B, Denver, CO 80220 USA. EM michael.ho@uchsc.edu NR 25 TC 19 Z9 19 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAY PY 2008 VL 155 IS 5 BP 855 EP 861 DI 10.1016/j.ahj.2007.11.032 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 302WU UT WOS:000256001500009 PM 18440332 ER PT J AU Aqel, RA Hage, FG Zohgbi, GJ Tabereaux, PB Lawson, D Heo, J Perry, G Epstein, AE Italia, LJD Iskandrian, AE AF Aqel, Raed A. Hage, Fadi G. Zohgbi, Gilbert J. Tabereaux, Paul B. Lawson, David Heo, Jaekyeong Perry, Gilbert Epstein, Andrew E. Italia, Louis J. Dell' Iskandrian, Ami E. TI Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricullar outflow pressure gradients SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CARDIAC MAGNETIC-RESONANCE; OBSTRUCTIVE CARDIOMYOPATHY; CONTRAST ECHOCARDIOGRAPHY; PERFUSION; THERAPY; EMBOLIZATION; ANGIOGENESIS; REPERFUSION; PROGRESSION; MODEL AB Alcohol septal ablation (ASA) as a treatment for obstructive hypertrophic cardiomyopathy produces septal infarction. There is a concern that such infarcts could be detrimental. Changes in the size of these infarcts by serial perfusion testing have not been studied. We performed resting serial-gated single-photon emission computed tomographic myocardial perfusion imaging in 30 patients (age 51 +/- 17 years, 57% were women) who had ASA between September 2003 and March 2007 before, 2 +/- 0.8 days (early), and 8.4 +/- 6.9 months (late) after ASA. Patients were also followed clinically and with serial 2-dimensional echocardiography. New York Heart Association class decreased from 3.50 +/- 0.51 before to 1.14 +/- 0.36 (p < 0.0001) 3 months after ASA. The left ventricular (LV) outflow gradient (by Doppler echocardiography) decreased from 63 +/- 32 mm Hg before to 28 +/- 23 mm Hg after ASA (p < 0.005). None of the patients had perfusion defects at rest before ASA. After ASA, perfusion defect size, involving the basal septum, decreased from 9.4 +/- 5.8% early to 5.2 +/- 4.2% of LV myocardium late after ASA (p < 0.001). There were no changes in LV size and ejection fraction after ASA. In conclusion, ASA produces small basal ventricular septal infarcts (resting perfusion abnormality) involving < 10% of the LV myocardium (including ventricular septum). There is a significant reduction in the perfusion abnormality late after ASA without an increase in LV outflow obstruction or recurrence of symptoms. (c) 2008 Elsevier Inc. All rights reserved. C1 [Aqel, Raed A.] Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Aqel, RA (reprint author), Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. EM raed.aqel@med.va.gov NR 30 TC 14 Z9 15 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAY 1 PY 2008 VL 101 IS 9 BP 1328 EP 1333 DI 10.1016/j.amjcard.2007.12.042 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 298EW UT WOS:000255670200020 PM 18435966 ER PT J AU Shrubsole, MJ Wu, H Ness, RM Shyr, Y Smalley, WE Zheng, W AF Shrubsole, Martha J. Wu, Huiyun Ness, Reid M. Shyr, Yu Smalley, Walter E. Zheng, Wei TI Alcohol drinking, cigarette smoking, and risk of colorectal adenomatous and hyperplastic polyps SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE adenomatous polyps; alcohol drinking; colonic polyps; colorectal neoplasms; intestinal polyps; smoking ID UNITED-STATES; TOBACCO SMOKING; SERRATED ADENOMAS; LARGE-INTESTINE; POOLED ANALYSIS; DOSE-RESPONSE; CANCER RISK; CONSUMPTION; ASSOCIATION; POLYMORPHISM AB The authors evaluated alcohol drinking and cigarette smoking in relation to risk of colorectal polyps in a Nashville, Tennessee, colonoscopy-based case-control study. In 2003-2005, cases with adenomatous polyps only (n 639), hyperplastic polyps only (n = 294), and both types of polyps (n = 235) were compared with 1,773 polyp-free controls. Unordered polytomous logistic regression was used to calculate adjusted odds ratios and 95% confidence intervals. Consumption of at least five alcoholic drinks per week was not strongly associated with development of polyps. Odds ratios for all polyp types were increased for dose, duration, and pack-years of cigarette smoking and were stronger for hyperplastic polyps than for adenoma. Compared with never smoking, dose-response relations were particularly strong for current smoking and duration; for >= 35 years of smoking, odds ratios were 1.9 ( 95% confidence interval (CI): 1.4, 2.5) for adenomatous polyps only, 5.0 ( 95% CI: 3.3, 7.3) for hyperplastic polyps only, and 6.9 ( 95% CI: 4.4, 11.1) for both types of polyps. Compared with current smoking, time since cessation was associated with substantially reduced odds; for >= 20 years since quitting, odds ratios were 0.4 ( 95% CI: 0.3, 0.6) for adenoma only, 0.2 ( 95% CI: 0.1, 0.3) for hyperplastic polyps only, and 0.2 ( 95% CI: 0.2, 0.4) for both polyp types. These findings support the adverse role of cigarette smoking in colorectal tumorigenesis and suggest that quitting smoking may substantially reduce the risk of colorectal polyps. C1 [Shrubsole, Martha J.; Smalley, Walter E.; Zheng, Wei] Vanderbilt Univ, Med Ctr, Vanderbilt Epidemiol Ctr, Nashville, TN 37203 USA. [Shrubsole, Martha J.; Zheng, Wei] Vanderbilt Univ, Sch Med, Div Gen Internal Med & Publ Hlth, Nashville, TN 37212 USA. [Shrubsole, Martha J.; Ness, Reid M.; Smalley, Walter E.; Zheng, Wei] US Dept Vet Affairs, Tennessee Vallet Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. [Shrubsole, Martha J.; Wu, Huiyun; Ness, Reid M.; Shyr, Yu; Smalley, Walter E.; Zheng, Wei] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Smalley, Walter E.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Ness, Reid M.; Smalley, Walter E.] Vanderbilt Univ, Sch Med, Div Gastroenterol, Nashville, TN 37212 USA. RP Shrubsole, MJ (reprint author), Vanderbilt Univ, Med Ctr, Vanderbilt Epidemiol Ctr, 2525 W End Ave,Suite 800, Nashville, TN 37203 USA. EM martha.shrubsole@vanderbilt.edu RI Shrubsole, Martha/K-5052-2015 OI Shrubsole, Martha/0000-0002-5591-7575 FU NCI NIH HHS [P50 CA095103, P50CA950103, R01 CA097386, R01CA97386] NR 69 TC 60 Z9 61 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAY 1 PY 2008 VL 167 IS 9 BP 1050 EP 1058 DI 10.1093/aje/kwm400 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 293BQ UT WOS:000255310200005 PM 18304959 ER PT J AU Bush, RK AF Bush, Robert K. TI Approach to patients with symptoms of food allergy SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE anaphylaxis; epinephrine; food allergy; food intolerance AB "Allergy" is a term often used by patients to describe symptoms that arise after eating. The term "adverse reaction to food" is preferred unless the event has an immunologic basis. True food allergy, primarily mediated by immunoglobulin (Ig) E antibodies to food proteins, is present in 3% to 4% of US adults. Symptoms range from mild mouth itching ("oral allergy syndrome") to anaphylaxis. The diagnosis is established by history and appropriately performed skin testing or in vitro assays for specific IgE antibodies to the suspected food. Because food-allergic reactions can be fatal, it is important to identify and avoid the causative food. Food-allergic reactions are treated by prompt use of intramuscular epinephrine. Patients may be referred to an allergy/immunology specialist when the diagnosis is uncertain or if avoidance measures are not successful. Investigational therapies may ultimately be preventative or curative. (C) 2008 Elsevier Inc. All rights reserved. C1 [Bush, Robert K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Bush, Robert K.] Univ Wisconsin, Dept Med, Sect Allergy Immunol Pulm Sleep & Crit Care Med, Madison, WI USA. RP Bush, RK (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM Robert.Bush@va.gov NR 7 TC 5 Z9 6 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAY PY 2008 VL 121 IS 5 BP 376 EP 378 DI 10.1016/j.amjmed.2007.07.036 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 295ZI UT WOS:000255512900006 PM 18456029 ER PT J AU Madaras-Kelly, KJ Remington, RE Oliphant, CM Sloan, KL Bearden, DT AF Madaras-Kelly, Karl J. Remington, Richard E. Oliphant, Catherine M. Sloan, Kevin L. Bearden, David T. TI Efficacy of oral beta-lactam versus non-beta-lactam treatment of uncomplicated cellulitis SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE antibiotics; cellulitis; epidemiology; outcomes; skin and soft tissue infections ID RESISTANT STAPHYLOCOCCUS-AUREUS; SOFT-TISSUE INFECTIONS; ACQUIRED METHICILLIN-RESISTANT; SKIN; MANAGEMENT; CEPHALEXIN; IMPACT AB BACKGROUND: Preferred therapy for purulent skin and soft tissue infections is incision and drainage, but many infections cannot be drained. Empiric therapies for these infections are ill-defined in the era of community-acquired methicillin-resistant Staphylococcus aureus. METHODS: A multicenter retrospective cohort study of outpatients treated for cellulitis was conducted to compare clinical failure rates of oral beta-lactam and non-beta-lactam treatments. Exclusion criteria included purulent infection requiring incision and drainage, complicated skin and soft tissue infection, chronic ulceration, and intravenous antibiotics. Failure rates were compared using logistic regression to adjust for both covariates associated with failure and a propensity score for beta-lactam treatment. RESULTS: Of 2977 patients, 861 met inclusion criteria and were classified by treatment: beta-lactam (n = 631) or non-beta-lactam therapy (n = 230). Failure rates were 14.7% versus 17.0% (odds ratio [OR] 0.85, 95% confidence interval [CI], 0.56-1.31) for beta-lactam and non-beta-lactam therapy, respectively. Failure was associated with: age (P = .02), acute symptom severity (P = .03), animal bites (P = .03), Charlson score >3 (P = .02), and histamine-2 receptor antagonist use (P = .09). Relative efficacy of beta-lactam therapy was greater after adjustment for factors associated with failure but remained statistically insignificant (adjusted OR 0.81, 95% CI, 0.53-1.24); adjusted including propensity score covariate (OR 0.71, 95% CI, 0.45-1.13). Discontinuation due to adverse effects differed between beta-lactam (0.5%) and non-beta-lactam (2.2%) therapies (P = .04). CONCLUSION: There was no significant difference in clinical failure between beta-lactam and non-beta-lactam antibiotics for the treatment of uncomplicated cellulitis. Increased discontinuation due to adverse events with non-beta-lactam therapy was observed. (C) 2008 Elsevier Inc. All rights reserved. C1 [Madaras-Kelly, Karl J.; Oliphant, Catherine M.] Idaho State Univ, Coll Pharm, Boise, ID USA. [Madaras-Kelly, Karl J.; Oliphant, Catherine M.] Dept Vet Affairs Med Ctr, Boise, ID USA. [Remington, Richard E.] Quantified Inc, Boise, ID USA. [Sloan, Kevin L.] Univ Washington, Sch Med, Seattle, WA USA. [Sloan, Kevin L.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Bearden, David T.] Oregon State Univ, Coll Pharm, Portland, OR USA. [Bearden, David T.] Dept Vet Affairs Med Ctr, Portland, OR USA. RP Madaras-Kelly, KJ (reprint author), VA Med Ctr, 500 W Ft St 119A, Boise, ID 83702 USA. EM KMK@otc.isu.edu NR 18 TC 14 Z9 14 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAY PY 2008 VL 121 IS 5 BP 419 EP 425 DI 10.1016/j.amjmed.2008.01.028 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 295ZI UT WOS:000255512900015 PM 18456038 ER PT J AU Wintermark, M Jawadi, SS Rapp, JH Tihan, T Tong, E Glidden, DV Abedin, S Schaeffer, S Acevedo-Bolton, G Boudignon, B Orwoll, B Pan, X Saloner, D AF Wintermark, M. Jawadi, S. S. Rapp, J. H. Tihan, T. Tong, E. Glidden, D. V. Abedin, S. Schaeffer, S. Acevedo-Bolton, G. Boudignon, B. Orwoll, B. Pan, X. Saloner, D. TI High-resolution CT imaging of carotid artery atherosclerotic plaques SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID INTIMA-MEDIA THICKNESS; AMERICAN-HEART-ASSOCIATION; MAGNETIC-RESONANCE IMAGES; COMPUTED-TOMOGRAPHY; SURFACE-MORPHOLOGY; VASCULAR-LESIONS; ISCHEMIC-STROKE; RISK-FACTORS; STENOSIS; ENDARTERECTOMY AB BACKGROUND AND PURPOSE: Plaque morphologic features have been suggested as a complement to luminal narrowing measurements for assessing the risk of stroke associated with carotid atherosclerotic disease, giving rise to the concept of "vulnerable plaque." The purpose of this study was to evaluate the ability of multidetector-row CT angiography (CTA) to assess the composition and characteristics of carotid artery atherosclerotic plaques with use of histologic examination as the gold standard. MATERIALS AND METHODS: Eight patients with transient ischemic attacks who underwent carotid CTA and "en bloc" endarterectomy were enrolled in a prospective study. An ex vivo micro-CT study of each endarterectomy specimen was obtained, followed by histologic examination. A systematic comparison of CTA images with histologic sections and micro-CT images was performed to determine the CT attenuation associated with each component of the atherosclerotic plaques. A computer algorithm was subsequently developed that automatically identifies the components of the carotid atherosclerotic plaques, based on the density of each pixel. A neuroradiologist's reading of this computer analysis was compared with the interpretation of the histologic slides by a pathologist with respect to the types and characteristics of the carotid plaques. RESULTS: There was a 72.6% agreement between CTA and histologic examination in carotid plaque characterization. CTA showed perfect concordance for calcifications. A significant overlap between densities associated with lipid-rich necrotic core, connective tissue, and hemorrhage limited the reliability of individual pixel readings to identify these components. However, CTA showed good correlation with histologic examination for large lipid cores (kappa = 0.796; P < .001) and large hemorrhages (kappa = 0.712; P = .102). CTA performed well in detecting ulcerations (kappa = 0.855) and in measuring the fibrous cap thickness (R-2 = 0.77; P < .001). CONCLUSION: The composition of carotid atherosclerotic plaques determined by CTA reflects plaque composition defined by histologic examination. C1 [Wintermark, M.; Tong, E.; Schaeffer, S.; Acevedo-Bolton, G.; Saloner, D.] Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, San Francisco, CA 94143 USA. [Glidden, D. V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Boudignon, B.; Orwoll, B.] Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA. [Rapp, J. H.; Pan, X.] San Francisco Vet Adm Med Ctr, Dept Vasc Surg, San Francisco, CA USA. [Jawadi, S. S.; Abedin, S.] Univ Missouri, Kansas City Sch Med, Dept Diagnost Radiol, Kansas City, MO 64110 USA. RP Wintermark, M (reprint author), Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. EM max.wintermark@radiology.ucsf.edu OI Wintermark, Max/0000-0002-6726-3951 FU NCRR NIH HHS [KL2 RR024130] NR 50 TC 131 Z9 145 U1 1 U2 15 PU AMER SOC NEURORADIOLOGY PI OAK BROOK PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA SN 0195-6108 J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD MAY PY 2008 VL 29 IS 5 BP 875 EP 882 DI 10.3174/ajnr.A0950 PG 8 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 302KI UT WOS:000255966800010 PM 18272562 ER PT J AU El-Amouri, SS Zhu, H Yu, J Marr, R Verma, IM Kindy, MS AF El-Amouri, Salim S. Zhu, Hong Yu, Jin Marr, Robert Verma, Inder M. Kindy, Mark S. TI Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID AMYLOID-BETA-PEPTIDE; LONG-TERM POTENTIATION; APPSWE/PS1DE9 MOUSE MODEL; NITRIC-OXIDE MECHANISM; A-BETA; TRANSGENIC MICE; PLAQUE-FORMATION; IN-VIVO; ACTIVATED MICROGLIA; LENTIVIRUS VECTOR AB it is well established that the extracellular deposition of amyloid beta (A beta) peptide plays a central role in the development of Alzheimer's disease (AD). Therefore, either preventing the accumulation of A beta peptide in the brain or accelerating its clearance may slow the rate of AD onset. Neprilysin (NEP) is the dominant A beta peptide-degrading enzyme in the brain; NEP becomes inactivated and down-regulated during both the early stages of AD and aging. in this study, we investigated the effect of human (h)NEP gene transfer to the brain in a mouse model of AD before the development of amyloid plaques, and assessed how this treatment modality affected the accumulation of A beta peptide and associated pathogenetic changes (eg, inflammation, oxidative stress, and memory impairment). Overexpression of hNEP for 4 months in young APP/Delta PS1 double-transgenic mice resulted in reduction in A beta peptide levels, attenuation of amyloid load, oxidative stress, and inflammation, and improved spatial orientation. Moreover, the overall reduction in amyloidosis and associated pathogenetic changes in the brain resulted in decreased memory impairment by similar to 50%. These data suggest that restoring NEP levels in the brain at the early stages of AD is an effective strategy to prevent or attenuate disease progression. C1 [El-Amouri, Salim S.; Zhu, Hong; Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [El-Amouri, Salim S.; Kindy, Mark S.] Med Univ S Carolina, Dept Mol & Cellular Biochem, Charleston, SC 29425 USA. [Kindy, Mark S.] Ralph H Johnston Vet Adm Ctr, Charleston, SC USA. [Marr, Robert; Verma, Inder M.] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Basic Sci Bldg,Room 403,173 Ashley Ave, Charleston, SC 29425 USA. EM kindyms@musc.edu FU NIA NIH HHS [AG019323, R01 AG019323] NR 74 TC 86 Z9 90 U1 0 U2 7 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD MAY PY 2008 VL 172 IS 5 BP 1342 EP 1354 DI 10.2353/ajpath.2008.070620 PG 13 WC Pathology SC Pathology GA 294CP UT WOS:000255382000018 PM 18403590 ER PT J AU Sanders, NM Wilkinson, CW Taborsky, GJ Al-Noori, S Daumen, W Zavosh, A Figlewicz, DP AF Sanders, Nicole M. Wilkinson, Charles W. Taborsky, Gerald J., Jr. Al-Noori, Salwa Daumen, Wendi Zavosh, Aryana Figlewicz, Dianne P. TI The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE epinephrine; adrenomedullary; hypoglycemia-associated autonomic failure ID DEPENDENT DIABETES-MELLITUS; PITUITARY-ADRENOCORTICAL AXIS; PLACEBO-CONTROLLED TRIAL; GLUCOSE DISPOSAL; CONSCIOUS DOGS; SYMPATHOADRENOMEDULLARY SYSTEM; CHROMAFFIN CELLS; MESSENGER-RNA; ADRENAL-GLAND; DOUBLE-BLIND AB Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for patients with comorbid diabetes and depression. Clinical case studies in diabetic patients, however, suggest that SSRI therapy may exacerbate hypoglycemia. We hypothesized that SSRIs might increase the risk of hypoglycemia by impairing hormonal counterregulatory responses (CRR). We evaluated the effect of the SSRI sertraline on hormonal CRR to single or recurrent hypoglycemia in nondiabetic rats. Since there are time-dependent effects of SSRIs on serotonin neurotransmission that correspond with therapeutic action, we evaluated the effect of 6- or 20-day sertraline treatment on hypoglycemia CRR. We found that 6- day sertraline (SERT) treatment specifically enhanced the epinephrine response to a single bout of hypoglycemia vs. vehicle (VEH)-treated rats (t = 120: VEH, 2,573 +/- 448 vs. SERT, 4,202 +/- 545 pg/ml, P < 0.05). In response to recurrent hypoglycemia, VEH-treated rats exhibited the expected impairment in epinephrine secretion t = 60: 678 +/- 73 pg/ml) vs. VEH-treated rats experiencing first-time hypoglycemia ( t = 60: 2,081 +/- 436 pg/ml, P < 0.01). SERT treatment prevented the impaired epinephrine response in recurrent hypoglycemic rats ( t = 60: 1,794 +/- 276 pgl/ml). In 20-day SERT-treated rats, epinephrine, norepinephrine, and glucagon CRR were all significantly elevated above VEH-treated controls in response to hypoglycemia. Similarly to 6- day SERT treatment, 20-day SERT treatment rescued the impaired epinephrine response in recurrent hypoglycemic rats. Our data demonstrate that neither 6- nor 20-day sertraline treatment impaired hormonal CRR to hypoglycemia in nondiabetic rats. Instead, sertraline treatment resulted in an enhancement of hypoglycemia CRR and prevented the impaired adrenomedullary response normally observed in recurrent hypoglycemic rats. C1 [Sanders, Nicole M.; Taborsky, Gerald J., Jr.; Figlewicz, Dianne P.] Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. [Wilkinson, Charles W.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Sanders, Nicole M.; Wilkinson, Charles W.; Al-Noori, Salwa; Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Taborsky, Gerald J., Jr.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Al-Noori, Salwa; Daumen, Wendi; Zavosh, Aryana] Seattle Inst Biomed & Clin Res, Seattle, WA USA. RP Sanders, NM (reprint author), VA Puget Sound Hlth Care Syst, 1660 So Columbian Way, Seattle, WA 98108 USA. EM sandersn@u.washington.edu FU NIDDK NIH HHS [R01 DK050154-10, DK-50154, R56 DK050154, R01 DK040963, DK-40963, R01 DK050154] NR 50 TC 13 Z9 13 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD MAY PY 2008 VL 294 IS 5 BP E853 EP E860 DI 10.1152/ajpendo.00772.2007 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 295VI UT WOS:000255501600008 PM 18334609 ER PT J AU Guth, PH Kaunitz, JD AF Guth, Paul H. Kaunitz, Jonathan D. TI Personal reminiscences about morton grossman and the founding of the center for ulcer research and education (CURE) SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE history of physiology ID GASTRIC SECRETION; PEPTIC-ULCER AB Personal reminiscences about Morton Grossman and the founding of the Center for Ulcer Research and Education ( CURE). Am J Physiol Gastrointest Liver Physiol 294: G1109-G1113, 2008. First published March 20, 2008; doi:10.1152/ajpgi.00594.2007.-The Center for Ulcer Research and Education ( CURE) from its onset was primarily the work of one man: Professor Morton Grossman, or "Mort" as he was known and called by all. Mort's legacy includes a large body of scientific publications, the first National Institutes of Health Digestive Diseases Center ( CURE), and, most importantly, a group of scientists who have become academic leaders and who have made important contributions in the fields of upper gastrointestinal (GI) tract secretion, hormones and receptors, mucosal defense mechanisms, the design and conduct of randomized clinical trials, and ulcer epidemiology. Indeed, Mort is considered to be a founding father of modern academic GI research. I was fortunate to have known and worked with Mort and would like to memorialize his contributions so that his memory can inspire the next generation of academicians. C1 [Guth, Paul H.; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Sch Med, Dept Med, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK054221] NR 10 TC 3 Z9 3 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD MAY PY 2008 VL 294 IS 5 BP G1109 EP G1113 DI 10.1152/ajpgi.00594.2007 PG 5 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 296TS UT WOS:000255569300003 PM 18356532 ER PT J AU Sipe, WEB Brierley, SM Martin, CM Phillis, BD Cruz, FB Grady, EF Liedtke, W Cohen, DM Vanner, S Blackshaw, LA Bunnett, NW AF Sipe, Walter E. B. Brierley, Stuart M. Martin, Christopher M. Phillis, Benjamin D. Cruz, Francisco Bautista Grady, Eileen F. Liedtke, Wolfgang Cohen, David M. Vanner, Stephen Blackshaw, L. Ashley Bunnett, Nigel W. TI Transient receptor potential vanilloid 4 mediates protease activated receptor 2-induced sensitization of colonic afferent nerves and visceral hyperalgesia SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE visceral pain; proteases; protease-activated receptors; transient receptor potential channels ID MAST-CELL TRYPTASE; IRRITABLE-BOWEL-SYNDROME; ION-CHANNEL; MOUSE COLON; PROTEASE-ACTIVATED-RECEPTOR-2 SENSITIZES; PARACELLULAR PERMEABILITY; MECHANOSENSORY FUNCTION; INFLAMMATORY MEDIATORS; NEUROGENIC MECHANISM; CAPSAICIN RECEPTOR AB Transient receptor potential vanilloid 4 mediates protease activated receptor 2-induced sensitization of colonic afferent nerves and visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol 294: G1288-G1298, 2008. First published March 6, 2008;doi:10.1152/ajpgi.00002.2008.-Protease- activated receptor (PAR(2)) is expressed by nociceptive neurons and activated during inflammation by proteases from mast cells, the intestinal lumen, and the circulation. Agonists of PAR2 cause hyperexcitability of intestinal sensory neurons and hyperalgesia to distensive stimuli by unknown mechanisms. We evaluated the role of the transient receptor potential vanilloid 4 ( TRPV4) in PAR(2)-induced mechanical hyperalgesia of the mouse colon. Colonic sensory neurons, identified by retrograde tracing, expressed immunoreactive TRPV4, PAR(2), and calcitonin generelated peptide and are thus implicated in nociception. To assess nociception, visceromotor responses (VMR) to colorectal distension (CRD) were measured by electromyography of abdominal muscles. In TRPV4 (+/+) mice, intraluminal PAR(2) activating peptide ( PAR(2)-AP) exacerbated VMR to graded CRD from 6-24 h, indicative of mechanical hyperalgesia. PAR(2)-induced hyperalgesia was not observed in TRPV4 (-/-) mice. PAR(2)-AP evoked discharge of action potentials from colonic afferent neurons in TRPV4 (+/+) mice, but not from TRPV4(-/-) mice. The TRPV4 agonists 5', 6'- epoxyeicosatrienoic acid and 4 alpha-phorbol 12,13-didecanoate stimulated discharge of action potentials in colonic afferent fibers and enhanced current responses recorded from retrogradely labeled colonic dorsal root ganglia neurons, confirming expression of functional TRPV4. PAR(2)-AP enhanced these responses, indicating sensitization of TRPV4. Thus TRPV4 is expressed by primary spinal afferent neurons innervating the colon. Activation of PAR(2) increases currents in these neurons, evokes discharge of action potentials from colonic afferent fibers, and induces mechanical hyperalgesia. These responses require the presence of functional TRPV4. Therefore, TRPV4 is required for PAR(2)-induced mechanical hyperalgesia and excitation of colonic afferent neurons. C1 [Grady, Eileen F.; Bunnett, Nigel W.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Sipe, Walter E. B.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Bunnett, Nigel W.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA. [Brierley, Stuart M.; Martin, Christopher M.; Phillis, Benjamin D.; Blackshaw, L. Ashley] Royal Adelaide Hosp, Hanson Inst, Dept Gastroenterol & Hepatol, Nerve Gut Res Lab, Adelaide, SA 5000, Australia. [Blackshaw, L. Ashley] Univ Adelaide, Sch Mol & Biomed Sci, Discipline Med, Adelaide, SA, Australia. [Brierley, Stuart M.; Blackshaw, L. Ashley] Univ Adelaide, Sch Mol & Biomed Sci, Discipline Physiol, Adelaide, SA, Australia. [Cruz, Francisco Bautista; Vanner, Stephen] Queens Univ, Div Gastroenterol, Gastrointestinal Dis Res Unit, Kingston, ON, Canada. [Liedtke, Wolfgang] Duke Univ, Med Ctr, Dept Med & Neurobiol, Durham, NC USA. [Cohen, David M.] Portland VA Med Ctr, Portland, OR USA. RP Bunnett, NW (reprint author), Univ Calif San Francisco, Dept Surg, 513 Parnassus Ave,Rm S-1268,Box 0660, San Francisco, CA 94143 USA. EM nigel.bunnett@ucsf.edu RI Liedtke, Wolfgang/G-4633-2011; Blackshaw, Ashley/K-7287-2014 OI Blackshaw, Ashley/0000-0003-1565-0850; Brierley, Stuart/0000-0002-2527-2905 FU NIDDK NIH HHS [DK 43207, DK 07762, DK 54840] NR 58 TC 70 Z9 72 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD MAY PY 2008 VL 294 IS 5 BP G1288 EP G1298 DI 10.1152/ajpgi.00002.2008 PG 11 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 296TS UT WOS:000255569300023 PM 18325985 ER PT J AU Venkatachalam, K Mummidi, S Cortez, DM Prabhu, SD Valente, AJ Chandrasekar, B AF Venkatachalam, Kaliyamurthi Mummidi, Srinivas Cortez, Dolores M. Prabhu, Sumanth D. Valente, Anthony J. Chandrasekar, Bysani TI Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE signal transduction; proinflammatory cytokines ID PHOSPHOINOSITIDE 3-KINASE PATHWAY; SMOOTH-MUSCLE-CELLS; FACTOR-KAPPA-B; CANCER CELLS; DIABETIC CARDIOMYOPATHY; PROSTATE-CANCER; HEART-FAILURE; NITRIC-OXIDE; KINASE-B; PROLIFERATION AB We investigated the expression of the proinflammatory cytokine interleukin (IL)-17 in cardiac fibroblasts and its induction by high glucose (HG). Our results show that primary mouse cardiac fibroblasts (mCFs) secrete low basal levels of IL-17 and that HG (25 mM D-glucose) as opposed to low glucose (5 mM D-glucose + 20 mM mannitol) significantly enhances its secretion. HG induces IL-17 mRNA expression by both transcriptional and posttranscriptional mechanisms. HG induces phosphoinositide 3-kinase [PI3K; inhibited by adenoviral (Ad). dominant negative (dn) PI3Kp85], Akt (inhibited by Ad.dnAkt1), and ERK (inhibited by PD-98059) activation and induces IL-17 expression via PI3K -> 3Akt -> ERK-dependent signaling. Moreover, mCFs express both IL-17 receptors A and C, and although IL-17RA is upregulated, HG fails to modulate IL-17RC expression. Furthermore, IL-17 stimulates net collagen production by mCFs. Pretreatment with the phytoalexin resveratrol blocks HG-induced PI3K-, Akt-, and ERK-dependent IL-17 expression. These results demonstrate that 1) cardiac fibroblasts express IL-17 and its receptors; 2) HG upregulates IL-17 and IL-17RA, suggesting a positive amplification loop in IL-17 signaling in hyperglycemia; 3) IL-17 enhances net collagen production; and 4) resveratrol can inhibit these HG-induced changes. Thus, in hyperglycemic conditions, IL-17 may potentiate myocardial inflammation, injury, and remodeling through autocrine and paracrine mechanisms, and resveratrol has therapeutic potential in ameliorating this effect. C1 [Chandrasekar, Bysani] Univ Texas Hlth Sci Ctr San Antonio, Janey Briscoe Ctr Excellence Cardiovasc Res, San Antonio, TX 78229 USA. [Venkatachalam, Kaliyamurthi; Mummidi, Srinivas; Cortez, Dolores M.; Chandrasekar, Bysani] Audie L Murphy Div, S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. [Mummidi, Srinivas; Valente, Anthony J.; Chandrasekar, Bysani] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78284 USA. [Prabhu, Sumanth D.] Louisville Vet Adm Med Ctr, Med Serv, Louisville, KY USA. [Prabhu, Sumanth D.] Univ Louisville, Dept Med, Inst Mol Cardiol, Louisville, KY 40292 USA. RP Chandrasekar, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Janey Briscoe Ctr Excellence Cardiovasc Res, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chandraseka@uthscsa.edu RI Prabhu, Sumanth/D-5223-2009; Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 NR 51 TC 66 Z9 70 U1 1 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAY PY 2008 VL 294 IS 5 BP H2078 EP H2087 DI 10.1152/ajpheart.01363.2007 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 296UA UT WOS:000255570100016 PM 18310510 ER PT J AU Rousseau, CM Ioannou, GN Todd-Stenberg, JA Sloan, KL Larson, MF Forsberg, CW Dominitz, JA AF Rousseau, Christine M. Ioannou, George N. Todd-Stenberg, Jeffrey A. Sloan, Kevin L. Larson, Meaghan F. Forsberg, Christopher W. Dominitz, Jason A. TI Racial differences in the evaluation and treatment of hepatitis C among veterans: A retrospective cohort study SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES VETERANS; VIRUS-INFECTION; PEGINTERFERON ALPHA-2A; AMERICAN PATIENTS; PLUS RIBAVIRIN; MEDICAL-CARE; AFRICAN-AMERICANS; HEALTH-CARE; PREVALENCE; INTERFERON-ALPHA-2B AB Objectives. We examined the association between race and hepatitis C virus (HCV) evaluation and treatment of veterans in the Northwest Network of the Department of Veterans Affairs (VA). Methods. In our retrospective cohort study, we used medical records to determine antiviral treatment of 4263 HCV-infected patients from 8 VA medical centers. Secondary outcomes included specialty referrals, laboratory evaluation, viral genotype testing, and liver biopsy. Multiple logistic regression was used to adjust for clinical (measured through laboratory results and International Classification of Diseases, Ninth Revision, codes) and sociodemographic factors. Results. Blacks were less than half as likely as Whites to receive antiviral treatment (odds ratio [OR]=0.38; 95% confidence interval [CI]=0.23, 0.63). Both had similar odds of referral and liver biopsy. However, Blacks were significantly less likely to have complete laboratory evaluation (OR=0.67; 95% CI=0.52, 0.88) and viral genotype testing (OR=0.68; 95% CI=0.51, 0.90). Conclusions. Race is associated with receipt of medical care for various medical conditions. Further investigation is warranted to help understand whether patient preference or provider bias may explain why HCV-infected Blacks were less likely to receive medical care than Whites. C1 [Rousseau, Christine M.; Todd-Stenberg, Jeffrey A.; Forsberg, Christopher W.] VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Rousseau, Christine M.; Ioannou, George N.; Sloan, Kevin L.; Larson, Meaghan F.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, NW Hepatitis C Resource Ctr, Seattle, WA USA. [Ioannou, George N.; Sloan, Kevin L.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Ioannou, George N.; Dominitz, Jason A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Sloan, Kevin L.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Forsberg, Christopher W.] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA. RP Rousseau, CM (reprint author), Box 358070,1959 NE Pacific St, Seattle, WA 98195 USA. EM cmr@u.washington.edu OI Dominitz, Jason/0000-0002-8070-7086 NR 54 TC 16 Z9 16 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2008 VL 98 IS 5 BP 846 EP 852 DI 10.2105/AJPH.2007.113225 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 295RY UT WOS:000255492800021 PM 18382007 ER PT J AU Krueger, PM Chang, VW AF Krueger, Patrick M. Chang, Virginia W. TI Being poor and coping with stress: Health behaviors and the risk of death SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID TIME PHYSICAL-ACTIVITY; MALE BRITISH DOCTORS; SOCIOECONOMIC-STATUS; PERCEIVED STRESS; ALCOHOL-CONSUMPTION; UNITED-STATES; US ADULTS; SMOKING-CESSATION; CIGARETTE-SMOKING; WORKING ADULTS AB Objectives. Individuals may cope with perceived stress through unhealthy but often pleasurable behaviors. We examined whether smoking, alcohol use, and physical inactivity moderate the relationship between perceived stress and the risk of death in the US population as a whole and across socioeconomic strata. Methods. Data were derived from the 1990 National Health Interview Survey's Health Promotion and Disease Prevention Supplement, which involved a representative sample of the adult US population (n = 40335) and was linked to prospective National Death Index mortality data through 1997. Gompertz hazard models were used to estimate the risk of death. Results. High baseline levels of former smoking and physical inactivity increased the impact of stress on mortality in the general population as well as among those of low socioeconomic status (SES), but not middle or high SES. Conclusions. The combination of high stress levels and high levels of former smoking or physical inactivity is especially harmful among low-SES individuals. Stress, unhealthy behaviors, and low SES independently increase risk of death, and they combine to create a truly disadvantaged segment of the population. C1 [Krueger, Patrick M.] Univ Texas Houston, Sch Publ Hlth, Div Management Policy & Community Hlth, Houston, TX 77030 USA. [Krueger, Patrick M.] Univ Texas Austin, Populat Res Ctr, Austin, TX 78712 USA. [Chang, Virginia W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chang, Virginia W.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Krueger, PM (reprint author), Univ Texas Houston, Sch Publ Hlth, Div Management Policy & Community Hlth, 1200 Herman Pressler,RAS E-907, Houston, TX 77030 USA. EM patrick.m.krueger@uth.tmc.edu FU NICHD NIH HHS [K12 HD043459, K12 HD043459-05, K12-HD043459, R24 HD042849, R24 HD042849-08, R24-HD42849] NR 71 TC 82 Z9 83 U1 6 U2 31 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2008 VL 98 IS 5 BP 889 EP 896 DI 10.2105/AJPH.2007.114454 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 295RY UT WOS:000255492800027 PM 18382003 ER PT J AU Woodworth, BA Tamashiro, E Bhargave, G Cohen, NA Palmer, JN AF Woodworth, Bradford A. Tamashiro, Edwin Bhargave, Geeta Cohen, Noarn A. Palmer, James N. TI An in vitro model of Pseudomonas aeruginosa biofilms on viable airway epithelial cell monolayers SO AMERICAN JOURNAL OF RHINOLOGY LA English DT Article DE air-liquid interface; airway epithelium; bacteria; biofilm; PAO-1; Pseudomonas; rhinosinusitis; sinusitis; sinus surgery ID LIQUID INTERFACE CULTURES; QUORUM-SENSING SIGNALS; BACTERIAL BIOFILMS; CHRONIC RHINOSINUSITIS; CHRONIC SINUSITIS; RESISTANCE; MUCOSA AB Background: Chronic rhinosinusitis (CRS) that is refractory to medical or surgical intervention may involve a particularly resistant form of infection known as a bacterial biofilm. Bacterial biofilms are three-dimensional aggregates of bacteria that Often are recalcitrant to antibiotics secondary to physical barrier characteristics. To date, all studies investigating biofilms in CRS have been descriptive in either human or animal tissue. To better understand the interactions of bacterial biofilms with respiratory epithelium, we describe an in vitro model of biofilm sinusitis by establishing mature biofilms on airway epithelial air-liquid interface cultures. Methods: Airway epithelial cell cultures were grown on collagen-coated semipermeable support membranes as an air-liquid interface on tissue culture inserts. Confluent air-liquid interface cultures were inoculated with the biofilm-forming PAO-1 strain of Pseudomonas aeruginosa and compared with cultures inoculated with two mutant strains (sad-31 and sad-36) unable to form biofilms. Inoculated tissue transwells were incubated for 20 hours, allowing for biofilm growth. The semipermeable membranes were then harvested and imaged with confocal laser scanning microscopy and scanning electron microscopy. Results: Microscopic analysis revealed the formation of biofilm-forming towers in the PAO-1 inoculated wells. The bacterial biofilms were supported by a viable airway epithelial cell surface monolayer. Conclusion: This study shows a reliable method for analysis of in vitro interactions of bacterial biofilms and airway epithelium. The experimental manipulation of this air-liquid interface model will help explore novel treatment approaches for bacterial biofilm-associated CRS. C1 [Woodworth, Bradford A.; Tamashiro, Edwin; Bhargave, Geeta; Cohen, Noarn A.; Palmer, James N.] Univ Penn Hlth Syst, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA USA. [Woodworth, Bradford A.; Tamashiro, Edwin; Bhargave, Geeta; Cohen, Noarn A.; Palmer, James N.] Philadelphia Vet Affairs Med Ctr, Div Otolaryngol Head & Neck Surg, Philadelphia, PA USA. [Woodworth, Bradford A.] Univ Alabama, Birmingham Dept Surg, Div Otolaryngol, Birmingham, AL USA. RP Palmer, JN (reprint author), Univ Penn, Med Ctr, Div Rhinol, Dept Otorhinolaryngol Head & Neck Surg, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM james.palmer@uphs.upenn.edu RI Tamashiro, Edwin/C-5062-2012 OI Tamashiro, Edwin/0000-0002-3153-6292; Cohen, Noam/0000-0002-9462-3932 NR 18 TC 19 Z9 19 U1 1 U2 13 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1050-6586 J9 AM J RHINOL JI Am. J. Rhinol. PD MAY-JUN PY 2008 VL 22 IS 3 BP 235 EP 238 DI 10.2500/ajr.2008.22.3178 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA 304TP UT WOS:000256132300004 PM 18588754 ER PT J AU Streblow, DN Kreklywich, CN Yin, M Andoh, T Smith, PP Nelson, JA Orloff, SL AF Streblow, Daniel N. Kreklywich, Craig N. Yin, Michael Andoh, Takeshi Smith, Patsy P. Nelson, Jay A. Orloff, Susan L. TI Source and replication state of CMV infection are important for acceleration of TVS. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT 8th American Transplant Congress CY MAY 31-JUN 04, 2008 CL Toronto, CANADA SP Amer Soc Transplant Surg, Amer Soc Transplantat C1 [Streblow, Daniel N.; Smith, Patsy P.; Nelson, Jay A.] Oregon Hlth & Sci Univ, VGTI, Beaverton, OR USA. [Kreklywich, Craig N.; Yin, Michael; Andoh, Takeshi; Orloff, Susan L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kreklywich, Craig N.; Yin, Michael; Andoh, Takeshi; Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA. [Smith, Patsy P.; Nelson, Jay A.; Orloff, Susan L.] Oregon Hlth & Sci Univ, MMI, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2008 VL 8 SU 2 BP 344 EP 344 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 299NV UT WOS:000255763201032 ER PT J AU Osaki, S Malone, J Thomas, H Comwell, RD Meyer, KC Edwards, NM De Oliveira, NC AF Osaki, Satoru Malone, James Thomas, Holly Comwell, Richard D. Meyer, Keith C. Edwards, Niloo M. De Oliveira, Nilto C. TI The impact of lung allocation score at the single national veterans affairs hospital lung transplantation program SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT 8th American Transplant Congress CY MAY 31-JUN 04, 2008 CL Toronto, CANADA SP Amer Soc Transplant Surg, Amer Soc Transplantat C1 [Osaki, Satoru; Malone, James; Thomas, Holly; Comwell, Richard D.; Meyer, Keith C.; Edwards, Niloo M.; De Oliveira, Nilto C.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2008 VL 8 SU 2 BP 546 EP 546 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 299NV UT WOS:000255763202196 ER PT J AU Yaffe, K Covinsky, KE AF Yaffe, Kristine Covinsky, Kenneth E. TI Coronary bypass surgery and long-term cognitive decline SO ANNALS OF NEUROLOGY LA English DT Editorial Material ID NONSURGICAL CONTROLS; GRAFT-SURGERY; DISEASE; PUMP C1 [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Psychiat Neurol & Epidemiol, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Psychiat Neurol & Epidemiol, San Francisco, CA 94143 USA. NR 9 TC 0 Z9 0 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD MAY PY 2008 VL 63 IS 5 BP 547 EP 548 DI 10.1002/ana.21396 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 302HY UT WOS:000255960600003 PM 18481289 ER PT J AU Gazdzinski, S Kornak, J Weiner, MW Meyerhoff, DJ Nat, R AF Gazdzinski, Stefan Kornak, John Weiner, Michael W. Meyerhoff, Dieter J. Nat, Rer TI Body mass index and magnetic resonance markers of brain integrity in adults SO ANNALS OF NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; N-ACETYLASPARTATE; COGNITIVE FUNCTION; FAMILY-HISTORY; HEAVY DRINKING; HEALTHY-ADULTS; HUMAN OBESITY; RISK-FACTORS; PROTON MRS; FOLLOW-UP AB Objective: Obesity and being over-weight during adulthood have been consistently linked to increased risk for development of dementia later in life, especially Alzheimer's disease. They have also been associated with cognitive dysfunction and brain structural alterations in otherwise healthy adults. Although proton magnetic resonance spectroscopy may distinguish between neuronal and glial components of the brain and may point to neurobiological mechanisms underlying brain atrophy and cognitive changes, no spectroscopic studies have yet assessed the relationships between adiposity and brain metabolites. Methods: We have utilized magnetic resonance imaging and proton magnetic resonance spectroscopic imaging data from 50 healthy middle-aged participants (mean age, 41.7 +/- 8.5 years; 17 women), who were scanned as control subjects for another study. Results: After adjustment for age and sex, greater body mass indices (BMIs) correlated with: (1) lower concentrations of N-acetylaspartate (spectroscopic marker of neuronal viability) in frontal (p = 0.001), parietal (p = 0.006), and temporal (p = 0.008) white matter; (2) lower N-acetylaspartate in frontal gray matter (p = 0.01); and (3) lower concentrations of choline-containing metabolites (associated with membrane metabolism) in frontal white matter (p = 0.05). Interpretation: These results suggest that increased BMI at midlife is associated with neuronal and/or myelin abnormalities, primarily in the frontal lobe. Because white matter in the frontal lobes is more prone to the effects of aging than in other lobes, our results may reflect accelerated aging in individuals with high levels of adiposity. Thus, greater BMI may increase the odds of developing an age-related disease, such as Alzheimer's disease. C1 [Gazdzinski, Stefan; Weiner, Michael W.; Nat, Rer] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco Vet Adm Med Ctr, VAMC, San Francisco, CA 94121 USA. [Kornak, John; Weiner, Michael W.; Nat, Rer] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94121 USA. [Kornak, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. RP Gazdzinski, S (reprint author), Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco Vet Adm Med Ctr, VAMC, 4150 Clement St 114M, San Francisco, CA 94121 USA. EM stefan.gazdzinski@ucsf.edu FU NIAAA NIH HHS [R01 AA010788, P01 AA011493, P01 AA011493-03, P01 AA011493-04, P01 AA011493-05, P01 AA11493, R01 AA010788-11, R01 AA010788-12, R01 AA010788-13, R01 AA10788] NR 50 TC 99 Z9 101 U1 3 U2 11 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD MAY PY 2008 VL 63 IS 5 BP 652 EP 657 DI 10.1002/ana.21377 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 302HY UT WOS:000255960600014 PM 18409192 ER PT J AU Gundiah, N Kam, K Matthews, PB Guccione, J Dwyer, HA Saloner, D Chuter, TAM Guy, TS Ratcliffe, MB Tseng, EE AF Gundiah, Namrata Kam, Kimberly Matthews, Peter B. Guccione, Julius Dwyer, Harry A. Saloner, David Chuter, Timothy A. M. Guy, T. Sloane Ratcliffe, Mark B. Tseng, Elaine E. TI Asymmetric mechanical properties of porcine aortic sinuses SO ANNALS OF THORACIC SURGERY LA English DT Article ID FINITE-ELEMENT MODEL; VALVE INCOMPETENCE; ARTERIAL-WALL; ROOT; BEHAVIOR AB Background. Aortic sinuses are crucial components of the aortic root and important for aortic valve function. Mathematical modeling of various aortic valve or root replacements requires tissue material properties, and those of the aortic sinuses are unknown. The aim of this study is to compare the biaxial mechanical properties of the individual porcine aortic sinuses. Methods. Square specimens, oriented in the longitudinal and circumferential directions, were excised from the left coronary, right coronary, and noncoronary porcine sinuses. Tissue thickness was measured, and specimens were subjected to equibiaxial mechanical testing. Stressstrain data corresponding to a 35% stretch were fitted to a Fung strain energy function. Tissue stiffness and anisotropy were compared at 0.3 strain. Results. The circumferential direction was more compliant than the longitudinal one for left coronary (183.03 +/- 40.78 kPa versus 231.17 +/- 45.38 kPa, respectively; p=0.04) and right coronary sinuses (321.74 +/- 129.68 kPa versus 443.49 +/- 143.59 kPa, respectively; p=0.02) at 30% strain. No such differences were noted for noncoronary sinuses (331.74 +/- 129.68 kPa versus 415.98 +/- 191.38 kPa; p=0.19). Left coronary sinus was also significantly more compliant than right and noncoronary sinuses. There were no differences between right coronary and noncoronary sinus tissues. Conclusions. We demonstrate that the material properties of the porcine aortic sinuses are not symmetric. The left coronary sinus is significantly more compliant than the remaining sinuses. Realistic modeling of the aortic root must take into account the asymmetric differences in tissue material properties of the aortic sinuses. C1 Univ Calif San Francisco, Med Ctr, Dept Surg & Radiol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif Davis, Dept Mech & Aeronaut Engn, Davis, CA 95616 USA. RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, 500 Parnassus Ave,Suite W405,Box 0118, San Francisco, CA 94143 USA. EM tsenge@surgery.ucsf.edu NR 25 TC 26 Z9 27 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2008 VL 85 IS 5 BP 1631 EP 1638 DI 10.1016/j.athoracsur.2008.01.035 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 293FE UT WOS:000255319900019 PM 18442553 ER PT J AU Jung, KH Judge, JW Wong, MH Melby, PC Rosenberg, B Morrey, JD Gowen, BB AF Jung, Kie-Hoon Judge, John W. Wong, Min-Hui Melby, Peter C. Rosenberg, Barnett Morrey, John D. Gowen, Brian B. TI Immunoprophylaxis of phleboviral infection in hamsters with recombinant eimeria protozoan surface antigen SO ANTIVIRAL RESEARCH LA English DT Meeting Abstract CT 21st International Conference on Antiviral Research CY APR 13-17, 2008 CL Montreal, CANADA SP Int Soc Antiviral Res C1 [Jung, Kie-Hoon; Wong, Min-Hui; Morrey, John D.; Gowen, Brian B.] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA. [Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Res Serv, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 J9 ANTIVIR RES JI Antiviral Res. PD MAY PY 2008 VL 78 IS 2 MA 109 BP A58 EP A58 DI 10.1016/j.antiviral.2008.01.123 PG 1 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 295PN UT WOS:000255486500100 ER PT J AU Belogrudov, GI AF Belogrudov, Grigory I. TI The proximal N-terminal amino acid residues are required for the coupling activity of the bovine heart mitochondrial factor B SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE factor B; limited proteolysis; cross-link; energy coupling; proton leak; oxidative phosphorylation; mitochondria ID ATP SYNTHASE COMPLEX; F0 PROTON CHANNEL; OXIDATIVE-PHOSPHORYLATION; ESCHERICHIA-COLI; MEMBRANE INTERFACES; P-I; PURIFICATION; RESOLUTION; PROTEINS; SUBUNITS AB Treatment of the recombinant bovine factor B with trypsin yielded a fragment (amino acid residues 62-175) devoid of coupling activity . Removal of the N-terminal Trp2-Gly3-Trp4 peptide resulted in a significant loss of coupling activity in the FB Delta w2- w(4) deletion mutant. Sucrose density gradient centrifugation demonstrated co-sedimentation of recombinant factor B with the ADP/ATP carrier, which is present in preparations of H+-translocating F0F1-ATPase, but not in preparations of complex V. The N-terminally truncated factor B mutant FB Delta w (2)-w(4) did not co-sediment with the ADP/ATP carrier. Recombinant factor B co-sedimented with partially purified membrane sector F-0, extracted from F-1-stripped bovine submitochondrial particles with n-dodecyl-beta-D-maltoside. Factor B inhibited the passive proton conductance catalyzed by F0 reconstituted into asolectin liposomes. A factor B mutant, bearing a photoreactive unnatural amino acid pbenzoyl-L-phenylalanine (pBpa) substituted for Trp2, cross-linked with F-0 subunits e and g as well as the ADP/ATP carrier. These results suggest that the N-terminal domain and, in particular, the proximal N-terminal amino acids are important for the coupling activity and protein-protein interactions of bovine factor B. (c) 2008 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Belogrudov, GI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, VA Greater Los Angeles Healthcare Syst, Rm 324, Los Angeles, CA 90073 USA. EM gbelo@ucla.edu FU NIGMS NIH HHS [GM066085, R01 GM066085-05, R01 GM066085] NR 43 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD MAY 1 PY 2008 VL 473 IS 1 BP 76 EP 87 DI 10.1016/j.abb.2008.02.022 PG 12 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 291UY UT WOS:000255223700010 PM 18319055 ER PT J AU Choi, P Jordan, CD Mendez, E Houck, J Yueh, B Farwell, DG Futran, N Chen, C AF Choi, Peter Jordan, C. Diana Mendez, Eduardo Houck, John Yueh, Bevan Farwell, D. Gregory Futran, Neal Chen, Chu TI Examination of oral cancer biomarkers by tissue microarray analysis SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION PROFILES; NECK-CANCER; CDNA MICROARRAY; HEAD; TENASCIN; TRANSGLUTAMINASE-3; PERIOSTIN; DIFFERENTIATION; FIBROBLASTS AB Objective: To validate the DNA microarray results on a subset of genes that could potentially serve as biomarkers of oral squamous cell carcinoma (OSCC) by examining their expression with an alternate quantitative method and by assessing their protein levels. Design: Based on DNA microarray data from our laboratory and data reported in the literature, we identified 6 potential biomarkers of OSCC to investigate further. We used quantitative real-time polymerase chain reaction to examine expression changes of CDH11, MMP3, SPARC, POSTN, TNC, and TGM3 in OSCC and histologically normal control tissues. We further examined validated markers at the protein level by immunohistochemical analysis of OSCC tissue microarray sections. Results: Quantitative real-time polymerase chain reaction analysis revealed upregulation of CDH11, SPARC, POSTN, and TNC gene expression and decreased TGM3 expression in OSCC tissue compared with control tissue; MMP3 was not found to be differentially expressed. In tissue microarray immunohistochemical analyses, SPARC (secreted protein, acidic, rich in cysteine), periostin, and tenascin C exhibited increased protein expression in tumor tissue compared with control tissue, and their expression was primarily localized within tumor-associated stroma rather than tumor epithelium. Conversely, transglutaminase 3 protein expression was found only within keratinocytes in control tissue and was significantly downregulated in cancer cells. Conclusions: Of 6 potential gene markers of OSCC, initially identified by DNA microarray analyses, differential expression of CDH11, SPARC, POSTN, TNC, and TGM3 were validated by quantitative real-time polymerase chain reaction. Differential expression and localization of proteins encoded by SPARC, POSTN, TNC, and TGM3 were clearly shown by tissue microarray immunohistochemical analysis. C1 [Houck, John; Chen, Chu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98109 USA. [Choi, Peter; Mendez, Eduardo; Futran, Neal; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Jordan, C. Diana] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Mendez, Eduardo] Vet Affairs Puget Sound Hlth Care Syst, Dept Otolaryngol Head & Neck Surg, Seattle, WA USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Farwell, D. Gregory] Univ Calif Davis, Davis, CA USA. RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, 1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA. EM cchen@fhcrc.org OI Yueh, Bevan/0000-0003-1380-1053 FU NCI NIH HHS [R01 CA095419-01A1, R01 CA095419, R01 CA 095419-01A1]; NIDCD NIH HHS [T32 DC000018-26, T32 DC00018, T32 DC000018] NR 46 TC 30 Z9 30 U1 0 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD MAY PY 2008 VL 134 IS 5 BP 539 EP 546 DI 10.1001/archotol.134.5.539 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 301OK UT WOS:000255905300014 PM 18490578 ER PT J AU Rivera, PA Elliott, TR Berry, JW Grant, JS AF Rivera, Patricia A. Elliott, Timothy R. Berry, Jack W. Grant, Joan S. TI Problem-solving training for family caregivers of persons with traumatic brain injuries: A randomized controlled trial SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE brain injuries; caregivers; problem-solving; randomized controlled trials; rehabilitation ID STROKE SURVIVORS; PHYSICAL HEALTH; INITIAL YEAR; DEPRESSION; REHABILITATION; INTERVENTION; CHILDREN; THERAPY; STRESS; MODEL AB Objective: To test the hypothesis that a problem-solving training program Would lower depression, health complaints. and burden, and increase well-being reported by community-residing family caregivers of persons with traumatic brain injuries (TBIs). Design: Randomized controlled trial. Setting: General community. Participants: Of the 180 people who expressed interest in the Study, 113 did not meet eligibility criteria. A consenting sample of family caregivers were randomized into a problem-solving training group (4 men, 29 women; average age, 5 1.3y) or an education-only control group (34 women, average age, 50.8y). Care recipients included 26 men and 7 women in the intervention group (average age, 36.5y) and 24 men and 10 women in the control group (average age, 37.2y). Intervention: Problem-solving training based oil the 9 D'Zurilla and Nezu social problem-solving model was provided to caregivers in the intervention group in 4 in-home sessions and 8 telephone follow-up calls over the course of their year-long participation. Control group participants received written educational materials and telephone calls at set intervals throughout their 12 months of participation. Main Outcome Measures: Caregiver depression, health complaints, well-being, and social problem-solving abilities. Results: Hierarchical linear models revealed caregivers receiving problem-solving training reported significant decreases in depression, health complaints, and in dysfunctional problem-solving styles over time. No effects were observed oil caregiver well-being, burden, or Constructive problem-solving styles. Conclusions: Problem-solving training provided in file home appears to be effective in alleviating distress and in decreasing dysfunctional problem-solving styles among family caregivers of persons with TBI. Methodologic limitations and the implications for interventions and future research are discussed. C1 [Rivera, Patricia A.] Birmingham VAMC, Birmingham, AL 35233 USA. [Elliott, Timothy R.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA. [Berry, Jack W.] Univ Alabama, Injury Control Res Ctr, Birmingham, AL USA. [Grant, Joan S.] Univ Alabama, Sch Nursing, Birmingham, AL USA. RP Rivera, PA (reprint author), Birmingham VAMC, 700 19th St S, Birmingham, AL 35233 USA. EM patricia.rivera@va.gov RI Elliott, Timothy/I-5301-2012 OI Elliott, Timothy/0000-0002-6608-7714; Grant, Joan/0000-0001-6000-4060 FU National Institute for Disability and Rehabilitation Research [H133A02050]; U.S. Department of health and Human Services, Centers for Disease Control and Prevention - National Center for Injury Prevention [R49/CE000191]; National Institute oil Child Health and Human Development [T32 HD07420] FX Supported by the National Institute for Disability and Rehabilitation Research (grant no. H133A02050) by the U.S. Department of health and Human Services, Centers for Disease Control and Prevention - National Center for Injury Prevention (grant no. R49/CE000191). and by the National Institute oil Child Health and Human Development (grant no. T32 HD07420). NR 52 TC 57 Z9 60 U1 9 U2 24 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAY PY 2008 VL 89 IS 5 BP 931 EP 941 DI 10.1016/j.apmr.2007.12.032 PG 11 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 341ST UT WOS:000258735900020 PM 18452743 ER PT J AU Spaeth, DM Mahajan, H Karmarkar, A Collins, D Cooper, RA Boninger, ML AF Spaeth, Donald M. Mahajan, Harshal Karmarkar, Amol Collins, Diane Cooper, Rory A. Boninger, Michael L. TI Development of a wheelchair virtual driving environment: Trials with subjects with traumatic brain injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE brain injuries; rehabilitation; wheelchairs ID ELECTRIC-POWERED WHEELCHAIRS; ISOMETRIC JOYSTICKS; AMNESIA; TECHNOLOGY; POSITION; STATES AB Objective: To develop and test a wheelchair virtual driving environment that can provide quantifiable measures of driving ability, offer driver training, and measure the performance of alternative controls. Design: A virtual driving environment was developed. The wheelchair icon is displayed in a 2-dimensional, bird's eye view and has realistic steering and inertial properties. Eight subjects were recruited to test the virtual driving environment. They were clinically evaluated for range of motion, muscle strength, and visual field function. Driving capacity was assessed by a brief trial with an actual wheelchair. During virtual trials, subjects were seated in a stationary wheelchair: a standard motion sensing joystick (MSJ) was compared with an experimental isometric joystick by using a repeated-measures design. Setting: Subjects made 2 laboratory visits. The first visit included clinical evaluation, tuning the isometric joystick. familiarization with virtual driving environment, and 4 driving tasks. The second visit included 40 trials with each joystick. Participants: Subjects (n=8; 7 men, I woman) with a mean age of 22.65 +/- 2y and traumatic brain injury, both ambulatory and nonambulatory, were recruited. Interventions: The MSJ used factory settings. A tuning program customized the isometric joystick transfer functions during visit 1. During the second visit, subjects performed 40 trials with each joystick. Main Outcome Measure: The root mean square error (RMSE) was defined as the average deviation from track centerline (in meters) and speed (in m/s). Results: Data analysis from the first 8 subjects showed no statistically significant differences between joysticks. RMSE averaged.12 to .21m; speed averaged.75 m/s. For all tasks and joysticks, driving in reverse resulted in a higher RMSE and more virtual collisions than forward driving. RMSE rates were greater in left and right turns than straight and docking tasks. Conclusions: Testing with instrumented real wheelchairs can validate the virtual driving environment and assess whether virtual driving skills transfer to actual driving. C1 [Spaeth, Donald M.] VA Pittsburgh HealthCare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. [Spaeth, Donald M.; Mahajan, Harshal; Karmarkar, Amol; Collins, Diane; Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Spaeth, Donald M.; Mahajan, Harshal; Karmarkar, Amol; Collins, Diane; Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Spaeth, DM (reprint author), VA Pittsburgh HealthCare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, 7180 Highland Dr,Bldg 4,2nd F1 E,151R1-H, Pittsburgh, PA 15206 USA. EM spaethd@herlpitt.org RI Karmarkar, Amol/E-6030-2011 OI Karmarkar, Amol/0000-0001-8355-1585; Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research; U.S. Department of Education [H133A020502]; Human Engineering Research Laboratories FX Supported by the National Institute on Disability and Rehabilitation Research. U.S. Department of Education (grant no. H133A020502) and supported with resources and facilities by the Human Engineering Research Laboratories. VA Pittsburgh Healthcare System. NR 25 TC 12 Z9 14 U1 6 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAY PY 2008 VL 89 IS 5 BP 996 EP 1003 DI 10.1016/j.apmr.2007.11.030 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 341ST UT WOS:000258735900028 PM 18452751 ER PT J AU Kamen, DL Barron, M Parker, TM Shaftman, SR Bruner, GR Aberle, T James, JA Scofield, RH Harley, JB Gilkeson, GS AF Kamen, Diane L. Barron, Mia Parker, Tia M. Shaftman, Stephanie R. Bruner, Gail R. Aberle, Teresa James, Judith A. Scofield, R. Hal Harley, John B. Gilkeson, Gary S. TI Autoantibody prevalence and lupus characteristics in a unique African American population SO ARTHRITIS AND RHEUMATISM LA English DT Article ID 3 ETHNIC-GROUPS; CLINICAL-MANIFESTATIONS; FAMILIAL AGGREGATION; REVISED CRITERIA; RISK-FACTORS; ERYTHEMATOSUS; COHORT; FEATURES; DISEASE; DAMAGE AB Objective. The Gullah population of the Sea Islands of South Carolina is a unique group of African Americans who, due to geographic and cultural factors, remained isolated with minimal genetic admixture until the 1950s. Because of the unique homogeneous nature of the Gullah, we sought to define the genetic and environmental factors contributing to systemic lupus erythematosus (SLE) in this population. Methods. Using data from our ongoing cohort study of lupus in the Gullah population, which we established in 2003, disease characteristics and serologic profiles were summarized for 184 patients with SLE, 144 unaffected first-degree relatives, and 144 matched unrelated, unaffected control subjects. These findings were compared with those in 2 other large cohorts of African Americans with SLE. Results. In the Gullah cohort, we observed a high prevalence of SLE multiplex families (26.6%), malar rash (56.0%), discoid rash (34.2%), photosensitivity (60.9%), and oral/nasal ulcerations (43.5%), but a lower prevalence of hematologic and pleuropericardial disease than has been reported in other African American cohorts. Overall renal and central nervous system involvement, number of American College of Rheumatology disease criteria met, and SLE Damage Index scores were similar to those reported in other cohorts. Of interest, male and female first-degree relatives and male and female control subjects in this cohort had similar rates of antinuclear antibody positivity, whereas lupus-specific antibodies were more prevalent in the women than in the men. Conclusion. These data indicate that the severity of lupus in the Gullah population is similar to that in other African American populations, whereas skin disease and familial disease prevalence are increased in the Gullah. These findings suggest that there is an increased genetic influence on overall disease in this cohort compared with that in other African American cohorts, which confirms the unique nature of this cohort. C1 [Kamen, Diane L.; Barron, Mia; Parker, Tia M.; Shaftman, Stephanie R.; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Scofield, R. Hal; Harley, John B.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Scofield, R. Hal; Harley, John B.] Oklahoma City VAMC, Oklahoma City, OK USA. [Gilkeson, Gary S.] Ralph H Johnson VAMC, Charleston, SC USA. RP Kamen, DL (reprint author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA. EM kamend@musc.edu FU NCRR NIH HHS [RR-020143, M01 RR001070, RR-01070]; NIAID NIH HHS [AI-24717, AI-31584, AI-53747]; NIAMS NIH HHS [1-P60-AR-049459-01, AR-12253, AR-42460, AR-48940, AR49084, P30 AR053483] NR 41 TC 30 Z9 30 U1 1 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD MAY PY 2008 VL 58 IS 5 BP 1237 EP 1247 DI 10.1002/art.23416 PG 11 WC Rheumatology SC Rheumatology GA 300TP UT WOS:000255848400006 PM 18438839 ER PT J AU Bahjat, FR Pine, PR Reitsma, A Cassafer, G Baluom, M Grillo, S Chang, B Zhao, FF Payan, DG Grossbard, EB Daikh, DI AF Bahjat, Frances Rena Pine, Polly R. Reitsma, Andrea Cassafer, Gail Baluom, Muhammad Grillo, Sunny Chang, Betty Zhao, Fei Fei Payan, Donald G. Grossbard, Elliott B. Daikh, David I. TI An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus SO ARTHRITIS AND RHEUMATISM LA English DT Article ID REGULATORY T-CELLS; FC-GAMMA RECEPTORS; DENDRITIC CELLS; AIRWAY HYPERRESPONSIVENESS; ANTIGEN PRESENTATION; AUTOIMMUNE-DISEASE; ADOPTIVE TRANSFER; DEFICIENT MICE; ERYTHEMATOSUS; NEPHRITIS AB Objective. To assess whether R788, an orally bioavailable small molecule inhibitor of spleen tyrosine kinase (Syk)-dependent signaling, could modulate disease in lupus-prone (NZB x NZW)F-1 (NZB/NZW) mice via inhibition of Fc receptor (FcR) and B cell receptor signaling. Methods. R788 was administered to NZB/NZW mice before and after disease onset. Proteinuria, blood urea nitrogen levels, and autoantibody titers were examined periodically, and overall survival and renal pathologic features were assessed following long-term treatment (24-34 weeks). The distribution and immunophenotype of various splenic T cell and B cell subpopulations were evaluated at the time of study termination. Arthus responses in NZB/NZW mice pretreated with R788 or Fc-blocking antibody (anti-CD16/32) were also examined. Results. When R788 was administered prior to or after disease onset, it delayed the onset of proteinuria and azotemia, reduced renal pathology and kidney infiltrates, and significantly prolonged survival of lupus-prone NZB/NZW mice; autoantibody titers were minimally affected throughout the study. Dose-dependent reductions in the numbers of CD4+ activated T cells expressing high levels of CD44 or CD69 were apparent in spleens from R788-treated mice. Minimal effects on the numbers of naive T cells expressing CD62 ligand and total CD8+ T cells per spleen were observed following long-term drug treatment. R788 pretreatment resulted in reduced Arthus responses in NZB/NZW mice, similar to results obtained in mice pretreated with FcR-blocking antibody. Conclusion. We demonstrate that a novel Syk-selective inhibitor prevents the development of renal disease and treats established murine lupus nephritis. These data suggest that Syk inhibitors may be of therapeutic benefit in human lupus and related disorders. C1 [Cassafer, Gail; Daikh, David I.] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Cassafer, Gail; Daikh, David I.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Bahjat, Frances Rena; Pine, Polly R.; Reitsma, Andrea; Baluom, Muhammad; Grillo, Sunny; Chang, Betty; Zhao, Fei Fei; Payan, Donald G.; Grossbard, Elliott B.] Rigel Pharmaceut, San Francisco, CA USA. RP Daikh, DI (reprint author), Univ Calif San Francisco, 4150 Clement St,Immunol Arthritis 111R, San Francisco, CA 94121 USA. EM david.daikh@ucsf.edu NR 51 TC 98 Z9 102 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD MAY PY 2008 VL 58 IS 5 BP 1433 EP 1444 DI 10.1002/art.23428 PG 12 WC Rheumatology SC Rheumatology GA 300TP UT WOS:000255848400026 PM 18438845 ER PT J AU Bis, JC Heckbert, SR Smith, NL Reiner, AP Rice, K Lumley, T Hindorff, LA Marciante, KD Enquobahrie, DA Monks, SA Psaty, BM AF Bis, Joshua C. Heckbert, Susan R. Smith, Nicholas L. Reiner, Alexander P. Rice, Kenneth Lumley, Thomas Hindorff, Lucia A. Marciante, Kristin D. Enquobahrie, Daniel A. Monks, Stephanie A. Psaty, Bruce M. TI Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke SO ATHEROSCLEROSIS LA English DT Article DE myocardial infarction; ischemic stroke; inflammation; genetic epidemiology ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; LYMPHOTOXIN-ALPHA GENE; LINKAGE DISEQUILIBRIUM; CARDIOVASCULAR-DISEASE; MACULAR DEGENERATION; HUMAN GENOME; COPY NUMBER; ASSOCIATION; POLYMORPHISMS AB Background: From initiation to plaque rupture, immune system components contribute to atherosclerosis. We investigated variation in inflammation-related genes - interleukin (IL)-1 beta, IL-6, C-reactive protein (CRP), IL-10, IL-18, and the tumor necrosis factor (TNF) superfamily [lymphotoxin(LT)-alpha, TNF-alpha, LT-beta] - with respect to nonfatal incident myocardial infarction (MI) or ischemic stroke risk. Methods and results: A population-based case-control study recruited postmenopausal and/or hypertensive Group Health members aged 30-79 years. We chose a subset of single nucleotide polymorphisms (SNPs) to describe common gene-wide variation on the basis of linkage disequilibrium. 36 SNPs, describing 38 common haplotypes for 5 genes and a 3-gene cluster, were genotyped among 856 MI cases, 368 stroke cases, and 2688 controls. Associations of SNPs or PHASE-inferred haplotypes and risk were estimated using logistic regression; significance of gene-level associations was assessed with global Wald tests and permutation tests. Gene-wide IL-18 variation was associated with higher MI risk and an IL-1B haplotype was associated with lower stroke risk. In secondary analyses of SNPs, we observed associations of several IL-1B polymorphisms with risk of MI or stroke. IL-6, CRP, IL-10, and TNF superfamily gene variation was not associated with MI or stroke risk. Conclusions: Our results support prior reports associating an IL-18 gene variant and M1 risk, contribute additional evidence to reports of IL-1B and cardiovascular risk, and fail to confirm risk differences previously observed for CRP, IL-6, and TNF-a promoter variants. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Bis, Joshua C.; Marciante, Kristin D.; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA. [Heckbert, Susan R.; Smith, Nicholas L.; Reiner, Alexander P.; Hindorff, Lucia A.; Enquobahrie, Daniel A.; Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Rice, Kenneth; Lumley, Thomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Monks, Stephanie A.] Oklahoma State Univ, Dept Stat, Stillwater, OK 74078 USA. [Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seatle Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Bis, JC (reprint author), Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. EM johbis@u.washington.edu RI Rice, Kenneth/A-4150-2013 OI Rice, Kenneth/0000-0001-5779-4495 FU NHLBI NIH HHS [R01 HL068639-03, HL43201, HL68639, HL68986, HL73410, HL74745, R01 HL043201, R01 HL043201-08, R01 HL043201-09A1, R01 HL043201-10, R01 HL043201-11, R01 HL043201-12, R01 HL043201-13, R01 HL060739, R01 HL060739-02, R01 HL060739-03, R01 HL060739-04, R01 HL068639, R01 HL068639-01, R01 HL068639-02, R01 HL068639-04, R01 HL068986, R01 HL073410, R01 HL074745, R01 HL074745-01, R01 HL074745-02, R01 HL074745-03, R01 HL074745-04]; NIA NIH HHS [AG09556, R01 AG009556, R01 AG009556-05, R01 AG009556-06A2, R01 AG009556-07, R01 AG009556-08, R01 AG009556-09] NR 31 TC 43 Z9 47 U1 0 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAY PY 2008 VL 198 IS 1 BP 166 EP 173 DI 10.1016/j.atheroselerosis.2007.09.031 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 295RO UT WOS:000255491800020 PM 17981284 ER PT J AU Sorror, M Storer, B Sandmaier, BM Maloney, DG Chauncey, TR Langston, A Maziarz, RT Pulsipher, M McSweeney, PA Storb, R AF Sorror, Mohamed Storer, Barry Sandmaier, Brenda M. Maloney, David G. Chauncey, Thomas R. Langston, Amelia Maziarz, Richard T. Pulsipher, Michael McSweeney, Peter A. Storb, Rainer TI Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation SO CANCER LA English DT Article DE hematopoietic cell transplantation-specific comorbidity index; Karnofsky performance status; hematologic malignancies; nonmyeloablative conditioning; allogeneic hematopoietic cell transplantation; post-transplantation toxicities; nonrelapse mortality; survival ID ACUTE-MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; VERSUS-HOST-DISEASE; ADVANCED HEMATOLOGIC MALIGNANCIES; CHRONIC LYMPHOCYTIC-LEUKEMIA; MATCHED RELATED DONORS; MYELODYSPLASTIC-SYNDROME; PROGNOSTIC-FACTORS; AUTOLOGOUS TRANSPLANTATION AB BACKGROUND. Elderly and medically infirm cancer patients are increasingly offered allogeneic nonmyeloablative hematopoietic cell transplantation (HCT). A better understanding of the impact of health status on HCT outcomes is warranted. Herein, a recently developed HCT-specific comorbidity index (HCT-CI) was compared with a widely acceptable measure of health status, the Karnofsky performance status (KPS). METHODS. The outcomes of 341 patients were evaluated, conditioned for either related or unrelated HCT by 2-gray (Gy) total body irradiation given alone or 2 combined with fludarabine at a dose of 90 mg/m(2). Comorbidities were assessed retrospectively by the HCT-CI. Performance status before and toxicities after HCT were graded prospectively using the KPS and National Cancer Institute Common Toxicity criteria, respectively. RESULTS. Weak Spearman rank correlations were noted between HCT-CI and KPS and between the 2 measures and age, number of prior chemotherapy regimens, and intervals between diagnosis and HCT (all r < 0.20). High-risk diseases correlated significantly with higher mean HCT-CI scores (P =.009) but not low KPS (P=.37). In multivariate models, the HCT-CI had significantly greater independent predictive power for toxicities (P =.004), nonrelapse mortality (P =.0002), and overall mortality (P =.0002) compared with the KPS (P =.05,.13, and .05, respectively). Using consolidated HCT-CI and KPS scores, patients were stratified into 4 risk groups with 2-year survivals of 68%, 58%, 41%, and 32%, respectively. CONCLUSIONS. HCT-CI and KPS should be assessed simultaneously before HCT. The use of both tools combined likely refines risk-stratification for HCT outcomes. Novel guidelines for assessment of performance status among HCT patients are warranted. C1 [Sorror, Mohamed; Storer, Barry; Sandmaier, Brenda M.; Maloney, David G.; Chauncey, Thomas R.; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Storer, Barry; Sandmaier, Brenda M.; Maloney, David G.; Chauncey, Thomas R.; Storb, Rainer] Univ Washington, Seattle, WA 98195 USA. [Chauncey, Thomas R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Langston, Amelia] Emory Univ, Atlanta, GA 30322 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Pulsipher, Michael] Univ Utah, Salt Lake City, UT USA. [McSweeney, Peter A.] Rocky Mt Canc Ctr, Denver, CO USA. RP Sorror, M (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM msorror@fhcrc.org FU NCI NIH HHS [CA 18029, P01 CA078902, CA 15704, CA 78902, P01 CA018029]; NHLBI NIH HHS [HL 088021, HL 36444] NR 75 TC 121 Z9 124 U1 3 U2 8 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD MAY 1 PY 2008 VL 112 IS 9 BP 1992 EP 2001 DI 10.1002/cncr.23375 PG 10 WC Oncology SC Oncology GA 291YD UT WOS:000255232400016 PM 18311781 ER PT J AU Siddiqa, A Marciniak, R AF Siddiqa, Aisha Marciniak, Robert TI Targeting the hallmarks of cancer SO CANCER BIOLOGY & THERAPY LA English DT Editorial Material DE gene silencing; gene therapy; cancer targets ID THERAPY; CELLS; INHIBITION; ADDICTION; SCREEN C1 [Marciniak, Robert] Univ Texas Hlth Sci Ctr San Antonio, Div Haematol & Oncol MS 7884, Dept Med, San Antonio, TX 78229 USA. [Marciniak, Robert] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Marciniak, Robert] S Texas Vet Healthcare Adm, San Antonio, TX 78229 USA. RP Marciniak, R (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Haematol & Oncol MS 7884, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Marciniak@uthscsa.edu NR 23 TC 4 Z9 4 U1 2 U2 10 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4047 J9 CANCER BIOL THER JI Cancer Biol. Ther. PD MAY PY 2008 VL 7 IS 5 BP 740 EP 741 DI 10.4161/cbt.7.5.6163 PG 2 WC Oncology SC Oncology GA 322SC UT WOS:000257394600020 PM 18443426 ER PT J AU Geiger, GA Fu, WL Kao, GD AF Geiger, Geoffrey A. Fu, Weili Kao, Gary D. TI Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system SO CANCER RESEARCH LA English DT Article ID NEWLY-DIAGNOSED GLIOBLASTOMA; IONIZING-RADIATION; VERTEBRATE EMBRYO; PHASE-II; IN-VIVO; RADIOTHERAPY; MULTIFORME; DISCOVERY; SCREEN; THYMUS AB The zebrafish (Danio, rerio) is a popular vertebrate model for biomedical research. The rapid development, transparency, and experimental accessibility of the embryo offer opportunities for assessing the developmental effects of anticancer treatment strategies. We therefore systematically investigated parameters for growing U251 human glioma cells expressing red fluorescent protein (U251-RFP) in zebrafish embryos. Factors optimized include injection volume, number of cells injected, anatomic site of injection, age of the embryo at the time of injection, and postinjection incubation temperature. After injection into the embryos, the U251-RFP cells proliferated and the resultant tumors, and even individual cells, could be visualized in real-time via fluorescence microscopy without the need for sacrifice. These tumors recruited host zebrafish vasculature, suggesting cancer cell-host tissue interactions. Having optimized parameters for introducing and growing these human cells in the zebrafish embryos, we exposed both embryos and transplanted cancer cells to ionizing radiation and temozolomide, either alone or in combination. The human tumors in each embryo were substantially diminished following exposure to ionizing radiation and the decrease was further enhanced by pretreatment with temozolomide. In contrast, temozolomide had no discernible effects on embryonic development. These results together support the relative safety of temozolomide during embryonic development, as well as its anticancer efficacy when combined with radiation. These results suggest the value of the zebrafish model for in vivo testing of the efficacy and safety of anticancer strategies, especially on the very young. C1 [Geiger, Geoffrey A.; Fu, Weili; Kao, Gary D.] Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Geiger, Geoffrey A.; Fu, Weili; Kao, Gary D.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Kao, GD (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, John Morgan 180 H Hamilton Walk, Philadelphia, PA 19104 USA. EM Kao@xrt.upenn.edu FU NCI NIH HHS [C5T32CA009677, CA107956, P01 CA075138, P01CA075138, R01 CA107956, T32 CA009677]; NINDS NIH HHS [1R21NS061737, R21 NS061737, R21 NS061737-01] NR 34 TC 36 Z9 39 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2008 VL 68 IS 9 BP 3396 EP 3404 DI 10.1158/0008-5471CAN-07-6396 PG 9 WC Oncology SC Oncology GA 297FN UT WOS:000255602600040 PM 18451167 ER PT J AU Anderson, JA Willson, P AF Anderson, Jane A. Willson, Pamela TI Clinical decision support systems in nursing SO CIN-COMPUTERS INFORMATICS NURSING LA English DT Article DE computer-assisted decision making; decisions support systems; evidence-based medicine; information systems; practice guidelines ID CANCER PAIN MANAGEMENT; COMPUTER-PROGRAM; CARE; NURSES; PERFORMANCE; GUIDELINES AB The aim of this article is to present a synthesis of the research literature on the state of nursing science regarding the development, use, and application of clinical decision support systems for the implementation of evidence-based practice in nursing, The authors sought to answer three specific questions in this metasynthesis: (1) What progress has nursing science made regarding the development and use of clinical decision support systems?; (2) What research methods and theoretical models are being applied by nurse researchers in this area?; and (3) Are there evidence-adaptive clinical decision support systems designed specifically to aid nurses' decisions related to evidence-based practice? Of 183 articles, 17 were included in the final analysis, and six were specific for clinical decision support systems to aid nurses in evidence-based practice. Implications for practice are considered, and recommendations for future research are made. C1 [Anderson, Jane A.] Michael E DeBakey Vet Affairs Med Ctr, Stroke Ctr, Houston, TX 77030 USA. [Willson, Pamela] Prairie View A&M Univ, Coll Nursing, Houston, TX USA. RP Anderson, JA (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Stroke Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM jane.anderson@med.va.gov NR 38 TC 23 Z9 24 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1538-2931 J9 CIN-COMPUT INFORM NU JI CIN-Comput. Inform. Nurs. PD MAY-JUN PY 2008 VL 26 IS 3 BP 151 EP 158 DI 10.1097/01.NCN.0000304783.72811.8e PG 8 WC Computer Science, Interdisciplinary Applications; Medical Informatics; Nursing SC Computer Science; Medical Informatics; Nursing GA 297FB UT WOS:000255601400008 PM 18438151 ER PT J AU Dorfman, TA Iskandrian, AE Aqel, R AF Dorfman, Todd A. Iskandrian, Ami E. Aqel, Raed TI An unusual manifestation of tako-tsubo cardiomyopathy SO CLINICAL CARDIOLOGY LA English DT Review DE tako-tsubo cardiomyopathy; left ventricular outflow tract obstruction; coronary vasospasm; left ventricular apical ballooning ID LEFT-VENTRICULAR DYSFUNCTION; ST-SEGMENT ELEVATION; ACUTE MYOCARDIAL-INFARCTION; APICAL BALLOONING SYNDROME; TAKOTSUBO CARDIOMYOPATHY; EMOTIONAL-STRESS; FEATURES; WOMEN AB Tako-tsubo cardiomyopathy (TC) typically presents with chest pain, ST changes, and transient left ventricular (LV) apical ballooning in the absence of epicardial coronary artery disease (CAD). This process is reversible and usually benign. An unusual manifestation is that of left ventricular outflow tract (LVOT) obstruction with systolic anterior motion of the mitral valve. Recognition of this finding is critical in patient management especially in the setting of cardiogenic shock, as inotropes are likely to aggravate and worsen the clinical condition. We provide a systematic review and an illustrative case, and discuss treatment strategies. C1 [Dorfman, Todd A.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Dorfman, TA (reprint author), Univ Alabama, Div Cardiovasc Dis, LHRB 306,1530 3rd Ave S, Birmingham, AL 35294 USA. EM tdorman@cardmail.dom.uab.edu NR 25 TC 8 Z9 9 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0160-9289 J9 CLIN CARDIOL JI Clin. Cardiol. PD MAY PY 2008 VL 31 IS 5 BP 194 EP 200 DI 10.1002/clc.20212 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 304WO UT WOS:000256140000002 PM 17847035 ER PT J AU Thakkar, K El-Serag, HB Mattek, N Gilger, M AF Thakkar, Kalpesh El-Serag, Hashem B. Mattek, Nora Gilger, Mark TI Complications of pediatric colonoscopy: A five-year multicenter experience SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID GENERAL-ANESTHESIA; GASTROINTESTINAL PROCEDURES; ENDOSCOPIC PROCEDURES; COLONIC POLYPS; CHILDREN; POLYPECTOMY; BACTEREMIA; TRACT C1 [Thakkar, Kalpesh; Gilger, Mark] Texas Childrens Hosp, Sect Pediat Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA. [Thakkar, Kalpesh; Gilger, Mark] Baylor Coll Med, Houston, TX 77030 USA. [El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. [El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Mattek, Nora] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. RP Thakkar, K (reprint author), 6621 Fannin St,CCC 1010, Houston, TX 77030 USA. EM kthakkar@bcm.tmc.edu FU NIDDK NIH HHS [U01 DK057132] NR 33 TC 16 Z9 16 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAY PY 2008 VL 6 IS 5 BP 515 EP 520 DI 10.1016/j.cgh.2008.01.007 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300ED UT WOS:000255806200010 PM 18356115 ER PT J AU Ma, ZJ Choudhury, A Kang, SA Monestier, M Cohen, PL Eisenberg, RA AF Ma, Zhongjie Choudhury, Arpita Kang, Sun-Ah Monestier, Marc Cohen, Philip L. Eisenberg, Robert A. TI Accelerated atherosclerosis in ApoE deficient lupus mouse models SO CLINICAL IMMUNOLOGY LA English DT Article DE autoimmunity; atherosclerosis; apolipoprotein E; graft versus host disease; lpr; systemic lupus erythematosus ID LOW-DENSITY-LIPOPROTEIN; GRAFT-VERSUS-HOST; DNA B-CELLS; AUTOIMMUNE-DISEASE; APOPTOTIC CELLS; ANTIPHOSPHOLIPID ANTIBODIES; IMPAIRED CLEARANCE; IMMUNE-RESPONSES; FAS LIGAND; T-CELLS AB The accelerated development of atherosclerosis with increased risk of cardiovascular disease in systemic lupus erythematosus (SLE) patients is not well understood. An appropriate mouse model would greatly help to understand the mechanisms of this association. We have therefore combined the ApoE(-/-) model of atherosclerosis with three different murine models of SLE. We found that induction of cGVH in B6.ApoE(-/-) mice, breeding a Fas null gene onto the B6.ApoE(-/-) mice, and breeding the ApoE(-/-) defect onto MRL/lpr mice all caused a modest increase of atherosclerosis at 24 weeks of age compared to B6.ApoE(-/-) controls. B cells in B6.ApoE(-/-) mice had certain phenotypic differences compared to congenic C57BL/6 mice, as indicated by high expression of MHC II, Fas, CD86, and by increased number of cells bearing marginal zone phenotype. Furthermore, B6ApoE(-/-) mice had significant titers of anti-oxLDL and anti-cardiolipin autoantibodies compared to their B6 counterparts. Our studies also indicate that, following induction of cGVH, marginal zone B cells in B6.ApoE(-/-) are depleted, and there is considerable increase in anti-oxLDL and anti-cardiolipin abs along with secretion of lupus-specific autoantibodies, such as anti-dsDNA and anti-chromatin abs. Histological sections showed that cGVH and/or Fas deficiency could exacerbate atherosclerosis. The production of anti-oxLDL and anti-cardiolipin in ApoE(-/-) mice was also increased. These observations define a connection between induction of lupus-like symptoms and development of severe atherosclerosis in ApoE deficient lupus mouse models. (C) 2008 Elsevier Inc. All rights reserved. C1 [Ma, Zhongjie; Choudhury, Arpita; Cohen, Philip L.; Eisenberg, Robert A.] Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Kang, Sun-Ah; Monestier, Marc] Temple Univ, Sch Med, Dept Immunol & Microbiol, Philadelphia, PA 19104 USA. [Cohen, Philip L.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Eisenberg, RA (reprint author), Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA. EM raemd@mail.med.upenn.edu OI Kang, SunAh/0000-0002-6327-184X FU NIAID NIH HHS [U19-AI-46358, R01-AI063626, R01 AI063626-23, R01 AI063626, U19 AI046358, R01 AI063626-25, R01 AI063626-22A1, R01 AI063626-24]; NIAMS NIH HHS [R01-AR-34156, R01 AR034156-21, R01 AR034156-18, R01 AR034156-20, R01 AR034156, R01 AR034156-22A1, R01 AR034156-19]; NIDDK NIH HHS [R01-DK53088, R01 DK053088] NR 45 TC 28 Z9 29 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD MAY PY 2008 VL 127 IS 2 BP 168 EP 175 DI 10.1016/j.clim.2008.01.002 PG 8 WC Immunology SC Immunology GA 291XQ UT WOS:000255231100009 PM 18325838 ER PT J AU Schneider, H Cristian, A AF Schneider, Hyon Cristian, Adrian TI Role of rehabilitation medicine in the management of pain in older adults SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID MUSCULOSKELETAL PAIN; EXERCISE; KNEE; BALANCE; PREVALENCE; THERAPIES; RESIDENTS; ARTHRITIS; ORTHOSES; EFFICACY AB Pain management may play an important role in contributing to optimal quality of life in the elderly population. Pain lowers overall quality of life in part by decreasing function and by amplifying the psychologicic stress of aging. A comprehensive, multidisciplinary approach to pain management, with preservation and restoration of function in older adults, is the cornerstone of an effective pain management program. C1 [Cristian, Adrian] James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Bronx, NY 10468 USA. [Schneider, Hyon] Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA. [Cristian, Adrian] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Cristian, A (reprint author), James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Room 3D-16,526-117,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM adrian.cristian@va.gov NR 56 TC 3 Z9 4 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2008 VL 24 IS 2 BP 313 EP + DI 10.1016/j.cger.2007.12.003 PG 23 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 295KE UT WOS:000255472600009 PM 18387458 ER PT J AU DeGaetano, N Yehuda, R AF DeGaetano, Noah Yehuda, Rachel TI Diagnosing PTSD: Does it help us heal? SO CNS SPECTRUMS LA English DT Article C1 [DeGaetano, Noah; Yehuda, Rachel] Mt Sinai Sch Med, Traumat Stress Studies Div, New York, NY 10029 USA. [Yehuda, Rachel] James J Peters Vet Affairs, PTSD Program, Bronx, NY USA. RP DeGaetano, N (reprint author), Mt Sinai Sch Med, Traumat Stress Studies Div, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU M B L COMMUNICATIONS, INC PI NEW YORK PA 333 HUDSON ST, 7TH FLOOR, NEW YORK, NY 10013 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD MAY PY 2008 VL 13 IS 5 BP 385 EP 392 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 305MS UT WOS:000256183100009 PM 18496476 ER PT J AU Sevick, MA Zickmund, S Korytkowski, M Piraino, B Sereika, S Mihalko, S Snetselaar, L Stumbo, P Hausmann, L Ren, DX Marsh, R Sakraida, T Gibson, J Safaien, M Starrett, TJ Burke, LE AF Sevick, Mary Ann Zickmund, Susan Korytkowski, Mary Piraino, Beth Sereika, Susan Mihalko, Shannon Snetselaar, Linda Stumbo, Phyllis Hausmann, Leslie Ren, Dianxu Marsh, Rita Sakraida, Teresa Gibson, Jolynn Safaien, Mehry Starrett, Terry J. Burke, Lora E. TI Design, feasibility, and acceptability of an intervention using personal digital assistant-based self-monitoring in managing type 2 diabetes SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE diabetes mellitus; type 2; self care; computers; handheld; personal digital assistant; randomized clinical trial; behavioral research; adherence ID QUALITY-OF-LIFE; OLDER ADULTS; HAND-HELD; QUESTIONNAIRE; OUTCOMES; DIARIES AB Background: The information processing demands associated with behavioral self-management of diabetes are extensive. Pairing personal digital assistant (PDA)-based self-monitoring with a behavioral self-management intervention may improve adherence and patient outcomes. Methods: ENHANCE is a randomized controlled trial to test an intervention designed to improve regimen adherence in adults with type 2 diabetes. The intervention, based on Social Cognitive Theory (SCT), is paired with PDA-based self-monitoring. In this paper we describe the: (a) manner in which PDA-based self-monitoring is integrated within the SCT-based intervention, (b) feasibility and acceptability of PDA-based dietary self-monitoring, and (c) issues encountered in teaching participants to self-monitor using a PDA. Results: During the first 30 months of this 5-year study, 232 participants were screened and 151 were randomized. To date, 6 cohorts have completed the study. The retention rate is 85% (n = 129). Of those randomized to the intervention (n = 74) and completing the study (n = 61), 88% reported understanding the usefulness of PDA-monitoring, 85% reported ease in entering foods into the device, 70% reported ease in interpreting feedback graphs, and 82% indicated that they would continue to use the PDA for self-monitoring after the study concluded. Assuming 3 meals per day, participants entered an average of 58% of their meals in their PDA, and 43% were entered assuming 4 meals per day. If we eliminate from the analysis those individuals who entered less than 10% of their expected meals (n = 12), the average rate of self-monitoring was 69% assuming 3 meals per day, and 52% assuming 4 meals per day. Conclusions: PDA-based dietary monitoring is perceived by participants to be useful and acceptable. The approach used to instruct participants in use of the PDA and lessons learned are discussed. PDA technology shows promise as a tool for assisting those with type 2 diabetes in their efforts to manage their disease. (C) 2007 Elsevier Inc. All rights reserved. C1 [Sevick, Mary Ann; Zickmund, Susan; Hausmann, Leslie] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA. [Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Sevick, Mary Ann; Zickmund, Susan; Korytkowski, Mary; Piraino, Beth; Marsh, Rita; Starrett, Terry J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Sevick, Mary Ann; Burke, Lora E.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Sereika, Susan; Ren, Dianxu] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15213 USA. [Mihalko, Shannon] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA. [Snetselaar, Linda; Stumbo, Phyllis] Univ Iowa, Iowa City, IA 52242 USA. [Sakraida, Teresa] Univ Colorado Denver, Denver, CO 80202 USA. [Sakraida, Teresa] Hlth Sci Ctr, Denver, CO USA. [Gibson, Jolynn; Safaien, Mehry] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA. RP Sevick, MA (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA. EM sevick@pitt.edu OI Piraino, Beth/0000-0001-5061-0841 FU NCATS NIH HHS [UL1 TR000005]; NCRR NIH HHS [UL1 RR024153, M01 RR000056-45, M01-RR000056, UL1 RR024153-010004, M01 RR000056, UL1-RR024153, M01 RR000056-440968]; NINR NIH HHS [R01 NR008792-05, R01 NR008792-01, R01 NR008792-03, R01 NR008792, R01 NR008792-02, R01 NR008792-04]; PHS HHS [R01008792] NR 38 TC 23 Z9 23 U1 4 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAY PY 2008 VL 29 IS 3 BP 396 EP 409 DI 10.1016/j.cct.2007.09.004 PG 14 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 311DL UT WOS:000256580500009 PM 17997364 ER PT J AU Tobin, MJ Jubran, A AF Tobin, Martin J. Jubran, Arnal TI Pressure support ventilation: A significant confounding factor in the determination of the rapid shallow breathing index - Reply SO CRITICAL CARE MEDICINE LA English DT Letter C1 [Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA. RP Tobin, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAY PY 2008 VL 36 IS 5 BP 1693 EP 1694 DI 10.1097/CCM.0b013e3181710a82 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 297NJ UT WOS:000255623100077 ER PT J AU Das, A Abraham, S Deswal, A AF Das, Aparajita Abraham, Selwin Deswal, Anita TI Advances in the treatment of heart failure with a preserved ejection fraction SO CURRENT OPINION IN CARDIOLOGY LA English DT Review DE diastolic heart failure; heart failure; treatment ID VENTRICULAR SYSTOLIC FUNCTION; CONVERTING-ENZYME-INHIBITORS; PRIOR MYOCARDIAL-INFARCTION; DIASTOLIC DYSFUNCTION; ELDERLY-PATIENTS; DIGITALIS GLYCOSIDES; MORTALITY; ANGIOTENSIN; MECHANISMS; TRIAL AB Purpose of review Heart failure with preserved ejection fraction (HF-PEF) occurs in approximately 50% of patients with heart failure (HF) and is associated with high morbidity and mortality. A recent study demonstrated that, although survival improved significantly over time among HF patients with reduced ejection fraction (EF), there was no such trend toward improvement among patients with HF-PEF Therefore, there exists an urgent need to develop effective treatment strategies specifically for patients with HF-PEF Recently completed and ongoing research in the treatment of HF-PEF is reviewed in this article. Recent findings The two large randomized clinical trials completed in HF-PEF patients did not achieve statistical significance in benefit of renin-angiotensin system blockade on their primary combined endpoints of morbidity and mortality. Both trials, however, suggested the benefit of the angiotensin receptor and angiotensin-converting enzyme blockade on HF hospitalization. In addition, no clear benefit of beta-blockers has been demonstrated specifically in patients with HF-PEF. Summary Current therapeutic recommendations for HF-PEF are aimed mostly at symptomatic management and treatment of concomitant comorbidities. Results of ongoing clinical trials further evaluating inhibition of the angiotensin and the aldosterone receptors as well as examining other novel therapeutic targets in HF-PEF are keenly awaited. C1 [Deswal, Anita] Michael E DeBakey Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Cardiol Sect, Houston, TX 77030 USA. [Das, Aparajita; Abraham, Selwin] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Deswal, A (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Cardiol Sect, 111B,2002 Holcombe Blvd, Houston, TX 77030 USA. EM adeswal@bcm.tmc.edu NR 40 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-4705 J9 CURR OPIN CARDIOL JI Curr. Opin. Cardiol. PD MAY PY 2008 VL 23 IS 3 BP 233 EP 240 DI 10.1097/HCO.0b013e3282f73317 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 290GD UT WOS:000255110400010 PM 18382212 ER PT J AU de Aguilar-Nascimento, JE Kudsk, KA AF de Aguilar-Nascimento, Jose E. Kudsk, Kenneth A. TI Early nutritional therapy: the role of enteral and parenteral routes SO CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE LA English DT Article DE critical care; enteral nutrition; parenteral nutrition; perioperative care ID CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; RANDOMIZED CLINICAL-TRIAL; INTENSIVE-CARE UNITS; OF-THE-LITERATURE; ACUTE-PANCREATITIS; SEPTIC MORBIDITY; ESPEN GUIDELINES; ABDOMINAL-TRAUMA; GLUCOSE CONTROL AB Purpose of review Early nutrition is defined as the initiation of nutritional therapy within 48 h of either hospital admission or surgery. However, optimal timing for initiation of nutritional therapy through either enteral or parenteral routes remains poorly defined with the existing data. We reviewed the recent literature investigating the role of early enteral and parenteral nutrition in critical illness and perioperative care. Recent findings Recent studies in both trauma/surgical and nonsurgical patients support the superiority of early enteral over early parenteral nutrition. However, late commencement of enteral feeding should be avoided if the gastrointestinal tract is functional. Both prolonged hypocaloric enteral feeding and hypercaloric parenteral nutrition should be avoided, although the precise caloric target remains controversial. Summary Early enteral nutrition remains the first option for the critically ill patient. However, there seems to be increased favor for combined enteral-parenteral therapy in cases of sustained hypocaloric enteral nutrition. The key issue is when the dual regimen should be initiated. Although more study is required to determine the optimal timing to initiate a combined enteral-parenteral approach, enteral nutrition should be initiated early and parenteral nutrition added if caloric-protein targets cannot be achieved after a few days. C1 [de Aguilar-Nascimento, Jose E.] Univ Fed Mato Grosso, Dept Surg, Cuiaba, Brazil. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Kudsk, Kenneth A.] Univ Wisconsin, Coll Med, Dept Surg, Madison, WI USA. RP de Aguilar-Nascimento, JE (reprint author), Rua Estevao Mendonca 81 Apto 801, BR-78043300 Cuiaba, Brazil. EM aguilar@terra.com.br NR 56 TC 7 Z9 9 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1363-1950 J9 CURR OPIN CLIN NUTR JI Curr. Opin. Clin. Nutr. Metab. Care PD MAY PY 2008 VL 11 IS 3 BP 255 EP 260 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 306AK UT WOS:000256218800010 PM 18403921 ER PT J AU Campbell, KH O'Hare, AM AF Campbell, Kellie Hunter O'Hare, Ann M. TI Kidney disease in the elderly: update on recent literature SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE aging; chronic kidney disease; CKD; elderly ID CONVERTING ENZYME-INHIBITION; DEPENDENT DIABETES-MELLITUS; CHRONIC RENAL-INSUFFICIENCY; GLOMERULAR-FILTRATION RATE; BLOOD-PRESSURE CONTROL; BODY-COMPOSITION; MORTALITY RISK; UNITED-STATES; CARDIOVASCULAR OUTCOMES; TYPE-2 DIABETES/ AB Purpose of review We review recent literature on the epidemiology and outcomes of chronic kidney disease in the elderly and discuss implications for management. Recent findings Chronic kidney disease is common in the elderly and associated with substantial morbidity and mortality. The prognostic significance of a given level of estimated glomerular filtration rate, however, varies substantially by age. Estimates of the prevalence of chronic kidney disease at the population level and estimates glomerular filtration rate at the individual level are exquisitely sensitive to the methods used to arrive at these estimates. At present there is no clear consensus on the optimal approach to estimating glomerular filtration rate in elderly individuals in the clinical setting. Available evidence to guide management of chronic kidney disease is based largely on trials in younger individuals. It is unclear to what extent the results of these trials can be extrapolated to older individuals with chronic kidney disease. Summary We advise caution in applying current guidelines to the care of the large number of individuals aged 70 years and older with chronic kidney disease. Ideally, the care of these patients should be individualized and carefully integrated with the management of other comorbid conditions and with patient preferences. C1 [O'Hare, Ann M.] Univ Washington, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. [Campbell, Kellie Hunter] Univ Chicago, Sect Geriatr, Chicago, IL 60637 USA. RP O'Hare, AM (reprint author), Univ Washington, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. EM Ann.OHare@va.gov NR 59 TC 28 Z9 28 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD MAY PY 2008 VL 17 IS 3 BP 298 EP 303 PG 6 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 297GS UT WOS:000255605700009 PM 18408482 ER PT J AU Kahn, SE Zinman, B Lachin, JM Haffner, SM Herman, WH Holman, RR Kravitz, BG Yu, DH Heise, MA Aftring, RP Viberti, G AF Kahn, Steven E. Zinman, Bernard Lachin, John M. Haffner, Steven M. Herman, William H. Holman, Rury R. Kravitz, Barbara G. Yu, Dahong Heise, Mark A. Aftring, R. Paul Viberti, Giancarlo CA Progression Trial (ADOPT) Study Gr TI Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT) SO DIABETES CARE LA English DT Article ID BONE-MINERAL DENSITY; OSTEOBLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN; BODY-COMPOSITION; HIP-FRACTURES; OLDER WHITE; PPAR-GAMMA; RISK; HEALTH; MELLITUS AB OBJECTIVE - The purpose of this study was to examine possible factors associated with the increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). RESEARCH DESIGN AND METHODS - Data from the 1,840 women and 2,511 men randomly assigned in ADOPT to rosiglitazone, metformin, or glyburide for a median of 4.0 years were examined with respect to time to first fracture, rates of occurrence, and sites of fractures. RESULTS - In men, fracture rates did not differ between treatment groups. In women, at least one fracture was reported with rosiglitazone in 60 patients (9.3% of patients, 2.74 per 100 patient-years), metformin in 30 patients (5.1%, 1.54 per 100 patient-years), and glyburide in 21 patients (3.5%, 129 per 100 patient-years). The cumulative incidence (95% CI) of fractures in women at 5 years was 15.1% (11.2-19.1) with rosiglitazone, 7.3% (4.4-10.1) with metformin, and 7.7% (3.7-11.7) with glyburide, representing hazard ratios (95% CI) of 1.81 (1.17-2-80) and 2.13 (1.30-3.51) for rosiglitazone compared with metformin and glyburide, respectively. The increase in fractures with rosiglitazone occurred in pre- and postmenopausal women, and fractures were seen predominantly in the lower and upper limbs. No particular risk factor underlying the increased fractures in female patients who received rosiglitazone therapy was identified. CONCLUSIONS - Further investigation into the risk factors and underlying pathophysiology for the increased fracture rate in women taking rosiglitazone is required to relate them to preclinical data and better understand the clinical implications of and possible interventions for these findings. C1 [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Zinman, Bernard] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Zinman, Bernard] Univ Toronto, Toronto, ON, Canada. [Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Haffner, Steven M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Herman, William H.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Herman, William H.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Holman, Rury R.] Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England. [Kravitz, Barbara G.; Yu, Dahong; Heise, Mark A.; Aftring, R. Paul] GlaxoSmithKline Inc, King Of Prussia, PA USA. [Viberti, Giancarlo] Kings Coll London, Kings Coll London Sch Med, London WC2R 2LS, England. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu RI Zinman, Bernard/E-7266-2013 OI Kahn, Steven/0000-0001-7307-9002 NR 22 TC 259 Z9 272 U1 1 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2008 VL 31 IS 5 BP 845 EP 851 DI 10.2337/dc07-2270 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 303CE UT WOS:000256016300002 PM 18223031 ER PT J AU Tuerk, PW Mueller, M Egede, LE AF Tuerk, Peter W. Mueller, Martina Egede, Leonard E. TI Estimating physician effects on glycemic control in the treatment of diabetes - Methods, effects sizes, and implications for treatment policy SO DIABETES CARE LA English DT Article ID RANDOMIZED CONTROLLED-TRIALS; BLOOD-PRESSURE CONTROL; PAY-FOR-PERFORMANCE; GLUCOSE CONTROL; CARE; COMPLICATIONS; QUALITY; PATIENT; METAANALYSIS; ADULTS AB OBJECTIVE - Researchers have only just begun to investigate physician-related effects on medical outcomes. Such research is necessary for developing empirically informed practice guidelines and policy. The primary goal of this study was to investigate whether glucose management in type 2 diabetes varies by randomly assigned physicians over the course of a year in treatment. A second goal of the study was to investigate whether physician-related effects vary across differential patient characteristics. A tertiary goal was to investigate potential patient-level effects on glucose management. RESEARCH DESIGN AND METHODS - Hierarchical linear models were used to investigate AlC among 1,381 patients, nested within 42 randomly assigned primary care physicians at a Veterans Affairs medical center in the southeastern U.S. The primary Outcome measure was change in AlC over the course of I year in treatment. On average, each study physician had 33 patients with diabetes. RESULTS - Overall, physician-related factors were associated with statistically significant but modest variability in AlC change (2%), whereas patient-level factors accounted for the majority of variation in AlC change (98%). Physician effects varied by patient characteristics, mattering more for black patients, patients aged 65 years, and patients whose glucose management improved over the treatment year. CONCLUSIONS - The results of this study indicate that differential physician effects have minimal impact on glycemic control. Results suggest that it is logical to support policies encouraging the development of patient-level behavioral interventions because that is the level that accounts for the majority of variance in glycemic control. C1 [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Tuerk, Peter W.] Ralph H Johnson Vet Affairs Med Ctr, Psychol Serv, Charleston, SC USA. [Mueller, Martina] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Mueller, Martina; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, Vet Affairs Targeted Res Enhancement Program, Charleston, SC USA. RP Tuerk, PW (reprint author), MUSC 165 Cannon St,3rd Fl,POB 250852, Charleston, SC 29425 USA. EM tuerk@musc.edu NR 28 TC 33 Z9 35 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2008 VL 31 IS 5 BP 869 EP 873 DI 10.2337/dc07-1662 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 303CE UT WOS:000256016300006 PM 18285552 ER PT J AU Mapppsy, LKR Egede, LE Mueller, M AF Mapppsy, Lisa K. Richardson Egede, Leonard E. Mueller, Martina TI Effect of race/ethnicity and persistent recognition of depression on mortality in elderly men with type 2 diabetes and depression SO DIABETES CARE LA English DT Article ID OF-VETERANS-AFFAIRS; PRIMARY-CARE AB OBJECTIVE - To determine whether mortality risk from depression among elderly men with type 2 diabetes differs by ethnicity and persistent recognition of depression. RESEARCH DESIGN AND METHODS - Data on a cohort of 14,500 male veterans with type 2 diabetes were analyzed. Diagnoses of depression and diabetes were based on ICD-9 codes. Persistent recognition was defined as an ICD-9 code for depression documented in at least the second or third visit after the initial diagnosis of depression. Hazards of death were compared using Cox proportional hazards regression models adjusting for relevant covariates. RESULTS - Over 10 years, 2,305 deaths were documented. Mortality risk was higher for depressed than nondepressed veterans with diabetes (hazard ratio [HR] 1.6 [95% CI 1.3-1.8]). Among those with depression, mortality risk was lower with persistent recognition (0-2 visits vs. >= 3 visits after initial diagnosis, HIZ 0.58 [0.40-0.89]) but higher for whites than blacks (1.60 [1.11-2.31]). CONCLUSIONS - increased mortality from depression differs by ethnicity and persistent recognition. C1 [Mapppsy, Lisa K. Richardson] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Mapppsy, Lisa K. Richardson] Murdoch Univ, Sch Psychol, Perth, WA, Australia. [Egede, Leonard E.; Mueller, Martina] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Mueller, Martina] Med Univ S Carolina, Dept Biostat Bioinformat Epidemiol, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2008 VL 31 IS 5 BP 880 EP 881 DI 10.2337/dc07-2215 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 303CE UT WOS:000256016300008 ER PT J AU Reaven, PD Emanuele, N Moritz, T Klein, R Davis, M Glander, K Duckworth, W Abraira, C AF Reaven, Peter D. Emanuele, Nicholas Moritz, Thomas Klein, Ronald Davis, Mathew Glander, Kathy Duckworth, William Abraira, Carlos CA Vet Affairs Diabet Trial (VADT) TI Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT) SO DIABETES CARE LA English DT Article; Proceedings Paper CT 67th Annual Meeting of the American-Diabetes-Association CY JUN 22-26, 2007 CL Chicago, IL SP Amer Diabet Assoc ID CARDIOVASCULAR RISK-FACTORS; ABDOMINAL AORTIC CALCIFICATION; BEAM COMPUTED-TOMOGRAPHY; HEART-DISEASE; ATHEROSCLEROSIS MESA; GLYCEMIC CONTROL; FOLLOW-UP; MELLITUS; MORTALITY; MICROALBUMINURIA AB OBJECTIVE - increasing evidence suggests that macrovascular disease and retinopathy may be more closely linked than previously believed. We determined the relationship between retinopathy and coronary atherosclerosis as measured by computed tomography-detectable coronary artery calcium (CAC). RESEARCH DESIGN AND METHODS - The cross-sectional association between CAC and retinopathy was assessed on a Veteran Affairs Diabetes Trial subsample of 204 subjects with a mean duration of type 2 diabetes of 12.3 +/- 8.3 years. RESULTS - Retinopathy was correlated with CAC (r = 0.19, P = 0.006). Median CAC increased across retinopathy categories: 197 in those with no retinopathy, 229 in those with microaneurysms only, 364 in those with mild nonproliferative diabetic retinopathy (NPDR), 300 in those with moderate to severe NPDR, and 981 in those with proliferative diabetic retinopathy (PDR). Stepwise multivariable linear regression analysis was performed to find a parsimonious subset of relevant risk factors to include along with PDR in predicting CAC. After adjustment for either this subset of standard factors (P = 0.047) or a more extensive panel of risk factors (P = 0.035), PDR was significantly associated with CAC. Moreover, using logistic regression, individuals With PDR were approximately sixfold more likely to have CAC > 400 than those with no PDR, even after adjustment for other CVD risk factors. CONCLUSIONS - These data indicate an important relationship between retinopathy and extent of CAC and suggest the potential to identify and treat shared risk factors for these common micro- and macrovascular complications. C1 [Reaven, Peter D.; Duckworth, William] Carl T Hayden VA Med Ctr, Phoenix, AZ USA. [Moritz, Thomas] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program, Coordinating Ctr, Hines, IL 60141 USA. [Klein, Ronald; Davis, Mathew; Glander, Kathy] Univ Wisconsin, Madison, WI USA. [Abraira, Carlos] Miami VA Med Ctr, Miami, FL USA. RP Reaven, PD (reprint author), Phoenix VAMC, 650,E Indian Sch Rd 111E, Phoenix, AZ 85012 USA. EM peter.reaven@va.gov OI Klein, Ronald/0000-0002-4428-6237 FU NHLBI NIH HHS [R01 HL067690]; PHS HHS [R01067690] NR 39 TC 17 Z9 19 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2008 VL 31 IS 5 BP 952 EP 957 DI 10.2337/dc07-1926 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 303CE UT WOS:000256016300024 PM 18316393 ER PT J AU Carr, DB Newton, KM Utzschneider, KM Tong, J Gerchman, F Kahn, SE Heckbert, SR AF Carr, Darcy B. Newton, Katherine M. Utzschneider, Kristina M. Tong, Jenny Gerchman, Fernando Kahn, Steven E. Heckbert, Susan R. TI Modestly elevated glucose levels during pregnancy are associated with a higher risk of future diabetes among women without gestational diabetes mellitus SO DIABETES CARE LA English DT Article ID LIFE-STYLE; TOLERANCE AB OBJECTIVE - To determine whether 1-h oral glucose challenge test (OGCT) or 3-h oral glucose tolerance test (OGTT) results below gestational diabetes mellitus (GDM) criteria are associated with developing diabetes. RESEARCH DESIGN AND METHODS - A retrospective cohort study was performed among women without GDM who had a pregnancy OGCT (n = 24,780) or OGTT (it = 6,222). Subsequent diabetes was ascertained by ICD-9 codes or pharmacy or laboratory data over a median follow-up of 8.8 years. RESULTS - Diabetes risk increased across OGCT quartiles: adjusted hazard ratio (HR) 1.67 (95% CI 1.07-2.61) for 5.4-6.2 mmol/l, 2.13 (1.39-3.25) for 6.3-7.3 mmol/l, and 3.60 (2.41-5.39) for >= 7.4 mmol/l compared with <= 53 mmol/l. Women with one abnormal OGTT result had a higher risk compared with those with normal Values (HR 2.08 [95% CI 1.35-3.201). CONCLUSIONS - Women with modestly elevated glucose levels below the threshold for GDM had a higher risk for diabetes. C1 [Carr, Darcy B.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Newton, Katherine M.; Heckbert, Susan R.] Grp Hlth Ctr Hlth Studies, Seattle, WA USA. [Newton, Katherine M.; Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Utzschneider, Kristina M.; Gerchman, Fernando; Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Heckbert, Susan R.] Cardiovasc Hlth Res Unit, Seattle, WA USA. RP Carr, DB (reprint author), Univ Washington, Dept Obstet & Gynecol, Box 356460, Seattle, WA 98195 USA. EM darcarr@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU NCRR NIH HHS [K23RR16066, K30RR022293] NR 15 TC 31 Z9 31 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2008 VL 31 IS 5 BP 1037 EP 1039 DI 10.2337/dc07-1957 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 303CE UT WOS:000256016300041 PM 18223032 ER PT J AU Lipsky, BA AF Lipsky, Benjamin A. TI New developments in diagnosing and treating diabetic foot infections SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Article; Proceedings Paper CT 5th International Symposium on Diabetic Foot CY MAY 09-12, 2007 CL Noordwijkerhout, NETHERLANDS DE diabetic foot infection; diagnosis of infection; antimicrobial therapy; microbiology ID RESISTANT STAPHYLOCOCCUS-AUREUS; VS. SUPERFICIAL SWAB; RISK-FACTORS; ULCERS; OSTEOMYELITIS; PREVALENCE; PATHOGENS; TRIAL; BONE; MICROORGANISMS AB Foot infections are common in persons with diabetes and are often the proximate cause of lower extremity amputation. There have been many publications in the past few years dealing with the appropriate ways to diagnose and treat diabetic foot infections. This review presents information gathered from a comprehensive, ongoing surveillance of the literature (published and abstracts) over the past 4 years. Prospective studies have now defined the epidemiology of diabetic foot infections, as well as methods to score and classify the wounds. Several recently published guidelines can assist clinicians in managing these infections. The etiologic agents of infection have been well-defined, and the prevalence of multi-drug-resistance pathogens is growing. Molecular methods offer great promise for quicker and more sensitive diagnosis of infection. New antimicrobial agents, both systemic and topical, as well as novel local treatments, have been shown to be effective in various studies. Improved methods of deploying older agents have added to the variety of treatment approaches now available. Several adjunctive treatments may benefit some patients but their role is as yet unclear. While there is much yet to learn about the most cost-effective ways to diagnose and treat diabetic foot infections the main effort is now to disseminate the available information and facilitate employing the evidence-based guideline recommendations. Published in 2008 by John Wiley & Sons, Ltd. C1 Univ Washington, Primary Care Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Lipsky, BA (reprint author), Univ Washington, Primary Care Clin, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way S-111-PCC, Seattle, WA 98108 USA. EM balipsky@u.washington.edu RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 67 TC 22 Z9 27 U1 0 U2 6 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1520-7552 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD MAY-JUN PY 2008 VL 24 SU 1 BP S66 EP S71 DI 10.1002/dmrr.828 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 308RS UT WOS:000256408300014 PM 18395871 ER PT J AU Olson, JS Lieberman, DA Sonnenberg, A AF Olson, Jeffrey S. Lieberman, David A. Sonnenberg, Amnon TI Empiric dilation in non-obstructive dysphagia SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE dysphagia; esophageal dilation; esophageal ring; gastro-esophageal reflux disease; peptic stricture; schatzki ring ID ESOPHAGEAL DILATION; REFLUX ESOPHAGITIS; PH; ENDOSCOPY AB Aims To study practice patterns in the management of non-obstructive dysphagia among U.S. gastroenterologists. Data source Endoscopic data repository from 100 U.S. gastroenterology practices during 1998-2003 (Clinical Outcomes Research Initiative, CORI). Methods All initial esophago-gastro-duodenoscopies (EGDs) performed in adult patients between 1998 and 2003 (n = 181,261) were evaluated for demographic data, endoscopic findings, and the occurrence of esophageal dilation. A case population of 7256 patients receiving empiric dilation for dysphagia for non-obstructive dysphagia was compared to a control population of 5764 patients with dilation for peptic strictures. Results The group of patients with empiric dilation was younger than the group of patients with peptic strictures and contained more women. Reflux symptoms and erosive esophagitis were less frequent in the empiric dilation group than in the strictures group. Empiric dilations were mostly performed using rubber bougies, whereas strictures were most frequently dilated over a guidewire. For all types of dilators, the diameters were significantly larger in empiric than stricture dilation. Repeat dilations within 1 year after the initial procedure occurred in 4% of the empiric and 13% of the stricture dilations. Conclusions Compared with the dilation of peptic strictures, empiric dilation of non-obstructive dysphagia is a more common clinical practice that is performed in a different patient population and utilizes different techniques. C1 [Olson, Jeffrey S.; Lieberman, David A.; Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Lieberman, David A.; Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu FU NIDDK NIH HHS [R33 DK061778, U01 DK 057132-06A1, U01 DK057132] NR 18 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAY PY 2008 VL 53 IS 5 BP 1192 EP 1197 DI 10.1007/s10620-007-0024-x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 286LU UT WOS:000254848200004 PM 17932762 ER PT J AU Slade, EP Stuart, EA Alkever, DSS Karakus, M Green, KM Ialongo, N AF Slade, Eric P. Stuart, Elizabeth A. Alkever, David S. S. Karakus, Mustafa Green, Kerry M. Ialongo, Nicholas TI Impacts of age of onset of substance use disorders on risk of adult incarceration among disadvantaged urban youth: A propensity score matching approach SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE incarceration; substance use disorder; adolescence; longitudinal; African American ID NATIONAL-COMORBIDITY-SURVEY; EFFECTS REGRESSION-ANALYSIS; DRUG-USE; YOUNG ADULTHOOD; PSYCHOSOCIAL ADJUSTMENT; AGGRESSIVE-BEHAVIOR; MULTIPLE IMPUTATION; SURVEY REPLICATION; TOBACCO SMOKING; ABUSE TREATMENT AB Background: Age of onset of substance use disorders in adolescence and early adulthood could be associated with higher rates of adult criminal incarceration in the U.S., but evidence of these associations is scarce. Methods: Propensity score matching was used to estimate the association between adolescent-onset substance use disorders and the rate of incarceration, as well as incarceration costs and self-reported criminal arrests and convictions, of young men predominantly from African American, lower income, urban households. Age of onset was differentiated by whether onset of the first disorder occurred by age 16. Results: Onset of a substance use disorder by age 16, but not later onset, was associated with a fourfold greater risk of adult incarceration for substance related offenses as compared to no disorder (0.35 vs. 0.09, P = 0.044). Onset by age 16 and later onset were both positively associated with incarceration costs and risk of arrest and conviction, though associations with crime outcomes were more consistent with respect to onset by age 16. Results were robust to propensity score adjustment for observable predictors of substance use in adolescence and involvement in crime as an adult. Conclusion: Among young men in this high risk minority sample, having a substance use disorder by age 16 was associated with higher risk of incarceration for substance related offenses in early adulthood and with more extensive criminal justice system involvement as compared to having no disorder or having a disorder beginning at a later age. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Slade, Eric P.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Slade, Eric P.] US Dept Vet Affairs, Baltimore, MD 21201 USA. [Stuart, Elizabeth A.; Alkever, David S. S.; Green, Kerry M.; Ialongo, Nicholas] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Alkever, David S. S.] Univ Maryland, Dept Publ Policy, Baltimore, MD 21250 USA. [Karakus, Mustafa] WESTAT Corp, Rockville, MD 20850 USA. RP Slade, EP (reprint author), Univ Maryland, Sch Med, 737 W Lombard St,Room 526, Baltimore, MD 21201 USA. EM eslade@psych.umaryland.edu OI Stuart, Elizabeth/0000-0002-9042-8611 FU NIMH NIH HHS [R34-MH081303, P30 MH066247, P30 MH066247-01A29002, P30-MH066247, R03 MH069796, R03 MH069796-03, R34 MH081303, R34 MH081303-01] NR 65 TC 36 Z9 37 U1 4 U2 16 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAY 1 PY 2008 VL 95 IS 1-2 BP 1 EP 13 DI 10.1016/j.drugalcdep.2007.11.019 PG 13 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 290WG UT WOS:000255152900001 PM 18242006 ER PT J AU Fenton, MS Marion, KM Hershman, JM AF Fenton, Mike S. Marion, Kenneth M. Hershman, Jerome M. TI Identification of cyclic adenosine 3 ',5 '- monophosphate response element modulator as an activator of the human Sodium/Iodide symporter upstream enhancer SO ENDOCRINOLOGY LA English DT Article ID THYROID TRANSCRIPTION FACTOR; CARCINOMA CELL-LINES; NA+/I-SYMPORTER; GENE-EXPRESSION; PROTEIN-LEVELS; PROMOTER CHARACTERIZATION; DIFFERENTIAL REGULATION; MESSENGER-RNA; FRTL-5 CELLS; CANCER CELLS AB The lack of Na+/ I- symporter (NIS) gene expression in some thyroid cancer patients has been a major hurdle that limits the efficacy of standard radioactive iodide therapy. The molecular mechanism that contributes to low NIS expression is not well understood. Activated NIS gene expression is stimulated by thyroid-stimulating hormone-mediated cAMP/ protein kinase A signaling through a NIS upstream enhancer (NUE). The cAMP pathway is also stimulated by forskolin. In the current work, we studied the mechanism of transcriptional activation of NIS in normal thyroid cells and thyroid cancer cells. We identified the cAMP response element modulator ( CREM) activator as a new component of the transcription complex that is important for NIS gene expression. The CREM complex is seen in the normal thyroid cells and BRAF ( V600E) thyroid cancer cells ( BHP 17 - 10) but is missing in rearranged in transformation/papillary thyroid carcinoma-1 rearrangement thyroid cancer cells ( BHP 2 - 7). This complex is believed to be responsible for the loss of NUE activity and reduced NIS expression in the BHP 2 - 7 cell line. In BHP 2 - 7 cells, forskolin stimulated the thyroid-specific transcription factor Pax 8, but CREM activator mRNA did not increase, and this produced a small increase in NUE activity. Ectopic expression of CREM activator enhanced activity of the NUE, indicating that CREM is an essential regulator of NIS gene expression. C1 [Fenton, Mike S.; Marion, Kenneth M.; Hershman, Jerome M.] Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Endocrinol Res Lab,Endocrinol Div, Los Angeles, CA 90073 USA. [Fenton, Mike S.; Marion, Kenneth M.; Hershman, Jerome M.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Fenton, MS (reprint author), Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Endocrinol Res Lab,Endocrinol Div, Bldg 114,Room 200,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM fenton@ucla.edu NR 40 TC 9 Z9 9 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD MAY PY 2008 VL 149 IS 5 BP 2592 EP 2606 DI 10.1210/en.2007-1390 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 291LX UT WOS:000255200000060 PM 18202121 ER PT J AU Hermann, B Seidenberg, M Sager, M Carlsson, C Gidal, B Sheth, R Rutecki, P Asthana, S AF Hermann, Bruce Seidenberg, Michael Sager, Mark Carlsson, Cynthia Gidal, Barry Sheth, Raj Rutecki, Paul Asthana, Sanjay TI Growing old with epilepsy: The neglected issue of cognitive and brain health in aging and elder persons with chronic epilepsy SO EPILEPSIA LA English DT Review DE aging; cognition; chronic epilepsy; risk factors ID TEMPORAL-LOBE EPILEPSY; CARDIOVASCULAR RISK-FACTORS; ELEVATED PLASMA-CONCENTRATIONS; APOLIPOPROTEIN-E EPSILON-4; VOXEL-BASED MORPHOMETRY; MIDLIFE BLOOD-PRESSURE; ALZHEIMERS-DISEASE; LATE-LIFE; ANTIEPILEPTIC DRUGS; WHITE-MATTER AB The purpose of this review is to examine what is known about cognitive and brain aging in elders with chronic epilepsy. We contend that much remains to be learned about the ultimate course of cognition and brain structure in persons with chronic epilepsy and concern appears warranted. Individuals with chronic epilepsy are exposed to many risk factors demonstrated to be associated with abnormal cognitive and brain aging in the general population, with many of these risk factors present in persons with chronic epilepsy as early as midlife. We suggest that a research agenda be developed to systematically identify and treat known modifiable risk factors in order to protect and promote cognitive and brain health in aging and elder persons with chronic epilepsy. C1 [Hermann, Bruce; Sheth, Raj; Rutecki, Paul] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Mathews Neuropsychol Lab, Madison, WI 53792 USA. [Seidenberg, Michael] Rosalind Franklin Sch Med & Sci, Dept Psychol, N Chicago, IL USA. [Sager, Mark; Carlsson, Cynthia; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Dept Geriatr Med, Madison, WI 53792 USA. [Hermann, Bruce; Sager, Mark] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53792 USA. [Carlsson, Cynthia; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Gidal, Barry] Univ Wisconsin, Sch Med & Publ Hlth, Sch Pharm, Madison, WI 53792 USA. [Rutecki, Paul] William S Middleton Mem Vet Adm Med Ctr, Dept Neurol, Madison, WI USA. RP Hermann, B (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Mathews Neuropsychol Lab, 600 N Highland, Madison, WI 53792 USA. EM hermann@neurology.wisc.edu FU NIA NIH HHS [K07 AG021582, K07 AG021582-03]; NINDS NIH HHS [R01 NS037738, R01 NS037738-02]; PHS HHS [2R01 37738, R01 44351] NR 159 TC 19 Z9 19 U1 2 U2 11 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD MAY PY 2008 VL 49 IS 5 BP 731 EP 740 DI 10.1111/j.1528-1167.2007.01435.x PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 295NF UT WOS:000255480500001 PM 18031544 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Diminishing returns on sequential interventions of gastroenterology SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Review DE gastrointestinal endoscopy; law of diminishing returns; medical decision analysis; random walk; side effects of medical interventions AB Gastroenterological treatment is often comprised of a series of multiple interventions, each one associated with a potential benefit, as well as harm. The analysis addresses the question of when to stop a series of consecutive interventions and maximize medical benefit. The benefit and harm associated with gastroenterological interventions are modeled as 'continuous' influences on patient health or as a 'discrete' sequence of random events. The analysis suggests that the benefit of a sequence of gastroenterological interventions is likely to accumulate following few interventions at the beginning of therapy and that any prolonged sequence is likely to inflict as much harm as benefit. It is impossible to reach a state of perfect health with inherently imperfect interventions. Health cannot be raised above a level that equals the ratio of expected benefit/(expected benefit+expected harm). As the achievement of perfect health constitutes an unattainable goal, a sequence of gastroenterological interventions should not be continued much further beyond its initial success. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Gastroenterol Sect, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Gastroenterol Sect, P3-Gl,3710 SW US Veterans Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 8 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD MAY PY 2008 VL 20 IS 5 BP 465 EP 468 DI 10.1097/MEG.0b013e3282f47982 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 325WR UT WOS:000257619900014 PM 18403949 ER PT J AU Pozdeyev, N Tosini, G Li, L Ali, F Rozov, S Lee, RH Iuvone, PM AF Pozdeyev, Nikita Tosini, Gianluca Li, Li Ali, Fatima Rozov, Stanislav Lee, Rehwa H. Iuvone, P. Michael TI Dopamine modulates diurnal and circadian rhythms of protein phosphorylation in photoreceptor cells of mouse retina SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE circadian clocks; dopamine D4 receptors; phosducin; retina ID TRANSDUCIN BETA-GAMMA; MAMMALIAN RETINA; MELATONIN SYNTHESIS; D4 RECEPTORS; IN-VIVO; PHOSDUCIN; CLOCK; COMPLEX; PHOSPHOPROTEIN; RELEASE AB Many aspects of photoreceptor metabolism are regulated as diurnal or circadian rhythms. The nature of the signals that drive rhythms in mouse photoreceptors is unknown. Dopamine amacrine cells in mouse retina express core circadian clock genes, leading us to test the hypothesis that dopamine regulates rhythms of protein phosphorylation in photoreceptor cells. To this end we investigated the phosphorylation of phosducin, an abundant photoreceptor-specific phosphoprotein. In mice exposed to a daily light-dark cycle, robust daily rhythms of phosducin phosphorylation and retinal dopamine metabolism were observed. Phospho-phosducin levels were low during the daytime and high at night, and correlated negatively with levels of the dopamine metabolite 3,4-dihydroxyphenylacetic acid. The effect of light on phospho-phosducin levels was mimicked by pharmacological activation of dopamine D4 receptors. The amplitude of the diurnal rhythm of phospho-phosducin was reduced by > 50% in D4 receptor-knockout mice, due to higher daytime levels of phospho-phosducin. In addition, the daytime level of phospho-phosducin was significantly elevated by L-745,870, a dopamine D4 receptor antagonist. These data indicate that dopamine and other light-dependent processes cooperatively regulate the diurnal rhythm of phosducin phosphorylation. Under conditions of constant darkness a circadian rhythm of phosducin phosphorylation was observed, which correlated negatively with the circadian rhythm of 3,4-dihydroxyphenylacetic acid levels. The circadian fluctuation of phospho-phosducin was completely abolished by constant infusion of L-745,870, indicating that the rhythm of phospho-phosducin level is driven by dopamine. Thus, dopamine release in response to light and circadian clocks drives daily rhythms of protein phosphorylation in photoreceptor cells. C1 [Pozdeyev, Nikita; Li, Li; Ali, Fatima; Rozov, Stanislav; Iuvone, P. Michael] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA. [Pozdeyev, Nikita; Rozov, Stanislav] IM Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia. [Tosini, Gianluca] Morehouse Sch Med, Inst Neurosci, Atlanta, GA 30310 USA. [Lee, Rehwa H.] VA Greater LA Healthcare Syst Sepulveda, North Hills, CA USA. [Lee, Rehwa H.] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. [Iuvone, P. Michael] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA. RP Iuvone, PM (reprint author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA. EM miuvone@pharm.emory.edu RI Li, Li/C-8981-2011 OI tosini, gianluca/0000-0003-3645-4533 FU NCATS NIH HHS [UL1 TR000454]; NEI NIH HHS [R01 EY014764, EY004864, EY014764, P30 EY006360, R01 EY004864, R01 EY004864-25, R01 EY014764-04]; NINDS NIH HHS [NS43459, R01 NS043459, R01 NS043459-05A2, R56 NS043459] NR 53 TC 38 Z9 38 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0953-816X EI 1460-9568 J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD MAY PY 2008 VL 27 IS 10 BP 2691 EP 2700 DI 10.1111/j.1460-9568.2008.06224.x PG 10 WC Neurosciences SC Neurosciences & Neurology GA 308MX UT WOS:000256395800021 PM 18547251 ER PT J AU Gingo, MR Silveira, LJ Miller, YE Friedlander, AL Cosgrove, GP Chan, ED Maier, LA Bowler, RP AF Gingo, M. R. Silveira, L. J. Miller, Y. E. Friedlander, A. L. Cosgrove, G. P. Chan, E. D. Maier, L. A. Bowler, R. P. TI Tumour necrosis factor gene polymorphisms are associated with COPD SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article DE gene polymorphism; genetics; smoking ID OBSTRUCTIVE PULMONARY-DISEASE; ALPHA TNF-ALPHA; SINGLE NUCLEOTIDE POLYMORPHISMS; INFLAMMATORY-BOWEL-DISEASE; PROMOTER POLYMORPHISM; CHRONIC-BRONCHITIS; MACROPHAGE METALLOELASTASE; MULTIPLE-SCLEROSIS; LYMPHOTOXIN-ALPHA; GENOTYPE CHANGES AB Tumour necrosis factor (TNF)-alpha has been shown to be an important factor in animal models of chronic obstructive pulmonary disease (COPD). However, human studies of TNF polymorphisms in COPD have been equivocal. Six TNF single nucleotide polymorphisms (-1031C/T, -863C/A, -857C/T, -237G/A, -308G/A and +487G/A) and their haplotypes were investigated in 423 Caucasian smokers (298 patients with spirometric evidence of COPD and 125 without airflow obstruction). The -308 minor allele (A) had a higher odds ratio (OR) of being associated with COPD in multivariate analysis (controlling for age, sex, pack-yrs; OR 1.9, 95% confidence interval (CI) 1.1-3.2) and was also associated with worse forced expiratory volume in one second/forced vital capacity. The -237 minor allele (A) had a lower OR of being associated with COPD (OR 0.40, 95% CI 0.19-0.86). In COPD patients, the -857 minor allele (T) had a lower OR of being associated with severe stages of COPD (Global Initiative for Obstructive Lung Disease stage III and IV versus stage I and II, OR 0.46, 95% CI 0.24-0.88). Other TNF single nucleotide polymorphisms were not associated with COPD but the -1031/-863 haplotype CC/TC had a lower OR in COPD patients versus smoking controls (OR 0.22, 95% CI 0.05-0.97). The present study adds further evidence that tumour necrosis factor genotypes play a role in susceptibility to cigarette smoke. C1 [Bowler, R. P.] Natl Jewish Med & Res Ctr, Div Pulm Med, Dept Med, Denver, CO 80206 USA. [Gingo, M. R.; Chan, E. D.] Univ Colorado, Dept Med, Denver, CO USA. [Gingo, M. R.; Chan, E. D.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Miller, Y. E.; Chan, E. D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. RP Bowler, RP (reprint author), Natl Jewish Med & Res Ctr, Div Pulm Med, Dept Med, 1400 Jackson St,Room K715a, Denver, CO 80206 USA. EM BowlerR@njc.org RI Gingo, Matthew/K-7203-2013 FU NCI NIH HHS [CA58187]; NCRR NIH HHS [M01 RR000051] NR 64 TC 35 Z9 40 U1 0 U2 2 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD MAY PY 2008 VL 31 IS 5 BP 1005 EP 1012 DI 10.1183/09031936.00100307 PG 8 WC Respiratory System SC Respiratory System GA 298SI UT WOS:000255707000017 PM 18256059 ER PT J AU Starr, PA Kang, GA Heath, S Shimamoto, S Turner, RS AF Starr, Philip A. Kang, Gail A. Heath, Susan Shimamoto, Shoichi Turner, Robert S. TI Pallidal neuronal discharge in Huntington's disease: Support for selective loss of striatal cells originating the indirect pathway SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Huntington's disease; Parkinson's disease; globus pallidus; microelectrode recording; electrophysiology; basal ganglia; indirect pathway ID DEEP BRAIN STIMULATORS; HUMAN BASAL GANGLIA; PARKINSONS-DISEASE; GLOBUS-PALLIDUS; SUBTHALAMIC NUCLEUS; SOMATOTOPIC ORGANIZATION; TECHNICAL APPROACH; PREFERENTIAL LOSS; DIFFERENTIAL LOSS; CORTEX NEURONS AB Chorea is the predominant motor manifestation in the early symptomatic phase of adult onset Huntington's disease (HD). Pathologically, this stage is marked by differential loss of striatal neurons contributing to the indirect pathway. This pattern of neuronal loss predicts decreased neuronal firing rates in GPi and increased firing rates in GPe, the opposite of the changes in firing rate known to occur in Parkinson's disease (PD). We present single-unit discharge characteristics (33 neurons) observed in an awake patient with HD (41 CAG repeats) undergoing microelectrode guided surgery for pallidal deep brain stimulation. Pallidal single-unit activity at "rest" and during voluntary movement was discriminated off line by principal component analysis and evaluated with respect to discharge rate, bursting, and oscillatory activity in the 0-200 Hz range. 24 GPi and 9 GPe units were studied, and compared with 132 GPi and 50 GPe units from 14 patients with PD. The mean (+/-SEM) spontaneous discharge rate for HD was 58+/-4 for GPi and 73+/-5 for GPe. This contrasted with discharge rates in PD of 95+/-2 for GPi and 57+/-3 for GPe. HD GPi units showed more bursting than PD GPi units but much less oscillatory activity in the 2-35 Hz frequency range at rest. These findings are consistent with selective early loss of striatal cells originating the indirect pathway. (C) 2008 Elsevier Inc. All rights reserved. C1 [Starr, Philip A.; Shimamoto, Shoichi; Turner, Robert S.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Starr, Philip A.; Kang, Gail A.; Heath, Susan; Turner, Robert S.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94143 USA. [Turner, Robert S.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15261 USA. [Turner, Robert S.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15261 USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurosurg, 533 Parnassus Box 0445, San Francisco, CA 94143 USA. EM starrp@neurosurg.ucsf.edu RI Turner, Robert/A-9695-2008 OI Turner, Robert/0000-0002-6074-4365 FU NINDS NIH HHS [K08 NS002201, K08 NS 02201, R01 NS044551, R01 NS044551-05] NR 38 TC 35 Z9 35 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD MAY PY 2008 VL 211 IS 1 BP 227 EP 233 DI 10.1016/j.expneurol.2008.01.023 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 298ZM UT WOS:000255725600023 PM 18342309 ER PT J AU Wardell, DW Rintala, D Tan, G AF Wardell, Diane Wind Rintala, Diana Tan, Gabriel TI Study descriptions of Healing Touch with veterans experiencing chronic neuropathic pain from spinal cord injury SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING LA English DT Article DE Healing Touch; qualitative; case study; energy field; biofield therapy; energy medicine AB Context: Spinal cord injury often results in chronic pain syndromes that conventional pain management is unable to resolve. Healing Touch (HT) is a biofield therapy that involves using the hands to promote healing and mediate the perception of pain by affecting the energy field of the person. The practice of HT is based on the premise that the energy field has the ability to provide valuable information about the person's physical, emotional, mental, and spiritual condition and can influence the dense matter of physical form. Objective: This secondary analysis using case study reviews describes two different experiences of receiving a HT session for management of chronic neuropathic pain and its sequelae, utilizing energy field data and reports of participants and their HT practitioners. Design: Qualitative case study approach was used. Setting: Data were obtained from 42 HT sessions that took place within the homes of seven veterans with spinal cord injury. Method: Two cases involving the most common patterns of response were selected from seven cases to represent the participants' and practitioners' experiences. A descriptive qualitative approach informed the results. Results: The findings indicate that a variety of experiences can exist in individuals with chronic pain due to spinal cord injury; experiences will also vary with their healing touch practitioners. There are commonalities in the perception of the practitioners in the damage to the energy field and energy centers, with individualized and consistent resolution of the field over time. C1 [Wardell, Diane Wind] Univ Texas Houston, Hlth Sci Ctr, Sch Nursing, Houston, TX USA. [Rintala, Diana; Tan, Gabriel] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Wardell, DW (reprint author), 6901 Bertner Ave Suite 793, Houston, TX 77030 USA. EM diane.wardell@uth.tmc.edu NR 28 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-8307 J9 EXPLORE-NY JI Explore-J Sci. Heal. PD MAY-JUN PY 2008 VL 4 IS 3 BP 187 EP 195 DI 10.1016/j.explore.2008.02.003 PG 9 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 306FZ UT WOS:000256235000010 PM 18466849 ER PT J AU Ioannou, GN Perkins, JD Carithers, RL AF Ioannou, George N. Perkins, James D. Carithers, Robert L., Jr. TI Liver transplantation for hepatocellular carcinoma: Impact of the MELD allocation system and predictors of survival SO GASTROENTEROLOGY LA English DT Article ID RADIOFREQUENCY ABLATION; ETHANOL INJECTION; EXPANDED CRITERIA; RECURRENCE; CIRRHOSIS; RESECTION AB Background & Aims: Since February 27, 2002, patients with early-stage hepatocellular carcinoma (HCC) have received priority for liver transplantation in the United States under the Model for End-Stage Liver Disease (MELD) allocation system. We aimed to determine the impact of this system on liver transplantation for HCC. Methods: Data were provided by the United Network for Organ Sharing on 19,404 first-time, cadaveric, adult liver transplantations performed in the United States between 2002 and 2007 and 15,906 performed between 1997 and 2002, an equal-duration period immediately preceding the MELD allocation system. Results: in 1997-2002, 4.6% of liver transplant recipients had HCC compared with 26% in 2002-2007, the majority of whom received "HCC-MELD-exceptions" allowing expedited transplantation. Posttransplantation survival of patients with HCC without an "HCC-MELD-exception" was significantly worse than the survival of patients without HCC. In 20022007, patients with an "HCC-MELD-exception" had similar survival to patients without HCC. However, for the subgroup of patients with tumors 3-5 cm in size had significantly worse survival. When compared with patients with similar MELD scores, patients in the "HCC-MELD-exception" group had worse posttransplantation survival than patients without HCC. The most important predictors of poor posttransplantation survival were MELD score >= 20 (hazard ratio, 1.61; 95% CI: 1.3-2.1) and serum a-fetoprotein level >= 455 ng/mL (hazard ratio, 2.15; 95% CI: 1.5-2.0). Conclusions: The adoption of the MELD allocation system has led to a 6-fold increase in the proportion of transplantation patients with HCC. Patients with larger (3-5 cm) tumors, serum a-fetoprotein level >= 455 ng/mL, or a MELD score >= 20 have poor posttransplantation survival. C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA 98108 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA. [Perkins, James D.] Univ Washington, Dept Surg, Div Transplantat, Seattle, WA 98195 USA. [Ioannou, George N.; Carithers, Robert L., Jr.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, S 111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU PHS HHS [231-00-0115] NR 21 TC 136 Z9 140 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD MAY PY 2008 VL 134 IS 5 BP 1342 EP 1351 DI 10.1053/j.gastro.2008.02.013 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 298HJ UT WOS:000255676700014 PM 18471511 ER PT J AU Frosch, DL Kimmel, S Volpp, K AF Frosch, Dominick L. Kimmel, Stephen Volpp, Kevin TI What role do lay beliefs about hypertension etiology play in perceptions of medication effectiveness? SO HEALTH PSYCHOLOGY LA English DT Article DE hypertension; medication adherence; lay beliefs ID HIGH BLOOD-PRESSURE; JOINT NATIONAL COMMITTEE; AFRICAN-AMERICAN; KIDNEY-DISEASE; TRUST; PHYSICIAN; ADHERENCE; PATIENT; CARE; PREVENTION AB Background: Some people take the disease label "hypertension" literally; leading to the belief that increasing relaxation instead of medication is the best treatment for this condition. We experimentally tested the effect of such underlying beliefs on ratings of interventions for hypertension and compared alternative communication strategies to increase medication effectiveness ratings. Methods: Outpatients (N = 152) with a known diagnosis of hypertension read a vignette describing an asymptomatic condition and recommended treatment. Experimental factors were the disease label (Hypertension vs. Korotkoff s Syndrome) and type of argument designed to persuade the reader that medication is most effective (Causal vs. Correlational). Measures: Background measures included demographics, beliefs that stress causes health problems and trust in physicians. Outcomes were effectiveness ratings for interventions to treat the condition. Results: Participants who read a vignette describing "Hypertension" rated "relaxing more" as significantly more effective than participants exposed to the same condition but with the unfamiliar "Korotkoff's Syndrome" label, [F(1, 14 1) = 5.22, p =.024]. However, medication, reducing salty foods and losing weight were rated as more effective than relaxing more. Intervention ratings did not differ by type of argument presented. There was a significant interaction of disease label and trust in physicians [F(1, 125) = 7.01, p =.009]. Individuals with low trust rated medication as significantly less effective when exposed to an unfamiliar disease label. Conclusions: This study confirms the effect of the hypertension disease label on ratings of different interventions for the condition. However, participants rated biomedically recommended interventions as more effective than those not endorsed. C1 [Frosch, Dominick L.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Kimmel, Stephen; Volpp, Kevin] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kimmel, Stephen] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, Kevin] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Frosch, DL (reprint author), Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, 911 Broxton Ave, Los Angeles, CA 90024 USA. EM dfrosch@mednet.ucla.edu NR 27 TC 5 Z9 5 U1 2 U2 3 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 J9 HEALTH PSYCHOL JI Health Psychol. PD MAY PY 2008 VL 27 IS 3 BP 320 EP 326 DI 10.1037/0278-6133.27.3.320 PG 7 WC Psychology, Clinical; Psychology SC Psychology GA 323LE UT WOS:000257446800005 PM 18624596 ER PT J AU Groeneved, PW Farmer, SA Suh, JJ Matta, MA Yang, FF AF Groeneved, Peter W. Farmer, Steven A. Suh, Janice J. Matta, Mary Anne Yang, Feifei TI Outcomes and costs of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death among the elderly SO HEART RHYTHM LA English DT Article DE death; sudden; defibrittation; prognosis; survival; cost-benefit analysis ID PROPENSITY SCORE METHODS; HEART-FAILURE; MEDICARE BENEFICIARIES; MYOCARDIAL-INFARCTION; COMPLICATIONS; TECHNOLOGIES; AMIODARONE; THERAPY; BIAS AB BACKGROUND The clinical outcomes and costs of implantable cardioverter-defibrillators (ICDs) used for primary prevention of sudden cardiac death in nonexperimental settings are uncertain. OBJECTIVE The purpose of this study was to measure the health outcomes and costs among a nationally representative cohort of elderly, primary-prevention ICD recipients. METHODS We collected health-care cost and utilization data from all Medicare beneficiaries hospitalized for congestive heart failure (CHF) who had received primary-prevention ICDs between October 2003 and September 2005 as well as propensity-score-matched control Medicare beneficiaries hospitalized for CHF during the same period. A muttivariable Cox proportional hazards model was fitted to the cohort, which comprised 7125 ICD recipients and 7125 controls and which was followed through December 2005. Medicare claims in the first year inclusive of the index hospitalization were used to assess differences in health-care costs. RESULTS ICD receipt was associated with a significant reduction in mortality (adjusted hazard ratio = 0.62, 95% confidence interval 0.58-0.67). ICD patients had higher median hospital costs in the first 30 days after initial hospitalization (median difference = $41,542, P <.001) and at 1 year (median difference = $41,503, P <.001) as well as higher outpatient and physician costs at 6 months (median difference = $1828, P <.001). CONCLUSIONS ICD implantation was associated with reduced mortality in a nonexperimental, elderly, primary-prevention patient population hospitalized for CHF. The additional health-care costs of ICD implantation were substantial but comparable to published cost-effectiveness models that have projected ICDs to be cost-effective. C1 [Groeneved, Peter W.] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Groeneved, Peter W.; Suh, Janice J.; Matta, Mary Anne; Yang, Feifei] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneved, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Farmer, Steven A.] Univ Penn, Sch Med, Div Cardiol, Philadelphia, PA 19104 USA. RP Groeneved, PW (reprint author), 1229 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM peter.groeneveld@va.gov FU PHS HHS [IRDIHS016478] NR 32 TC 30 Z9 31 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD MAY PY 2008 VL 5 IS 5 BP 646 EP 653 DI 10.1016/j.hrthm.2008.01.038 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 297OV UT WOS:000255626900003 PM 18452864 ER PT J AU Heshka, S Ruggiero, A Bray, GA Foreyt, J Kahn, SE Lewis, CE Saad, M Schwartz, AV AF Heshka, S. Ruggiero, A. Bray, G. A. Foreyt, J. Kahn, S. E. Lewis, C. E. Saad, M. Schwartz, A. V. CA Look AHEAD Res Grp TI Altered body composition in type 2 diabetes mellitus SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE type 2 diabetes mellitus; fat mass; lean mass; men; women ID X-RAY ABSORPTIOMETRY; INSULIN SENSITIVITY; FAT DISTRIBUTION; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; ARTERIAL STIFFNESS; GLUCOSE-TOLERANCE; ABDOMINAL FAT; WEIGHT-LOSS; THIGH FAT AB Objective: To identify differences in amount and distribution of fat and lean soft tissue in a cross-sectional study of subjects with and without type 2 diabetes and to determine whether any differences are affected by race/ethnicity or sex. Design and methods: Overweight and obese (body mass index, BMI >= 25 kg m(-2)) Black, White and Hispanic men (490) and women (825) with type 2 diabetes ((mean +/- s.d.) age 58.5 +/- 6.6; BMI 35.3 +/- 5.3) who had a baseline dual energy X-ray absorptiometry whole-body scan at the time of enrollment in the Look AHEAD clinical trial, and 242 healthy controls, 91 males and 151 females (age 55.3 +/- 8.6 years, BMI 30.7 +/- 4.2 kg m(-2)) who were participating in unrelated research and were scanned on the same densitometers. Results: Adjusted for gender, age, race, clinical site and body size, total fat mass was smaller in persons with type 2 diabetes than in controls (-1.4 +/- 0.3 (s.e.); 34.5 vs 35.8 kg, P<0.001) while trunk fat was larger (1.3 +/- 0.2 (s.e.); 19.9 vs 18.6 kg, P<0.001) and leg fat was smaller (-1.5 +/- 0.2 (s.e.); 10.7 vs 12.3 kg, P<0.001). The arms of subjects with type 2 diabetes did not have significantly less fat compared to controls. Adjusted trunk lean mass was larger in type 2 diabetes by 0.6 kg (28.4 vs 27.8 kg, P<0.001) while leg lean was smaller by 0.5 kg (18.1 vs 18.6 kg, P<0.001). Conclusions: Type 2 diabetes is associated with less total fat, leg fat and leg lean mass and more truncal fat and lean mass than controls. The physiological processes producing these deviations in tissue distribution and their metabolic significance warrant further investigation. C1 [Heshka, S.] St Lukes Roosevelt Hosp, Obes Res Ctr, New York, NY 10025 USA. [Ruggiero, A.] Wake Forest Univ, Sch Med, Dept Biostat Sci, Winston Salem, NC 27109 USA. [Bray, G. A.] Louisiana State Univ, Pennington Biomed Res Ctr, Dept Clin Res, Baton Rouge, LA USA. [Foreyt, J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kahn, S. E.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98195 USA. [Lewis, C. E.] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL USA. [Saad, M.] SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY USA. [Schwartz, A. V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. RP Schwartz, AV (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 185 Berry St,Suite 5700, San Francisco, CA 94107 USA. EM aschwartz@psg.ucsf.edu OI Kahn, Steven/0000-0001-7307-9002 FU NCRR NIH HHS [M01 RR000051, M01 RR000056, M01 RR000211, M01 RR001066, M01 RR002719]; NIDDK NIH HHS [U01 DK057078, P30 DK046204, P30 DK048520, U01 DK056990, U01 DK056992, U01 DK057002, U01 DK057008, U01 DK057131, U01 DK057135, U01 DK057136, U01 DK057136-09, U01 DK057149, U01 DK057151, U01 DK057154, U01 DK057171, U01 DK057177, U01 DK057178, U01 DK057182, U01 DK057219] NR 27 TC 23 Z9 26 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD MAY PY 2008 VL 32 IS 5 BP 780 EP 787 DI 10.1038/sj.ijo.0803802 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 299LB UT WOS:000255756000008 PM 18227843 ER PT J AU Mauldin, PD Simpson, KN Palesch, YY Spilker, JS Hill, MD Khatri, P Broderick, JP AF Mauldin, Patrick D. Simpson, Kit N. Palesch, Yuko Y. Spilker, Judy S. Hill, Michael D. Khatri, Pooja Broderick, Joseph P. CA IMS III Investigators TI Design of the economic evaluation for the Interventional Management of Stroke (III) trial SO INTERNATIONAL JOURNAL OF STROKE LA English DT Article DE cost-effectiveness; economic evaluation; quality of life; resource utilization ID TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; COST-EFFECTIVENESS; UNITED-STATES; HOSPITAL COSTS; HEALTH; CARE; SERVICES; MODEL AB Rationale Stroke is a common and costly condition where an effective early treatment may be expected to affect patients' future quality of life, the cost of acute medical treatment, and the cost of rehabilitation and any supportive care needed for their remaining lifetime. To assist in informing discussions on early adoption of potential treatments, economic analyses should accompany investigations that seek to improve outcomes for stroke patients. Aims The primary aim is to assess whether i.v./i.a. rt-PA therapy is cost-effective at 3 months compared with i.v. rt-PA, and provides cost-savings or is cost-neutral by 12 months. Design Cost-effectiveness of the two treatment arms will be measured at months 3, 6, 9, and 12. Cost-effectiveness will be calculated using 1.standard cost-effectiveness methodology (incremental cost-effectiveness ratios), and 2an econometric model to assess multiple outcome measures while controlling for multiple subject and treatment-related factors that are known to affect both outcomes and costs. Study outcomes Total cost for the initial hospitalization of treating stroke subjects randomized to either i.v./i.a. or i.v. rt-PA treatment arms will be measured, as will differences in types of resource utilization over 12 months between the two arms of the trial. Quality-of-life data (EuroQol EQ-5D) will be collected over a 12-month period and quality-adjusted life years will be used as a morbidity-adjusted measure of effectiveness. Subgroup analyses will include dichotomized NIH Stroke Scale (< 20, >= 20), country, time between onset and randomization, and i.a. devices. C1 [Mauldin, Patrick D.] Med Univ S Carolina, Coll Pharm, Dept Pharm & Clin Sci, Charleston, SC 29425 USA. [Mauldin, Patrick D.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Simpson, Kit N.] Med Univ S Carolina, Dept Hlth Adm & Policy, Charleston, SC 29425 USA. [Palesch, Yuko Y.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Spilker, Judy S.; Khatri, Pooja; Broderick, Joseph P.] Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, Cincinnati, OH USA. [Hill, Michael D.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. RP Mauldin, PD (reprint author), Med Univ S Carolina, Coll Pharm, Dept Pharm & Clin Sci, POB 250144,QF213B, Charleston, SC 29425 USA. EM mauldinp@musc.edu OI Hill, Michael/0000-0002-6269-1543 FU NINDS NIH HHS [T32 NS047996, U01 NS052220, U01 NS052220-04, U01 NS054630, U01 NS054630-04] NR 27 TC 9 Z9 9 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1747-4930 J9 INT J STROKE JI Int. J. Stroke PD MAY PY 2008 VL 3 IS 2 BP 138 EP 144 DI 10.1111/j.1747-4949.2008.00190.x PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 289NF UT WOS:000255060500011 PM 18706008 ER PT J AU Piper, SL Kim, HT AF Piper, Samantha L. Kim, Hubert T. TI Comparison of ropivacaine and bupivacaine toxicity in human articular chondrocytes SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID ARTHROSCOPIC KNEE SURGERY; IN-VITRO; CARTILAGE; CELLS AB Background: It has been shown that bupivacaine, the most commonly used local anesthetic for postoperative intra-articular use, is cytotoxic to bovine articular chondrocytes in vitro. Ropivacaine is as effective as bupivacaine for intra-articular analgesia and has less systemic toxicity. We compared the in vitro viability of human articular chondrocytes after exposure to bupivacaine, ropivacaine, and saline solution control. Methods: Macroscopically normal human articular cartilage was harvested from the femoral head or tibial plateau of five patients. Full-thickness cartilage explants and cultured chondrocytes isolated from these patients were treated with 0.9% normal saline solution, 0.5% ropivacaine, or 0.5% bupivacaine for thirty minutes. Twenty-four hours after treatment, chondrocyte viability was measured with use of the LIVE/DEAD Viability/Cytotoxicity Kit for cartilage explants and with use of the CellTiter-Glo Luminescent Cell Viability Assay for cultured chondrocytes. Results: Chondrocyte viability in cartilage explants was significantly greater after treatment with ropivacaine as compared with bupivacaine (94.4%+/- 9.0% compared with 78%+/- 12.6%; p = 0.0004). There was no difference in viability after treatment with ropivacaine as compared with saline solution (94.4% 9.0% compared with 95.8% +/- 5.7%; p = 0.6). The viability of cultured chondrocytes was significantly greater after treatment with ropivacaine as compared with bupivacaine (63.9%+/- 19% as compared with 37.4%+/- 12% of the value in the saline solution group; p < 0.0001). Conclusions: In vitro, 0.5% ropivacaine is significantly less toxic than 0.5% bupivacaine in both intact human articular cartilage and chondrocyte culture. Clinical Relevance: Although bupivacaine is the most commonly used local anesthetic for intra-articular analgesia, the demonstrated toxicity to human articular chondrocytes is cause for concern. The present study demonstrated that ropivacaine is less chondrotoxic than bupivacaine and, therefore, may be safer for intra-articular analgesia. C1 [Piper, Samantha L.; Kim, Hubert T.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Piper, SL (reprint author), 360 Frederick St 3, San Francisco, CA 94117 USA. EM Samantha.piper@ucsf.edu; kimh@orthosurg.ucsf.edu NR 15 TC 142 Z9 144 U1 1 U2 7 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD MAY PY 2008 VL 90A IS 5 BP 986 EP 991 DI 10.2106/JBJS.G.01033 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 297KG UT WOS:000255615000006 PM 18451389 ER PT J AU Goodlin, SJ Wingate, S Pressler, SJ Teerlink, JR Storey, CP AF Goodlin, Sarah J. Wingate, Sue Pressler, Susan J. Teerlink, John R. Storey, C. Porter TI Investigating pain in heart failure patients: Rationale and design of the pain assessment, incidence & nature in heart failure (PAIN-HF) study SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE heart failure; symptoms; pain; advanced heart failure ID QUALITY-OF-LIFE; SYMPTOM ASSESSMENT SCALE; ELDERLY-PATIENTS; COGNITIVE IMPAIRMENT; HEALTH-STATUS; ILL PATIENTS; MINI-COG; QUESTIONNAIRE; VALIDATION; EXPERIENCE AB Background: Heart failure is a major cause of morbidity and mortality and is increasing in prevalence. Treatments for heart failure permit a growing number of persons to live with the illness for many years. The burden of symptoms in persons with advanced heart failure is high. Fatigue, limited exertion, dyspnea, and depression are commonly associated with heart failure, but pain is common as well. Methods and Results: Although it is known that underlying comorbidities modify the response to and experience of pain, the interaction between pain and the clinical syndrome of heart failure has not been studied to date. The Pain Assessment, Incidence & Nature in Heart Failure (PAIN-HF) study will evaluate pain in patients with advanced heart failure. Specifically, PAIN-HF will examine the anatomical location of pain, prevalence of pain, its association with aspects of patients' heart failure and comorbid conditions, and its relation to interventions and medications to treat pain. Conclusions: This study to identify the nature, incidence, and character of pain is an important step in relieving distress and discomfort in persons with heart failure. C1 [Goodlin, Sarah J.] Inst Hlth Care Delivery Res, Salt Lake City, UT 84111 USA. [Wingate, Sue] Kaiser Permanente Mid Atlantic States, Silver Spring, MD USA. [Pressler, Susan J.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Storey, C. Porter] Palliat Care, Denver, CO USA. RP Goodlin, SJ (reprint author), Inst Hlth Care Delivery Res, 36 S State St,21st Floor, Salt Lake City, UT 84111 USA. RI Teerlink, John/D-2986-2012 NR 53 TC 14 Z9 14 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD MAY PY 2008 VL 14 IS 4 BP 276 EP 282 DI 10.1016/j.cardfail.2008.01.008 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 304IS UT WOS:000256103800002 PM 18474339 ER PT J AU Liu, PY Swerdloff, RS Anawalt, BD Anderson, RA Bremner, WJ Elliesen, J Gu, YQ Kersemaekers, WM McLachlan, RI Meriggiola, MC Nieschlag, E Sitruk-Ware, R Vogelsong, K Wang, XH Wu, FCW Zitzmann, M Handelsman, DJ Wang, C AF Liu, Peter Y. Swerdloff, Ronald S. Anawalt, Bradley D. Anderson, Richard A. Bremner, William J. Elliesen, Joerg Gu, Yi-Qun Kersemaekers, Wendy M. McLachlan, Robert. I. Meriggiola, M. Cristina Nieschlag, Eberhard Sitruk-Ware, Regine Vogelsong, Kirsten Wang, Xing-Hai Wu, Frederick C. W. Zitzmann, Michael Handelsman, David J. Wang, Christina TI Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: An integrated analysis SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID INTRAMUSCULAR TESTOSTERONE UNDECANOATE; DEPOT-MEDROXYPROGESTERONE ACETATE; NORMAL MEN; CYPROTERONE-ACETATE; NORETHISTERONE ENANTHATE; LEVONORGESTREL IMPLANTS; INJECTABLE TESTOSTERONE; ETONOGESTREL IMPLANTS; ORAL DESOGESTREL; CLINICAL-TRIAL AB Context: Male hormonal contraceptive methods require effective suppression of sperm output. Objective: The objective of the study was to define the covariables that influence the rate and extent of suppression of spermatogenesis to a level shown in previous World Health Organization-sponsored studies to be sufficient for contraceptive purposes (<= 1 million/ml). Design: This was an integrated analysis of all published male hormonal contraceptive studies of at least 3 months' treatment duration. Setting: Deidentified individual subject data were provided by investigators of 30 studies published between 1990 and 2006. Participants: A total of 1756 healthy men (by physical, blood, and semen exam) aged 18-51 yr of predominantly Caucasian (two thirds) or Asian (one third) descent were studied. This represents about 85% of all the published data. Intervention(s): Men were treated with different preparations of testosterone, with or without various progestins. Main Outcome Measure: Semen analysis was the main measure. Results: Progestin coadministration increased both the rate and extent of suppression. Caucasian men suppressed sperm output faster initially but ultimately to a less complete extent than did non-Caucasians. Younger age and lower initial blood testosterone or sperm concentration were also associated with faster suppression, but the independent effect sizes for age and baseline testicular function were relatively small. Conclusion: Male hormonal contraceptives can be practically applied to a wide range of men but require coadministration of an androgen with a second agent (i.e. progestin) for earlier and more complete suppression of sperm output. Whereas considerable progress has been made toward defining clinically effective combinations, further optimization of androgen-progestin treatment regimens is still required. C1 [Liu, Peter Y.; Handelsman, David J.] Univ Sydney, Dept Androl, ANZAC Res Inst, Concord, NSW 2139, Australia. [Liu, Peter Y.] Concord Hosp, Concord, NSW 2139, Australia. [Wang, Christina] Harbor UCLA Med Ctr, Gen Clin Res Ctr, Torrance, CA 90509 USA. [Swerdloff, Ronald S.] LABiomed, Div Endocrinol, Dept Med, Torrance, CA 90509 USA. Univ Washington, Seattle, WA 98195 USA. [Anawalt, Bradley D.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98195 USA. [Anderson, Richard A.] Univ Edinburgh, Queens Med Res Inst, Div Reprod & Dev Sci, Edinburgh EH16 4TJ, Midlothian, Scotland. [Bremner, William J.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Elliesen, Joerg] Schering Pharma AG, Berlin, Germany. [Gu, Yi-Qun] Natl Res Inst Family Planning, Dept Endocrinol, Beijing 100081, Peoples R China. [Kersemaekers, Wendy M.] Schering Plough Corp, NV Organon, Translat Med Dept, NL-5340 BH Oss, Netherlands. [McLachlan, Robert. I.] Monash Univ, Monash Med Ctr, Clayton, Vic 3168, Australia. [McLachlan, Robert. I.] Monash Univ, Prince Henrys Inst, Clayton, Vic 3168, Australia. Univ Bologna, I-40138 Bologna, Italy. [Meriggiola, M. Cristina] St Orsola Marcello Malpighi Hosp, Dept Obstet, I-40138 Bologna, Italy. [Meriggiola, M. Cristina] St Orsola Marcello Malpighi Hosp, Dept Gynecol, I-40138 Bologna, Italy. [Nieschlag, Eberhard; Zitzmann, Michael] Univ Hosp, Inst Reprod Med, D-48149 Munster, Germany. Rockefeller Univ, New York, NY 10021 USA. [Sitruk-Ware, Regine] Populat Council, Ctr Biomed Res, New York, NY 10021 USA. [Vogelsong, Kirsten] WHO, Dept Reprod Hlth & Res, World Bank Special Programme Res, United Nations Fund Populat Act,United Nations De, CH-1211 Geneva 27, Switzerland. [Wang, Xing-Hai] Jiangsu Family Planning Res Inst, Jiangsu 210029, Peoples R China. [Wu, Frederick C. W.] Univ Manchester, Manchester Royal Infirm, Dept Endocrinol, Manchester M13 9WL, Lancs, England. [Wang, Christina] LABiomed, Gen Clin Res Ctr, Torrance, CA 90509 USA. RP Liu, PY (reprint author), Univ Sydney, Dept Androl, ANZAC Res Inst, Concord, NSW 2139, Australia. EM pliu@mail.usyd.edu.au; wang@labiomed.org RI Kersemaekers, Wendy/F-8034-2016 FU NICHD NIH HHS [U54 HD029990] NR 73 TC 44 Z9 45 U1 2 U2 8 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2008 VL 93 IS 5 BP 1774 EP 1783 DI 10.1210/jc.2007-2768 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 298CD UT WOS:000255663100034 PM 18303073 ER PT J AU Etminan, M Carleton, BC Samii, A AF Etminan, Mahyar Carleton, Bruce C. Samii, Ali TI Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: A retrospective cohort study SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Parkinson disease; NSAID; inflammation; neuroprotection; apoptosis ID INFLAMMATION AB Using the British Columbia Linked Health Databases, we explored the association between nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of developing Parkinson's disease (PD). We followed a cohort of older adults in the Province of British Columbia from 1997 to 2003. A time-dependent Cox model was used to estimate adjusted rate ratios for users and non-users of NSAIDs. The results of our study did not show a protective effect of NSAIDs for PD (rate ratio 0.84, 95% CI 0.81-1.09). (C) 2007 Elsevier Ltd. All rights reserved. C1 [Etminan, Mahyar] Vancouver Gen Hosp, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada. [Carleton, Bruce C.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada. [Carleton, Bruce C.] Childrens & Womens Hlth Ctr British Columbia, Pharmaceut Outcomes & Policy Innovat, Vancouver, BC, Canada. [Carleton, Bruce C.] Child & Family Res Inst, Vancouver, BC, Canada. [Samii, Ali] Univ Washington, Seattle, WA 98195 USA. [Samii, Ali] Seattle VA Parkinson Dis Res Educ & Clin Ctr, Seattle, WA USA. RP Samii, A (reprint author), VA Puget Sound Hlth Care Syst, Dept Neurol, 1660 S Columbian Way,MS-127, Seattle, WA 98108 USA. EM asamii@u.washington.edu OI /0000-0002-4485-4054 NR 7 TC 30 Z9 30 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD MAY PY 2008 VL 15 IS 5 BP 576 EP 577 DI 10.1016/j.jocn.2007.02.095 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 293MI UT WOS:000255339000016 PM 18343119 ER PT J AU Nelligan, JA Loftis, JM Matthews, AM Zucker, BL Linke, AM Hauser, P AF Nelligan, Julie A. Loftis, Jennifer M. Matthews, Annette M. Zucker, Betsy L. Linke, Alex M. Hauser, Peter TI Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: Results from a retrospective chart review SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID INTERFERON-ALPHA; VIRUS-INFECTION; PSYCHIATRIC-DISORDERS; PLUS RIBAVIRIN; COPING STYLES; UNITED-STATES; PRIMARY-CARE; PREVALENCE; THERAPY; SYMPTOMS AB Background. The 2002 National Institutes of Health Consensus Conference Statement recommended that both clinical and research efforts be made to increase the availability of hepatitis C virus (HCV) treatment to patients who were previously ineligible because of comorbid psychiatric illness and substance use disorders. However, little research on patients with HCV and comorbid depression has been conducted that can serve to inform and guide treatment of HCV. In this study we characterize the prevalence and severity of comorbid depression, as well as antidepressant and other psychotropic prescribing patterns, in a sample of U.S. veterans with HCV. Method: Participants were recruited between November 2002 and July 2005 from the liver specialty clinic and from a 1-time HCV patient education class conducted through the Portland Department of Veterans Affairs Northwest Hepatitis C Resource Center. Patients who signed informed consent were asked to complete the Beck Depression Inventory, Second Edition (BDI-II), and their medical records were reviewed for information regarding active prescriptions for psychotropic medications and prior psychiatric diagnoses. Results: Of-the 881 veterans enrolled in the study, 783 (89%) completed the BDI-II. Approximately one third (34%, 264/783) of the veterans endorsed moderate to severe symptoms of depression (BDI-II score >= 20), and 37% (290/783) were prescribed an antidepressant; however, 48% (140/290) of veterans prescribed an antidepressant continued to endorse moderate to severe depressive symptoms. Furthermore, of all veterans endorsing moderate to severe symptoms of depression (N = 264), only about half (56%, 148/264) were prescribed an antidepressant. Conclusion: On the basis of BDI-II scores, a significant proportion of veterans with HCV experience moderate to severe depressive symptoms. Although antidepressants were the most commonly prescribed psychotropic medication, many who were prescribed an antidepressant continued to experience high levels of depressive symptoms, an important consideration when deciding whether to initiate antiviral therapy to treat HCV. C1 [Zucker, Betsy L.; Hauser, Peter] Oregon Hlth & Sci Univ, Div Gastroenterol, Dept Internal Med, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Nelligan, Julie A.; Loftis, Jennifer M.; Matthews, Annette M.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Nelligan, Julie A.; Loftis, Jennifer M.; Matthews, Annette M.; Hauser, Peter] Portland Dept VA Med Ctr, Behav Hlth & Clin Neurosci, Portland, OR USA. [Nelligan, Julie A.; Loftis, Jennifer M.; Matthews, Annette M.; Hauser, Peter] Portland Dept VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR USA. RP Hauser, P (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,POB 1034 P3MHADM, Portland, OR 97207 USA. EM peter.hauser2@va.gov NR 39 TC 23 Z9 23 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2008 VL 69 IS 5 BP 810 EP 816 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 306WU UT WOS:000256279600014 PM 18426262 ER PT J AU Tatum, RP Shalhub, S Oelschlager, BK Pellegrini, CA AF Tatum, Roger P. Shalhub, Sherene Oelschlager, Brant K. Pellegrini, Carlos A. TI Complications of PTFE mesh at the diaphragmatic hiatus SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE paraesophageal hernia; surgical mesh; PTFE; visceral erosion; dysphagia ID LAPAROSCOPIC NISSEN FUNDOPLICATION; ANGELCHIK ANTIREFLUX PROSTHESIS; PARAESOPHAGEAL HERNIA REPAIR; ADHESION FORMATION; POLYTETRAFLUOROETHYLENE MESH; POLYPROPYLENE MESH; RANDOMIZED-TRIAL; RECURRENCE; MANAGEMENT; CLOSURE AB Paraesophageal hernia repair has been associated with a recurrence rate of up to 42%. Thus, in the last decade, there has been increasing interest in the use of mesh reinforcement of the hiatal repair. Polytetrafluoroethylene (PTFE) is one of the materials that have been used for this purpose, as it is thought to induce minimal tissue reaction. We report two cases in which complications specific to the use of PTFE mesh in this location developed over time. In the first patient, a gastrectomy was required to remove a large PTFE mesh which had eroded into the esophagogastric junction and gastric cardia. The second patient experienced severe dysphagia resulting from a stricture caused by the implant, requiring removal of the mesh. Although such complications have only rarely been reported, the severity and consequences of these incidents, as reported in the literature and in light of our observations, suggest that an alternative to PTFE should be considered for crural reinforcement during paraesophageal hernia repair. C1 [Tatum, Roger P.; Shalhub, Sherene; Oelschlager, Brant K.; Pellegrini, Carlos A.] Univ Washington, Dept Surg, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Tatum, RP (reprint author), Univ Washington, Dept Surg, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-112-Gs, Seattle, WA 98108 USA. EM rtatum@u.washington.edu NR 31 TC 54 Z9 58 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD MAY PY 2008 VL 12 IS 5 BP 953 EP 957 DI 10.1007/s11605-007-0316-7 PG 5 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 291KF UT WOS:000255195200026 PM 17882502 ER PT J AU Chew, LD Griffin, JM Partin, MR Noorbaloochi, S Grill, JP Snyder, A Bradley, KA Nugent, SM Baines, AD VanRyn, M AF Chew, Lisa D. Griffin, Joan M. Partin, Melissa R. Noorbaloochi, Siamak Grill, Joseph P. Snyder, Annamay Bradley, Katharine A. Nugent, Sean M. Baines, Alisha D. VanRyn, Michelle TI Validation of screening questions for limited health literacy in a large VA outpatient population SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE health literacy; screening; validation; questions ID IDENTIFY PATIENTS; HOSPITAL ADMISSION; LIKELIHOOD RATIOS; DIAGNOSTIC-TEST; CARE; KNOWLEDGE; RISK; ASSOCIATION; SKILLS AB OBJECTIVES: Previous studies have shown that a single question may identify individuals with inadequate health literacy. We evaluated and compared the performance of 3 health literacy screening questions for detecting patients with inadequate or marginal health literacy in a large VA population. METHODS: We conducted in-person interviews among a random sample of patients from 4 VA medical centers that included 3 health literacy screening questions and 2 validated health literacy measures. Patients were classified as having inadequate, marginal, or adequate health literacy based on the Short Test of Functional Health Literacy in Adults (S-TOFHLA) and the Rapid Estimate of Adult Literacy in Medicine (REALM). We evaluated the ability of each of 3 questions to detect: 1) inadequate and the combination of "inadequate or marginal" health literacy based on the S-TOFHLA and 2) inadequate and the combination of "inadequate or marginal" health literacy based on the REALM. MEASUREMENTS AND MAIN RESULTS: Of 4,384 patients, 1,796 (41%) completed interviews. The prevalences of inadequate health literacy were 6.8% and 4.2%, based on the S-TOHFLA and REALM, respectively. Comparable prevalences for marginal health literacy were 7.4% and 17%, respectively. For detecting inadequate health literacy, "How confident are you filling out medical forms by yourself?" had the largest area under the Receiver Operating Characteristic Curve (AUROC) of 0.74 (95% CI: 0.69-0.79) and 0.84 (95% CI: 0.79-0.89) based on the S-TOFHLA and REALM, respectively. AUROCs were lower for detecting "inadequate or marginal" health literacy than for detecting inadequate health literacy for each of the 3 questions. CONCLUSIONS: A single question may be useful for detecting patients with inadequate health literacy in a VA population. C1 [Chew, Lisa D.] Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, Seattle, WA 98104 USA. [Griffin, Joan M.; Partin, Melissa R.; Noorbaloochi, Siamak; Grill, Joseph P.; Snyder, Annamay; Nugent, Sean M.; Baines, Alisha D.] Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Griffin, Joan M.; Partin, Melissa R.; Noorbaloochi, Siamak] Univ Minnesota, Dept Med, Div Gen Internal Med, Minneapolis, MN 55455 USA. [Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA USA. [Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Primary & Special Med Care, Seattle, WA USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Hlth Serv, Seattle, WA 98195 USA. [VanRyn, Michelle] Univ Minnesota, Dept Family Med & Commun Hlth, Minneapolis, MN 55455 USA. RP Chew, LD (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, 352 9Th Ave,Box 359780, Seattle, WA 98104 USA. EM lchew@u.washington.edu RI VAN RYN, MICHELLE/B-1664-2010 NR 30 TC 295 Z9 299 U1 4 U2 29 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2008 VL 23 IS 5 BP 561 EP 566 DI 10.1007/s11606-008-0520-5 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 291KG UT WOS:000255195300008 PM 18335281 ER PT J AU Singhal, R Rubenstein, LV Wang, M Lee, ML Raza, A Holschneider, CH AF Singhal, Rita Rubenstein, Lisa V. Wang, Mingming Lee, Martin L. Raza, Anwar Holschneider, Christine H. TI Variations in practice guideline adherence for abnormal cervical cytology in a county healthcare system SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT AcademyHealth Annual Meeting CY JUN, 2004 CL San Diego, CA DE cytology; quality of care; practice guidelines; cervical cancer ID ATYPICAL GLANDULAR CELLS; SCREENING FOLLOW-UP; PAP-SMEARS; CLINICAL-SIGNIFICANCE; RANDOMIZED-TRIAL; UNITED-STATES; WOMEN; MANAGEMENT; CANCER; GYNECOLOGISTS AB BACKGROUND: Reduction in cervical cancer incidence and mortality is not only dependant on promoting cervical cancer screening but also on providing appropriate follow-up and treatment of abnormal cervical cytology. OBJECTIVES: The objective of this study was to determine variations in guideline adherence for women requiring abnormal cervical cytology follow-up. SUBJECTS: Subjects of the study are women 18 years or older with an abnormal Pap test in 2000 within a large county healthcare system (n=8,571). MEASUREMENTS: Guideline adherence was determined by the presence or absence of the appropriate follow-up procedure within an acceptable time interval for each degree of cytological abnormality. Patients with no follow-up studies were deemed to be lost to follow-up. RESULTS: Of study subjects, 18.5% were lost to follow-up care. Of the remaining 6,987 women, 60.3% received optimal care, 9.4% received suboptimal care, and 30.3% received poor care. Follow-up rates were higher for patients with higher degree of cytological abnormality (OR, 1.29, 95% CI, 1.17-1.42), older patients (OR, 1.03, 95% CI, 1.02-1.030) and those receiving the index Pap test at a larger healthcare facility (OR, 1.13; 95% CI, 1.01-1.27). Receiving optimal care was positively correlated with higher degree of cytological abnormality (p<.0001) and larger facility size (p=.002). Regional variations in care demonstrated the largest cluster having the lowest lost to follow-up rate and the most optimal care. CONCLUSIONS: A significant number of women with abnormal cervical cytology are receiving less than optimal care. Further studies are required to determine the specific healthcare delivery practices that need to be targeted to improve guideline adherence for follow-up of abnormal cytology. C1 [Singhal, Rita] Off Womens Hlth, Los Angeles Cty Dept Publ Hlth, El Monte, CA 91731 USA. [Singhal, Rita] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA. [Rubenstein, Lisa V.; Wang, Mingming; Lee, Martin L.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Raza, Anwar] Univ So Calif, Womens & Childrens Hosp, Los Angeles, CA USA. [Holschneider, Christine H.] Olive View UCLA Med Ctr, Dept Obstet & Gynecol, Sylmar, CA 91342 USA. RP Singhal, R (reprint author), Off Womens Hlth, Los Angeles Cty Dept Publ Hlth, 3400 Aerojet Ave,3rd Floor, El Monte, CA 91731 USA. EM risinghal@ph.lacounty.gov NR 29 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2008 VL 23 IS 5 BP 575 EP 580 DI 10.1007/s11606-008-0528-x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 291KG UT WOS:000255195300010 PM 18286344 ER PT J AU Moore, EE Hawes, SE Scholes, D Boyko, EJ Hughes, JP Fihn, SD AF Moore, Elya E. Hawes, Stephen E. Scholes, Delia Boyko, Edward J. Hughes, James P. Fihn, Stephan D. TI Sexual intercourse and risk of symptomatic urinary tract infection in post-menopausal women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 33rd Annual Meeting of the Infectious-Disease-Society-for-Obstetrics-and-Gynecology CY AUG 03-05, 2006 CL Monterey, CA SP Infect Dis Soc Obstet & Gynecol DE coitus; diaries; postmenopause; urinary tract infections ID ASYMPTOMATIC BACTERIURIA; UNITED-STATES; YOUNG-WOMEN; EPIDEMIOLOGY; PREDICTORS; VALIDITY; HEALTH; COSTS AB BACKGROUND: Sexual intercourse increases the risk of symptomatic urinary tract infections (UTI) in young women, but its role among post-menopausal women is unclear. OBJECTIVE: To determine whether recent sexual intercourse, as documented by daily diaries, is associated with an increased risk of symptomatic UTI in post-menopausal women. DESIGN: A 2-year prospective cohort study conducted from 1998 to 2002. PARTICIPANTS: One thousand and seventeen randomly selected post-menopausal women enrolled at Group Health Cooperative (GHC), a Washington State HMO. MEASUREMENTS AND MAIN RESULTS: Women were asked to enter daily diary information on vaginal intercourse, medication use, and genito-urinary symptoms. The outcome of interest, symptomatic UTI, was defined as a positive urine culture >= 10(5) CFU/mL of a uropathogen and the presence of >= 2 acute urinary symptoms. Nine hundred thirteen women returned diaries and were included in this study. Seventy-eight women experienced 108 symptomatic UTIs, and 361 (40%) reported sexual intercourse in their diaries. There was an increased hazard for UTI 2 calendar days after the reporting of sexual intercourse in the diaries (adjusted hazard ratio [HR], 3.42, 95% CI 1.49-7.80), while there was no evidence for an increased hazard associated with intercourse at other times. When the UTI criterion was relaxed from >= 10(5) CFU/mL to >= 10(4) CFU/mL, adding 9 UTI events to the analysis, the HR for UTI 2 days after intercourse changed slightly to 3.26 (95% CI 1.43-7.43). CONCLUSIONS: Our data suggest that, as with younger women, recent sexual intercourse is strongly associated with incident UTI in generally healthy post-menopausal women. C1 [Moore, Elya E.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia. [Moore, Elya E.; Hawes, Stephen E.; Scholes, Delia; Boyko, Edward J.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Moore, Elya E.; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Scholes, Delia] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA USA. [Boyko, Edward J.; Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Hughes, James P.] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA. [Moore, Elya E.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia. RP Moore, EE (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia. EM elya.moore@mcri.edu.au OI Boyko, Edward/0000-0002-3695-192X FU NIAID NIH HHS [T32 AI007140, T32AI07140]; NIDDK NIH HHS [K23DK02660, K23 DK002660, R01 DK43134] NR 30 TC 13 Z9 13 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2008 VL 23 IS 5 BP 595 EP 599 DI 10.1007/s11606-008-0535-y PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 291KG UT WOS:000255195300013 PM 18266044 ER PT J AU Saha, S Freeman, M Toure, J Tippens, KM Weeks, C Ibrahim, S AF Saha, Somnath Freeman, Michele Toure, Joahd Tippens, Kimberly M. Weeks, Christine Ibrahim, Said TI Racial and ethnic disparities in the VA health care system: A systematic review SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE racial and ethnic disparities; medication adherence; health care utilization ID OF-VETERANS-AFFAIRS; ACUTE MYOCARDIAL-INFARCTION; INVASIVE CARDIAC PROCEDURES; WHITE MALE VETERANS; CAROTID-ENDARTERECTOMY; RACIAL/ETHNIC VARIATIONS; AFRICAN-AMERICAN; PHYSICIAN COMMUNICATION; CARDIOVASCULAR-DISEASE; SMOKING-CESSATION AB OBJECTIVES: To better understand the causes of racial disparities in health care, we reviewed and synthesized existing evidence related to disparities in the "equal access" Veterans Affairs (VA) health care system. METHODS: We systematically reviewed and synthesized evidence from studies comparing health care utilization and quality by race within the VA. RESULTS: Racial disparities in the VA exist across a wide range of clinical areas and service types. Disparities appear most prevalent for medication adherence and surgery and other invasive procedures, processes that are likely to be affected by the quantity and quality of patient-provider communication, shared decision making, and patient participation. Studies indicate a variety of likely root causes of disparities including: racial differences in patients' medical knowledge and information sources, trust and skepticism, levels of participation in health care interactions and decisions, and social support and resources; clinician judgment/bias; the racial/cultural milieu of health care settings; and differences in the quality of care at facilities attended by different racial groups. CONCLUSIONS: Existing evidence from the VA indicates several promising targets for interventions to reduce racial disparities in the quality of health care. C1 [Saha, Somnath; Freeman, Michele] Portland VA Med Ctr, Portland, OR 97239 USA. [Saha, Somnath; Freeman, Michele] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Toure, Joahd] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Tippens, Kimberly M.] Natl Coll Nat Med, Helfgott Res Inst, Portland, OR USA. [Weeks, Christine; Ibrahim, Said] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Ibrahim, Said] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Saha, S (reprint author), Portland VA Med Ctr, 3710 SW US,Vet Hosp Rd, Portland, OR 97239 USA. EM sahas@ohsu.edu FU HSRD VA [ESP 05-225] NR 84 TC 87 Z9 87 U1 2 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2008 VL 23 IS 5 BP 654 EP 671 DI 10.1007/s11606-008-0521-4 PG 18 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 291KG UT WOS:000255195300026 PM 18301951 ER PT J AU Egede, LE Bosworth, H AF Egede, Leonard E. Bosworth, Hayden TI The future of health disparities research: 2008 and beyond SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID QUALITY-OF-CARE; RACIAL DISPARITIES; DIABETES CARE; IMPROVEMENT C1 [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlt Disparities Res, Charleston, SC 29425 USA. [Bosworth, Hayden] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bosworth, Hayden] Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Bosworth, Hayden] Duke Univ, Dept Med, Durham, NC USA. [Bosworth, Hayden] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. [Bosworth, Hayden] Duke Univ, Ctr Aging & Human Dev, Durham, NC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Div Gen Internal Med, Ctr Hlt Disparities Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu NR 16 TC 4 Z9 4 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2008 VL 23 IS 5 BP 706 EP 708 DI 10.1007/s11606-008-0580-6 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 291KG UT WOS:000255195300032 PM 18392662 ER PT J AU Conway, PH Konetzka, RT Zhu, JS Volpp, KG Sochalski, J AF Conway, Patrick H. Konetzka, R. Tamara Zhu, Jingsan Volpp, Kevin G. Sochalski, Julie TI Nurse staffing ratios: Trends and policy implications for hospitalists and the safety net SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE nurse staffing; hospital staffing; hospitalist; nurse workforce; safety net ID WORKING-CONDITIONS; PATIENT SAFETY; CALIFORNIA; OUTCOMES; SUPPORT AB BACKGROUND: Mandated minimum nurse-to-patient staffing ratio legislation was passed in California in 1999 and implemented January 1, 2004. Nurse staffing legislation is being considered in at least 25 other states. OBJECTIVES: The objectives of this study were: (1) to evaluate nurse staffing trends in California from 1993 to 2004, (2) to identify types of hospitals below minimum staffing ratios and staffing changes in 2004, the first year post-implementation; and (3) to discuss possible implications of nurse staffing on hospitalists and their hospital-based initiatives. DESIGN, SETTING, PATIENTS: We analyzed data from the medical-surgical units of all short-term acute-care general hospitals in California from 1993 to 2004. The annual hospital staffing ratio is composed of the combined hours of registered nurses and licensed vocational nurses and total number of patient days on medical-surgical units. RESULTS: Nurse staffing ratios were relatively unchanged from 1993 to 1999 and then increased significantly from 1999 to 2004, with the largest increase in 2004, the year the nurse staffing ratio was implemented. Types of hospitals more likely to be below minimum ratios had a high Medicaid/uninsured patient population and were government owned, nonteaching, urban, and in more competitive markets. Most hospitals below ratios were considered part of the health care "safety net." CONCLUSIONS: Nurse staffing legislation may increase nurse staffing. However, mandated nurse staffing ratios without mechanisms to help achieve ratios may force hospitals, especially safety-net hospitals, to make tradeoffs in other services or investments with unintended negative consequences for patients. Nurse staffing likely influences the outcomes of hospitalist-led quality initiatives, but these effects need to be explored further. C1 [Conway, Patrick H.] Cincinnati Childrens Hosp, Med Ctr, Ctr Hlth Care Qual, Cincinnati, OH 45215 USA. [Conway, Patrick H.] Cincinnati Childrens Hosp, Med Ctr, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45215 USA. [Conway, Patrick H.] Cincinnati Childrens Hosp, Med Ctr, Div Gen Pediat, Cincinnati, OH 45215 USA. [Conway, Patrick H.] Univ Penn, Clin Scholars Program, Robert Wood Johnson Fdn, Philadelphia, PA 19104 USA. [Conway, Patrick H.; Volpp, Kevin G.; Sochalski, Julie] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Zhu, Jingsan; Volpp, Kevin G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. [Sochalski, Julie] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Conway, PH (reprint author), Cincinnati Childrens Hosp, Med Ctr, Ctr Hlth Care Qual, 3333 Burnet Ave,MLC 2044, Cincinnati, OH 45215 USA. EM patrick.conway@cchmc.org NR 18 TC 14 Z9 14 U1 1 U2 5 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAY-JUN PY 2008 VL 3 IS 3 BP 193 EP 199 DI 10.1002/jhm.314 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 320JQ UT WOS:000257229900004 PM 18570346 ER PT J AU Yamaoka, Y AF Yamaoka, Yoshio TI Roles of the plasticity regions of Helicobacter pylori in gastroduodenal pathogenesis SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Review ID CAG PATHOGENICITY-ISLAND; GASTRIC EPITHELIAL-CELLS; COMPLETE GENOME SEQUENCE; OUTER-MEMBRANE PROTEINS; IV SECRETION APPARATUS; ULCER-PROMOTING GENE; DUODENAL-ULCER; NATURAL TRANSFORMATION; CLINICAL PRESENTATION; VIRULENCE FACTORS AB Putative virulence genes of Helicobacter pylori are generally classified into three categories: strain-specific genes, phase-variable genes and genes with variable structures/genotypes. Among these, there has recently been considerable interest in strain-specific genes found outside of the cag pathogenicity island, especially genes in the plasticity regions. Nearly half of the strain-specific genes of H. pylori are located in the plasticity regions in strains 26695 and J99. Strain HPAG1, however, seems to lack a typical plasticity region; instead it has 43 HPAG1-specific genes which are either undetectable or incompletely represented in the genomes of strains 26695 and J99. Recent studies showed that certain genes or combination of genes in this region may play important roles in the pathogenesis of H. pylori-associated gastroduodenal diseases. Most previous studies have focused on the plasticity region in strain J99 (jhp0914-jhp0961) and the jhp0947 gene and the buodenal ulcer promoting (dupA) gene are good candidate markers for gastroduodenal diseases although there are some paradoxical findings. The jhp0947 gene is reported to be associated with an increased risk of both duodenal ulcers and gastric cancers, whereas the dupA gene, which encompasses jhp0917 and jhp0918, is reported to be associated with an increased risk of duodenal ulcers and protection against gastric cancers. In addition, recent studies showed that approximately 10-30 % of clinical isolates possess a 16.3 kb type IV secretion apparatus (tfs3) in the plasticity region. Studies on the plasticity region have only just begun, and further investigation is necessary to elucidate the roles of genes in this region in gastroduodenal pathogenesis. C1 [Yamaoka, Yoshio] Baylor Coll Med, Dept Med Gastroenterol, Houston, TX 77030 USA. [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Baylor Coll Med, Dept Med Gastroenterol, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [R01 DK062813-05, R01 DK062813, R01 DK62813] NR 51 TC 53 Z9 56 U1 0 U2 2 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD MAY PY 2008 VL 57 IS 5 BP 545 EP 553 DI 10.1099/jmm.0.2008/000570-0 PG 9 WC Microbiology SC Microbiology GA 299AF UT WOS:000255727500002 PM 18436586 ER PT J AU Jakupcak, M Luterek, J Hunt, S Conybeare, D McFall, M AF Jakupcak, Matthew Luterek, Jane Hunt, Stephen Conybeare, Daniel McFall, Miles TI Posttraumatic stress and its relationship to physical health functioning in a sample of Iraq and Afghanistan War veterans seeking postdeployment VA health care SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Afghanistan; combat; Iraq; physical health functioning; posttraumatic stress ID COMBAT VETERANS; GULF-WAR; DISORDER; SYMPTOMS; PREDICTORS; TRAUMA AB The relationship between posttraumatic stress and physical health functioning was examined in a sample of Iraq and Afghanistan War veterans seeking postdeployment VA care. Iraq and Afghanistan War veterans (N = 108) who presented for treatment to a specialty postdeployment care clinic completed self-report questionnaires that assessed symptoms of postraumatic stress disorder (PTSD), chemical exposure, combat exposure, and physical health functioning. As predicted, PTSD symptom severity was significantly associated with poorer health functioning, even after accounting for demographic factors, combat and chemical exposure, and health risk behaviors. These results highlight the unique influence of PTSD on the physical health in treatment seeking Iraq and Afghanistan War veterans. C1 [Jakupcak, Matthew] Puget Sound Hlth Care Syst, Deployment Hlth Clin, Seattle, WA 98108 USA. [Jakupcak, Matthew; Luterek, Jane; Hunt, Stephen; Conybeare, Daniel; McFall, Miles] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Luterek, Jane; Conybeare, Daniel; McFall, Miles] Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Jakupcak, M (reprint author), Puget Sound Hlth Care Syst, Deployment Hlth Clin, Seattle, WA 98108 USA. EM matthew.jakupcak@va.gov NR 20 TC 61 Z9 62 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD MAY PY 2008 VL 196 IS 5 BP 425 EP 428 DI 10.1097/NMD.0b013e31817108ed PG 4 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 303QM UT WOS:000256055600011 PM 18477887 ER PT J AU Paintlia, MK Paintlia, AS Khan, M Singh, I Singh, AK AF Paintlia, Manjeet K. Paintlia, Ajaib S. Khan, Mushfiquddin Singh, Inderjit Singh, Avtar K. TI Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE cerebral white matter injury; lipopolysaccharide; oligodendrocyte; peroxisome proliferator-activated receptor-alpha and N-acetyl cysteine; reactive oxygen species ID NECROSIS-FACTOR-ALPHA; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; BRAIN-INJURY; KAPPA-B; PERIVENTRICULAR LEUKOMALACIA; INTRAUTERINE INFECTION; DEMYELINATING DISEASES; INFLAMMATORY DISEASE AB Glial cells secrete proinflammatory mediators in the brain in response to exogenous stimuli such as infection and injury. Previously, we documented that systemic maternal lipopolysaccharide (LPS)-exposure at embryonic gestation day 18 causes oligodendrocyte (OL)-injury/hypomyelination in the developing brain which can be attenuated by N-acetyl cysteine (NAC; precursor of glutathione). The present study delineates the underlying mechanism of NAC-mediated attenuation of inhibition of OL development in LPS-stimulated mixed glial cultures. Factors released by LPS-stimulated mixed glial cultures inhibited OL development as shown by decrease in both proliferation 3bromo-deoxyuridine(+)/chondroitin sulfate proteoglycan-NG2(+), hereafter BrdU(+)/NG(+) and differentiation (O4(+) and myelin basic protein(+)) of OL-progenitors. Correspondingly, an impairment of peroxisomal proliferation was shown by a decrease in the level of peroxisomal proteins in the developing OLs following exposure to LPS-conditioned media (LCM). Both NAC and WY14643, a peroxisome proliferator-activated receptor (PPAR)-alpha agonist attenuated these LCM-induced effects in OL-progenitors. Similar to WY14643, NAC attenuated LCM-induced inhibition of PPAR-alpha activity in developing OLs. Studies conducted with cytokines and diamide (a thiol-depleting agent) confirmed that cytokines are active agents in LCM which may be responsible for inhibition of OL development via peroxisomal dysfunction and induction of oxidative stress. These findings were further corroborated by similar treatment of developing OLs generated from PPAR-alpha((-/-)) and wild-type mice or B12 oligodendroglial cells co-transfected with PPAR-alpha small interfering RNAs/pTK-PPREx3-Luc plasmids. Collectively, these data provide evidence that the modulation of PPAR-alpha activity, thus peroxisomal function by NAC attenuates LPS-induced glial factors-mediated inhibition of OL development suggesting new therapeutic interventions to prevent the devastating effects of maternal infections. C1 [Paintlia, Manjeet K.; Paintlia, Ajaib S.; Khan, Mushfiquddin; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst 513, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst 513, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NCRR NIH HHS [C06 RR015455, C06 RR018823]; NINDS NIH HHS [R01 NS040810, R01 NS034741-12, NS-37766, NS-22576, R01 NS034741, R01 NS037766-10, NS-40810, R37 NS022576, R01 NS037766, NS-34741, R37 NS022576-24, R01 NS022576, R01 NS022576-17] NR 67 TC 21 Z9 22 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2008 VL 105 IS 3 BP 956 EP 970 DI 10.1111/j.1471-4159.2007.05199.x PG 15 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 290RF UT WOS:000255139200035 PM 18205750 ER PT J AU Won, JS Im, YB Khan, M Contreras, M Singh, AK Singh, I AF Won, Je-Seong Im, Yeong-Bin Khan, Mushfiquddin Contreras, Miguel Singh, Avtar K. Singh, Inderjit TI Lovastatin inhibits amyloid precursor protein (APP) beta-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE beta-amyloid and endocytosis; Alzheimer's disease; geranylgeranylation; lipid rafts; lovastatin ID CELL-SURFACE RECEPTOR; ALZHEIMERS-DISEASE; A-BETA; CHOLESTEROL DEPLETION; ENDOCYTIC PATHWAY; ANCHORED PROTEINS; MEMBRANE DOMAINS; PLASMA-MEMBRANE; ALPHA-SECRETASE; GAMMA-SECRETASE AB Previous studies have described that statins (inhibitors of cholesterol and isoprenoid biosynthesis) inhibit the output of amyloid-beta (A beta) in the animal model and thus decrease risk of Alzheimer's disease. However, their action mechanism(s) in A beta precursor protein (APP) processing and A beta generation is not fully understood. In this study, we report that lovastatin treatment reduced A beta output in cultured hippocampal neurons as a result of reduced APP levels and beta-secretase activities in low density Lubrol WX (non-ionic detergent) extractable lipid rafts (LDLR). Rather than altering cholesterol levels in lipid raft fractions and thus disrupting lipid raft structure, lovastatin decreased A beta generation through down-regulating geranylgeranyl-pyrophosphate dependent endocytosis pathway. The inhibition of APP endocytosis by treatment with lovastatin and reduction of APP levels in LDLR fractions by treatment with phenylarsine oxide (a general endocytosis inhibitor) support the involvement of APP endocytosis in APP distribution in LDLR fractions and subsequent APP beta-cleavage. Moreover, lovastatin-mediated down-regulation of endocytosis regulators, such as early endosomal antigen 1, dynamin-1, and phosphatidylinositol 3-kinase activity, indicates that lovastatin modulates APP endocytosis possibly through its pleiotropic effects on endocytic regulators. Collectively, these data report that lovastatin mediates inhibition of LDLR distribution and beta-cleavage of APP in a geranylgeranyl-pyrophosphate and endocytosis-dependent manner. C1 [Won, Je-Seong; Singh, Avtar K.; Singh, Inderjit] Med Univ S Carolina, Charles P Darby Childrens Res Inst, Dept Pathol, Charleston, SC 29425 USA. [Won, Je-Seong; Im, Yeong-Bin; Khan, Mushfiquddin; Contreras, Miguel] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Lab Med Serv, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Charles P Darby Childrens Res Inst, Dept Pathol, 173 Ashley Ave,Rm 516, Charleston, SC 29425 USA. EM singhi@musc.edu FU NCRR NIH HHS [C06 RR018823, C06 RR015455, RR015455, RR018823]; NIA NIH HHS [R56 AG025307, AG-25307, R56 AG025307-02]; NINDS NIH HHS [R01 NS034741, NS-22576, NS-37766, R01 NS034741-12, R01 NS037766-10, R01 NS037766, R01 NS022576-17, NS-34741, R01 NS022576, R37 NS022576] NR 66 TC 28 Z9 29 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2008 VL 105 IS 4 BP 1536 EP 1549 DI 10.1111/j.1471-4159.2008.05283.x PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 292SO UT WOS:000255286600041 PM 18266936 ER PT J AU Rhodes, ME Rubin, RT McKlveen, JM Karwoski, TE Fulton, BA Czambel, RK AF Rhodes, M. E. Rubin, R. T. McKlveen, J. M. Karwoski, T. E. Fulton, B. A. Czambel, R. K. TI Pituitary-adrenal responses to oxotremorine and acute stress in male and female M-1 muscarinic receptor knockout mice: Comparisons to M-2 muscarinic receptor knockout mice SO JOURNAL OF NEUROENDOCRINOLOGY LA English DT Article DE cholinergic; diergism; knockout; muscarinic; sex differences ID ACETYLCHOLINE-RECEPTOR; CHOLINERGIC RECEPTORS; SEXUAL DIERGISM; CORTICAL RESPONSES; SEIZURE ACTIVITY; AXIS RESPONSES; RAT PITUITARY; M1 RECEPTOR; YOUNG; M2 AB Both within the brain and in the periphery, M-1 muscarinic receptors function primarily as postsynaptic receptors and M-2 muscarinic receptors function primarily as presynaptic autoreceptors. In addition to classical parasympathetic effectors, cholinergic stimulation of central muscarinic receptors influences the release of adrenocorticotrophic hormone (ACTH) and corticosterone. We previously reported that oxotremorine administration to male and female M-2 receptor knockout and wild-type mice increased ACTH to a significantly greater degree in knockout males compared to all other groups, and that M-2 knockout mice of both sexes were significantly more responsive to the mild stress of saline injection than were wild-type mice. These results accord with the primary function of M-2 receptors as presynaptic autoreceptors. In the present study, we explored the role of the M-1 receptor in pituitary-adrenal responses to oxotremorine and saline in male and female M-1 knockout and wild-type mice. Because these mice responded differently to the mild stress of saline injection than did the M-2 knockout and wild-type mice, we also determined hormone responses to restraint stress in both M-1 and M-2 knockout and wild-type mice. Male and female M-1 knockout and wild-type mice were equally unresponsive to the stress of saline injection. Oxotremorine increased both ACTH and corticosterone in M-1 wild-type mice to a significantly greater degree than in knockout mice. In both M-1 knockout and wild-type animals, ACTH responses were greater in males compared to females, and corticosterone responses were greater in females compared to males. Hormone responses to restraint stress were increased in M-2 knockout mice and decreased in M-1 knockout mice compared to their wild-type counterparts. These findings suggest that M-1 and M-2 muscarinic receptor subtypes differentially influence male and female pituitary-adrenal responses to cholinergic stimulation and stress. The decreased pituitary-adrenal sensitivity to oxotremorine and restraint stress noted in M-1 knockout mice is consistent with M-1 being primarily a postsynaptic receptor. Conversely, the increased pituitary-adrenal sensitivity to these challenges noted in M-2 knockout mice is consistent with M-2 being primarily a presynaptic autoreceptor. C1 [Rhodes, M. E.; McKlveen, J. M.] St Vincent Coll, Dept Biol, Latrobe, PA 15650 USA. [Rubin, R. T.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Mental Hlth, Los Angeles, CA USA. [Karwoski, T. E.; Fulton, B. A.; Czambel, R. K.] Drexel Univ, Coll Med, Neurosci Res Ctr, Pittsburgh, PA USA. RP Rhodes, ME (reprint author), St Vincent Coll, Dept Biol, 300 Fraser Purchase Rd, Latrobe, PA 15650 USA. EM michael.rhodes@email.stvincent.edu FU NIMH NIH HHS [MH28380] NR 48 TC 5 Z9 5 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0953-8194 J9 J NEUROENDOCRINOL JI J. Neuroendocrinol. PD MAY PY 2008 VL 20 IS 5 BP 617 EP 625 DI 10.1111/j.1365-2826.2008.01700.x PG 9 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 289FR UT WOS:000255040900009 PM 18363805 ER PT J AU Goy, ER Carter, J Ganzini, L AF Goy, Elizabeth Ruth Carter, Julie Ganzini, Linda TI Neurologic disease at the end of life: Caregiver descriptions of Parkinson disease and amyotrophic lateral sclerosis SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID PALLIATIVE CARE; MORTALITY; PROXY AB Objective: Amyotrophic lateral sclerosis (ALS) is well recognized as a terminal illness with an established need for palliative care. Parkinson's disease is a substantially more common cause of death, yet little has been written about the palliative needs of these patients at the end of life. To highlight the palliative care needs and experiences of patients with Parkinson's disease and related disorders (PDRD), we compared them to patients with ALS. Methods: Family caregivers of decedent PDRD and ALS patients in Oregon and Washington were surveyed about their loved one's symptoms, treatment preferences, health care usage, and psychosocial experiences during the last month of life. Results: Fifty-two PDRD and 50 ALS caregivers completed the survey. Overall suffering (1 = none to 6 = severe) was rated a median of 4 for both groups. Pain was moderately severe or worse in 42% of PDRD patients and 52% of ALS patients; of these, 27% of PDRD and 19% of ALS patients received no pain medication in the last month. PDRD featured more severe effects of confusion than ALS, although less dyspnea and difficulty eating. PDRD patients had significantly shorter hospice enrollments than ALS patients (p = 0.01). Conclusions: In the views of caregivers, suffering associated with ALS is no more severe than suffering associated with PDRD, and both groups appear to have unmet palliative care needs in the last months of life. Studies to define hospice readiness and special needs in hospice might improve end-of-life care for PDRD patients. C1 [Goy, Elizabeth Ruth] Portland VA Med Ctr, Dept Res Mental Hlth, Portland, OR 97207 USA. [Carter, Julie] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Ganzini, Linda] Portland VA Med Ctr, Dept Psychiat, Portland, OR 97207 USA. RP Goy, ER (reprint author), Portland VA Med Ctr, Dept Res Mental Hlth, R&D 66,3710 SW US Vet Hop Rd,POB 1034, Portland, OR 97207 USA. EM elizabeth.goy@va.gov NR 22 TC 20 Z9 20 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAY PY 2008 VL 11 IS 4 BP 548 EP 554 DI 10.1089/jpm.2007.0258 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 306IK UT WOS:000256241300005 PM 18454605 ER PT J AU Kamath, BD Box, TL Simpson, M Hernandez, JA AF Kamath, B. D. Box, T. L. Simpson, M. Hernandez, J. A. TI Infants born at the threshold of viability in relation to neonatal mortality: Colorado, 1991 to 2003 SO JOURNAL OF PERINATOLOGY LA English DT Article DE neonatal mortality rate; threshold of viability; regionalization; ELBW infants; prematurity ID LOW-BIRTH-WEIGHT; PERINATAL-CARE; REGIONALIZATION; SURFACTANT AB Objective: To determine the contribution of infants born at the threshold of viability (defined as <750 g birth weight) and the role of regionalization of perinatal care on the neonatal mortality rate (NMR) in Colorado. Study Design: We performed a retrospective cohort study, evaluating all live births in Colorado from 1991 to 2003, and comparing the periods 1991 to 1996 versus 1997 to 2003. Result: The overall unadjusted NMR of the two time periods was 4.3 and 4.4 per 1000 live births, respectively (P=0.42). The contribution of infants with birth weights <750 g to the overall NMR increased from 45.0 to 54.5% (P<0.01). The odds of death for infants <750 g increased between time periods (Odd ratio 1.3, 95% Confidence interval 1.11, 1.61). However, NMR decreased between time periods for all birth weight categories, until infants <600 g. With respect to regionalization, the number of infants <750 g born in a level III care center increased slightly between the two time periods (69.6 versus 73.3%; P=0.04); however, adjusted analysis showed no difference in the practice of regionalization between time periods. Regardless of time period, infants who weighed <750 g born in a level III center had 60% lower mortality risk when compared to <750 g infants born in a non-level III center (P<0.01; 95% CI 0.30, 0.52). Conclusion: Despite advances in neonatal medicine, the overall NMR in the state of Colorado remained unchanged between the time periods of 1991 to 1996 and 1997 to 2003. Infants at the threshold of viability continue to have a large impact on the Colorado NMR, making up a larger proportion of overall neonatal deaths. While the results demonstrate that the risk of mortality is significantly reduced for <750 g infants born in a level III center, the practice of regionalization has not changed between the two time periods. Improved efforts to standardize the referral practices to ensure delivery of <750 g infants in level III centers could potentially reduce the impact of these infants on the NMR. While the overall NMR in Colorado has not changed between the two time periods, the NMR for infants >600 g has significantly decreased, suggesting that the boundary delineating the threshold of viability needs reevaluation, as it may have been pushed lower than previously defined. C1 [Kamath, B. D.] Univ Colorado, Dept Pediat, Sect Neonatol, Denver, CO 80045 USA. [Box, T. L.] Denver VA Med Ctr, Eastern Colorado Hlth Care Syst, Denver, CO USA. [Simpson, M.] Univ Colorado, Dept Epidemiol, Denver, CO 80045 USA. [Hernandez, J. A.] Childrens Hosp, Hlth Sci Ctr, Denver, CO 80218 USA. RP Kamath, BD (reprint author), Univ Colorado, Dept Pediat, Sect Neonatol, Mail Stop 8402,Educ 2 S,Box 6508,13121 E 17th Ave, Denver, CO 80045 USA. EM Beena.Kamath@uchsc.edu OI Kamath-Rayne, Beena/0000-0002-8482-4802 FU NICHD NIH HHS [T32 HD007186] NR 21 TC 14 Z9 14 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0743-8346 J9 J PERINATOL JI J. Perinatol. PD MAY PY 2008 VL 28 IS 5 BP 354 EP 360 DI 10.1038/sj.jp.7211918 PG 7 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 294MZ UT WOS:000255411500008 PM 18273030 ER PT J AU Tarica, DY Brajevic, FJ AF Tarica, Diane Yoshinobu Brajevic, Frank J. TI Duplication of an existing implant-supported bar for an auricular prosthesis SO JOURNAL OF PROSTHETIC DENTISTRY LA English DT Article ID OSSEOINTEGRATED IMPLANTS; FACIAL PROSTHESES; RETENTION; CONSTRUCTION C1 [Tarica, Diane Yoshinobu; Brajevic, Frank J.] Vet Adm Greater Los Angeles Healthcare Syst, Dent Dept 160, Los Angeles, CA 90073 USA. RP Tarica, DY (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Dent Dept 160, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dctarica@earthlink.net NR 17 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3913 J9 J PROSTHET DENT JI J. Prosthet. Dent. PD MAY PY 2008 VL 99 IS 5 BP 408 EP 409 DI 10.1016/S0022-3913(08)60092-X PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 303IR UT WOS:000256034700011 PM 18456053 ER PT J AU Bjorgvinsson, T Wetterneck, CT Powell, DM Chasson, GS Webb, SA Hart, J Heffelfinger, S Azzouz, R Entricht, TL Davidson, JE Stanley, MA AF Bjorgvinsson, Throstur Wetterneck, Chad T. Powell, Dana M. Chasson, Gregory S. Webb, Sarah A. Hart, John Heffelfinger, Susan Azzouz, Renee Entricht, Terri L. Davidson, Joyce E. Stanley, Melinda A. TI Treatment outcome for adolescent obsessive-compulsive disorder in a specialized hospital setting SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Article DE obsessive-compulsive disorder; cognitive-behavior therapy; treatment resistance; treatment effectiveness; inpatient; exposure and response prevention; Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS); Reynolds Adolescent Depression Scale, 2nd edition (RADS-2); State-Trait Anxiety Inventory (STAI); Thought Action Fusion Scale-Revised (TAF-R); the Intolerance of Uncertainty Scale (IUS-12); Obsessional Belief Questionnaire (OBQ-44) ID THOUGHT-ACTION FUSION; INTRUSIONS INVENTORY; PSYCHOMETRIC VALIDATION; BELIEFS QUESTIONNAIRE; SCALE; SYMPTOMS; EPIDEMIOLOGY; RELIABILITY; VALIDITY; VERSION AB Although few data are available concerning adolescents with obsessive-compulsive disorder (OCD), the existing literature suggests that cognitive-behavioral therapy (CBT) is the first-line treatment of choice for adolescents with mild to moderate OCD. A combination of CBT and serotonin reuptake inhibitors (SRIs) is recommended for more severe forms of OCD, based on the Expert Consensus Guidelines for the Treatment of Obsessive-Compulsive Disorder and the Pediatric OCD Treatment Study (POTS). Despite the effectiveness of CBT, a recent meta-analysis found that 27% of adolescent outpatients fail to show clinically significant improvement following CBT and many also fail to show improvement with pharmacotherapy. One alternative for those who do not improve with outpatient treatment is an intensive inpatient program. Within the last 10 years, two specialty hospitals have created programs that provide intensive CBT milieu treatment with multidisciplinary support (e.g., nursing, psychopharmacology) to treat adolescents with OCD. This naturalistic study describes treatment outcomes in 23 patients who received treatment in one of these programs between 2005 and 2006. Results suggest significant improvements on the majority of outcome measures, with 70% of the patients judged to meet criteria for clinically significant change. Thus, inpatient treatment appears potentially efficacious, although future controlled trials with larger samples are needed. C1 [Bjorgvinsson, Throstur; Powell, Dana M.; Chasson, Gregory S.; Hart, John; Heffelfinger, Susan; Azzouz, Renee; Entricht, Terri L.; Davidson, Joyce E.] Menninger Clin, Houston, TX 77080 USA. [Bjorgvinsson, Throstur; Powell, Dana M.; Heffelfinger, Susan; Davidson, Joyce E.; Stanley, Melinda A.] Baylor Coll Med, Houston, TX 77030 USA. [Stanley, Melinda A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Bjorgvinsson, T (reprint author), Menninger Clin, 2801 Gessner Rd, Houston, TX 77080 USA. EM tbjorgvinsson@menninger.edu OI Barrera, Terri/0000-0003-0854-4216 NR 38 TC 19 Z9 19 U1 3 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-4160 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD MAY PY 2008 VL 14 IS 3 BP 137 EP 145 PG 9 WC Psychiatry SC Psychiatry GA 310IS UT WOS:000256522700002 PM 18520782 ER PT J AU Kraus, CA Seignourel, P Balasubramanyam, V Snow, AL Wilson, NL Kunik, ME Schulz, PE Stanley, MA AF Kraus, Cynthia A. Seignourel, Paul Balasubramanyam, Valli Snow, A. Lynn Wilson, Nancy L. Kunik, Mark E. Schulz, Paul E. Stanley, Melinda A. TI Cognitive-behavioral treatment for anxiety in patients with dementia: two case studies SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Article DE dementia; anxiety; cognitive-behavioral therapy; caregivers; collaterals ID CONTROLLED CLINICAL-TRIAL; ALZHEIMERS-DISEASE; PRIMARY-CARE; MAJOR DEPRESSION; NURSING-HOME; OLDER-ADULTS; DISORDER; INTERVENTION; MANAGEMENT; THERAPY AB Anxiety is common in dementia and is associated with decreased independence and increased risk of nursing home placement. However, little is known about the treatment of anxiety in dementia. This article reports results from two patients who were treated with a modified version of cognitive-behavioral therapy for anxiety in dementia (CBT-AD). Modifications were made in the content, structure, and learning strategies of CBT to adapt skills to the cognitive limitations of these patients and include collaterals (i.e., family members, friends, or other caregivers) in the treatment process. The patients received education and awareness training and were taught the skills of diaphragmatic breathing, coping self-statements, exposure, and behavioral activation. The Clinical Dementia Rating (CDR) Scale was used to characterize dementia severity and determine eligibility for treatment (a CDR score of 0.5 to 2.0 was required for participation). Other measures included the Rating Anxiety in Dementia scale, the Neuropsychiatric Inventory Anxiety subscale, and the Mini International Neuropsychiatric Interview. Outcome data showed improvement in anxiety as measured by standardized rating scales. We conclude that CBT AD is potentially useful in treating anxiety in dementia patients and that this technique merits further study. C1 [Wilson, Nancy L.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Seignourel, Paul] Univ Texas Houston, Sch Med, Houston, TX USA. [Snow, A. Lynn] Univ Alabama, Tuscaloosa Vet Affairs Med Ctr, Tuscaloosa, AL 35487 USA. [Snow, A. Lynn] VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA. [Wilson, Nancy L.] Baylor Coll Med, Houston, TX 77030 USA. [Stanley, Melinda A.] Michael E DeBakey Vet Affairs Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX USA. RP Stanley, MA (reprint author), Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mstanley@bcm.tmc.edu FU NIMH NIH HHS [R34 MH078925, R34 MH078925-01A1, R34 MH078925-02]; PHS HHS [53932] NR 41 TC 22 Z9 23 U1 4 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-4160 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD MAY PY 2008 VL 14 IS 3 BP 186 EP 192 DI 10.1097/01.pra.0000320120.68928.e5 PG 7 WC Psychiatry SC Psychiatry GA 310IS UT WOS:000256522700010 PM 18520790 ER PT J AU Sacks, MB Flood, AM Dennis, MF Hertzberg, MA Beckham, JC AF Sacks, Matthew B. Flood, Amanda M. Dennis, Michelle F. Hertzberg, Michael A. Beckham, Jean C. TI Self-mutilative behaviors in male veterans with posttraumatic stress disorder SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE self-mutilation; self-injury; posttraumatic stress disorder; male veterans ID BORDERLINE PERSONALITY-DISORDER; SUICIDAL-BEHAVIOR; RISK-FACTORS; DRUG-DEPENDENCE; MENTAL-HEALTH; SKIN-PICKING; HARM; PTSD; POPULATION; PREVALENCE AB Self-mutilative behaviors (SMB) were examined in a sample of male veterans with posttraumatic stress disorder (PTSD). The primary objective was to determine the prevalence of SMB and any physical, cognitive, or affective antecedents and correlates for these behaviors. Participants included 509 male veterans with PTSD and levels of PTSD, depression, alcohol use, hostility, and impulsivity were evaluated to determine if these variables were related to SMB. Antecedents and sequelae of SMB were also examined to generate hypotheses regarding the functions of these behaviors. A second type of habit behavior, body-focused repetitive behaviors (BFRB), was also examined as part of the study. Findings indicated that veterans who engaged in either type of habit behavior were younger than those who did not engage in SMB or BFRB. Veterans reporting SMB also reported higher levels of PTSD, depression, hostility, and impulsivity compared to the BFRB and no-habit groups. Examination of habit antecedents and sequelae showed support for the automatic-positive reinforcement function of SMB. These findings are discussed in the context of research and treatment involving male veterans with PTSD who engage in SMB. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Hertzberg, Michael A.; Beckham, Jean C.] Durham Vet Affairs Med Ctr, Durham, NC 27705 USA. [Sacks, Matthew B.] San Francisco VA Med Ctr, San Francisco, CA USA. [Flood, Amanda M.; Dennis, Michelle F.; Hertzberg, Michael A.; Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Beckham, Jean C.] MIRECC, VA Mid Atlantic Reg, Durham, NC USA. RP Beckham, JC (reprint author), Durham Vet Affairs Med Ctr, 116B,508 Fulton St, Durham, NC 27705 USA. EM beckham@duke.edu FU NCI NIH HHS [R01 CA081595-06, 2R01CA081595, R01 CA081595]; NIDA NIH HHS [K24DA016388, K24 DA016388-05, R21DA019704, R21 DA019704, R21 DA019704-02, K24 DA016388]; NIMH NIH HHS [R01 MH062482, R01MH62482, R01 MH062482-04] NR 58 TC 27 Z9 27 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD MAY PY 2008 VL 42 IS 6 BP 487 EP 494 DI 10.1016/j.jpsychires.2007.05.001 PG 8 WC Psychiatry SC Psychiatry GA 284QG UT WOS:000254720300008 PM 17606271 ER PT J AU Zhao, WD Pan, JP Zhao, ZB Wu, Y Bauman, WA Cardozo, CP AF Zhao, Weidong Pan, Jiangping Zhao, Zingbo Wu, Yong Bauman, William A. Cardozo, Christopher P. TI Testosterone protects against dexamethasone-induced muscle atrophy, protein degradation and MAFbx upregulation SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article DE glucocorticods; muscle atrophy; testosterone; ubiquitin ligases; protein catabolism ID SKELETAL-MUSCLE; UBIQUITIN LIGASE; GENE-EXPRESSION; MEN; ATROGIN-1; SEPSIS; GLUCOCORTICOIDS; PROTEOLYSIS; MECHANISMS; PROTEASOME AB Administration of glucocorticoids in pharmacological amounts results in muscle atrophy due, in part, to accelerated degradation of muscle proteins by the ubiquitin-proteasome pathway. The ubiquitin ligase MAFbx is upregulated during muscle loss including that caused by glucocorticoids and has been implicated in accelerated muscle protein catabolism during such loss. Testosterone has been found to reverse glucocorticoid-induced muscle loss due to prolonged glucocorticoid administration. Here, we tested the possibility that testosterone would block muscle loss, upregulation of MAFbx, and protein catabolism when begun at the time of glucocorticoid administration. Coadministration of testosterone to male rats blocked dexamethasone-induced reduction in gastrocnernius muscle mass and upregulation of MAFbx mRNA levels. Administration of testosterone together with dexamethasone also prevented glucocorticoid induced upregulation of MAFbx mRNA levels and protein catabolism in C2C12 myotube expressing the androgen receptor. Half-life of MAFbx was not altered by testosterone, dexamethasone or the combination. Testosterone blocked dexamethasone-induced increases in activity of the human MAFbx promotor. The findings indicate that administration testosterone prevents glucocorticoid-induced muscle atrophy and suggest that this results, in part at least, from reductions in muscle protein catabolism and expression of MAFbx. (c) Published by Elsevier Ltd. C1 [Zhao, Weidong; Pan, Jiangping; Zhao, Zingbo; Wu, Yong; Bauman, William A.; Cardozo, Christopher P.] James J Peters VA Med Ctr, Dept Vet Affairs, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA. RP Cardozo, CP (reprint author), James J Peters VA Med Ctr, Dept Vet Affairs, Room 1E-02, Bronx, NY 10468 USA. EM Chris.Cardozo@mssm.edu NR 31 TC 40 Z9 41 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD MAY PY 2008 VL 110 IS 1-2 BP 125 EP 129 DI 10.1016/j.jsbmb.2008.03.024 PG 5 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 322XQ UT WOS:000257409000014 PM 18436443 ER PT J AU Maisto, SA Conigliaro, JC Gordon, AJ McGinnis, KA Justice, AC AF Maisto, Stephen A. Conigliaro, Joseph C. Gordon, Adam J. McGinnis, Kathleen A. Justice, Amy C. TI An experimental study of the agreement of self-administration and telephone administration of the timeline followback interview SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID ALCOHOL; BEHAVIOR; VETERANS AB Objective: The Timeline Followback (TLFB) interview has become state-of-the-science for the collection of retrospective selfreports of daily alcohol consumption. Such data are especially useful for addressing questions of the co-occurrence of quantity of alcohol consumption and other behaviors, such as HIV-related risky sex, on the event level. The purpose of this study was to determine if the TLFB could be used effectively by self-administration compared with the more costly telephone interview in a large, multisite observational study of HIV-positive and HIV-negative adults. Method: An experimental design was used to compare self-administered and telephone-administered TLFB modes in a subsample (N = 70) of the Veterans Aging Cohort Study, an ongoing longitudinal study of more than 6,000 HIV-positive and HIV-negative men and women presenting for treatment at eight Department of Veterans Affairs Infectious Disease or General Medicine clinics. Participants were randomly assigned to one of four experimental groups defined by mode and sequence of a TLFB administration on two occasions occurring within 1 week: telephone-telephone, telephone-self, self-telephone, and self-self. Results: Analyses showed no differences in median total number of drinks reported between modes of TLFB administration or sequence of mode of administration. The same findings held for classification of participants as "hazardous" drinkers. Additional analyses showed good-to-excel lent test-retest reliability of self-reports for both modes of TLFB administration. Conclusions: The data derived from this study provide strong experimental evidence for the utility of the self-administered, 30-day TLFB in collecting daily alcohol consumption in large observational studies of HIV-positive and HIV-negative individuals. C1 [Maisto, Stephen A.; Conigliaro, Joseph C.; Gordon, Adam J.; McGinnis, Kathleen A.; Justice, Amy C.] Syracuse Univ, Dept Psychol, Ctr Hlth & Behav, Syracuse, NY 13244 USA. [Conigliaro, Joseph C.] Univ Kentucky, Albert B Chandler Med Ctr, Lexington, KY 40536 USA. [Gordon, Adam J.; McGinnis, Kathleen A.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Justice, Amy C.] Yale Univ, Vet Aging Cohort Study, New Haven, CT USA. RP Maisto, SA (reprint author), Syracuse Univ, Dept Psychol, Ctr Hlth & Behav, 430 Huntington Hall, Syracuse, NY 13244 USA. EM samaisto@syr.edu FU NIAAA NIH HHS [U10 AA013566-08, U10 AA013566-07, U10 AA13566, U10 AA013566] NR 9 TC 16 Z9 16 U1 0 U2 3 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2008 VL 69 IS 3 BP 468 EP 471 PG 4 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 295OK UT WOS:000255483600017 PM 18432391 ER PT J AU Howe, W Reed, B Dellavalle, RP AF Howe, William Reed, Barbara Dellavalle, Robert P. TI Adding over-the-counter dihydroxyacetone self-tanners to sunscreen regimens to increase ultraviolet A light protection SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter C1 [Howe, William; Reed, Barbara; Dellavalle, Robert P.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Dellavalle, RP (reprint author), Dept Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucbsc.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X NR 6 TC 2 Z9 2 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2008 VL 58 IS 5 BP 894 EP 894 DI 10.1016/j.jaad.2008.02.013 PG 1 WC Dermatology SC Dermatology GA 292VA UT WOS:000255293000025 PM 18423264 ER PT J AU Handler, SM Hanlon, JT Perera, S Roumani, YF Nace, DA Fridsma, DB Saul, MI Castle, NG Studenski, SA AF Handler, Steven M. Hanlon, Joseph T. Perera, Subashan Roumani, Yazan F. Nace, David A. Fridsma, Douglas B. Saul, Melissa I. Castle, Nicholas G. Studenski, Stephanie A. TI Consensus list of signals to detect potential adverse drug reactions in nursing homes SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE adverse drug events; adverse drug reactions; nursing homes; Delphi technique ID HEALTH INFORMATION NETWORK; COMPUTERIZED SURVEILLANCE; RESPONSE RATES; EVENTS; CARE; INDICATORS; OUTPATIENTS; MORBIDITY; MONITOR; QUALITY AB OBJECTIVES: To develop a consensus list of agreed-upon laboratory, pharmacy, and Minimum Data Set signals that a computer system can use in the nursing home to detect potential adverse drug reactions (ADRs). DESIGN: Literature search for potential ADR signals, followed by an internet-based, a two-round, modified Delphi survey. SETTING: A nationally representative survey of experts in geriatrics. PARTICIPANTS: Panel of 13 physicians, 10 pharmacists, and 13 advanced practitioners. MEASUREMENTS: Mean score and 95% confidence interval (CI) for each of 80 signals rated on a 5-point Likert scale (5=strong agreement with likelihood of indicating potential ADRs). Consensus agreement indicated by a lower-limit 95% CI of 4.0 or greater. RESULTS: Panelists reached consensus agreement on 40 signals: 15 laboratory and medication combinations, 12 medication concentrations, 10 antidotes, and three Resident Assessment Protocols (RAPs). Highest consensus scores (4.6, 95% CI=4.4-4.9 or 4.4-4.8) were for naloxone when taking opioid analgesics; phytonadione when taking warfarin; dextrose, glucagon, or liquid glucose when taking hypoglycemic agents; medication-induced hypoglycemia; supratherapeutic international normalized ratio when taking warfarin; and triggering the Falls RAP when taking certain medications. CONCLUSION: A multidisciplinary expert panel was able to reach consensus agreement on a list of signals to detect potential ADRs in nursing home residents. The results of this study can be used to prioritize an initial list of signals to be included in paper- or computer-based methods for potential ADR detection. C1 [Handler, Steven M.; Fridsma, Douglas B.; Saul, Melissa I.] Vet Affairs Pittsburgh Healthcare Syst, Sch Med, Dept Biomed Informat, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Hanlon, Joseph T.; Studenski, Stephanie A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Handler, Steven M.; Hanlon, Joseph T.; Perera, Subashan; Roumani, Yazan F.; Nace, David A.; Studenski, Stephanie A.] Vet Affairs Pittsburgh Healthcare Syst, Div Geriatr Med, Dept Med, Pittsburgh, PA USA. [Perera, Subashan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA. [Castle, Nicholas G.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA. RP Handler, SM (reprint author), Univ Pittsburgh, Div Geriatr Med, Dept Med, 3471 5th Ave,Suite 500, Pittsburgh, PA 15213 USA. EM handler@pitt.edu RI Nace, David/D-2638-2014; Perera, Subashan/D-7603-2014 OI Handler, Steven/0000-0002-3940-3224 FU NCRR NIH HHS [1 KL2 RR024154-01, KL2 RR024154]; NIA NIH HHS [R01 AG027017, 5T32AG021885, P30 AG024827, P30 AG024827-05, P30AG024827, R01AG027017, T32 AG021885] NR 52 TC 20 Z9 21 U1 6 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2008 VL 56 IS 5 BP 808 EP 815 DI 10.1111/j.1532-5415.2008.01665.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 295PI UT WOS:000255486000004 PM 18363678 ER PT J AU Connor, KI McNeese-Smith, DK Vickrey, BG van Servellen, GM Chang, BL Lee, ML Vassar, SD Chodosh, J AF Connor, Karen I. McNeese-Smith, Donna K. Vickrey, Barbara G. van Servellen, Gwen M. Chang, Betty L. Lee, Martin L. Vassar, Stefanie D. Chodosh, Joshua TI Determining care management activities associated with mastery and relationship strain for dementia caregivers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE mastery; relationship strain; care management; dementia; family ID ALZHEIMERS-DISEASE; BEHAVIOR PROBLEMS; INTERVENTION; HEALTH; PREDICTORS; SYMPTOMS; QUALITY; IMPACT AB OBJECTIVES: To identify specific care management activities within a dementia care management intervention that are associated with 18-month change in caregiver mastery and relationship strain. DESIGN: Exploratory analysis, using secondary data (care management processes and caregiver outcomes) from the intervention arm of a clinic-level randomized, controlled trial of a dementia care management quality improvement program. SETTING: Nine primary care clinics in three managed care and fee-for-service southern California healthcare organizations. PARTICIPANTS: Two hundred thirty-eight pairs: individuals with dementia and their informal, nonprofessional caregivers. MEASUREMENTS: Care management activity types extracted from an electronic database were used as predictors of caregiver mastery and relationship strain, which were measured through mailed surveys. Multivariable linear regression models were used to predict caregiver mastery and relationship strain. RESULTS: For each care manager home environment assessment, caregiver mastery increased 4 points (range 0-100, mean +/- standard deviation 57.1 +/- 26.6, 95% confidence interval (CI)=2.4-5.7; P=.001) between baseline and 18 months. For every action linking caregivers to community agencies for nonspecific needs, caregiver mastery decreased 6.2 points (95% CI=-8.5 to -3.9; P <.001). No other care management activities were significantly associated with this outcome, and no specific activities were associated with a change in caregiver relationship strain. CONCLUSION: Home assessments for specific needs of caregivers and persons with dementia are associated with improvements in caregivers' sense of mastery. Future work is needed to determine whether this increase is sustained over time and decreases the need for institutionalization. C1 [Connor, Karen I.; McNeese-Smith, Donna K.; van Servellen, Gwen M.; Chang, Betty L.] Greater Los Angeles Vet Affairs Med Ctr, Sch Nursing, Los Angeles, CA USA. [Connor, Karen I.; Vickrey, Barbara G.; Vassar, Stefanie D.] Greater Los Angeles Vet Affairs Med Ctr, Dept Neurol, Los Angeles, CA USA. [Lee, Martin L.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Lee, Martin L.] Vet Affairs Greater Los Angeles, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Univ Calif Los Angeles, Multi Campus Program Geriatr Med & Gerontol, Los Angeles, CA USA. [Chodosh, Joshua] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Connor, KI (reprint author), C-109 RNRC,Box 951769, Los Angeles, CA 90095 USA. EM kiconnor@ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 NR 34 TC 11 Z9 13 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2008 VL 56 IS 5 BP 891 EP 897 DI 10.1111/j.1532-5415.2008.01643.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 295PI UT WOS:000255486000016 PM 18384590 ER PT J AU Ries, ML Carlsson, CM Rowley, HA Sager, MA Gleason, CE Asthana, S Johnson, SC AF Ries, Michele L. Carlsson, Cynthia M. Rowley, Howard A. Sager, Mark A. Gleason, Carey E. Asthana, Sanjay Johnson, Sterling C. TI Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: A review SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE Alzheimer's disease; mild cognitive impairment; MRI ID VOXEL-BASED MORPHOMETRY; EARLY ALZHEIMERS-DISEASE; TEMPORAL-LOBE ATROPHY; GRAY-MATTER LOSS; ENTORHINAL CORTEX; HIPPOCAMPAL ATROPHY; PREDICTS DEMENTIA; MRI; MEMORY; AD AB Given the predicted increase in prevalence of Alzheimer's disease (AD) in the coming decades, early detection and intervention in persons with the predementia condition known as mild cognitive impairment (MCI) is of paramount importance. Recent years have seen remarkable advances in the application of neuroimaging and other biomarkers to the study of MCI. This article reviews the most recent developments in the use of magnetic resonance imaging (MRI) to characterize brain changes and to prognosticate clinical outcomes of patients with MCI. The review begins with description of methods and findings in structural MRI research, delineating findings regarding both gross atrophy and microstructural brain changes in MCI. Second, we describe the most recent findings regarding brain function in MCI, enumerating findings from functional MRI and brain perfusion studies. Third, we will make recommendations regarding the current clinical use of MRI in identification of MCI. As a conclusion, we will look to the future of neuroimaging as a tool in early AD detection. C1 [Ries, Michele L.; Carlsson, Cynthia M.; Gleason, Carey E.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. [Ries, Michele L.; Carlsson, Cynthia M.; Rowley, Howard A.; Sager, Mark A.; Gleason, Carey E.; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sect Geriatr, Madison, WI USA. RP Ries, ML (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM mlr@medicine.wisc.edu FU NCRR NIH HHS [8K12RR023268-02]; NIA NIH HHS [R01 AG021155-05, R01 AG021155-03, L30 AG026886-02, R01 AG021155, R01 AG021155-02, R01 AG021155-04, L30 AG026886-01] NR 81 TC 71 Z9 74 U1 0 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2008 VL 56 IS 5 BP 920 EP 934 DI 10.1111/j.1532-5415.2008.01684.x PG 15 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 295PI UT WOS:000255486000021 PM 18410325 ER PT J AU Flaherty, JH Rudolph, J Shay, K Kamholz, B Boockvar, KS Shaughnessy, M Shapiro, R Stein, J Weir, C Edes, T AF Flaherty, Joseph H. Rudolph, James Shay, Kenneth Kamholz, Barbara Boockvar, Kenneth S. Shaughnessy, Marianne Shapiro, Rita Stein, Joan Weir, Charlene Edes, Thomas TI Delirium as the sixth vital sign - Response to the letter to the editor by Bellelli and Trabucchi SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Letter C1 [Flaherty, Joseph H.] St Louis Univ, Sch Med, St Louis VA Med Ctr, Ctr Geriatr Res Educ & Clin, St Louis, MO 63103 USA. [Rudolph, James] Harvard Univ, Dept Med, Brigham & Womens Hosp,Ctr Geriatr Res Educ & Clin, VA Boston Healthcare Syst Div Aging, Boston, MA USA. [Shay, Kenneth] VA Med Ctr, Off Geriatr & Extended Care, Ann Arbor, MI USA. [Kamholz, Barbara] Univ Michigan, VA Ann Arbor Hlth Syst, Ann Arbor, MI USA. [Boockvar, Kenneth S.] James J Peter VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Shaughnessy, Marianne] Boston VA Med Ctr, Ctr Geriatr Res Educ & Clin, CRNP, Baltimore, MD USA. [Shapiro, Rita] VA Chicago Hlth Care Syst, Chicago, IL USA. [Weir, Charlene] Salt Lake City VA Med Ctr, Ctr Geriatr Res Educ & Clin, Salt Lake City, UT USA. [Edes, Thomas] US Dept Vet Affairs, Off Geriatr & Extended Care, Home & Commun Based Care, Washington, DC USA. [Stein, Joan] VA Ann Arbor Hlth Syst, Ann Arbor, MI USA. RP Flaherty, JH (reprint author), St Louis Univ, Sch Med, St Louis VA Med Ctr, Ctr Geriatr Res Educ & Clin, St Louis, MO 63103 USA. NR 2 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAY PY 2008 VL 9 IS 4 BP 281 EP 282 DI 10.1016/j.jamda.2008.02.001 PG 2 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 313JJ UT WOS:000256736600015 ER PT J AU Korgaonkar, SN Feng, XB Ross, MD Lu, TC D'Agati, V Iyengar, R Klotman, PE He, JCJ AF Korgaonkar, Sonal Navin Feng, Xiaobei Ross, Michael D. Lu, Ting-Chi D'Agati, Vivette Iyengar, Ravi Klotman, Paul E. He, John Cijiang TI HIV-1 upregulates VEGF in podocytes SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the American-Society-of-Nephrology CY NOV 14-19, 2006 CL San Diego, CA SP Amer Soc Nephrol ID ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; IN-VIVO; NEF; GLOMERULOSCLEROSIS; SURVIVAL; DEDIFFERENTIATION; PROLIFERATION; ANGIOGENESIS; NEPHROPATHY AB HIV-associated nephropathy (HIVAN) is characterized by collapsing FSGS. Because transgenic mice with podocyte-specific overexpression of the vascular endothelial growth factor 164 (VEGF(164)) isoform also develop collapsing FSGS, we sought to determine whether VEGF plays a role in HIVAN. Compared with controls, immunohistochemistry revealed that kidneys from HIV-1-transgenic mice (Tg26) and from patients with HIVAN had greater expression of both VEGF and its transcriptional regulator, hypoxia-inducible factor 2 alpha (HIF-2 alpha). Similarly, mRNA and protein levels of VEGF and HIF-2a were increased in HIV-infected podocytes in vitro, and this transcriptional upregulation was found to be stimulated by the HIV viral protein Nef in a Src kinase- and Stat3-dependent manner. HIV-1 also upregulated VEGFR2 and its co-receptor neuropilin-1 and suppressed the expression of semaphorin 3a in the podocyte. Exogenous VEGF stimulated proliferation and de-differentiation of podocytes, which are features of collapsing FSGS, and VEGFR2 neutralizing antibodies reversed these features in podocytes infected with HIV-1 or isolated from Tg26 mice. In conclusion, HIV-1 induces VEGF and VEGFR2 expression in podocytes, and this may be a critical step in the pathogenesis of HIVAN. C1 [Korgaonkar, Sonal Navin; Ross, Michael D.; Lu, Ting-Chi; Klotman, Paul E.; He, John Cijiang] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Iyengar, Ravi] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA. [Lu, Ting-Chi; He, John Cijiang] James J Peters VA Med Ctr, Bronx, NY USA. [D'Agati, Vivette] Columbia Univ, Dept Pathol, New York, NY USA. [Feng, Xiaobei] Ruijin Hosp, Dept Nephrol, Shanghai, Peoples R China. RP He, JCJ (reprint author), 1 Gustave Levy Pl, New York, NY 10029 USA. EM cijiang.he@mssm.edu FU NIDDK NIH HHS [R01 DK038761, P01 DK056492, K08 DK079781, DK038761, DK056492, R01 DK078897, DK079781, F32 DK076523, DK078897, DK076523, DK065495, K08 DK065495]; NIGMS NIH HHS [R01 GM054508] NR 30 TC 41 Z9 44 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAY PY 2008 VL 19 IS 5 BP 877 EP 883 DI 10.1681/ASN2007050629 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 294RN UT WOS:000255423300011 PM 18443354 ER PT J AU Hallam, BJ Brown, WS Ross, C Buckwalter, JG Bigler, ED Tschanz, JT Norton, MC Welsh-Bohmer, KA Breitner, JCS AF Hallam, Bradley J. Brown, Warren S. Ross, Chris Buckwalter, J. Galen Bigler, Erin D. Tschanz, Joann T. Norton, Maria C. Welsh-Bohmer, Kathleen A. Breitner, John C. S. CA Cache Cty Investigators TI Regional atrophy of the corpus callosum in dementia SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Alzheimer's disease; vascular dementia; corpus callosum; neurodegnerative diseases; magnetic resonance imaging; mild cognitive impairment; MRI morphology; corpus callosum regions; brain atrophy; white matter degeneration ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE CERAD; PROGRESSIVE SUPRANUCLEAR PALSY; TEMPORAL-LOBE ATROPHY; NEUROPSYCHOLOGICAL ASSESSMENT; CORTICAL HYPOMETABOLISM; FRONTOTEMPORAL DEMENTIA; CACHE COUNTY; REGISTRY; PATTERN AB The regional distribution of degeneration of the corpus callosum (CC) in dementia is not yet clear. This Study compared regional CC size in participants (n = 179) from the Cache County Memory and Aging Study. Participants represented a range of cognitive function: Alzheimer's disease (AD). vascular dementia (VaD). mild ambiguous (MA-cognitive problems. but not severe enough for diagnosis of dementia), and health), older adults. CC Outlines obtained from midsagittal magnetic resonance images were divided into 99 equally spaced widths. Factor analysis of these callosal widths identified 10 callosal regions. Multivariate analysis of variance revealed significant group differences for anterior and posterior callosal regions. Post-hoc pairwise comparisons of CC regions in patient groups as compared to the control group (controlling for age) revealed trends toward smaller anterior and posterior re-ions, but riot all were statistically significant. As compared to controls, significantly smaller anterior and posterior CC regions were found in the AD group: significantly smaller anterior CC regions in the VaD group: but no significant CC regional differences in the MA group. Findings suggest that dementia-related CC atrophy occurs primarily in the anterior and posterior portions. C1 [Hallam, Bradley J.; Brown, Warren S.; Ross, Chris; Buckwalter, J. Galen] Fuller Grad Sch Psychol, Ctr Biopsychosocial Res, Travis Res Inst, Pasadena, CA 91101 USA. [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Brain Imaging & Behav Lab, Provo, UT 84602 USA. [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Brain Imaging & Behav Lab, Provo, UT 84602 USA. [Buckwalter, J. Galen] eHarmony, Res & Dev, Pasadena, CA USA. [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA. [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA. [Tschanz, Joann T.; Norton, Maria C.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Tschanz, Joann T.; Norton, Maria C.] Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. [Welsh-Bohmer, Kathleen A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Welsh-Bohmer, Kathleen A.] Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA. [Breitner, John C. S.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Breitner, John C. S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. [Hallam, Bradley J.] Univ British Columbia, Dept Med, Div Neurol, Vancouver, BC V6T 1W5, Canada. RP Brown, WS (reprint author), Fuller Grad Sch Psychol, Ctr Biopsychosocial Res, Travis Res Inst, 180 N Oakland Ave, Pasadena, CA 91101 USA. EM wsbrown@fuller.edu RI Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013 FU National Institutes of Health [AG-11380, MH-14592]; Ira Fulton Foundation FX This research was supported in part by National Institutes of Health Grants AG-11380 and MH-14592 and the Ira Fulton Foundation. Patricia Cowell is gratefully acknowled for providing LIS With a copy of KSS Stereology, and David Wright for rewriting the source code for a Java based application. Lastly, the technical assistance of Tracy J. Abildskov and the Support of the entire Cache County, Utah, Memory and Aging research team are gratefully acknowledged. NR 67 TC 22 Z9 22 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAY PY 2008 VL 14 IS 3 BP 414 EP 423 DI 10.1017/S1355617708080533 PG 10 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 338VK UT WOS:000258537300007 PM 18419840 ER PT J AU Leung, WW Bowie, CR Harvey, PD AF Leung, Winnie W. Bowie, Christopher R. Harvey, Philip D. TI Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE cognition; normal range; outcome; adjustment; social behavior; independent living ID DOUBLE-BLIND; NEUROCOGNITIVE DEFICITS; SOCIAL COGNITION; MENTAL-ILLNESS; SKILLS; PERFORMANCE; CRITERIA; TRIAL; EMPLOYMENT; OLANZAPINE AB Cognitive impairments in schizophrenia are well documented and correlated with functional disability. Although some patients demonstrate normal neuropsychological (NP) functioning, little is known about their functional disability. We examined the cross-sectional functional implications of NP normality and symptomatic remission in older Outpatients diagnosed with schizophrenia or schizoaffective disorder, who were administered a NP battery and performance-based measures Of functional and social competence, with their real-world functioning rated by case managers. NP status was classified by the General Deficit Score (GDS) and remission status was based on the Positive and Negative Syndrome Scale (PANSS), yielding four subsamples of patients: NP normal-remitted (n = 21), NP normal-symptomatic (n = 22), NP impaired-remitted (n = 90), and NP impaired-symptomatic (n = 97). NP normal patients demonstrated better functional and social competence and better ratings of real world functioning, after controlling for premorbid abilities. However, compared to normative date, NP normal patients manifested disability in several real-world domains, including residential status. These results suggest that NP status is a better predictor of functional outcome then symptom status or the interaction of the two factors. The disability seen in NP normal cases indicates that factors other than cognitive impairments may determine aspects of everyday outcomes in schizophrenia. C1 [Leung, Winnie W.] VISN Mental Illness Res Educ & Clin Ctr MIRECC 3, Dept Vet Affairs, Bronx, NY USA. [Leung, Winnie W.; Bowie, Christopher R.; Harvey, Philip D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Bowie, Christopher R.] James J Peters Bronx VA Med Ctr, Bronx, NY USA. [Harvey, Philip D.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA. RP Leung, WW (reprint author), New York State Psychiat Inst & Hosp, Lieber Ctr Schizophrenia Res & Treatment, 1051 Riverside Dr,Unit 14, New York, NY 10032 USA. EM leungwi@pi.cpmc.columbia.edu FU NIMH [MH 63116]; Conte Neuroscience Center [NIMH MH 36692] FX This research was supported by NIMH Grant Number MH 63116 to Dr. Harvey, the Mt. Sinai Silvio Conte Neuroscience Center (NIMH MH 36692: KL Davis PI), and the VA VISN 3 MIRECC. NR 61 TC 51 Z9 52 U1 8 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAY PY 2008 VL 14 IS 3 BP 479 EP 488 DI 10.1017/S1355617708080600 PG 10 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 338VK UT WOS:000258537300013 PM 18419846 ER PT J AU Hamilton, RJ Aronson, WJ Terris, MK Kane, CJ Presti, JC Amling, CL Freedland, SJ AF Hamilton, Robert J. Aronson, William J. Terris, Martha K. Kane, Christopher J. Presti, Joseph C., Jr. Amling, Christopher L. Freedland, Stephen J. TI Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: Results from the SEARCH database SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; neoplasm recurrence; local; prostatectomy; prostate-specific antigen ID CANCER-SPECIFIC MORTALITY; RADIATION-THERAPY; HORMONAL-THERAPY; OBESITY; RADIOTHERAPY; PROGRESSION AB Purpose: Prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy is a powerful predictor of prostate cancer specific and overall death. To calculate prostate specific antigen doubling time requires multiple prostate specific antigen determinations that are unaltered by secondary therapy and separated by sufficient time. Physicians and patients may be unwilling to wait before starting secondary therapy, especially for high risk recurrences. Hence, those with calculable prostate specific antigen doubling time may represent a select lower risk group relative to all men with biochemical recurrence. Materials and Methods: We compared clinical and pathological features between patients with and without calculable prostate specific antigen doubling time. We assessed time trends in the proportion with calculable prostate specific antigen doubling time in 535 patients with biochemical recurrence after radical prostatectomy at 5 Veterans Affairs medical centers comprising the SEARCH (Shared Equal Access Regional Cancer Hospital) database between 1988 and 2003. Results: Prostate specific antigen doubling time was not calculable in 187 patients (35%) due to secondary therapy in 155 (83%). With time the proportion of patients with calculable prostate specific antigen doubling time decreased significantly (p < 0.001). Adverse pathological features, more rapid time to recurrence, higher body mass index and differing surgical centers were associated with not having a calculable prostate specific antigen doubling time. Of all men with recurrence in the most recent year of analysis the adjusted probability of having a calculable prostate specific antigen doubling time was only 43%, that is 61% in patients with favorable pathological results but only 30% in those with seminal vesicle invasion. Conclusions: Those with calculable prostate specific antigen doubling time represented a select, lower risk cohort and the proportion of patients with calculable prostate specific antigen doubling time decreased with time. This highlights the need for alternative markers in men with recurrent prostate cancer because one of our best current markers, prostate specific antigen doubling time, is only available in a limited number of patients. C1 [Hamilton, Robert J.; Freedland, Stephen J.] Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC 27710 USA. [Hamilton, Robert J.; Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Hamilton, Robert J.] Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada. [Aronson, William J.] Univ Calif Los Angeles, Dept Surg, Urol Sect, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Kane, Christopher J.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. [Kane, Christopher J.] Vet Affairs Med Ctr, Urol Sect, San Francisco, CA 94121 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr Palo Alto, Urol Sect, Palo Alto, CA USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Vet Affairs Med Ctr, Augusta, GA 30912 USA. [Amling, Christopher L.] Univ Alabama, Dept Urol, Birmingham, AL USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Box 2626 DUMC, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Hamilton, Robert/0000-0002-6715-5934; Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50 CA092131, P50 CA092131-01A1, P50 CA92131-01A1, R01 CA100938, R01CA100938] NR 20 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD MAY PY 2008 VL 179 IS 5 BP 1785 EP 1789 DI 10.1016/j.juro.2008.01.040 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 288SE UT WOS:000255005300038 PM 18343434 ER PT J AU Jayachandran, J Banez, LL Levy, DE Aronson, WJ Terris, MK Presti, JC Amling, CL Kane, CJ Freedland, SJ AF Jayachandran, Jayakrishnan Banez, Lionel L. Levy, Donna E. Aronson, William J. Terris, Martha K. Presti, Joseph C., Jr. Amling, Christopher L. Kane, Christopher J. Freedland, Stephen J. CA SEARCH Database Study Grp TI Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: Results from the SEARCH database SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; prostatectomy; prostate-specific antigen; risk ID RETROPUBIC PROSTATECTOMY; ADJUVANT THERAPY; CANCER; PROGRESSION; RADIOTHERAPY; SELECTION; IMPACT; TRIAL AB Purpose: In men with extracapsular disease or positive surgical margins after radical prostatectomy immediate adjuvant therapy decreases the risk of biochemical recurrence at the cost of increased toxicity. We further stratified these men into a low risk group in which watchful waiting after surgery may be preferred and a high risk cohort in which adjuvant therapy may be preferred. Materials and Methods: We performed a retrospective analysis of the records of 902 men treated with radical prostatectomy in the Shared Equal-Access Regional Cancer Hospital (SEARCH) database between 1988 and 2007 with positive surgical margins and/or extracapsular disease without seminal vesicle invasion or lymph node metastasis. The significant independent predictors of biochemical recurrence were determined using a multivariate Cox proportional hazards model. Based on the recurrence risk generated from the multivariate Cox proportional hazards regression model we generated tables to estimate the risk of recurrence-free survival 1, 3 and 5 years after surgery. Results: At a median of 3 years of followup, 346 patients (39%) had biochemical recurrence. On multivariate analysis the significant predictors of biochemical recurrence were age more than 60 years, prostate specific antigen more than 10 ng/ml, Gleason score 4 + 3 and 8-10, 2 or more sites of positive surgical margins and prostate specimen weight 30 gm or less. As determined by the concordance index, the overall predictive accuracy of the model was 0.67, while it was 0.60 for the postoperative Kattan nomogram in this patient population. Conclusions: We have developed a simple instrument that, once validated, may aid in the postoperative decision making process for men at intermediate risk for recurrence after prostatectomy. C1 [Jayachandran, Jayakrishnan; Banez, Lionel L.; Levy, Donna E.; Freedland, Stephen J.] Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC USA. [Jayachandran, Jayakrishnan; Banez, Lionel L.; Levy, Donna E.; Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Div Urol Surg, Durham, NC USA. [Jayachandran, Jayakrishnan; Banez, Lionel L.; Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Urol Sect, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Kane, Christopher J.] Vet Affairs Med Ctr, Urol Sect, San Francisco, CA 94121 USA. [Kane, Christopher J.] Univ Calif San Francisco, Dept Urol, San Francisco Sch Med, San Francisco, CA 94143 USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Terris, Martha K.] Vet Affairs Med Ctr Augusta, Urol Sect, Augusta, GA 30912 USA. [Amling, Christopher L.] Univ Alabama, Dept Urol, Birmingham, AL USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Box 2626 DUMC, Durham, NC 27706 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50 CA092131, P50 CA092131-07, P50 CA92131-01A1, R01 CA100938, R01CA100938] NR 20 TC 23 Z9 24 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD MAY PY 2008 VL 179 IS 5 BP 1791 EP 1796 DI 10.1016/j.juro.2008.01.043 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 288SE UT WOS:000255005300040 PM 18343426 ER PT J AU Norton, MC Singh, A Skoog, I Corcoran, C Tschanz, JT Zandi, PP Breitner, JCS Welsh-Bohmer, KA Steffens, DC AF Norton, Maria C. Singh, Archana Skoog, Ingmar Corcoran, Christopher Tschanz, JoAnn T. Zandi, Peter P. Breitner, John C. S. Welsh-Bohmer, Kathleen A. Steffens, David C. CA Cache Cty Investigators TI Church attendance and new episodes of major depression in a community study of older adults: The Cache County Study SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE church attendance; depression; Latter Day Saints ID DIAGNOSTIC-INTERVIEW-SCHEDULE; LATE-LIFE DEPRESSION; MENTAL-HEALTH; GERIATRIC DEPRESSION; ELDERLY POPULATION; GENDER-DIFFERENCES; FOLLOW-UP; RELIGIOSITY; PREVALENCE; AGE AB We examined the relation between church attendance, membership in the Church of Jesus Christ of Latter-Day Saints (LDS), and major depressive episode, in a population-based study of aging and dementia in Cache County, Utah. Participants included 2,989 nondemented individuals aged between 65 and 100 years who were interviewed initially in 1995 to 1996 and again in 1998 to 1999. LDS church members reported twice the rate of major depression that non-LDS members did (odds ratio = 2.56, 95% confidence interval = 1.07-6.08). Individuals attending church weekly or more often had a significantly lower risk for major depression. After controlling for demographic and health variables and the strongest predictor of future episodes of depression, a prior depression history, we found that church attendance more often than weekly remained a significant protectant (odds ratio = 0.51, 95% confidence interval = 0.28-0.92). Results suggest that there may be a threshold of church attendance that is necessary for a person to garner long-term protection from depression. We discuss sociological factors relevant to LDS culture. C1 [Norton, Maria C.; Singh, Archana] Utah State Univ, Dept Family Consumer & Human Dev, Cache Cty Study Memory Hlth & Aging, Logan, UT 84322 USA. [Norton, Maria C.; Tschanz, JoAnn T.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Corcoran, Christopher] Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA. [Norton, Maria C.; Corcoran, Christopher; Tschanz, JoAnn T.] Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. [Skoog, Ingmar] Univ Gothenburg, Inst Clin Neurosci, Gothenburg, Sweden. [Zandi, Peter P.] Johns Hopkins Univ, Dept Mental Hyg, Baltimore, MD USA. [Breitner, John C. S.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Breitner, John C. S.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Welsh-Bohmer, Kathleen A.; Steffens, David C.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. [Welsh-Bohmer, Kathleen A.] Duke Univ, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA. RP Norton, MC (reprint author), Utah State Univ, Dept Family Consumer & Human Dev, Cache Cty Study Memory Hlth & Aging, 4440 Old Main Hill, Logan, UT 84322 USA. EM maria.norton@usu.edu RI Corcoran, Chris/F-2155-2010; Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013 FU NIA NIH HHS [AG 11380, AG 21136, R01 AG011380, R01 AG011380-13, R01 AG021136, R01 AG021136-05] NR 67 TC 9 Z9 9 U1 5 U2 8 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5014 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAY PY 2008 VL 63 IS 3 BP P129 EP P137 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA 316CF UT WOS:000256925800002 PM 18559677 ER PT J AU Van Deerlin, VM Leverenz, JB Bekris, LM Bird, TD Yuan, WX Elman, LB Clay, D Wood, EM Chen-Plotkin, AS Martinez-Lage, M Steinbart, E McCluskey, L Grossman, M Neumann, M Wu, IL Yang, WS Kalb, R Galasko, DR Montine, TJ Trojanowski, JQ Lee, VMY Schellenberg, GD Yu, CE AF Van Deerlin, Vivianna M. Leverenz, James B. Bekris, Lynn M. Bird, Thomas D. Yuan, Wuxing Elman, Lauren B. Clay, Dona Wood, Elisabeth McCarty Chen-Plotkin, Alice S. Martinez-Lage, Maria Steinbart, Ellen McCluskey, Leo Grossman, Murray Neumann, Manueia Wu, I-Lin Yang, Wei-Shiung Kalb, Robert Galasko, Douglas R. Montine, Thomas J. Trojanowski, John Q. Lee, Virginia M-Y Schellenberg, Gerard D. Yu, Chang-En TI TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis SO LANCET NEUROLOGY LA English DT Article ID FRONTOTEMPORAL LOBAR DEGENERATION; MOTOR-NEURON DISEASE; NUCLEAR FACTOR TDP-43; ALPHA-SYNUCLEIN; CHROMOSOME 9P; DEMENTIA; PROTEIN; EXON-9; ALS; IMPAIRMENT AB Background TDP-43 is a major component of the ubiquitinated inclusions that characterise amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) with ubiquitin inclusions (FTLD-U). TDP-43 is an RNA-binding and DNA-binding protein that has many functions and is encoded by the TAR DNA-binding protein gene (TARDBP) on chromosome 1. Our aim was to investigate whether TARDBP is a candidate disease gene for familial ALS that is not associated with mutations in superoxide dismutase 1 (SOD1). Methods TARDBP was sequenced in 259 patients with ALS, FTLD, or both. We used TaqMan-based SNP genotyping to screen for the identified variants in control groups matched to two kindreds of patients for age and ethnic origin. Additional clinical, genetic, and pathological assessments were made in these two families. Findings We identified two variants in TARDBP, which would encode Gly290Ala and Gly298Ser forms of TDP-43, in two kindreds with familial ALS. The variants seem to be pathogenic because they co-segregated with disease in both families, were absent in controls, and were associated with TDP-43 neuropathology in both members of one of these families for whom CNS tissue was available. Interpretation The Gly290Ala and Gly298Ser mutations are located in the glycine-rich domain of TDP-43, which regulates gene expression and mediates protein-protein interactions such as those with heterogeneous ribonucleoproteins. Owing to the varied and important cellular functions of TDP-43, these mutations might cause neurodegeneration through both gains and losses of function. The finding of pathogenic mutations in TARDBP implicates TDP-43 as an active mediator of neurodegeneration in TDP-43 proteinopathies, a class of disorder that includes ALS and FTLD-U. Funding National Institutes of Health (AG10124, AG17586, AG005136-22, PO1 AG14382), Department of Veterans Affairs, Friedrich-Baur Stiftung (0017/2007), US Public Health Service, ALS Association, and Fundacio 'la Caixa'. C1 [Van Deerlin, Vivianna M.; Yuan, Wuxing; Clay, Dona; Wood, Elisabeth McCarty; Chen-Plotkin, Alice S.; Martinez-Lage, Maria; Trojanowski, John Q.; Lee, Virginia M-Y] Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Elman, Lauren B.; McCluskey, Leo; Grossman, Murray] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Van Deerlin, Vivianna M.; Trojanowski, John Q.; Lee, Virginia M-Y] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA. [Bekris, Lynn M.; Bird, Thomas D.; Steinbart, Ellen; Schellenberg, Gerard D.; Yu, Chang-En] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Yu, Chang-En] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Neumann, Manueia] Univ Munich, Ctr Neuropathol & Pr Res, Munich, Germany. [Wu, I-Lin; Yang, Wei-Shiung] Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan. [Wu, I-Lin; Yang, Wei-Shiung] Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taipei, Taiwan. [Kalb, Robert] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Galasko, Douglas R.] Univ San Diego, Dept Neurosci, La Jolla, CA USA. RP Schellenberg, GD (reprint author), Vet Adm Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM zachdad@u.washington.edu RI Neumann, Manuela/F-6558-2011 OI Martinez-Lage, Maria/0000-0002-5859-7562; YANG, WEI-SHIUNG/0000-0001-5087-373X FU NIA NIH HHS [P01 AG014382, P01 AG017586, P30 AG010124, P50 AG005136, P50 AG005136-25] NR 38 TC 364 Z9 371 U1 3 U2 36 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD MAY PY 2008 VL 7 IS 5 BP 409 EP 416 DI 10.1016/S1474-4422(08)70071-1 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 296AB UT WOS:000255514800013 PM 18396105 ER PT J AU Lai, DW Loughran, TP Maciejewski, JP Sasu, S Song, SX Epling-Burnette, PK Paquette, RL AF Lai, Dominic W. Loughran, Thomas P., Jr. Maciejewski, Jaroslaw P. Sasu, Sebastian Song, Sophie X. Epling-Burnette, P. K. Paquette, Ronald L. TI Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia SO LEUKEMIA RESEARCH LA English DT Article DE large granular lymphocyte leukemia; pure red cell aplasia; amegakaryocytic thrombocytopenia; cyclosporine; glucocorticoids; intravenous immunoglobulin ID T-CELL; LYMPHOPROLIFERATIVE DISEASE; SJOGRENS-SYNDROME; NATURAL-KILLER; CLINICAL COURSE; RECEPTORS; SEROREACTIVITY; ABNORMALITIES; EXPRESSION; DISORDERS AB Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia rarely occur concurrently. We report a case in which these disorders were associated with an occult large granular lymphocyte leukemia. The peripheral blood cytopenias improved after glucocorticoids and intravenous immunoglobulin were administered, and response was maintained with cyclosporine. Large granular lymphocyte leukemia should be suspected in the setting of unexplained bone marrow failure. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Paquette, Ronald L.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Lai, Dominic W.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Loughran, Thomas P., Jr.] Penn State Coll Med, Penn State Canc Inst, Hershey, PA USA. [Maciejewski, Jaroslaw P.] Cleveland Clin Fdn, Expt Hematol & Hematopoiesis Sect, Cleveland, OH 44195 USA. [Sasu, Sebastian; Song, Sophie X.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA. [Epling-Burnette, P. K.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. RP Paquette, RL (reprint author), Univ Calif Los Angeles, Dept Med, 42-121 Ctr Hlth Sci,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM paquette@ucla.edu FU CSRD VA [I01 CX000114] NR 25 TC 12 Z9 14 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2126 J9 LEUKEMIA RES JI Leuk. Res. PD MAY PY 2008 VL 32 IS 5 BP 823 EP 827 DI 10.1016/j.leukres.2007.08.012 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 284FK UT WOS:000254692000018 PM 17915315 ER PT J AU Cohen, B Hooks, RB Elghanayan, JB Abolian, AM Figoni, SF AF Cohen, Babak Hooks, Roy B., Jr. Elghanayan, Jeanousse B. Abolian, Anna M. Figoni, Stephen F. TI Rates of Improvement during Treadmill and Calf Exercise Training in Peripheral Arterial Disease SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Cohen, Babak] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM babak2060@yahoo.com NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2008 VL 40 IS 5 SU S BP S159 EP S159 DI 10.1249/01.mss.0000322154.27112.d8 PG 1 WC Sport Sciences SC Sport Sciences GA V19KI UT WOS:000208070901581 ER PT J AU Ellingson, LD McLoughlin, MJ Stegner, AJ Cook, DB AF Ellingson, Laura D. McLoughlin, Michael J. Stegner, Aaron J. Cook, Dane B. TI Imaging the Relationship Between Physical Activity and Cognition in Women with Fibromyalgia SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Ellingson, Laura D.; McLoughlin, Michael J.; Stegner, Aaron J.] Univ Wisconsin, Madison, WI USA. [Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. EM lellingson@wisc.edu NR 0 TC 0 Z9 0 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2008 VL 40 IS 5 SU S BP S364 EP S364 DI 10.1249/01.mss.0000323456.52618.db PG 1 WC Sport Sciences SC Sport Sciences GA V19KI UT WOS:000208070903136 ER PT J AU Figoni, SF Kunkel, CF Scremin, AME Scremin, OU AF Figoni, Stephen F. Kunkel, Charles F. Scremin, A. M. Erika Scremin, Oscar U. TI Calf Muscle Oxygenation during Treadmill and Calf Exercise and Recovery in Peripheral Arterial Disease SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Figoni, Stephen F.; Kunkel, Charles F.; Scremin, A. M. Erika; Scremin, Oscar U.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM stephen.figoni@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2008 VL 40 IS 5 SU S BP S158 EP S158 DI 10.1249/01.mss.0000322153.19489.c2 PG 1 WC Sport Sciences SC Sport Sciences GA V19KI UT WOS:000208070901580 ER PT J AU Beckham, JC Becker, ME Hamlett-Berry, KW Drury, PD Kang, HK Wiley, MT Calhoun, PS Moore, SD Bright, MA McFall, ME AF Beckham, Jean C. Becker, Mary E. Hamlett-Berry, Kim W. Drury, Pamela D. Kang, Han K. Wiley, Matthew T. Calhoun, Patrick S. Moore, Scott D. Bright, Mary Anne McFall, Miles E. TI Preliminary findings from a clinical demonstration project for veterans returning from Iraq or Afghanistan SO MILITARY MEDICINE LA English DT Article ID NICOTINE REPLACEMENT THERAPY; SMOKING-CESSATION; CIGARETTE-SMOKING; UNITED-STATES; TOBACCO USE; INTERVENTIONS; PERSONNEL; QUITLINE; ACCESS; DEATH AB Military veterans are at high risk for nicotine dependence. This clinical demonstration project used invitational letters, referral to the National Cancer Institute's Smoking Quitline, and local Veteran Affairs prescriptions for tobacco cessation to evaluate whether this low-cost method would potentially reduce smoking in separated veterans who served in Afghanistan and Iraq. Three cohorts (500 each) of recently separated veterans from Afghanistan and Iraq were contacted by survey letters. Interested veterans received follow-up telephone calls using standardized scripts. They were referred to the National Cancer Institute's Smoking Quitline (1-877-44U-QUIT) and offered local Veteran Affairs pharmacologic treatment for smoking cessation. Forty-three percent of respondents who were smokers were interested in the clinical program; of these, 77% participated. At 2 months follow-up, 38% of participants self-reported maintained smoking abstinence. Results suggested that the intervention was feasible and assisted the small number of veterans who participated. C1 [Beckham, Jean C.; Becker, Mary E.; Drury, Pamela D.; Wiley, Matthew T.; Calhoun, Patrick S.; Moore, Scott D.] Durham Vet Adm Med Ctr, Durham, NC 27705 USA. [Beckham, Jean C.; Calhoun, Patrick S.; Moore, Scott D.] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC 27710 USA. [Beckham, Jean C.; Calhoun, Patrick S.; Moore, Scott D.] Durham VA Med Ctr, VA Mid Atlant Reg Mental Illness Res Educ & Clin, Durham, NC 27705 USA. [Hamlett-Berry, Kim W.] VA Publ Hlth Strateg, Dept Vet Affairs 13B, Hlth Care Grp, Washington, DC 20420 USA. [Kang, Han K.] Dept Vet Affairs 135, VA Environm Epidemiol Serv, Washington, DC 20422 USA. [Bright, Mary Anne] NCI, Office Canc Informat Serv, Rockville, MD 20852 USA. [McFall, Miles E.] Seattle Vet Adm Med Ctr, Seattle, WA 98108 USA. [McFall, Miles E.] Portland VA Med Ctr, VA Pacific NW Mental Illness Res Educ & Clin Ctr, Portland, OR 97207 USA. RP Beckham, JC (reprint author), Durham Vet Adm Med Ctr, 508 Fulton St,116B, Durham, NC 27705 USA. NR 30 TC 16 Z9 16 U1 1 U2 4 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD MAY PY 2008 VL 173 IS 5 BP 448 EP 451 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 300SY UT WOS:000255846700010 PM 18543565 ER PT J AU Paintlia, AS Paintlia, MK Singh, AK Singh, I AF Paintlia, Ajaib Singh Paintlia, Manjeet Kaur Singh, Avtar Kaur Singh, Inderjit TI Inhibition of Rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis SO MOLECULAR PHARMACOLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; COA REDUCTASE INHIBITOR; ACTIN STRESS FIBERS; MULTIPLE-SCLEROSIS; OLIGODENDROCYTE PROGENITORS; ENDOTHELIAL-CELLS; T-LYMPHOCYTES; ANIMAL-MODEL; NITRIC-OXIDE; STATINS AB Impaired remyelination is critical to neuroinflammation in multiple sclerosis (MS), which causes chronic and relapsing neurological impairments. Recent studies revealed that immunomodulatory activity of statins in an experimental autoimmune encephalomyelitis (EAE) model of MS are via depletion of isoprenoids (farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate) rather than cholesterol in immune cells. In addition, we previously documented that lovastatin impedes demyelination and promotes myelin repair in treated EAE animals. To this end, we revealed the underlying mechanism of lovastatin-induced myelin repair in EAE using in vitro and in vivo approaches. Survival, proliferation (chondroitin sulfate proteoglycan-NG2(+) and late oligodendrocyte progenitor marker(+)), and terminal-differentiation (myelin basic protein(+)) of OPs was significantly increased in association with induction of a promyelinating milieu by lovastatin in mixed glial cultures stimulated with proinflammatory cytokines. Lovastatin-induced effects were reversed by cotreatment with mevalonolactone or geranylgeranyl-pyrophosphate, but not by farnesyl-pyrophosphate or cholesterol, suggesting that depletion of geranygeranyl-pyrophosphate is more critical than farnesyl-pyrophosphate in glial cells. These effects of lovastatin were mimicked by inhibitors of geranylgeranyl-transferase (geranylgeranyl transferase inhibitor-298) and downstream effectors {i.e., Rho-family functions (C3-exoenzyme) and Rho kinase [Y27632 (N-(4- pyridyl)-4-(1-aminoethyl) cyclohexanecarboxamide dihydrochloride)]} but not by an inhibitor of farnesyl-transferase (farnesyl transferase inhibitor-277). Moreover, activities of Rho/Ras family GTPases were reduced by lovastatin in glial cells. Corresponding with these findings, EAE animals exhibiting demyelination (on peak clinical day; clinical scores >= 3.0) when treated with lovastatin and aforementioned agents validated these in vitro findings. Together, these data provide unprecedented evidence that - like immune cells - geranylgeranyl-pyrophosphate depletion and thus inhibition of Rho family functions in glial cells by lovastatin promotes myelin repair in ameliorating EAE. C1 [Paintlia, Ajaib Singh; Paintlia, Manjeet Kaur; Singh, Inderjit] Med Univ S Carolina, Darby Children Res Inst, Dept Pediat, Charleston, SC 29425 USA. [Singh, Avtar Kaur] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Darby Children Res Inst, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NCRR NIH HHS [C06 RR015455, C06 RR018823, C06-RR015455, C06-RR018823]; NINDS NIH HHS [R01 NS034741, NS-34741, NS22576, NS37766, NS40810, R01 NS022576, R01 NS034741-08, R01 NS034741-12, R01 NS037766, R01 NS037766-10, R01 NS040810, R37 NS022576, R37 NS022576-24] NR 39 TC 42 Z9 44 U1 0 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD MAY PY 2008 VL 73 IS 5 BP 1381 EP 1393 DI 10.1124/mol.107.044230 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 288VP UT WOS:000255014200008 PM 18239032 ER PT J AU Galofre, JC Lomvardias, S Davies, TF AF Galofre, Juan C. Lomvardias, Stylianos Davies, Terry F. TI Evaluation and treatment of thyroid nodules: A clinical guide SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Editorial Material DE benign; diagnosis; malignant; management; multinodular; nodules; thyroid; treatment ID NONTOXIC MULTINODULAR GOITER; FINE-NEEDLE-ASPIRATION; RECOMBINANT HUMAN THYROTROPIN; ROUTINE MEASUREMENT; ENDOCRINE SURGEONS; SERUM CALCITONIN; FOLLOW-UP; MANAGEMENT; CANCER; SOLITARY AB Thyroid nodules are inexplicably frequent and affect approximately one-third of the adult population. The appropriate clinical management is focused primarily oil excluding thyroid cancer and also on evaluating thyroid dysfunction and mechanical obstruction. There remains no evidence that a benign thyroid nodule, once diagnosed appropriately, will progress to a malignant lesion. The initial evaluation should include a complete clinical review, a thyroid sonogram by an experienced sonographer, a laboratory assessment of thyroid function, and, where indicated, a cytological assessment of the nodule(s) by fine needle aspiration under ultrasound guidance. Only patients with suppressed serum thyroid-stimulating hormone levels, indicating hyperthyroidism, may need further evaluation by radioactive iodine uptake and scanning. Optimal treatment depends oil the patient as well as the nodule characteristics. The usual options remain a simple annual follow-up to detect changes in nodule size and thyroid function and surgical removal. Levothyroxine therapy is now seldom indicated because of poor efficacy in nodule suppression and its inability to differentiate benign lesions front thyroid carcinoma. Clinical guidelines have a very arbitrary recommendation of aspiration biopsy in all lesions greater than 1 cm in size, but this proposal has no scientific basis and should always be viewed in the clinical context. C1 [Galofre, Juan C.; Davies, Terry F.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, New York, NY USA. [Galofre, Juan C.] Univ Navarra, Clin Univ, Dept Endocrinol & Nutr, E-31080 Pamplona, Spain. [Lomvardias, Stylianos] James J Peters VA Med Ctr, Dept Pathol, New York, NY USA. RP Galofre, JC (reprint author), Mt Sinai Med Ctr, Thyroid Res Unit, Miami Beach, FL 33140 USA. EM terry.davies@mssm.edu NR 61 TC 2 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0027-2507 EI 1931-7581 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD MAY-JUN PY 2008 VL 75 IS 3 BP 299 EP 311 DI 10.1002/msj.20040 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 343MT UT WOS:000258858900010 PM 18704984 ER PT J AU Chen, WL Song, BB Marvizon, JC AF Chen, Wenling Song, Bingbing Marvizon, Juan Carlos G. TI Inhibition of opioid release in the rat spinal cord by alpha(2C) adrenergic receptors SO NEUROPHARMACOLOGY LA English DT Article DE clonidine; dorsal horn; dynorphin; enkephalin; guanfacine; internalization; JP-1302; medetomidine; mu-opioid receptor; norepinephrine; opioid; UK-14304 ID ENKEPHALIN-DEGRADING ENZYMES; DORSAL-HORN NEURONS; NOXIOUS MECHANICAL STIMULI; MEDIAL PREOPTIC NUCLEUS; RECEPTOR INTERNALIZATION; CALCIUM-CHANNELS; MIXED INHIBITOR; SUBSTANCE-P; PRIMARY AFFERENTS; GLUTAMATE RELEASE AB Neurotransmitter receptors that control the release of opioid peptides in the spinal cord may play an important role in pain modulation. Norepinephrine, released by a descending pathway originating in the brainstem, is a powerful inducer of analgesia in the spinal cord. Adrenergic alpha(2C) receptors are present in opioid-containing terminals in the dorsal horn, where they could modulate opioid release. The goal of this study was to investigate this possibility. Opioid release was evoked from rat spinal cord slices by incubating them with the sodium channel opener veratridine in the presence of peptidase inhibitors (actinonin, captopril and thiorphan), and was measured in situ through the internalization of mu-opioid receptors in dorsal horn neurons. Veratridine produced internalization in 70% of these neurons. The alpha(2) receptor agonists clonidine, guanfacine, medetomidine and UK-14304 inhibited the evoked mu-opioid receptor internalization with IC(50)S of 1.7 mu M, 248 nM, 0.3 nM and 22 nM, respectively. However, inhibition by medetomidine was only partial, and inhibition by UK-14304 reversed itself at concentrations higher than 50 nM. None of these agonists inhibited mu-opioid receptor internalization produced by endomorphin-2, showing that they inhibited opioid release and not the internalization itself. The inhibitions produced by clonidine, guanfacine or UK-14304 were completely reversed by the selective alpha(2C) antagonist JP-1203. In contrast, inhibition by guanfacine was not prevented by the alpha(2A) antagonist BRL-44408. These results show that alpha(2C) receptors inhibit the release of opioids in the dorsal horn. This action may serve to shut down the opioid system when the adrenergic system is active. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Chen, Wenling; Song, Bingbing; Marvizon, Juan Carlos G.] Vet Affairs Greater Los Angels Healthcare Syst, Los Angeles, CA 90073 USA. [Chen, Wenling; Song, Bingbing; Marvizon, Juan Carlos G.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Chen, Wenling; Song, Bingbing; Marvizon, Juan Carlos G.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. RP Marvizon, JC (reprint author), Vet Affairs Greater Los Angels Healthcare Syst, Los Angeles, CA 90073 USA. EM marvizon@ucla.edu FU NIDA NIH HHS [R01 DA012609-07, R01 DA012609-08, R01 DA012609, 2 R01 DA012609, R01 DA012609-06A1] NR 70 TC 15 Z9 17 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD MAY PY 2008 VL 54 IS 6 BP 944 EP 953 DI 10.1016/j.neuropharm.2008.02.002 PG 10 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 305TL UT WOS:000256200600005 PM 18343461 ER PT J AU Goldstein, G Allen, DN Minshew, NJ Williams, DL Volkmar, F Klin, A Schultz, RT AF Goldstein, Gerald Allen, Daniel N. Minshew, Nancy J. Williams, Diane L. Volkmar, Fred Klin, Ami Schultz, Robert T. TI The structure of intelligence in children and adults with high functioning autism SO NEUROPSYCHOLOGY LA English DT Article DE autism; intelligence testing; confirmatory factor analysis ID CONFIRMATORY FACTOR-ANALYSIS; DIAGNOSTIC OBSERVATION SCHEDULE; SENTENCE COMPREHENSION; WAIS-R; SCHIZOPHRENIA; INDIVIDUALS; FIT; UNDERCONNECTIVITY; CONNECTIVITY; VALIDATION AB Confirmatory factor analyses of the commonly used 11 subtests of the Wechsler child and adult intelligence scales were accomplished for 137 children and 117 adults with high functioning autism (HFA) and for comparable age groups from the standardization samples contained in the Wechsler manuals. The objectives were to determine whether the structure of intelligence in HFA groups was similar to that found in the normative samples, and whether a separate "social context" factor would emerge that was unique to HFA. Four-factor models incorporating a Social Context factor provided the best fit in both the autism and normative samples, but the subtest intercorrelations were generally lower in the autism samples. Findings suggest similar organization of cognitive abilities in HFA, but with the possibility of underconnectivity or reduced communication among brain regions in autism. C1 [Goldstein, Gerald] VA Pittsburgh Hlth Care Syst, Res Serv 151R, Pittsburgh, PA 15206 USA. [Allen, Daniel N.] Univ Nevada Las Vegas, Dept Psychol, Las Vegas, NV USA. [Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA. [Williams, Diane L.] Duquesne Univ, Dept Speech Language Pathol, Pittsburgh, PA USA. [Volkmar, Fred; Klin, Ami] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Schultz, Robert T.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA USA. RP Goldstein, G (reprint author), VA Pittsburgh Hlth Care Syst, Res Serv 151R, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM ggold@nb.net RI Williams, Diane/B-4128-2017 FU NICHD NIH HHS [U19 HD035469-10, P50 HD055748, U19 HD035469, U19 HD035469-06, U19 HD035469-07, U19 HD035469-08, U19 HD035469-09] NR 44 TC 30 Z9 32 U1 2 U2 13 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 J9 NEUROPSYCHOLOGY JI Neuropsychology PD MAY PY 2008 VL 22 IS 3 BP 301 EP 312 DI 10.1037/0894-4105.22.3.301 PG 12 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA 294AX UT WOS:000255377600003 PM 18444708 ER PT J AU Carmody, TP Duncan, C Simon, JA Solkowitz, S Huggins, J Lee, S Delucchi, K AF Carmody, Timothy P. Duncan, Carol Simon, Joel A. Solkowitz, Sharon Huggins, Joy Lee, Sharon Delucchi, Kevin TI Hypnosis for smoking cessation: A randomized trial SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SUGGESTIBILITY; PAIN AB The purpose of this study was to determine whether hypnosis would be more effective in helping smokers quit than standard behavioral counseling when both interventions are combined with nicotine patches (NP). A total of 286 current smokers were enrolled in a randomized controlled smoking cessation trial at the San Francisco Veterans Affairs Medical Center. Participants in both treatment conditions were seen for two 60-min sessions, and received three follow-up phone calls and 2 months of NP. At 6 months, 29% of the hypnosis group reported 7-day point-prevalence abstinence compared with 23% of the behavioral counseling group (relative risk [RR]=1.27; 95% confidence interval, CI 0.84-1.92). Based on biochemical or proxy confirmation, 26% of the participants in the hypnosis group were abstinent at 6 months compared with 18% of the behavioral group (RR = 1.44; 95% CI 0.91-2.30). At 12 months, the self-reported 7-day point-prevalence quit rate was 24% for the hypnosis group and 16% for the behavioral group (RR = 1.47; 95% CI 0.90-2.40). Based on biochemical or proxy confirmation, 20% of the participants in the hypnosis group were abstinent at 12 months compared with 14% of the behavioral group (RR=1.40; 95% CI 0.81-2.42). Among participants with a history of depression, hypnosis yielded significantly higher validated point-prevalence quit rates at 6 and 12 months than standard treatment. It was concluded that hypnosis combined with NP compares favorably with standard behavioral counseling in generating long-term quit rates. C1 [Carmody, Timothy P.; Duncan, Carol; Simon, Joel A.; Solkowitz, Sharon; Huggins, Joy; Lee, Sharon; Delucchi, Kevin] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Carmody, TP (reprint author), Vet Affairs Med Ctr, Mental Hlth Serv 116B, 4150 Clement St, San Francisco, CA 94121 USA. EM Timothy.Carmody@ucsf.edu OI Delucchi, Kevin/0000-0003-2195-9627 NR 27 TC 24 Z9 25 U1 3 U2 11 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2008 VL 10 IS 5 BP 811 EP 818 DI 10.1080/14622200802023833 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 303QP UT WOS:000256055900006 PM 18569754 ER PT J AU Nurgalieva, Z Goodman, KJ Phillips, CV Fischbach, L de La Rosa, JM Gold, BD AF Nurgalieva, Zhannat Goodman, Karen J. Phillips, Carl V. Fischbach, Lori de la Rosa, J. Manuel Gold, Benjamin D. TI Correspondence between Helicobacter pylori antibodies and urea breath test results in a US-Mexico birth cohort SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE Helicobacter pylori infection; serology; urea breath test; methodology ID LINKED-IMMUNOSORBENT-ASSAY; FOLLOW-UP; DIAGNOSTIC-ACCURACY; STOOL SAMPLES; CHILDREN; INFECTION; ERADICATION; ACQUISITION; CHILDHOOD; SEROLOGY AB The uncertain accuracy of methods for detecting Helicobacter pylori infection in young children complicates research on this infection in early life. The aim of the present report was to describe the correspondence between positive serology and positive urea breath test (UBT) in children followed from age 0 to 24 months in the Pasitos Cohort Study, conducted along the US-Mexico border at El Paso and Juarez. Children were recruited before birth during 1998-2000 and examined at target ages of 6, 12, 18 and 24 months. H. pylori infection was detected using an enzyme immunoassay for serum immunoglobulin G antibodies and the C-13-urea breath test corrected for age-dependent variation in CO2 production. Of 472 children, 125 had one or more positive UBT results and 46 had one or more positive serology results. The prevalence of H. pylori infection at target ages of 6, 12, 18 and 24 months was 7%, 14%, 16% and 19%, respectively, by UBT and 8%, 2%, 3% and 3%, respectively, by serology. Few (< 1%) of those tested on both tests were positive on both at any age. Among UBT-positive children, 6% were concurrently seropositive and 6% became seropositive later. Because UBT positivity cut points were selected to minimise false positives, these results suggest that H. pylori infection occurred frequently in this cohort, but rarely produced detectable antibodies. For clinical or epidemiological investigations, serology should not be used as the sole method for detecting H. pylori infection in children aged 2 years or less. C1 [Nurgalieva, Zhannat; Goodman, Karen J.] Univ Texas Hlth Sci Ctr San Antonio, Sch Publ Hlth, Houston, TX USA. [Fischbach, Lori] Univ Texas Hlth Sci Ctr San Antonio, Sch Publ Hlth, Ft Worth, TX USA. [de la Rosa, J. Manuel] Texas Tech Univ, Hlth Sci Ctr, Sch Med, El Paso, TX USA. [Gold, Benjamin D.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Goodman, Karen J.] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada. [Goodman, Karen J.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada. RP Nurgalieva, Z (reprint author), Houston VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM zhannatn@bcm.tmc.edu RI Goodman, Karen/D-6823-2013 OI Goodman, Karen/0000-0002-3790-3217 FU NIDDK NIH HHS [DK-53708-07, R01-DK053664] NR 46 TC 4 Z9 4 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-5022 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAY PY 2008 VL 22 IS 3 BP 302 EP 312 DI 10.1111/j.1365-3016.2008.00932.x PG 11 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 289NS UT WOS:000255061800011 PM 18426526 ER PT J AU Sutton, R Petersen, OH Pandol, SJ AF Sutton, Robert Petersen, Ole H. Pandol, Stephen J. TI Pancreatitis and calcium signalling - Report of an international workshop SO PANCREAS LA English DT Editorial Material ID KAPPA-B ACTIVATION; PROTEIN-KINASE-C; MITOCHONDRIAL PERMEABILITY TRANSITION; INOSITOL TRISPHOSPHATE RECEPTORS; ADENINE-NUCLEOTIDE TRANSLOCASE; MEMBRANE NA+/CA2+ EXCHANGER; HUMAN CATIONIC TRYPSINOGEN; LEUKOTRIENE C-4 SECRETION; NECROSIS-FACTOR-ALPHA; ACINAR-CELLS AB Pancreatitis and Calcium Signalling was an international research workshop organized by the authors and held at the Liverpool Medical Institution, Liverpool, United Kingdom, from Sunday 12th to Tuesday 14th November 2006. The overall goal of the workshop was to review progress and explore new opportunities for understanding the mechanisms of acute pancreatitis with an emphasis on the role of pathological calcium signaling. The participants included those with significant interest and expertise in pancreatitis research and others who are in fields outside gastroenterology but with significant expertise in areas of cell biology relevant to pancreatitis. The workshop was designed to enhance interchange of ideas and collaborations, to engage and encourage younger researchers in the field, and promote biomedical research through the participating and supporting organizations and societies. The workshop was divided into 8 topic-oriented sessions. The sessions were: (1) Physiology and pathophysiology of calcium signaling; (2) Interacting signaling mechanisms; (3) Premature digestive enzyme activation; (4) Physiology Society Lecture: Aberrant Ca2+ signaling, bicarbonate secretion, and pancreatitis; (5) NF kappa B, cytokines, and immune mechanisms; (6) Mitochondrial injury; (7) Cell death pathways; and (8) Overview of areas for future research. In each session, speakers presented work appropriate to the topic followed by discussion of the material presented by the group. The publication of these proceedings is intended to provide a platform for enhancing research and therapeutic development for acute pancreatitis. C1 [Sutton, Robert] Univ Liverpool, Div Surg & Oncol, MRC Grp, Liverpool L69 3BX, Merseyside, England. [Petersen, Ole H.] Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England. [Pandol, Stephen J.] Univ Calif Los Angeles, USC, Res Ctr Alcohol Liver & Pancreat Dis, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Sutton, R (reprint author), Univ Liverpool, Div Surg & Oncol, Royal Liverpool Univ Hosp, Daulby St, Liverpool L69 3GA, Merseyside, England. EM r.sutton@liverpool.ac.uk RI Sutton, Robert/I-3587-2016 OI Sutton, Robert/0000-0001-6600-562X NR 110 TC 15 Z9 15 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAY PY 2008 VL 36 IS 4 BP E1 EP E14 DI 10.1097/MPA.0b013e3181675010 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 294YT UT WOS:000255442900018 PM 18437073 ER PT J AU Seo, Y Mari, C Hasegawa, BH AF Seo, Youngho Mari, Carina Hasegawa, Bruce H. TI Technological development and advances in single-photon emission computed tomography/computed tomography SO SEMINARS IN NUCLEAR MEDICINE LA English DT Review ID X-RAY CT; MYOCARDIAL-PERFUSION SPECT; LEFT-VENTRICULAR FUNCTION; LOW-DOSE CT; SENTINEL NODE IDENTIFICATION; HEPATIC ARTERIAL INFUSION; SQUAMOUS-CELL CARCINOMA; MEDICAL IMAGING-SYSTEM; NON-HODGKINS-LYMPHOMA; ATTENUATION CORRECTION AB Single-photon emission computed tomography/computed tomography (SPECT/CT) has emerged during the past decade as a means of correlating anatomical information from CT with functional information from SPECT. The integration of SPECT and CT in a single imaging device facilitates anatomical localization of the radiopharmaceutical to differentiate physiological uptake from that associated with disease and patient-specific attenuation correction to improve the visual quality and quantitative accuracy of the SPECT image. The first clinically available SPECT/CT systems performed emission-transmission imaging using a dual-headed SPECT camera and a low-power x-ray CT subsystem. Newer SPECT/CT systems are available with high-power CT subsystems suitable for detailed anatomical diagnosis, including CT coronary angiography and coronary calcification that can be correlated with myocardial perfusion measurements. The high-performance CT capabilities also offer the potential to improve compensation of partial volume errors for more accurate quantitation of radionuclide measurement of myocardial blood flow and other physiological processes and for radiation dosimetry for radionuclide therapy. In addition, new SPECT technologies are being developed that significantly improve the detection efficiency and spatial resolution for radionuclide imaging of small organs including the heart, brain, and breast, and therefore may provide new capabilities for SPECT/CT imaging in these important clinical applications. C1 [Seo, Youngho; Mari, Carina; Hasegawa, Bruce H.] Univ Calif San Francisco, Dept Radiol, Phys Res Lab, San Francisco, CA 94107 USA. [Seo, Youngho; Hasegawa, Bruce H.] Univ Calif San Francisco, Joint Bioengn Grad Grp, San Francisco, CA 94107 USA. [Mari, Carina] San Francisco Vet Adm Med Ctr, Nucl Med Serv, San Francisco, CA USA. [Hasegawa, Bruce H.] Univ Calif Berkeley, Dept Nucl Engn, Berkeley, CA 94720 USA. RP Hasegawa, BH (reprint author), Univ Calif San Francisco, Dept Radiol, Phys Res Lab, 185 Berry St,Suite 350, San Francisco, CA 94107 USA. EM bruce.hasegawa@radiology.ucsf.edu FU NCI NIH HHS [K25 CA114254-03, R44 CA095936, 2 R44 CA095936, 5 K25 CA114254, K25 CA114254]; NHLBI NIH HHS [R21 HL083073, 1 R21 HL083073]; NIA NIH HHS [R41 AG030241, 1 R41 AG030241]; NIBIB NIH HHS [4 R44 EB001685, R01 EB000288, 5 R21 EB006373, R21 EB001685, R33 EB001685, R21 EB006373, 5 R01 EB000288]; NIEHS NIH HHS [2 R44 ES012361, R44 ES012361]; PHS HHS [2 R44 H083494] NR 228 TC 60 Z9 63 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0001-2998 J9 SEMIN NUCL MED JI Semin. Nucl. Med. PD MAY PY 2008 VL 38 IS 3 BP 177 EP 198 DI 10.1053/j.semnuclmed.2008.01.001 PG 22 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 285UO UT WOS:000254801900005 PM 18396178 ER PT J AU Gilbertson, L Ahn, SH Teng, PN Studer, RK Niyibizi, C Kang, JD AF Gilbertson, Lars Ahn, Sang-Ho Teng, Pang-Ning Studer, Rebecca K. Niyibizi, Christopher Kang, James D. TI The effects of recombinant human bone morphogenetic protein-2, recombinant human bone morphogenetic protein-12, and adenoviral bone morphogenetic protein-12 on matrix synthesis in human annulus fibrosis and nucleus pulposus cells SO SPINE JOURNAL LA English DT Review DE human intervertebral disc; nucleus pulposus cells; annulus fibrosis cells; BMP-2; BMP-12; matrix protein synthesis; gene therapy ID INTERVERTEBRAL DISC CELLS; MEDIATED GENE-TRANSFER; GROWTH-FACTOR; IN-VIVO; EXTRACELLULAR-MATRIX; CULTURE SYSTEM; DEGENERATION; EXPRESSION; THERAPY; RABBIT AB BACKGROUND CONTEXT: Bone morphogenetic proteins (BMPs) are potential therapeutic factors for degenerative discs, and BMP-12 does not have the osteogenic potential of BMP-2, making it better suited for intradiscal injection. However, no reports have compared the actions of BMP-2 and -12 on human annulus fibrosus (AF) and nucleus pulposus (NP) cells nor evaluated adenoviral-mediated gene therapy in human AF cells. PURPOSE: To evaluate and compare the effects of recombinant human (rh) BMP-2, rhBMP-12, and adenoviral BMP-12 (Ad-BMP-12) on nucleus pulposus and annulus fibrosis cell matrix protein synthesis. STUDY DESIGN: In vitro study using rhBMP-2 and -12 and adenoviral BMP-12 with human intervertebral disc (IVD) cells. METHODS: Human NP and AF IVD cells were isolated, maintained in monolayer, and incubated with BMP-2 or - 12 for 2 days. AF and NP cells were transduced with Ad-BMP-12, pellets formed, and incubated for 6 days. Growth factor-treated cells were labelled with either 35-S or 3H-proline to assay matrix protein synthesis. RESULTS: rhBMP-2 increased NP proteoglycan, collagen, and noncollagen protein synthesis to 355%, 388%, and 234% of control. RhBMP-12 increased the same NP matrix proteins' synthesis to 140%, 143%, and 160% of control. Effects on AF matrix protein synthesis were minimal. Ad-BMP-12 significantly increased matrix protein synthesis and DNA content of AF and NP cells in pellet culture. NP synthesis of all matrix proteins and AF synthesis of proteoglycans was increased when the data were normalized to pellet DNA. AF synthesis of noncollagen protein and collagen was not modulated by Ad-BMP-12 if the data are normalized to pellet DNA content. CONCLUSIONS: Both rhBMP-2 and -12 increase human NP cell matrix protein synthesis while having minimal effects on AF cells. However, Ad-BMP-12 did increase matrix protein synthesis in both NP and AF cells, making it a potential therapy for enhancing matrix production in the IVD. These responses plus the proliferative action of Ad-BMP-12 seen in the current studies, and the lack of an osteogenic action noted in other studies justifies future studies to determine if gene therapy with BMP-12 could provide protective and/or reparative actions in degenerating discs. (C) 2008 Elsevier Inc. All rights reserved. C1 [Gilbertson, Lars; Teng, Pang-Ning; Kang, James D.] Univ Pittsburgh, Dept Orthoped Surg, Ferguson Lab, Pittsburgh, PA 15261 USA. [Ahn, Sang-Ho] Yeungnam Univ, Dept Rehabil Med, Taegu, South Korea. [Studer, Rebecca K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Niyibizi, Christopher] Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Hershey, PA 17033 USA. RP Kang, JD (reprint author), Univ Pittsburgh, Dept Orthoped Surg, Ferguson Lab, E1641 BST,200 Lothrop St, Pittsburgh, PA 15261 USA. EM Kangjd@UPMC.edu NR 43 TC 50 Z9 62 U1 5 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 J9 SPINE J JI Spine Journal PD MAY-JUN PY 2008 VL 8 IS 3 BP 449 EP 456 DI 10.1016/j.spinee.2006.11.006 PG 8 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 305MA UT WOS:000256181300005 PM 18455111 ER PT J AU Xu, JM Filetti, S Hershman, JM AF Xu, Jimin Filetti, Sebastiano Hershman, Jerome M. TI Expression of hepatocyte nuclear factor-1 alpha mRNA in human anaplastic thyroid cancer cell lines and tumors SO THYROID LA English DT Article ID NICOTINAMIDE N-METHYLTRANSFERASE; GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTORS; CLEAR-CELL; HNF-1-ALPHA; HNF-1-BETA; ACTIVATION; INACTIVATION; HETERODIMERS AB Background: Hepatocyte nuclear factor (HNF)-1 alpha and HNF-1 beta are related transcription factors that are mainly expressed in liver cells. Our previous study showed that HNF-1 beta was highly expressed in papillary thyroid cancer cell lines and tumors. HNF-1 alpha mRNA, however, was not detected in differentiated thyroid cancer cell lines. The objective of this study was to determine whether HNF-1 alpha is expressed in dedifferentiated anaplastic thyroid cancer cells. Methods: Total RNA isolated from six anaplastic thyroid cancer cell lines and 38 surgical samples was analyzed for HNF-1 alpha mRNA by conventional reverse-transcription polymerase chain reaction (RT-PCR) or real-time RTPCR. HNF-1 alpha DNA binding activity was measured by gel retardation assay and HNF-1 alpha protein was identified by Western blotting. Results: HNF-1 alpha mRNA was expressed in four of the six anaplastic cell lines. The presence of HNF-1 alpha protein and DNA binding activity was detected in three lines with higher HNF-1 alpha mRNA level. Three cell lines also expressed HNF-1b. HNF-1 alpha transcripts were also detected in five out of six anaplastic tumors, but not in the papillary tumors except one with weak PCR signal. Conclusion: HNF-1 alpha mRNA was detected in high frequency in anaplastic thyroid cancer cell lines and tumors. HNF-1 alpha might play a role in the pathogenesis of anaplastic thyroid cancer. C1 [Hershman, Jerome M.] Univ Calif Los Angeles, Sch Med, Dept Med, Endocrinol & Diabet Div, Los Angeles, CA 90024 USA. [Xu, Jimin] Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA. [Filetti, Sebastiano] Univ Roma La Sapienza, Dept Clin Sci, Rome, Italy. RP Hershman, JM (reprint author), VA Greater Los Angeles Healthcare Syst, Endocrinol Div 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 23 TC 2 Z9 2 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD MAY PY 2008 VL 18 IS 5 BP 533 EP 539 DI 10.1089/thy.2007.0312 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 306IF UT WOS:000256240800008 PM 18399756 ER PT J AU Campbell, R Cooper, GS Gilkeson, GS AF Campbell, R., Jr. Cooper, G. S. Gilkeson, G. S. TI The economic burden of systemic lupus erythematosus among patients of the carolina lupus study early in the course of disease SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Campbell, R., Jr.] Med Univ S Carolina, Charleston, SC 29425 USA. [Cooper, G. S.] US EPA, Washington, DC 20460 USA. [Gilkeson, G. S.] Med Univ S Carolina, Ralph Johnson Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2008 VL 11 IS 3 BP A154 EP A154 DI 10.1016/S1098-3015(10)70489-7 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 302CC UT WOS:000255945400488 ER PT J AU Harding, G Roberts, L Spiegel, BM Mody, RR Revicki, D Kahrilas, PJ Camilleri, ML Walter, K AF Harding, G. Roberts, L. Spiegel, B. M. Mody, R. R. Revicki, D. Kahrilas, P. J. Camilleri, M. L. Walter, K. TI Validation of a nocturnal gastroesophageal reflux disease (GERD) symptom severity and impact instrument SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Harding, G.; Roberts, L.; Revicki, D.; Walter, K.] United BioSource Corp, Bethesda, MD USA. [Spiegel, B. M.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Spiegel, B. M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Mody, R. R.] TAP Pharmaceut Prod Inc, Lake Forest, IL USA. [Kahrilas, P. J.] Northwestern Univ, Chicago, IL 60611 USA. [Camilleri, M. L.] Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2008 VL 11 IS 3 BP A90 EP A90 DI 10.1016/S1098-3015(10)70293-X PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 302CC UT WOS:000255945400292 ER PT J AU Parikh, NM Singh, H Ashton, C Sharma, M Yadav, R Walder, A Johnson, M AF Parikh, N. M. Singh, H. Ashton, C. Sharma, M. Yadav, R. Walder, A. Johnson, M. TI Patterns of diuretic use in multi-drug anti-hypertensive regimens in the post ALLHAT era SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Parikh, N. M.; Sharma, M.; Yadav, R.] Univ Houston, Houston, TX USA. [Singh, H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Walder, A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Johnson, M.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Ashton, C.] Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2008 VL 11 IS 3 BP A212 EP A212 DI 10.1016/S1098-3015(10)70672-0 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 302CC UT WOS:000255945400671 ER PT J AU Sharma, M Deswal, A Henderson, L Desai, R Chitnis, A Petersen, N Ashton, C Johnson, M AF Sharma, M. Deswal, A. Henderson, L. Desai, R. Chitnis, A. Petersen, N. Ashton, C. Johnson, M. TI Effectiveness of combined beta-blocker and ACEI or ARB therapy in chronic heart failure SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Sharma, M.; Desai, R.; Chitnis, A.] Univ Houston, Houston, TX USA. [Deswal, A.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA. [Deswal, A.; Petersen, N.; Johnson, M.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Henderson, L.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ashton, C.] Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2008 VL 11 IS 3 BP A16 EP A16 DI 10.1016/S1098-3015(10)70064-4 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 302CC UT WOS:000255945400063 ER PT J AU Spiegel, BM Patel, V Chiou, CF Esrailian, E AF Spiegel, B. M. Patel, V Chiou, C. F. Esrailian, E. TI Using cost-utility analysis to assess the budget impact of biologics for the treatment of psoriasis (PSO) SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Spiegel, B. M.; Esrailian, E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Spiegel, B. M.; Esrailian, E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Patel, V; Chiou, C. F.] Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2008 VL 11 IS 3 BP A292 EP A292 DI 10.1016/S1098-3015(10)70921-9 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 302CC UT WOS:000255945400920 ER PT J AU Seelig, MD Yano, EM Bean-Mayberry, B Lanto, AB Washington, DL AF Seelig, Michelle D. Yano, Elizabeth M. Bean-Mayberry, Bevanne Lanto, Andy B. Washington, Donna L. TI Availability of gynecologic services in the department of veterans affairs SO WOMENS HEALTH ISSUES LA English DT Article ID WOMENS HEALTH-CARE; NATIONAL CENTERS; MEDICAL-CENTER; CLINICS; SATISFACTION; ORGANIZATION; EXCELLENCE; DELIVERY AB Purpose. The optimum approach to providing the Congressionally mandated gender-specific services for which women veterans are eligible is unknown. We evaluated onsite availability of gynecologic services, clinic type and staffing arrangements, and the impact of having a gynecology clinic (GYN) and/or an obstetrician gynecologist (OBGYN) routinely available. Methods. We analyzed data from the 2001 national VHA Survey of Women Veterans Health Programs and Practices (n = 136 sites; response rate, 83%). We assessed availability of gynecologic services, and evaluated differences in availability by clinic type (designated women's health provider in primary care [PC], separate women's health clinic for primary care [WHC], and/or separate GYN) and staffing arrangements (OBGYN routinely involved versus not). Main Findings. Out of 133 sites, 77 sites (58%) offered services through a GYN and 56 sites (42%) did not have GYN. Seventy-two (54%) sites had a WHC. More sites with an OBGYN provided endometrial biopsies (91% vs. 20%), IUD insertion (85% vs. 14%), infertility evaluation (56% vs. 23%), infertility treatment (25% vs. none), gynecologic surgery (65 vs. 28%), p < .01. In comparison to sites without WHC, those with WHC were more likely to offer services onsite: endometrial biopsy odds ratio (OR) 6.0 (95% confidence interval [CI], 2.0-18.1); IUD insertion 4.4 (1.6-12.2); infertility evaluation 2.8 (1.2-6.3); and gynecologic surgery 2.3 (1.0-5.4). Conclusion. As the VA develops strategic plans for accommodating the growing number of women veterans, leaders should consider focusing on establishing WHC for primary care and routine availability of OBGYN or other qualified clinicians, rather than establishing separate GYN. C1 [Seelig, Michelle D.] HSR&D Ctr Excellence, Dept Vet Affairs Puget Sound Healthcare System, Seattle, WA USA. [Yano, Elizabeth M.; Bean-Mayberry, Bevanne; Lanto, Andy B.; Washington, Donna L.] Ctr Study Healthcare Provider Behav, VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA USA. [Bean-Mayberry, Bevanne; Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Seelig, MD (reprint author), Puget Sound Hlth Alliance, 2003 Western Ave,Suite 600, Seattle, WA 98105 USA. EM seelip@mac.com NR 19 TC 19 Z9 19 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAY-JUN PY 2008 VL 18 IS 3 BP 167 EP 173 DI 10.1016/j.whi.2007.1.2.006 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 303GK UT WOS:000256028800003 PM 18329895 ER PT J AU Huang, AJ Grady, D Jacoby, VL Blackwell, TL Bauer, DC Sawaya, GF AF Huang, Alison J. Grady, Deborah Jacoby, Vanessa L. Blackwell, Terri L. Bauer, Douglas C. Sawaya, George F. TI Persistent hot flushes in older postmenopausal women SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID HORMONE REPLACEMENT THERAPY; MENOPAUSAL SYMPTOMS; SERUM-LIPIDS; POPULATION; TRANSITION; FLASHES; STRESS; TRIAL; RISK; AGE AB Objective: To examine the prevalence, natural history, and predictors of hot flushes in older postmenopausal women. Methods:.Prevalence, severity, and 3-year change in severity of hot flushes were assessed by questionnaire in 3167 older postmenopausal women with osteoporosis. Logistic regression was used to identify characteristics associated with symptoms at baseline and after 3 years of follow-up. Results: At baseline, 375 women (11.8%) reported bothersome hot flushes. Women were more likely to have baseline symptoms if they were less educated (odds ratio [ OR], 1.28; 95% confidence interval [CI], 1.06-1.53 per 4-year decrease), more recently menopausal (OR, 1.44; 95% Cl, 1.34-1.56 per 5-year decrease), had previously used estrogen (OR, 1.57; 95% Cl, 1.23-2.00), or had. undergone hysterectomy (OR, 1.51; 95% Cl, 1.14-1.99). Hot flushes were also associated with higher body rnass index (OR, 1.22; 95% Cl, 1.08-1.38 per 1 SD) higher follicle-stimulating hormone levels (OR, 1.34; 95% Cl, 1.20-1. 51 per I SD), lower high-density lipoprotein levels (OR, 1. 17; 95% Cl, 1.03-1.34 per 1SD decrease), vaginal dryness (OR, 1.52; 95% Cl, 1.19-1.93), and trouble sleeping (OR., 2.48; 95% Cl, 1.94-3.16), but not estradiol levels. Of the 375 women with baseline symptoms, 278 contributed 3-year data, and 157 (56.5%) of these women reported persistent symptoms after 3 years. Fewer years since menopause (OR, 1.15; 95% Cl, 1.01-1.32 per 5-year decrease) and trouble sleeping (OR, 1.97; 95% Cl, 1. 19-3.26) were associated with symptom persistence. Conclusions: For a substantial minority of women, hot flushes are a persistent source of discomfort into the late postmenopausal years. Identification of risk factors for hot flushes may help guide evaluation and treatment in this population. C1 [Huang, Alison J.; Grady, Deborah; Bauer, Douglas C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Grady, Deborah; Bauer, Douglas C.; Sawaya, George F.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Jacoby, Vanessa L.; Sawaya, George F.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Grady, Deborah] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Blackwell, Terri L.] Calif Pacific Med Ctr Res Inst, San Francisco, CA USA. RP Huang, AJ (reprint author), 1635 Divisadero St,Ste 600, San Francisco, CA 94115 USA. EM ahuang@ucsfmed.org FU NCRR NIH HHS [KL2 RR024130]; NICHD NIH HHS [K12 HD001262] NR 34 TC 41 Z9 42 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 28 PY 2008 VL 168 IS 8 BP 840 EP 846 DI 10.1001/archinte.168.8.840 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 292EI UT WOS:000255248900010 PM 18443259 ER PT J AU Haasl, RJ Ahmadi, MR Meethal, SV Gleason, CE Johnson, SC Asthana, S Bowen, RL Atwood, CS AF Haasl, Ryan J. Ahmadi, M. Reza Meethal, Sivan Vadakkadath Gleason, Carey E. Johnson, Sterling C. Asthana, Sanjay Bowen, Richard L. Atwood, Craig S. TI A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E epsilon 4 allele SO BMC MEDICAL GENETICS LA English DT Article ID MULTIFACTOR-DIMENSIONALITY REDUCTION; GENE-GENE INTERACTIONS; LOGISTIC-REGRESSION; BREAST-CANCER; BETA-SUBUNIT; GONADOTROPIN; MUTATIONS; PROTEIN; PEPTIDE; WOMEN AB Genetic and biochemical studies support the apolipoprotein E (APOE) epsilon 4 allele as a major risk factor for late-onset Alzheimer's disease (AD), though similar to 50% of AD patients do not carry the allele. APOE transports cholesterol for luteinizing hormone (LH)-regulated steroidogenesis, and both LH and neurosteroids have been implicated in the etiology of AD. Since polymorphisms of LH beta-subunit (LHB) and its receptor (LHCGR) have not been tested for their association with AD, we scored AD and age-matched control samples for APOE genotype and 14 polymorphisms of LHB and LHCGR. Thirteen gene-gene interactions between the loci of LHB, LHCGR, and APOE were associated with AD. The most strongly supported of these interactions was between an LHCGR intronic polymorphism (rs4073366; lhcgr2) and APOE in males, which was detected using all three interaction analyses: linkage disequilibrium, multi-dimensionality reduction, and logistic regression. While the APOE e4 allele carried significant risk of AD in males [p = 0.007, odds ratio (OR) = 3.08(95% confidence interval: 1.37, 6.91)], epsilon 4-positive males carrying 1 or 2 C-alleles at lhcgr2 exhibited significantly decreased risk of AD [OR = 0.06(0.01, 0.38); p = 0.003]. This suggests that the lhcgr2 C-allele or a closely linked locus greatly reduces the risk of AD in males carrying an APOE e4 allele. The reversal of risk embodied in this interaction powerfully supports the importance of considering the role gene-gene interactions play in the etiology of complex biological diseases and demonstrates the importance of using multiple analytic methods to detect well-supported gene-gene interactions. C1 [Haasl, Ryan J.; Ahmadi, M. Reza; Meethal, Sivan Vadakkadath; Gleason, Carey E.; Johnson, Sterling C.; Asthana, Sanjay; Atwood, Craig S.] Univ Wisconsin, Sch Med & Publ Hlth, Sect Geriatr & Gerontol, Dept Med, Madison, WI 53705 USA. [Haasl, Ryan J.; Meethal, Sivan Vadakkadath; Gleason, Carey E.; Johnson, Sterling C.; Asthana, Sanjay; Atwood, Craig S.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Bowen, Richard L.] OTB Res, Charleston, SC 29464 USA. [Atwood, Craig S.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Joondalup, WA 6027, Australia. RP Atwood, CS (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Sect Geriatr & Gerontol, Dept Med, Madison, WI 53705 USA. EM haasl@wisc.edu; mrahmadi@wisc.edu; svm@medicine.wisc.edu; ceg@medicine.wisc.edu; scj@medicine.wisc.edu; sa@medicine.wisc.edu; richard.bowen@yahoo.com; csa@medicine.wisc.edu FU NIA NIH HHS [U24 AG021886] NR 60 TC 11 Z9 12 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2350 J9 BMC MED GENET JI BMC Med. Genet. PD APR 25 PY 2008 VL 9 AR 37 DI 10.1186/1471-2350-9-37 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 307EK UT WOS:000256300600001 PM 18439297 ER PT J AU Thaler, JP Cummings, DE AF Thaler, Joshua P. Cummings, David E. TI Metabolism - Food alert SO NATURE LA English DT Editorial Material ID GLUCOSE-HOMEOSTASIS C1 [Thaler, Joshua P.; Cummings, David E.] Univ Washington, Harborview Med Ctr, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Thaler, Joshua P.; Cummings, David E.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Thaler, JP (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way,S-111 Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu NR 11 TC 10 Z9 10 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD APR 24 PY 2008 VL 452 IS 7190 BP 941 EP 942 DI 10.1038/452941a PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 291PF UT WOS:000255208600023 PM 18432230 ER PT J AU Bowman, CC Sobo, EJ Asch, SM Gifford, AL AF Bowman, Candice C. Sobo, Elisa J. Asch, Steven M. Gifford, Allen L. CA Hiv Hepatitis Quality Enhancement TI Measuring persistence of implementation: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; QUALITY-IMPROVEMENT; ADOLESCENT HEALTH; PROGRAMS; SUSTAINABILITY; INNOVATIONS; PREVENTION; INTERVENTION; SERVICES AB As more quality improvement programs are implemented to achieve gains in performance, the need to evaluate their lasting effects has become increasingly evident. However, such long-term follow-up evaluations are scarce in healthcare implementation science, being largely relegated to the "need for further research" section of most project write-ups. This article explores the variety of conceptualizations of implementation sustainability, as well as behavioral and organizational factors that influence the maintenance of gains. It highlights the finer points of design considerations and draws on our own experiences with measuring sustainability, framed within the rich theoretical and empirical contributions of others. In addition, recommendations are made for designing sustainability analyses. This article is one in a Series of articles documenting implementation science frameworks and approaches developed by the U. S. Department of Veterans Affairs Quality Enhancement Research Initiative (QUERI). C1 [Bowman, Candice C.] VA San Diego Healthcare Syst, Hlth Serv Res & Dev, San Diego, CA USA. [Sobo, Elisa J.] San Diego State Univ, Dept Anthropol, San Diego, CA 92182 USA. [Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Gifford, Allen L.] VA New England Healthcare Syst, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. RP Bowman, CC (reprint author), VA San Diego Healthcare Syst, Hlth Serv Res & Dev, San Diego, CA USA. EM candybowman@gmail.com; esobo@mail.sdsu.edu; steven.asch@va.gov; agifford@bu.edu FU VA Health Services Research and Development [01-090] FX The authors would like to acknowledge all the members of the QUERI-HIV/Hepatitis project team who contributed to the many aspects of both the main project and the supplemental evaluation. This project was funded by a VA Health Services Research and Development grant (HIT 01-090, Improving HIV Care Quality). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 55 TC 35 Z9 35 U1 0 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD APR 22 PY 2008 VL 3 AR 21 DI 10.1186/1748-5908-3-21 PG 13 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432QW UT WOS:000265150200002 PM 18430200 ER PT J AU Smith, MW Barnett, PG AF Smith, Mark W. Barnett, Paul G. TI The role of economics in the QUERI program: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID COST-EFFECTIVENESS ANALYSIS; CARE DECISION-MAKING; ISPOR TASK-FORCE; GUIDELINE IMPLEMENTATION; INFLUENZA VACCINATION; HEALTH-PROFESSIONALS; VETERANS; STRATEGIES; RECOMMENDATIONS; INTERVENTIONS AB Background: The United States (U. S.) Department of Veterans Affairs (VA) Quality Enhancement Research Initiative (QUERI) has implemented economic analyses in single-site and multi-site clinical trials. To date, no one has reviewed whether the QUERI Centers are taking an optimal approach to doing so. Consistent with the continuous learning culture of the QUERI Program, this paper provides such a reflection. Methods: We present a case study of QUERI as an example of how economic considerations can and should be integrated into implementation research within both single and multi-site studies. We review theoretical and applied cost research in implementation studies outside and within VA. We also present a critique of the use of economic research within the QUERI program. Results: Economic evaluation is a key element of implementation research. QUERI has contributed many developments in the field of implementation but has only recently begun multisite implementation trials across multiple regions within the national VA healthcare system. These trials are unusual in their emphasis on developing detailed costs of implementation, as well as in the use of business case analyses (budget impact analyses). Conclusion: Economics appears to play an important role in QUERI implementation studies, only after implementation has reached the stage of multi-site trials. Economic analysis could better inform the choice of which clinical best practices to implement and the choice of implementation interventions to employ. QUERI economics also would benefit from research on costing methods and development of widely accepted international standards for implementation economics. C1 [Smith, Mark W.; Barnett, Paul G.] US Dept Vet Affairs, Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Smith, Mark W.; Barnett, Paul G.] Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Palo Alto, CA 94304 USA. [Barnett, Paul G.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. RP Smith, MW (reprint author), US Dept Vet Affairs, Hlth Econ Resource Ctr, Menlo Pk, CA USA. EM mark.smith9@va.gov; paul.barnett@va.gov RI Smith, Mark/G-1522-2012 OI Smith, Mark/0000-0002-4582-9088 FU VA Health Services Research and Development Service [TRA 05-081] FX The QUERI Program of the VA Health Services Research and Development Service funded this research through grant TRA 05-081. We gratefully acknowledge comments from the editors and referees, and the research assistance of Andrea Shane. The findings and conclusions in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 51 TC 7 Z9 7 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD APR 22 PY 2008 VL 3 AR 20 DI 10.1186/1748-5908-3-20 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432QW UT WOS:000265150200001 PM 18430199 ER PT J AU Wallace, CM Legro, MW AF Wallace, Carolyn M. Legro, Marcia W. TI Using formative evaluation in an implementation project to increase vaccination rates in high-risk veterans: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID INFLUENZA VACCINATION; QUALITY AB Background: Implementation of research into practice in health care systems is a challenging and often unsuccessful endeavor. The United States Department of Veterans Affairs (VA) Quality Enhancement Research Initiative (QUERI) research teams include formative evaluations (FE) in their action-oriented VA implementation projects to identify critical information about the processes of implementation that can guide adjustments to project activities, in order to better meet project goals. This article describes the development and use of FE in an action-oriented implementation research project. Methods: This two-year action-oriented implementation research project was conducted at 23 VA Spinal Cord Injury (SCI) Centers, and targeted patients, staff and the system of care, such as administration and information technology. Data for FE were collected by electronic and paper surveys, semi-structured and open-ended interviews, notes during conference calls, and exchange of e-mail messages. Specific questions were developed for each intervention (designed to improve vaccination rates for influenza in veterans with spinal cord injury and disorder); informants were selected for their knowledge of interventions and their use in SCI Centers. Results: Data from FE were compiled separately for each intervention to describe barriers to progress and guide adjustments to implementation activities. These data addressed the processes of implementing the interventions, problem-solving activities and the status of interventions at SCI Centers. Conclusion: Formative evaluations provided the project team with a broad view of the processes of implementing multi-targeted interventions as well as the evolving status of the related best practice. Using FE was useful, although the challenges of conducting FE for non-field researchers should be addressed. Work is needed to develop methods for conducting FE across multiple sites, as well as acknowledging variations in local contexts that affect implementation of interventions. C1 [Wallace, Carolyn M.; Legro, Marcia W.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. RP Wallace, CM (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. EM Carolyn.Wallace1@va.gov; mwlegro@msn.com FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service (HSRD) [SCT 01-169]; U. S. Department of Veterans Affairs FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (HSR&D), SCT 01-169. The authors' salaries were supported by the Department of Veterans Affairs during this project. The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of the U. S. Department of Veterans Affairs. NR 10 TC 6 Z9 6 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD APR 22 PY 2008 VL 3 AR 22 DI 10.1186/1748-5908-3-22 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432QW UT WOS:000265150200003 PM 18430201 ER PT J AU Martin, TR Wurfel, MM AF Martin, Thomas R. Wurfel, Mark M. TI A TRIFfic perspective on acute lung injury SO CELL LA English DT Editorial Material ID RESPIRATORY-DISTRESS-SYNDROME AB Acute lung injury (ALI) is a leading cause of death in people infected with H5N1 avian influenza virus or the SARS-coronavirus. Imai et al. (2008) now report that ALI is triggered by the signaling of oxidized phospholipids through Toll-like receptor 4 (TLR4) and the adaptor protein TRIF. These findings provide insight into the molecular pathogenesis of ALI, a condition for which treatment options are currently very limited. C1 [Martin, Thomas R.; Wurfel, Mark M.] Univ Washington, Med Res Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Martin, Thomas R.; Wurfel, Mark M.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98108 USA. RP Martin, TR (reprint author), Univ Washington, Med Res Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM trmartin@u.washington.edu FU NHLBI NIH HHS [HL081764, HL073996, HL629063] NR 11 TC 13 Z9 16 U1 1 U2 4 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD APR 18 PY 2008 VL 133 IS 2 BP 208 EP 210 DI 10.1016/j.cell.2008.04.006 PG 4 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 289JY UT WOS:000255052000009 PM 18423191 ER PT J AU Yang, L Clinton, JM Blackburn, ML Zhang, Q Zou, JH Zielinska-Kwiatkowska, A Tang, BL Chansky, HA AF Yang, Liu Clinton, Jeremiah M. Blackburn, Michael L. Zhang, Qi Zou, Junhui Zielinska-Kwiatkowska, Anna Tang, Bor Luen Chansky, Howard A. TI Rab23 regulates differentiation of ATDC5 chondroprogenitor cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CAMPOMELIC DYSPLASIA; NEGATIVE REGULATOR; GROWTH-PLATE; NEURAL-TUBE; OPEN BRAIN; MOUSE; SOX9; MUTATIONS AB Insulin treatment of mouse ATDC5 chondroprogenitors induces these cells to differentiate into mature chondrocytes. To identify novel factors that are involved in this process, we carried out mutagenesis of ATDC5 cells through retroviral insertion and isolated two mutant clones incapable of differentiation. Inverse PCR analysis of these clones revealed that the retroviral DNA was inserted into the promoter region of the Rab23 gene, resulting in increased Rab23 expression. To investigate whether an elevated level of Rab23 protein led to inhibition of chondrogenic differentiation, we characterized ATDC5 cells that either overexpress endogenous Rab23 or stably express ectopic Rab23. Our results revealed that up-regulation of Rab23 can indeed inhibit chondrogenic differentiation with a concomitant down-regulation of matrix genes such as type II collagen and aggrecan. In addition, stable small interfering RNA knockdown of Rab23 also resulted in inhibition of chondrogenic differentiation as well as down-regulation of Sox9, a master regulator of chondrogenesis. Interestingly, Sox9 expression has recently been linked to Gli1, and we found that Rab23 knockdown decreased Gli1 expression in chondrocytes. Because the phenotypes of Rab23 mutations in mice and humans include defects in cartilage and bone development, our study suggests that Rab23 is involved in the control of Sox9 expression via Gli1 protein. C1 [Yang, Liu; Clinton, Jeremiah M.; Zhang, Qi; Zou, Junhui; Zielinska-Kwiatkowska, Anna; Chansky, Howard A.] Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98195 USA. [Yang, Liu; Blackburn, Michael L.; Chansky, Howard A.] Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. [Tang, Bor Luen] Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore. RP Yang, L (reprint author), Univ Washington, Dept Orthoped, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA. EM lyang@u.washington.edu RI Tang, Bor Luen/E-4548-2012 OI Tang, Bor Luen/0000-0002-1925-636X FU NIAMS NIH HHS [R01 AR051455] NR 27 TC 14 Z9 16 U1 1 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 18 PY 2008 VL 283 IS 16 BP 10649 EP 10657 DI 10.1074/jbc.M706795200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 287CQ UT WOS:000254894700047 PM 18218620 ER PT J AU Taylor, AB Hu, G Hart, PJ McAlister-Henn, L AF Taylor, Alexander B. Hu, Gang Hart, P. John McAlister-Henn, Lee TI Allosteric motions in structures of yeast NAD(+)-specific isocitrate dehydrogenase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMINO-ACID-SEQUENCES; SACCHAROMYCES-CEREVISIAE; ANOMALOUS DIFFRACTION; BINDING-SITES; 3-DIMENSIONAL STRUCTURE; THERMUS-THERMOPHILUS; COMPARATIVE GENOMICS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS AB Mitochondrial NAD(+)-specific isocitrate dehydrogenases (IDHs) are key regulators of flux through biosynthetic and oxidative pathways in response to cellular energy levels. Here we present the first structures of a eukaryotic member of this enzyme family, the allosteric, hetero-octameric, NAD(+)-specific IDH from yeast in three forms: 1) without ligands, 2) with bound analog citrate, and 3) with bound citrate + AMP. The structures reveal the molecular basis for ligand binding to homologous but distinct regulatory and catalytic sites positioned at the interfaces between IDH1 and IDH2 subunits and define pathways of communication between heterodimers and heterotetramers in the hetero-octamer. Disulfide bonds observed at the heterotetrameric interfaces in the unliganded IDH hetero-octamer are reduced in the ligand-bound forms, suggesting a redox regulatory mechanism that may be analogous to the "on-off" regulation of non-allosteric bacterial IDHs via phosphorylation. The results strongly suggest that eukaryotic IDH enzymes are exquisitely tuned to ensure that allosteric activation occurs only when concentrations of isocitrate are elevated. C1 [Taylor, Alexander B.; Hu, Gang; Hart, P. John; McAlister-Henn, Lee] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu; henn@uthscsa.edu FU NIGMS NIH HHS [5R01GM051256] NR 47 TC 27 Z9 27 U1 1 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 18 PY 2008 VL 283 IS 16 BP 10872 EP 10880 DI 10.1074/jbc.M708719200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 287CQ UT WOS:000254894700069 PM 18256028 ER PT J AU Goldstein, NE Genden, E Morrison, RS AF Goldstein, Nathan E. Genden, Eric Morrison, R. Sean TI Palliative care for patients with head and neck cancer - "I would like a quick return to a normal lifestyle" SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID QUALITY-OF-LIFE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; RADIATION-INDUCED XEROSTOMIA; SQUAMOUS-CELL CARCINOMA; INDUCED ORAL MUCOSITIS; HUMAN-PAPILLOMAVIRUS; PROGNOSTIC-FACTORS; LARYNGEAL-CANCER; PHASE-III; MANAGEMENT AB Head and neck cancers constitute a diverse group of diseases including malignancies of the oral cavity, oropharynx, larynx, sinuses, and skull base. Treatment of these cancers includes a combination of surgical resection, chemotherapy, and radiation. Due to both the patterns of disease recurrence and the adverse effects of treatments, patients with head and neck cancer often have a complex and prolonged course of illness that is marked by periods of freedom from disease and symptoms interspersed with bouts of serious illness, debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia. Thus, management of this disease is best provided by an interdisciplinary team that includes individuals from the disciplines of otolaryngology, palliative care, radiation oncology, oncology, nutrition, speech, and physical and occupational therapy. Using the case of Mr K, we describe the symptoms encountered by patients with head and neck cancer and suggest options for management. We discuss the psychological aspects that affect these patients, including issues such as changes in body image, quality of life, anxiety, and guilt. Finally, we discuss the importance of the interdisciplinary team in the care of these patients and outline the roles of each team member. By providing comprehensive care to patients with malignancies of the head and neck, clinicians can increase the likelihood that patients and their families will be able to obtain the best possible outcomes and quality of life. C1 [Goldstein, Nathan E.; Morrison, R. Sean] Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Genden, Eric] Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA. [Goldstein, Nathan E.; Morrison, R. Sean] James J Peters VA Med Ctr, Bronx, NY USA. RP Goldstein, NE (reprint author), Mt Sinai Sch Med, Dept Geriatr, Box 1070,1 Gustave Levy Pl, New York, NY 10029 USA. EM nathan.goldstein@mssm.edu FU NIA NIH HHS [K24AG22345, K23AG025933] NR 81 TC 23 Z9 23 U1 3 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 16 PY 2008 VL 299 IS 15 BP 1818 EP 1825 DI 10.1001/jama.299.15.1818 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 287ZA UT WOS:000254954800026 PM 18413876 ER PT J AU Cavusoglu, E Chopra, V Battala, V Ruwende, C Yanarnadala, S Eng, C Pinsky, DJ Marmur, JD AF Cavusoglu, Erdal Chopra, Vineet Battala, Venkata Ruwende, Cyril Yanarnadala, Sunitha Eng, Calvin Pinsky, David J. Marmur, Jonathan D. TI Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CHRONIC HEART-FAILURE; MYOCARDIAL-INFARCTION; MORTALITY; PROTEIN AB The objective of the present study was to determine the association between plasma adiponectin and left ventricular (LV) systolic function. Baseline plasma adiponectin was measured in 389 patients undergoing coronary angiography for a variety of indications at a Veterans Affairs Medical Center. Detailed demographic, clinical, laboratory, and angiographic data were available for patients. LV systolic function was assessed using ventriculography, and patients were grouped into those with normal or mild dysfunction (ejection fraction >= 45%) versus those with moderate to severe systolic dysfunction (ejection fraction <45%). After adjusting for a variety of clinically relevant covariates known to affect LV systolic function, adiponectin was independently associated with LV systolic function in the entire cohort of patients (p = 0.0002) using multivariate linear regression analysis. In addition, using multivariate logistic regression analysis, adiponectin was an independent predictor of the presence of moderate to severe LV dysfunction (odds ratio 1.54, 95% confidence interval 1.21 to 1.97, p = 0.0005). Moreover, baseline adiponectin was also independently associated with LV function in both the myocardial infarction (MI) and non-MI subpopulations of patients (p = 0.0401 and p = 0.0023, respectively). Finally, in the non-MI subpopulation, baseline adiponectin was an independent predictor of moderate to severe LV systolic dysfunction (odds ratio 1.52, 95% confidence interval 1.15 to 2.02, p = 0.0034). In conclusion, baseline plasma adiponectin was an independent predictor of LV systolic dysfunction in a population of patients referred for coronary angiography. (C) 2008 Elsevier Inc. All rights reserved. C1 [Cavusoglu, Erdal; Battala, Venkata; Marmur, Jonathan D.] SUNY Hlth Sci Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. [Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA. [Ruwende, Cyril; Yanarnadala, Sunitha; Pinsky, David J.] Univ Michigan, Dept Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA. RP Cavusoglu, E (reprint author), SUNY Hlth Sci Ctr, Dept Med, Div Cardiol, 450 Clarkson Ave, Brooklyn, NY 11203 USA. EM ecavusoglu@aol.com NR 14 TC 15 Z9 17 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2008 VL 101 IS 8 BP 1073 EP 1078 DI 10.1016/j.amjcird.2007.12.008 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 288XT UT WOS:000255020200001 PM 18394435 ER PT J AU Camtbell, R Cooper, GS Gilkeson, GS AF Camtbell, Robert, Jr. Cooper, Glinda S. Gilkeson, Gary S. TI Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: Mortality risk and quality of life early in the course of disease SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article ID STAGE RENAL-DISEASE; HEALTH-STATUS; DEATH; IMPACT; RACE; AGE; POPULATION; PREDICTORS; PROGNOSIS; OUTCOMES AB Objective. To evaluate mortality risk and predictors among recently diagnosed systemic lupus erythematosus (SLE) patients. Methods. The vital status of 265 SLE patients and 355 controls enrolled in the Carolina Lupus Study (median time since diagnosis 13 months) was determined similar to 5 years after enrollment. We also assessed the utility of an 8-item quality of life instrument, derived from the standard 36-item Medical Outcomes Study Short Form 36, as an additional measure of disease impact. Results. Five years after diagnosis, 9.7% of patients compared with 0.3% of controls had died (P < 0.0001). Increased mortality risk was seen among older patients (adjusted hazard ratio [HR] 1.03, 95% confidence interval [95% CI] 1.01-1.06 per 1-year increment in age) and among men, African Americans, patients with lupus nephritis, and patients with anti-double-stranded DNA antibodies (adjusted HR similar to 2.0 for each of these factors). In addition, patients who did not provide a blood sample at study enrollment experienced increased mortality risk (age-, sex-, and race-adjusted HR 3.7, 95% CI 1.5-9.1). Similar results were seen in analyses limited to time from study enrollment. Physical component scores of the quality of life measure were 7.7 points lower (P < 0.0001) and mental component scores were 1.8 points lower (P = 0.07) in patients compared with controls. Conclusion. The mortality risk among SLE patients is significant, particularly among African Americans, even early in the disease process and even with currently available treatments. Differences between cases and controls in health-related quality of life using the Short Form 8 also demonstrate the multidimensional burden of SLE. C1 [Camtbell, Robert, Jr.; Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Cooper, Glinda S.] US EPA, Washington, DC 20460 USA. [Gilkeson, Gary S.] Ralph H. Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Camtbell, R (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. FU Intramural NIH HHS; NIAMS NIH HHS [1T32-AR050958, 2R01-AR045476, P60-AR049459] NR 28 TC 6 Z9 8 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD APR 15 PY 2008 VL 59 IS 4 BP 458 EP 464 DI 10.1002/art.23539 PG 7 WC Rheumatology SC Rheumatology GA 288JT UT WOS:000254983400002 PM 18383420 ER PT J AU Kobayashi, N Barnard, RJ Said, J Hong-Gonzalez, J Corman, DM Ku, M Doan, NB Gui, D Elashoff, D Cohen, P Aronson, WJ AF Kobayashi, Naoko Barnard, R. James Said, Jonathan Hong-Gonzalez, Jenny Corman, Dan M. Ku, Melvin Doan, Ngan Bao Gui, Dorina Elashoff, David Cohen, Pinchas Aronson, William J. TI Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model SO CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR-I; INTRAEPITHELIAL NEOPLASIA; CYCLIN D1; C-MYC; BINDING PROTEIN-1; CELL-GROWTH; NOBLE RAT; IGF-I; RISK; PROGRESSION AB This study evaluated the effect of dietary fat on prostate cancer development by using the Hi-Myc mouse transgenic prostate cancer model. Hi-Myc mice develop marine prostatic intraepithelial neoplasia (mPIN) as early as 2 to 4 weeks and invasive adenocarcinoma between 6 and 9 months due to the overexpression of human c-Myc in the mouse prostate. Three-week-old male Hi-Myc mice were placed on high-fat (HF; 42% Kcal) or low-fat (LF; 12% Kcal) diets, and equal caloric intake was maintained until euthanasia at 7 months. The number of mice that developed invasive adenocarcinoma at 7 months was 27% less in the LF diet group (12/28) compared with the HF diet group (23/33, P < 0.05). Epithelial cells in mPIN lesions in the LF group had a significantly lower proliferative index compared with epithelial cells in the HF group (21.7% versus 28.9%, P < 0.05). During the mPIN phase of carcinogenesis (4 months), the LF group had higher serum insulin-like growth factor (IGF) binding protein-1 levels (21.0 +/- 8.9 ng/mL versus 3.2 +/- 0.8 ng/mL, P < 0.05) relative to the HF group. Akt (Ser(473)) phosphorylation, Akt kinase activity, and phosphorylation of downstream targets of Akt in prostates were significantly reduced in the LF diet group compared with the HF group. We conclude that dietary fat reduction delays transition from mPIN to invasive cancer in this Myc-driven transgenic mouse model, possibly through suppression of the IGF-Akt pathway and decreased proliferation of mPIN epithelial cells. C1 [Kobayashi, Naoko; Aronson, William J.] Univ Calif Los Angeles, Dept Urol, Ctr Hlth Sci 66 124, Los Angeles, CA 90095 USA. [Elashoff, David] Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA USA. [Barnard, R. James; Hong-Gonzalez, Jenny; Corman, Dan M.; Ku, Melvin] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA USA. [Said, Jonathan; Doan, Ngan Bao; Gui, Dorina] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA. [Cohen, Pinchas] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. [Cohen, Pinchas] Univ Calif Los Angeles, Div Pediat Endocrinol, Los Angeles, CA USA. [Aronson, William J.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. RP Aronson, WJ (reprint author), Univ Calif Los Angeles, Dept Urol, Ctr Hlth Sci 66 124, Box 951738, Los Angeles, CA 90095 USA. EM waronson@ucla.edu FU NCI NIH HHS [1R01CA100938, P50 CA092131, P50 CA092131-01A10005, P50 CA92131-01A1, R01 CA100938, R01 CA100938-04] NR 50 TC 43 Z9 44 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2008 VL 68 IS 8 BP 3066 EP 3073 DI 10.1158/0008-5472.CAN-07-5616 PG 8 WC Oncology SC Oncology GA 290CM UT WOS:000255100500062 PM 18413778 ER PT J AU Edberg, JC Wu, JM Langefeld, CD Brown, EE Marion, MC McGwin, G Petri, M Ramsey-Goldman, R Reveille, JD Frank, SG Kaufman, KM Harley, JB Alarcon, GS Kimberly, RP AF Edberg, Jeffrey C. Wu, Jianming Langefeld, Carl D. Brown, Elizabeth E. Marion, Miranda C. McGwin, Gerald, Jr. Petri, Michelle Ramsey-Goldman, Rosalind Reveille, John D. Frank, Summer G. Kaufman, Kenneth M. Harley, John B. Alarcon, Graciela S. Kimberly, Robert P. TI Genetic variation in the CRP promoter: association with systemic lupus erythematosus SO HUMAN MOLECULAR GENETICS LA English DT Article ID C-REACTIVE PROTEIN; CARDIOVASCULAR EVENTS; REVISED CRITERIA; POLYMORPHISMS; MICE; COMPLEMENT; DISEASE; RISK; SLE; AUTOIMMUNITY AB The pentraxin C-reactive protein (CRP), an innate immune system opsonin which binds nuclear debris and apoptotic bodies, may protect against autoimmunity. A relative deficiency of CRP levels in patients with systemic lupus erythematosus (SLE) might contribute to altered handling of self-antigens. We report that the proximal 5' promoter region of CRP contains several polymorphisms that exhibit association with SLE in multiple populations. Strongest association was observed at the proximal promoter single nucleotide polymorphism (SNP) rs3093061 (CRP-707) (P = 6.41 x 10(-7) and P = 2.13 x 10(-6) in African-American and Caucasian case-control samples respectively). This association remains after adjustment for admixture. Linkage disequilibrium exists between SNPs in the proximal promoter and association of functional haplotypes containing rs3091244/rs3093062 (CRP-409/-390) appear to be driven by the rs3093061 (CRP-707) association. These data demonstrate that rs3093061 at the -707 site within the CRP gene is an SLE susceptibility locus. C1 [Edberg, Jeffrey C.; Wu, Jianming; Alarcon, Graciela S.; Kimberly, Robert P.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Brown, Elizabeth E.] Univ Alabama, Dept Epidemiol, Birmingham, AL 35294 USA. [McGwin, Gerald, Jr.] Univ Alabama, Dept Surg, Sect Trauma Burns & Crit Care, Birmingham, AL 35294 USA. [Langefeld, Carl D.] Wake Forest Univ, Dept Biostat Sci, Div Publ Hlth Sci, Sect Stat Genet & Bioinformat, Winston Salem, NC 27109 USA. [Petri, Michelle] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA. [Reveille, John D.] Univ Texas Houston, Hlth Sci Ctr, Dept Med, Div Rheumatol, Houston, TX USA. [Frank, Summer G.; Kaufman, Kenneth M.; Harley, John B.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Oklahoma City, OK USA. [Kaufman, Kenneth M.; Harley, John B.] Univ Oklahoma, Dept Med, Oklahoma City, OK USA. RP Edberg, JC (reprint author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, SHEL207,1825 Univ Blvd, Birmingham, AL 35294 USA. EM jedberg@uab.edu OI Kimberly, Robert/0000-0002-5330-3086; Frank, Summer/0000-0003-0779-4926 FU NCRR NIH HHS [M01 RR000048, M01-RR00032, M01-RR00048, M01-RR00052, M01-RR02558, RR020143]; NIAID NIH HHS [AI24717]; NIAMS NIH HHS [AR048940, AR42460, AR43727, K24 AR002138, P01 AR49084, P30 AR053483, P60 AR048098] NR 45 TC 41 Z9 43 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD APR 15 PY 2008 VL 17 IS 8 BP 1147 EP 1155 DI 10.1093/hmg/ddn004 PG 9 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 284LP UT WOS:000254708200009 PM 18182444 ER PT J AU Johnson, SW AF Johnson, Steven W. TI Rebound bursts following inhibition: how dopamine modifies firing pattern in subthalamic neurons SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Editorial Material ID NUCLEUS NEURONS; BASAL GANGLIA; IN-VITRO C1 Oregon Hlth & Sci Univ, Dept Neurol, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. EM johnsost@ohsu.edu NR 9 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD APR 15 PY 2008 VL 586 IS 8 BP 2033 EP 2033 DI 10.1113/jphysiol.2008.153643 PG 1 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 288PM UT WOS:000254998300002 PM 18413336 ER PT J AU Hudson, LA Rollins, YD Anderson, CA Johnston-Brooks, C Tyler, KL Filley, CM AF Hudson, Lynsee A. Rollins, Yvonne D. Anderson, C. Alan Johnston-Brooks, Catharine Tyler, Kenneth L. Filley, Christopher M. TI Reduplicative paramnesia in Morvan's syndrome SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE reduplicative paramnesia; encephalopathy; VGKC antibodies; myokymia; myoclonus ID POTASSIUM CHANNEL ANTIBODY; CENTRAL-NERVOUS-SYSTEM; LIMBIC ENCEPHALITIS; MISIDENTIFICATION SYNDROMES; ENCEPHALOPATHY; LOCALIZATION; DISORDERS AB Background: Morvan's syndrome is characterized by peripheral nervous system hyperexcitibility (myokymia and neuromyotonia), hyperhydrosis, sleep disorder, limb paresthesias, and encephalopathy. Voltage gated potassium channel antibodies (VGKC abs) are frequently present. Reduplicative paramnesia (RP) has not been reported with this disorder. Objective: To describe a patient with Morvan's syndrome presenting with R-P. Design: Single case study. Patient: A 64-year-old man with several years of myokymia and myoclonus with escalating parasomnia and confusion developed the delusion that a replica of his house and its contents existed 40 mi away. Results: Serum VGKC ab titer was elevated. Neuropsychological testing disclosed executive function and memory deficits. Electromyography demonstrated diffuse myokymia. Treatment with intravenous immunoglobulin and prednisone produced improvement of RP and myoclonus, but not myokymia. Conclusion: RP may occur in patients with VGKC ab-associated Morvan's syndrome. Both RP and nervous system hyperexcitability may respond to immunotherapy including intravenous immunoglobulin and corticosteroids. (C) 2007 Elsevier B.V. All rights reserved. C1 [Hudson, Lynsee A.; Rollins, Yvonne D.; Anderson, C. Alan; Tyler, Kenneth L.; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Colorado Springs, CO 80907 USA. [Anderson, C. Alan; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Colorado Springs, CO 80907 USA. [Tyler, Kenneth L.] Univ Colorado, Sch Med, Dept Med, Colorado Springs, CO 80907 USA. [Tyler, Kenneth L.] Univ Colorado, Sch Med, Dept Microbiol, Colorado Springs, CO 80907 USA. [Rollins, Yvonne D.; Anderson, C. Alan; Johnston-Brooks, Catharine; Tyler, Kenneth L.; Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Filley, CM (reprint author), UCHSC B-183,4200 E 9th Ave, Denver, CO 80262 USA. EM christopher.filley@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 NR 29 TC 7 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD APR 15 PY 2008 VL 267 IS 1-2 BP 154 EP 157 DI 10.1016/j.jns.2007.09.030 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 276YW UT WOS:000254180600025 PM 17928004 ER PT J AU Haugarvoll, K Rademakers, R Kachergus, JM Nuytemans, K Ross, OA Gibson, JM Tan, EK Gaig, C Tolosa, E Goldwurm, S Guidi, M Riboldazzi, G Brown, L Walter, U Benecke, R Berg, D Gasser, T Theuns, J Pals, P Cras, P De Deyn, PP Engelborghs, S Pickut, B Uitti, RJ Foroud, T Nichols, WC Hagenah, J Klein, C Samii, A Zabetian, CP Bonifati, V Van Broeckhoven, C Farrer, MJ Wszolek, ZK AF Haugarvoll, K. Rademakers, R. Kachergus, J. M. Nuytemans, K. Ross, O. A. Gibson, J. M. Tan, E. -K. Gaig, C. Tolosa, E. Goldwurm, S. Guidi, M. Riboldazzi, G. Brown, L. Walter, U. Benecke, R. Berg, D. Gasser, T. Theuns, J. Pals, P. Cras, P. De Deyn, P. Paul Engelborghs, S. Pickut, B. Uitti, R. J. Foroud, T. Nichols, W. C. Hagenah, J. Klein, C. Samii, A. Zabetian, C. P. Bonifati, V. Van Broeckhoven, C. Farrer, M. J. Wszolek, Z. K. TI Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease SO NEUROLOGY LA English DT Article ID AUTOSOMAL-DOMINANT PARKINSONISM; KINASE-ACTIVITY; RISK-FACTOR; MUTATIONS; G2019S; POPULATION; VARIANT; GENE; PENETRANCE; GLY2385ARG AB Objective: Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common cause of Parkinson disease (PD). Several dominantly inherited pathogenic substitutions have been identified in different domains of the Lrrk2 protein. Herein, we characterize the clinical and genetic features associated with Lrrk2 p. R1441C. Methods: We identified 33 affected and 15 unaffected LRRK2 c. 4321C>T (p. R1441C) mutation carriers through an international consortium originating from three continents. The age-specific cumulative incidence of PD was calculated by Kaplan-Meier analysis. Results: The clinical presentation of Lrrk2 p.R1441C carriers was similar to sporadic PD and Lrrk2 p.G2019S parkinsonism. The mean age at onset for parkinsonism was 60 years, range 30-79 years; fewer than 20% of the patients had symptoms before the age 50 years, while by 75 years >90% of them had developed symptoms. Haplotype analysis suggests four independent founders for the p. R1441C mutation. Conclusions: The distribution in age at onset and clinical features in Lrrk2 p.R1441C patients are similar to idiopathic and Lrrk2 p.G2019S parkinsonism. Several independent founders of the p.R1441C substitution suggest this site is prone to recurrent mutagenesis. C1 [Haugarvoll, K.; Rademakers, R.; Kachergus, J. M.; Ross, O. A.; Brown, L.; Uitti, R. J.; Farrer, M. J.; Wszolek, Z. K.] Mayo Clin, Coll Med, Dept Neurol, Jacksonville, FL 32224 USA. [Haugarvoll, K.; Rademakers, R.; Kachergus, J. M.; Ross, O. A.; Brown, L.; Uitti, R. J.; Farrer, M. J.; Wszolek, Z. K.] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA. [Haugarvoll, K.] NTNU Norwegian Univ Sci & Technol, Dept Neurosci, Trondheim, Norway. [Rademakers, R.; Nuytemans, K.; Theuns, J.; Van Broeckhoven, C.] Inst Born Bunge, Neurodegenerat Brain Dis Grp, Antwerp, Belgium. [Rademakers, R.; Nuytemans, K.; Theuns, J.; Van Broeckhoven, C.] Inst Born Bunge, Dept Mol Genet, VIB, Neurogenet Lab, Antwerp, Belgium. [Rademakers, R.; Nuytemans, K.; Theuns, J.; Pals, P.; Cras, P.; De Deyn, P. Paul; Engelborghs, S.; Van Broeckhoven, C.] Univ Antwerp, B-2020 Antwerp, Belgium. [Gibson, J. M.] Royal Victoria Hosp, Dept Neurol, Belfast BT12 6BA, Antrim, North Ireland. [Tan, E. -K.] Singapore Gen Hosp, Singapore 0316, Singapore. [Gaig, C.; Tolosa, E.] Univ Barcelona, Parkinsons Dis & Movement Disorders Unit, E-08007 Barcelona, Spain. Univ Barcelona, Inst Clin Neurociencies, E-08007 Barcelona, Spain. [Gaig, C.; Tolosa, E.] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Ctr Invest Biomed Red Enfermedades Neurodegenerat, E-08007 Barcelona, Spain. [Goldwurm, S.] Ist Clin Perfezionamento, Parkinson Inst, Milan, Italy. [Guidi, M.] INRCA Inst, Div Neurol, Ancona, Italy. [Riboldazzi, G.] Univ Insubria, Dept Neurol, Varese, Italy. [Walter, U.; Benecke, R.] Univ Rostock, Dept Neurol, D-2500 Rostock 1, Germany. [Berg, D.; Gasser, T.] Hertie Inst Clin Brain Res, Tubingen, Germany. [Pals, P.; Cras, P.] Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium. [Pals, P.; Cras, P.] Inst Born Bunge, Neurobiol Lab, Antwerp, Belgium. [De Deyn, P. Paul; Engelborghs, S.] Inst Born Bunge, Lab Neurochem & Behav, Antwerp, Belgium. [De Deyn, P. Paul; Engelborghs, S.; Pickut, B.] ZNA Middelheim Antwerp, Div Neurol, Antwerp, Belgium. [Foroud, T.] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. [Nichols, W. C.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA. [Nichols, W. C.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA. [Hagenah, J.; Klein, C.] Uni Lubeck, Dept Neurol & Human Genet, Lubeck, Germany. [Samii, A.; Zabetian, C. P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Bonifati, V.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands. RP Wszolek, ZK (reprint author), Mayo Clin, Coll Med, Dept Neurol, Cannady Bldg 2E,4500 San Pablo Rd, Jacksonville, FL 32224 USA. EM wszolek.zbigniew@mayo.edu RI Ross, Owen/D-7573-2013; Nuytemans, Karen/F-4797-2012; Haugarvoll, Kristoffer/L-1486-2015; Goldwurm, Stefano/Q-8978-2016 OI Haugarvoll, Kristoffer/0000-0001-9381-1109; Goldwurm, Stefano/0000-0002-1651-567X FU NINDS NIH HHS [K08 NS044138, P50 NS040256, P50 NS40256, R01 NS037167, R01 NS37167]; Telethon [GTB07001] NR 30 TC 67 Z9 67 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR 15 PY 2008 VL 70 IS 16 BP 1456 EP 1460 DI 10.1212/01.wnl.0000304044.22253.03 PN 2 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 312XW UT WOS:000256706700015 PM 18337586 ER PT J AU Aujesky, D Stone, RA Kim, S Crick, EJ Fine, MJ AF Aujesky, Drahomir Stone, Roslyn A. Kim, Sunghee Crick, Elsa J. Fine, Michael J. TI Length of hospital stay and postdischarge mortality in patients with pulmonary embolism SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID DEEP VENOUS THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; OUTPATIENT TREATMENT; ANTICOAGULATION THERAPY; THROMBOEMBOLISM; OUTCOMES; VALIDATION; MODEL AB Background: The optimal length of stay (LOS) for patients with pulmonary embolism (PE) is unknown. Although reducing LOS is likely to save costs, the effects on patient safety are unclear. We sought to identify patient and hospital factors associated with LOS and assess whether LOS was associated with postdischarge mortality. Methods: We evaluated patients discharged with a primary diagnosis of PE from 186 acute care hospitals in Pennsylvania (January 2000 through November 2002). We used discrete survival models to examine the association between (1) patient and hospital factors and the time to discharge and (2) LOS and postdischarge mortality within 30 days of presentation, adjusting for patient and hospital factors. Results: Among 15 531 patient discharges with PE, the median LOS was 6 days, and postdischarge mortality rate was 33%. In multivariate analysis, patients from Philadelphia were less likely to be discharged on a given day (odds ratio [OR], 0.82; 95% confidence interval [CI], 0.730.93), as were black patients (OR, 0.88; 95% CI, 0.820.94). The odds of discharge decreased notably with greater patient severity of illness and in patients without private health insurance. Adjusted postdischarge mortality was significantly higher for patients with an LOS of 4 days or less (OR, 1.55; 95% CI, 1.21-2.00) relative to those with an LOS of 5 to 6 days. Conclusions: Several hospital and patient factors were independently associated with LOS. Patients with a very short LOS had greater postdischarge mortality relative to patients with a typical LOS, suggesting that physicians may inappropriately select patients with PE for early discharge who are at increased risk of complications. C1 [Aujesky, Drahomir] Univ Lausanne, Div Internal Med, Lausanne, Switzerland. [Kim, Sunghee; Crick, Elsa J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Stone, Roslyn A.; Kim, Sunghee] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA USA. RP Aujesky, D (reprint author), CHU Vaudois, Serv Med Interne, BH 10-622, CH-1011 Lausanne, Switzerland. EM drahomir.aujesky@chuv.ch FU NHLBI NIH HHS [1 R21 HL075521-01A1] NR 24 TC 36 Z9 36 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 14 PY 2008 VL 168 IS 7 BP 706 EP 712 DI 10.1001/archinte.168.7.706 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 286HC UT WOS:000254836000005 PM 18413552 ER PT J AU Kobelt, P Wisser, AS Stengel, A Goebel, M Inhoff, T Noetzel, S Veh, RW Bannert, N van der Voort, I Wiedenmann, B Klapp, BF Tache, Y Monnikes, H AF Kobelt, Peter Wisser, Anna-Sophia Stengel, Andreas Goebel, Miriam Inhoff, Tobias Noetzel, Steffen Veh, Ruediger W. Bannert, Norbert van der Voort, Iva Wiedenmann, Bertram Klapp, Burghard F. Tache, Yvette Moennikes, Hubert TI Peripheral injection of ghrelin induces Fos expression in the dorsomedial hypothalamic nucleus in rats SO BRAIN RESEARCH LA English DT Article DE ghrelin; dorsomedial hypothalamic nucleus; Fos; brain; rat; food intake ID GROWTH-HORMONE-SECRETION; AGOUTI-RELATED PROTEIN; ARCUATE NUCLEUS; NEUROPEPTIDE-Y; FOOD-INTAKE; C-FOS; PARAVENTRICULAR NUCLEUS; FEEDING-BEHAVIOR; ACYLATED PEPTIDE; MESSENGER-RNA AB Peripheral ghrelin has been shown to act as a gut-brain peptide exerting a potent orexigenic effect on food intake. The dorsomedial nucleus of the hypothalamus (DMH) is innervated by projections from other brain areas being part of the network of nuclei controlling energy homeostasis, among others NPY/AgRP-positive fibers arising from the arcuate nucleus (ARC). The aim of the study was to determine if peripherally administered ghrelin affects neuronal activity in the DMH, as assessed by Fos expression. The number of Fos positive neurons was determined in the DMH, paraventricular nucleus of the hypothalamus (PVN), ARC, ventromedial hypothalamic nucleus (VMH), nucleus of the solitary tract (NTS) and in the area postrema (AP) in non-fasted Sprague-Dawley rats in response to intraperitoneally (ip) injected ghrelin (3 nmol/rat) or vehicle (0.15 M NaCI). Peripheral ghrelin induced a significant increase in the number of Fos-ir positive neurons/section compared with vehicle in the ARC (mean SEM: 49 +/- 2 us. 23 +/- 2 neurons/section, p = 0.001), PVN (69 +/- 5 us. 34 +/- 3, p = 0.001), and DMH (142 +/- 5 us. 83 5, p<0.001). Fos-ir positive neurons were mainly localized within the ventral part of the DMH. No change in Fos expression was observed in the VMH (53 +/- 8 vs.48 +/- 6,p = 0.581), NTS (42 +/- 2 vs. 40 +/- 3,p = 0.603), and in the AP (7 +/- 1 vs. 5 +/- 1, p = 0.096). Additional double-labelling with anti-Fos and anti-AgRP revealed that Fos positive neurons in the DMH were encircled by a network of AgRP-ir positive fibers. These data indicate that peripheral ghrelin activates DMH neurons and that NPY-/AgRP-positive fibers may be involved in the response. (C) 2008 Elsevier B.V. All rights reserved. C1 [Kobelt, Peter; Wisser, Anna-Sophia; Stengel, Andreas; Goebel, Miriam; Inhoff, Tobias; Noetzel, Steffen; van der Voort, Iva; Wiedenmann, Bertram; Moennikes, Hubert] Acad Training Inst Charite Univmed Berlin, Martin Luther Hosp, Dept Med, D-14133 Berlin, Germany. [Moennikes, Hubert] Acad Training Inst Charite Univmed Berlin, Martin Luther Hosp, Inst Neurogastroenterol, D-14133 Berlin, Germany. [Kobelt, Peter; Klapp, Burghard F.] Univmed Berlin, Div Psychosomat Med & Psychotherapy, Dept Med, Berlin, Germany. [Bannert, Norbert] Robert Koch Inst, D-1000 Berlin, Germany. [Tache, Yvette] Vet Affairs Greater Los Angeles Hlthcare Syst, Los Angeles, CA USA. [Tache, Yvette] Univ Calif Los Angeles, CURE Digest Res Ctr, Div Digest Dis, Dept Med, Los Angeles, CA USA. [Tache, Yvette] Univ Calif Los Angeles, Ctr Neurovisceral Sci, Los Angeles, CA USA. [Moennikes, Hubert] Martin Luther Hosp, Dept Med, Berlin, Germany. [Moennikes, Hubert] Martin Luther Hosp, Inst Neurogasteroenterol, Berlin, Germany. RP Monnikes, H (reprint author), Acad Training Inst Charite Univmed Berlin, Martin Luther Hosp, Dept Med, Casper Theyss Str 27-31, D-14133 Berlin, Germany. EM moennikes@web.de FU NIDDK NIH HHS [DK R01 33061, R01 DK033061, R01 DK033061-22] NR 45 TC 22 Z9 24 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD APR 14 PY 2008 VL 1204 BP 77 EP 86 DI 10.1016/j.brainres.2008.01.054 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 296SV UT WOS:000255567000008 PM 18329635 ER PT J AU Pagan, JA Asch, DA Brown, CJ Guerra, CE Armstrong, K AF Pagan, Jose A. Asch, David A. Brown, Cynthia J. Guerra, Carmen E. Armstrong, Katrina TI Lack of community insurance and mammography screening rates among insured and uninsured women SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID HEALTH-INSURANCE; INCOME INEQUALITY; UNITED-STATES; MANAGED CARE; SELF-REPORT; CANCER; ACCURACY; ADULTS; NEEDS AB Purpose To evaluate whether the proportion of the local population without health insurance coverage is related to whether women undergo mammography screening. Methods Survey data on 12,595 women 40 to 69 years of age from the 2000 to 2001 Community Tracking Study Household Survey were used to analyze the relation between community lack of insurance and whether the respondent had a mammogram within the past year. Results Women age 40 to 69 were less likely to report that they had a mammogram within the last year if they resided in communities with a relatively high uninsurance rate, even after adjusting for other factors. After adjusting for individual insurance and other factors, a 10-percentage-point decrease in the proportion of the local insured population is associated with a 17% (95% CI, 13% to 21%) decrease in the odds that a woman age 40 to 69 years will undergo mammography screening within a year. Conclusion Women living in communities with high uninsurance are substantially less likely to undergo mammography screening. These results are consistent with the view that the negative impact of uninsurance extends to everyone in the community regardless of individual health insurance status. C1 [Pagan, Jose A.] Univ Texas Pan Amer, Dept Econ & Finance, Coll Business Adm, Edinburg, TX 78539 USA. Univ Texas Pan Amer, Inst Populat Hlth Policy, Coll Business Adm, Edinburg, TX 78541 USA. Univ Penn, Sch Med, Davis Inst Hlth Econ, Div Gen Internal Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Pagan, JA (reprint author), Univ Texas Pan Amer, Dept Econ & Finance, Coll Business Adm, 1201 W Univ Dr, Edinburg, TX 78539 USA. EM jpagan@utpa.edu OI Asch, David/0000-0002-7970-286X NR 32 TC 9 Z9 9 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR 10 PY 2008 VL 26 IS 11 BP 1865 EP 1870 DI 10.1200/JCO.2007.14.5664 PG 6 WC Oncology SC Oncology GA 289KY UT WOS:000255054600017 PM 18398151 ER PT J AU Raitt, MH AF Raitt, Merritt H. TI Implantable cardioverter-defibrillator shocks SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID CONGESTIVE-HEART-FAILURE; HOSPITALIZATION; DEPRESSION; ATTITUDES; ANXIETY; TRIAL; DEATH C1 [Raitt, Merritt H.] Portland VA Med Ctr, Div Cardiol, Portland, OR USA. RP Raitt, MH (reprint author), 3710 SW US Vet Rd, Portland, OR 97239 USA. EM merritt.raitt@va.gov NR 20 TC 11 Z9 11 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 8 PY 2008 VL 51 IS 14 BP 1366 EP 1368 DI 10.1016/j.jacc.2007.12.032 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 284AL UT WOS:000254677500006 PM 18387437 ER PT J AU Rumsfeld, JS Nallamothu, BK AF Rumsfeld, John S. Nallamothu, Brahmajee K. TI The hope and fear of Rimonabant SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; CORONARY ATHEROSCLEROSIS; RISK-FACTORS; OVERWEIGHT; OBESITY; PROGRESSION; DISEASE; WEIGHT C1 [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Sect Cardiol 111B, Denver, CO 80220 USA. [Rumsfeld, John S.] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Nallamothu, Brahmajee K.] Ann Arbor Vet Affairs Med Ctr, Cardiol Sect, Ann Arbor, MI USA. [Nallamothu, Brahmajee K.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. RP Rumsfeld, JS (reprint author), Denver Vet Affairs Med Ctr, Sect Cardiol 111B, 1055 Clermont St, Denver, CO 80220 USA. EM john.rumsfeld@va.gov NR 14 TC 18 Z9 19 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 2 PY 2008 VL 299 IS 13 BP 1601 EP 1602 DI 10.1001/jama.299.13.1601 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 281RZ UT WOS:000254517900028 PM 18387935 ER PT J AU Diem, K Nickle, DC Motoshige, A Fox, A Ross, S Mullins, JI Corey, L Coombs, RW Krieger, JN AF Diem, Kurt Nickle, David C. Motoshige, Alexis Fox, Alan Ross, Susan Mullins, James I. Corey, Lawrence Coombs, Robert W. Krieger, John N. TI Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV) SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article; Proceedings Paper CT 44th Interscience Conference on Antimicrobial Agents and Chemotherapy CY OCT 30-NOV 02, 2004 CL Washington, DC ID N-LINKED GLYCOSYLATION; V3 LOOP; BLOOD; SEMEN; INFECTION; CELLS; RESERVOIRS; ENV AB We present phylogenetic evidence supporting viral compartmentalization between the blood ( peripheral blood mononuclear cells or plasma) and multiple genitourinary sites in HIV-infected men. Four of the five subjects evaluated demonstrated compartmentalization of viral sequences between urogenital tract specimens ( tissue or fluid) and at least one blood category. HIV sequence migration from blood to urogenital tract was detected in four of five men, with migration from urogenital tract to blood in the fifth, and cross migration between both compartments noted in one man. These observations add 5 additional cases to the 27 total reported cases in which male urogenital tract compartmentalization has been studied, investigate surgical samples/specimens that have not been evaluated previously, and provide further evidence for restricted flow of HIV between the blood and the genital tract. As such, our study findings are important for understanding the long-term response to antiretroviral therapy, the design of vaccines, and the sexual transmission of HIV. C1 [Ross, Susan; Krieger, John N.] Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Diem, Kurt; Motoshige, Alexis; Fox, Alan; Corey, Lawrence; Coombs, Robert W.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Nickle, David C.; Mullins, James I.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. RP Krieger, JN (reprint author), Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Box 358280,Room 6B-127,GU-112, Seattle, WA 98195 USA. EM jkrieger@u.washington.edu FU NIAID NIH HHS [AI-27664, AI-27757, AI-38858, AI-57005]; NICHD NIH HHS [HD-40540]; NIDDK NIH HHS [DK-49477] NR 25 TC 37 Z9 37 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD APR PY 2008 VL 24 IS 4 BP 561 EP 571 DI 10.1089/aid.2007.0115 PG 11 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 294GV UT WOS:000255394900006 PM 18426336 ER PT J AU Mak, KM Ren, CL Ponomarenko, A Cao, Q Lieber, CS AF Mak, Ki M. Ren, Chaoling Ponomarenko, Anatoly Cao, Qi Lieber, Charles S. TI Adipose differentiation-related protein is a reliable lipid droplet marker in alcoholic fatty liver of rats SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE adipose differentiation-related protein; immunohistochemistry; lipid droplet marker; alcoholic fatty liver; medium-chain triglycerides ID MEDIUM-CHAIN TRIGLYCERIDES; DIMINISHED DEPOSITION; ACCUMULATION; ADIPOPHILIN; HEPATOCYTES; METABOLISM; STORAGE; LONG; DIET AB Background: Adipose differentiation-related protein (ADRP) is a lipid droplet-associated protein that coats cytoplasmic lipid droplets. The present study evaluated whether alcohol feeding enhances ADRP expression and whether ADRP is a lipid droplet marker in alcoholic fatty liver of rats. Because medium-chain triglycerides (MCT) reduce alcoholic hepatosteatosis, their effects on ADRP were also evaluated. Methods: Fatty liver was induced in rats by the consumption of the Lieber-DeCarli alcohol liquid diet with or without replacement of long-chain triglycerides (LCT) by MCT (32% of calories). Immunohistochemical staining for ADRP was performed in formalin-fixed, paraffin-embedded liver sections. ADRP immunostaining was quantified by image analysis. Triacylglycerol was measured chemically. ADRP mRNA and protein were analyzed by real-time polymerase chain reaction and western blot, respectively. Double staining technique was performed to distinguish ADRP from glycogen in hepatocytes. Results: Alcohol feeding for 21 days increased ADRP staining in the centrilobular and mid zonal regions of the liver lobules coincident with fat deposition in the liver. Replacing LCT in the alcohol diet with MCT diminished ADRP immunostaining in parallel with reduced steatosis. MCT also attenuated the up-regulation of ADRP mRNA and protein after alcohol. In steatotic hepatocytes ADRP selectively stained the surface of macrovesicular and microvesicular lipid droplets. ADRP immunostaining quantitatively correlated with hepatic triacylglycerol levels, validating ADRP as a reliable lipid droplet marker. Compared with hematoxylin and eosin stains, ADRP was more sensitive in detecting microvesicular lipid droplets. ADRP immunostaining also distinguished lipid droplets from glycogen, as demonstrated by double staining for ADRP and glycogen. Conclusions: Alcohol induction of fatty liver enhances ADRP expression and MCT oppose the alcohol effects. ADRP is a reliable and sensitive marker for lipid droplets in alcoholic fatty liver. ADRP immunostaining permits quantification of fatty change in hepatocytes and can be used as an ancillary technique in assessing the efficacy of diets or drugs against hepatosteatosis. C1 [Ponomarenko, Anatoly; Lieber, Charles S.] James J VA Med Ctr, Bronx, NY 10468 USA. [Mak, Ki M.; Ren, Chaoling; Cao, Qi; Lieber, Charles S.] Mt Sinai Sch Med, New York, NY USA. RP Lieber, CS (reprint author), James J VA Med Ctr, 130 W Kingsbridge Rd 151-2, Bronx, NY 10468 USA. EM liebercs@aol.com FU NIAAA NIH HHS [R01 AA012867] NR 24 TC 26 Z9 29 U1 2 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD APR PY 2008 VL 32 IS 4 BP 683 EP 689 DI 10.1111/j.1530-0277.2008.00624.x PG 7 WC Substance Abuse SC Substance Abuse GA 278FV UT WOS:000254271200015 PM 18341646 ER PT J AU Ho, PM Magid, DJ Shetterly, SM Olson, KL Maddox, TM Peterson, PN Masoudi, FA Rumsfeld, JS AF Ho, P. Michael Magid, David J. Shetterly, Susan M. Olson, Kari L. Maddox, Thomas M. Peterson, Pamela N. Masoudi, Frederick A. Rumsfeld, John S. TI Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease SO AMERICAN HEART JOURNAL LA English DT Article ID CONVERTING ENZYME-INHIBITORS; ACUTE MYOCARDIAL-INFARCTION; HEALTH MAINTENANCE ORGANIZATION; RANDOMIZED CONTROLLED-TRIAL; BETA-BLOCKERS; SECONDARY PREVENTION; ELDERLY PATIENTS; STATIN THERAPY; BLOOD-PRESSURE; DRUG-THERAPY AB Background Little is known about the effect of nonadherence among patients with coronary artery disease (CAD) on a broad spectrum of outcomes including cardiovascular mortality, cardiovascular hospitalizations, and revascularization procedures. Methods This was a retrospective cohort study of 15767 patients with CAD. Medication adherence was calculated as proportion of days covered for filled prescriptions of)beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statin medications. Multivariable Cox regression assessed the association between medication nonadherence as a time-varying covariate and a broad range of outcomes, adjusting for demographics and clinical characteristics. Median follow-up was 4.1 years. Results Rates of medication nonadherence were 28.8% for beta-blockers, 21.6% for ACE inhibitors, and 26.0% for statins. In unadjusted analysis, nonadherence to each class of medication was associated with higher all-cause and cardiovascular mortality. In multivariable analysis, nonadherence remained significantly associated with increased all-cause mortality risk for (beta-blockers (hazard ratio [HR] 1.50, 95 % CI 1.33-1.71), ACE inhibitors (HR 1.74, 95 % CI 1.52-1.98), and statins (HR 1.85, 95 % CI 1.63-2.09). In addition, nonadherence remained significantly associated with higher risk of cardiovascular mortality for (beta-blockers (HR 1.53, 95% CI 1.16-2.01), ACE inhibitors (HR 1.66, 95% CI 1.26-2.20), and statins (HR 1.62, 95 % CI 1.124-2.13). The findings of increased risk associated with nonadherence were consistent for cardiovascular hospitalization and revascularization procedures. Conclusions Nonadherence to cardioprotective medications is common in clinical practice and associated with a broad range of adverse outcomes. These findings suggest that medication nonadherence should be a target for quality improvement interventions to maximize the outcomes of patients with CAD. C1 [Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.] Denver VA Med Ctr, Cardiol Sect, Denver, CO USA. [Ho, P. Michael; Magid, David J.; Olson, Kari L.; Maddox, Thomas M.; Peterson, Pamela N.; Masoudi, Frederick A.; Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Ho, P. Michael; Magid, David J.; Shetterly, Susan M.; Maddox, Thomas M.; Peterson, Pamela N.; Masoudi, Frederick A.; Rumsfeld, John S.] Kaiser Permanente Colorado, Clin Res Unit, Aurora, CO USA. [Olson, Kari L.] Kaiser Permanente Colorado, Dept Pharm & Clin Pharm, Cardiac Risk Serv, Aurora, CO USA. [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Dept Med, Denver, CO USA. RP Ho, PM (reprint author), 1055 Clermont St 111B, Denver, CO 80220 USA. EM michael.ho@uchsc.edu NR 26 TC 233 Z9 240 U1 1 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD APR PY 2008 VL 155 IS 4 BP 772 EP 779 DI 10.1016/j.ahj.2007.12.011 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 285WY UT WOS:000254808100030 PM 18371492 ER PT J AU Zhang, J Sokal, I Peskind, ER Quinn, JF Jankovic, J Kenney, C Chung, KA Millard, SP Nutt, JG Montine, TJ AF Zhang, Jing Sokal, Izabela Peskind, Elaine R. Quinn, Joseph F. Jankovic, Joseph Kenney, Christopher Chung, Kathryn A. Millard, Steven P. Nutt, John G. Montine, Thomas J. TI CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE cerebrospinal fluid; Alzheimer disease; Parkinson disease; biomarkers; analyte profile; random forest algorithm ID MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; DIAGNOSTIC-CRITERIA; TASK-FORCE; BIOMARKERS; PROTEOMICS AB The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) tau and decreased amyloid (A) beta(42) have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): tau, brain-derived neurotrophic factor, interleukin 8, A beta(42), beta(2)-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD. C1 [Zhang, Jing; Sokal, Izabela; Montine, Thomas J.] Univ Washington, Harborview Med Ctr, Dept Pathol, Sch Med, Seattle, WA 98104 USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Peskind, Elaine R.; Millard, Steven P.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Quinn, Joseph F.; Chung, Kathryn A.; Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Jankovic, Joseph; Kenney, Christopher] Baylor Coll Med, Dept Neurol, Parkinsons Dis Ctr, Houston, TX 77030 USA. [Jankovic, Joseph; Kenney, Christopher] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA. RP Montine, TJ (reprint author), Univ Washington, Harborview Med Ctr, Dept Pathol, Sch Med, 300 9th Ave, Seattle, WA 98104 USA. FU NIA NIH HHS [AG05136, P50 AG005136, P50 AG005136-25] NR 18 TC 147 Z9 158 U1 1 U2 9 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD APR PY 2008 VL 129 IS 4 BP 526 EP 529 DI 10.1309/W01Y0B808EMEH12L PG 4 WC Pathology SC Pathology GA 276FV UT WOS:000254127600002 PM 18343778 ER PT J AU Wahecd, S AF Wahecd, SaInian TI Characterizing treatment of stage 3 chronic kidney disease (CKD) amongst hispanics, African-Americans (AA), and caucasians SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY APR 02-06, 2008 CL Dallas, TX SP Natl Kidney Fdn C1 [Wahecd, SaInian] James J Peters VA Med Ctr, Dept Med, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2008 VL 51 IS 4 MA 271 BP A95 EP A95 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 286VP UT WOS:000254874400298 ER PT J AU Tran, N Valentin-Blasini, L Blount, BC McCuistion, CG Fenton, MS Gin, E Salem, A Hershman, JM AF Tran, Neil Valentin-Blasini, Liza Blount, Benjamin C. McCuistion, Caroline Gibbs Fenton, Mike S. Gin, Eric Salem, Andrew Hershman, Jerome M. TI Thyroid-stimulating hormone increases active transport of perchlorate into thyroid cells SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE iodide; Na+/I- symporter ID TANDEM MASS-SPECTROMETRY; SODIUM-IODIDE SYMPORTER; TUMOR-NECROSIS-FACTOR; SODIUM/IODIDE SYMPORTER; RADIOACTIVE PERCHLORATE; ION CHROMATOGRAPHY; NA+/I-SYMPORTER; UNITED-STATES; FRTL-5 CELLS; BREAST-MILK AB Perchlorate blocks thyroidal iodide transport in a dose-dependent manner. The human sodium/iodide symporter (NIS) has a 30-fold higher affinity for perchlorate than for iodide. However, active transport of perchlorate into thyroid cells has not previously been demonstrated by direct measurement techniques. To demonstrate intracellular perchlorate accumulation, we incubated NIS-expressing FRTL-5 rat thyroid cells in various concentrations of perchlorate, and we used a sensitive ion chromatography tandem mass spectrometry method to measure perchlorate accumulation in the cells. Perchlorate caused a dose-related inhibition of 125-iodide uptake at 1-10 mu M. The perchlorate content from cell lysate was analyzed, showing a higher amount of perchlorate in cells that were incubated in medium with higher perchlorate concentration. Thyroid-stimulating hormone increased perchlorate uptake in a dose-related manner, thus supporting the hypothesis that perchlorate is actively transported into thyroid cells. Incubation with nonradiolabeled iodide led to a dose-related reduction of intracellular accumulation of perchlorate. To determine potential toxicity of perchlorate, the cells were incubated in 1 nM to 100 mu M perchlorate and cell proliferation was measured. Even the highest concentration of perchlorate (100 mu M) did not inhibit cell proliferation after 72 h of incubation. In conclusion, perchlorate is actively transported into thyroid cells and does not inhibit cell proliferation. C1 [Hershman, Jerome M.] Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Endocrine Res Lab, Los Angeles, CA 90073 USA. Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Hershman, JM (reprint author), Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Endocrine Res Lab, Endocrinol 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 37 TC 43 Z9 44 U1 0 U2 11 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD APR PY 2008 VL 294 IS 4 BP E802 EP E806 DI 10.1152/ajpendo.00013.2008 PG 5 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 282NU UT WOS:000254575300018 PM 18303123 ER PT J AU Nagami, GT AF Nagami, Glenn T. TI Role of angiotensin II in the enhancement of ammonia production and secretion by the proximal tubule in metabolic acidosis SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE ammonia transport; ammoniagenesis; acid-base physiology; losartan; sodium-hydrogen exchanger ID PERFUSED IN-VITRO; RAT; ALDOSTERONE; TRANSPORT; SEGMENTS; INVITRO; BASE; NEPHRON; KIDNEY AB Acidosis and angiotensin II stimulate ammonia production and transport by the proximal tubule. We examined the modulatory effect of the type 1 angiotensin II receptor blocker losartan on the ability of metabolic acidosis to stimulate ammonia production and secretion by mouse S2 proximal tubule segments. Mice given NH(4)Cl for 7 days developed metabolic acidosis (low serum bicarbonate concentration) and increased urinary excretion of ammonia. S2 tubule segments from acidotic mice displayed higher rates of ammonia production and secretion compared with those from control mice. However, when losartan was coadministered in vivo with NH(4)Cl, both the acidosis-induced increase in urinary ammonia excretion and the adaptive increase in ammonia production and secretion of microperfused S2 segments were largely blocked. In renal cortical tissue, losartan blocked the acid-induced increase in brush-border membrane NHE3 expression but had no effect on the acid-induced upregulation of phosphate-dependent glutaminase or phosphoenolpyruvate carboxykinase 1 in cortical homogenates. Addition of angiotensin II to the microperfusion solution enhanced ammonia secretion and production rates in tubules from NH(4)Cl-treated and control mice in a losartan-inhibitable manner. These results demonstrate that a 7-day acid challenge induces an adaptive increase in ammonia production and secretion by the proximal tubule and suggest that during metabolic acidosis, angiotensin II signaling is necessary for adaptive enhancements of ammonia excretion by the kidney and ammonia production and secretion by S2 proximal tubule segments, as mediated, in part, by angiotensin receptor-dependent enhancement of NHE3 expression. C1 [Nagami, Glenn T.] Vet Affairs Greater Los Angels Healthcare Syst W, Nephrol Sect, Med & Res Serv, Los Angeles, CA USA. [Nagami, Glenn T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Nagami, GT (reprint author), VA Greater Los Angels Healthcare Syst W Los Angel, Nephrol Sect 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM glenn.nagami@va.gov NR 37 TC 19 Z9 19 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2008 VL 294 IS 4 BP F874 EP F880 DI 10.1152/ajprenal.00286.2007 PG 7 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 283FX UT WOS:000254623200023 PM 18287403 ER PT J AU Siever, LJ AF Siever, Larry J. TI Neurobiology of aggression and violence SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Review ID BORDERLINE PERSONALITY-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; INTERMITTENT EXPLOSIVE DISORDER; MONOAMINE-OXIDASE-A; IMPULSIVE-AGGRESSION; CEREBROSPINAL-FLUID; RECEPTOR-BINDING; 5-HYDROXYINDOLEACETIC ACID; EMOTIONAL DYSREGULATION; TRYPTOPHAN DEPLETION AB Acts of violence account for an estimated 1.43 million deaths worldwide annually. While violence can occur in many contexts, individual acts of aggression account for the majority of instances. In some individuals, repetitive acts of aggression are grounded in an underlying neurobiological susceptibility that is just beginning to be understood. The failure of "top-down" control systems in the prefrontal cortex to modulate aggressive acts that are triggered by anger provoking stimuli appears to play an important role. An imbalance between prefrontal regulatory influences and hyper-responsivity of the amygdala and other limbic regions involved in affective evaluation are implicated. Insufficient serotonergic facilitation of "top-down" control, excessive catecholaminergic stimulation, and subcortical imbalances of glutamatergic/gabaminergic systems as well as pathology in neuropeptide systems involved in the regulation of affiliative behavior may contribute to abnormalities in this circuitry. Thus, pharmacological interventions such as mood stabilizers, which dampen limbic irritability, or selective serotonin reuptake inhibitors (SSRIs), which may enhance "top-down" control, as well as psychosocial interventions to develop alternative coping skills and reinforce reflective delays may be therapeutic. C1 [Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Siever, Larry J.] VISN 3 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. RP Siever, LJ (reprint author), Dept Psychiat OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Larry.Siever@va.gov FU NCRR NIH HHS [M01 RR000071, M01-RR-00071]; NIMH NIH HHS [MH-56140, MH-63875, R01 MH056140, R01 MH063875] NR 136 TC 311 Z9 320 U1 12 U2 72 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2008 VL 165 IS 4 BP 429 EP 442 DI 10.1176/appi.ajp.2008.07111774 PG 14 WC Psychiatry SC Psychiatry GA 282OT UT WOS:000254577800007 PM 18346997 ER PT J AU Seal, KH Bertenthal, D Maguen, S Gima, K Chu, A Marmar, CR AF Seal, Karen H. Bertenthal, Daniel Maguen, Shira Gima, Kristian Chu, Ann Marmar, Charles R. TI Getting beyond "Don't Ask; Don't Tell": an evaluation of US veterans administration postdeployment mental health screening of veterans returning from Iraq and Afghanistan SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; POPULATION-BASED SURVEY; PRIMARY-CARE; GULF-WAR; DEPRESSION; MILITARY AB Objectives. We sought to evaluate outcomes of the Veterans Administration (VA) Afghan and Iraq Post-Deployment Screen for mental health symptoms. Methods. Veterans Administration clinicians were encouraged to refer Iraq or Afghanistan veterans who screened positive for posttraumatic stress disorder, depression, or high-risk alcohol use to a VA mental health clinic. Multivariate methods were used to determine predictors of screening, the proportions who screened positive for particular mental health problems, and predictors of VA mental health clinic attendance. Results. Among 750 Iraq and Afghanistan veterans who were referred to a VA medical center and 5 associated community clinics, 338 underwent postdeployment screening; 233 (69%) screened positive for mental health problems. Having been seen in primary care (adjusted odd ratio [AOR] = 13.3; 95% confidence interval [CI] = 8.311, 21.3) and at a VA community clinic (AOR= 3.28; 95% CI=2.03, 5.28) predicted screening. African American veterans were less likely to have been screened than were White veterans (AOR= 0.45; 95% CI = 0.22, 0.91). Of 233 veterans who screened positive, 170 (73%) completed a mental health follow-up visit. Conclusions. A substantial proportion of veterans met screening criteria for co-occurring mental health problems, suggesting that the VA screens may help overcome a "don't ask, don't tell" climate that surrounds stigmatized mental illness. Based on data from 1 VA facility, VA postdeployment screening increases mental health clinic attendance among Iraq and Afghanistan veterans. C1 [Seal, Karen H.; Bertenthal, Daniel; Maguen, Shira; Gima, Kristian; Chu, Ann; Marmar, Charles R.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA 94121 USA. [Seal, Karen H.; Maguen, Shira; Marmar, Charles R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Seal, Karen H.; Maguen, Shira; Marmar, Charles R.] San Francisco Vet Adm Hlth Serv, Res & Dev Res Enhancement Award Program, San Francisco, CA USA. RP Seal, KH (reprint author), San Francisco VA Med Ctr, Div Gen Internal Med, Box 111A-1,4150 Clement St, San Francisco, CA 94121 USA. EM karen.seal@ucsf.edu NR 26 TC 64 Z9 64 U1 1 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2008 VL 98 IS 4 BP 714 EP 720 DI 10.2105/AJPH.2007.115519 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 282VO UT WOS:000254595500030 PM 18309130 ER PT J AU Bogart, LM Howerton, D Lange, J Becker, K Setodji, CM Asch, SM AF Bogart, Laura M. Howerton, Devery Lange, James Becker, Kirsten Setodji, Claude Messan Asch, Steven M. TI Scope of rapid HIV testing in private nonprofit urban community health settings in the United States SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; SERVICES UTILIZATION; EXPERIENCE; ROUTINE; TRIAL; COST AB Objectives. We examined patterns of rapid HIV testing in a multistage national random sample of private, nonprofit, urban community clinics and community-based organizations to determine the extent of rapid HIV test availability outside the public health system. Methods. We randomly sampled 12 primary metropolitan statistical areas in 4 regions; 746 sites were randomly sampled across areas and telephoned. Staff at 575 of the sites (78%) were reached, of which 375 were eligible and subsequently interviewed from 2005 to 2006. Results. Seventeen percent of the sites offered rapid HIV tests (22% of clinics, 10% of community-based organizations). In multivariate models, rapid test availability was more likely among community clinics in the South (vs West), clinics in high HIV/AIDS prevalence areas, clinics with on-site laboratories and multiple locations, and clinics that performed other diagnostic tests. Conclusions. Rapid HIV tests were provided infrequently in private, nonprofit, urban community settings. Policies that encourage greater diffusion of rapid testing are needed, especially in community-based organizations and venues with fewer resources and less access to laboratories. C1 [Bogart, Laura M.; Becker, Kirsten; Setodji, Claude Messan; Asch, Steven M.] RAND Corp, Santa Monica, CA 90407 USA. [Howerton, Devery; Lange, James] Ctr Dis Control & Prevent, Lab Practice Evaluat & Genom Branch, Atlanta, GA USA. [Asch, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bogart, LM (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM lbog-art@rand.org FU NCCDPHP CDC HHS [U48 DP000056, U48/DP000056]; PHS HHS [U65/CCU924523-01] NR 34 TC 15 Z9 15 U1 2 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2008 VL 98 IS 4 BP 736 EP 742 DI 10.2105/AJPH.2007.111567 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 282VO UT WOS:000254595500033 PM 18309135 ER PT J AU Elkassabany, NM Meny, GM Doria, RR Marcucci, C AF Elkassabany, Nabil M. Meny, Geralyn M. Doria, Rafael R. Marcucci, Catherine TI Green plasma - Revisited SO ANESTHESIOLOGY LA English DT Letter C1 [Elkassabany, Nabil M.; Meny, Geralyn M.; Doria, Rafael R.; Marcucci, Catherine] Univ Penn, Pjiladelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Elkassabany, NM (reprint author), Univ Penn, Pjiladelphia VA Med Ctr, Philadelphia, PA 19104 USA. EM nabil.elkassabany@va.gov NR 7 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-3022 J9 ANESTHESIOLOGY JI Anesthesiology PD APR PY 2008 VL 108 IS 4 BP 764 EP 765 PG 2 WC Anesthesiology SC Anesthesiology GA 281AE UT WOS:000254467500034 PM 18362615 ER PT J AU Hakeem, A Bhatti, S Williams, EM Biring, T Kosolcharoen, P Chang, SM AF Hakeem, Abdul Bhatti, Sabha Williams, Eric M. Biring, Timinder Kosolcharoen, Peter Chang, Su Min TI Coronary steal due to bilateral internal mammary artery-pulmonary artery fistulas: A rare cause of chest pain after coronary artery bypass grafting SO ANGIOLOGY LA English DT Article DE IMA-PA fistula; CABG; coronary steal ID LUNG PARENCHYMA FISTULA; RECURRENT ANGINA; ARTERIOVENOUS-FISTULA; VASCULATURE AB A 54-year-old man with a history of coronary artery bypass grafting (CABG) presented with chest pain and was found to have non-ST-segment elevation myocardial infarction. Left heart catheterization with coronary angiography demonstrated 100% occlusion of the right internal mammary artery (IMA) to the right coronary artery graft in its midsegment and a patent left IMA to the left anterior descending graft. An unusually large extensive fistulous collateral formation was observed between the right IMA and the left IMA to the pulmonary arterial system, causing left to right shunting. His angina was attributed to substantial coronary steal caused by the shunt. The patient refused any further intervention or surgery and opted for medical treatment. As a complication of CABG, IMA to pulmonary artery (PA) fistulas are rare. Thus far, more than 20 cases have been reported; most have been unilateral. This is the second reported case to date of bilateral IMA-PA fistula formation after CABG. An IMA-PA fistula should be considered in the differential diagnosis of patients presenting with chest pain after CABG and can be diagnosed by selective angiography of IMA grafts. C1 Univ Wisconsin, Hosp & Clin, Dept Cardiovasc Med, Madison, WI 53705 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Hakeem, A (reprint author), Univ Wisconsin, Hosp & Clin, Dept Cardiovasc Med, 2705 Univ Ave,11, Madison, WI 53705 USA. EM a.hakeem@hosp.wisc.edu NR 22 TC 5 Z9 5 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-3197 J9 ANGIOLOGY JI Angiology PD APR-MAY PY 2008 VL 59 IS 2 BP 244 EP 247 DI 10.1177/0003319707304880 PG 4 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 290QL UT WOS:000255137200018 PM 18403464 ER PT J AU Kestenbaum, B Rudser, KD de Boer, IH Peralta, CA Fried, LF Shlipak, MG Palmas, W Stehman-Breen, C Siscovick, DS AF Kestenbaum, Bryan Rudser, Kyle D. de Boer, Ian H. Peralta, Carmen A. Fried, Linda F. Shlipak, Michael G. Palmas, Walter Stehman-Breen, Catherine Siscovick, David S. TI Differences in kidney function and incident hypertension: The multi-ethnic study of atherosclerosis SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; SALT-SENSITIVE HYPERTENSION; BLOOD-PRESSURE; RENAL-DISEASE; GENERAL-POPULATION; BIRTH-WEIGHT; CREATININE; PROTEINURIA; RISK AB Background: Kidney disease and hypertension commonly coexist, yet the direction of their association is still debated. Objective: To evaluate whether early kidney dysfunction, measured by serum cystatin C levels and urinary albumin excretion, predates hypertension in adults without clinically recognized kidney or cardiovascular disease. Design: Observational cohort study using data from 2000 to 2005. Setting: The MESA (Multi-Ethnic Study of Atherosclerosis), a community-based study of subclinical cardiovascular disease in adults age 45 to 84 years. Participants: 2767 MESA participants without prevalent hypertension, cardiovascular disease, or clinically recognized kidney disease (an estimated glomerular filtration rate <60 mL/min per 1.73 m(2) or microalbuminuria). Measurements: Cystatin C was measured by using a nephelometer, and urinary albumin and creatinine were measured from a spot morning collection. The primary outcome was incident hypertension, defined as systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, or use of an anti hypertensive medication. Results: During a median follow-up of 3.1 years, 19.7% of the cohort (545 participants) developed hypertension. After adjustment for established hypertension risk factors, each 15-nmol/L increase in cystatin C was associated with a statistically significant 15% greater incidence of hypertension (P = 0.017). The highest sex-specific quartile of urinary albumin-creatinine ratio was associated with a statistically insignificant 16% greater incidence of hypertension (P = 0.192) compared with the lowest quartile. No statistical evidence suggested a multiplicative interaction. Limitations: Unmeasured characteristics may have confounded observed associations of kidney markers with hypertension. Follow-up was relatively short. Hypertension that may have occurred between study visits or hypertension that was not captured by standard cuff measurements may have been missed. Conclusion: Differences in kidney function, indicated by cystatin C levels, are associated with incident hypertension among individuals without clinical kidney or cardiovascular disease. These population-based findings complement experimental work implicating early kidney damage in the pathogenesis of essential hypertension. C1 [Kestenbaum, Bryan] Univ Washington, Harborview Med Ctr, Div Nephrol, Seattle, WA 98104 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Columbia Univ, New York, NY USA. Amgen Inc, Thousand Oaks, CA USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Kestenbaum, B (reprint author), Univ Washington, Harborview Med Ctr, Div Nephrol, Room 10EH11,325 9Th Ave, Seattle, WA 98104 USA. EM brk@u.washington.edu FU NCATS NIH HHS [TL1 TR000422, UL1 TR000423]; NCRR NIH HHS [KL2 RR025015, KL2 RR025015-01]; NHLBI NIH HHS [N01-HC-95163, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95164, N01-HC-95165, N01-HC-95169, N01HC95159, N01HC95165, N01HC95169]; NIDDK NIH HHS [K23 DK063274, K23 DK63274-01] NR 39 TC 58 Z9 63 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 1 PY 2008 VL 148 IS 7 BP 501 EP 508 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 284IV UT WOS:000254701000002 PM 18378946 ER PT J AU Robbins, J Gensler, G Hind, J Logemann, JA Lindblad, AS Brandt, D Baum, H Lilienfeld, D Kosek, S Lundy, D Dikeman, K Kazandjian, M Gramigna, GD McGarvey-Toler, S Gardner, PJM AF Robbins, JoAnne Gensler, Gary Hind, Jacqueline Logemann, Jeri A. Lindblad, Anne S. Brandt, Diane Baum, Herbert Lilienfeld, David Kosek, Steven Lundy, Donna Dikeman, Karen Kazandjian, Marta Gramigna, Gary D. McGarvey-Toler, Susan Gardner, Patricia J. Miller TI Comparison of 2 interventions for liquid aspiration on pneumonia incidence SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CLINICAL-TRIALS; RISK-FACTORS; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; MORTALITY; INFECTIONS; PREDICTORS; POSTURE; DESIGN AB Background: Aspiration pneumonia is common among frail elderly persons with dysphagia. Although interventions to prevent aspiration are routinely used in these patients, little is known about the effectiveness of those interventions. Objective: To compare the effectiveness of chin-down posture and 2 consistencies (nectar or honey) of thickened liquids on the 3-month cumulative incidence of pneumonia in patients with dementia or Parkinson disease. Design: Randomized, controlled, parallel-design trial in which patients were enrolled for 3-month periods from 9 June 1998 to 19 September 2005. Setting: 47 hospitals and 79 subacute care facilities. Patients: 515 patients age 50 years or older with dementia or Parkinson disease who aspirated thin liquids (demonstrated video-fluoroscopically). Of these, 504 were followed until death or for 3 months. Intervention: Participants were randomly assigned to drink all liquids in a chin-down posture (n = 259) or to drink nectar-thick (n = 133) or honey-thick (n = 123) liquids in a head-neutral position. Measurements: The primary outcome was pneumonia diagnosed by chest radiography or by the presence of 3 respiratory indicators. Results: 52 participants had pneumonia, yielding an overall estimated 3-month cumulative incidence of 11%. The 3-month cumulative incidence of pneumonia was 0.098 and 0.116 in the chin-down posture and thickened-liquid groups, respectively (hazard ratio, 0.84 [95% Cl, 0.49 to 1.45]; P = 0.53). The 3-month cumulative incidence of pneumonia was 0.084 in the nectar-thick liquid group compared with 0.150 in the honey-thick liquid group (hazard ratio, 0.50 [Cl, 0.23 to 1.09]; P = 0.083). More patients assigned to thickened liquids than those assigned to the chin-down posture intervention had dehydration (6% vs. 2%), urinary tract infection (6% vs. 3%), and fever (4% vs. 2%). Limitations: A no-treatment control group was not included. Follow-up was limited to 3 months. Care providers were not blinded, and differences in cumulative pneumonia incidence between interventions had wide Cls. Conclusion: No definitive conclusions about the superiority of any of the tested interventions can be made. The 3-month cumulative incidence of pneumonia was much lower than expected in this frail elderly population. Future investigation of chin-down posture combined with nectar-thick liquid may be warranted to determine whether this combination better prevents pneumonia than either intervention independently. C1 [Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin 11G, Madison, WI 53705 USA. Univ Wisconsin, Madison, WI USA. EMMES Corp & Amer Speech Language Hearing Assoc, Rockville, MD USA. Northwestern Univ, Evanston, IL USA. ORC Macro, Calverton, MD USA. Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA. Univ Miami, Hosp & Clin, Miami, FL 33152 USA. New York Hosp, Queens Med Ctr, Flushing, NY USA. Vet Affairs Boston Healthcare Syst, W Roxbury, MA USA. Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA. RP Robbins, J (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin 11G, 2500 Overlook Terrace, Madison, WI 53705 USA. EM jrobbin2@wisc.edu FU NCRR NIH HHS [M01 RR003186-140295, M01 RR003186, M01 RR003186-150295, M01 RR003186-15S30295, M01 RR003186-160295, M01 RR003186-16S10295, M01 RR003186-170295, M01 RR003186-180295, M01 RR003186-190295]; NIDCD NIH HHS [DC03206, U01 DC003206] NR 32 TC 90 Z9 91 U1 1 U2 18 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 1 PY 2008 VL 148 IS 7 BP 509 EP 518 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 284IV UT WOS:000254701000003 PM 18378947 ER PT J AU Sawalha, AH Kaufman, KM Kelly, JA Adler, AJ Aberle, T Kilpatrick, J Wakeland, EK Li, QZ Wandstrat, AE Karp, DR James, JA Merrill, JT Lipsky, P Harley, JB AF Sawalha, A. H. Kaufman, K. M. Kelly, J. A. Adler, A. J. Aberle, T. Kilpatrick, J. Wakeland, E. K. Li, Q-Z Wandstrat, A. E. Karp, D. R. James, J. A. Merrill, J. T. Lipsky, P. Harley, J. B. TI Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID B-CELLS; IL-21 RECEPTOR; CUTTING EDGE; T-CELLS; DIFFERENTIATION; CHAIN AB Objective: The aetiology of systemic lupus erythematosus (SLE) is incompletely understood. Both genetic and environmental factors are implicated in the pathogenesis of the disease. Herein, we describe genetic association between SLE and polymorphisms in the interleukin (IL)-21 gene. The reported effect of IL-21 on B-cell differentiation into plasma cells and its effect on dendritic cell maturation and T-cell responses make IL-21 an attractive candidate gene for SLE. Methods: Three single nucleotide polymorphisms (SNPs) in the IL-21 gene were genotyped in a total of 2636 individuals (1318 cases and 1318 controls matched for age, sex and race). Population-based case-control association analyses were performed. Results: We found a genetic association with SLE and two SNPs located within the IL-21 gene (rs907715: chi(2) = 11.55, p<0.001; rs2221903: chi(2) = 5.49, p = 0.019). Furthermore, genotypes homozygous for the risk alleles were more frequent than genotypes homozygous for the non-risk alleles in European-American patients as compared to controls (rs907715 (GG versus AA): odds ratio (OR)= 1.66, p = 0.0049; rs2221903 (GG versus AA): OR = 1.60, p = 0.025). Conclusion: Our findings indicate that IL-21 polymorphism is a candidate association with SLE. The functional effects of this association, when revealed, might improve our understanding of the disease and provide new therapeutic targets. C1 [Sawalha, A. H.; Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Sawalha, A. H.; Kaufman, K. M.; Merrill, J. T.; Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Sawalha, A. H.; Kaufman, K. M.; Kelly, J. A.; Adler, A. J.; Aberle, T.; Kilpatrick, J.; James, J. A.; Merrill, J. T.; Harley, J. B.] Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. [Wakeland, E. K.; Li, Q-Z; Wandstrat, A. E.] Univ Texas SW Med Ctr Dallas, Ctr Immunol, Dallas, TX 75390 USA. [Karp, D. R.] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA. [Lipsky, P.] NIAMSD, Autoimmun Branch, Bethesda, MD 20892 USA. RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu FU NCRR NIH HHS [P20-RR015577, RR020143]; NIAID NIH HHS [AI053747, AI24717, AI31584]; NIAMS NIH HHS [AR12253, AR42460, AR4894, P30 AR053483] NR 19 TC 114 Z9 121 U1 0 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD APR PY 2008 VL 67 IS 4 BP 458 EP 461 DI 10.1136/ard.2007.075424 PG 4 WC Rheumatology SC Rheumatology GA 276DI UT WOS:000254121100006 PM 17720724 ER PT J AU Bird, TD Lipe, HP Steinbart, E AF Bird, Thomas D. Lipe, Hillary P. Steinbart, Ellenj. TI Geriatric neurogenetics - Oxymoron or reality? SO ARCHIVES OF NEUROLOGY LA English DT Article ID ATAXIA AB Background: Primary genetic diseases are generally associated with pediatric and young adult populations. Little information is available about the occurrence of single-gene mendelian diseases in elderly populations. Objective: To describe the occurrence of single-gene neurogenetic disorders in a group of elderly patients. Design: Retrospective review of neurogenetic cases in an academic medical center. Setting: Academic university and Veterans Affairs medical centers. Patients: Eight elderly patients with single-gene neurogenetic diseases were studied. These patients included an 87-year-old man and an 85-year-old man with Huntington disease, an 84-year-old woman with limb-girdle muscular dystrophy type 2A, a 78-year-old man with spinocerebellar ataxia type 14, an 86-year-old man with spinocerebellar ataxia type 5, an 85-year-old man with a presenilin 1 familial Alzheimer disease mutation, an 87-year-old man with autosomal dominant hereditary neuropathy, and a 78-year-old man with spinocerebellar ataxia type 6. Three patients had no family history of neurologic disease. Main Outcome Measures: Medical histories, physical examination results, and genetic testing results. Conclusions: Single-gene mendelian neurogenetic diseases can be found in the oldest old population (> 85 years). Such cases are currently underrecognized and will become more commonly observed in the future. This phenomenon is a result of (1) the aging of the general population, (2) better recognition of the highly variable ages at onset of genetic diseases, and (3) the availability of specific DNA-based genetic testing. C1 [Bird, Thomas D.; Lipe, Hillary P.] VA Puget Sound Health Care Syst, Geriatr Res Educ Clin Ctr, Seattle, WA 98108 USA. [Bird, Thomas D.; Steinbart, Ellenj.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Bird, TD (reprint author), VA Puget Sound Health Care Syst, Geriatr Res Educ Clin Ctr, 1660 S Columbian Way,S-182-GRECC, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu FU NIA NIH HHS [P50 AG005136, P50 AG 005136-22, P50 AG005136-25] NR 7 TC 5 Z9 5 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD APR PY 2008 VL 65 IS 4 BP 537 EP 539 DI 10.1001/archneur.65.4.537 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 286GZ UT WOS:000254835700016 PM 18413479 ER PT J AU Collinger, JL Boninger, ML Koontz, AM Price, R Sisto, SA Tolerico, ML Cooper, RA AF Collinger, Jennifer L. Boninger, Michael L. Koontz, Alicia M. Price, Robert Sisto, Sue Ann Tolerico, Michelle L. Cooper, Rory A. TI Shoulder biomechanics during the push phase of wheelchair propulsion: A multisite study of persons with paraplegia SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE biomechanics; rehabilitation; shoulder; spinal cord injuries; wheelchairs ID SPINAL-CORD-INJURY; AFT SEAT POSITION; COORDINATE SYSTEM; 2 SPEEDS; KINEMATICS; KINETICS; MOTION; USERS; PAIN; PATHOLOGY AB Objectives: To present a descriptive analysis and comparison of shoulder kinetics and kinematics during wheelchair propulsion at multiple speeds (self-selected and steady-state target speeds) for a large group of manual wheelchair users with paraplegia while also investigating the effect of pain and subject demographics on propulsion. Design: Case series. Setting: Three biomechanics laboratories at research institutions. Participants: Volunteer sample of 61 persons with paraplegia who use a manual wheelchair for mobility. Intervention: Subjects propelled their own wheelchairs on a dynamometer at 3 speeds (self-selected, 0.9m/s, 1.8m/s) while kinetic and kinematic data were recorded. Main Outcome Measures: Differences in demographics between sites, correlations between subject characteristics, comparison of demographics and biomechanics between persons with and without pain, linear regression using subject characteristics to predict shoulder biomechanics, comparison of biomechanics between speed conditions. Results: Significant increases in shoulder joint loading with increased propulsion velocity were observed. Resultant force increased from 54.4 +/- 13.5N during the 0.9m/s trial to 75.7 +/- 20.7N at 1.8m/s (P<.001). Body weight was the primary demographic variable that affected shoulder forces, whereas pain did not affect biomechanics. Peak shoulder joint loading occurs when the arm is extended and internally rotated, which may leave the shoulder at risk for injury. Conclusions: Body-weight maintenance, as well as other interventions designed to reduce the force required to propel a wheelchair, should be implemented to reduce the prevalence of shoulder pain and injury among manual wheelchair users. C1 [Collinger, Jennifer L.; Boninger, Michael L.; Koontz, Alicia M.; Tolerico, Michelle L.; Cooper, Rory A.] VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, Pittsburgh, PA 15206 USA. [Collinger, Jennifer L.; Boninger, Michael L.; Koontz, Alicia M.; Tolerico, Michelle L.; Cooper, Rory A.] VA Pittsburgh Hlthcare Syst, Dev Ctr, Pittsburgh, PA USA. [Collinger, Jennifer L.; Boninger, Michael L.; Koontz, Alicia M.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Collinger, Jennifer L.; Boninger, Michael L.; Tolerico, Michelle L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, Michael L.; Koontz, Alicia M.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Price, Robert] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Sisto, Sue Ann] Kessler Med Rehabil Res & Educ Corp, Spinal Cord Injury Rehabil Res, W Orange, NJ USA. [Sisto, Sue Ann] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Boninger, ML (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, 7180 Highland Dr 151R1-H, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu RI Moro, Juan Carlos/A-4315-2015 OI Moro, Juan Carlos/0000-0002-4886-2967; Boninger, Michael/0000-0001-6966-919X NR 32 TC 41 Z9 42 U1 3 U2 19 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2008 VL 89 IS 4 BP 667 EP 676 DI 10.1016/j.apmr.2007.09.052 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 289IG UT WOS:000255047600011 PM 18373997 ER PT J AU Sawalha, AH Richardson, B AF Sawalha, Amr H. Richardson, Bruce TI MEK/ERK pathway inhibitors as a treatment for inflammatory arthritis might result in the development of lupus: comment on the article by Thiel et al SO ARTHRITIS AND RHEUMATISM LA English DT Letter ID DNA METHYLATION INHIBITORS; KINASE PATHWAY; T-CELLS; HYPOMETHYLATION; AUTOIMMUNITY; HYDRALAZINE; MECHANISMS C1 [Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, US Dept Vet Affairs, Oklahoma Med Res Fdn,Med Ctr, Oklahoma City, OK 73190 USA. [Richardson, Bruce] Univ Michigan, US Dept Vet Affairs, Med Ctr, Ann Arbor, MI 48109 USA. RP Sawalha, AH (reprint author), Univ Oklahoma, Hlth Sci Ctr, US Dept Vet Affairs, Oklahoma Med Res Fdn,Med Ctr, Oklahoma City, OK 73190 USA. FU NIAMS NIH HHS [P30 AR053483] NR 9 TC 2 Z9 3 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD APR PY 2008 VL 58 IS 4 BP 1203 EP 1204 DI 10.1002/art.23382 PG 2 WC Rheumatology SC Rheumatology GA 293OS UT WOS:000255345200037 PM 18383376 ER PT J AU Koenigsberg, HW Fan, J Ochsner, K Pizzarello, S Guise, K Tecuta, L New, A Goodman, M Siever, LJ AF Koenigsberg, Harold W. Fan, Jin Ochsner, Kevin Pizzarello, Scott Guise, Kevin Tecuta, Lucia New, Antonia Goodman, Marianne Siever, Larry J. TI Dysregulated networks in the cognitive control of emotion in borderline personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Koenigsberg, Harold W.; Fan, Jin; Pizzarello, Scott; Guise, Kevin; Tecuta, Lucia; New, Antonia; Goodman, Marianne; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA. [Koenigsberg, Harold W.; Goodman, Marianne] James J Peters VA Med Ctr, Bronx, NY USA. [Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA. [Siever, Larry J.] Mirecc, James J Peters VA Med Ctr, New York, NY USA. RI Guise, Kevin/C-1145-2009 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 145 BP 51S EP 52S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700162 ER PT J AU Radant, A Dobie, D Meichle, S Goodnow, S Pritzl, D Tsuang, D AF Radant, Allen Dobie, Dorcas Meichle, Sean Goodnow, Sara Pritzl, Denise Tsuang, Debby TI Novel analog of the antisaccade task with manual response: Application to schizophrenia patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Radant, Allen; Dobie, Dorcas; Meichle, Sean; Goodnow, Sara; Pritzl, Denise; Tsuang, Debby] Univ Washington, Seattle, WA 98195 USA. [Radant, Allen; Dobie, Dorcas; Meichle, Sean; Goodnow, Sara; Pritzl, Denise; Tsuang, Debby] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 229 BP 77S EP 77S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700246 ER PT J AU Greenwood, TA Light, GA Cadenhead, KS Freedman, R Green, MF Gur, RE Kelsoe, JR Murray, SS Nuechterlein, KH Olincy, A Radant, AD Schork, NJ Seidman, LJ Siever, LJ Silverman, JM Swerdlow, NR Tsuang, DW Turetsky, BI Weinberger, DR Braff, DL AF Greenwood, Tiffany A. Light, Gregory A. Cadenhead, Kristin S. Freedman, Robert Green, Michael F. Gur, Raquel E. Kelsoe, John R. Murray, Sarah S. Nuechterlein, Keith H. Olincy, Ann Radant, Allen D. Schork, Nicholas J. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Swerdlow, Neal R. Tsuang, Debby W. Turetsky, Bruce I. Weinberger, Daniel R. Braff, David L. TI Initial analyses of 94 candidate genes and twelve endophenotypes for schizophrenia from the consortium on the genetics of schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Greenwood, Tiffany A.; Light, Gregory A.; Cadenhead, Kristin S.; Kelsoe, John R.; Swerdlow, Neal R.; Braff, David L.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Greenwood, Tiffany A.; Kelsoe, John R.] Univ Colorado, Hlth Sci Ctr, Hlth Care Syst, San Diego, CA USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. [Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gur, Raquel E.; Turetsky, Bruce I.] Univ Penn, Philadelphia, PA 19104 USA. [Murray, Sarah S.] Scripps, La Jolla, CA USA. [Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Seattle, WA 98195 USA. [Radant, Allen D.; Tsuang, Debby W.] Puget Sound Vet Adm, Hlth Care Syst, Seattle, WA USA. [Schork, Nicholas J.] Scripps Res Inst, La Jolla, CA USA. [Seidman, Larry J.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr Publ Psychiat Div, Boston, MA USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, New York, NY USA. [Siever, Larry J.] James J Peters VA Med Ctr, New York, NY USA. [Weinberger, Daniel R.] NIMH, Clin Brain Disorders Branch, Genes Cognit & Psychosis Program, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 247 BP 82S EP 83S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700264 ER PT J AU Yao, JK Dougherty, GG Reddy, RD Keshavan, MS Montrose, DM Matson, WR Rozen, S McEvoy, J Kaddurah-Daouk, R AF Yao, Jeffrey K. Dougherty, George G. Reddy, Ravinder D. Keshavan, Matcheri S. Montrose, Debra M. Matson, Wayne R. Rozen, Steve McEvoy, Joseph Kaddurah-Daouk, Rima TI Discriminative tryptophan pathway in first-episode neuroleptic-naive patients with schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Yao, Jeffrey K.; Dougherty, George G.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Yao, Jeffrey K.; Dougherty, George G.; Reddy, Ravinder D.; Keshavan, Matcheri S.; Montrose, Debra M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Keshavan, Matcheri S.] Wayne State Univ, Dept Psychiat, Detroit, MI USA. [Matson, Wayne R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA. [Rozen, Steve] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [McEvoy, Joseph; Kaddurah-Daouk, Rima] Duke Univ, Ctr Med, Dept Psychiat, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 272 BP 91S EP 91S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700289 ER PT J AU Koenigsberg, HW Fan, J Ochsner, K Pizzarello, S Guise, K Dorantes, C New, A Goodman, M Siever, LJ AF Koenigsberg, Harold W. Fan, Jin Ochsner, Kevin Pizzarello, Scott Guise, Kevin Dorantes, Christine New, Antonia Goodman, Marianne Siever, Larry J. TI Neural networks activated during cognitive reappraisal by emotional detachment SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Koenigsberg, Harold W.; Fan, Jin; Pizzarello, Scott; Guise, Kevin; Dorantes, Christine; New, Antonia; Goodman, Marianne; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA. [Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA. [Koenigsberg, Harold W.; Goodman, Marianne; Siever, Larry J.] James J Peters VA Med Ctr, Bronx, NY USA. RI Guise, Kevin/C-1145-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 413 BP 135S EP 135S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700430 ER PT J AU Katzman, M Brawman-Mintzer, O Reyes, E Olausson, B Liu, S Brecher, M AF Katzman, Martin Brawman-Mintzer, Olga Reyes, Efren Olausson, Bengt Liu, Sherry Brecher, Martin TI Extended release quetiapine fumarate (quetiapine XR) monotherapy in long-term treatment of generalized anxiety disorder (GAD): Efficacy and tolerability results from a randomized, placebo-controlled trial SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Katzman, Martin] START Clin, Toronto, ON, Canada. [Katzman, Martin] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Katzman, Martin] No Ontario Sch Med, Thunder Bay, ON, Canada. [Katzman, Martin] Lakehead Univ, Dept Psychol, Thunder Bay, ON P7B 5E1, Canada. [Brawman-Mintzer, Olga] Med Univ S Carolina, Dept Psychiat & Behav Sci, N Charleston, SC USA. [Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, N Charleston, SC USA. [Reyes, Efren] Natl Ctr Mental Hlth, Mandaluyong City, Philippines. [Olausson, Bengt] AstraZeneca, Res & Dev, Sodertalje, Sweden. [Liu, Sherry; Brecher, Martin] AstraZeneca, Wilmington, DE USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 435 BP 141S EP 141S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700451 ER PT J AU Koenigsberg, HW Fan, J Ochsner, K Pizzarello, S Dorantes, C Goodman, M New, A Siever, LJ AF Koenigsberg, Harold W. Fan, Jin Ochsner, Kevin Pizzarello, Scott Dorantes, Christine Goodman, Marianne New, Antonia Siever, Larry J. TI Neural networks activated during cognitive reappraisal by emotional detachment SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Koenigsberg, Harold W.; Fan, Jin; Pizzarello, Scott; Dorantes, Christine; Goodman, Marianne; New, Antonia; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Koenigsberg, Harold W.; Goodman, Marianne; Siever, Larry J.] James J Peters VA Med Ctr, Bronx, NY USA. [Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 473 BP 151S EP 151S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700483 ER PT J AU Buck, K AF Buck, Kari TI Genetic control of sedative-hypnotic drug physiological dependence and associated withdrawal in mice SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Buck, Kari] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Buck, Kari] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 492 BP 157S EP 157S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700502 ER PT J AU Siever, LJ Ducci, F Hodgkinson, CA New, AS Koenigsberg, HW Goodman, M Goldman, D AF Siever, Larry J. Ducci, Francesca Hodgkinson, Colin A. New, Antonia S. Koenigsberg, Harold W. Goodman, Marianne Goldman, David TI Genotypes and endophenotypes in borderline personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Siever, Larry J.; New, Antonia S.; Koenigsberg, Harold W.; Goodman, Marianne] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.; New, Antonia S.; Koenigsberg, Harold W.; Goodman, Marianne] Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Ducci, Francesca; Hodgkinson, Colin A.; Goldman, David] NIAAA, Neurogenet Lab, NIH, Rockville, MD 20852 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 505 BP 161S EP 161S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700515 ER PT J AU Liebman, RE aan het Rot, M New, AS Charney, DS AF Liebman, Rachel E. aan het Rot, Marije New, Antonia S. Charney, Dennis S. TI Interpersonal functioning in women after sexual assault: Is it determined by trauma burden? SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY MAY 01-03, 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Liebman, Rachel E.; aan het Rot, Marije; New, Antonia S.; Charney, Dennis S.] Mt Sinai Sch Med, New York, NY USA. [New, Antonia S.] Bronx Vet Affairs Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 552 BP 176S EP 176S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700562 ER PT J AU Wang, LY Petrie, EC Rohde, K Hart, KL Hoff, DJ Shofer, JB Raskind, MA Peskind, ER AF Wang, Lucy Y. Petrie, Eric C. Rohde, Kirsten Hart, Kim L. Hoff, David J. Shofer, Jane B. Raskind, Murray A. Peskind, Elaine R. TI Prazosin for treatment of disruptive agitation in Alzheimer's disease SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Wang, Lucy Y.; Petrie, Eric C.; Shofer, Jane B.; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Wang, Lucy Y.; Petrie, Eric C.; Rohde, Kirsten; Hart, Kim L.; Hoff, David J.; Raskind, Murray A.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 629 BP 200S EP 200S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700639 ER PT J AU Goodman, M Patil, U Triebwasser, J Diamond, E New, A Siever, L AF Goodman, Marianne Patil, Uday Triebwasser, Joseph Diamond, Elizabeth New, Antonia Siever, Larry TI Gender differences in the developmental trajectories of borderline personality SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 [Goodman, Marianne; Triebwasser, Joseph; New, Antonia; Siever, Larry] James J Peter Va Med Ctr, Bronx, NY USA. [Goodman, Marianne; Patil, Uday; Triebwasser, Joseph; Diamond, Elizabeth; New, Antonia; Siever, Larry] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 770 BP 245S EP 246S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700780 ER PT J AU Kanellopoulou, I Bowie, C Anderson, H Halpern, B Harvey, PD AF Kanellopoulou, Isabella Bowie, Christopher Anderson, Hannah Halpern, Brooke Harvey, Phil D. TI Effect of metabolic syndrome on cognition in older schizophrenic patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 63rd Annual Convention of the Society-of-Biological-Psychiatry CY 2008 CL Washington, DC SP Soc Biol Psychiat C1 Mt Sinai Sch Med, James J Peters VAMC, Bronx, NY USA. [Harvey, Phil D.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2008 VL 63 IS 7 SU S MA 804 BP 256S EP 256S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 276SV UT WOS:000254163700814 ER PT J AU Wakao, M Saito, A Ohishi, K Kishimoto, Y Nishimura, T Sobel, M Suda, Y AF Wakao, Masahiro Saito, Akihiro Ohishi, Koh Kishimoto, Yuko Nishimura, Tomoaki Sobel, Michael Suda, Yasuo TI Sugar Chips immobilized with synthetic sulfated disaccharides of heparin/heparan sulfate partial structure SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Sugar; carbohydrate; chip; heparin; heparan sulfate; carbohydrate-protein interaction; surface plasmon resonance; SPR; SPR-imaging ID HEPARAN-SULFATE; CARBOHYDRATE MICROARRAYS; BIOLOGICAL-ACTIVITIES; BUILDING-BLOCKS; DNA CHIPS; BINDING; PROTEIN; SURFACE; ARRAY; OLIGOSACCHARIDES AB Carbohydrate chip technology has a great potential for the high-throughput evaluation of carbohydrate-protein interactions. Herein, we report syntheses of novel sulfated oligosaccharides possessing heparin and heparan sulfate partial disaccharide structures, their immobilization on gold-coated chips to prepare array-type Sugar Chips, and evaluation of binding potencies of proteins by surface plasmon resonance (SPR) imaging technology. Sulfated oligosaccharides were efficiently synthesized from glucosamine and uronic acid moieties. Synthesized sulfated oligosaccharides were then easily immobilized on gold-coated chips using previously reported methods. The effectiveness of this analytical method was confirmed in binding experiments between the chips and heparin binding proteins, fibronectin and recombinant human von Willebrand factor A1 domain ( rh-vWf-A1), where specific partial structures of heparin or heparan sulfate responsible for binding were identified. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Wakao, Masahiro; Saito, Akihiro; Ohishi, Koh; Nishimura, Tomoaki; Suda, Yasuo] Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostruct & Adv Mat, Kagoshima 8900065, Japan. [Kishimoto, Yuko; Nishimura, Tomoaki; Suda, Yasuo] SUDx Biotec Corp, Kobe, Hyogo 6500047, Japan. [Sobel, Michael] Univ Washington, Dept Surg, Seattle, WA 98108 USA. [Sobel, Michael] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Suda, Y (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostruct & Adv Mat, 1-21-40 Korimoto, Kagoshima 8900065, Japan. EM ysuda@eng.kagoshima-u.ac.jp FU NHLBI NIH HHS [R01 HL079182, R01 HL079182-03, HL079182] NR 50 TC 27 Z9 27 U1 1 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD APR 1 PY 2008 VL 18 IS 7 BP 2499 EP 2504 DI 10.1016/j.bmcl.2008.01.069 PG 6 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA 292DI UT WOS:000255246300052 PM 18343110 ER PT J AU Hagopian, K Ramsey, JJ Weindruch, R AF Hagopian, Kevork Ramsey, Jon J. Weindruch, Richard TI Enzymes of glycerol and glyceraldehyde metabolism in mouse liver: effects of caloric restriction and age on activities SO BIOSCIENCE REPORTS LA English DT Article DE aging; caloric restriction; energy source; glyceralclehyde metabolism; glycerol metabolism; liver ID KETO REDUCTASE SUPERFAMILY; ALDEHYDE DEHYDROGENASE-ACTIVITY; ALCOHOL-DEHYDROGENASE; RAT-LIVER; FRUCTOSE METABOLISM; THYROID-HORMONES; FOOD RESTRICTION; LIFE-SPAN; MUSCLE; OXIDATION AB The influence of caloric restriction on hepatic glyceraldehyde- and glycerol-metabolizing enzyme activities of young and old mice were studied. Glycerol kinase and cytoplasmic glycerol-3-phosphate dehydrogenase activities were increased in both young and old CR (calorie-restricted) mice when compared with controls, whereas triokinase increased only in old CR mice. Aldehyde dehydrogenase and aldehyde reductase activities in both young and old CR mice were unchanged by caloric restriction. Mitochondrial glycerol-3-phosphate dehydrogenase showed a trend towards an increased activity in old CR mice, whereas a trend towards a decreased activity in alcohol dehydrogenase was observed in both young and old CR mice. Serum glycerol levels decreased in young and old CR mice. Therefore increases in glycerol kinase and glycerol-3-phosphate dehydrogenase were associated with a decrease in fasting blood glycerol levels in CR animals. A prominent role for triokinase in glyceraldehyde metabolism with CR was also observed. The results indicate that long-term caloric restriction induces sustained increases in the capacity for gluconeogenesis from glycerol. C1 [Hagopian, Kevork; Ramsey, Jon J.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA. [Weindruch, Richard] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA. [Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP Hagopian, K (reprint author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA. EM khagopian@ucdavis.edu FU NIA NIH HHS [P01 AG11915, R01 AG028125, P01 AG011915-06A1, R01 AG028125-01A1, P01 AG011915, R01 AG28125] NR 73 TC 11 Z9 13 U1 0 U2 0 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0144-8463 J9 BIOSCIENCE REP JI Biosci. Rep. PD APR PY 2008 VL 28 IS 2 BP 107 EP 115 DI 10.1042/BSR20080015 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 317KS UT WOS:000257019700006 PM 18429748 ER PT J AU Leverenz, JB Hamilton, R Tsuang, DW Schantz, A Vavrek, D Larson, EB Kukull, WA Lopez, O Galasko, D Masliah, E Kaye, J Woltjer, R Clark, C Trojanowski, JQ Montine, TJ AF Leverenz, James B. Hamilton, Ronald Tsuang, Debby W. Schantz, Aimee Vavrek, Darcy Larson, Eric B. Kukull, Walter A. Lopez, Oscar Galasko, Douglas Masliah, Eliezer Kaye, Jeffrey Woltjer, Randall Clark, Christopher Trojanowski, John Q. Montine, Thomas J. TI Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient SO BRAIN PATHOLOGY LA English DT Article DE Lewy bodies; dementia; alpha-synuclein ID SPORADIC PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; INTERNATIONAL WORKSHOP; BODY PATHOLOGY; BODIES; DIAGNOSIS; CONSORTIUM; BRAINS; DLB AB Lewy-related pathology (LRP) is a common pathologic finding at autopsy in dementia patients. Recently criteria for categorizing types of LRP in dementia patients were published, though these criteria have yet to be systematically applied to large dementia samples. We examined a large (n = 208) referral-based autopsy sample for LRP, and applied the published criteria for LRP categorization to these cases. We found almost half (49%) of LRP positive cases from this sample were not classifiable. However, modifying the published criteria by reducing the number of regions requiring examination, allowing more variability in LRP severity scores within specific brain regions, and adding an amygdala predominant category permitted classification of 97% of LRP positive cases from the referral-based sample. Application of the modified criteria to an unrelated community-based autopsy sample (n = 226) allowed classification of 96% of LRP positive cases. Modest modifications in the published criteria permit a significantly greater number of dementia cases with LRP to be classified. In addition, this modification allows for more limited sampling of brain regions for classification of LRP. We propose that these modified criteria for the categorization of LRP be utilized in patients with a history of dementia. C1 [Leverenz, James B.; Tsuang, Debby W.; Vavrek, Darcy] Univ Washington, Dept Vet Affairs NW Network Mental Illness, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Parkinsons Dis Res, Educ & Clin Ctr, Seattle, WA 98195 USA. [Kukull, Walter A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Larson, Eric B.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Schantz, Aimee; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Leverenz, James B.; Tsuang, Debby W.; Vavrek, Darcy] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. [Lopez, Oscar] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Hamilton, Ronald] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurol, San Diego, CA USA. [Masliah, Eliezer] Univ Calif San Diego, Dept Pathol, San Diego, CA USA. [Kaye, Jeffrey; Montine, Thomas J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Woltjer, Randall] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Clark, Christopher] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Trojanowski, John Q.] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA. RP Leverenz, JB (reprint author), VA Puget Sound Hlth Care Syst, MIRECC 116MIRECC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM leverenz@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Kukull, Walter/0000-0001-8761-9014; Kaye, Jeffrey/0000-0002-9971-3478 FU NIA NIH HHS [AG06781, AG05133, AG05136, AG10124, AG10845, P30 AG010124, P30 AG010124-09, P50 AG005133, P50 AG005133-229002, P50 AG005136, P50 AG005136-229003, P50 AG005136-25, U01 AG006781, U01 AG006781-13, U01 AG016976]; NINDS NIH HHS [NS053488, NS48595, P50 NS053488, P50 NS053488-01A2, R01 NS048595, R01 NS048595-01, R01 NS048595-05] NR 22 TC 57 Z9 57 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1015-6305 J9 BRAIN PATHOL JI Brain Pathol. PD APR PY 2008 VL 18 IS 2 BP 220 EP 224 DI 10.1111/j.1750-3639.2007.00117.xd PG 5 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 278GJ UT WOS:000254272700008 PM 18241240 ER PT J AU Tabassam, FH Graham, DY Yamaoka, Y AF Tabassam, Fazal H. Graham, David Y. Yamaoka, Yoshio TI OipA plays a role in Helicobacter pylori-induced focal adhesion kinase activation and cytoskeletal re-organization SO CELLULAR MICROBIOLOGY LA English DT Article ID GASTRIC EPITHELIAL-CELLS; MUCOSAL INTERLEUKIN-8 PRODUCTION; GROWTH-FACTOR; PATHOGENICITY ISLAND; SIGNAL-TRANSDUCTION; TYROSINE KINASE; IV SECRETION; IN-VIVO; SRC; INTEGRIN AB The initial signalling events leading to Helicobacter pylori infection associated changes in motility, cytoskeletal reorganization and elongation of gastric epithelial cells remain poorly understood. Because focal adhesion kinase (FAK) is known to play important roles in regulating actin cytoskeletal organization and cell motility we examined the effect of H. pylori in gastric epithelial cells co-cultured with H. pylori or its isogenic cag pathogenicity island (PAI) or oipA mutants. H. pylori induced FAK phosphorylation at distinct tyrosine residues in a dose- and time-dependent manner. Autophosphorylation of FAK Y397 was followed by phosphorylation of Src Y418 and resulted in phosphorylation of the five remaining FAK tyrosine sites. Phosphorylated FAK and Src activated Erk and induced actin stress fibre formation. FAK knock-down by FAK-siRNA inhibited H. pylori-mediated Erk phosphorylation and abolished stress fibre formation. Infection with oipA mutants reduced phosphorylation of Y397, Y576, Y577, Y861 and Y925, inhibited stress fibre formation and altered cell morphology. cag PAI mutants reduced phosphorylation of only FAK Y407 and had less effect on stress fibre formation than oipA mutants. We propose that activation of FAK and Src are responsible for H. pylori-induced induction of signalling pathways resulting in the changes in cell phenotype important for pathogenesis. C1 [Yamaoka, Yoshio] Michael DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Michael DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [DK62813, DK56338, P30 DK056338, R01 DK062813, R01 DK062813-04, R01 DK062813-05] NR 49 TC 31 Z9 31 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1462-5814 J9 CELL MICROBIOL JI Cell Microbiol. PD APR PY 2008 VL 10 IS 4 BP 1008 EP 1020 DI 10.1111/j.1462-5822.2007.01104.x PG 13 WC Cell Biology; Microbiology SC Cell Biology; Microbiology GA 274BY UT WOS:000253978000016 PM 18067607 ER PT J AU Mathalon, DH Ford, JM AF Mathalon, Daniel H. Ford, Judith M. TI Corollary discharge dysfunction in schizophrenia: Evidence for an elemental deficit SO CLINICAL EEG AND NEUROSCIENCE LA English DT Article DE apathy; corollary discharge; efference copy; electroencephalography; hallucination; schizophrenia ID AUDITORY-CORTEX; CORTICAL RESPONSIVENESS; POTENTIAL STUDY/; HALLUCINATIONS; SPEECH; CONSCIOUSNESS; DISORDERS; DYNAMICS; THINKING; TALKING AB Evidence is accumulating that schizophrenia is characterized by dysfunction of efference copy/corollary discharge mechanisms that normally allow us to unconsciously recognize and disregard sensations resulting from our own actions. This dysfunction may give rise to subtle but pervasive sensory/perceptual aberrations in schizophrenic patients, altering their experience of their own overt and covert actions, as well as their interactions with the environment. It may also contribute to symptoms such as hallucinations and delusions, and may disrupt the motivation to engage with people and in activities. We developed neurophysiological paradigms to study motor-sensory feed-forward processes, or efference copy/corollary discharge mechanisms, in the speech-auditory system, and showed these processes to be deficient in chronic schizophrenia. Specifically, we observed neural responses during talking that made evident the suppressive consequences of a successful corollary discharge mechanism. We also observed synchronous neural activity preceding talking that we believe reflects the efference copy in action. Recently, we extended this neurophysiological research to the somatosensory system, again finding evidence of deficient motor-sensory feed-forward processes in schizophrenia. If dysfunction of this elemental mechanism is reliable, valid, and not the result of antipsychotic medications, it might represent a major new class of electrophysiological measures sensitive to a fundamental and ubiquitous pathophysiological process in schizophrenia. C1 [Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA USA. RP Mathalon, DH (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Mathalon, Daniel/0000-0001-6090-4974 FU NIMH NIH HHS [R01 MH040052, K02 MH067967, MH067967, MH40052, MH58262] NR 31 TC 23 Z9 24 U1 0 U2 6 PU EEG & CLINICAL NEUROSCIENCE SOC (E C N S) PI WHEATON PA 805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA SN 1550-0594 J9 CLIN EEG NEUROSCI JI Clin. EEG Neurosci. PD APR PY 2008 VL 39 IS 2 BP 82 EP 86 PG 5 WC Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 289WB UT WOS:000255083500008 PM 18450174 ER PT J AU Fujitani, S Rowlinson, MC George, WL AF Fujitani, Shigeki Rowlinson, Marie-Claire George, W. Lance TI Penicillin G-resistant viridans group streptococcal endocarditis and interpretation of the American Heart Association's guidelines for the treatment of infective endocarditis SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID COMBINATION AB We report a case of endocarditis due to a penicillin-"resistant" Streptococcus parasanguinis, discuss interpretations of the American Heart Association's guidelines for the treatment of viridans group streptococcal infection, and comment on therapy for infective endocarditis due to penicillin-resistant viridans group streptococci. C1 [George, W. Lance] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Fujitani, Shigeki] Univ Calif Los Angeles, Affiliated Infect Dis Fellowship Training Program, Los Angeles, CA USA. [Rowlinson, Marie-Claire] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [George, W. Lance] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP George, WL (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM William.george@med.va.gov NR 8 TC 6 Z9 7 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2008 VL 46 IS 7 BP 1064 EP 1066 DI 10.1086/529199 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 271VW UT WOS:000253817800016 PM 18444825 ER PT J AU Rodriguez-Barradas, MC Goulet, J Brown, S Goetz, MB Rimland, D Simberkoff, MS Crothers, K Justice, AC AF Rodriguez-Barradas, Maria C. Goulet, Joseph Brown, Sheldon Goetz, Matthew Bidwell Rimland, David Simberkoff, Michael S. Crothers, Kristina Justice, Amy C. TI Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the veterans aging cohort 5-Site Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; POLYSACCHARIDE VACCINE; RISK-FACTORS; BACTERIAL PNEUMONIA; CIGARETTE-SMOKING; DISEASE; ADULTS; INDIVIDUALS; ERA AB Background. Human immunodeficiency virus (HIV)-infected persons have a high incidence of pneumonia and pneumococcal disease. Benefits of vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) among these patients continue to be debated. Methods. The impact of PPV vaccination on the incidence of pneumonia events (i.e., the composite of pneumococcal pneumonia and pneumonia due to nonspecified organisms) was examined among participants in the Veterans Aging Cohort 5-Site Study, an ongoing prospective study of HIV-infected patients matched to an HIV-uninfected control group. Dates of PPV vaccination and pneumonia were determined by retrospective review of electronic medical records. Time to events was measured for up to 2 years from PPV vaccination or from enrollment for vaccinated and unvaccinated patients, respectively. Kaplan-Meier and Cox proportional hazards regression methods were used to examine the incidence of pneumonia by HIV infection and PPV vaccination status. Results. Among 692 HIV-uninfected and 934 HIV-infected study participants, 59% were vaccinated with PPV. The 2-year incidence of pneumonia was 6% (97 participants developed pneumonia). HIV-infected patients had a higher rate of pneumonia (hazard ratio, 5.81; 95% confidence interval, 3.15-10.71); overall, vaccinated patients showed a trend toward lower risk of pneumonia (hazard ratio, 0.75; 95% confidence interval, 0.50-1.13). Among HIV-infected patients, after controlling for HIV-specific and other variables, vaccination significantly reduced the risk of pneumonia (hazard ratio, 0.65; 95% confidence interval, 0.42-1.00); current smoking, low hemoglobin level, and low CD4 cell count significantly increased such risk. The effect of PPV vaccination among HIV-uninfected patients was not significant. Conclusions. Among HIV-infected patients, PPV vaccination offered protection against pneumonia. Smoking cessation needs to be pursued as an additional strategy for preventing pneumonia. C1 [Rodriguez-Barradas, Maria C.] Michael E DeBakey VAMC, Med Serv, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Goulet, Joseph; Crothers, Kristina; Justice, Amy C.] VA Connecticut Healthcare Syst, Vet Aging Cohort Study Ctr, New Haven, CT USA. [Goulet, Joseph; Crothers, Kristina; Justice, Amy C.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Brown, Sheldon] Bronx VA Med Ctr, New York, NY USA. [Brown, Sheldon] Mt Sinai Sch Med, New York, NY USA. [Simberkoff, Michael S.] VA New York Harbor Healthcare Syst, New York, NY USA. [Simberkoff, Michael S.] NYU, Sch Med, New York, NY USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. RP Rodriguez-Barradas, MC (reprint author), Michael E DeBakey VAMC, Med Serv, 2002 Holcombe Blvd MS 111G, Houston, TX 77030 USA. EM maria.rodriguez-barradas2@med.va.gov OI Goetz, Matthew/0000-0003-4542-992X; Goulet, Joseph/0000-0002-0842-804X; Crothers, Kristina/0000-0001-9702-0371 FU NIA NIH HHS [K23 AG00826]; NIAAA NIH HHS [U01 AA 13566, U01 AA013566, U10 AA 13566, U10 AA013566, U10 AA013566-07] NR 33 TC 51 Z9 51 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2008 VL 46 IS 7 BP 1093 EP 1100 DI 10.1086/529201 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 271VW UT WOS:000253817800021 PM 18444830 ER PT J AU Malluche, HH Monier-Faugere, MC Wang, G Frazao, JM Charytan, C Coburn, JW Coyne, DW Kaplan, MR Baker, N McCary, LC Turner, SA Goodman, WG AF Malluche, H. H. Monier-Faugere, M. -C. Wang, G. Frazao, J. M. Charytan, C. Coburn, J. W. Coyne, D. W. Kaplan, M. R. Baker, N. McCary, L. C. Turner, S. A. Goodman, W. G. TI An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism SO CLINICAL NEPHROLOGY LA English DT Article DE cinacalcet; randomized; clinical trial; renal; osteodystrophy secondary; hyperparathyroidism ID HEMODIALYSIS-PATIENTS; CALCIMIMETIC AGENT; RENAL-FAILURE; DOUBLE-BLIND; MARKERS; TURNOVER; THERAPY AB Aims: Cinacalcet lowers plasma parathyroid hormone (PTH) levels in patients with secondary hyperparathyroidism (sHPT), but the bone histologic response has not been described. This prospective, double-blind, placebo-controlled trial assessed the effects of cinacalcet on bone histology and serum markers of bone metabolism in dialysis patients with sHPT. Methods: Patients with intact PTH (iPTH) >= 300 pg/ml were randomly assigned 2:1 to receive cinacalcet or placebo with concurrent vitamin D and/or phosphate bindertherapy. Cinacalcet (30-180 mg/day) was used to achieve iPTH levels! 200 pg/ml. Bone biopsies were performed before and after one year of treatment. Results: Baseline and end-of-study data were available from 32 patients (19 cinacalcet, 13 placebo). Baseline bone tunnover was elevated in 27, reduced in 3 and normal in 2 patients. Serum bone-specific alkaline phosphatase (BSAP) and N-telopeptide (NTx) were elevated. Cinacalcet treatment decreased PTH and diminished activation frequency, bone formation rate/bone surface, and fibrosis surface/bone surface. Adynamic bone was observed in three patients receiving cinacalcet; in two of these, PTH levels were persistently low (< 100 pg/ml). The histomorphometric parameter changes in bone corresponded to PTH, BSAP and NTx reductions. Bone mineralization parameters remained normal. Conclusions: Treatment with cinacalcet lowered PTH and reduced bone turnover and tissue fibrosis among most dialysis patients with biochemical evience of sHPT. C1 [Malluche, H. H.; Monier-Faugere, M. -C.; Wang, G.] Univ Kentucky, Div Nephrol Bone & Mineral Metab, Lexington, KY 40536 USA. [Frazao, J. M.] Univ Porto, Sch Med, Nephrol Res & Dev Unit, Oporto, Portugal. [Charytan, C.] New York Hosp, Queens Med Ctr, Flushing, NY USA. [Coburn, J. W.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Coyne, D. W.] Washington Univ, Sch Med, St Louis, MO USA. [Kaplan, M. R.] Nephrol Assoc, Nashville, TN USA. [Baker, N.; McCary, L. C.; Turner, S. A.] Amgen Inc, Thousand Oaks, CA USA. [Goodman, W. G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Malluche, HH (reprint author), Univ Kentucky, Div Nephrol Bone & Mineral Metab, Room MN 564,800 Rose St, Lexington, KY 40536 USA. EM hhmall@uky.edu RI Frazao, Joao/J-9811-2013 OI Frazao, Joao/0000-0002-8081-5474 NR 19 TC 62 Z9 66 U1 0 U2 4 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD APR PY 2008 VL 69 IS 4 BP 269 EP 278 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 287NM UT WOS:000254923800006 PM 18397701 ER PT J AU Fan, VS Giardino, ND Blough, DK Kaplan, RM Ramsey, SD AF Fan, Vincent S. Giardino, Nicholas D. Blough, David K. Kaplan, Robert M. Ramsey, Scott D. CA NETT Res Grp TI Costs of Pulmonary Rehabilitation and Predictors of Adherence in the National Emphysema Treatment Trial SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE Rehabilitation; Chronic Obstructive Pulmonary Disease; Depression ID VOLUME-REDUCTION SURGERY; AIR-FLOW OBSTRUCTION; RESPIRATORY REHABILITATION; DISEASE; MORBIDITY; MORTALITY; INDEX; COPD AB This study reports the costs associated with rehabilitation among participants in the National Emphysema Treatment Trial (NETT), and evaluates factors associated with adherence to rehabilitation. Pulmonary rehabilitation is recommended for moderate-to-severe COPD and required by the Centers for Medicare and Medicaid Services (CMS) prior to lung volume reduction surgery (LVRS). Between January 1998 and July 2002,1,218 subjects with emphysema and severe airflow limitation (FEV(1) < 45% predicted) were randomized. Primary outcome measures were designated as mortality and maximal exercise capacity 2 years after randomization. Pre-randomization, estimated mean total cost per patient of rehabilitation was $2,218 (SD $314; 2006 dollars) for the medical group and $2,187 (SD $304) for the surgical group. Post-randomization, mean cost per patient in the medical and surgical groups was $766 and $962 respectively. Among patients who attended >= 1 post-randomization rehabilitation session, LVRS patients, patients with an FEV(1) >= 20% predicted, and higher education were significantly more likely to complete rehabilitation. Patients with depressive and anxiety symptoms, and those who live > 36 miles compared to < 6 miles away were less likely to be adherent. Patients who underwent LVRS completed more exercise sessions than those in the medical group and were more likely to be adherent with post-randomization rehabilitation. A better understanding of patient factors such as socioeconomic status, depression, anxiety and transportation issues may improve adherence to pulmonary rehabilitation. C1 [Blough, David K.; Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Fan, Vincent S.] Hlth Serv Res & Dev Ctr Excellence, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fan, Vincent S.; Ramsey, Scott D.] Univ Washington, Dept Med, Seattle, WA USA. [Giardino, Nicholas D.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Kaplan, Robert M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA. RP Ramsey, SD (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,Box 19024,M3-B232, Seattle, WA 98109 USA. EM Vincent.Fan@med.va.gov; ngiardin@umich.edu; dkblough@u.washington.edu; rmkaplan@ucla.edu; sramsey@fhcrc.org FU National Heart, Lung, and Blood Institute [N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR761 10, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, N01HR76119]; Centers for Medicare and Medicaid Services; Agency for Healthcare Research and Quality FX The research reported here was supported by the Department of Veteran Affairs, Health Services Research and Development Service Grants RCD 02-170-2 and by the NETT Coordinating Center. The National Emphysema Treatment Trial (NETT) is supported by contracts with the National Heart, Lung, and Blood Institute (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR761 10, N01HR7611 1, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119), the Centers for Medicare and Medicaid Services (CMS; formerly the Health Care Financing Administration); and the Agency for Healthcare Research and Quality (AHRO). NR 25 TC 38 Z9 39 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1541-2555 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD APR PY 2008 VL 5 IS 2 BP 105 EP 116 DI 10.1080/15412550801941190 PG 12 WC Respiratory System SC Respiratory System GA 428GP UT WOS:000264836300005 PM 18415809 ER PT J AU Musher, DM Aslam, S AF Musher, Daniel M. Aslam, Saima TI Treatment of Clostridium difficile colitis in the critical care setting SO CRITICAL CARE CLINICS LA English DT Article ID ANTIBIOTIC-ASSOCIATED COLITIS; IN-VITRO ACTIVITY; CLINDAMYCIN-ASSOCIATED COLITIS; 15 ANTIMICROBIAL AGENTS; PSEUDOMEMBRANOUS COLITIS; ORAL VANCOMYCIN; DISEASE SEVERITY; DOUBLE-BLIND; STAPHYLOCOCCAL ENTEROCOLITIS; INTRAVENOUS IMMUNOGLOBULIN AB Clostridium difficile colitis is a debilitating infection with a remarkably high associated mortality. Infection is contagious and spreads especially rapidly in an intensive care setting because patients who are there have all the associated risk factors, including major underlying illnesses, prior antibiotic therapy, and use of agents that suppress gastric acidity. Prevention of disease is the responsibility of every health care provider in the critical care setting. This article emphasizes treatment of Clostridium difficile colitis, considers diagnostic techniques, and describes means for preventing the spread of this infection in the intensive care setting. C1 [Musher, Daniel M.; Aslam, Saima] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Musher, Daniel M.; Aslam, Saima] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 84 TC 11 Z9 12 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0704 J9 CRIT CARE CLIN JI Crit. Care Clin. PD APR PY 2008 VL 24 IS 2 BP 279 EP + DI 10.1016/j.ccc.2007.12.006 PG 14 WC Critical Care Medicine SC General & Internal Medicine GA 291XK UT WOS:000255230400005 PM 18361946 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Indications and timing of renal replacement therapy in acute kidney injury SO CRITICAL CARE MEDICINE LA English DT Article DE renal replacement therapy; acute kidney injury; volume overload; hyperkalemia; metabolic acidosis ID CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; RANDOMIZED-TRIAL; CARDIAC-SURGERY; COHORT ANALYSIS; FAILURE; DIALYSIS; INTERMITTENT; HEMODIALYSIS; MORTALITY AB The optimal timing for initiation of renal replacement therapy in patients with acute kidney injury remains uncertain. Conventionally accepted indications include volume overload, hyperkalemia, metabolic acidosis, overt uremia, and even progressive azotemia in the absence of specific symptoms; however, precise definitions for these indications are lacking, Data from recent observational. trials have suggested that early initiation of renal replacement therapy may be associated with decreased mortality; however, the results of these studies are inconclusive. Existing data on timing of initiation of renal replacement therapy in acute kidney injury that guide current clinical practice are summarized and issues that need to be addressed in future clinical trials are discussed. C1 [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15260 USA. [Palevsky, Paul M.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15260 USA. EM palevsky@piff.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 32 TC 26 Z9 28 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2008 VL 36 IS 4 SU S BP S224 EP S228 DI 10.1097/CCM.0b013e318168e3fb PG 5 WC Critical Care Medicine SC General & Internal Medicine GA 284BO UT WOS:000254680400014 PM 18382198 ER PT J AU Modi, S Rosen, T AF Modi, Sapna Rosen, Ted TI Micropapular cutaneous sarcoidosis: Case series successfully managed with hydroxychloroquine sulfate SO CUTIS LA English DT Article ID CHILDREN AB Micropapular lesions constitute a rare morphologic variety of cutaneous sarcoidosis. We report 3 patients with this unusual entity and highlight the universal suppressive response to oral hydroxy-chloroquine sulfate. Although ocular involvement has been found to be common in conjunction with micropapular cutaneous sarcoidosis, none of our patients had demonstrable eye disease. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Modi, S (reprint author), Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA. NR 12 TC 3 Z9 3 U1 0 U2 0 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 J9 CUTIS JI Cutis PD APR PY 2008 VL 81 IS 4 BP 351 EP 354 PG 4 WC Dermatology SC Dermatology GA 291YF UT WOS:000255232700011 PM 18491485 ER PT J AU Del Rossi, G Lisman, P Signorile, J AF Del Rossi, Gianluca Lisman, Peter Signorile, Joseph TI Fabricating a better mouthguard. Part II: The effect of color on adaptation and fit SO DENTAL TRAUMATOLOGY LA English DT Article ID PLAYERS AB The thermoforming process involves the heating of plastic sheets to a critical temperature followed by the shaping of the heated material into a three-dimensional structure. Given that custom-fabricated mouthguards are produced using the thermoforming process, the adaptation of plastic sheets to a stone model of the dentition is likely to be affected by the ability of the mouthguard material to be heated. The purpose of this study was to establish if material color affected the adaptation and fit of custom-made mouthguards. Twelve stone models were used in this investigation. Five mouthguards were produced using each model. These mouthguards were made using clear-, white-, black-, blue- and green-colored ethyl vinyl acetate. The force required to remove the various colored mouthguards from the corresponding stone models was determined using a strain gauge housed within a specially designed apparatus. Each of the mouthguards were tested three times at two different angles of pull -45 degrees and 90 degrees. Statistical tests performed using the average amount of force required for mouthguard removal revealed an angle by color interaction. Post hoc analyses revealed that the mean force required to remove the clear-colored mouthguards from their respective stone models was significantly less than the force required to pull away blue-, black- and green-colored mouthguards. This difference between clear- and dark-colored mouthguards was observed at both angles tested with the exception of the black mouthguard which differed from the clear-colored mouthguard only when removed at an angle of 90 degrees. The results of the present study indicate that by using dark-colored mouthguard material, one can achieve superior adaptation and thus produce a more firmly fitting mouthguard. C1 [Del Rossi, Gianluca] Univ S Florida, Coll Med, Dept Orthopaed & Sports Med, Athelet Training Educ Program, Tampa, FL 33612 USA. [Lisman, Peter; Signorile, Joseph] Univ Miami, Dept Exercise & Sport Sci, Coral Gables, FL 33124 USA. [Signorile, Joseph] US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Miami, FL USA. RP Del Rossi, G (reprint author), Univ S Florida, Coll Med, Dept Orthopaed & Sports Med, Athelet Training Educ Program, 3500 E,Fletcher Ave,Suite 511, Tampa, FL 33612 USA. EM gdelross@health.usf.edu RI Del Rossi, Gianluca/I-4963-2012 NR 8 TC 14 Z9 14 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1600-4469 J9 DENT TRAUMATOL JI Dent. Traumatol. PD APR PY 2008 VL 24 IS 2 BP 197 EP 200 DI 10.1111/j.1600-9657.2007.00570.x PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 277CU UT WOS:000254191100010 PM 18352924 ER PT J AU Mather, KJ Funahashi, T Matsuzawa, Y Edelstein, S Bray, GA Kahn, SE Crandall, J Marcovina, S Goldstein, B Goldberg, R AF Mather, Kieren J. Funahashi, Tohru Matsuzawa, Yuji Edelstein, Sharon Bray, George A. Kahn, Steven E. Crandall, Jill Marcovina, Santica Goldstein, Barry Goldberg, Ronald CA Diabet Prevention Program TI Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program SO DIABETES LA English DT Article ID LIFE-STYLE INTERVENTION; INSULIN-RESISTANCE; METABOLIC SYNDROME; JAPANESE POPULATION; PLASMA ADIPONECTIN; METFORMIN; RISK; SENSITIVITY; GLUCOSE; RECEPTORS AB OBJECTIVE - To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS - Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS-Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per similar to 3 mu g/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means +/- SE] 0.83 +/- 0.05 mu g/ml in the lifestyle group, 0.23 +/- 0.05 mu g/ml in the metformin group, and 0.10 +/- 0.05 mu g/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the metformin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per similar to 1 mu g/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS-Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels. C1 [Edelstein, Sharon] George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, Rockville, MD 20852 USA. [Mather, Kieren J.] Indiana Univ, Sch Med, Div Endocrinol & Metab, Indianapolis, IN USA. [Funahashi, Tohru; Matsuzawa, Yuji] Osaka Univ, Dept Internal Med & Mol Sci, Osaka, Japan. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Crandall, Jill] Albert Einstein Coll Med, Diabet Res Ctr, Bronx, NY 10467 USA. [Goldstein, Barry] Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Goldstein, Barry] Thomas Jefferson Univ, Jefferson Med Coll, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA USA. [Goldberg, Ronald] Univ Miami, Sch Med, Diabet Res Inst, Miami, FL USA. RP Mather, KJ (reprint author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA. EM dppmail@biostat.bsc.gwu.edu OI Kahn, Steven/0000-0001-7307-9002 FU NIDDK NIH HHS [U01 DK048489, U01 DK048489-06] NR 36 TC 92 Z9 99 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD APR PY 2008 VL 57 IS 4 BP 980 EP 986 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282UC UT WOS:000254591700022 PM 18192541 ER PT J AU Lu, L Reiter, MJ Xu, Y Chicco, A Greyson, CR Schwartz, GG AF Lu, L. Reiter, M. J. Xu, Y. Chicco, A. Greyson, C. R. Schwartz, G. G. TI Thiazolidinedione drugs block cardiac K-ATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs SO DIABETOLOGIA LA English DT Article DE action potential; ischaemia; K-ATP channels; thiazolidinedione; ventricular fibrillation ID SENSITIVE POTASSIUM CHANNEL; ACTION-POTENTIAL DURATION; LOW-FLOW ISCHEMIA; MYOCARDIAL-ISCHEMIA; HMR 1883; INSULIN-SENSITIZERS; GAMMA-ACTIVATOR; SMOOTH-MUSCLE; CANINE HEART; REPERFUSION AB Aims/hypothesis Opening of ATP-sensitive potassium (K-ATP) channels during myocardial ischaemia shortens action potential duration and is believed to be an adaptive, energy-sparing response. Thiazolidinedione drugs block K-ATP channels in non-cardiac cells in vitro. This study determined whether thiazolidinedione drugs block cardiac K-ATP channels in vivo. Methods Experiments in 68 anaesthetised pigs determined: (1) effects of inert vehicle, troglitazone (10 mg/kg i.v.) or rosiglitazone (0.1 or 1.0 mg/kg i.v.) on epicardial monophasic action potential (MAP) during 90 min low-flow ischaemia; (2) effects of troglitazone, rosiglitazone or pioglitazone (1 mg/kg i.v.) on response of MAP to intracoronary infusion of a K-ATP channel opener, levcromakalim; and (3) effects of inert vehicle, rosiglitazone (1 mg/kg i.v.) or the sarcolemmal K-ATP blocker HMR-1098 on time to onset of ventricular fibrillation following complete coronary occlusion. Results With vehicle, epicardial MAP shortened by 44 +/- 9 ms during ischaemia. This effect was attenuated to 12 +/- 8 ms with troglitazone and 6 +/- 6 ms with rosiglitazone (p < 0.01 for both vs vehicle), suggesting K-ATP blockade. Intracoronary levcromakalim shortened MAP by 38 +/- 10 ms, an effect attenuated to 12 +/- 8, 13 +/- 4 and 9 +/- 5 ms during co-treatment with troglitazone, rosiglitazone or pioglitazone (p < 0.05 for each), confirming K-ATP blockade. During coronary occlusion, median time to ventricular fibrillation was 29 min in pigs treated with vehicle and 6 min in pigs treated with rosiglitazone or HMR-1098 (p < 0.05 for both vs vehicle), indicating that K-ATP blockade promotes ischaemic ventricular fibrillation in this model. Conclusions/interpretation Thiazolidinedione drugs block cardiac K-ATP channels at clinically relevant doses and promote onset of ventricular fibrillation during severe ischaemia. C1 [Schwartz, G. G.] Denver VA Med Ctr, Cardiol Sect 111B, Denver, CO 80220 USA. [Lu, L.; Reiter, M. J.; Xu, Y.; Chicco, A.; Greyson, C. R.; Schwartz, G. G.] VA Med Ctr, Denver, CO USA. [Lu, L.; Reiter, M. J.; Xu, Y.; Chicco, A.; Greyson, C. R.; Schwartz, G. G.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Schwartz, GG (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM Gregory.Schwartz@va.gov FU NHLBI NIH HHS [HL49944, R01 HL049944, R56 HL049944, R01 HL049944-10] NR 50 TC 29 Z9 29 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD APR PY 2008 VL 51 IS 4 BP 675 EP 685 DI 10.1007/s00125-008-0924-0 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 277SO UT WOS:000254235200020 PM 18251006 ER PT J AU Bennett, JW Murray, CK Holmes, RL Patterson, JE Jorgensen, JH AF Bennett, Jason W. Murray, Clinton K. Holmes, Robert L. Patterson, Jan E. Jorgensen, James H. TI Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE vancomycin tolerance; daptomycin resistance; MRSA bacteremia; minimum inhibitory concentration; bactericidal effect ID BACTERICIDAL ACTIVITY; GLYCOPEPTIDE TOLERANCE; ANTIBIOTIC TOLERANCE; IN-VIVO; STRAINS; ENDOCARDITIS; EFFICACY AB An elderly patient with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia was treated sequentially with vancomycin plus rifampin then daptomycin plus gentamicin. The MRSA strain developed diminished susceptibility to vancomycin (MIC increase and tolerance), daptomycin, and gentamicin, and resistance to rifampin during therapy. (C) 2008 Elsevier Inc. All rights reserved. C1 [Bennett, Jason W.; Murray, Clinton K.] Brooke Army Med Ctr, Infect Dis MCHE MDI, Dept Med, Ft Sam Houston, TX 78234 USA. [Holmes, Robert L.] Wilford Hall USAF Med Ctr, Dept Infect Dis, San Antonio, TX 78201 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Infect Dis & Pathol, San Antonio, TX 78229 USA. [Patterson, Jan E.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Jorgensen, James H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Bennett, JW (reprint author), Brooke Army Med Ctr, Infect Dis MCHE MDI, Dept Med, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM jason.bennett@amedd.army.mil RI Valle, Ruben/A-7512-2013 NR 22 TC 17 Z9 17 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD APR PY 2008 VL 60 IS 4 BP 437 EP 440 DI 10.1016/j.diagmicrobio.2007.11.002 PG 4 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 282KA UT WOS:000254565300019 PM 18096352 ER PT J AU Pimentel, M Chatterjee, S Chang, C Low, K Song, Y Liu, CX Morales, W Ali, L Lezcano, S Conklin, J Finegold, S AF Pimentel, Mark Chatterjee, Soumya Chang, Christopher Low, Kimberly Song, Yuli Liu, Chengxu Morales, Walter Ali, Lemeesa Lezcano, Sheila Conklin, Jeffery Finegold, Sydney TI A new rat model links two contemporary theories in irritable bowel syndrome SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE bacterial overgrowth; Campylobacter jejuni; post-infectious IBS ID INTESTINAL BACTERIAL OVERGROWTH; DOUBLE-BLIND; SYMPTOMS; GASTROENTERITIS; PREVALENCE; RIFAXIMIN; COMPLEX; TRIAL AB Rationale Two proposed hypotheses for irritable bowel syndrome (IBS) are acute gastroenteritis and bacterial overgrowth. We studied whether acute infection with Campylobacter could precipitate bacterial overgrowth in a rat model in order to link the two hypotheses. Methods Sprague-Dawley outbred rats were randomly administered a vehicle or Campylobacter jejuni strain 81-176 by oral gavage. Three months after clearance of the infectious agent, rats had a stool consistency evaluation. After euthanasia, lumenal bacteria counts were measured via quantitative real-time PCR from self-contained segments of the duodenum, jejunum, ileum, cecum and left colon. Adjacent sections of bowel were fixed in formalin for evaluation of intraepithelial lymphocyte counts. Results Three months after clearance of Campylobacter infection, 57% of Campylobacter infected rats had some alteration in stool consistency compared to 7.4% in mock-infected controls (P < 0.001). Among the rats that received Campylobacter, 27% had evidence of bacterial overgrowth by PCR. These rats also had the highest prevalence of altered stool form and had lower body weight. Consistent with post-infectious IBS in humans, bacterial overgrowth rats demonstrated a significant increase in rectal and left colon intraepithelial lymphocytes. Conclusions Acute infection with C. jejuni 81-176 precipitates alterations in stool consistency, bacterial overgrowth and rectal lymphocytosis consistent with findings in IBS patients. C1 [Pimentel, Mark; Chatterjee, Soumya; Low, Kimberly; Morales, Walter; Ali, Lemeesa; Lezcano, Sheila; Conklin, Jeffery] Cedars Sinai Med Ctr, GI Motilty Program, Burns & Allen Res Inst, Los Angeles, CA 90048 USA. [Chang, Christopher; Finegold, Sydney] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. [Song, Yuli; Liu, Chengxu; Finegold, Sydney] W Los Angeles Vet Affairs Med Ctr, Div Gastroenterol & Infect Dis, Los Angeles, CA 90073 USA. RP Pimentel, M (reprint author), Cedars Sinai Med Ctr, GI Motilty Program, Burns & Allen Res Inst, 8730 Alden Dr,Suite 225E, Los Angeles, CA 90048 USA. EM pimentelm@cshs.org RI Chatterjee, Soumya/E-2009-2013 NR 23 TC 32 Z9 36 U1 1 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 2008 VL 53 IS 4 BP 982 EP 989 DI 10.1007/s10620-007-9977-z PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 274AS UT WOS:000253974800017 PM 17934822 ER PT J AU Nosek, MA Robinson-Whelen, S Hughes, RB Petersen, NJ Taylor, HB Byrne, MM Morgan, R AF Nosek, Margaret A. Robinson-Whelen, Susan Hughes, Rosemary B. Petersen, Nancy J. Taylor, Heather B. Byrne, Margaret M. Morgan, Robert TI Overweight and obesity in women with physical disabilities: Associations with demographic and disability characteristics and secondary conditions SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Disabled persons; Minority groups; Overweight; Obesity; Rehabilitation; Women ID SPINAL-CORD-INJURY; BODY-MASS INDEX; AFRICAN-AMERICAN WOMEN; HEALTH-PROMOTION; MULTIPLE-SCLEROSIS; NEUROMUSCULAR DISEASE; US ADULTS; INTERVENTION; PREVALENCE; BARRIERS AB Background: This cross-sectional study was designed to examine weight in association with demographic and disability characteristics and secondary conditions in a sample of community living women with physical disabilities. Methods: 443 predominantly ethnic minority women with physical disabilities were recruited through public and private health clinics and community organizations. They completed questionnaires including measures of body mass index and a health conditions checklist. Results: Data showed that nearly three-quarters of the sample were overweight (26.6%) or obese (47.6%) with 14% extremely obese. Obesity was highest among middle aged women (aged 45-54, 52.7%; aged 55-64, 52.5%; compared to aged 18-44, 37.8%; or aged >= 65, 39.1%). Black (84.0%) and Hispanic women (83.8%) were more likely to be overweight or obese compared to non-Hispanic white women (56.7%). Women with joint and connective tissue diseases and women with more extensive functional limitations were more likely to have excess weight. Disability factors were more strongly associated with excess weight than demographic factors other than age. Weight classification was significantly related to whether or not the women had ever had diabetes or blood pressure problems. Diabetes was reported 4 times as often as among women in general (36.3% versus 8.9%), and hypertension nearly twice as often (56.2% versus 30.9%). Conclusions: These findings indicate extremely high rates of overweight and obesity in women with physical disabilities, a growing population greatly in need of effective weight management interventions. Overweight and obesity in combination with disability in women was associated with disproportionately high rates of diabetes and hypertension. (C) 2008 Elsevier Inc. All rights reserved. C1 [Nosek, Margaret A.; Robinson-Whelen, Susan] Baylor Coll Med, Ctr Res Women Disabil, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Hughes, Rosemary B.] Univ Montana, Rural Inst Disabil, Missoula, MT 59812 USA. [Petersen, Nancy J.; Morgan, Robert] Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77021 USA. [Petersen, Nancy J.; Morgan, Robert] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77021 USA. [Taylor, Heather B.] Univ Texas Hlth Sci Ctr, Div Dev Pediat, Houston, TX 77030 USA. [Byrne, Margaret M.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. EM mnosek@bcm.edu FU Centers for Disease Control and Prevention [RO4/CCR618805] FX This work was supported by the Centers for Disease Control and Prevention (grant RO4/CCR618805). NR 73 TC 15 Z9 15 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD APR PY 2008 VL 1 IS 2 BP 89 EP 98 DI 10.1016/j.dhjo.2008.01.003 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA V18JS UT WOS:000208001700004 PM 21122716 ER PT J AU Becker, WC Fiellin, DA Merrill, JO Schulman, B Finkelstein, R Olsen, Y Busch, SH AF Becker, William C. Fiellin, David A. Merrill, Joseph O. Schulman, Beryl Finkelstein, Ruth Olsen, Yngvild Busch, Susan H. TI Opioid use disorder in the United States: Insurance status and treatment access SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article; Proceedings Paper CT 69th Annual Meeting of the College-of-Problems-on-Drug-Dependence CY JUN 19, 2007 CL Quebec City, CANADA SP Coll Problems Drug Dependence DE opioid use disorder; insurance; access to care ID METHADONE AB Background: In the United States, insurance status and rates of treatment for individuals with opioid use disorder are unknown. Methods: Cross-sectional survey: 2002-2004 National Survey on Drug Use and Health (NSDUH). Bivariate and multivariate associations between demographics, treatment and insurance status and presence or absence of opioid use disorder were investigated. Results: On unadjusted analysis, young respondents, respondents of Hispanic ethnicity (OR 1.5; 95% CI 1.1-2.2), unemployed respondents (OR 2.6; 95% CI 1.8-3.8) and respondents with Medicaid (OR 4.5; 95% CI 2.5-8.3) or lack of insurance (OR 3.2; 95% CI 1.8-5.9) were more likely to have opioid use disorder. On unadjusted analysis among those with any substance use disorder, 12-16 year olds were more likely to have opioid use disorder (OR 3.4; 95% CI 2.0-5.8) than a non-opioid substance use disorder, as were women (OR for men 0.6; 95% CI 0.5-0.7) and unemployed respondents (OR 1.5; 95% CI 1.02-2.1). Only 15.2% of those with past-year opioid use disorder received treatment in the past year. Respondents treated for opioid use had higher rates of Medicaid (p < 0.01), Medicare (p < 0.01) and other public assistance (P = 0.01) compared with those treated for other substances. Treatments for opioid use were more likely to be hospital (p = 0.04) and inpatient rehabilitation (p = 0.02) settings compared to treatment for other substance use. Among those with opioid use disorder, not being employed was independently associated with receiving treatment (AOR 3.5; 95% CI 1.4-8.5). Conclusions: In the U.S., high rates of unemployment, Medicaid and uninsurance among those with opioid use disorder and low rates of treatment suggest that efforts to expand treatment must include policy strategies to help reach a population with significant barriers to treatment access. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Becker, William C.] Philadelphia Vet Affairs Med Ctr, Dept Internal Med, Philadelphia, PA 19104 USA. [Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Busch, Susan H.] Yale Univ, Sch Med, Sch Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Merrill, Joseph O.; Schulman, Beryl] Univ Washington, Dept Med, Seattle, WA USA. [Finkelstein, Ruth] New York Acad Med, New York, NY USA. [Olsen, Yngvild] Johns Hopkins Univ, Baltimore, MD USA. RP Becker, WC (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Internal Med, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM william.becker4@va.gov OI Becker, William/0000-0002-0788-1467; Fiellin, David/0000-0002-4006-010X FU NIDA NIH HHS [T32DA007238] NR 9 TC 26 Z9 26 U1 2 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2008 VL 94 IS 1-3 BP 207 EP 213 DI 10.1016/j.drugalcdep.2007.11.018 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 273KS UT WOS:000253929700025 PM 18222051 ER PT J AU Wilkinson, CW AF Wilkinson, Charles W. TI Circadian clocks: Showtime for the adrenal cortex SO ENDOCRINOLOGY LA English DT Editorial Material ID GENE-EXPRESSION; LOCOMOTOR-ACTIVITY; GLAND; MELATONIN; RHYTHM; ENDOCRINE; DRINKING; TISSUES; LESIONS; RATS C1 [Wilkinson, Charles W.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Wilkinson, CW (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM wilkinso@u.washington.edu NR 23 TC 3 Z9 4 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD APR PY 2008 VL 149 IS 4 BP 1451 EP 1453 DI 10.1210/en.2008-0166 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 278DO UT WOS:000254264100003 PM 18359750 ER PT J AU Li, Z Aronson, WJ Arteaga, JR Hong, K Thames, G Henning, SM Liu, W Elashoff, R Ashley, JM Heber, D AF Li, Z. Aronson, W. J. Arteaga, J. R. Hong, K. Thames, G. Henning, S. M. Liu, W. Elashoff, R. Ashley, J. M. Heber, D. TI Feasibility of a low-fat/high-fiber diet intervention with soy supplementation in prostate cancer patients after prostatectomy SO EUROPEAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE prostate cancer; low fat diet; soy supplement; high fiber ID FACTOR-BINDING-PROTEINS; GROWTH-FACTOR AXIS; LOW-FAT DIET; PHYSICAL-ACTIVITY; UNITED-STATES; HIGH-FRUIT; FACTOR-I; INSULIN; MEN; ANTIGEN AB Objectives: To evaluate the feasibility and long- term compliance with a low- fat diet supplemented with soy protein in men at increased risk for recurrence after radical prostatectomy. Design: Randomized, control study. Setting: Academic center in USA. Subject: Forty men who had undergone radical prostatectomy and were at increased risk for recurrence. Intervention: Low- fat ( 15% fat), high- fiber ( 18 g/ 1000 kcal) diet supplemented with 40 g soy protein isolate ( n 26) was compared to USDA recommended diet ( n 14). Results: Over 4 years, subjects in the intervention group but not in the control group made and sustained significant changes in their diet as measured by the dietary assessment instruments and urinary isoflavone excretion. In the intervention group, dietary fat intake was reduced from 33.46 +/- 1.27% energy/ day to 21.04 +/- 1.74% ( P<0.05), fiber intake increased from 14.6 +/- 1.06 to 21.05 +/- 2.29 g/ day. The insulin growth factor- 1 ( IGF- 1) level was decreased from 260.4 +/- 8.6 ng/ ml at baseline to 220.5 +/- 7.9 ng/ ml at 6 months ( P<0.05) in the intervention group with no significant change in the control group. An ex vivo assay demonstrated inhibition of LNCaP cell growth ( - 20.0 +/- 7.7%, P<0.05) by sera from patients in the intervention group after 6 months of dietary change compared to baseline. Conclusion: These data suggest that long- term low- fat dietary interventions as part of prospective randomized trials in prostate cancer survivors are feasible, and lead to reductions in circulating hormones or other growth factors stimulating prostate cancer growth ex vivo. C1 [Li, Z.; Arteaga, J. R.; Hong, K.; Thames, G.; Henning, S. M.; Heber, D.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Los Angeles, CA 90095 USA. [Li, Z.; Aronson, W. J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aronson, W. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Liu, W.; Elashoff, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Ashley, J. M.] Univ Nevada, Reno, NV 89557 USA. RP Li, Z (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, 900 Vet Ave,Room 12-217, Los Angeles, CA 90095 USA. EM zli@mednet.ucla.edu FU NCI NIH HHS [P50 CA92131, P30 CA 42710, CA100938]; NIDDK NIH HHS [T32 DK 57688] NR 32 TC 10 Z9 10 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0954-3007 J9 EUR J CLIN NUTR JI Eur. J. Clin. Nutr. PD APR PY 2008 VL 62 IS 4 BP 526 EP 536 DI 10.1038/sj.ejcn.1602743 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 282IH UT WOS:000254560600010 PM 17392697 ER PT J AU Kennedy, A Wood, AE Tapp, A AF Kennedy, A. Wood, A. E. Tapp, A. TI Adjunctive galantamine's effect on functioning in schizophrenia: No clear benefit SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Kennedy, A.; Wood, A. E.; Tapp, A.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. [Kennedy, A.; Wood, A. E.; Tapp, A.] VA Puget Sound Hlth Care Syst, MIRECC, Tacoma, WA USA. [Kennedy, A.] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Wood, A. E.; Tapp, A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S240 EP S240 DI 10.1016/j.eurpsy.2008.01.454 PG 1 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987801107 ER PT J AU Tapp, A Kilzieh, N AF Tapp, A. Kilzieh, N. TI Time to discontinuation of olanzapine and risperidone as a measure of effectiveness in a clinical setting SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Tapp, A.; Kilzieh, N.] Va Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA USA. [Tapp, A.; Kilzieh, N.] Mental Illness Res Educ & Clin Ctr MIRREC, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PD APR PY 2008 VL 23 SU 2 BP S149 EP S150 DI 10.1016/j.eurpsy.2008.01.901 PG 2 WC Psychiatry SC Psychiatry GA 288LL UT WOS:000254987800520 ER PT J AU Freedland, SJ Hotaling, JM Fitzsimons, NJ Presti, JC Kane, CJ Terris, MK Aronson, WJ Amling, CL AF Freedland, Stephen J. Hotaling, James M. Fitzsimons, Nicholas J. Presti, Joseph C., Jr. Kane, Christopher J. Terris, Martha K. Aronson, William J. Amling, Christopher L. TI PSA in the new millennium: A powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes - Results from the SEARCH database SO EUROPEAN UROLOGY LA English DT Article DE biochemical recurrence; prostate cancer; PSA; radical prostatectomy ID ANTIGEN ERA; BIOCHEMICAL RECURRENCE; PREOPERATIVE PSA; FREE SURVIVAL; SERUM; MEN; PROGRESSION; CARCINOMA; THERAPY; FAILURE AB Objectives: As a result of prostate-specific antigen (PSA) screening, most men today with prostate cancer present with localized disease and serum PSA values < 10 ng/ml. Within this context, it is debated whether PSA remains an important prognostic variable in more recently treated patients. We examined the prognostic significance of preoperative PSA to predict pathologic stage and biochemical progression among men undergoing radical prostatectomy in the new millennium (2000-2006). Methods: We performed a review of 925 men with prostate cancer treated by radical prostatectomy since 2000 within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. We examined the association between preoperative PSA and risk of adverse pathologic features and biochemical progression using logistic regression and Cox proportional hazards analysis. Results: After adjusting for multiple clinical preoperative characteristics, higher preoperative PSA values were associated with increased odds of extracapsular extension (p < 0.001), positive surgical margins (p < 0.001), and seminal vesicle invasion (p < 0.001) and increased risk of biochemical progression (p = 0.009). When the analyses were limited to the 690 men with a preoperative PSA < 10 ng/ml and after adjusting for multiple clinical characteristics, higher preoperative PSA values remained associated with increased risk of biochemical progression (hazard ratio [HR] 1.16, 95% confidence interval [CI] 1.06-1.28, p = 0.002). Even among the 448 men with a PSA < 10 ng/ml and clinical stage T1c disease, preoperative PSA was associated with increased risk of biochemical progression (HR 1.14, 95% CI 1.00-1.31, p = 0.047). Conclusions: PSA remains an important prognostic marker among men diagnosed with prostate cancer in the new millennium treated with radical prostatectomy and remains an important predictor of outcome even among men with preoperative PSA level < 10 ng/ml. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. C1 [Freedland, Stephen J.; Hotaling, James M.; Fitzsimons, Nicholas J.] Duke Univ, Sch Med, Div Urol Surg, Durham, NC 27710 USA. [Freedland, Stephen J.; Hotaling, James M.; Fitzsimons, Nicholas J.] Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC 27710 USA. [Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Kane, Christopher J.] Vet Affairs Med Ctr, Urol Sect, San Francisco, CA 94121 USA. [Kane, Christopher J.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Amling, Christopher L.] Univ Alabama, Dept Surg, Div Urol, Birmingham, AL 35294 USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol Surg, Box 2626 DUMC, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [P50 CA92131-01A1, R01CA100938] NR 34 TC 18 Z9 19 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 J9 EUR UROL JI Eur. Urol. PD APR PY 2008 VL 53 IS 4 BP 758 EP 766 DI 10.1016/j.eururo.2007.08.047 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 283XT UT WOS:000254670500015 PM 17868976 ER PT J AU Paintlia, MK Paintlia, AS Contreras, MA Singh, I Singh, AK AF Paintlia, Manjeet K. Paintlia, Ajaib S. Contreras, Miguel A. Singh, Inderjit Singh, Avtar K. TI Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: Attenuation by N-acetyl cysteine SO EXPERIMENTAL NEUROLOGY LA English DT Article DE lipopolysaccharide; periventricular leukomalacia; cerebral white matter injury; cerebral palsy; peroxisome proliferators-activated receptor-alpha; N-acetyl cysteine ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LATE OLIGODENDROCYTE PROGENITORS; RECEPTOR-ALPHA ACTIVATION; PERINATAL BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; DEVELOPING RAT-BRAIN; KAPPA-B; OXIDATIVE STRESS; PERIVENTRICULAR LEUKOMALACIA AB Cerebral white matter injury during prenatal maternal infection characterized as periventricular leukomalacia is the main substrate for cerebral palsy (CP) in premature infants. Previously, we reported that maternal LPS exposure causes oligodendrocyte (OL)-injury/hypomyelination in the developing brain which can be attenuated by an antioxidant agent, N-acetyl cysteine (NAC). Herein, we elucidated the role of peroxisomes in LPS-induced neuroinflammation and cerebral white matter injury. Peroxisomes are important for detoxification of reactive oxidative species (ROS) and metabolism of myelin-lipids in OLs. Maternal LPS exposure induced selective depletion of developing OLs in the fetal brain which was associated with ROS generation, glutathione depletion and peroxisomal dysfunction. Likewise, hypomyelination in the postnatal brain was associated with decrease in peroxisomes and OLs after maternal LPS exposure. Conversely, NAC abolished these LPS-induced effects in the developing brain. CP brains imitated these observed changes in peroxisomal/myelin proteins in the postnatal brain after maternal LPS exposure. In vitro studies revealed that pro-inflammatory cytokines cause OL-injury via peroxisomal dysfunction and ROS generation. NAC or WY14643 (peroxisome proliferators activated receptor (PPAR)-alpha agonist) reverses these effects of pro-inflammatory cytokines in the wild-type OLs, but not in PPAR-alpha((-/-)) OLs. Similarly treated B 12 oligodenroglial cells co-transfected with PPAR-alpha siRNAs/pTK-PPREx3-Luc, and LPS exposed PPAR-alpha((-/-)) pregnant mice treated with NAC or WY14643 further suggested that PPAR-a activity mediates NAC-induced protective effects. Collectively, these data provide unprecedented evidence that LPS-induced peroxisomal dysfunction exacerbates cerebral white matter injury and its attenuation by NAC via a PPAR-a dependent mechanism expands therapeutic avenues for CP and related demyclinating diseases. Published by Elsevier Inc. C1 [Paintlia, Manjeet K.; Paintlia, Ajaib S.; Contreras, Miguel A.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst 513, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst 513, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NCRR NIH HHS [C06 RR015455, C06 RR018823]; NINDS NIH HHS [NS-34741, NS-22576, NS-37766, NS-40810, R01 NS022576, R01 NS034741, R01 NS034741-08, R01 NS037766, R01 NS037766-08, R01 NS040810, R37 NS022576, R37 NS022576-22] NR 76 TC 51 Z9 52 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD APR PY 2008 VL 210 IS 2 BP 560 EP 576 DI 10.1016/j.expneurol.2007.12.011 PG 17 WC Neurosciences SC Neurosciences & Neurology GA 287CL UT WOS:000254894200029 PM 18291369 ER PT J AU Cornia, PB Davidson, HL Lipsky, BA AF Cornia, Paul B. Davidson, Heather L. Lipsky, Benjamin A. TI The evaluation and treatment of complicated skin and skin structure infections SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE bacterial myonecrosis; complicated skin and skin structure infection; necrotizing fasciitis ID SOFT-TISSUE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; DIABETIC FOOT INFECTIONS; GRAM-POSITIVE BACTERIA; ENTEROCOCCUS-FAECIUM INFECTIONS; DOUBLE-BLIND; NECROTIZING FASCIITIS; HOSPITALIZED-PATIENTS; TRIMETHOPRIM-SULFAMETHOXAZOLE; QUINUPRISTIN-DALFOPRISTIN AB Background: Skin and skin structure infections are frequently encountered in clinical practice. Fortunately, these infections usually produce only mild to moderate symptoms and signs. Some, however, are severe and may even be life-threatening. Objective: To review the approach to the evaluation and treatment of patients with complicated skin and skin structure infections and to discuss when to consider using either established antibiotics or recently licensed agents for treating these infections. Methods: In addition to a non-systematic literature review of complicated skin and skin structure infections and necrotizing fasciitis, we identified recent articles examining the microbiology and describing recently licensed antibiotics for treating these infections. Results/conclusions: Clinicians must learn to recognize the early symptoms and signs of severe skin and skin structure infections to ensure they select appropriate empiric antibiotic therapy and, when needed, obtain prompt surgical consultation. While the recent approvals of new agents for treating these infections are welcome, particularly in light of the continued emergence of anti biotic-resistant bacteria, traditional antibiotic regimens remain appropriate for most cases. C1 [Cornia, Paul B.; Davidson, Heather L.; Lipsky, Benjamin A.] Univ Washington, Sch Med, Primary & Specialty Med Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Cornia, Paul B.; Davidson, Heather L.; Lipsky, Benjamin A.] Univ Washington, Sch Med, Primary & Specialty Med Serv, Dept Med, Seattle, WA 98108 USA. [Cornia, Paul B.] Univ Washington, VA Puget Sound Hlth Care Syst S111, Seattle, WA 98108 USA. RP Cornia, PB (reprint author), Univ Washington, Sch Med, Primary & Specialty Med Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM paul.cornia@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 99 TC 4 Z9 5 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1465-6566 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD APR PY 2008 VL 9 IS 5 BP 717 EP 730 DI 10.1517/14656S66.9.5.717 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 285MI UT WOS:000254780500005 PM 18345950 ER PT J AU Bunni, MA Kramarenko, II Walker, L Raymond, JR Garnovskaya, MN AF Bunni, Marlene A. Kramarenko, Inga I. Walker, Linda Raymond, John R. Garnovskaya, Maria N. TI Role of Integrins in Angiotensin II-induced Proliferation of Vascular Smooth Muscle Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Bunni, Marlene A.; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Med Serv, Charleston, SC USA. [Bunni, Marlene A.; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. [Bunni, Marlene A.; Kramarenko, Inga I.; Walker, Linda; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467806379 ER PT J AU Chattergoon, NN Louey, S Grandy, DK Scanlan, TS Hohimer, R Giraud, GD Thornburg, KL AF Chattergoon, Natasha N. Louey, Samantha Grandy, David K. Scanlan, Thomas S. Hohimer, Roger Giraud, George D. Thornburg, Kent L. TI 3-Iodothyronamine is a novel suppressor of fetal sheep cardiomyocyte proliferation in vitro SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Chattergoon, Natasha N.; Louey, Samantha; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR USA. [Grandy, David K.; Scanlan, Thomas S.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR USA. [Hohimer, Roger] Oregon Hlth & Sci Univ, OB GYN Perinatal Div, Portland, OR USA. [Giraud, George D.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804144 ER PT J AU Coaxum, SD Raymond, JR AF Coaxum, Sonya Denise Raymond, John R. TI Mutations in the i3N loop calmodulin (CaM)-binding domain of 5-HT1A receptor attenuate ERK phosphorylation in CHO-K1 cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Coaxum, Sonya Denise; Raymond, John R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Coaxum, Sonya Denise; Raymond, John R.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467806101 ER PT J AU Garnovskaya, MN Bunni, M Kramarenko, I Raymond, JR Morinelli, TA AF Garnovskaya, Maria N. Bunni, Marlene Kramarenko, Inga Raymond, John R. Morinelli, Thomas A. TI Bradykinin B-2 Receptor Induces Multiple Cellular Responses Leading to Proliferation of Renal Carcinoma Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Garnovskaya, Maria N.; Bunni, Marlene; Raymond, John R.; Morinelli, Thomas A.] Ralph H Johnson VAMC, Med Serv, Charleston, SC USA. [Garnovskaya, Maria N.; Bunni, Marlene; Raymond, John R.; Morinelli, Thomas A.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. [Garnovskaya, Maria N.; Bunni, Marlene; Kramarenko, Inga; Raymond, John R.; Morinelli, Thomas A.] Med Univ S Carolina, Nephrol Div, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700282 ER PT J AU Goldman, RK Azar, AS Mulvaney, JM Brooks, VL AF Goldman, Robert K. Azar, Afaf S. Mulvaney, Julia M. Brooks, Virginia L. TI Baroreflex sensitivity varies during the estrus cycle of the rat SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Goldman, Robert K.; Azar, Afaf S.; Mulvaney, Julia M.; Brooks, Virginia L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Goldman, Robert K.] Portland VA Med Ctr, Surgery, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467808766 ER PT J AU Goldman, RK Azar, AS Mulaney, JM Brooks, VL AF Goldman, Robert K. Azar, Afaf S. Mulaney, Julia M. Brooks, Virginia L. TI Changes in gain of baroreflex control of heart rate during delivery and the early post partum period of the rat SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Goldman, Robert K.; Azar, Afaf S.; Mulaney, Julia M.; Brooks, Virginia L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Goldman, Robert K.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804650 ER PT J AU Hsu, HC Yang, PA Wu, Q Job, G Guentert, T Wang, J Mountz, JD AF Hsu, Hui-Chen Yang, PingAr Wu, Qi Job, Godwin Guentert, Tanja Wang, John Mountz, John D. TI Inhibition of Activation-Induced Cytidine Deaminase (AID) Preserved Spontaneous Germinal Centers but Suppressed Autoimmune Disease in BXD2 Mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Job, Godwin; Guentert, Tanja; Wang, John; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802571 ER PT J AU Kramarenko, I Bunni, M Raymond, JR Garnovskaya, MN AF Kramarenko, Inga Bunni, Marlene Raymond, John R. Garnovskaya, Maria N. TI Identification of a Functional Bradykinin B-2 Receptor Expressed in HEK293 Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Kramarenko, Inga; Bunni, Marlene; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Bunni, Marlene; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Med Serv, Charleston, SC USA. [Bunni, Marlene; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700479 ER PT J AU Kramarenko, II Bunni, M Raymond, JR Garnovskaya, MN AF Kramarenko, Inga I. Bunni, Marlene Raymond, John R. Garnovskaya, Maria N. TI Bradykinin B-2 Receptor Interacts with Integrin alpha 5 beta 1 to Transactivate Epidermal Growth Factor Receptor in Kidney Cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Kramarenko, Inga I.; Bunni, Marlene; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Charleston, SC 29425 USA. [Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Med Serv, Charleston, SC USA. [Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804688 ER PT J AU La Fountaine, M Radulovic, M Wecht, J Cardozo, C Spungen, A De Meersman, R Bauman, W AF La Fountaine, Michael Radulovic, Miroslav Wecht, Jill Cardozo, Chrstopher Spungen, Ann De Meersman, Ronald Bauman, William TI Vascular reactivity to L-NAME administration in chronic tetraplegia SO FASEB JOURNAL LA English DT Meeting Abstract C1 [La Fountaine, Michael; Radulovic, Miroslav; Wecht, Jill; Cardozo, Chrstopher; Spungen, Ann; Bauman, William] James J Peters VAMC, VA Ctr Excellence Med Consequences Spinal Cord In, Bronx, NY USA. [La Fountaine, Michael; De Meersman, Ronald] Columbia Univ Teachers Coll, New York, NY 10027 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467801272 ER PT J AU Lam, F Burns, A Rumbaut, R AF Lam, Fong Burns, Alan Rumbaut, Rolando TI Activated platelets enhance early neutrophil transmigration across IL-1 beta stimulated endothelium SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Lam, Fong; Burns, Alan] Baylor Coll Med, Houston, TX 77030 USA. [Rumbaut, Rolando] VA Med Ctr, MCL, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GY UT WOS:000208467700556 ER PT J AU Mailloux, AW Young, MRI AF Mailloux, Adam William Young, M. Rita I. TI Lewis Lung Carcinoma (LLC) alters the phenotype of murine lung mast cells resulting in a phenotype consistent with myeloid-derived suppressor cells (MDSCs) SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mailloux, Adam William; Young, M. Rita I.] Med Univ S Carolina, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Dept Otolaryngol, Charleston, SC USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Dept Med, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804792 ER PT J AU Mailloux, AW Young, MRI AF Mailloux, Adam William Young, M. Rita I. TI Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) produce CCL22 which selectively recruits regulatory T-cells (Tregs) to the tumor microenvironment SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804693 ER PT J AU Mayhew, D Roth, C Cross, J Bamman, M AF Mayhew, David Roth, Christopher Cross, James Bamman, Marcas TI p70S6K signaling induces load-mediated myofiber hypertrophy in humans in an mTOR- and RPS6-indedpendent manner SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mayhew, David] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL USA. [Roth, Christopher] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Bamman, Marcas] Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467809154 ER PT J AU Mershon, KL Vasuthasawat, A Morrison, SL Beenhouwer, DO AF Mershon, Kileen Louise Vasuthasawat, Alex Morrison, Sherie L. Beenhouwer, David O. TI Both the lectin and alternative pathways of complement activation play roles in Cryptococcus gattii infection SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mershon, Kileen Louise; Vasuthasawat, Alex; Morrison, Sherie L.; Beenhouwer, David O.] Univ Calif Los Angeles, Los Angeles, CA USA. [Beenhouwer, David O.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467803341 ER PT J AU Mountz, JD Yang, PA Wu, Q Guentert, T Wang, J Hsu, HC AF Mountz, John D. Yang, PingAr Wu, Qi Guentert, Tanja Wang, John Hsu, Hui-Chen TI IL-17 Upregulates Regulator of G-protein Signaling (Rgs)13 and Rgs16 for the Formation of Autoreactive Germinal Centers in BXD2 Mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mountz, John D.; Yang, PingAr; Wu, Qi; Guentert, Tanja; Wang, John; Hsu, Hui-Chen] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802581 ER PT J AU Mulligan, J Young, MRI AF Mulligan, Jennifer Young, M. Rita I. TI Role of Endothelial Cells in a Novel Mechanism of Tumor-Induced Immune Suppression SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Mulligan, Jennifer; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Mulligan, Jennifer; Young, M. Rita I.] Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804167 ER PT J AU Myers, RC Carter, RH AF Myers, Riley C. Carter, Robert H. TI B cells fail to mature or form LZ despite GC formation in CD19-deficient mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Myers, Riley C.; Carter, Robert H.] Univ Alabama Birmingham, Birmingham, AL USA. [Carter, Robert H.] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804775 ER PT J AU Nath, N Khan, M Singh, AK Singh, I Giri, S AF Nath, Narender Khan, Mushfiquddin Singh, Avtar K. Singh, Inderjit Giri, Shailendra TI Metformin, a diabetic drug attenuated autoimmune inflammatory disease of CNS in animal models of multiple sclerosis SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Nath, Narender; Khan, Mushfiquddin; Singh, Inderjit; Giri, Shailendra] Med Univ S Carolina, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph Johnson Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807722 ER PT J AU Neve, KA Liu, Y AF Neve, Kim A. Liu, Yong TI Interactions of the Dopamine D2 Receptor with the Calcium-Binding Protein S100B SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Neve, Kim A.] Portland VA Med Ctr, Portland, OR USA. [Neve, Kim A.; Liu, Yong] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804617 ER PT J AU O'Tierney, PF Chattergoon, N Louey, S Giraud, G Thornburg, K AF O'Tierney, Perrie Faye Chattergoon, Natasha Louey, Samantha Giraud, George Thornburg, Kent TI Atrial natriuretic peptide inhibits angiotensin II-induced cell proliferation in fetal sheep cardiomyocytes in vitro SO FASEB JOURNAL LA English DT Meeting Abstract C1 [O'Tierney, Perrie Faye; Chattergoon, Natasha; Louey, Samantha; Giraud, George; Thornburg, Kent] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. [Giraud, George] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802639 ER PT J AU Osorio, YE Travi, BL Melby, PC AF Osorio, Yaneth E. Travi, Bruno L. Melby, Peter C. TI An ex vivo splenic explant model system for the identification of small molecule therapeutics for visceral leishmaniasis SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467805262 ER PT J AU Osorio, YE Zhao, WG Espitia, C Travi, BL Hawel, L Byus, CV Saldarriaga, OA Melby, PC AF Osorio, Yaneth E. Zhao, Weiguo Espitia, Claudia Travi, Bruno L. Hawel, Leo Byus, Craig V. Saldarriaga, Omar A. Melby, Peter C. TI Dominant arginase expression in a model of progressive visceral leishmaniasis SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Osorio, Yaneth E.; Zhao, Weiguo; Espitia, Claudia; Travi, Bruno L.; Saldarriaga, Omar A.; Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Osorio, Yaneth E.; Zhao, Weiguo; Espitia, Claudia; Travi, Bruno L.; Saldarriaga, Omar A.; Melby, Peter C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Hawel, Leo; Byus, Craig V.] Univ Calif Riverside, Riverside, CA 92521 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802511 ER PT J AU Peebles, ER Roberts, MF Giraud, GD Holden, WE AF Peebles, Evan Richard Roberts, M. F. Giraud, G. D. Holden, W. E. TI Inhalation of Dry, Normobaric Hypoxic Air Impairs Thermal Conditioning of Nasal Air in Humans: Potential Role of Nitric Oxide SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Peebles, Evan Richard; Roberts, M. F.] Linfield Coll, Mcminnville, OR USA. [Giraud, G. D.; Holden, W. E.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467801516 ER PT J AU Ross, ES Johnson, SL Shroyer, AL Prochazka, A Dickinson, LM Krebs, N Pharo, SA AF Ross, Erin Sundseth Johnson, Susan L. Shroyer, A. Laurie Prochazka, Allan Dickinson, L. Miriam Krebs, Nancy Pharo, Susan A. TI Early growth velocity predicts longitudinal growth failure SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Ross, Erin Sundseth; Johnson, Susan L.; Krebs, Nancy] Univ Colorado, Sect Nutr, Denver, CO 80202 USA. [Shroyer, A. Laurie] VA Hosp Northport, Northport, NY USA. [Prochazka, Allan] Denver VA Hosp, Denver, CO USA. [Pharo, Susan A.] Kaiser Permanente, Aurora, CO USA. RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467805217 ER PT J AU Scalapino, KJ Daikh, DI AF Scalapino, Kenneth John Daikh, David I. TI In vitro and in vivo activation of CD4+CD25-Foxp3+Tregs in NZB/W mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Scalapino, Kenneth John; Daikh, David I.] San Francisco VA Med Ctr, Div Rheumatol, San Francisco, CA USA. [Daikh, David I.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467805279 ER PT J AU Shi, Y Liang, HY Liu, YH Ward, WF Van Remmen, H AF Shi, Yun Liang, Huiyun Liu, Yuhong Ward, Walter F. Van Remmen, Holly TI PGC-1 alpha plays a protective role against oxidative stress in skeletal muscle SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Shi, Yun; Liang, Huiyun; Liu, Yuhong; Ward, Walter F.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr, San Antonio, TX USA. [Ward, Walter F.] Barshop Inst Longev & Aging Studies, San Antonio, TX USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467807817 ER PT J AU Smithey, MJ Higgins, D Freitag, NE Bouwer, HGA AF Smithey, Megan J. Higgins, Darren Freitag, Nancy E. Bouwer, H. G. Archie TI Influence of virulence attenuation on the efficacy of Listeria monocytogenes as a vaccine vector for stimulating anti-tumor immunity SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Smithey, Megan J.; Bouwer, H. G. Archie] Portland VA Med Ctr, Portland, OR USA. [Higgins, Darren] Harvard Univ, Sch Med, Boston, MA USA. [Freitag, Nancy E.] Univ Illinois, Chicago, IL USA. [Bouwer, H. G. Archie] EACRI, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467804523 ER PT J AU Wainwright, DA Xin, JP Mesnard, NA Sanders, VM Jones, KJ AF Wainwright, Derek Alan Xin, Junping Mesnard, Nicole A. Sanders, Virginia M. Jones, Kathryn J. TI T cells and chemokine expression in the CNS: relevance to motoneuron injury and ALS SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Wainwright, Derek Alan; Xin, Junping; Mesnard, Nicole A.; Jones, Kathryn J.] Loyola Univ Chicago, Maywood, IL USA. [Wainwright, Derek Alan; Xin, Junping; Mesnard, Nicole A.; Jones, Kathryn J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Sanders, Virginia M.] Ohio State Univ, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467801330 ER PT J AU Walsh, JE Young, MRI AF Walsh, Jarrett E. Young, M. Rita I. TI Phosphatase regulation of cellular motility in the tumor microenvironment SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Walsh, Jarrett E.; Young, M. Rita I.] Med Univ S Carolina, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467802437 ER PT J AU Zang, S Hsu, HC Yang, P Wu, Q Job, G Guentert, T Nandakumar, KS Holmdahl, R Mountz, JD AF Zang, Song Hsu, Hui-Chen Yang, PingAr Wu, Qi Job, Godwin Guentert, Tanja Nandakumar, Kutty Selva Holmdahl, Rikard Mountz, John D. TI Development of Collagen II (CII)-induced Arthritis Was Associated with High AID and IL-17 Expression in BXD2 Mice SO FASEB JOURNAL LA English DT Meeting Abstract C1 [Zang, Song; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Job, Godwin; Guentert, Tanja; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Nandakumar, Kutty Selva; Holmdahl, Rikard] Lund Univ, Lund, Sweden. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RI Nandakumar, Kutty Selva/D-5438-2011 OI Nandakumar, Kutty Selva/0000-0001-7790-8197 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2008 VL 22 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA V25GZ UT WOS:000208467803086 ER PT J AU Doolittle, MH Peterfy, M AF Doolittle, Mark H. Peterfy, Miklos TI Lipase maturation factor 1 (Lmf1), a new gene in hypertriglyceridemia SO FUTURE LIPIDOLOGY LA English DT Editorial Material ID LIPOPROTEIN-LIPASE; ENDOPLASMIC-RETICULUM; MUTATIONS; CLD; DEFICIENCY C1 [Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. [Doolittle, Mark H.; Peterfy, Miklos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Doolittle, Mark H.; Peterfy, Miklos] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Peterfy, M (reprint author), Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. EM mpeterfy@ucla.edu NR 14 TC 1 Z9 1 U1 0 U2 2 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0875 J9 FUTURE LIPIDOL JI Future Lipidol. PD APR PY 2008 VL 3 IS 2 BP 119 EP 122 DI 10.2217/17460875.3.2.119 PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 343EQ UT WOS:000258836100001 ER PT J AU Ogiwara, H Graham, DY Yamaoka, Y AF Ogiwara, Hiroaki Graham, David Y. Yamaoka, Yoshio TI vacA i-region subtyping SO GASTROENTEROLOGY LA English DT Letter ID HELICOBACTER-PYLORI; CYTOTOXIN PRODUCTION; VIRULENCE FACTORS C1 [Ogiwara, Hiroaki] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Ogiwara, H (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX USA. NR 7 TC 39 Z9 40 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2008 VL 134 IS 4 BP 1267 EP 1267 DI 10.1053/j.gastro.2007.11.062 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 286NY UT WOS:000254853800047 PM 18395110 ER PT J AU Gross, RG Reiter, B Korsten, MA AF Gross, Rebekah G. Reiter, Bruce Korsten, Mark A. TI Pyogenic liver abscess complicating colonoscopic polypectomy SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID ULCERATIVE-COLITIS C1 [Gross, Rebekah G.] Mt Sinai Sch Med, Div Gastroenterol, New York, NY 10029 USA. [Reiter, Bruce] James J Peters Vet Affairs Med Ctr, Dept Radiol, Bronx, NY USA. [Korsten, Mark A.] James J Peters Vet Affairs Med Ctr, Div Gastroenterol, Bronx, NY USA. RP Gross, RG (reprint author), Mt Sinai Sch Med, Div Gastroenterol, 1 Gustave L Levy Pl,POB 1069, New York, NY 10029 USA. NR 11 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2008 VL 67 IS 4 BP 767 EP 768 DI 10.1016/j.gie.2007.08.028 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 282VW UT WOS:000254596300042 PM 18155212 ER PT J AU Kelly, JA Kelley, JM Kaufman, KM Kilpatrick, J Bruner, GR Merrill, JT James, JA Frank, SG Reams, E Brown, EE Gibson, AW Marion, MC Langefeld, CD Li, QZ Karp, DR Wakeland, EK Petri, M Ramsey-Goldman, R Reveille, JD Vila, LM Alarcon, GS Kimberly, RP Harley, JB Edberg, JC AF Kelly, J. A. Kelley, J. M. Kaufman, K. M. Kilpatrick, J. Bruner, G. R. Merrill, J. T. James, J. A. Frank, S. G. Reams, E. Brown, E. E. Gibson, A. W. Marion, M. C. Langefeld, C. D. Li, Q-Z Karp, D. R. Wakeland, E. K. Petri, M. Ramsey-Goldman, R. Reveille, J. D. Vila, L. M. Alarcon, G. S. Kimberly, R. P. Harley, J. B. Edberg, J. C. TI Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans SO GENES AND IMMUNITY LA English DT Article DE SLE; African Americans; IRF5; genetic association ID REVISED CRITERIA; RISK HAPLOTYPE; IRF5; POLYMORPHISM; SLE; POPULATION; GENE; COHORT; CLASSIFICATION; REPLICATION AB Increased expression of interferon (IFN)-inducible genes is implicated in the pathogenesis of systemic lupus erythematosus (SLE). One transcription factor responsible for regulating IFN, interferon regulatory factor-5 (IRF5), has been associated with SLE in genetic studies of Asian, Caucasian and Hispanic populations. We genotyped up to seven polymorphic loci in or near IRF5 in a total of 4870 African-American and Caucasian subjects ( 1829 SLE sporadic cases and 3041 controls) from two independent studies. Population-based case-control comparisons were performed using the Pearson's x(2)-test statistics and haplotypes were inferred using Haplo View. We observed significant novel associations with the IRF5 variants rs2004640 and rs3807306 in African Americans and replicated previously reported associations in Caucasians. While we identified risk haplotypes, the majority of haplotypic effects were accounted for by one SNP ( rs3807306) in conditional analyses. We conclude that genetic variants of IRF5 associate with SLE in multiple populations, providing evidence that IRF5 is likely to be a crucial component in SLE pathogenesis among multiple ethnic groups. C1 [Kelly, J. A.; Kaufman, K. M.; Kilpatrick, J.; Bruner, G. R.; Merrill, J. T.; James, J. A.; Frank, S. G.; Harley, J. B.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Kelley, J. M.; Reams, E.; Brown, E. E.; Gibson, A. W.; Alarcon, G. S.; Kimberly, R. P.; Edberg, J. C.] Univ Alabama, Birmingham, AL USA. [Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Kaufman, K. M.; James, J. A.; Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Langefeld, C. D.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Li, Q-Z; Karp, D. R.; Wakeland, E. K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Petri, M.] Johns Hopkins Univ, Baltimore, MD USA. [Ramsey-Goldman, R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Reveille, J. D.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA. [Vila, L. M.] Univ Puerto Rico, San Juan, PR 00936 USA. RP Harley, JB (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM john-harley@mail.omrf.ouhsc.edu; jedberg@uab.edu RI Frank, Summer/E-6861-2016 OI Frank, Summer/0000-0003-0779-4926; Kimberly, Robert/0000-0002-5330-3086 FU NCRR NIH HHS [M01-RR00052, MO1-RR00032, MO1-RR00048, RR15577, RR20143]; NIAID NIH HHS [AI24717, AI31584, AI53747, AI62629]; NIAMS NIH HHS [AR12253, AR33062, AR42460, AR42476, AR43727, K24-AR02138, P01-AR49084, P30 AR053483, P60-AR48098, R01 AR033062, T32-AR07450]; NIDCR NIH HHS [DE15223] NR 32 TC 65 Z9 71 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD APR PY 2008 VL 9 IS 3 BP 187 EP 194 DI 10.1038/gene.2008.4 PG 8 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 292LP UT WOS:000255267800001 PM 18288123 ER PT J AU Bird, TD AF Bird, Thomas D. TI Genetic aspects of Alzheimer disease SO GENETICS IN MEDICINE LA English DT Review DE Alzheimer; dementia; amyloid; neurogenetics ID PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; APOLIPOPROTEIN-E GENOTYPE; DOWN-SYNDROME; PREIMPLANTATION DIAGNOSIS; NEUROPATHOLOGIC CHANGES; COGNITIVE IMPAIRMENT; SUSCEPTIBILITY LOCUS; PROSPECTIVE COHORT; BETA IMMUNIZATION AB Alzheimer disease is the most common cause of dementia and represents a major public health problem. The neuropathologic findings of amyloid-beta plaques and tau containing neurofibrillary tangles represent important molecular clues to the underlying pathogenesis. Genetic factors are well recognized, but complicated. Three rare forms of autosomal-dominant early-onset familial Alzheimer disease have been identified and are associated with mutations in amyloid precursor protein, presenilin 1, and presenilin 2 genes. The more common late-onset form of Alzheimer disease is assumed to be polygenic/multifactorial. However, thus far the only clearly identified genetic risk factor for Alzheimer disease is Apo lipoprotein E. The epsilon 4 allele of Apo lipoprotein E influences age at onset of Alzheimer disease, but is neither necessary nor Sufficient for the disease. The search continues for the discovery of additional genetic influences. C1 Univ Washington, Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Bird, TD (reprint author), Univ Washington, Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM tomnroz@u.washington.com FU NIA NIH HHS [P50 AG005136-25, P50 AG 005136-22, P50 AG005136, P50 AG005136-140003, P50 AG005136-229007] NR 113 TC 80 Z9 87 U1 3 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD APR PY 2008 VL 10 IS 4 BP 231 EP 239 DI 10.1097/GIM.0b013e31816b64dc PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 291XP UT WOS:000255231000001 PM 18414205 ER PT J AU Pizer, SD Frakt, AB Feldmanc, R AF Pizer, Steven D. Frakt, Austin B. Feldmanc, Roger TI Predicting risk selection following major changes in medicare SO HEALTH ECONOMICS LA English DT Article DE medicare; adverse selection; econometrics; financing and insurance ID COMPETITION; PROGRAM AB The Medicare Modernization Act of 2003 created several new types of private insurance plans within Medicare, starting in 2006. Some of these plan types previously did not exist in the commercial market and there was great uncertainty about their prospects. In this paper, we show that statistical models and historical data from the Medicare Current Beneficiary Survey can be used to predict the experience of new plan types with reasonable accuracy. This lays the foundation for the analysis of program modifications currently under consideration. We predict market share, risk selection, and stability for the most prominent new plan type, the stand-alone Medicare prescription drug plan (PDP). First, we estimate a model of consumer choice across Medicare insurance plans available in the data. Next, we modify the data to include PDPs and use the model to predict the probability of enrollment for each beneficiary in each plan type. Finally, we calculate mean-adjusted actual spending by plan type. We predict that adverse selection into PDPs will be substantial, but that enrollment and premiums will be stable. Our predictions correspond well to actual experience in 2006. Copyright (c) 2007 John Wiley & Sons, Ltd. C1 [Pizer, Steven D.; Frakt, Austin B.] US Dept Vet Affairs, Hlth Care Financing & Econ, Boston, MA 02130 USA. [Pizer, Steven D.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Feldmanc, Roger] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. RP Pizer, SD (reprint author), US Dept Vet Affairs, Hlth Care Financing & Econ, 150 S Huntington Ave,Mail Stop 152H, Boston, MA 02130 USA. EM pizer@bu.edu NR 25 TC 9 Z9 9 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD APR PY 2008 VL 17 IS 4 BP 453 EP 468 DI 10.1002/hec.1252 PG 16 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 293GW UT WOS:000255324600002 PM 17557273 ER PT J AU Carreon, M Fried, LF Palevsky, PM Kimmel, PL Arnold, RM Weisbord, SD AF Carreon, Myra Fried, Linda F. Palevsky, Paul M. Kimmel, Paul L. Arnold, Robert M. Weisbord, Steven D. TI Clinical correlates and treatment of bone/joint pain and difficulty with sexual arousal in patients on maintenance hemodialysis SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE pain; sexual dysfunction; hemodialysis; treatment ID QUALITY-OF-LIFE; CHRONIC-RENAL-FAILURE; SYMPTOM ASSESSMENT SYSTEM; ERECTILE DYSFUNCTION; DIALYSIS PATIENTS; PALLIATIVE CARE; MINI-COG; PREVALENCE; SEVERITY; DISEASE AB Bone/joint pain and difficulty with sexual arousal are prevalent, frequently severe, and potentially treatable in patients on maintenance hemodialysis. However, the mediators and adequacy of treatment for these symptoms have been less well studied. We sought to assess the clinical correlates and treatment of these symptoms in patients receiving chronic hemodialysis. Using the Dialysis Symptom Index, we assessed the presence and severity of bone/joint pain and difficulty with sexual arousal in 75 patients on chronic hemodialysis. Associations of demographic and clinical variables with these 2 symptoms were assessed. We also recorded the use of analgesics for bone/joint pain and, among men, phosphodiesterase-5 inhibitors for difficulty with sexual arousal. Twenty-eight patients (37%) reported bone/joint pain, of whom 20 (71%) described it as moderate to severe. Nineteen of 50 male patients (38%) reported difficulty with sexual arousal, which was described as moderate to severe by 15 (79%). Patients' demographic and clinical characteristics were not correlated with bone/joint pain. Among men, there were no correlations between patients' demographic and clinical characteristics and difficulty with sexual arousal. Only 48% of patients with bone/joint pain were receiving analgesics, while 2 1 % of men who described difficulty with sexual arousal were receiving phosphodiesterase-5 inhibitors. Demographic, clinical, and dialysis-related variables are poorly correlated with bone/joint pain and difficulty with sexual arousal. However, these symptoms are prevalent and under-treated, which should spur efforts to assess the impact of improving provider assessment and treatment of these symptoms on patient outcomes, including health-related quality of life. C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Carreon, Myra; Arnold, Robert M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fried, Linda F.; Palevsky, Paul M.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Kimmel, Paul L.] George Washington Univ, Sch Med, Div Renal Dis & Hypertens, Washington, DC USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Ctr Hlth Equ Res & Promot, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU NCATS NIH HHS [UL1 TR000005] NR 29 TC 10 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD APR PY 2008 VL 12 IS 2 BP 268 EP 274 DI 10.1111/j.1542-4758.2008.00264.x PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 307WG UT WOS:000256348900013 PM 18394062 ER PT J AU Tyrka, AR Wier, LM Price, LH Rikhye, K Ross, NS Anderson, GM Wilkinson, CW Carpenter, LL AF Tyrka, Audrey R. Wier, Lauren M. Price, Lawrence H. Rikhye, Kobita Ross, Nicole S. Anderson, George M. Wilkinson, Charles W. Carpenter, Linda L. TI Cortisol and ACTH responses to the Dex/CRH test: Influence of temperament SO HORMONES AND BEHAVIOR LA English DT Article DE cortisol; Dex/CRH test; HPA axis; temperament; personality; inhibition ID POPULATION-BASED TWIN; CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENAL AXIS; DEXAMETHASONE-CRH TEST; MAJOR DEPRESSION; BEHAVIORAL-INHIBITION; ADRENOCORTICOTROPIC HORMONE; PSYCHOBIOLOGICAL MODEL; INDIVIDUAL-DIFFERENCES; PREMORBID PERSONALITY AB Temperament and personality traits such as neuroticism and behavioral inhibition are prospective predictors of the onset of depression and anxiety disorders. Exposure to stress is also linked to the development of these disorders, and neuroticism and inhibition may confer or reflect sensitivity to stressors. Several lines of research have documented hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in some patients with major depression, as well as in children and non-human primates with inhibited temperaments. The present investigation tested the hypothesis that stressreactive temperaments would be predictive of plasma adrenocorticotropin (ACTH) and cortisol concentrations in the dexamethasone/corticotropinreleasing hormone (Dex/CRH) test. Sixty adults completed diagnostic interviews and questionnaires assessing the temperament domains of novelty seeking and harm avoidance and symptoms of anxiety and depression. All subjects were free of any current or past Axis I psychiatric disorder. The Dex/CRH test was performed on a separate visit. A repeated-measures general linear model (GLM) showed a main effect of harm avoidance in predicting cortisol concentrations in the test (F(1, 58)=4.86, p <.05). The GLM for novelty seeking and corfisol response also showed a main effect (F(2, 58)= 5.28,p <.05). Higher cortisol concentrations were associated with higher levels of harm avoidance and lower levels of novelty seeking. A significant interaction of time with harm avoidance and novelty seeking (F(4, 53)= 3.37, p <.05) revealed that participants with both high levels of harm avoidance and low levels of novelty seeking had the highest cortisol responses to the Dex/CRH test. Plasma ACTH concentrations did not differ as a function of temperament. The results indicate that temperament traits linked to sensitivity to negative stimuli are associated with greater cortisol reactivity during the Dex/CRH test. Increased adrenocortical reactivity, which previously has been linked to major depression and anxiety disorders, may contribute to the association between temperament/personality traits and these disorders. (c) 2007 Elsevier Inc. All rights reserved. C1 [Tyrka, Audrey R.; Wier, Lauren M.; Price, Lawrence H.; Rikhye, Kobita; Ross, Nicole S.; Carpenter, Linda L.] Butler Hosp, Mood Disorders Res Program, Providence, RI 02906 USA. Butler Hosp, Lab Clin Neurosci, Providence, RI 02906 USA. [Tyrka, Audrey R.; Price, Lawrence H.; Rikhye, Kobita; Carpenter, Linda L.] Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA. [Anderson, George M.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA. [Wilkinson, Charles W.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Tyrka, AR (reprint author), Butler Hosp, Mood Disorders Res Program, 345 Blackstone Blvd, Providence, RI 02906 USA. EM Audrey_Tyrka@Brown.edu RI Tyrka, Audrey/L-2504-2014 FU NIMH NIH HHS [1K23 MH067947, K23 MH067947, K23 MH067947-01A1, R01 MH068767] NR 75 TC 39 Z9 39 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0018-506X J9 HORM BEHAV JI Horm. Behav. PD APR PY 2008 VL 53 IS 4 BP 518 EP 525 DI 10.1016/j.yhbeh.2007.12.004 PG 8 WC Behavioral Sciences; Endocrinology & Metabolism SC Behavioral Sciences; Endocrinology & Metabolism GA 290CN UT WOS:000255100700003 PM 18294637 ER PT J AU McCulloch, CC Kay, DM Factor, SA Samii, A Nutt, JG Higgins, DS Griffith, A Roberts, JW Leis, BC Montimurro, JS Zabetian, CP Payami, H AF McCulloch, Colin C. Kay, Denise M. Factor, Stewart A. Samii, Ali Nutt, John G. Higgins, Donald S. Griffith, Alida Roberts, John W. Leis, Berta C. Montimurro, Jennifer S. Zabetian, Cyrus P. Payami, Haydeh TI Exploring gene-environment interactions in Parkinson's disease SO HUMAN GENETICS LA English DT Article ID SUSCEPTIBILITY GENE; COMPLEX DISEASES; TAU-GENE; ASSOCIATION; HAPLOTYPE; ANTAGONISTS; NEURONS AB The objective of this study was to explore combined effects of four candidate susceptibility genes and two exposures on Parkinson's disease (PD) risk; namely, alpha-synuclein (SNCA) promoter polymorphism REP1, microtubule-associated protein tau (MAPT) H1/H2 haplotypes, apolipoprotein E (APOE) epsilon 2/epsilon 3/epsilon 4 polymorphism, ubiquitin carboxy-terminal esterase L1 (UCHL1) S18Y variant, cigarette smoking and caffeinated coffee consumption. 932 PD patients and 664 control subjects from the NeuroGenetics Research Consortium, with complete data on all six factors, were studied. Uniform protocols were used for diagnosis, recruitment, data collection and genotyping. A logistic regression model which included gene-exposure interactions was applied. Likelihood ratio tests (LRTs) were used for significance testing and Bayesian inference was used to estimate odds ratios (ORs). MAPT (P = 0.007), SNCA REP1 (P = 0.012), smoking (P = 0.001), and coffee (P = 0.011) were associated with PD risk. Two novel interactions were detected: APOE with coffee (P = 0.005), and REP1 with smoking (P = 0.021). While the individual main effects were modest, each yielding OR < 1.6, the effects were cumulative, with some combinations reaching OR = 12.6 (95% CI: 5.9-26.8). This study provides evidence for the long-held notion that PD risk is modulated by cumulative and interactive effects of genes and exposures. Furthermore, the study demonstrates that while interaction studies are useful for exploring risk relationships that might otherwise go undetected, results should be interpreted with caution because of the inherent loss of power due to multiple testing. The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk. C1 [Kay, Denise M.; Montimurro, Jennifer S.; Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Albany, NY 12201 USA. [McCulloch, Colin C.] Gen Elect Global Res Ctr, Appl Stat Lab, Niskayuna, NY USA. [Samii, Ali; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Samii, Ali; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Higgins, Donald S.] Albany Med Ctr, Parkinsons Dis & Movement Disorder Clin, Albany, NY USA. [Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Griffith, Alida; Leis, Berta C.] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Genom Inst, POB 22002, Albany, NY 12201 USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306; Kay, Denise/0000-0002-9928-2698 FU NINDS NIH HHS [K08-NS044138, NS R01-36960] NR 34 TC 56 Z9 59 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD APR PY 2008 VL 123 IS 3 BP 257 EP 265 DI 10.1007/s00439-008-0466-z PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 277AL UT WOS:000254184700004 PM 18210157 ER PT J AU Keyhani, S Scobie, JV Hebert, PL McLaughlin, MA AF Keyhani, Salomeh Scobie, Janice V. Hebert, Paul L. McLaughlin, Mary Ann TI Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits SO HYPERTENSION LA English DT Article DE women's health; quality of health care; hypertension; chronic disease; ambulatory care ID NUTRITION EXAMINATION SURVEY; CORONARY-ARTERY-DISEASE; HEART-DISEASE; UNITED-STATES; ASPIRIN USE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; WOMENS AWARENESS; SEX DISPARITIES; TRENDS AB The purpose of this study was to provide an analysis of gender-based disparities in hypertension and cardiovascular disease care in ambulatory practices across the United States. Using data from the 2005 National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, we conducted a cross-sectional analysis of patient visits with their primary care providers and examined the association between gender and blood pressure control, use of any antihypertensive medication or initiation of new therapy for patients with uncontrolled hypertension, and receipt of recommended therapy for select cardiovascular conditions. Multivariable models were estimated to examine the association between gender and each outcome controlling for other variables. A total of 12 064 patient visits were identified (7786 women and 4278 men). Among patients with hypertension, women were less likely than men to meet blood pressure control targets (54.0% versus 58.7%; P < 0.02). In multivariate analyses, women aged 65 to 80 years were less likely than men to have controlled hypertension (odds ratio: 0.62; 95% CI: 0.45 to 0.85). There was no association between gender and use of any antihypertensive medication or initiating a new therapy among patients with uncontrolled hypertension. In multivariate analyses, women were less likely than men to receive aspirin (odds ratio: 0.43; 95% CI: 0.27 to 0.67) and beta-blockers (odds ratio: 0.60; 95% CI: 0.36 to 0.99) for secondary prevention of cardiovascular disease. Our study highlights the persistent gender disparities in blood pressure control and cardiovascular disease management and also reveals the inadequate delivery of cardiovascular care to all patients. C1 [Keyhani, Salomeh] Ctr Geriatr Res Educ & Clin, James J Peters Vet Adm Med Ctr, Bronx, NY USA. [Keyhani, Salomeh; Hebert, Paul L.; McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA. [Scobie, Janice V.; McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Med, New York, NY USA. [McLaughlin, Mary Ann] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Gen Internal Med, New York, NY USA. RP Keyhani, S (reprint author), Mt Sinai Sch Med, Dept Hlth Policy, Box 1077,1 Gustave L Levy Pl, New York, NY 10029 USA. EM salomeh.keyhani@mountsinai.org NR 33 TC 61 Z9 63 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD APR PY 2008 VL 51 IS 4 BP 1149 EP 1155 DI 10.1161/HYPERTENSIONAHA.107.107342 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 276SA UT WOS:000254161300060 PM 18259013 ER PT J AU Miller, G Randolph, S Patterson, JE AF Miller, George Randolph, Stephen Patterson, Jan E. TI Responding to simulated pandemic influenza in San Antonio, Texas SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID COMMUNITY TRANSMISSION PARAMETERS; STRATEGIES; HOUSEHOLD AB OBJECTIVE. To describe the results of a simulation study of the spread of pandemic influenza, the effects of public health measures on the simulated pandemic, and the resultant adequacy of the surge capacity of the hospital infrastructure and to investigate the adequacy of key elements of the national pandemic influenza plan to reduce the overall attack rate so that surge capacity would not be overwhelmed. DESIGN. We used 2 discrete-event simulation models: the first model simulates the contact and disease transmission process, as affected by public health interventions, to produce a stream of arriving patients, and the second model simulates the diagnosis and treatment process and determines patient outcomes. SETTING. Hypothetical scenarios were based on the response plans, infrastructure, and demographic data of the population of San Antonio, Texas. RESULTS. Use of a mix of strategies, including social distancing, antiviral medications, and targeted vaccination, may limit the overall attack rate so that demand for care would not exceed the capacity of the infrastructure. Additional simulations to assess social distancing as a sole mitigation strategy suggest that a reduction of infectious community contacts to half of normal levels would have to occur within approximately 7 days. CONCLUSIONS. Under ideal conditions, the mix of strategies may limit demand, which can then be met by community surge capacity. Given inadequate supplies of vaccines and antiviral medications, aggressive social distancing alone might allow for the control of a local epidemic without reliance on outside support. C1 [Miller, George] Altarum Inst, Ann Arbor, MI 48113 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Patterson, Jan E.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Randolph, Stephen] Altarum Inst, San Antonio, TX USA. RP Miller, G (reprint author), Altarum Inst, POB 134001, Ann Arbor, MI 48113 USA. EM george.miller@altarum.org NR 26 TC 4 Z9 4 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2008 VL 29 IS 4 BP 320 EP 326 DI 10.1086/529212 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 271VP UT WOS:000253817100007 PM 18462144 ER PT J AU Fowler, CG Chiasson, KB Hart, DB Beasley, TM Kemnitz, J Weindruch, R AF Fowler, Cynthia G. Chiasson, Kirstin Beach Hart, Dianna Brown Beasley, T. Mark Kemnitz, Joseph Weindruch, Richard TI Tympanometry in rhesus monkeys: Effects of aging and caloric restriction SO INTERNATIONAL JOURNAL OF AUDIOLOGY LA English DT Article; Proceedings Paper CT Annual Convention of the American-Speech-Language-Hearing-Association CY NOV 18-20, 2004 CL Philadelphia, PA SP Amer Speech Language Hearing Assoc DE caloric restriction; aging; rhesus monkeys; tympanometry; middle ear; hearing ID MACACA-MULATTA; MIDDLE-EAR; OTOACOUSTIC EMISSIONS; AUDITORY FUNCTION; OLDER-ADULTS; WISCONSIN; HEARING; HUMANS; AGE AB Caloric restriction is the only known method of increasing lifespan in laboratory animals. The present study was conducted as part of a larger investigation into the effect of caloric restriction on longevity of rhesus monkeys as a model for human aging. This study focused on the effects of caloric restriction and aging on measures of middle-ear function measured with tympanometry. Peak compensated static acoustic admittance (peak Y-tm) tended to be reduced with aging. For tympanometric width (TW), the effect of age was significant with TW increasing with age. Males had a trend of narrower TW than females. A significant age by sex interaction indicated that TW for males stays relatively constant, whereas TW for females increases with age. The equivalent ear canal volume (V,,) was significantly larger in male monkeys than in female monkeys, and marginally larger for the control monkeys than for the caloric restricted monkeys. These results parallel many findings in middle-car function in aging humans. Longitudinal studies are planned. C1 [Fowler, Cynthia G.] Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53706 USA. [Chiasson, Kirstin Beach] Oregon Inst Technol, Klamath Falls, OR USA. [Hart, Dianna Brown] Univ Minnesota, Med Ctr, Fairview, MN USA. [Beasley, T. Mark] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Kemnitz, Joseph] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA. [Kemnitz, Joseph] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA. [Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Weindruch, Richard] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. RP Fowler, CG (reprint author), Univ Wisconsin, Dept Communicat Disorders, 1975 Willow Dr, Madison, WI 53706 USA. EM cgfowler@wisc.edu FU NIA NIH HHS [R01 AG040178, P01 AG11915, P01 AG011915]; NIH HHS [P51 OD011106] NR 27 TC 3 Z9 4 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1499-2027 J9 INT J AUDIOL JI Int. J. Audiol. PD APR PY 2008 VL 47 IS 4 BP 209 EP 214 DI 10.1080/14992020701851882 PG 6 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 293NA UT WOS:000255340800008 PM 18389417 ER PT J AU Zeber, JE Copeland, LA Good, CB Fine, MJ Bauer, MS Kilbourne, AM AF Zeber, John E. Copeland, Laurel A. Good, Chester B. Fine, Michael J. Bauer, Mark S. Kilbourne, Amy M. TI Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE therapeutic alliance; medication adherence; treatment barriers; ethnicity; veterans ID COST-EFFECTIVENESS; LITHIUM TREATMENT; AFRICAN-AMERICAN; WHITE PATIENTS; GLOBAL BURDEN; NONADHERENCE; MAINTENANCE; SCHIZOPHRENIA; PHARMACOTHERAPY; INTERVENTIONS AB Background: Despite the dissemination of practice guidelines for bipolar disorder, outcomes remain suboptimal, largely due to poor treatment adherence. The episodic nature of bipolar disorder disrupts appropriate patient-provider dynamics, interfering with appropriate care. Maintaining a beneficial therapeutic alliance with providers is one important strategy for improving adherence. We examine the association between adherence and therapeutic environment perceptions among veterans with bipolar disorder. Methods: Participants were recruited from the Continuous Improvement for Veterans in Care - Mood Disorders (CIVIC-MD) study (N=435). Individual items and a summary score from the Health Care Climate Questionnaire (HCCQ) for bipolar disorder solicited patient evaluations of their therapeutic environment. Multivariable logistic analyses examined the association between therapeutic alliance and two measures of adherence (missed medication days and intrapersonal barriers), adjusting for relevant patient characteristics. Results: Adherence difficulty was reported on both measures, with substantial differences between perceived barriers and actual medication behavior. Significantly fewer minority veterans endorsed good adherence than white patients (59% versus 77%), although no ethnic differences were noted in therapeutic environment perceptions. Multivariable results indicated that positive therapeutic alliance was associated with better adherence (HCCQ effect sizes 13-20%). Notably, patients reporting providers encouraged "staying in regular contact" were more likely to be adherent, as were patients whose "providers regularly review their progress". Limitations: Generalizability from observational study; adherence defined by cross-sectional patient self-report. Conclusions: The observed association between medication adherence and therapeutic alliance with bipolar treatment supports intervention efforts to strengthen the patient-provider relationship, a bond likely to yield positive clinical outcomes. Published by Elsevier B.V. C1 [Zeber, John E.; Copeland, Laurel A.] S Texas Vet Hlth Care Syst VERDICT, Vet Affairs HSR&D, San Antonio, TX 78229 USA. [Zeber, John E.; Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Good, Chester B.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Good, Chester B.; Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. [Good, Chester B.; Fine, Michael J.] Brown Univ, Dept Psychiat, Providence, RI 02912 USA. [Bauer, Mark S.] Vet Affairs Med Ctr, Providence, RI USA. [Kilbourne, Amy M.] Serious Mental Illness Treatment Res & Evaluat Ct, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst VERDICT, Vet Affairs HSR&D, 7400 Merton Minter Blvd Verdict 11c6, San Antonio, TX 78229 USA. EM zeber@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209 NR 48 TC 55 Z9 55 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2008 VL 107 IS 1-3 BP 53 EP 62 DI 10.1016/j.jad.2007.07.026 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 282CU UT WOS:000254546000007 PM 17822779 ER PT J AU Bekris, LM Millard, SP Galloway, NM Vuletic, S Albers, JJ Lie, G Galasko, DR DeCarli, C Farlow, MR Clark, CM Quinn, JF Kaye, JA Schellenberg, GD Tsuang, D Peskind, ER Yu, CE AF Bekris, Lynn M. Millard, Steven P. Galloway, Nichole M. Vuletic, Simona Albers, John J. Lie, Ge Galasko, Douglas R. DeCarli, Charles Farlow, Martin R. Clark, Chris M. Quinn, Joseph F. Kaye, Jeffrey A. Schellenberg, Gerard D. Tsuang, Debby Peskind, Elaine R. Yu, Chang-En TI Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE apolipoprotein E gene; apolipoprotein E protein; cerebroshinal fluid; enhancer; promoter; SNP ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE BRAIN; TRANSGENIC MICE; PROMOTER POLYMORPHISMS; LINKAGE DISEQUILIBRIUM; APOE POLYMORPHISM; REGULATORY REGION; EXPRESSION; RISK; BETA AB The epsilon 4 allele of the apolipoprotein E gene (APOE) is associated with increased risk and earlier age at onset in late onset Alzheimer's disease (AD). Other factors, such as expression level of apolipoprotein E protein (apoE), have been postulated to modify the APOE related risk of developing AD. Multiple loci in and outside of APOE are associated with a high risk of AD. The aim of this exploratory hypothesis generating investigation was to determine if some of these loci predict cerebrospinal fluid (CSF) apoE levels in healthy non-demented subjects. CSF apoE levels were measured from healthy non-demented subjects 21-87 years of age (n = 134). Backward regression models were used to evaluate the influence of 21 SNPs, within and surrounding APOE, on CSF apoE levels while taking into account age, gender, APOE epsilon 4 and correlation between SNPs (linkage disequilibrium). APOE epsilon 4 genotype does not predict CSF apoE levels. Three SNPs within the TOMM40 gene, one APOE promoter SNP and two SNPs within distal APOE enhancer elements (MEI and BCR) predict CSF apoE levels. Further investigation of the genetic influence of these loci on apoE expression levels in the central nervous system is likely to provide new insight into apoE regulation as well as AD pathogenesis. C1 [Bekris, Lynn M.; Yu, Chang-En] Univ Washington, Dept Med, Seattle, WA 98108 USA. [Bekris, Lynn M.; Millard, Steven P.; Galloway, Nichole M.; Schellenberg, Gerard D.; Yu, Chang-En] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Galloway, Nichole M.; Tsuang, Debby; Peskind, Elaine R.] Univ Washington, Sch Med, NW Network VISN 20, MIRECC, Seattle, WA 98108 USA. [Vuletic, Simona; Albers, John J.] Univ Washington, Sch Med, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98108 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Galasko, Douglas R.] VA Med Ctr, San Diego, CA USA. [DeCarli, Charles] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. [Farlow, Martin R.] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. [Clark, Chris M.] Univ Penn, Dept Neurol, Inst Aging, Philadelphia, PA 19104 USA. [Quinn, Joseph F.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. [Schellenberg, Gerard D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98108 USA. RP Bekris, LM (reprint author), Univ Washington, Dept Med, Box 358280,VAPSHCS GRECC 182B,1660 S Columbian Wa, Seattle, WA 98108 USA. EM lbekris@u.washington.edu RI DeCarli, Charles/B-5541-2009; Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Kaye, Jeffrey/0000-0002-9971-3478 FU NHLBI NIH HHS [P01 HL030086, P01HL30086]; NIA NIH HHS [U01 AG016976, 5T32AG000258-07, AG05136, AG08017, P30 AG008017, P30 AG010129, P30 AG010129-18, P50 AG005136, P50 AG005136-25, R21 AG024486, R21 AG24486-01, T32 AG000258]; NINDS NIH HHS [R01 NS048595, R01 NS48595] NR 47 TC 46 Z9 46 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD APR PY 2008 VL 13 IS 3 BP 255 EP 266 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 306EA UT WOS:000256229900003 PM 18430993 ER PT J AU Reger, MA Watson, GS Green, PS Baker, LD Cholerton, B Fishel, MA Plymate, SR Cherrier, MM Schellenberg, GD Frey, WH Craft, S AF Reger, Mark A. Watson, G. Stennis Green, Pattie S. Baker, Laura D. Cholerton, Brenna Fishel, Mark A. Plymate, Stephen R. Cherrier, Monique M. Schellenberg, Gerard D. Frey, William H., II Craft, Suzanne TI Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; insulin; intranasal administration; memory; mild cognitive impairment ID CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-E GENOTYPE; POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; ADMINISTERED INSULIN; CEREBROSPINAL-FLUID; GLUCOSE-UTILIZATION; GENETICALLY-OBESE AB Intranasal insulin administration raises central nervous system (CNS) insulin levels in humans and acutely facilitates verbal memory in patients with Alzheimer's disease (AD), an effect that may differ by APOE genotype. The purpose of this study was to examine the cognitive dose response curves for intranasal insulin administration, and determine whether the effects of insulin differ between participants with (epsilon 4+) and without (epsilon 4-) the APOE- epsilon 4 allele. On separate mornings, 33 memory-impaired adults with AD or amnestic mild cognitive impairment and 59 normal adults each underwent five intranasal treatment conditions consisting of insulin (10, 20, 40, or 60 IU) or placebo. Cognition was tested 15-minutes post-treatment, and blood was acquired at baseline and 45-minutes post-treatment. Plasma insulin and glucose levels were unaffected by treatment. Insulin administration facilitated recall on two measures of verbal memory in memory-impaired epsilon 4- adults, with performance generally peaking at 20 IU. In contrast, memory-impaired epsilon 4+ subjects demonstrated a relative decline in verbal memory. Insulin also differentially modulated plasma amyloid-beta for memory-impaired subjects and normal controls, effects that again differed by APOE genotype. These findings suggest that groups with different genetic risks for AD may show differential dose-response curves following intranasal insulin administration. C1 [Reger, Mark A.; Watson, G. Stennis; Green, Pattie S.; Baker, Laura D.; Cholerton, Brenna; Fishel, Mark A.; Plymate, Stephen R.; Schellenberg, Gerard D.; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Reger, Mark A.; Watson, G. Stennis; Baker, Laura D.; Cholerton, Brenna; Cherrier, Monique M.; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA. [Reger, Mark A.; Watson, G. Stennis; Baker, Laura D.; Cholerton, Brenna; Cherrier, Monique M.; Craft, Suzanne] Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA 98195 USA. [Frey, William H., II] Reg Hosp, Alzheimers Res Ctr, St Paul, MN 55101 USA. RP Craft, S (reprint author), 1660 S Columbian Way,S182-GRECC, Seattle, WA 98108 USA. EM scraft@u.washington.edu FU NIA NIH HHS [P50 AG005136, P50 AG005136-25] NR 60 TC 216 Z9 222 U1 1 U2 13 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD APR PY 2008 VL 13 IS 3 BP 323 EP 331 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 306EA UT WOS:000256229900009 PM 18430999 ER PT J AU Dobalian, A Rivers, PA AF Dobalian, Aram Rivers, Patrick A. TI Racial and ethnic disparities in the use of mental health services SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID UNITED-STATES; PSYCHIATRIC-DISORDERS; PRIMARY-CARE; DEPRESSION; POPULATION; AMERICANS; BARRIERS; BLACK; DETERMINANTS; PREVALENCE AB The authors used data from the 1998-1999 Community Tracking Study (CTS) household survey to examine variations in predictors of use of mental health services among different racial and ethnic groups (white, African American, Hispanic, and other). African Americans and Hispanics were less likely to have visited a mental health professional (MHP) in the prior year than were whites. Independent of health insurance and health status, low- to middle-income African Americans may be at particular risk for inadequate use of an MHP compared to higher-income African Americans. Similarly, upper-income Hispanics were more likely to have visited an MHP than Hispanics in the lowest income range. Adults aged 50 and older were less likely to visit an MHP than individuals aged 18-49. Depressed men were more likely to visit an MHP than depressed women. Efforts to reduce disparities should focus on lower-income racial and ethnic minorities. C1 [Dobalian, Aram] Sepulveda Ambulatory Care Ctr & Nusing Home, HSR & D Ctr Excellence Study Healthcare Provider, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. [Rivers, Patrick A.] So Illinois Univ, Coll Appl Sci & Arts, Carbondale, IL 62901 USA. RP Dobalian, A (reprint author), Sepulveda Ambulatory Care Ctr & Nusing Home, HSR & D Ctr Excellence Study Healthcare Provider, VA Greater Los Angeles Healthcare Syst, 16111 Plummer St 152, Sepulveda, CA 91343 USA. EM adobalia@ucla.edu NR 45 TC 31 Z9 31 U1 4 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1094-3412 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD APR PY 2008 VL 35 IS 2 BP 128 EP 141 DI 10.1007/s11414-007-9097-8 PG 14 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 289MT UT WOS:000255059300002 PM 18074230 ER PT J AU Ivancic, V Mastali, M Percy, N Gornbein, J Babbitt, JT Li, Y Landaw, EM Bruckner, DA Churchill, BM Haake, DA AF Ivancic, Vesna Mastali, Mitra Percy, Neil Gornbein, Jeffrey Babbitt, Jane T. Li, Yang Landaw, Elliot M. Bruckner, David A. Churchill, Bernard M. Haake, David A. TI Rapid antimicrobial susceptibility determination of uropathogens in clinical urine specimens by use of ATP bioluminescence SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ANTIBIOTIC SUSCEPTIBILITY; ADENOSINE-TRIPHOSPHATE; SIGNIFICANT BACTERIURIA; ACUTE PYELONEPHRITIS; LUCIFERASE ASSAY; TRACT-INFECTION; LUMAC SYSTEMS; TESTS; RESISTANCE; WOMEN AB We describe the first direct testing of the antimicrobial susceptibilities of bacterial pathogens in human clinical fluid samples by the use of ATP bioluminescence. We developed an ATP bioluminescence assay that eliminates somatic sources of ATP to selectively quantify the bacterial load in clinical urine specimens with a sensitivity of < 1,000 CFU per milliliter. There was a log-log relationship between light emission and the numbers of CFU in clinical urine specimens. A clinical study was performed to evaluate the accuracy of the ATP bioluminescence assay for determination of the antimicrobial susceptibilities of uropathogens in clinical urine specimens tested in a blinded manner. ATP bioluminescent bacterial density quantitation was used to determine the inoculation volume in growth medium with and without antibiotics. After incubation at 37 degrees C for 120 min, the ATP bioluminescence assay was repeated to evaluate the uropathogen response to antibiotics. The ability of the ATP bioluminescence assay to discriminate between antimicrobial susceptibility and resistance was determined by comparison of the results obtained by the ATP bioluminescence assay with the results obtained by standard clinical microbiology methods. Receiver operator characteristic curves were used to determine the optimal threshold for discriminating between susceptibility and resistance. Susceptibility and resistance were correctly predicted in 87% and 95% of cases, respectively, for an overall unweighted accuracy of 91%, when the results were stratified by antibiotic. For samples in which the pathogen was susceptible, the accuracy improved to 95% when the results for samples with less than a 25-fold increase in the amount of bacterial ATP in the medium without antibiotics were excluded. These data indicate that a rapid bioluminescent antimicrobial susceptibility assay may be useful for the management of urinary tract infections. C1 [Ivancic, Vesna; Li, Yang; Churchill, Bernard M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Mastali, Mitra; Babbitt, Jane T.; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Gornbein, Jeffrey; Landaw, Elliot M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Bruckner, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Percy, Neil] Hygiena, Camarillo, CA 93012 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Haake, DA (reprint author), VA Greater LA Healthcare, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu FU NIAID NIH HHS [U01 AI075565, U01 AI075565-01, AI075565]; NIBIB NIH HHS [EB00127, R01 EB000127] NR 32 TC 17 Z9 18 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2008 VL 46 IS 4 BP 1213 EP 1219 DI 10.1128/JCM.02036-07 PG 7 WC Microbiology SC Microbiology GA 286SN UT WOS:000254866400009 PM 18272708 ER PT J AU Kennedy, A Wood, AE Saxon, AJ Malte, C Harvey, M Jurik, J Kilzieh, N Lofgreen, C Tapp, A AF Kennedy, Annette Wood, Amanda Ernst Saxon, Andrew J. Malte, Carol Harvey, Megan Jurik, Jennifer Kilzieh, Nael Lofgreen, Cassin Tapp, Andre TI Quetiapine for the treatment of cocaine dependence - An open-label trial SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article; Proceedings Paper CT 2nd International Congress of Biological Psychiatry CY APR 17-21, 2007 CL Santiago, CHILE ID INDUCED WEIGHT-GAIN; RATING-SCALE; RISPERIDONE; OLANZAPINE; RECEPTORS AB The monaminergic properties of second generation antipsychotics are prompting research on their use to treat cocaine dependence, with inconclusive results to date. In preliminary reports, the atypical antipsychotic quetiapine has shown promise for the treatment of substance abuse disorders. The primary objective of the current study was to assess the efficacy of quetiapine in reducing cocaine cravings and use in nonpsychotic subjects with cocaine dependence over 6 weeks of open-label treatment. Twenty-two cocaine-dependent, nonpsychotic men were initiated to open-label treatment with quetiapine (300-600 mg/d). The primary outcome measure was weekly self-report of cocaine cravings as assessed with the Brief Substance Craving Scale. Cocaine use was captured with a self-report Timeline Follow-back calendar, administered every 2 weeks. Side effect monitoring was conducted weekly, and movement disorders were assessed every 2 weeks. Intent-to-treat regression analyses (n = 22) indicated that the Brief Substance Craving Scale total score decreased significantly overtime (P < 0.001). Self-reports also suggested decreased cocaine use. There was no treatment-related increase in movement disorders, and most side effects were mild. However, all subjects did experience sedation, and several subjects dropped out because of it. What is more, weight increased significantly over time (P < 0.001). Open-label quetiapine treatment reduced cravings and improved some aspects of cocaine dependence in nonpsychotic individuals. Additional research is needed to confirm the current findings and to further delineate the role quetiapine may play in the treatment of cocaine use disorders. C1 [Kennedy, Annette; Wood, Amanda Ernst; Harvey, Megan; Jurik, Jennifer; Kilzieh, Nael; Lofgreen, Cassin; Tapp, Andre] Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, MIRECC, Tacoma, WA 98493 USA. [Kennedy, Annette; Wood, Amanda Ernst; Harvey, Megan; Jurik, Jennifer; Kilzieh, Nael; Lofgreen, Cassin; Tapp, Andre] Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, MIRECC, Seattle, WA USA. [Kennedy, Annette] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Wood, Amanda Ernst; Saxon, Andrew J.; Kilzieh, Nael; Tapp, Andre] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Saxon, Andrew J.; Malte, Carol] Vet Affairs Puget Sound Hlth Care Syst, CESATE, Tacoma, WA 98493 USA. [Saxon, Andrew J.; Malte, Carol] Vet Affairs Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA. RP Kennedy, A (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, MIRECC, 9600 Vet Dr,A-116-R, Tacoma, WA 98493 USA. EM Annette.Kennedy@va.gov NR 23 TC 23 Z9 23 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD APR PY 2008 VL 28 IS 2 BP 221 EP 224 DI 10.1097/JCP.0b013e318166f50d PG 4 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 277JR UT WOS:000254209000015 PM 18344735 ER PT J AU Operskalski, EA Mack, WJ Strickler, HD French, AL Augenbraun, M Tien, PC Villacres, MC Spencer, LY DeGiacomo, M Kovacs, A AF Operskalski, Eva A. Mack, Wendy J. Strickler, Howard D. French, Audrey L. Augenbraun, Michael Tien, Phyllis C. Villacres, Maria C. Spencer, LaShonda Y. DeGiacomo, Marina Kovacs, Andrea TI Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE hepatitis C; hepatitis C RNA levels; hepatitis C viremia; HIV/hepatitis C virus co-infection ID HUMAN-IMMUNODEFICIENCY-VIRUS; MONONUCLEAR CELL-CULTURES; DRUG-USERS; RNA LEVELS; UNITED-STATES; SMOKING; TRANSMISSION; HEMOPHILIA; SUPPRESSION; PREVALENCE AB Background: Co-infection with hepatitis C virus (HCV) is common among HIV-infected women. Objective: To further our understanding of the risk factors for HCV viremia and the predictors of HCV viral load among women. Study design: We investigated sociodemographic, immunologic, and virologic factors associated with presence and level of HCV viremia among 1049 HCV-seropositive women, 882 of whom were HIV-infected and 167 HIV-uninfected at their entry into the Women's Interagency HIV Study. Results: Plasma HCV RNA was detected in 852 (81%) of these 1049 women (range: 1.2-7.8 log(10) copies/ml). HCV-viremic women were more likely to have an HIV RNA level >100,000copies/ml (P=0.0004), to have reported smoking (P=0.01), or to be Black (P=0.005). They were less likely to have current or resolved hepatitis B infection. HCV RNA levels were higher in women who were >35 years old, or HIV-infected. Current smoking and history of drug use (crack/freebase cocaine, marijuana, amphetamines, or heroin) were each associated with both presence and level of viremia. Conclusions: Substance abuse counseling aimed at eliminating ongoing use of illicit drugs and tobacco may reduce clinical progression, improve response to treatment, and decrease HCV transmission by lowering levels of HCV viremia in women. (C) 2007 Elsevier B.V. All rights reserved. C1 [Operskalski, Eva A.; Villacres, Maria C.; Spencer, LaShonda Y.; DeGiacomo, Marina; Kovacs, Andrea] Univ So Calif, Keck Sch Med, Dept Pediat, Mat Child & Adolescent Ctr Infect Dis & Virol, Los Angeles, CA 90033 USA. [Mack, Wendy J.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Strickler, Howard D.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [French, Audrey L.] CORE Ctr Stroger Cook Cty Hosp, Rush Med Coll, Chicago, IL USA. [Augenbraun, Michael] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Operskalski, EA (reprint author), Univ So Calif, Keck Sch Med, Dept Pediat, Mat Child & Adolescent Ctr Infect Dis & Virol, 1640 Marengo St,Suite 300, Los Angeles, CA 90033 USA. EM eva@usc.edu FU NCRR NIH HHS [M01 RR000071, M01 RR000079, M01 RR000083, M01-RR-00079, M01-RR-00083, M01-RR-0071]; NIAID NIH HHS [U01 AI042590-06, K23 AI066943, K23 AI066943-05, R01 AI052065, R01 AI052065-01, R01 AI052065-04, R01 AI057006, R01 AI057006-04, R01-AI0577006, U01 AI031834, U01 AI031834-15, U01 AI034989, U01 AI034993, U01 AI034993-13, U01 AI034993-14, U01 AI034994, U01 AI034994-09, U01 AI035004, U01 AI035004-14, U01 AI042590, U01 AI042590-07, U01-AI-31834, U01-AI-34989, U01-AI-34993, U01-AI-34994, U01-AI-35004, U01-AI-42590]; NICHD NIH HHS [U01 HD032632-14]; NIDDK NIH HHS [U01 DK066116]; OID CDC HHS [U01-CH-32632] NR 45 TC 24 Z9 24 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD APR PY 2008 VL 41 IS 4 BP 255 EP 263 DI 10.1016/j.jcv.2007.08.021 PG 9 WC Virology SC Virology GA 291PK UT WOS:000255209100002 PM 18243785 ER PT J AU Ahdout, J Mandel, H Chiu, M AF Ahdout, Jennifer Mandel, Hilary Chiu, Melvin TI Case reports: Erythroderma in a patient taking acitretin for plaque psoriasis SO JOURNAL OF DRUGS IN DERMATOLOGY LA English DT Article ID MULTICENTER; ETRETINATE AB Acitretin is a second generation retinoid used in the treatment of psoriasis. It has shown particular efficacy in the treatment of pustular or erythrodermic psoriasis. A case of a patient who was being treated for plaque psoriasis with acitretin, who subsequently developed erythrodermic psoriasis is reported. The patient's erythroderma promptly resolved after discontinuing acitretin and initiating treatment with cyclosporine. Acitretin has been reported to induce erythrodermic psoriasis on occasion, but is more frequently reported as a treatment for it. C1 [Ahdout, Jennifer; Chiu, Melvin] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA. [Mandel, Hilary; Chiu, Melvin] Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. RP Chiu, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, 52-121 Ctr Hlth Sci, Los Angeles, CA 90095 USA. EM mchiu@mednet.ucta.edu NR 7 TC 2 Z9 2 U1 1 U2 1 PU JOURNAL OF DRUGS IN DERMATOLOGY PI NEW YORK PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA SN 1545-9616 J9 J DRUGS DERMATOL JI J. Drugs Dermatol. PD APR PY 2008 VL 7 IS 4 BP 391 EP 394 PG 4 WC Dermatology SC Dermatology GA 294AH UT WOS:000255376000012 PM 18459522 ER PT J AU Fung, CH Tsai, JS Lulejian, A Glassman, P Patterson, E Doebbeling, BN Asch, SM AF Fung, Constance H. Tsai, Jerry S. Lulejian, Armine Glassman, Peter Patterson, Emily Doebbeling, Brad N. Asch, Steven M. TI An evaluation of the veterans health administration's clinical reminders system: A national survey of generalists SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE decision support systems clinical; primary health care; quality of health care; evidence-based medicine; medical records systems computerized ID PREVENTIVE CARE; OF-CARE; COMPUTER; COMPLETION; MANAGEMENT; PHYSICIANS; BARRIERS; QUALITY; TRIAL AB BACKGROUND: The Veterans Health Administration (VHA) is a leader in developing computerized clinical reminders (CCRs). Primary care physicians' (PCPs) evaluation of VHA CCRs could influence their future development and use within and outside the VHA. OBJECTIVE: Survey PCPs about usefulness and usability of VHA CCRs. DESIGN AND PARTICIPANTS: In a national survey, VHA PCPs rated on a 7-point scale usefulness and usability of VHA CCRs, and standardized scales (0-100) were constructed. A hierarchical linear mixed (HLM) model predicted physician- and facility-level variables associated with more positive global assessment of CCRs. RESULTS: Four hundred sixty-one PCPs participated (response rate, 69%). Scale Cronbach's alpha ranged from 0.62 to 0.82. Perceptions of VHA CCRs were primarily in the midrange, where higher ratings indicate more favorable attitudes (weighted standardized median, IQR): global assessment (50, 28-61), clinical/situational specificity (29, 17-42), integration with workflow/workload (39, 17-50), training (50, 33-67), VHA's management of CCR use (67, 50-83), design/interface (53, 40-67), perceived role in CCR use (67, 50-83), and self-efficacy (67, 57-78). In a HLM model, design/interface (p <.001), self-efficacy (p <.001), integration with workflow/workload (p <.001), and training (p <.001) were associated with more favorable global assessments of CCRs. Facilities in the west as compared to the south (p=.033), and physicians with academic affiliation (p=.045) had less favorable global assessment of CCRs. CONCLUSIONS: Our systematic assessment of end-users' perceptions of VHA CCRs suggests that CCRs need to be developed and implemented with a continual focus on improvement based on end-user feedback. Potential target areas include better integration into the primary care clinic workflow/workload. C1 [Fung, Constance H.; Tsai, Jerry S.; Lulejian, Armine; Glassman, Peter; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fung, Constance H.; Glassman, Peter; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Patterson, Emily] VA Getting Patient Safety GAPS Ctr, Cincinnati, OH USA. [Patterson, Emily] Ohio State Univ, Columbus, OH 43210 USA. [Doebbeling, Brad N.] Richard L Roudebush Vet Affairs Med Ctr, VA Ctr Excellence Implementing Evidence Based Pra, Indianapolis, IN 46202 USA. [Doebbeling, Brad N.] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Indianapolis, IN 46204 USA. [Doebbeling, Brad N.] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46204 USA. RP Fung, CH (reprint author), 10880 Wilshire Blvd,Suite 300, Los Angeles, CA 90024 USA. EM cfung@stanfordalumni.org RI Patterson, Emily/B-4398-2011 OI Patterson, Emily/0000-0002-4514-2075 NR 29 TC 23 Z9 23 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2008 VL 23 IS 4 BP 392 EP 398 DI 10.1007/s11606-007-0417-8 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 280WD UT WOS:000254456400008 PM 18373135 ER PT J AU Schnickel, GT Bastani, S Hsieh, GR Shefizadeh, A Bhatia, R Fishbein, MC Belperio, J Ardehali, A AF Schnickel, Gabriel T. Bastani, Sam Hsieh, George R. Shefizadeh, Ali Bhatia, Rubina Fishbein, Michael C. Belperio, John Ardehali, Abbas TI Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ACUTE ALLOGRAFT-REJECTION; REGULATORY T-CELLS; HUMAN CARDIAC ALLOGRAFTS; CHEMOKINE RECEPTOR; IFN-GAMMA; IN-VIVO; CCR5; MICE; PATHOGENESIS; TOLERANCE AB Chemokine-chemokine receptor interactions orchestrate mononuclear cells recruitment to the allograft, leading to acute and chronic rejection. Despite biologic redundancy, several experimental studies have demonstrated the importance of CXCR3 and CCR5 in acute rejection of allografts. In these studies, deficiency or blockade of CXCR3 or CCR5 led to prolongation of allograft survival, yet allografts were ultimately lost to acute rejection. Given the above findings and the specificity of mononuclear cells bearing CXCR3 and CCR5, we hypothesized that combined blockade of CXCR3 and CCR5 will lead to indefinite (>100 days) graft survival in a full MHC-mismatched murine cardiac allograft model. The donor hearts in the control group were rejected in 6 +/- 1 days after transplantation. Combined blockade of CXCR3 and CCR5 prolonged allograft survival >15-fold vs the control group; all allografts survived for >100 days. More importantly, the donor hearts did not display any intimal lesions characteristic of chronic rejection. Further analysis of the donor hearts in the CXCR3/CCR5 blockade group demonstrated graft infiltration with CD4(+)CD25(+) T cells expressing the Foxp3 gene. Depletion of CD25(+) cells in the combined CXCR3 and CCR5 blockade group resulted in acute rejection of the allografts in 22 +/- 2 days. Combined CXCR3 and CCR5 blockade also reduced alloantigen-specific T lymphocyte proliferation. Combined CXCR3 and CCR5 blockade is effective in preventing acute and chronic rejection in a robust murine model. This effect is mediated, in part, by CD25(+) regulatory T cell recruitment and control of T lymphocyte proliferation. C1 [Fishbein, Michael C.] Univ Calif Los Angeles, David Geffen Sch Med, Lab Med, Los Angeles, CA 90095 USA. [Belperio, John] Univ Calif Los Angeles, Div Cardiothorac Surg, Med Ctr, Div Pulm & Crit Care Med,David Geffen Sch Med, Los Angeles, CA 90095 USA. [Schnickel, Gabriel T.; Bastani, Sam; Hsieh, George R.; Shefizadeh, Ali; Bhatia, Rubina; Ardehali, Abbas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Fishbein, Michael C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Schnickel, Gabriel T.; Bastani, Sam; Hsieh, George R.; Ardehali, Abbas] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Ardehali, A (reprint author), Univ Calif Los Angeles, Div Cardiothorac Surg, Med Ctr, Div Pulm & Crit Care Med,David Geffen Sch Med, 62-182 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM aardehali@mednet.ucla.edu OI Schnickel, Gabriel/0000-0003-4392-2200 NR 33 TC 42 Z9 46 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2008 VL 180 IS 7 BP 4714 EP 4721 PG 8 WC Immunology SC Immunology GA 324GT UT WOS:000257506700044 PM 18354195 ER PT J AU Jensen, J Howe, W Vance, K Dunnick, CA Dellavalle, RP AF Jensen, J. Howe, W. Vance, K. Dunnick, C. A. Dellavalle, R. P. TI Dermatology patient information on Gargle: An appraisal of the top three most highly ranked websites addressing each of the top ten most common dermatologic conditions SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT International Investigative Dermatology Meeting CY MAY 14-17, 2008 CL Kyoto, JAPAN SP Japanese Soc Investigat Dermatol, Soc Investigat Dermatol, European Soc Dermatol Res, Federat Pharmaceut Manufactures Assoc Japan, Galderma, Janssen Pharmaceut KK, Maruho Co Ltd, Sanofi Aventis KK, Torii Pharmaceut Co Ltd, Abbott Japan Co Ltd, CERIES, Chanel, Clin Labs KK, Dainippon Sumitomo Pharma, Eisai Co Ltd, GlaxoSmithKline KK, Kyowa Hakko Kogyo Co Ltd, Mistubishi Tanabe Pharma Corp, Nippon Boehringer Ingelheim, Novartis Pharma KK, Schering Plough, Shionogi & Co Ltd, Shiseido Co Ltd, Japan Cosmet Ind Assoc, Igaku Shoin, Pierre Fabre Japan Co Ltd C1 [Jensen, J.; Howe, W.; Vance, K.; Dunnick, C. A.; Dellavalle, R. P.] Univ Colorado, Denver, CO 80202 USA. [Dellavalle, R. P.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2008 VL 128 SU 1 BP S87 EP S87 PG 1 WC Dermatology SC Dermatology GA 279KJ UT WOS:000254353800517 ER PT J AU Balu, N Chu, BC Hatsukami, TS Yuan, C Yarnykh, VL AF Balu, Niranjan Chu, Baocheng Hatsukami, Thomas S. Yuan, Chun Yarnykh, Vasily L. TI Comparison between 2D and 3D high-resolution black-blood techniques for carotid artery wall Imaging in clinically significant atherosclerosis SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE serial MRI; 3D carotid black-blood imaging; morphological measurements; vulnerable plaque imaging; plaque composition ID TURBO SPIN-ECHO; IN-VIVO; MEASUREMENT PRECISION; MR-ANGIOGRAPHY; PLAQUE AB Purpose: To compare two- (2D) and three-dimensional (3D) black-blood imaging methods for morphological measurements of the carotid artery wall and atherosclerotic plaque. Materials and Methods: A total of 18 subjects with 50% to 79% carotid stenosis were scanned with 2D (2-mm slice thickness) and 3D (1-mm/0.5-mm actual/interpolated slice thickness) T1-weighted fast spin-echo (FSE) black-blood imaging sequences with double inversion-recovery (DIR) blood suppression. Morphological measurements (lumen area, wall area, vessel area, mean wall thickness, and maximal wall thickness), signal-to-noise ratio (SNR) in the wall and lumen, and wall-lumen contrast-to-noise ratio (CNR) were compared between 2D and 3D images. The effect of improved slice resolution in 3D imaging was evaluated for visualization of small plaque components. Results: Lumen SNR (P = 0. 16), wall SNR (P = 0.65), and CNR (P = 0.94) were comparable between 2D/3D. There was no difference in average lumen area (P = 0. 16), average wall area (P = 0.99), average vessel area (P = 0. 0. 58), mean wall thickness (P = 0.09), and maximum wall thickness (P = 0.06) between 2D/3D. Distributions of small plaque components such as calcification were better characterized by the 3D acquisition. There was a higher sensitivity to motion artifacts with 3D imaging, resulting in three examinations with low image quality. Conclusion: 2D and 3D protocols provided comparable morphometric measurements of the carotid artery. The major advantage of 3D imaging is improved small plaque component visualization, while the 2D technique provides higher reliability for image quality.. C1 [Balu, Niranjan] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA. [Chu, Baocheng; Yuan, Chun; Yarnykh, Vasily L.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Hatsukami, Thomas S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Hatsukami, Thomas S.] VA Puget Sound HCS, Seattle, WA 98195 USA. RP Balu, N (reprint author), Vasc Imaging Lab, 815 Mercer St,Box 358050, Seattle, WA 98019 USA. EM ninja@u.washington.edu RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014 OI Yarnykh, Vasily/0000-0002-1583-8979; FU NHLBI NIH HHS [R01 HL061851-04, R01 HL061851, R01 HL056874-08, R01-HL061851, R01 HL056874, R01-HL056784] NR 23 TC 47 Z9 51 U1 0 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD APR PY 2008 VL 27 IS 4 BP 918 EP 924 DI 10.1002/jmri.21282 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 284MC UT WOS:000254709500032 PM 18383253 ER PT J AU Ma, YB Sun, CP Fields, M Li, Y Haake, DA Churchill, BM Ho, CM AF Ma, Yanbao Sun, Chien-Pin Fields, Michael Li, Yang Haake, David A. Churchill, Bernard M. Ho, Chih-Ming TI An unsteady microfluidic T-form mixer perturbed by hydrodynamic pressure SO JOURNAL OF MICROMECHANICS AND MICROENGINEERING LA English DT Article ID ELECTROOSMOTIC FLOW; CHAOTIC MIXER; MICROCHANNELS; MICROMIXERS; GEOMETRY; CHANNELS; DEVICES; DRIVEN; CHIP AB An unsteady microfluidic T-form mixer driven by pressure disturbances was designed and investigated. The performance of the mixer was examined both through numerical simulation and experimentation. Linear Stokes equations were used for these low Reynolds number flows. Unsteady mixing in a micro-channel of two aqueous solutions differing in concentrations of chemical species was described using a convection-dominated diffusion equation. The task was greatly simplified by employing linear superimposition of a velocity field for solving a scalar species concentration equation. Low-order-based numerical codes were found not to be suitable for simulation of a convection-dominated mixing process due to erroneous computational dissipation. The convection-dominated diffusion problem was addressed by designing a numerical algorithm with high numerical accuracy and computational-cost effectiveness. This numerical scheme was validated by examining a test case prior to being applied to the mixing simulation. Parametric analysis was performed using this newly developed numerical algorithm to determine the best mixing conditions. Numerical simulation identified the best mixing condition to have a Strouhal number (St) of 0.42. For a T-junction mixer (with channel width = 196 mu m), about 75% mixing can be finished within a mixing distance of less than 3 mm (i.e. 15 channel width) at St = 0.42 for flow with a Reynolds number less than 0.24. Numerical results were validated experimentally by mixing two aqueous solutions containing yellow and blue dyes. Visualization of the flow field under the microscope revealed a high level of agreement between numerical simulation and experimental results. C1 [Ma, Yanbao; Sun, Chien-Pin; Fields, Michael; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA. [Li, Yang; Haake, David A.; Churchill, Bernard M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. [Ho, Chih-Ming] NIH, Ctr Cell Control, Nanomed Dev Ctr, Bethesda, MD USA. RP Ma, YB (reprint author), Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA. EM yanbao@seas.ucla.edu FU NIAID NIH HHS [U01 AI075565-01, U54 AI065359, U01 AI075565, U54 AI065359-030019]; NIBIB NIH HHS [R01 EB000127]; NIDDK NIH HHS [R33 DK070328-02, R33 DK070328] NR 43 TC 8 Z9 8 U1 1 U2 19 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0960-1317 J9 J MICROMECH MICROENG JI J. Micromech. Microeng. PD APR PY 2008 VL 18 IS 4 AR 045015 DI 10.1088/0960-1317/18/4/045015 PG 14 WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Applied SC Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Physics GA 276OL UT WOS:000254151800015 PM 19177174 ER PT J AU Levy, C Bemski, J Kutner, JS AF Levy, Cari Bemski, Julie Kutner, Jean S. TI Are hospices establishing pre-hospice/palliative care programs? SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Letter C1 [Levy, Cari; Kutner, Jean S.] Univ Colorado, Denver Sch Med, Denver, CO 80220 USA. [Levy, Cari] Denver Vet Affairs Med Ctr, Denver, CO USA. [Bemski, Julie] Lewis & Clark Coll, Portland, OR 97219 USA. RP Levy, C (reprint author), Univ Colorado, Denver Sch Med, 6646 E 17th Ave, Denver, CO 80220 USA. EM Cari.Levy@uchsc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2008 VL 11 IS 3 BP 413 EP 414 DI 10.1089/jpm.2007.0274 PG 2 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 283QO UT WOS:000254651800003 PM 18363479 ER PT J AU Carlson, MDA Morrison, RS Bradley, EH AF Carlson, Melissa D. A. Morrison, R. Sean Bradley, Elizabeth H. TI Improving access to hospice care: Informing the debate SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID PALLIATIVE CARE; PROGNOSTIC CRITERIA; UNITED-STATES; LIFE; SERVICES; END; ELIGIBILITY; ENROLLMENT; HOSPITALS; BARRIERS AB The most frequently cited policy solution for improving access to hospice care for patients and families is to expand hospice eligibility criteria under the Medicare Hospice Benefit. However, the substantial implications of such a policy change have not been fully articulated or evaluated. This paper seeks to identify and describe the implications of expanding Medicare Hospice Benefit eligibility on the nature of hospice care, the cost of hospice care to the Medicare program, and the very structure of hospice and palliative care delivery in the United States. The growth in hospice has been dramatic and the central issue facing policymakers and the hospice industry is defining the appropriate target population for hospice care. As policymakers and the hospice industry discuss the future of hospice and potential changes to the Medicare Hospice Benefit, it is critical to clearly delineate the options - and the implications and challenges of each option - for improving access to hospice care for patients and families. C1 [Carlson, Melissa D. A.; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bradley, Elizabeth H.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. RP Carlson, MDA (reprint author), Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM melissa.carlson@mssm.edu FU NINR NIH HHS [K99 NR010495, K99 NR010495-01] NR 40 TC 18 Z9 18 U1 2 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2008 VL 11 IS 3 BP 438 EP 443 DI 10.1089/jpm.2007.0152 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 283QO UT WOS:000254651800011 PM 18363486 ER PT J AU Novak, MJ Potter, RM Blodgett, J Ebersole, JL AF Novak, M. John Potter, Richard M. Blodgett, Janet Ebersole, Jeffrey L. TI Periodontal disease in Hispanic Americans with type 2 diabetes SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE calculus; diabetes; Hispanic Americans; periodontitis; smoking; tooth loss ID BLOOD-GLUCOSE LEVELS; CIGARETTE-SMOKING; RISK FACTOR; CARDIOVASCULAR-DISEASE; MEXICAN-AMERICANS; ATTACHMENT LOSS; PIMA-INDIANS; MELLITUS; INSULIN; HYPERTENSION AB Background: Diabetes is a major risk factor for the development of periodontal disease in certain populations. The prevalence of type 2 diabetes is increased in Hispanic Americans, but its impact on the extent and severity of periodontal disease in this population has not been determined. Methods: Sixty-three Hispanic Americans, aged 33 to 72 years, from South Texas were grouped based on the presence or absence of type 2 diabetes. Past medical histories, including smoking, were obtained. Periodontal status was evaluated by measuring probing depth (PD), clinical attachment level (CAL), plaque, bleeding on probing, visual gingival inflammation, and calculus. Results: Type 2 diabetes was associated frequently with major medical complications in this population. Diabetes was associated with significantly more calculus formation and tooth loss and an increased extent and severity of periodontitis. Subjects with diabetes had nearly three times the mean CAL and frequency of PD >6 mm than subjects without diabetes and nearly twice the frequency of moderate to advanced attachment loss ( >= 3 mm). Smoking and diabetes had significant independent effects on mean CAL and the frequency of deep pockets. Diabetes and smoking combined were associated with a significantly higher frequency of sites with CAL 3 mm compared to healthy non-smokers, healthy smokers, and nonsmokers with diabetes. Conclusions: Hispanic Americans with type 2 diabetes had more supra- and subgingival calculus, an increased extent and severity of periodontal destruction, and an increased frequency of tooth loss due to periodontitis. An additive/synergistic contribution of type 2 diabetes and smoking for increasing the extent of periodontal disease was observed. C1 [Novak, M. John; Ebersole, Jeffrey L.] Univ Kentucky, Ctr Oral Hlth Res, Lexington, KY 40536 USA. [Blodgett, Janet] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Novak, MJ (reprint author), Univ Kentucky, Ctr Oral Hlth Res, 414 Hlth Sci Res Bldg, Lexington, KY 40536 USA. EM mjnova2@uky.edu FU NIDCR NIH HHS [DE-10589] NR 58 TC 31 Z9 37 U1 0 U2 3 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD APR PY 2008 VL 79 IS 4 BP 629 EP 636 DI 10.1902/jop.2008.070442 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 294RK UT WOS:000255423000009 PM 18380555 ER PT J AU Bush, RL Kallen, MA Liles, DR Bates, JT Petersen, LA AF Bush, Ruth L. Kallen, Michael A. Liles, Debra R. Bates, Jeffrey T. Petersen, Laura A. TI Knowledge and awareness of peripheral vascular disease are poor among women at risk for cardiovascular disease SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE women; cardiovascular disease; screening; peripheral vascular disease; risk factor ID ANKLE-BRACHIAL INDEX; ARTERIAL-DISEASE; OCCLUSIVE DISEASE; VETERANS HEALTH; SEX-DIFFERENCES; HEART-DISEASE; PREVALENCE; ATHEROSCLEROSIS; PREVENTION; CORONARY AB Objective. Peripheral vascular disease (PVD), a manifestation of systemic atherosclerosis, is an independent risk factor for cardiovascular (CV) morbidity and mortality. PVD research has traditionally focused on male patients; thus, there is a lack of current studies focusing specifically on women. In a cross-sectional study, we assessed the prevalence of PVD and associated atherosclerotic risk factors in ambulatory women veterans as well as knowledge and awareness of PVD and its consequences. Materials and methods. We screened 162 ambulatory women veterans aged 40 to 85 who were enrolled for outpatient care at an urban, tertiary care, teaching hospital. Of 207 women who responded to advertisements or mailings about the study, 78.3% met eligibility criteria and gave informed consent to participate. The participants (N = 162, mean age 54.8 +/- 9.3 years) were evaluated via chart review and noninvasive screening procedures (ankle-brachial index [ABI]; carotid artery intimal-medial thickness [IMT]). PVD was defined by having an ABI <= 0.9, carotid IMT > 1.0 mm, documented PVD, or previous leg revascularization. CV risk levels were determined using a modification of the Framingham risk level score: low risk, +0-1 risk factor; moderate risk, +2 risk factors; and high risk, >= 2 risk factors. Women's knowledge and awareness were assessed with a psychometrically sound survey (average subscale reliability: 0.942) about risk factors, symptoms, and health consequences associated with PVD. Results. Of 162 patients, 66.2% were white and 84.2% had at least some college education. An ABI <= 0.9 was detected in 3.7% of patients and a carotid IMT > 1.0 mm was detected in 21.1%, while 1.2% had a prior diagnosis of PVD and 1.9% had previous leg revascularization. Risk factor stratification was as follows: low risk in 32.1%, moderate risk in 20.4%, and high risk in 47.5% of patients. Knowledge and awareness scores (% correct) for PVD were low regardless of CV risk factor group: low-risk average score was 45.7%; moderate risk, 42.1%; and high risk, 46.9% (F = 0.431, P = 0.650). Likewise, low scores for knowledge of CV risk factors and consequences were found in all CV risk factor groups: low-risk average score was 53.6%; moderate risk, 53.8%; and high risk, 54.4% (F =.013, P = 0.987). More than 68% of the women reported they had never discussed PVD or risk reduction with their physician, yet more than 44% believed they were at an increased risk for PVD. Conclusions. Despite the presence of multiple PVD risk factors, women in this study had low levels of knowledge and awareness about vascular diseases. Future work is needed to develop and disseminate information about PVD in women and its role in women's CV health. Improving education about the significance of PVD will allow women and their physicians to assess risk factors and implement preventive measures. (C) 2008 Elsevier Inc. All rights reserved. C1 [Bush, Ruth L.; Liles, Debra R.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey Dept Surg, Houston, TX USA. [Kallen, Michael A.; Bates, Jeffrey T.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Dept Med, Houston, TX USA. [Kallen, Michael A.; Petersen, Laura A.] VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Div Hlth Policy & Qual, Houston, TX USA. [Kallen, Michael A.; Petersen, Laura A.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Bush, RL (reprint author), Texas A&M Univ, Hlth Sci Ctr, Div Vasc Surg, Scott & White Hosp, 2401 S 31st St, Temple, TX 76508 USA. EM dliles@bcm.edu NR 35 TC 6 Z9 6 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD APR PY 2008 VL 145 IS 2 BP 313 EP 319 DI 10.1016/j.jss.2007.03.022 PG 7 WC Surgery SC Surgery GA 274KE UT WOS:000253999400020 PM 18222479 ER PT J AU Casarett, D Pickard, A Bailey, FA Ritchie, C Furman, C Rosenfeld, K Shreve, S Chen, Z Shea, JA AF Casarett, David Pickard, Amy Bailey, F. Amos Ritchie, Christine Furman, Christian Rosenfeld, Ken Shreve, Scott Chen, Zhen Shea, Judy A. TI Do palliative consultations improve patient outcomes? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE end-of-life care; quality improvement; measurement; veterans ID OF-LIFE CARE; FAMILY SATISFACTION; PROPENSITY SCORES; END; IMPACT; CANCER; MEDICINE; HOSPICE; MEMBERS; TRIAL AB OBJECTIVES: To determine whether inpatient palliative consultation services improve outcomes of care. DESIGN: Retrospective telephone surveys conducted with family members of veterans who received inpatient or outpatient care from a Department of Veterans Affairs (VA) medical facility in the last month of life. SETTING: Five VA Medical Centers or their affiliated nursing homes and outpatient clinics. PARTICIPANTS: Veterans had received inpatient or outpatient care from a participating VA in the last month of life. One family member completed each survey. MEASUREMENTS: The telephone survey assessed nine aspects of the care the patient received in his or her last month of life: the patient's well-being and dignity (4 items), adequacy of communication (5 items), respect for treatment preferences (2 items), emotional and spiritual support (3 items), management of symptoms (4 items), access to the inpatient facility of choice (1 item), care around the time of death (6 items), access to home care services (4 items), and access to benefits and services after the patient's death (3 items). RESULTS: Interviews were completed with 524 respondents. In a multivariable linear regression model, after adjusting for the likelihood of receiving a palliative consultation (propensity score), palliative care patients had higher overall scores: 65 (95% confidence interval (CI)=62-66) versus 54 (95% CI=51-56; P <.001) and higher scores for almost all domains. Earlier consultations were independently associated with better overall scores (beta=0.003; P=.006), a difference that was attributable primarily to improvements in communication and emotional support. CONCLUSION: Palliative consultations improve outcomes of care, and earlier consultations may confer additional benefit. C1 [Casarett, David; Pickard, Amy; Shea, Judy A.] Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA USA. [Bailey, F. Amos; Ritchie, Christine] Dept Vet Affairs, Birmingham, AL USA. [Furman, Christian] Dept Vet Affairs, Louisville, KY USA. [Rosenfeld, Ken] Dept Vet Affairs, West Los Angeles, CA USA. [Shreve, Scott] Dept Vet Affairs, Lebanon, PA USA. [Chen, Zhen] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Casarett, D (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu NR 34 TC 113 Z9 113 U1 1 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 BP 593 EP 599 DI 10.1111/j.1532-5415.2007.01610.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 282IX UT WOS:000254562200001 PM 18205757 ER PT J AU French, DD Bass, E Bradham, DD Campbell, RR Rubenstein, LZ AF French, Dustin D. Bass, Elizabeth Bradham, Douglas D. Campbell, Robert R. Rubenstein, Laurence Z. TI Rehospitalization after hip fracture: Predictors and prognosis from a national veterans study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hip fracture; comorbidities; readmissions; veterans; dual enrollment; Medicare ID ADMINISTRATIVE DATA; FUNCTIONAL STATUS; OUTCOMES; INJURY; RISK; BENZODIAZEPINES; COMMUNITY; MORTALITY; FALLS AB OBJECTIVES: To estimate the risk and long-term prognostic significance of 30-day readmission postdischarge of a 4-year cohort of elderly veterans first admitted to Medicare hospitals for treatment of hip fractures (HFx), controlling for comorbidities. DESIGN: Retrospective, national secondary data analysis. SETTING: National Medicare and Veterans Health Administration (VHA) facilities. PARTICIPANTS: The study cohort was 41,331 veterans with a HFx first admitted to a Medicare eligible facility during 1999 to 2002. MEASUREMENTS: HFxs were linked with all other Medicare and VHA inpatient discharge files to capture dual inpatient use. Logistic regression was used to examine the relationship between 30-day readmission and age, sex, inpatient length of stay, and selected Elixhauser comorbidities. RESULTS: Approximately 18.3% (7,579/41,331) of HFx patients were readmitted within 30 days. Of those with 30-day readmissions, 48.5% (3,675/7,579) died within 1 year, compared with 24.9% (8,388/33,752) of those without 30-day readmissions. Readmission risk was significantly greater in the presence of specific comorbidities, ranging from 11% greater risk for patients with fluid and electrolyte disorders (95% confidence interval (CI)=1.04-1.20) to 43% for renal failure (95% CI=1.29-1.60). For this cohort, cardiac arrhythmias (24%), chronic pulmonary disease (28%), and congestive heart failure (16%) were common comorbidities, and all affected the risk of 30-day readmission. CONCLUSION: Patients with HFx with 30-day readmissions were nearly twice as likely to die within 1 year. Identification of several predictive comorbidities at discharge and examination of reasons for subsequent readmission suggests that readmission was largely due to active comorbid clinical problems. These comorbidity findings have implications for the current Centers for Medicare and Medicaid Services (CMS) pay-for-performance initiatives, especially those related to better coordination of care for patients with chronic illnesses. These comorbidity findings for elderly patients with HFx may also provide data to enable CMS and healthcare providers to more accurately differentiate between comorbidities and hospital-acquired complications under the current CMS initiative related to nonpayment for certain types of medical conditions and hospital acquired infections. C1 [French, Dustin D.; Bass, Elizabeth; Campbell, Robert R.] James A Haley VAMC, VISN 8, Patient Safety Ctr Inquiry, Tampa, FL 33612 USA. [Bradham, Douglas D.] Cooperat Studies Program Coordinating Ctr, Cherry Point, MD USA. [Bradham, Douglas D.] Univ Maryland, Dept Epidemiol & Prevent Med, Sch Med, Baltimore, MD 21201 USA. [Rubenstein, Laurence Z.] Univ Calif Los Angeles, Div Geriatr Med, David Geffen Sch Med, Los Angeles, CA USA. [Rubenstein, Laurence Z.] Ctr Geriatr Res Educ & Clin, Vet Affairs Greater Los Angeles Hlthcare Syst, Sepulveda, CA USA. RP French, DD (reprint author), James A Haley VAMC, VISN 8, Patient Safety Ctr Inquiry, 13000 Bruce B Down Blvd 118M, Tampa, FL 33612 USA. EM Dustin.French@va.gov OI French, Dustin/0000-0003-4064-3206 NR 20 TC 39 Z9 40 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 BP 705 EP 710 DI 10.1111/j.1532-5415.2007.01479.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 282IX UT WOS:000254562200017 PM 18005354 ER PT J AU Alvarez, A Chiodo, L Kadakia, A AF Alvarez, A. Chiodo, L. Kadakia, A. TI Recurrent falls and orthostasis in an elderly male with brain radiation induced panhypopituitarism SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Alvarez, A.; Chiodo, L.; Kadakia, A.] UTHSCSA, San Antonio, TX USA. [Alvarez, A.; Chiodo, L.; Kadakia, A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D20 BP S165 EP S165 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300480 ER PT J AU Ashton, A Pierce, A Macias, D Chaudhuri, A Richardson, A Espinoza, S AF Ashton, A. Pierce, A. Macias, D. Chaudhuri, A. Richardson, A. Espinoza, S. TI Comparative proteomic analysis of plasma glycoproteins with age: a pilot study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Ashton, A.; Pierce, A.; Macias, D.; Chaudhuri, A.; Richardson, A.; Espinoza, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chaudhuri, A.; Richardson, A.; Espinoza, S.] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA C4 BP S112 EP S113 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300327 ER PT J AU Chi, R Neuzil, K AF Chi, R. Neuzil, K. TI Safety of intradermal influenza vaccination in elderly persons SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Neuzil, K.] PATH, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA C42 BP S125 EP S125 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300365 ER PT J AU Chodosh, J Edelen, MO Buchanan, JL Yosef, JA Ouslander, JG Berlowitz, DR Streim, JE Saliba, D AF Chodosh, J. Edelen, M. Orlando Buchanan, J. L. Yosef, J. A. Ouslander, J. G. Berlowitz, D. R. Streim, J. E. Saliba, D. TI Nursing home assessment of cognitive impairment: Development and testing of a brief instrument of mental status SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Chodosh, J.; Yosef, J. A.; Saliba, D.] VA Greater Los Angeles Healthcare Syst, GRECC, HSR&D, Ctr Excellence, Los Angeles, CA USA. [Chodosh, J.] Univ Calif Los Angeles, Div Geriatr, Los Angeles, CA USA. [Edelen, M. Orlando] Brown Univ, Sch Med, Dept Psychiat & Behav, Providence, RI 02912 USA. [Edelen, M. Orlando; Saliba, D.] Rand Hlth, Santa Monica, CA USA. [Buchanan, J. L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Ouslander, J. G.] Atlanta VA Med Ctr, Atlanta, GA USA. [Ouslander, J. G.] Emory Univ, Wesley Woods Geriatr Hosp, Atlanta, GA 30322 USA. [Berlowitz, D. R.] Ctr Hlth Qualit Outcomes & Econ Res, Bedford, MA USA. [Berlowitz, D. R.] Boston Univ, Sch Publ Hlth & Med, Boston, MA 02215 USA. [Streim, J. E.] Mental Illness Res Educ & Clin Care Ctr, Philadelphia, PA USA. [Streim, J. E.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA P16 BP S6 EP S7 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300017 ER PT J AU Ganz, DA Saliba, DM Shekelle, PG Yano, EM AF Ganz, D. A. Saliba, D. M. Shekelle, P. G. Yano, E. M. TI Health system variation in guideline adherence for falls SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Ganz, D. A.; Saliba, D. M.; Shekelle, P. G.; Yano, E. M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ganz, D. A.; Saliba, D. M.; Shekelle, P. G.; Yano, E. M.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D91 BP S190 EP S191 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300551 ER PT J AU Gupta, E Hartronft, S Prange, M AF Gupta, E. Hartronft, S. Prange, M. TI Neuroleptic malignant syndrome in a patient on chronic long-acting intramuscular (Depot) fluphenazine: A case report SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 GEC OOE, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA A28 BP S27 EP S27 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300074 ER PT J AU Gupta, E Hartronft, S Prange, M AF Gupta, E. Hartronft, S. Prange, M. TI Coca-cola: A new therapy for reflux SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 Univ Texas San Antonio, Ctr Hlth, GEC Ltd, OOE, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA A27 BP S27 EP S27 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300073 ER PT J AU Hanlon, JT Aspinall, S Handler, SM Rossi, M Fried, LF Weisbord, S Good, CB Fine, M Stone, R Pugh, M Semla, TP AF Hanlon, J. T. Aspinall, S. Handler, S. M. Rossi, M. Fried, L. F. Weisbord, S. Good, C. B. Fine, M. Stone, R. Pugh, M. Semla, T. P. TI Consensus guidelines for dosing primarily renally cleared medications in older outpatients SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Hanlon, J. T.; Aspinall, S.; Handler, S. M.; Rossi, M.; Fried, L. F.; Weisbord, S.; Good, C. B.; Fine, M.; Stone, R.] Univ Pittsburgh, Pittsburgh, PA USA. [Hanlon, J. T.; Aspinall, S.; Fried, L. F.; Weisbord, S.; Good, C. B.; Fine, M.; Stone, R.] CHERP, VAPHS, Pittsburgh, PA USA. [Pugh, M.] S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA. [Semla, T. P.] VA, PBM, Hines, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D89 BP S190 EP S190 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300549 ER PT J AU Karlawish, J Rubright, J Xie, S Casarett, DJ Gur, R Sankar, P AF Karlawish, J. Rubright, J. Xie, S. Casarett, D. J. Gur, R. Sankar, P. TI A memory and organizational aid improves research consent capacity in persons with Alzheimer's disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Karlawish, J.; Rubright, J.; Casarett, D. J.] Univ Penn, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. [Sankar, P.] Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. [Casarett, D. J.] Dept Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA P3 BP S1 EP S2 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300004 ER PT J AU Kinosian, B Tompkins, H Edes, T AF Kinosian, B. Tompkins, H. Edes, T. TI Factors associated with reduction in inpatient days by home based primary care(HBPC) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Kinosian, B.] VAMC, Philadelphia, PA USA. [Tompkins, H.; Edes, T.] US Dept Vet Affairs, Geriatr & Extended Care, Washington, DC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D111 BP S197 EP S198 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300571 ER PT J AU Lawrence, VA Hazuda, HP Cornell, JE AF Lawrence, V. A. Hazuda, H. P. Cornell, J. E. TI Perioperative depression and elders' recovery after major open abdominal surgery SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Lawrence, V. A.] S Texas Vet Hlth CAre Syst, San Antonio, TX USA. [Lawrence, V. A.; Hazuda, H. P.; Cornell, J. E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D148 BP S211 EP S211 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300608 ER PT J AU Lawrence, VA Cornell, JE Hazuda, HP AF Lawrence, V. A. Cornell, J. E. Hazuda, H. P. TI Elders' use of diverse adaptive strategies improves recovery after major abdominal surgery SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Lawrence, V. A.; Cornell, J. E.; Hazuda, H. P.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Lawrence, V. A.; Cornell, J. E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D146 BP S210 EP S210 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300606 ER PT J AU Ringman, JM Romano, JD Medina, L Rodriguez, Y Schaffer, B Varpetian, A Ortiz, F Fitten, J Cummings, JL Baloh, RW AF Ringman, J. M. Romano, J. D. Medina, L. Rodriguez, Y. Schaffer, B. Varpetian, A. Ortiz, F. Fitten, J. Cummings, J. L. Baloh, R. W. TI Increased prevalence of significant recurrent headache in pre-clinical familial Alzheimer's disease mutation carriers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Ringman, J. M.; Medina, L.; Schaffer, B.; Ortiz, F.; Fitten, J.; Cummings, J. L.] Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Los Angeles, CA USA. [Ringman, J. M.; Medina, L.; Schaffer, B.; Baloh, R. W.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Romano, J. D.] Virginia Commonwealth Univ, Richmond, VA USA. [Rodriguez, Y.] Natl Inst Neurol & Neurosurg, Expt Psychol Lab, Mexico City, DF, Mexico. [Varpetian, A.] USC, Keck Sch Med, Dept Neurol, Downey, CA USA. [Ortiz, F.] Olive View UCLA Med Ctr, Neuropsychiat Res Memory Clin, Sylmar, CA 91342 USA. [Fitten, J.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Baloh, R. W.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA A118 BP S57 EP S57 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300163 ER PT J AU Ross, JS Sanchez-Reilly, S Wittenberg-Lyles, E Lee, S AF Ross, J. S. Sanchez-Reilly, S. Wittenberg-Lyles, E. Lee, S. TI Assessment of geriatric attitudes in interdisciplinary palliative care healthcare providers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Ross, J. S.; Sanchez-Reilly, S.; Lee, S.] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 76203 USA. [Wittenberg-Lyles, E.] Univ N Texas, Denton, TX USA. [Ross, J. S.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA A66 BP S40 EP S40 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300112 ER PT J AU Sun, B Glenn, S Derose, S AF Sun, B. Glenn, S. Derose, S. TI Epidemiology and predictors of 30-day mortality after syncope SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Sun, B.] Univ Calif Los Angeles, W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. [Glenn, S.; Derose, S.] Kaiser Permanente So Calif, Pasadena, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA D27 BP S167 EP S168 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300487 ER PT J AU Waters, I Ross, J Wittenberg-Lyles, E Sanchez-Reilly, S AF Waters, I. Ross, J. Wittenberg-Lyles, E. Sanchez-Reilly, S. TI Assesing geriatric education and attitudes among interdisciplinary palliative care fellows: The AGE-PC study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 30-MAY 04, 2008 CL Washington, DC SP Amer Geriatr Soc C1 [Waters, I.; Ross, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 76203 USA. [Ross, J.; Wittenberg-Lyles, E.; Sanchez-Reilly, S.] GRECC, San Antonio, TX USA. [Wittenberg-Lyles, E.] Univ N Texas, Denton, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2008 VL 56 IS 4 SU S MA B81 BP S91 EP S92 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 286IT UT WOS:000254840300266 ER PT J AU Baumgarten, M Margolis, DJ Localio, R Kagan, SH Lowe, RA Kinosian, B Abbuhl, SB Kavesh, W Holmes, JH Ruffin, A Mehari, T AF Baumgarten, Mona Margolis, David J. Localio, Russell Kagan, Sarah H. Lowe, Robert A. Kinosian, Bruce Abbuhl, Stephanie B. Kavesh, William Holmes, John H. Ruffin, Althea Mehari, Tesfa TI Extrinsic risk factors for pressure ulcers early in the hospital stay: A nested case-control study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article; Proceedings Paper CT 14th Annual Meeting of the Wound-Healing-Society CY MAY 24, 2004 CL Atlanta, GA SP Wound Healing Soc DE pressure ulcers; intensive care unit; hospital patients; risk factors ID ELDERLY-PATIENTS; DEVICES; SORES; CARE; PREVENTION; SURGERY; PATIENT; PERIOD; RATES AB Background. Little is known about the impact of extrinsic factors on pressure ulcer risk. The objective of this study was to determine whether risk of pressure ulcers early in the hospital stay is associated with extrinsic factors such as longer emergency department (ED) stays, night or weekend admission, potentially immobilizing procedures and medications, and admission to an intensive care unit (ICU). Methods. A nested case-control study was performed in two teaching hospitals in Philadelphia, Pennsylvania. Participants were medical patients age >= 65 years admitted through the ED. Cases (n = 195) had >= 1 possibly or definitely hospital-acquired pressure ulcers. Three controls per case were sampled randomly from among noncases at the same hospital in the same month (n = 597). Pressure ulcer status was determined by a research nurse on the third day of hospitalization. Pressure ulcers were classified as preexisting, possibly hospital-acquired, or definitely hospital-acquired. Information on extrinsic factors was obtained by chart review. Results. The odds of pressure ulcers were twice as high for those with an ICU stay as for those without (adjusted odds ratio [aOR] 2.0, 95% confidence interval [CI], 1.2-3.5). The aOR was 0.6 (95% CI, 0.3-0.9) for use of any potentially immobilizing medications during the early inpatient period. Conclusions. Many of the procedures experienced by patients in the ED and early in the inpatient stay do not confer excess pressure ulcer risk. Having an ICU stay is associated with a doubling of risk. This finding emphasizes the importance of developing and evaluating interventions to prevent pressure ulcers among patients in the ICU. C1 [Baumgarten, Mona; Mehari, Tesfa] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Margolis, David J.; Localio, Russell; Kinosian, Bruce; Abbuhl, Stephanie B.; Holmes, John H.; Ruffin, Althea] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kagan, Sarah H.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Lowe, Robert A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kavesh, William] Philadelphia VA Med Ct, Philadelphia, PA USA. RP Baumgarten, M (reprint author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 W Redwood St,Suite 200, Baltimore, MD 21201 USA. EM mbaumgar@epi.umaryland.edu FU NIA NIH HHS [R01 AG014127-02, R01 AG014127-04, R01-AG-14127, R01 AG014127-03, R01 AG014127] NR 44 TC 24 Z9 24 U1 1 U2 10 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2008 VL 63 IS 4 BP 408 EP 413 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 294SO UT WOS:000255426100009 PM 18426965 ER PT J AU Davis, TR Young, BA Eisenberg, MS Rea, TD Copass, MK Cobb, LA AF Davis, T. R. Young, B. A. Eisenberg, M. S. Rea, T. D. Copass, M. K. Cobb, L. A. TI Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers SO KIDNEY INTERNATIONAL LA English DT Article DE cardiac arrest; dialysis; ESRD; emergency medical service ID CARDIOPULMONARY-RESUSCITATION; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; DEFIBRILLATION; SURVIVAL; SUDDEN; DEATH AB Cardiac arrest is the leading cause of death among dialysis patients in the United States. We measured the outcome of cardiac arrests attended by Emergency Medical Services (EMS) staff at hemodialysis facilities in a 14-year population-based retrospective study to identify cardiac arrest cases at a dialysis unit. Associated factors were determined using unconditional logistic regression. Of the 102 cardiac arrests identified around the time of dialysis, 10 occurred before, 72 during, and 20 after hemodialysis. The initial measured abnormality was ventricular fibrillation or tachycardia in 72 cases. Of those who survived transportation to a hospital, survival to discharge was 24 with 15% survival at 1 year. Compared to arrests that occurred prior to dialysis, the odds of ventricular fibrillation were 5-fold greater in patients on dialysis but 14-fold greater in those arresting after dialysis. One-third of cases occurred after the introduction of automated external defibrillators, and in half of the cases these devices were attached prior to EMS arrival. Once these devices were attached, most were used for defibrillation. We conclude that ventricular arrhythmias are the predominant features among arrested in-center dialysis patients with most occurrences during dialysis. The role of these devices in dialysis units will need a larger study to evaluate their efficacy. C1 [Davis, T. R.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Young, B. A.; Eisenberg, M. S.; Rea, T. D.; Copass, M. K.; Cobb, L. A.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Young, B. A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Eisenberg, M. S.; Rea, T. D.] Publ Hlth Seattle & King County, Emergency Med Serv Div, Seattle, WA USA. RP Young, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Nephrol, Mail Stop 152-E,1660 S Columbian Way, Seattle, WA 98108 USA. EM youngb@u.washington.edu NR 21 TC 35 Z9 36 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD APR PY 2008 VL 73 IS 8 BP 933 EP 939 DI 10.1038/sj.ki.5002749 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 282HQ UT WOS:000254558900009 PM 18172435 ER PT J AU Sajid-Crockett, S Singer, FR Hershman, JM AF Sajid-Crockett, Saima Singer, Frederick R. Hershman, Jerome M. TI Cinacalcet for the treatment of primary hyperparathyroidism SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID CALCIUM-SENSING RECEPTOR; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; CALCIMIMETIC AGENTS; ORAL ALENDRONATE; SERUM-CALCIUM; PARATHYROIDECTOMY; HYDROCHLORIDE; OSTEOPOROSIS; MANAGEMENT AB Primary hyperparathyroidism (HPT) is the leading cause of hypercalcemia in the outpatient setting, and it is treated primarily by parathyroidectomy. There are few nonsurgical treatment options for patients who do not wish to have surgery, who have failed surgery, or who have contraindications to surgery. Cinacalcet increases the sensitivity of parathyroid calcium-sensing receptors to extracellular calcium, thereby reducing serum calcium levels. We conducted a retrospective chart review from 2004 to 2006 to investigate the efficacy of cinacalcet in reducing serum total calcium, ionized calcium, and parathyroid hormone (PTH) in patients with primary HPT. Patients were started on cinacalcet if they met at least one indication for parathyroidectomy, which includes T score less than -2.5 standard deviations from the mean, serum calcium 1 mg/dL above the upper limit of normal, 24-hour urine calcium above 400 mg/dL, age less than 50 years, or a creatinine clearance that is 30% below age- and sex-inatched controls. The primary outcome was normalization of serum calcium. A total of 18 patients with primary HPT were started on cinacalcet: 16 men and 2 women with a mean age of 70 years. Mean baseline serum calcium was 10.60 +/- .53 mg/dL; ionized serum calcium, 1.45 +/- .07 mmol/L; and serum PTH, 141 +/- 78 pg/mL. After treatment with cinacalcet, the mean serum calcium decreased to 9.46 +/- .34 mg/dL, ionized calcium decreased. to 1.26 +/- 1.06 mmol/L, and PTH decreased to 108 +/- 64.5 pg/mL. Ninety-four percent of the patients on cinacalcet had normal total serum calcium, 81% had normal serum ionized calcium, whereas only 25% had a normal serum PTH level. Cinacalcet normalizes serum calcium in most patients while only modestly reducing serum PTH levels. (c) 2008 Elsevier Inc. All rights reserved. C1 [Sajid-Crockett, Saima; Singer, Frederick R.; Hershman, Jerome M.] VA Greater Los Angeles Hltcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. [Sajid-Crockett, Saima; Singer, Frederick R.; Hershman, Jerome M.] John Wayne Canc Inst, Santa Monica, CA 90404 USA. RP Sajid-Crockett, S (reprint author), VA Greater Los Angeles Hltcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. EM ssajid@sierraendocrine.com NR 26 TC 20 Z9 21 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD APR PY 2008 VL 57 IS 4 BP 517 EP 521 DI 10.1016/j.metabol.2007.11.014 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 275VJ UT WOS:000254099900013 PM 18328354 ER PT J AU Sohn, L Harada, ND AF Sohn, Linda Harada, Nancy D. TI Effects of racial/ethnic discrimination on the health status of minority veterans SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; RACIAL DISPARITIES; VIETNAM VETERANS; CARE-SYSTEM; US VETERANS; EDUCATION; AFFAIRS; LIFE; ASSOCIATION; COMMUNITY AB As the veteran population becomes ethnically diverse, it is important to understand complex interrelationships between racism and health. This study examined the association between perceptions of discrimination and self-reported mental and physical health for Asian/Pacific Islander, African American, and Hispanic veterans. The data for this study come from the 2001 Veteran Identity Program Survey, which measured utilization of outpatient care, discrimination, and health status across three minority veteran groups. Multivariate regression methods were used to model self-reported mental and physical health on perceptions of discrimination controlling for demographic and socioeconomic characteristics. Findings revealed that racial/ethnic discrimination during military service was significantly associated with lower physical, but not mental health. Satisfaction with health care provider's sensitivity toward racial/ethnic background was significantly associated with better mental health. Findings highlight the importance of developing policies that address racial/ethnic discrimination during military service while providing health care services for veterans. C1 [Sohn, Linda; Harada, Nancy D.] VA Greater Los Angeles Hlth Care Syst, Sepulveda, CA 91343 USA. RP Sohn, L (reprint author), VA Greater Los Angeles Hlth Care Syst, 16111 Plummer St,Mail Code 118B,NHCU Bldg 99, Sepulveda, CA 91343 USA. NR 38 TC 9 Z9 9 U1 3 U2 11 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD APR PY 2008 VL 173 IS 4 BP 331 EP 338 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 288CL UT WOS:000254963700004 PM 18472621 ER PT J AU Ahuja, SK Kulkarni, H Catano, G Agan, BK Camargo, JF He, W O'Connell, RJ Marconi, VC Delmar, J Eron, J Clark, RA Frost, S Martin, J Ahuja, SS Deeks, SG Little, S Richman, D Hecht, FM Dolan, MJ AF Ahuja, Sunil K. Kulkarni, Hemant Catano, Gabriel Agan, Brian K. Camargo, Jose F. He, Weijing O'Connell, Robert J. Marconi, Vincent C. Delmar, Judith Eron, Joseph Clark, Robert A. Frost, Simon Martin, Jeffrey Ahuja, Seema S. Deeks, Steven G. Little, Susan Richman, Douglas Hecht, Frederick M. Dolan, Matthew J. TI CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals SO NATURE MEDICINE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED ADULTS; CD4(+) CELL COUNT; PLASMA VIRAL LOAD; DISEASE PROGRESSION; VIROLOGICAL SUPPRESSION; GENETIC PROFILES; RNA LEVEL; AIDS; MORTALITY AB The basis for the extensive variability seen in the reconstitution of CD4(+) T cell counts in HIV- infected individuals receiving highly active antiretroviral therapy ( HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility complex HLA alleles, influence immune reconstitution, especially when HAART is initiated at <350 CD4(+) T cells/ mm(3). The CCL3L1- CCR5 genotypes favoring CD4(+) T cell recovery are similar to those that blunted CD4(+) T cell depletion during the time before HAART became available ( pre- HAART era), suggesting that a common CCL3L1- CCR5 genetic pathway regulates the balance between pathogenic and reparative processes from early in the disease course. Hence, CCL3L1-CCR5 variations influence HIV pathogenesis even in the presence of HAART and, therefore, may prospectively identify subjects in whom earlier initiation of therapy is more likely to mitigate immunologic failure despite viral suppression by HAART. Furthermore, as reconstitution of CD4(+) cells during HAART is more sensitive to CCL3L1 dose than to CCR5 genotypes, CCL3L1 analogs might be efficacious in supporting immunological reconstitution. C1 [Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Camargo, Jose F.; He, Weijing; Clark, Robert A.; Ahuja, Seema S.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV1 Infect, San Antonio, TX 78229 USA. [Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Camargo, Jose F.; He, Weijing; Clark, Robert A.; Ahuja, Seema S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Agan, Brian K.; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Dolan, Matthew J.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA. [Agan, Brian K.; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA. [Agan, Brian K.; Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA. [Agan, Brian K.; Marconi, Vincent C.; Delmar, Judith; Dolan, Matthew J.] San Antonio Mil Med Ctr, Ft Sam Houston, TX 78234 USA. [Eron, Joseph] Univ N Carolina, Chapel Hill, NC 27599 USA. [Frost, Simon; Little, Susan; Richman, Douglas] Univ Calif San Diego, Antiviral Res Ctr, Dept Med, San Diego, CA 92103 USA. [Frost, Simon; Richman, Douglas] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA. [Martin, Jeffrey] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. [Deeks, Steven G.; Hecht, Frederick M.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. RP Ahuja, SK (reprint author), S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV1 Infect, 7400 Merton Minister, San Antonio, TX 78229 USA. EM ahujas@uthscsa.edu; mdolan@hjf.org RI Frost, Simon/F-3648-2010; Marconi, Vincent/N-3210-2014 OI Frost, Simon/0000-0002-5207-9879; Marconi, Vincent/0000-0001-8409-4689; Agan, Brian/0000-0002-5114-1669 FU NIAID NIH HHS [P01 AI074621-01A10002, P30 AI050410, P01 AI074621] NR 50 TC 84 Z9 86 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD APR PY 2008 VL 14 IS 4 BP 413 EP 420 DI 10.1038/nm1741 PG 8 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 283ZD UT WOS:000254674100028 PM 18376407 ER PT J AU Mehta, KM Yaffe, K Perez-Stable, EJ Stewart, A Barnes, D Kurland, BF Miller, BL AF Mehta, K. M. Yaffe, K. Perez-Stable, E. J. Stewart, A. Barnes, D. Kurland, B. F. Miller, B. L. TI Race/ethnic differences in AD survival in US Alzheimer's disease Centers SO NEUROLOGY LA English DT Article ID COORDINATING-CENTER; DEMENTIA; INDIVIDUALS; DIAGNOSIS; HEALTH; PREDICTORS; MORTALITY; AMERICAN; ONSET AB Objective: Survival after Alzheimer disease (AD) is poorly understood for patients of diverse race/ethnic groups. We examined whether nonwhite AD patients (African American, Latino, Asian, American Indian) had different rates of survival compared with white AD patients. Methods: The National Alzheimer's Coordinating Center (NACC) cataloged data from more than 30 Alzheimer's Disease Centers in the United States from 1984 to 2005. Patients aged 65 years or older with a diagnosis of possible/probable AD were included (n = 30,916). Survival was calculated using Cox proportional hazards models with a primary outcome of time to death. Secondary outcomes of this study were neuropathologic characteristics on an autopsied subsample (n = 3,017). Results: The 30,916 AD patients in the NACC were followed up for 2.4 (+/-) 2.9 years (mean age 77.6 +/- 6.5 years; 65% women; 19% nonwhite [12% African American, 4% Latino, 1.5% Asian, 0.5% American Indian, and 1% other]). Median survival was 4.8 years. African American and Latino AD patients had a lower adjusted hazard for mortality compared with white AD patients (African American hazard ratio [HR] 0.85,95% CI 0.74 to 0.96; Latino HR 0.57,95% CI 0.46 to 0.69). Asians and American Indians had similar adjusted hazards for mortality compared with white AD patients (p > 0.10 for both). African American and Latino autopsied AD patients had similar neuropathologic characteristics compared with white AD patients with similar clinical severity. Conclusions: African American and Latino Alzheimer disease (AD) patients may have longer survival compared with white AD patients. Neuropathology findings did not explain survival differences by race. Determining the underlying factors behind survival differences may lead to longer survival for AD patients of all race/ethnic backgrounds. C1 [Mehta, K. M.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. [Yaffe, K.; Barnes, D.; Miller, B. L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, K.; Miller, B. L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, K.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94121 USA. [Perez-Stable, E. J.] Univ Calif San Francisco, Div Gen Internal Med, Dept Med, San Francisco, CA 94121 USA. [Stewart, A.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94121 USA. [Mehta, K. M.; Perez-Stable, E. J.; Stewart, A.] Univ Calif San Francisco, Med Effectiveness Res Ctr Diverse Populat, San Francisco, CA 94121 USA. [Kurland, B. F.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Mehta, K. M.; Yaffe, K.; Barnes, D.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Mehta, KM (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM kala.mehta@ucsf.edu OI Kurland, Brenda/0000-0002-5669-0595 FU NIA NIH HHS [K-01AG025444-01A1, K01 AG025444, K01 AG025444-01A1, P30 AG 15272, P30 AG015272, P50 AG023501, P50-AG023501, U01 AG016976, U01AG016976] NR 25 TC 34 Z9 34 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR 1 PY 2008 VL 70 IS 14 BP 1163 EP 1170 DI 10.1212/01.wnl.0000285287.99923.3c PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 282OH UT WOS:000254576600003 PM 18003939 ER PT J AU Hashimoto, JG Wiren, KM AF Hashimoto, Joel G. Wiren, Kristine M. TI Neurotoxic consequences of chronic alcohol withdrawal: Expression profiling reveals importance of gender over withdrawal severity SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE alcoholism; microarray; neurotoxicity; animal model ID NEUROENDOCRINE-SPECIFIC PROTEIN; ETHANOL-REGULATED GENE; MICROARRAY ANALYSIS; SEX-DIFFERENCES; RESISTANT MICE; BRAIN VOLUMES; SEIZURE-PRONE; SENSITIVITY; SUSCEPTIBILITY; CONSUMPTION AB While women are more vulnerable than men to many of the medical consequences of alcohol abuse, the role of sex in the response to ethanol is controversial. Neuroadaptive responses that result in the hyperexcitability associated with withdrawal from chronic ethanol likely reflect gene expression changes. We have examined both genders for the effects of withdrawal on brain gene expression using mice with divergent withdrawal severity that have been selectively bred from a genetically heterogeneous population. A total of 295 genes were identified as ethanol regulated from each gender of each selected line by microarray analyses. Hierarchical cluster analysis of the arrays revealed that the transcriptional response correlated with sex rather than with the selected withdrawal phenotype. Consistent with this, gene ontology category over-representation analysis identified cell death and DNA/RNA binding as targeted classes of genes in females, while in males, protein degradation, and calcium ion binding pathways were more altered by alcohol. Examination of ethanol-regulated genes and these distinct signaling pathways suggested enhanced neurotoxicity in females. Histopathological analysis of brain damage following ethanol withdrawal confirmed elevated cell death in female but not male mice. The sexually dimorphic response was observed irrespective of withdrawal phenotype. Combined, these results indicate a fundamentally distinct neuroadaptive response in females compared to males during chronic ethanol withdrawal and are consistent with observations that female alcoholics may be more vulnerable than males to ethanol-induced brain damage associated with alcohol abuse. C1 [Hashimoto, Joel G.; Wiren, Kristine M.] OHSU, Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA. [Hashimoto, Joel G.; Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. RP Wiren, KM (reprint author), OHSU, Portland VA Med Ctr, Res Serv, P3 R&D39, Portland, OR 97239 USA. EM wirenk@ohsu.edu OI Wiren, Kristine/0000-0002-6159-4450 FU NIAAA NIH HHS [AA-13783, P60 AA010760, R01 AA013194, R01 AA013194-03] NR 75 TC 34 Z9 35 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD APR PY 2008 VL 33 IS 5 BP 1084 EP 1096 DI 10.1038/sj.npp.1301494 PG 13 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 273UQ UT WOS:000253957600013 PM 17593928 ER PT J AU Peterson, AL Nutt, JG AF Peterson, Amie L. Nutt, John G. TI Treatment of Parkinson's disease with trophic factors SO NEUROTHERAPEUTICS LA English DT Review DE Parkinson's disease; trophic factors; clinical trials; glial-derived neurotrophic factors; neurturin ID BLOOD-BRAIN-BARRIER; NERVE GROWTH-FACTOR; NIGROSTRIATAL DOPAMINERGIC SYSTEM; NEUROTROPHIC FACTOR EXPRESSION; N-TERMINAL TRIPEPTIDE; PARTIAL LESION MODEL; SUBSTANTIA-NIGRA; IN-VIVO; INTRAPUTAMENAL INFUSION; RHESUS-MONKEYS AB Trophic factors are proteins that support and protect subpopulations of cells. A number have been reported to act on dopaminergic neurons in vitro and in vivo, making them potential therapeutic candidates for Parkinson's disease. All of these candidate factors protect dopaminergic neurons if given prior to, or with, selective neurotoxins. Fewer trophic factors, primarily glial-derived neurotrophic factor (GDNF) and its relative, neurturin (NRTN; also known as NTN), have been shown to restore function in damaged dopamine neurons after the acute effects of neurotoxins have subsided. A major barrier to clinical translation has been delivery. GDNF delivered by intracerebroventricular injection in patients was ineffective, probably because GDNF did not reach the target, the putamen, and intraputaminal infusion was ineffective, probably because of limited distribution within the putamen. A randomized clinical trial with gene therapy for NRTN is underway, in an attempt to overcome these problems with targeting and distribution. Other strategies are available to induce trophic effects in the CNS, but have not yet been the focus of human research. To date, clinical trials have focused on restoration of function (i.e., improvement of parkinsonism). Protection (i.e., slowing or halting disease progression and functional decline) might be a more robust effect of trophic agents. Laboratory research points to their effectiveness in protecting, neurons and even restoring dopaminergic function after a monophasic neurotoxic insult. Utility for such compounds in patients with Parkinson's disease and ongoing loss of dopaminergic neurons remains to be proven. C1 [Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. Portland VA Med Ctr, PADRECC, Portland, OR 97239 USA. RP Nutt, JG (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. EM nuttj@ohsu.edu FU NINDS NIH HHS [R01-NS21062] NR 104 TC 105 Z9 111 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-7213 J9 NEUROTHERAPEUTICS JI Neurotherapeutics PD APR PY 2008 VL 5 IS 2 BP 270 EP 280 DI 10.1016/j.nurt.2008.02.003 PG 11 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 288SC UT WOS:000255005100010 PM 18394569 ER PT J AU Subak, LL Brubaker, L Chai, TC Creasman, JM Diokno, AC Goode, PS Kraus, SR Kusek, JW Leng, WW Lukacz, ES Norton, P Tennstedt, S AF Subak, Leslee L. Brubaker, Linda Chai, Toby C. Creasman, Jennifer M. Diokno, Ananias C. Goode, Patricia S. Kraus, Stephen R. Kusek, John W. Leng, Wendy W. Lukacz, Emily S. Norton, Peggy Tennstedt, Sharon CA Urinary Incontinence Treatment Ne TI High costs of urinary incontinence among women electing surgery to treat stress incontinence SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID WILLINGNESS-TO-PAY; QUALITY-OF-LIFE; COMMUNITY; IMPACT; INSTRUMENT; DISEASE AB OBJECTIVE: To estimate costs for incontinence management, health-related quality of life, and willingness to pay for incontinence improvement in women electing surgery for stress urinary incontinence. METHODS: A total of 655 incontinent women enrolled in the Stress Incontinence Surgical Treatment Efficacy Trial, a randomized surgical trial. Baseline out-of-pocket costs for incontinence management were calculated by multiplying self-report of resources used (supplies, laundry, dry cleaning) by national resource costs ($2006). Health-related quality of life was estimated with the Health Utilities Index Mark 3. Participants estimated willingness to pay for 100% improvement in incontinence. Potential predictors of these outcomes were examined by using multivariable linear regression. RESULTS: Mean age was 52 +/- 10 years, and mean number of weekly incontinence episodes was 22 +/- 21. Mean and median (25%, 75% interquartile range) estimated personal costs for incontinence management among all women were $14 +/- $24 and $8 (interquartile range $3, $18) per week, and 617 (94%) women reported any cost. Costs increased significantly with incontinence frequency and mixed compared with stress incontinence. The mean and median Health Utilities Index Mark 3 scores were 0.73 +/- 0.25 and 0.84 (interquartile range 0.63, 0.92). Women were willing to pay a mean of $118 +/- $132 per month for complete resolution of incontinence, and willingness to pay increased significantly with greater expected incontinence improvement, household income, and incontinent episode frequency. CONCLUSION: Urinary incontinence is associated with substantial costs. Women spent nearly $750 per year out of pocket for incontinence management, had a significant decrement in quality of life, and were willing to pay nearly $1,400 per year for cure. C1 [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Loyola Univ, Dept Obstet Gynecol & Reprod Sci, Chicago, IL 60611 USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Univ Maryland, Dept Urol, Baltimore, MD 21201 USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] William Beaumont Hosp, Dept Urol, Royal Oak, MI 48072 USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Univ Alabama, Birmingham, AL USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Birmingham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Birmingham, AL USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] NIDDK, Bethesda, MD USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Univ Pittsburgh, Dept Urol, Pittsburgh, PA USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Univ Calif San Diego, Dept Reprod Med, San Diego, CA 92103 USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA. [Subak, Leslee L.; Brubaker, Linda; Chai, Toby C.; Creasman, Jennifer M.; Diokno, Ananias C.; Goode, Patricia S.; Kraus, Stephen R.; Kusek, John W.; Leng, Wendy W.; Lukacz, Emily S.; Norton, Peggy; Tennstedt, Sharon] New England Res Inst, Watertown, MA 02172 USA. RP Subak, LL (reprint author), UCSF, Mt Zions Womens Hlth Clin Res Ctr, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. EM subakl@obgyn.ucsf.edu FU NIDDK NIH HHS [U01 DK060395, U01 DK058225, U01 DK058229, U01 DK058231, U01 DK058234, U01 DK060379, U01 DK060379-05, U01 DK060380, U01 DK060393, U01 DK060397, U01 DK060401, U01 DK58225, U01 DK58229, U01 DK58231, U01 DK58234, U01 DK60379, U01 DK60380, U01 DK60393, U01 DK60395, U01 DK60397]; PHS HHS [60401] NR 34 TC 36 Z9 37 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2008 VL 111 IS 4 BP 899 EP 907 DI 10.1097/AOG.0b013e31816a1e12 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 280NO UT WOS:000254433700013 PM 18378749 ER PT J AU Friedlander, AH Farman, AG AF Friedlander, Arthur H. Farman, Allan G. TI Dentists' scope of professional responsibilities SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY LA English DT Letter ID CONE-BEAM CT; TOMOGRAPHY C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Farman, Allan G.] Univ Louisville, Sch Dent, Dept Surg, Louisville, KY 40292 USA. [Farman, Allan G.] Univ Louisville, Sch Dent, Hosp Dent, Louisville, KY 40292 USA. [Farman, Allan G.] Univ Louisville, Sch Med, Louisville, KY 40292 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Univ Calif Los Angeles, Med Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1079-2104 J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD APR PY 2008 VL 105 IS 4 BP 410 EP 410 DI 10.1016/j.tripleo.2007.12.020 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 281WV UT WOS:000254530500002 PM 18329576 ER PT J AU Meropol, SB Glick, HA Asch, DA AF Meropol, Sharon B. Glick, Henry A. Asch, David A. TI Age inconsistency in the American Academy of Pediatrics guidelines for acute otitis media SO PEDIATRICS LA English DT Article; Proceedings Paper CT 22nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management CY AUG 24-27, 2006 CL Lisbon, PORTUGAL DE antibiotic use; child; cost-effectiveness; guidelines; otitis media ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; RANDOMIZED CONTROLLED-TRIAL; MIDDLE-EAR EFFUSION; ANTIBIOTIC USE; COST-EFFECTIVENESS; CLINICAL-TRIAL; PNEUMOCOCCAL RESISTANCE; TYMPANOCENTESIS SKILLS; DIAGNOSTIC-ACCURACY; TREATMENT OPTIONS AB OBJECTIVE. The American Academy of Pediatrics acute otitis media guidelines could reduce antibiotic use. The objective was to compare strategies for diagnosing and treating otitis: ( 1) a commonly used, 2-criteria strategy, ( 2) the guidelines' 3-criteria algorithm, and ( 3) initially watching without antibiotics. METHODS. A decision analysis was performed with literature-based parameter. The target population was children presenting to primary care physicians with possible otitis media. Main outcomes were antibiotic use, sick days, mild adverse drug events, and number needed to treat/avoided sick day. RESULTS. For children 2 to <6 months of age, compared with the 2-criteria strategy, guideline use predicted 21% less antibiotic use, 13% more sick days, and 23% fewer adverse drug events; the number needed to treat for the 2-criteria strategy versus the American Academy of Pediatrics strategy was 1.2 children per avoided sick day. For children 6 to <24 months of age, guideline use, compared with the 2-criteria strategy, predicted 26% less antibiotic use, 14% more sick days, and 28% fewer adverse drug events; the number needed to treat for the 2-criteria strategy versus the American Academy of Pediatrics strategy was 1.4 children per avoided sick day. For children >2 years of age, guideline use, compared with the 2-criteria strategy, predicted 67% less antibiotic use, 4% more sick days, and 68% fewer adverse drug events. The number needed to treat for the guideline strategy versus the watch strategy was 6.3 children per avoided sick day; that for the 2-criteria strategy versus the guideline strategy was 12.3. Guideline use for children 2 years implies that our number needed to treat to avoid a sick day is 1.4; for children >2, guideline use implies we are willing to treat at least 6.3 children to avoid a sick day. Thus, the guidelines imply a greater willingness to treat older children, compared with younger children. CONCLUSIONS. The American Academy of Pediatrics guidelines are inconsistent in their outcomes across age groups. Guideline implementation under age 2 reduces antibiotic use but at a relatively heavy cost of sick days and parental missed work days. This trade-off may be particularly unfavorable for working parents, who might reasonably prefer greater antibiotic use. C1 [Meropol, Sharon B.; Asch, David A.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Meropol, Sharon B.] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. [Glick, Henry A.; Asch, David A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Glick, Henry A.; Asch, David A.] Univ Penn, Sch Med, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Meropol, SB (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 108 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM meropols@mail.med.upenn.edu OI Asch, David/0000-0002-7970-286X FU AHRQ HHS [HS10399] NR 60 TC 5 Z9 6 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2008 VL 121 IS 4 BP 657 EP 668 DI 10.1542/peds.2007-1913 PG 12 WC Pediatrics SC Pediatrics GA 282OJ UT WOS:000254576800001 PM 18381528 ER PT J AU Salzer, MS Wick, LC Rogers, JA AF Salzer, Mark S. Wick, Lindsay C. Rogers, Joseph A. TI Familiarity with and use of accommodations and supports among postsecondary students with mental illnesses SO PSYCHIATRIC SERVICES LA English DT Article ID PSYCHIATRIC DISABILITIES; UNIVERSITY-STUDENTS; HIGHER-EDUCATION; PERCEPTIONS; EXPERIENCE; COLLEGE AB Objective: Many persons with serious mental illnesses are interested in pursuing postsecondary education and are doing so in increasing numbers. Accommodations can be essential, but limited research suggests that few formally seek accommodations, although increased efforts to heighten awareness may be changing this. The purpose of this study was to examine whether students with mental illnesses are increasingly aware of, and utilize, accommodations and academic supports and to identify the supports that are most used and perceived to be most helpful. Methods: A national Internet survey was conducted from July 2005 to July 2006, resulting in responses from 190 current and 318 former students with mental illnesses. Results: The study found modest but significant negative correlations between how long ago students left college and their familiarity with accommodations, their request for or receipt of accommodations, and their use of the Office for Students With Disabilities. These results were particularly noticeable when comparing current and former students. Moderate positive correlations that were significant were found between familiarity with accommodations, use of campus disability offices, and request for or receipt of accommodations. Conclusions: There is increased awareness and use of accommodations among students with mental illnesses, but it is also clear that most receive supports directly from instructors without going through the formal accommodations process. Encouraging students to utilize disability offices and greater attention to accommodation barriers may further increase support seeking. Supports that are most used and viewed as most helpful provide direction for service providers and campus personnel in their efforts to facilitate students' educational goals. C1 [Salzer, Mark S.] Univ Penn, Sch Med, Dept Psychiat, Ctr Mental Hlth Policy & Serv Res, Philadelphia, PA 19104 USA. [Salzer, Mark S.] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet & Integrated Serv Network 4, Philadelphia, PA USA. [Rogers, Joseph A.] Mental Hlth Assoc Southeastern Penn, Philadelphia, PA USA. RP Salzer, MS (reprint author), Univ Penn, Sch Med, Dept Psychiat, Ctr Mental Hlth Policy & Serv Res, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA. EM mark.salzer@uphs.upenn.edu NR 25 TC 22 Z9 22 U1 2 U2 14 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2008 VL 59 IS 4 BP 370 EP 375 DI 10.1176/appi.ps.59.4.370 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 282OW UT WOS:000254578100007 PM 18378834 ER PT J AU Satre, D Wolfe, W Eisendrath, S Weisner, C AF Satre, Derek Wolfe, William Eisendrath, Stuart Weisner, Constance TI Computerized screening for alcohol and drug use among adults seeking outpatient psychiatric services SO PSYCHIATRIC SERVICES LA English DT Article ID HEALTH; INTERVENTION; CONSUMPTION; DEPRESSION; DRINKING; IMPACT AB Objective: This study examined routine computerized screening for alcohol and drug use of men and women seeking outpatient psychiatric services ( excluding chemical dependency treatment) and prevalence based on electronic medical records of consecutive admissions. Methods: The sample of 422 patients, ages 18 - 91, completed a self- administered questionnaire. Measures included 30- day, one- year, and lifetime substance use and alcohol-related problems. Results: Seventy-five percent of patients completed electronic intakes during the study period. Prior- month alcohol use was reported by 90 men ( 70%) and 180 women ( 62%). Of these patients, heavy drinking ( five or more drinks on one occasion) was reported by 37 men ( 41%) and 41 women ( 23%). Prior-month cannabis use was reported by 17 men ( 13%) and 32 women ( 11%). Conclusions: Computerized intake systems that include alcohol and drug screening can be integrated into outpatient psychiatric settings. Heavy drinking and use of nonprescribed drugs are commonly reported, which provides an important intervention opportunity. C1 [Satre, Derek; Wolfe, William; Eisendrath, Stuart; Weisner, Constance] Univ Calif San Francisco, Depress Ctr, San Francisco, CA 94143 USA. [Satre, Derek; Wolfe, William; Eisendrath, Stuart; Weisner, Constance] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Satre, Derek; Weisner, Constance] Kaiser Permanente, Div Res, Oakland, CA USA. [Wolfe, William] San Francisco VA Med Ctr, San Francisco, CA USA. RP Satre, D (reprint author), Univ Calif San Francisco, Depress Ctr, 401 Parnassus Ave,Box 0984, San Francisco, CA 94143 USA. EM dereks@lppi.ucsf.edu FU NIAAA NIH HHS [K23-AA015411, K23 AA015411]; NIDA NIH HHS [P50 DA009253, P50-DA09253, R37 DA010572, R37-DA10572]; NIMH NIH HHS [R25 MH060482] NR 16 TC 13 Z9 13 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2008 VL 59 IS 4 BP 441 EP 444 DI 10.1176/appi.ps.59.4.441 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 282OW UT WOS:000254578100019 PM 18378846 ER PT J AU Rasmussen, DD Crites, NJ Burke, BL AF Rasmussen, Dennis D. Crites, Norman J. Burke, Brianna L. TI Acoustic startle amplitude predicts vulnerability to develop post-traumatic stress hyper-responsivity and associated plasma corticosterone changes in rats SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE PTSD; trauma; startle; corticosterone; vulnerability; risk factors ID CORTICOTROPIN-RELEASING-FACTOR; FEAR-POTENTIATED STARTLE; LIGHT-ENHANCED STARTLE; STRIA TERMINALIS; ANIMAL-MODEL; BED NUCLEUS; SITUATIONAL REMINDERS; HPA AXIS; DISORDER; ANXIETY AB Following exposure to trauma, a vulnerable sub-population of individuals develops post-traumatic stress disorder (PTSD) with characteristic persistent autonomic hyper-responsivity, associated increased startle response, and commonly altered hypothalamopituitary-adrenal regulation. A goal of this investigation was to identify a predictive marker for this vulnerability. Previous investigators have developed a model for PTSD in which male mice were exposed to a single brief episode of inescapable footshock followed by 1-min contextual reminders of this trauma at weekly intervals for 6 weeks. Exposure to these reminders induced a progressive and persistent increase in the amplitude of acoustic startle consistent with the persistently increased acoustic startle of individuals exhibiting PTSD. We adapted this model to adult male Wistar rats, with added characterization of initial (pre-trauma) startle response. After one episode of inescapable footshock (10s, 2mA) or control treatment followed by six weekly 1-min contextual reminders, acoustic startle was re-tested. Data were analyzed after dividing rats within each treatment into LOW vs MID vs HIGH (33% in each group) pre-treatment startle responders. Rats which exhibited pre-treatment LOW- and MID-range acoustic startle responses did not develop increased acoustic startle responses following subsequent traumatic stress+reminders ([TS+R]) treatment. However, rats which exhibited HIGH pre-treatment startle responses exhibited further significant (p<0.01) [TS+R]induced persistent enhancement of this already elevated startle response. Furthermore, rats exhibiting HIGH pre-treatment startle responses were also the only subgroup which exhibited increased basal plasma corticosterone levels following [TS+R] treatment. These results suggest that initial pre-stress acoustic startle response can identify subgroups of rats which are predisposed to, or resistant to, developing a PTSD-like syndrome following subsequent trauma. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle, WA 98108 USA. [Rasmussen, Dennis D.; Crites, Norman J.; Burke, Brianna L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. RP Rasmussen, DD (reprint author), VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, 116 MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM drasmuss@u.washington.edu FU NIAAA NIH HHS [AA013881, R01 AA010567, R01 AA013881-04, R01 AA010567-09, R01 AA013881, AA10567] NR 40 TC 24 Z9 25 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD APR PY 2008 VL 33 IS 3 BP 282 EP 291 DI 10.1016/j.psyneuen.2007.11.010 PG 10 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 282LD UT WOS:000254568400003 PM 18164825 ER PT J AU Primack, BA Land, SR Fine, MJ AF Primack, Brian A. Land, Stephanie R. Fine, Michael J. TI Adolescent smoking and volume of exposure to various forms of media SO PUBLIC HEALTH LA English DT Article DE tobacco; smoking prevention; adolescent health; mass media; television; films; music; school health ID TOBACCO INDUSTRY; MUSIC VIDEOS; ALCOHOL-USE; TELEVISION; INITIATION; OBESITY; PROMOTION; CHILDREN; CIGARETTES; MOVIES AB Objective: To assess the association between adolescent smoking and volume Tobacco; of exposure to various forms of media after controlling for multiple relevant covariates. Methods: A survey of all adolescents at a large suburban high school assessed: (1) current smoking and susceptibility to future smoking; (2) volume of exposure to various media; and (3) covariates related to smoking. Multivariate logistic regression models assessed relationships between each of the independent variables (media exposures) and the two smoking outcomes after controlling for covariates. Results: Of the 1111 respondents, 11% (n = 211) reported current smoking. Forty percent (n = 342) of the non-smokers (n = 922) were susceptible to future smoking. Students reported exposure to an average of 8.6 (standard deviation 5.1) h of media daily, including 2.6 h of music. Those with high exposure to films and music were more Likely to be smokers (P-trend = 0.036 and P-trend<0.001, respectively), and those with high exposure to books were less likely to be smokers (P-trend<0.001). After controlling for all relevant covariates, those with high exposure to music had greater odds of being smokers than those with low exposure [odds ratio (OR) 1.90, 95% confidence intervals (CI) 1.10-3.30], and those with high exposure to books had lower odds of being current smokers (OR 0.55, 95% CI 0.33-0.94). Conclusion: Exposure to films and music are associated with smoking, but only the relationship between music exposure and smoking persists after rigorous covariate control. Exposure to books is associated with tower odds of smoking. (C) 2008 The Royal Institute of Public Health. Published by Elsevier Ltd. All rights reserved. C1 [Primack, Brian A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Primack, Brian A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Land, Stephanie R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Fine, Michael J.] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Primack, Brian A.] Univ Pittsburgh, Sch Med, Div Adolescent Med, Pittsburgh, PA 15213 USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, 230 McKee Pl Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu FU NCI NIH HHS [K07 CA114315, 1K07-CA114315, K07 CA114315-02]; NIAID NIH HHS [5K24-AI01769, K24 AI001769] NR 37 TC 12 Z9 12 U1 1 U2 8 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0033-3506 J9 PUBLIC HEALTH JI Public Health PD APR PY 2008 VL 122 IS 4 BP 379 EP 389 DI 10.1016/j.puhe.2007.07.022 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 286BA UT WOS:000254819000007 PM 18206196 ER PT J AU Williams, DL Goldstein, G Kojkowski, N Minshew, NJ AF Williams, Diane L. Goldstein, Gerald Kojkowski, Nicole Minshew, Nancy J. TI Do individuals with high functioning autism have the IQ profile associated with nonverbal learning disability? SO RESEARCH IN AUTISM SPECTRUM DISORDERS LA English DT Article DE Autism; Nonverbal learning disability; Asperger syndrome; Wechsler intelligence scales ID PHONOLOGICAL PROCESSING DISABILITIES; DIAGNOSTIC OBSERVATION SCHEDULE; ASPERGER-SYNDROME; RIGHT-HEMISPHERE; CHILDREN; CLASSIFICATION; INTERVIEW; LANGUAGE; VALIDITY; SPECTRUM AB Previously researchers have noted a high level of occurrence of the IQ profile associated with nonverbal learning disability (NLD) in Asperger syndrome (ASP) but not in high functioning autism (HFA). We examined the IQ profile scores of a large sample of children (n = 69) and adults (n = 77) with HFA. stringently diagnosed according to ADOS, ADI-R. and DSM-IV criteria. and a corresponding sample of typical child (it = 72) and adult controls (it = 107). At least one of the three primary components of the Wechsler pattern seen in NLD were found in 17-26% of the children and 20-32% of the adults with HFA. All three components occurred in slightly more than 5% of the children and adults with autism. Overall, the VIQ > PIQ profile seen in NLD occurred in 18% of the sample of individuals stringently diagnosed with HFA. Therefore, obtaining this IQ profile is not a valid clinical discriminator between NLD and HFA. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Williams, Diane L.] Duquesne Univ, Rangos Sch Hlth Sci, Dept Speech Language Pathol, Pittsburgh, PA 15282 USA. [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA. RP Williams, DL (reprint author), Duquesne Univ, Rangos Sch Hlth Sci, Dept Speech Language Pathol, 600 Forbes Ave, Pittsburgh, PA 15282 USA. EM williamsd2139@duq.edu RI Williams, Diane/B-4128-2017 FU NICHD NIH HHS [U19 HD035469, U19 HD035469-06, U19 HD035469-07, U19 HD035469-08, P50 HD055748, U19 HD035469-09, U19 HD035469-10]; NIDCD NIH HHS [K23 DC006691, K23 DC006691-01, K23 DC006691-04] NR 37 TC 27 Z9 29 U1 3 U2 19 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1750-9467 J9 RES AUTISM SPECT DIS JI Res. Autism Spectr. Disord. PD APR-JUN PY 2008 VL 2 IS 2 BP 353 EP 361 DI 10.1016/j.rasd.2007.08.005 PG 9 WC Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation SC Education & Educational Research; Psychology; Psychiatry; Rehabilitation GA 408DJ UT WOS:000263413800014 PM 18516234 ER PT J AU Siegel, RE AF Siegel, Robert E. TI Emerging gram-negative antibiotic resistance: Daunting challenges, declining sensitivities, and dire consequences SO RESPIRATORY CARE LA English DT Review DE antibiotics; multidrug resistance; Gram-negative pathogens; Pseudomonas aeruginosa; Acinetobacter baumannii; extended-spectrum beta lactamases; carbapenems; de-escalation ID VENTILATOR-ASSOCIATED PNEUMONIA; SPECTRUM BETA-LACTAMASES; COMMUNITY-ACQUIRED PNEUMONIA; FEBRILE NEUTROPENIC PATIENTS; III SECRETION SYSTEM; CARE-UNIT PATIENTS; PSEUDOMONAS-AERUGINOSA; ACINETOBACTER-BAUMANNII; KLEBSIELLA-PNEUMONIAE; NEW-YORK AB Emerging antibiotic resistance has created a major public health dilemma, compounded by a dearth of new antibiotic options. Multidrug-resistant Gram-negative organisms have received less attention than Gram-positive threats, such as methicillin-resistant Staphylococcus aureus, but are just as menacing. Pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii employ a variety of resistance mechanisms and are associated with dangerous nosocomial outbreaks. In some cases these pathogens have expressed resistance to all clinically available compounds. The emergence of extended-spectrum beta-lactamase-producing organisms in the community has raised alarm. Furthermore, the carbapenems, currently the most successful class of antibiotics, are showing signs of vulnerability. While the search for new antibiotic options continues, there is urgent need to employ strategies that will slow the development of resistance to the current armamentarium, such as avoiding prolonged antibiotic use or tinder-dosing, using pharmacokinetic and pharmacodynamic principles to choose dosing regimens, and encouraging early and aggressive empirical therapy, followed by de-escalation and narrowing the antimicrobial spectrum when culture results become available. C1 [Siegel, Robert E.] James J Peters Vet Affaors Med Ctr, Dept Pulm & Crit Care Med, Bronx, NY 10468 USA. [Siegel, Robert E.] Mt Sinai Sch Med, Bronx, NY USA. RP Siegel, RE (reprint author), James J Peters Vet Affaors Med Ctr, Dept Pulm & Crit Care Med, 130 Kingsbridge Rd, Bronx, NY 10468 USA. EM robert.siegel@va.gov NR 62 TC 57 Z9 58 U1 1 U2 4 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD APR PY 2008 VL 53 IS 4 BP 471 EP 479 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 285DW UT WOS:000254758500009 PM 18364060 ER PT J AU Goldberger, ZD AF Goldberger, Zachary D. TI Severe hypothermia with Osborn waves in diabetic ketoacidosis SO RESPIRATORY CARE LA English DT Article ID CLINICAL-SIGNIFICANCE; LIPASE AB Diabetic ketoacidosis causes substantial morbidity and mortality.(1) Though the management of acute diabetic ketoacidosis centers on correcting hyperglycemia and electrolyte abnormalities, other important metabolic derangements may be seen. Specifically, hypothermia may be both a cause and consequence of diabetic ketoacidosis, and the severity of the hypothermia correlates with the severity of the illness. The case presented below highlights a presentation of severe diabetic ketoacidosis associated with hypothermia, which caused distinctive changes (Osborn waves) on the electrocardiogram (ECG). In the setting of diabetic ketoacidosis the recognition of ECG changes characteristic of hypothermia will help guide management and avoid the misdiagnosis of an ST-segment elevation myocardial infarction. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Dept Internal Med, Seattle, WA USA. RP Goldberger, ZD (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Internal Med, 1660 S Columbian Way,Box S-111-CHF, Seattle, WA USA. EM zgoldber@u.washington.edu NR 12 TC 5 Z9 5 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD APR PY 2008 VL 53 IS 4 BP 500 EP 502 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 285DW UT WOS:000254758500012 PM 18364063 ER PT J AU Tashkin, DP Littner, M Andrews, CP Tomlinson, L Rinehart, M Denis-Mize, K AF Tashkin, Donald P. Littner, Michael Andrews, Charles P. Tomlinson, LaTanya Rinehart, Mike Denis-Mize, Kimberly TI Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial SO RESPIRATORY MEDICINE LA English DT Article DE formoterol; tiotropium; COPD; long-acting; beta(2)-agonist; nebulization ID OBSTRUCTIVE PULMONARY-DISEASE; STABLE COPD; MULTICENTER TRIAL; DRY POWDER; COMBINATION; DYSPNEA; SAFETY; EFFICACY; HYPERINFLATION; THEOPHYLLINE AB Adding a long-acting beta(2)-agonist (LABA) by dry powder inhaler (DPI) to tiotropium provides significantly increased and sustained bronchodilation in chronic obstructive pulmonary disease (COPD) patients over either product alone. To demonstrate similar benefits with a nebulized LABA, a placebo-controlled trial was conducted to evaluate the efficacy and safety of formoterol fumarate inhalation solution in subjects receiving tiotropium as a maintenance treatment for COPD. After a 7-14-day screening period using tiotropium 18 mu g once daily, subjects with diagnosed COPD (>= 25% to <65% predicted FEV1) were randomized to receive 20 mu g formoterol fumarate inhalation solution twice daily for nebulization plus tiotropium (FFIS/TIO) or nebulized placebo twice daily plus tiotropium (PLA/TIO) for 6 weeks. Efficacy was assessed with spirometry at each visit (Day 1, Week 1, 3, 6), the transition dyspnea index (TDI), and St. George's Respiratory Questionnaire (SGRQ). Baseline characteristics were comparable, including mean FEV1% predicted. At Week 6, FEV1 AUC(0-3) was 1.52L for FFIS/TIO-treated subjects vs. 1.34L for PLA/TIO-treated subjects (p<0.0001). The mean TDI scores in the FFIS/TIO and PLA/TIO groups were 2.30 and 0.16, respectively (p = 0.0002). SGRQ did not change significantly with 6 weeks treatment, with the exception of FFIS/TIO improvements in symptom score vs. PLA/TIO (p = 0.04). More PLA/TIO- than. FFIS/TIO-treated subjects experienced AEs (39.7% vs. 22.9%), COPD exacerbations (7.9% vs. 4.5%), and serious AEs (3.2% vs. 1.5%). C1 [Tashkin, Donald P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Littner, Michael] VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. [Andrews, Charles P.] Diagnost Res Grp, San Antonio, TX 78229 USA. [Tomlinson, LaTanya; Rinehart, Mike; Denis-Mize, Kimberly] Dey LP, Napa, CA 94558 USA. RP Tashkin, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, 10833 LeConte Ave,CHS 32-176, Los Angeles, CA 90095 USA. EM dtashkin@mednet.ucla.edu OI Andrews, Charles/0000-0002-8944-8404 NR 34 TC 60 Z9 65 U1 0 U2 2 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD APR PY 2008 VL 102 IS 4 BP 479 EP 487 DI 10.1016/j.rmed.2007.12.019 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 278QV UT WOS:000254302300001 PM 18258423 ER PT J AU Hazlett, EA Buchsbaum, MS Haznedar, MM Newmark, R Goldstein, KE Zelmanova, Y Glanton, CF Torosjan, Y New, AS Lo, JN Mitropoulou, V Siever, LJ AF Hazlett, Erin A. Buchsbaum, Monte S. Haznedar, M. Mehmet Newmark, Randall Goldstein, Kim E. Zelmanova, Yuliya Glanton, Cathryn F. Torosjan, Yuliya New, Antonia S. Lo, Jennifer N. Mitropoulou, Vivian Siever, Larry J. TI Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients SO SCHIZOPHRENIA RESEARCH LA English DT Article DE MRI; schizophrenia; schizotypal personality disorder; frontal lobe volume; temporal lobe volume; cingulate gyrus; negative symptoms; gray matter volume; white matter volume ID CINGULATE GYRUS VOLUME; PERSONALITY-DISORDER; VULNERABILITY INDICATOR; INDIVIDUAL-DIFFERENCES; PARAHIPPOCAMPAL GYRUS; SPECTRUM DISORDERS; VENTRICULAR VOLUME; GLUCOSE-METABOLISM; MRI ABNORMALITIES; PLANUM TEMPORALE AB Magnetic resonance imaging (MRI) studies have revealed fronto-temporal cortical gray matter volume reductions in schizophrenia. However, to date studies have not examined whether age- and sex-matched unmedicated schizotypal personality disorder (SPD) patients share some or all of the structural brain-imaging characteristics of schizophrenia patients. We examined cortical gray/white matter volumes in a large sample of unmedicated schizophrenia-spectrum patients (n = 79 SPD, n = 57 schizophrenia) and 148 healthy controls. MRI images were reoriented to standard position parallel to the anterior-posterior commissure line, segmented into gray and white matter tissue types, and assigned to Brodmann areas (BAs) using a postmortem-histological atlas. Group differences in regional volume of gray and white matter in the BAs were examined with MANOVA. Schizophrenia patients had significantly reduced gray matter volume widely across the cortex but more marked in frontal and temporal lobes. SPD patients had reductions in the same regions but only about half that observed in schizophrenia and sparing in key regions including BA10. In schizophrenia, greater fronto-temporal volume loss was associated with greater negative symptom severity and in SPD, greater interpersonal and cognitive impairment. Overall, our findings suggest that increased prefrontal volume in BA10 and sparing of volume loss in temporal cortex (BAs 22 and 20) may be a protective factor in SPD which reduces vulnerability to psychosis. Published by Elsevier B.V. C1 [Hazlett, Erin A.; Buchsbaum, Monte S.; Haznedar, M. Mehmet; Newmark, Randall; Goldstein, Kim E.; Zelmanova, Yuliya; Glanton, Cathryn F.; Torosjan, Yuliya; New, Antonia S.; Lo, Jennifer N.; Mitropoulou, Vivian; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [New, Antonia S.; Siever, Larry J.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. RP Hazlett, EA (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1505, New York, NY 10029 USA. EM erin.hazlett@mssm.edu FU NCRR NIH HHS [M01 RR000071, M01-RR00071]; NIMH NIH HHS [MH56489, R01 MH073911, R01 MH056489-02, R01 MH040071, R01 MH056606-03, MH073911, MH56606, R01 MH060023-05, R01 MH056606, R01 MH065554, R01 MH040071-06A2, R01 MH073911-02, R01 MH060023, MH60023, R01 MH056489, MH40071] NR 51 TC 64 Z9 65 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2008 VL 101 IS 1-3 BP 111 EP 123 DI 10.1016/j.schres.2007.12.472 PG 13 WC Psychiatry SC Psychiatry GA 305XX UT WOS:000256212200013 PM 18272348 ER PT J AU Wang, F Xiu, MH Cao, LY Zhang, XY AF Wang, Fan Xiu, Mei Hong Cao, Lian Yuan Zhang, Xiang Yang TI The CCR5 32-bp deletion allele is rare in a Chinese population SO SCHIZOPHRENIA RESEARCH LA English DT Letter ID SCHIZOPHRENIA C1 [Wang, Fan; Xiu, Mei Hong; Cao, Lian Yuan; Zhang, Xiang Yang] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, VA Med Ctr, Houston, TX 77030 USA. RP Zhang, XY (reprint author), Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. EM xyzhang@bcm.edu FU NIDA NIH HHS [K05-DA0454, P50-DA18827] NR 6 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2008 VL 101 IS 1-3 BP 341 EP 343 DI 10.1016/j.schres.2008.01.015 PG 3 WC Psychiatry SC Psychiatry GA 305XX UT WOS:000256212200039 PM 18295459 ER PT J AU Madan, V Brennan, FX Mann, GL Horball, AA Dunn, GA Ross, RJ Morrison, AR AF Madan, Vibha Brennan, Francis X. Mann, Graziella L. Horball, Apryle A. Dunn, Gregory A. Ross, Richard J. Morrison, Adrian R. TI Long-term effect of cued fear conditioning on REM sleep microarchitecture in rats SO SLEEP LA English DT Article DE anxiety; freezing; muscle twitches; fear conditioning; PTSD; REM sleep ID POSTTRAUMATIC-STRESS-DISORDER; CONTEXTUAL FEAR; BALB/CJ MICE; AMYGDALA; DISTURBANCE; NUCLEUS; PATTERN; MEMORY AB Study Objectives: To study long-term effects of conditioned fear on REM sleep (REMS) parameters in albino rats. Design: We have investigated disturbances in sleep architecture, including muscle twitch density as REMS phasic activity, and freezing behavior in wakefulness, upon reexposure to a conditioned stimulus (CS) on Day 1 and Day 14 postconditioning. Subjects: Male Sprague-Dawley rats prepared for polysomnographic recordings. Interventions: After baseline sleep recording, the animals in the experimental group received five pairings of a 5-sec tone, co-terminating with a 1-sec, 1 mA footshock. The control rats received similar numbers of tones and shocks, but explicitly unpaired. On postconditioning days, after reexposure to tones alone, sleep and freezing behavior were recorded. Measurements and Results: Conditioned fear significantly altered REMS microarchitecture (characterized as sequential-REMS -[seq-REMS: <= 3 min episode separation] and single-REMS [sin-REMS: >3 min episode separation]) on Day 14. The total amount and number of seq-REMS episodes decreased, while the total amount and number of sin-REMS episodes increased. Further, the CS induced significant increases in freezing and REMS myoclonic twitch density in the experimental group. Reexposure to the CS produced no alterations in controls. Conclusions: The results suggest that conditioned fear causes REMS alterations, including difficulty in initiating a REMS episode as indicated by the diminution in the number of seq-REMS episodes. Another finding, the increase in phasic activity, agrees with the inference from clinical investigations that retrieval of fearful memories can be associated with the long-term REMS disturbances characteristic of posttraumatic stress disorder. C1 [Madan, Vibha; Brennan, Francis X.; Mann, Graziella L.; Horball, Apryle A.; Dunn, Gregory A.; Ross, Richard J.; Morrison, Adrian R.] Univ Penn, Sch Vet Med, Dept Anim Biol, Lab Study Brain Sleep, Philadelphia, PA 19104 USA. [Brennan, Francis X.; Ross, Richard J.; Morrison, Adrian R.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Brennan, Francis X.; Ross, Richard J.] Vet Affairs Med Ctr, Philadelphia, PA USA. RP Morrison, AR (reprint author), Univ Penn, Sch Vet Med, Dept Anim Biol, Lab Study Brain Sleep, 3800 Spruce St, Philadelphia, PA 19104 USA. EM armsleep@vet.upenn.edu FU NIMH NIH HHS [R01 MH072897, R01-MH072897] NR 29 TC 18 Z9 19 U1 2 U2 5 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD APR 1 PY 2008 VL 31 IS 4 BP 497 EP 503 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 287SI UT WOS:000254936400009 PM 18457237 ER PT J AU Albo, D Farrow, B Berger, DH AF Albo, Daniel Farrow, Buckminster Berger, David H. TI Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer SO SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; PHASE-I TRIAL; ADVANCED SOLID TUMORS; MATRIX-METALLOPROTEINASE INHIBITOR; PROTEIN TRANSFERASE INHIBITOR; SMALL-CELL LUNG; MONOCLONAL-ANTIBODY; FACTOR RECEPTOR; RANDOMIZED-TRIAL; PEPTIDE VACCINATION AB Recent advances in understanding the molecular mechanisms of cancer progression have allowed for targeted approaches to the diagnosis and treatment of pancreatic cancer. New biologic markers are emerging that may improve the ability to detect these tumors earlier. Targeted biologic cancer therapies promise more effective and less toxic systemic treatment options. Although a clear "magic bullet" has yet to emerge, this type of targeted approach offers hope in the management of this dreadful disease. This article offers an update on these promising diagnostic and treatment modalities. C1 [Albo, Daniel; Farrow, Buckminster; Berger, David H.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. RP Albo, D (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112A, Houston, TX 77030 USA. EM dalbo@bcm.tmc.edu NR 82 TC 1 Z9 1 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1055-3207 J9 SURG ONCOL CLIN N AM JI Surg. Oncol. Clin. N. Am. PD APR PY 2008 VL 17 IS 2 BP 357 EP + DI 10.1016/j.soc.2007.12.004 PG 21 WC Oncology; Surgery SC Oncology; Surgery GA 294QL UT WOS:000255420500008 PM 18375357 ER PT J AU Shen, KZ Johnson, SW AF Shen, Ke-Zhong Johnson, Steven W. TI Complex EPSCs evoked in substantia nigra reticulata neurons are disrupted by repetitive stimulation of the subthalamic nucleus SO SYNAPSE LA English DT Article DE subthalamic nucleus; substantia nigra reticulata; patch clamp; synaptic transmission; brain slice; complex EPSC; high-frequency stimulation; low-frequency stimulation ID HIGH-FREQUENCY STIMULATION; DEEP BRAIN-STIMULATION; PARS-RETICULATA; PARKINSONS-DISEASE; GLOBUS-PALLIDUS; BASAL GANGLIA; RAT; RECEPTORS; TRANSMISSION; ACTIVATION AB Although substantia nigra reticulata (SNR) neurons fire bursts of action potentials during normal movement, excessive burst firing correlates with symptoms of Parkinson's disease. A major excitatory output from the subthalamic nucleus (STN) to the SNR is thought to provide the synaptic impetus for burst firing in SNR neurons. Using patch pipettes to record from SNR neurons in rat brain slices, we found that a single electrical stimulus delivered to the STN evokes a burst of action potentials. Under voltage-clamp conditions, STN stimulation evokes a complex EPSC that is comprised of an initial monosynaptic EPSC followed by a series of late EPSCs superimposed on a long-lasting inward current. Using varied stimulation frequencies, we found that the initial EPSC was significantly reduced or abolished after 2 s of 50-100 Hz STN stimulation. However, only 4 s of 1 Hz stimulation was required to abolish the late component of the complex EPSC. We suggest that differential effects of repetitive STN stimulation on early and late components of complex EPSCS may help explain the frequency-dependent effects of deep brain stimulation of the STN that is used in the treatment of Parkinson's disease. C1 [Shen, Ke-Zhong; Johnson, Steven W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Johnson, Steven W.] Vet Affairs Med Ctr, Portland, OR 97207 USA. RP Johnson, SW (reprint author), Portland VA Med Ctr, R&D 61,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM johnsost@ohsu.edu FU NINDS NIH HHS [R01 NS038715-09, NS 38175, R01 NS060662-01A1, R01 NS038715, R01 NS038175, R01 NS060662] NR 26 TC 10 Z9 10 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0887-4476 J9 SYNAPSE JI Synapse PD APR PY 2008 VL 62 IS 4 BP 237 EP 242 DI 10.1002/syn.20488 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 274ZB UT WOS:000254040200001 PM 18236470 ER PT J AU Krupinski, E Burdick, A Pak, H Bocachica, J Earles, L Edison, K Goldyne, M Hirota, T Kvedar, J Mckoy, K Oh, D Siegel, D Antoniotti, N Camacho, I Carnahan, L Boynton, P Bakalar, R Evans, R Kinel, A Kuzmak, P Madden, BC Peters, S Rosenthal, L Simmons, S Bernard, J Linkous, J AF Krupinski, Elizabeth Burdick, Anne Pak, Hon Bocachica, John Earles, Lucius Edison, Karen Goldyne, Marc Hirota, Tom Kvedar, Joseph Mckoy, Karen Oh, Dennis Siegel, Dan Antoniotti, Nina Camacho, Ivan Carnahan, Lisa Boynton, Paul Bakalar, Richard Evans, Richard Kinel, Al Kuzmak, Peter Madden, Brian C. Peters, Sandra Rosenthal, Lynne Simmons, Scott Bernard, Jordana Linkous, Jonathan TI American telemedicine association's practice guidelines for teledermatology SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; COST-MINIMIZATION ANALYSIS; REALTIME TELEDERMATOLOGY; FORWARD TELEDERMATOLOGY; MULTICENTER TELEDERMATOLOGY; DERMATOLOGY REFERRALS; PATIENT SATISFACTION; DIAGNOSTIC-ACCURACY; CONVENTIONAL CARE; NORTHERN-IRELAND AB The American Telemedicine Association ( ATA), with more than 2,500 members, is the principal organization of telemedicine practitioners in the United States. The ATA is a nonprofit society that seeks to bring together diverse groups from traditional medicine, nursing, allied health professionals, academic medical centers, technology and telecommunications companies, e- health, medical societies, government and others to overcome barriers to the advancement of telemedicine through the professional, ethical, and equitable improvement in healthcare delivery. The ATA has strong ties and strategic relationships with host organizations with other international telemedicine societies. The ATA will occasionally define new practice guidelines and technical standards for telehealth practice to help advance the science of telehealth and to improve the quality of service to patients. Existing practice guidelines and technical standards will be reviewed for revision or renewal periodically. The practice guidelines and technical standards generated by ATA have undergone a thorough consensus and rigorous review, with final approval by the ATA Board of Directors. The practice guidelines and technical standards recognize that safe and effective telehealth practices require specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guidelines and technical standard by entities that do not provide these services is not authorized. C1 [Krupinski, Elizabeth] Univ Arizona, Dept Radiol Res, Arizona Telemed Program, Tucson, AZ 85724 USA. [Burdick, Anne; Simmons, Scott] Univ Miami, Miller Sch Med, Miami, FL 33152 USA. [Pak, Hon] Telemed & Adv Technol Res Ctr, Adv Informat Technol Grp, Ft Detrick, MD USA. [Bocachica, John] Dept Dermatol & Teledermatol Alaska Fed Hlth Care, Anchorage, AK USA. [Earles, Lucius] Mt Sinai Hosp, Dermatol Sect, Dept Med, Chicago, IL USA. [Edison, Karen] Univ Missouri Hlth Care, Dept Dermatol, Columbia, MO USA. [Goldyne, Marc; Oh, Dennis] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Hirota, Tom] Uniformed Serv Univ Hlth Sci, Dermatol Serv, Madigan Army Med Ctr, Bethesda, MD 20814 USA. [Hirota, Tom] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Dermatol, Bethesda, MD 20814 USA. [Kvedar, Joseph] Harvard Univ, Sch Med, Dept Dermatol, Ctr Connected Hlth Partners HealthCare Syst Inc, Boston, MA 02115 USA. [Mckoy, Karen] Lahey Clin Fdn, Dept Dermatol, Burlington, MA USA. [Mckoy, Karen] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Oh, Dennis] Dermatol Serv, San Francisco VA Med Ctr, San Francisco, CA USA. [Siegel, Dan] Suny Downstate Med Ctr, Dept Dermatol, Brooklyn, NY 11203 USA. [Antoniotti, Nina] Marshfield Clin TeleHlth Network, Marshfield, WI USA. [Camacho, Ivan] Univ Miami, Dept Dermatol & Cutaneous Surg, Miami, FL 33152 USA. [Carnahan, Lisa; Boynton, Paul; Rosenthal, Lynne] Informat Technol Lab Natl Inst Stand & Technol, Gaithersburg, MD USA. [Bakalar, Richard] IBM Corp, IBM Global Healthcare, Armonk, NY 10504 USA. [Kinel, Al] Alliances Kodak Corp, Rochester, NY USA. [Kuzmak, Peter] Dept Vet Affairs VistA Imaging Project, Silver Spring, MD USA. [Madden, Brian C.] Univ Rochester, VISN Telemed Dept Vet Affairs 2, Rochester, NY USA. [Madden, Brian C.] Univ Rochester, Dept Dermatol, Rochester, NY 14627 USA. [Peters, Sandra] Amer Acad Dermatol, Washington, DC USA. [Bernard, Jordana; Linkous, Jonathan] Amer Telemed Assoc, Washington, DC USA. [Evans, Richard] Utah TeleHlth Network, Salt Lake City, UT USA. RP Krupinski, E (reprint author), Univ Arizona, Dept Radiol Res, Arizona Telemed Program, 1609 N Warren Bldg 211,Room 112, Tucson, AZ 85724 USA. EM krupinski@radiology.arizona.edu NR 58 TC 33 Z9 33 U1 1 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD APR PY 2008 VL 14 IS 3 BP 289 EP 302 DI 10.1089/tmj.2007.0129 PG 14 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 300KY UT WOS:000255823900043 PM 18570555 ER PT J AU Dransfield, MT Rowe, SM Johnson, JE Bailey, WC Gerald, LB AF Dransfield, M. T. Rowe, S. M. Johnson, J. E. Bailey, W. C. Gerald, L. B. TI Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD SO THORAX LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; MYOCARDIAL-INFARCTION; HEART-FAILURE; MORTALITY; MORBIDITY; CORONARY; INTERVENTION; EPIDEMIOLOGY; MANAGEMENT; REDUCTION AB Background: Cardiovascular disease is a major cause of death in patients with chronic obstructive pulmonary disease (COPD) and predicts hospitalisation for acute exacerbation, in-hospital death and post-discharge mortality. Although beta blockers improve cardiovascular outcomes, patients with COPD often do not receive them owing to concerns about possible adverse pulmonary effects. There are no published data about b blocker use among inpatients with COPD exacerbations. A study was undertaken to identify factors associated with b blocker use in this setting and to determine whether their use is associated with decreased in-hospital mortality. Methods: Administrative data from the University of Alabama Hospital were reviewed and patients admitted between October 1999 and September 2006 with an acute exacerbation of COPD as a primary diagnosis or as a secondary diagnosis with a primary diagnosis of acute respiratory failure were identified. Demographic data, comorbidities and medication use were recorded and subjects receiving beta blockers were compared with those who did not. Multivariate regression analysis was performed to determine predictors of in-hospital death after controlling for known covariates and the propensity to receive beta blockers. Results: 825 patients met the inclusion criteria. Inhospital mortality was 5.2%. Those receiving beta blockers (n = 142) were older and more frequently had cardiovascular disease than those who did not. In multivariate analysis adjusting for potential confounders including the propensity score, beta blocker use was associated with reduced mortality (OR = 0.39; 95% CI 0.14 to 0.99). Age, length of stay, number of prior exacerbations, the presence of respiratory failure, congestive heart failure, cerebrovascular disease or liver disease also predicted in-hospital mortality (p<0.05). Conclusions: The use of beta blockers by inpatients with exacerbations of COPD is well tolerated and may be associated with reduced mortality. The potential protective effect of beta blockers in this population warrants further study. C1 [Dransfield, M. T.; Rowe, S. M.; Johnson, J. E.; Bailey, W. C.; Gerald, L. B.] Univ Alabama, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Dransfield, M. T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Dransfield, MT (reprint author), 215 THT,1900 Univ Blvd, Birmingham, AL 35294 USA. EM mdransfield99@msn.com FU NIDDK NIH HHS [K23 DK075788-01] NR 38 TC 90 Z9 96 U1 1 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 J9 THORAX JI Thorax PD APR PY 2008 VL 63 IS 4 BP 301 EP 305 DI 10.1136/thx.2007.081893 PG 5 WC Respiratory System SC Respiratory System GA 278MF UT WOS:000254289500004 PM 17951276 ER PT J AU Lu, TC He, JC Wang, ZH Feng, X Fukumi-Tominaga, T Chen, N Xu, J Iyengar, R Klotman, PE AF Lu, Ting-chi He, John Cijiang Wang, Zhao-hui Feng, Xiaobei Fukumi-Tominaga, Tomoko Chen, Nan Xu, Jin Iyengar, Ravi Klotman, Paul E. TI HIV-1 nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SIGNALING PATHWAY; RHO ACTIVITY; NEPHROPATHY; ACTIVATION; TYPE-1; INFECTION; RAC; ORGANIZATION; DISEASE; AIDS AB The ability of the human immunodeficiency virus, type 1 (HIV-1) protein Nef to induce cytoskeleton changes in infected host cells is a key event in viral replication. In renal podocytes, we found that Nef induced loss of stress fibers and increased lamellipodia, pathological changes leading to proteinuria in HIV-associated nephropathy. These morphological changes were mediated by Nef-induced Rac1 activation and RhoA inhibition. We identified a new interaction between Nef and diaphanous interacting protein (DIP), a recently described regulator of Rho and Rac signaling. We found that the Src homology 3 binding domain of DIP and the Nef PXXP motif were required for this interaction. Nef also interacts with Vav2 in podocytes. DIP and Vav2 both interact directly with Nef in a competitive manner. DIP interacts with p190RhoGAP, and intact DIP was required for Nef-induced phosphorylation of p190RhoGAP. DIP also interacts with Vav2, and although DIP enhanced baseline phosphorylation of Vav2, it was not required for Nef- induced Vav2 activation. In Nef- infected podocytes, Src kinase induces phosphorylation of DIP, p190RhoGAP, and Vav2, leading to RhoA inhibition and Rac1 activation. Inhibition of the Nef- induced signaling pathway by using a dominant negative of either Src or DIP or siRNA for DIP or p190RhoAGAP restored RhoA activity and stress fiber formation in Nef- infected podocytes, whereas siRNA for Vav2 reduced Rac1 activity and formation of lamellipodia. We conclude that in HIV-infected podocytes, Nef, through the recruitment of DIP and p190RhoAGAP to Nef- Src complex, activates p190RhoAGAP and down-regulates RhoA activity. C1 [Lu, Ting-chi; He, John Cijiang; Wang, Zhao-hui; Feng, Xiaobei; Klotman, Paul E.] Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY 10029 USA. [Iyengar, Ravi] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [He, John Cijiang] James J Peters Vet Affair Med Ctr, Bronx, NY 10468 USA. [Wang, Zhao-hui; Feng, Xiaobei; Chen, Nan] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Nephrol, Shanghai 200025, Peoples R China. [Fukumi-Tominaga, Tomoko] Natl Inst Nat Sci, Natl Inst Physiol Sci, Sect Cell Signalling, Okazaki, Aichi 4448585, Japan. RP He, JC (reprint author), Mt Sinai Sch Med, Div Nephrol, Dept Med, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA. EM Cijiang.he@mssm.edu FU NIDDK NIH HHS [P01 DK 056492, R01 DK 078897, K08 DK 079781, K08 DK 065495]; NIGMS NIH HHS [R01 GM054508, R01 GM 54508] NR 47 TC 52 Z9 54 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 28 PY 2008 VL 283 IS 13 BP 8173 EP 8182 DI 10.1074/jbc.M708920200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 278LT UT WOS:000254288000014 PM 18234668 ER PT J AU Hoschneider, DP Scremin, OU Chialvo, DR Kay, BP Maarek, JMI AF Hoschneider, D. P. Scremin, O. U. Chialvo, D. R. Kay, B. P. Maarek, J. M. I. TI Flattened cortical maps of cerebral function in the rat: A region-of-interest approach to data sampling, analysis and display SO NEUROSCIENCE LETTERS LA English DT Article DE cerebral cortex; rats; brain mapping; topographic maps; software ID STEREOTAXIC SURGERY; VARIABILITY; BREGMA; CORTEX AB We describe a method for the measurement, analysis and display of cerebral cortical data obtained from coronal brain sections of the adult rat. In this method, regions-of-interest (ROI) are selected in the cortical mantle in a semiautomated fashion using a radial grid overlay, spaced in 15 degrees intervals from the midline. ROI measurements of intensity are mapped on a flattened two-dimensional surface. Topographic maps of statistical significance at each ROI allow for the rapid viewing of group differences. Cortical z-scores are displayed with the boundaries of brain regions defined according to a standard atlas of the rat brain. This method and accompanying software implementation (Matlab, Labview) allow for compact data display in a variety of autoradiographic and histologic studies of the structure and function of the rat brain. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Hoschneider, D. P.] Univ So Calif, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA. [Hoschneider, D. P.] Univ So Calif, Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. [Hoschneider, D. P.] Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. [Hoschneider, D. P.; Kay, B. P.; Maarek, J. M. I.] Univ So Calif, Sch Engn, Dept Biomed Engn, Los Angeles, CA 90089 USA. [Scremin, O. U.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. [Scremin, O. U.] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Chialvo, D. R.] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL USA. RP Hoschneider, DP (reprint author), Univ So Calif, Sch Med, Dept Cell & Neurobiol, 1333 San Pablo St,BMT403,MC9112, Los Angeles, CA 90033 USA. EM holschne@usc.edu RI Chialvo, Dante/A-4658-2009 OI Chialvo, Dante/0000-0002-1038-3637 NR 13 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 EI 1872-7972 J9 NEUROSCI LETT JI Neurosci. Lett. PD MAR 28 PY 2008 VL 434 IS 2 BP 179 EP 184 DI 10.1016/j.neulet.2008.01.061 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 288EC UT WOS:000254968000006 ER PT J AU Levine, S Nguyen, T Taylor, N Friscia, ME Budak, MT Rothenberg, P Zhu, JL Sachdeva, R Sonnad, S Kaiser, LR Rubinstein, NA Powers, SK Shrager, JB AF Levine, Sanford Nguyen, Taitan Taylor, Nyali Friscia, Michael E. Budak, Murat T. Rothenberg, Pamela Zhu, Jianliang Sachdeva, Rajeev Sonnad, Seema Kaiser, Larry R. Rubinstein, Neal A. Powers, Scott K. Shrager, Joseph B. TI Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; UBIQUITIN-PROTEASOME PATHWAY; SKELETAL-MUSCLE; OXIDATIVE STRESS; INJURY; MECHANISMS; EXPRESSION; CYTOKINES; FAILURE; MYOSIN AB Background: The combination of complete diaphragm inactivity and mechanical ventilation (for more than 18 hours) elicits disuse atrophy of myofibers in animals. We hypothesized that the same may also occur in the human diaphragm. Methods: We obtained biopsy specimens from the costal diaphragms of 14 brain-dead organ donors before organ harvest (case subjects) and compared them with intraoperative biopsy specimens from the diaphragms of 8 patients who were undergoing surgery for either benign lesions or localized lung cancer (control subjects). Case subjects had diaphragmatic inactivity and underwent mechanical ventilation for 18 to 69 hours; among control subjects diaphragmatic inactivity and mechanical ventilation were limited to 2 to 3 hours. We carried out histologic, biochemical, and gene-expression studies on these specimens. Results: As compared with diaphragm-biopsy specimens from controls, specimens from case subjects showed decreased cross-sectional areas of slow-twitch and fast-twitch fibers of 57% (P=0.001) and 53% (P=0.01), respectively, decreased glutathione concentration of 23% (P=0.01), increased active caspase-3 expression of 100% (P=0.05), a 200% higher ratio of atrogin-1 messenger RNA (mRNA) transcripts to MBD4 (a housekeeping gene) (P=0.002), and a 590% higher ratio of MuRF-1 mRNA transcripts to MBD4 (P=0.001). Conclusions: The combination of 18 to 69 hours of complete diaphragmatic inactivity and mechanical ventilation results in marked atrophy of human diaphragm myofibers. These findings are consistent with increased diaphragmatic proteolysis during inactivity. C1 [Levine, Sanford; Nguyen, Taitan; Taylor, Nyali; Friscia, Michael E.; Budak, Murat T.; Rothenberg, Pamela; Zhu, Jianliang; Sonnad, Seema; Kaiser, Larry R.; Shrager, Joseph B.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA. [Rubinstein, Neal A.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA. [Levine, Sanford; Budak, Murat T.; Rubinstein, Neal A.; Shrager, Joseph B.] Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA. [Levine, Sanford] Gift Life Donor Program, Philadelphia, PA USA. [Levine, Sanford; Nguyen, Taitan; Sachdeva, Rajeev; Shrager, Joseph B.] Dept Vet Affairs Med Ctr, Med Res Surg & Lab Med Serv, Philadelphia, PA 19104 USA. [Powers, Scott K.] Univ Florida, Ctr Exercise Sci, Gainesville, FL 32611 USA. RP Levine, S (reprint author), 1495 Wesleys Run, Gladwyne, PA 19035 USA. EM sdlevine@mail.med.upenn.edu RI Budak, Murat/I-8358-2013 OI Budak, Murat/0000-0002-5059-9651 FU NHLBI NIH HHS [R01-HL-078834] NR 29 TC 486 Z9 515 U1 4 U2 25 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 27 PY 2008 VL 358 IS 13 BP 1327 EP 1335 DI 10.1056/NEJMoa070447 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 278TE UT WOS:000254308400003 PM 18367735 ER PT J AU Newsome, BB Warnock, DG McClellan, WM Herzog, CA Kiefe, CI Eggers, PW Allison, JJ AF Newsome, Britt B. Warnock, David G. McClellan, William M. Herzog, Charles A. Kiefe, Catarina I. Eggers, Paul W. Allison, Jeroan J. TI Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 40th Annual Meeting of the American-Society-of-Nephrology CY OCT 31-NOV 05, 2007 CL San Francisco, CA SP Amer Soc Nephrol ID ACUTE KIDNEY INJURY; COOPERATIVE CARDIOVASCULAR PROJECT; QUALITY-OF-CARE; REPLACEMENT THERAPY; MEDICARE PATIENTS; INTENSIVE-CARE; HEART-FAILURE; OUTCOMES; POPULATION; PROGNOSIS AB Background: Although small changes in creatinine level during hospitalization have been associated with risk of short-term mortality, associations with posthospitalization end-stage renal disease (ESRD) and long-term mortality are unknown. We assessed the relationship between change in serum creatinine levels up to 3.0 mg/dL and death and ESRD among elderly survivors of hospitalization for acute myocardial infarction. Methods: Retrospective cohort study of a nationally representative sample of Medicare beneficiaries admitted with acute myocardial infarction to nonfederal US hospitals between February 1994 and July 1995. Outcomes were mortality and ESRD through June 2004. Results: The 87 094 eligible patients admitted to 4473 hospitals had a mean age of 77.1 years; for the 43.2% with some creatinine increase, quartiles of increase were 0.1, 0.2, 0.3 to 0.5, and 0.6 to 3.0 mg/dL. Incidence of ESRD and mortality ranged from 2.3 and 139.1 cases per 1000 person-years, respectively, among patients with no increase to 20.0 and 274.9 cases per 1000 person-years in the highest quartile of creatinine increase. Compared with patients without creatinine increase, adjusted hazard ratios by quartile of increase were 1.45, 1.97, 2.36, and 3.26 for ESRD and 1.14, 1.16, 1.26, and 1.39 for mortality, with no 95% confidence intervals overlapping 1.0 for,either end point. Conclusion: In a nationally representative sample of elderly patients discharged after hospitalization for acute myocardial infarction, small changes in serum creatinine level during hospitalization were associated with an independent higher risk of ESRD and death. C1 [Newsome, Britt B.; Warnock, David G.] Univ Alabama, Div Nephrol, Birmingham, AL 35294 USA. [Newsome, Britt B.; Kiefe, Catarina I.; Allison, Jeroan J.] Univ Alabama, Div Prevent Med, Birmingham, AL 35294 USA. [Allison, Jeroan J.] Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA. [Newsome, Britt B.; Kiefe, Catarina I.; Allison, Jeroan J.] Univ Alabama, Ctr Nephrol Res & Training, Dept Med, Birmingham, AL 35294 USA. [Kiefe, Catarina I.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [McClellan, William M.] Emory Univ, Sch Med, Dept Med, Div Renal, Atlanta, GA 30322 USA. [Herzog, Charles A.] US Renal Data Syst, Cardiovasc Special Studies Ctr, Minneapolis, MN USA. [Eggers, Paul W.] NIDDKD, Bethesda, MD 20892 USA. RP Newsome, BB (reprint author), Univ Alabama, Div Nephrol, 1530 3rd Ave,S Room 524, Birmingham, AL 35294 USA. OI Allison, Jeroan/0000-0003-4472-2112 NR 59 TC 151 Z9 157 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 24 PY 2008 VL 168 IS 6 BP 609 EP 616 DI 10.1001/archinte.168.6.609 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 277UY UT WOS:000254241400009 PM 18362253 ER PT J AU Murff, HJ Peterson, NB Fowke, JH Hargreaves, M Signorello, LB Dittus, RS Zheng, W Blot, WJ AF Murff, Harvey J. Peterson, Neeraja B. Fowke, Jay H. Hargreaves, Margaret Signorello, Lisa B. Dittus, Robert S. Zheng, Wei Blot, William J. TI Colonoscopy screening in African Americans and whites with affected first-degree relatives SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CANCER TEST USE; COLORECTAL-CANCER; COLON-CANCER; ADENOMATOUS POLYPS; FAMILY-HISTORY; RISK; SURVEILLANCE; INDIVIDUALS; POPULATION; US AB Background: Family history is a risk factor for colon cancer, and guidelines recommend initiating screening at age 40 years in individuals with affected relatives. Racial differences in colon cancer mortality could be related to variations in screening of increased-risk individuals. Methods: Baseline data from 41830 participants in the Southern Community Cohort Study were analyzed to determine the proportion of colonoscopy procedures in individuals with strong family histories of colon cancer, and whether differences existed based on race. Results: In participants with multiple affected first-degree relatives (FDRs) or relatives diagnosed before age 50 years, 27.3% (95% confidence interval [CI], 23.5%31.1%) of African Americans reported having a colonoscopy within the past 5 years compared with 43.1% (95% CI, 37.0%-49.2%) of white participants (P <.001). African Americans in this group had an odds ratio of 0.51 (95% CI, 0.38-0.68) of having undergone recommended screening procedures compared with white participants after adjusting for age, sex, educational status, annual income, insurance status, total number of affected and unaffected FDRs, and time since last medical visit. African Americans with multiple affected FDRs or relatives diagnosed before age 50 years and who had ever undergone endoscopy were less likely to report a personal history of colon polyps (odds ratio, 0.29; 95% CI, 0.20-0.42) when compared with whites with similar family histories. Conclusions: African Americans who have FDRs with colon cancer are less likely to undergo colonoscopy screening compared with whites who have affected relatives. Increased efforts need to be directed at identifying and managing underserved populations at increased risk for colon cancer based on their family histories. C1 [Murff, Harvey J.] Vanderbilt Epidemiol Ctr, Inst Med & Publ Hlth, Nashville, TN 37203 USA. [Fowke, Jay H.; Zheng, Wei; Blot, William J.] Vanderbilt Epidemiol Ctr, Nashville, TN 37203 USA. [Murff, Harvey J.; Peterson, Neeraja B.; Fowke, Jay H.; Signorello, Lisa B.; Dittus, Robert S.; Zheng, Wei; Blot, William J.] Vanderbilt Univ, Dept Med, Div Gen Internal Med & Publ Hlth, Nashville, TN USA. [Murff, Harvey J.; Peterson, Neeraja B.; Fowke, Jay H.; Signorello, Lisa B.; Zheng, Wei; Blot, William J.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Murff, Harvey J.; Dittus, Robert S.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Ctr Geriatr Res Educ & Clin, Nashville, TN USA. [Signorello, Lisa B.; Blot, William J.] Int Epidemiol Inst, Rockville, MD USA. RP Murff, HJ (reprint author), Vanderbilt Epidemiol Ctr, Inst Med & Publ Hlth, 2525 W End Ave, Nashville, TN 37203 USA. EM harvey.j.murff@vanderbilt.edu FU NCI NIH HHS [CA092447, CA114029, K07 CA114029, K07 CA114029-03, P50 CA095103, R01 CA092447] NR 35 TC 21 Z9 21 U1 2 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 24 PY 2008 VL 168 IS 6 BP 625 EP 631 DI 10.1001/archinte.168.6.625 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 277UY UT WOS:000254241400011 PM 18362255 ER PT J AU Zhang, H Li, ZH Zhang, MQ Katz, MS Zhang, BX AF Zhang, Hua Li, Zhen-Hua Zhang, Michael Q. Katz, Michael S. Zhang, Bin-Xian TI Heat shock protein 90 beta 1 is essential for polyunsaturated fatty acid-induced mitochondrial Ca2+ efflux SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TYPE-2 DIABETIC-PATIENTS; ENDOPLASMIC-RETICULUM; SUBSTRATE OXIDATION; INTRACELLULAR CA2+; CALCIUM-TRANSPORT; SKELETAL-MUSCLE; CELLS; HSP90; DYSFUNCTION; GLUCOSE AB Nonesterified fatty acids may influence mitochondrial function by alterations in gene expression, metabolism, and/or mitochondrial Ca2+ ([Ca2+](m)) homeostasis. We have previously reported that polyunsaturated fatty acids induce Ca2+ efflux from mitochondria, an action that may deplete [Ca2+](m) and thus contribute to nonesterified fatty acid-responsive mitochondrial dysfunction. Here we show that the chaperone protein heat shock protein 90 beta 1 (hsp90 beta 1) is required for polyunsaturated fatty acid-induced mitochondrial Ca2+ efflux (PIMCE). Retinoic acid induced differentiation of human teratocarcinoma NT2 cells in association with attenuation of PIMCE. Proteomic analysis of mitochondrial proteins revealed that hsp90 beta 1, among other proteins, was reduced in retinoic acid-differentiated cells. Blockade of PIMCE in NT2 cells by 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin, a known inhibitor of the chaperone activity of hsp90, and hsp90 beta 1 RNA interference demonstrated that hsp90 beta 1 is essential for PIMCE. We also show localization of hsp90 beta 1 in mitochondria by Western blot and immunofluorescence. Distinctive effects of inhibitors binding to the N or C terminus of hsp90 on PIMCE in isolated mitochondria suggested that the C terminus of hsp90 beta 1 plays a critical role in PIMCE. C1 [Zhang, Hua; Li, Zhen-Hua; Zhang, Michael Q.; Katz, Michael S.; Zhang, Bin-Xian] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Audie L Murphy Div, S Texas Vet Hlth Care Syst,Geriatr Res Educ & Cli, San Antonio, TX 78229 USA. RP Zhang, BX (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Audie L Murphy Div, S Texas Vet Hlth Care Syst,Geriatr Res Educ & Cli, GRECC 182,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. FU NHLBI NIH HHS [HL075011] NR 40 TC 8 Z9 8 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 21 PY 2008 VL 283 IS 12 BP 7580 EP 7589 DI 10.1074/jbc.M707192200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 274JP UT WOS:000253997900033 PM 18178560 ER PT J AU Kahn, S AF Kahn, Steven TI beta-cell function and volume in the development of Type 2 diabetes SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Meeting Abstract C1 [Kahn, Steven] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD MAR 20 PY 2008 VL 79 SU 1 BP S9 EP S9 DI 10.1016/S0168-8227(08)70667-3 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 350OQ UT WOS:000259362500024 ER PT J AU Goetz, MB Bowman, C Hoang, T Anaya, H Osborn, T Gifford, AL Asch, SM AF Goetz, Matthew B. Bowman, Candice Hoang, Tuyen Anaya, Henry Osborn, Teresa Gifford, Allen L. Asch, Steven M. TI Implementing and evaluating a regional strategy to improve testing rates in VA patients at risk for HIV, utilizing the QUERI process as a guiding framework: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID PREVENTIVE SERVICES; CLINICAL REMINDERS; COST-EFFECTIVENESS; CHRONIC ILLNESS; UNITED-STATES; PRIMARY-CARE; OF-CARE; INFECTION; BARRIERS; LESSONS AB Background: We describe how we used the framework of the U. S. Department of Veterans Affairs (VA) Quality Enhancement Research Initiative (QUERI) to develop a program to improve rates of diagnostic testing for the Human Immunodeficiency Virus (HIV). This venture was prompted by the observation by the CDC that 25% of HIV-infected patients do not know their diagnosis-a point of substantial importance to the VA, which is the largest provider of HIV care in the United States. Methods: Following the QUERI steps (or process), we evaluated: 1) whether undiagnosed HIV infection is a high-risk, high-volume clinical issue within the VA, 2) whether there are evidence-based recommendations for HIV testing, 3) whether there are gaps in the performance of VA HIV testing, and 4) the barriers and facilitators to improving current practice in the VA. Based on our findings, we developed and initiated a QUERI step 4/phase 1 pilot project using the precepts of the Chronic Care Model. Our improvement strategy relies upon electronic clinical reminders to provide decision support; audit/feedback as a clinical information system, and appropriate changes in delivery system design. These activities are complemented by academic detailing and social marketing interventions to achieve provider activation. Results: Our preliminary formative evaluation indicates the need to ensure leadership and team buy-in, address facility-specific barriers, refine the reminder, and address factors that contribute to inter-clinic variances in HIV testing rates. Preliminary unadjusted data from the first seven months of our program show 3-5 fold increases in the proportion of at-risk patients who are offered HIV testing at the VA sites (stations) where the pilot project has been undertaken; no change was seen at control stations. Discussion: This project demonstrates the early success of the application of the QUERI process to the development of a program to improve HIV testing rates. Preliminary unadjusted results show that the coordinated use of audit/feedback, provider activation, and organizational change can increase HIV testing rates for at-risk patients. We are refining our program prior to extending our work to a small-scale, multi-site evaluation (QUERI step 4/phase 2). We also plan to evaluate the durability/sustainability of the intervention effect, the costs of HIV testing, and the number of newly identified HIV-infected patients. Ultimately, we will evaluate this program in other geographically dispersed stations (QUERI step 4/phases 3 and 4). C1 [Goetz, Matthew B.] VA Greater Angeles Healthcare Syst, Infect Dis Sect 111F, Los Angeles, CA USA. [Bowman, Candice] VA San Diego Healthcare Syst, San Diego, CA USA. [Osborn, Teresa] Vet Integrate Serv Network 22, Long Beach, CA USA. [Gifford, Allen L.] Edith Nourse Rogers Mem Vet Adm Hosp, VA Bedford Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Hoang, Tuyen; Anaya, Henry; Asch, Steven M.] VA Greater Angeles Healthcare Syst, Gen Med 111G, Los Angeles, CA USA. RP Goetz, MB (reprint author), VA Greater Angeles Healthcare Syst, Infect Dis Sect 111F, Los Angeles, CA USA. EM Matthew.Goetz@va.gov; candybowman@gmail.com; Tuyen.Hoang@va.gov; Henry.Anaya@va.gov; Teresa.Osborn@va.gov; Allen.Gifford@va.gov; Steven.Asch@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU U. S. Department of Veterans Affairs, Health Services Research and Development Service [06-001] FX We acknowledge the contributions of Robert M. Smith, MD for his invaluable contributions to the development and implementation of the HIV testing clinical reminder. This work was supported by the U. S. Department of Veterans Affairs, Health Services Research and Development Service (Service Directed Project 06-001). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 47 TC 18 Z9 18 U1 2 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAR 19 PY 2008 VL 3 AR 16 DI 10.1186/1748-5908-3-16 PG 13 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432QT UT WOS:000265149900001 PM 18353185 ER PT J AU Krein, SL Bernstein, SJ Fletcher, CE Makki, F Goldzweig, CL Watts, B Vijan, S Hayward, RA AF Krein, Sarah L. Bernstein, Steven J. Fletcher, Carol E. Makki, Fatima Goldzweig, Caroline L. Watts, Brook Vijan, Sandeep Hayward, Rodney A. TI Improving eye care for veterans with diabetes: An example of using the QUERI steps to move from evidence to implementation: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID RESEARCH INITIATIVE QUERI; SELF-MANAGEMENT; MELLITUS; RETINOPATHY; SERVICES; PHOTOCOAGULATION; INTERVENTIONS; COMPLICATIONS; PROGRESSION; OUTPATIENT AB Background: Despite being a critical part of improving healthcare quality, little is known about how best to move important research findings into clinical practice. To address this issue, the Department of Veterans Affairs (VA) developed the Quality Enhancement Research Initiative (QUERI), which provides a framework, a supportive structure, and resources to promote the more rapid implementation of evidence into practice. Methods: This paper uses a practical example to demonstrate the use of the six-step QUERI process, which was developed as part of QUERI and provides a systematic approach for moving along the research to practice pipeline. Specifically, we describe a series of projects using the six-step framework to illustrate how this process guided work by the Diabetes Mellitus QUERI (DM-QUERI) Center to assess and improve eye care for veterans with diabetes. Results: Within a relatively short time, DM-QUERI identified a high-priority issue, developed evidence to support a change in the diabetes eye screening performance measure, and identified a gap in quality of care. A prototype scheduling system to address gaps in screening and follow-up also was tested as part of an implementation project. We did not succeed in developing a fully functional pro-active scheduling system. This work did, however, provide important information to help us further understand patients' risk status, gaps in follow-up at participating eye clinics, specific considerations for additional implementation work in the area of proactive scheduling, and contributed to a change in the prevailing diabetes eye care performance measure. Conclusion: Work by DM-QUERI to promote changes in the delivery of eye care services for veterans with diabetes demonstrates the value of the QUERI process in facilitating the more rapid implementation of evidence into practice. However, our experience with using the QUERI process also highlights certain challenges, including those related to the hybrid nature of the research-operations partnership as a mechanism for promoting rapid, system-wide implementation of important research findings. In addition, this paper suggests a number of important considerations for future implementation work, both in the area of pro-active scheduling interventions, as well as for implementation science in general. C1 [Krein, Sarah L.; Bernstein, Steven J.; Vijan, Sandeep; Hayward, Rodney A.] VA Ann Arbor Healthcare Syst, Hlth Serv Res & Dev, Ann Arbor, MI USA. [Krein, Sarah L.; Bernstein, Steven J.; Fletcher, Carol E.; Makki, Fatima; Vijan, Sandeep; Hayward, Rodney A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Goldzweig, Caroline L.] VA Greater Angeles Healthcare Syst, Gen Internal Med & Clin Informat, Los Angeles, CA USA. [Watts, Brook] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. RP Krein, SL (reprint author), VA Ann Arbor Healthcare Syst, Hlth Serv Res & Dev, Ann Arbor, MI USA. EM sarah.krein@va.gov; sbernste@umich.edu; carol.fletcher@va.gov; fatima.makki@va.gov; caroline.goldzweig@va.gov; brook.watts@va.gov; svijan@umich.edu; rhayward@umich.edu RI Krein, Sarah/E-2742-2014 OI Krein, Sarah/0000-0003-2111-8131 FU U. S. Department of Veterans Affairs, Health Services Research and Development Service [DIB 98-001, DIT 02-064]; NIDDK of the National Institutes of Health [P60DK-20572] FX This study was supported through grant funding from the U. S. Department of Veterans Affairs, Health Services Research and Development Service: DIB 98-001 and DIT 02-064. This work also was supported, in part, by the Michigan Diabetes Research and Training Center Grant P60DK-20572 from the NIDDK of the National Institutes of Health. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors wish to thank Matt Shevrin for assisting with data management throughout the project and, as needed, for this article. NR 39 TC 10 Z9 10 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAR 19 PY 2008 VL 3 AR 18 DI 10.1186/1748-5908-3-18 PG 11 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432QT UT WOS:000265149900003 PM 18353187 ER PT J AU Scheuner, MT Sieverding, P Shekelle, PG AF Scheuner, Maren T. Sieverding, Pauline Shekelle, Paul G. TI Delivery of genomic medicine for common chronic adult diseases - A systematic review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PHYSICIANS; FAMILIAL CANCER-RISK; BREAST-CANCER; GENETIC DISCRIMINATION; COLORECTAL-CANCER; PSYCHOLOGICAL OUTCOMES; INFORMATION NEEDS; HEALTH INSURERS; UNITED-STATES AB Context The greatest public health benefit of advances in understanding the human genome may be realized for common chronic diseases such as cardiovascular disease, diabetes mellitus, and cancer. Attempts to integrate such knowledge into clinical practice are still in the early stages, and as a result, many questions surround the current state of this translation. Objective To synthesize current information on genetic health services for common adult- onset conditions by examining studies that have addressed the outcomes, consumer information needs, delivery, and challenges in integrating these services. Data Sources MEDLINE articles published between January 2000 and February 2008. Study Selection Original research articles and systematic reviews dealing with common chronic adult- onset conditions were reviewed. A total of 3371 citations were reviewed, 170 articles retrieved, and 68 articles included in the analysis. Data Extraction Data were independently extracted by one reviewer and checked by another with disagreement resolved by consensus. Variables assessed included study design and 4 key areas: outcomes of genomic medicine, consumer information needs, delivery of genomic medicine, and challenges and barriers to integration of genomic medicine. Data Synthesis Sixty- eight articles contributed data to the synthesis: 5 systematic reviews, 8 experimental studies, 35 surveys, 7 pre/ post studies, 3 observational studies, and 10 qualitative reports. Three systematic reviews, 4 experimental studies, and 9 additional studies reported on outcomes of genetic services. Generally there were modest positive effects on psychological outcomes such as worry and anxiety, behavioral outcomes have shown mixed results, and clinical outcomes were less well studied. One systematic review, 1 randomized controlled trial, and 14 other studies assessed consumer information needs and found in general that genetics knowledge was reported to be low but that attitudes were generally positive. Three randomized controlled trials and 13 other studies assessed how genomic medicine is delivered and newer models of delivery. One systematic review and 19 other studies assessed barriers; the most consistent finding was the self- assessed inadequacy of the primary care work-force to deliver genetic services. Additional identified barriers included lack of oversight of genetic testing and concerns about privacy and discrimination. Conclusion Many gaps in knowledge about organization, clinician, and patient needs must be filled to translate basic and clinical science advances in genomics of common chronic diseases into practice. C1 [Scheuner, Maren T.; Shekelle, Paul G.] RAND Corp, Santa Monica, CA 90401 USA. [Sieverding, Pauline] Dept Vet Affairs, Hlth Serv Res & Dev Serv, Washington, DC USA. [Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Scheuner, MT (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM scheuner@rand.org NR 67 TC 170 Z9 172 U1 5 U2 17 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 19 PY 2008 VL 299 IS 11 BP 1320 EP 1334 DI 10.1001/jama.299.11.1320 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 275NO UT WOS:000254079100023 PM 18349093 ER PT J AU Naik, AD Kallen, MA Walder, A Street, RL AF Naik, Aanand D. Kallen, Michael A. Walder, Annette Street, Richard L. TI Improving hypertension control in diabetes mellitus the effects of collaborative and proactive health communication SO CIRCULATION LA English DT Article DE hypertension; diabetes mellitus; physician-patient relations; outcomes assessment; goals ID TREATMENT DECISION-MAKING; BLOOD-PRESSURE CONTROL; CHRONIC ILLNESS CARE; PATIENT COMMUNICATION; SELF-MANAGEMENT; OFFICE PRACTICE; UNITED-STATES; PATIENTS WANT; PHYSICIAN; INTERVENTIONS AB Background-Communication between patients and clinicians using collaborative goals and treatment plans may overcome barriers to achieving hypertension control in routine diabetes mellitus care. We assessed the interrelation of patient-clinician communication factors to determine their independent associations with hypertension control in diabetes care. Methods and Results-We identified 566 older adults with diabetes mellitus and hypertension at the DeBakey VA Medical Center in Houston, Tex. Clinical and pharmacy data were collected, and a patient questionnaire was sent to all participants. A total of 212 individuals returned surveys. Logistic regression analyses were performed to assess the effect of patient characteristics, self-management behaviors, and communication factors on hypertension control. Three communication factors had significant associations with hypertension control. Two factors, patients' endorsement of a shared decision-making style (odds ratio 1.61, 95% confidence interval 1.01 to 2.57) and proactive communication with one's clinician about abnormal results of blood pressure self-monitoring (odds ratio 1.89, 95% confidence interval 1.10 to 3.26), had direct, independent associations in multivariate regression. Path analysis was used to investigate the direct and indirect effects of communication factors and hypertension control. Decision-making style (beta=0.20, P < 0.01) and proactive communication (beta= 0.50, P < 0.0001) again demonstrated direct effects on hypertension control. A third factor, clinicians' use of collaborative communication when setting treatment goals, had a total effect on hypertension control of 0.16 ( P < 0.05) through its direct effects on decision-making style (beta=0.28, P < 0.001) and proactive communication (beta=0.22, P < 0.01). Conclusions-Three communication factors were found to have significant associations with hypertension control. Patient - clinician communication that facilitates collaborative blood pressure goals and patients' input related to the progress of treatment may improve rates of hypertension control in diabetes care independent of medication adherence. C1 [Naik, Aanand D.; Walder, Annette; Street, Richard L.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Naik, Aanand D.] Baylor Coll Med, Sect Geriatr, Houston, TX 77030 USA. [Kallen, Michael A.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med, Houston, TX USA. [Street, Richard L.] Texas A&M Univ, Dept Commun, College Stn, TX USA. [Naik, Aanand D.; Walder, Annette; Street, Richard L.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holocombe Blvd, Houston, TX 77030 USA. EM anaik@bcm.tmc.edu FU NIA NIH HHS [5K23AG027144, K23 AG027144, K23 AG027144-03] NR 48 TC 76 Z9 79 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 18 PY 2008 VL 117 IS 11 BP 1361 EP 1368 DI 10.1161/CIRCULATIONAHA.107.724005 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 275IN UT WOS:000254065200003 PM 18316489 ER PT J AU Shlipak, MG Katz, R Fried, L Kestenbaum, B Siscovick, D Sarnak, M AF Shlipak, Michael G. Katz, Ronit Fried, Linda Kestenbaum, Bryan Siscovick, David Sarnak, Mark TI Clinical and subclinical cardiovascular disease and kidney function decline in the elderly SO CIRCULATION LA English DT Meeting Abstract CT 48th Annal Scientific Conference on Cardiovascular Disease Epidemiology and Prevention CY MAR 13-15, 2008 CL Colorado Springs, CO C1 [Shlipak, Michael G.] San Francisco VA Med Cntr, San Francisco, CA USA. [Katz, Ronit; Siscovick, David] Univ Washington, Seattle, WA 98195 USA. [Fried, Linda] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kestenbaum, Bryan] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Sarnak, Mark] Tufts New England Med Cntr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 18 PY 2008 VL 117 IS 11 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 275IN UT WOS:000254065200043 ER PT J AU Teerlink, JR AF Teerlink, John R. TI Learning the points of COMPASS-HF - Assessing implantable hemodynamic monitoring in heart failure patients SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID PRECEDING HOSPITALIZATION; TRIAL; MULTICENTER; OUTCOMES C1 [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol Sect, Cardiol 111C,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu RI Teerlink, John/D-2986-2012 NR 18 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 18 PY 2008 VL 51 IS 11 BP 1080 EP 1082 DI 10.1016/j.jacc.2007.12.009 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 275HS UT WOS:000254063100005 PM 18342225 ER PT J AU Schur, EA Cummings, DE Callahan, HS Foster-Schubert, KE AF Schur, Ellen A. Cummings, David E. Callahan, Holly S. Foster-Schubert, Karen E. TI Association of cognitive restraint with ghrelin, leptin, and insulin levels in subjects who are not weight-reduced SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE restraint; ghrelin; leptin; insulin; obesity; body weight; eating disorders; appetite regulation ID 3-FACTOR EATING QUESTIONNAIRE; PLASMA GHRELIN; DIETARY RESTRAINT; ANOREXIA-NERVOSA; SERUM LEPTIN; BODY-WEIGHT; ENERGY-EXPENDITURE; PHYSICAL-ACTIVITY; OBESE HUMANS; WOMEN AB Despite widespread efforts at weight loss, the prevalence of obesity continues to rise. Restrained eating is a pattern of attempted weight control characterized by cognitive restriction of food intake that has paradoxically been linked with overeating and/or weight gain. It is not known whether restrained eating is associated with abnormalities in appetite-regulating hormones, independent of its effects on body weight. To address this question, we assessed cognitive restraint using the Three-Factor Eating Questionnaire and obtained fasting measurements of ghrelin, leptin and insulin from 24 healthy, non-obese (body mass index (BMI) 19.7 to 29.6 kg/m(2)) adult subjects who were at a stable, lifetime maximum weight. We chose to study subjects at stable maximum weight to avoid the secondary effects of weight reduction on body-weight regulating hormones. Subjects were classified by cognitive restraint scale score into Low, Indeterminate, and High Restraint groups. Higher ghrelin levels were significantly associated with restraint in an unadjusted model (P=0.004) and after adjustment for BMI (P=0.007). No relationships were found between restraint scores and either leptin (P=0.75) or insulin (P=0.36). These findings show an orexigenic hormonal profile in restrained eaters, independent of changes in body weight. (c) 2007 Elsevier Inc. All rights reserved. C1 [Schur, Ellen A.] Univ Washington, Harborview Med Ctr, Div Gen Internal Med, Seattle, WA 98104 USA. [Cummings, David E.; Foster-Schubert, Karen E.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA 98104 USA. [Callahan, Holly S.] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Callahan, Holly S.] Univ Washington, Sch Med, Seattle, WA 98104 USA. RP Schur, EA (reprint author), Univ Washington, Harborview Med Ctr, Div Gen Internal Med, Box 359780,325 9th Ave, Seattle, WA 98104 USA. EM ellschur@u.washington.edu FU NCRR NIH HHS [M01RR-00037, 5K12RR023265, K12 RR023265, M01 RR000037]; NIDDK NIH HHS [DK-35816, K23 DK070826, K23 DK070826-01, P30 DK035816, R01 DK061516, R01 DK61516] NR 60 TC 26 Z9 26 U1 2 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD MAR 18 PY 2008 VL 93 IS 4-5 BP 706 EP 712 DI 10.1016/j.physbeh.2007.11.025 PG 7 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 293BZ UT WOS:000255311100006 PM 18164043 ER PT J AU Sun, L Vukicevic, S Baliram, R Yang, G Sendak, R McPherson, J Zhu, LL Iqbal, J Latif, R Natrajan, A Arabi, A Yamoah, K Moonga, BS Gabet, Y Davies, TF Bab, I Abe, E Sampath, K Zaidi, M AF Sun, Li Vukicevic, Slobodan Baliram, Ramkumarie Yang, Guozhe Sendak, Rebecca McPherson, John Zhu, Ling-Ling Iqbal, Jameel Latif, Rauf Natrajan, Arjun Arabi, Ario Yamoah, Kosj Moonga, Baljit S. Gabet, Yankel Davies, Terry F. Bab, Itai Abe, Etsuko Sampath, Kuber Zaidi, Mone TI Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE osteoclast; osteoporosis; pituitary; osteoblast; bisphosphonate ID THYROID-STIMULATING HORMONE; HYPERTHYROIDISM; OSTEOPOROSIS; FRACTURE; WOMEN; RISK AB We recently described the direct effects of thyroid-stimulating hormone (TSH) on bone and suggested that the bone loss in hyperthyroidism, hitherto attributed solely to elevated thyroid hormone levels, could at least in part arise from accompanying decrements in serum TSH. Recent studies on both mice and human subjects provide compelling evidence that thyroid hormones and TSH have the opposite effects on the skeleton. Here, we show that TSH, when injected intermittently into rodents, even at intervals of 2 weeks, displays a powerful antiresorptive action in vivo. By virtue of this action, together with the possible anabolic effects shown earlier, TSH both prevents bone loss and restores the lost bone after ovariectomy. Importantly, the osteoclast inhibitory action of TSH persists ex vivo even after therapy is stopped for 4 weeks. This profound and lasting antiresorptive action of TSH is mimicked in cells that genetically overexpress the constitutively active ligand-independent TSH receptor (TSHR). In contrast, loss of function of a mutant TSHR (Pro -> Leu at 556) in congenital hypothyroid mice activates osteoclast differentiation, confirming once again our premise that TSHRs have a critical role in regulating bone remodeling. C1 [Sun, Li; Baliram, Ramkumarie; Yang, Guozhe; Zhu, Ling-Ling; Iqbal, Jameel; Latif, Rauf; Natrajan, Arjun; Arabi, Ario; Yamoah, Kosj; Moonga, Baljit S.; Davies, Terry F.; Abe, Etsuko; Zaidi, Mone] Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, Mt Sinai Bone Program, New York, NY 10029 USA. [Sun, Li; Baliram, Ramkumarie; Yang, Guozhe; Zhu, Ling-Ling; Iqbal, Jameel; Latif, Rauf; Natrajan, Arjun; Arabi, Ario; Yamoah, Kosj; Moonga, Baljit S.; Davies, Terry F.; Abe, Etsuko; Zaidi, Mone] Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, Thyroid Res Unit, New York, NY 10029 USA. [Vukicevic, Slobodan; McPherson, John] Lab Mineralized Tissues, Zagreb 10000, Croatia. [Sendak, Rebecca] Genzyme Corp, Framingham, MA 02142 USA. [Gabet, Yankel; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, IL-91904 Jerusalem, Israel. RP Zaidi, M (reprint author), Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, Mt Sinai Bone Program, New York, NY 10029 USA. EM mone.zaidi@mountsinai.org FU NIA NIH HHS [AG12951, AG14917, AG23176, R01 AG012951, R01 AG023176]; NIDDK NIH HHS [DK70526, R01 DK070526] NR 24 TC 51 Z9 55 U1 1 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 18 PY 2008 VL 105 IS 11 BP 4289 EP 4294 DI 10.1073/pnas.0712395105 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 278DH UT WOS:000254263300040 PM 18332426 ER PT J AU Pisegna, JR Sostek, MB Monyak, JT Miner, PB AF Pisegna, J. R. Sostek, M. B. Monyak, J. T. Miner, P. B., Jr. TI Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; SUPPRESSION; PANTOPRAZOLE; RABEPRAZOLE; SECRETION; PH AB Background Intravenous (IV) formulations of proton pump inhibitors are effective for patients in whom oral therapy is not appropriate. Aim To compare IV esomeprazole and W lansoprazole for the control of intragastric pH. Methods In this open-label crossover study, healthy, Helicobacter pylori-negative adults were randomized to one of two treatment sequences, each consisting of two 5-day dosing periods of TV esomeprazole 40 mg or IV lansoprazole 30 mg. Twenty- four-hour intragastric pH monitoring was conducted on days 1 and 5 of each dosing period. Results On days 1 and 5, intragastric pH was >4.0 significantly longer with esomeprazole than lansoprazole (least-squares means: day 1, 40.0% vs. 33.6%; day 5, 61.9% vs. 45.4%; both P < 0.0001). During the first 4 h of pH monitoring, intragastric pH was >4.0 significantly longer on days 1 and 5 with esomeprazole than lansoprazole (P < 0.0001). Kaplan-Meier estimates of median hours to stable pH >4.0 were 4.92 for esomeprazole and 5.75 for lansoprazole (P = 0.0014 for test on Gehan scores). Conclusion In healthy adults, IV esomeprazole 40 ing controlled intragastric acidity faster and more effectively than W lansoprazole 30 mg. C1 [Pisegna, J. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Pisegna, J. R.] VA Greater Los Angeles Hlthcare Syst, Los Angeles, CA 90095 USA. [Sostek, M. B.; Monyak, J. T.] AstraZeneca LP, Wilmington, DE USA. [Miner, P. B., Jr.] Oklahoma Fdn Digest Res, Oklahoma City, OK USA. RP Pisegna, JR (reprint author), Univ Calif Los Angeles, Vet Adm Med Ctr W, Dis Res Ctr, 11301 Wilshire Blvd,Bldg 115,Rm 315, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu FU NCRR NIH HHS [M01-RR00865] NR 15 TC 7 Z9 8 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD MAR 15 PY 2008 VL 27 IS 6 BP 483 EP 490 DI 10.1111/j.1365-2036.2007.03592.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 278OG UT WOS:000254295600004 PM 18162083 ER PT J AU Driver, CB Wallace, DJ Lee, JC Forbess, CJ Pourrabbani, S Minoshima, S Waxman, AD Weisman, MH AF Driver, Catherine B. Wallace, Daniel J. Lee, Jessica C. Forbess, Chelsey J. Pourrabbani, Shahram Minoshima, Satoshi Waxman, Alan D. Weisman, Michael H. TI Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article ID EMISSION COMPUTED-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; INVOLVEMENT; PREVALENCE AB Objective. To study the relationship between single-photon-emission computed tomography (SPECT) brain imaging and neuropsychiatric signs/symptoms in a cohort of patients with systemic lupus erythematosus (SLE), analyzed using a stereotactic surface projection (SSP) technique. Methods. Thirty-seven SLE patients were referred for Tc-99m-ethyl cysteinate dimer SPECT brain imaging because of neuropsychiatric signs/symptoms. Nineteen normal controls were studied with the identical protocol. Reconstructed images were computed and Z scores were calculated using the SSP technique with the 2-sample t-tests comparing normal controls with SLE patients, and patients with mild cognitive dysfunction with those with severe cognitive dysfunction. The clinical characteristics of SLE patients were collected by retrospective chart review and categorized according to American College of Rheumatology case definitions for neuropsychiatric SLE. Cognitive dysfunction was rated by the treating physician on a scale of 0-3. Results. Thirty of 37 SLE patients had abnormal SPECT results. SLE patients had reduced perfusion in the watershed areas of the frontal lobes bilaterally compared with controls. Additionally, SLE patients with severe cognitive dysfunction had more severe perfusion deficits than those with mild cognitive dysfunction. In some patients with severe cognitive dysfunction, the watershed areas had Z scores >= 4 SDs below controls. Conclusion. A convenience sample of patients with SLE and neuropsychiatric signs/symptoms demonstrated reduced perfusion in the watershed areas of the frontal lobes on SPECT scanning analyzed by the SSP technique. The severity of findings correlated with severity of cognitive dysfunction. The area of the brain affected is one that is susceptible to ischemia. C1 [Driver, Catherine B.; Wallace, Daniel J.; Lee, Jessica C.; Forbess, Chelsey J.; Waxman, Alan D.; Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Pourrabbani, Shahram] W Los Angeles VA Hosp, Los Angeles, CA USA. [Minoshima, Satoshi] Univ Washington, Med Ctr, Seattle, WA 98195 USA. RP Weisman, MH (reprint author), 8700 Beverly Blvd,Becker B-131, Los Angeles, CA 90048 USA. EM michael.weisman@cshs.org NR 21 TC 14 Z9 14 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD MAR 15 PY 2008 VL 59 IS 3 BP 332 EP 337 DI 10.1002/art.23308 PG 6 WC Rheumatology SC Rheumatology GA 272IA UT WOS:000253851900006 PM 18311758 ER PT J AU Krathen, MS Dunham, J Gaines, E Junkins-Hopkins, J Kim, E Kolasinski, SL Kovarik, C Kwan-Morley, J Okawa, J Propert, K Rogers, N Rose, M Thomas, P Troxel, AB Van Voorhees, A Von Feldt, J Weber, AL Werth, VP AF Krathen, M. S. Dunham, J. Gaines, E. Junkins-Hopkins, J. Kim, E. Kolasinski, S. L. Kovarik, C. Kwan-Morley, J. Okawa, J. Propert, K. Rogers, N. Rose, M. Thomas, P. Troxel, A. B. Van Voorhees, A. Von Feldt, J. Weber, A. L. Werth, V. P. TI The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: Expansion for rheumatology and dermatology SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article; Proceedings Paper CT 68th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2007 CL Los Angeles, CA SP Soc Investigat Dermatol ID MANIFESTATIONS AB Objective. To evaluate the validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) for use by rheumatologists via reliability testing, and to extend the validation for dermatologists. Methods. Fourteen subjects with cutaneous lupus erythematosus (CLE; n = 10), a mimicker skin disease only (a cutaneous lesion that may appear clinically similar to CLE; n = 1), or both (n = 3) were rated with the CLASI by academic-based dermatologists (n = 5) and rheumatologists (n = 5). Results. The dermatology intraclass correlation coefficient (ICC) was 0.92 for activity and 0.82 for damage; for rheumatology the ICC was 0.83 for activity and 0.86 for damage. For intrarater reliability, the dermatology Spearman's rho was 0.94 for activity and 0.97 for damage; for rheumatology the Spearman's rho was 0.91 for activity and 0.99 for damage. Conclusion. Our data confirm the reliability of the CLASI when used by dermatologists and support the CLASI as a reliable instrument for use by rheumatologists. C1 [Krathen, M. S.; Dunham, J.; Gaines, E.; Junkins-Hopkins, J.; Kim, E.; Kolasinski, S. L.; Kovarik, C.; Kwan-Morley, J.; Okawa, J.; Rose, M.; Thomas, P.; Van Voorhees, A.; Von Feldt, J.; Werth, V. P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19119 USA. [Propert, K.; Troxel, A. B.; Weber, A. L.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Rogers, N.] Tulane Univ, Sch Med, New Orleans, LA 70118 USA. [Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Werth, VP (reprint author), Univ Penn, Sch Med, Dept Dermatol, 2 Rhoads Pavilion,3600 Spruce St, Philadelphia, PA 19119 USA. EM werth@mail.med.upenn.edu OI Troxel, Andrea/0000-0002-1393-3075 FU NIAMS NIH HHS [K24 AR002207] NR 10 TC 28 Z9 30 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD MAR 15 PY 2008 VL 59 IS 3 BP 338 EP 344 DI 10.1002/art.23319 PG 7 WC Rheumatology SC Rheumatology GA 272IA UT WOS:000253851900007 PM 18311759 ER PT J AU Taylor, FB Martin, P Thompson, C Williams, J Mellman, TA Gross, C Peskind, ER Raskind, MA AF Taylor, Fletcher B. Martin, Patti Thompson, Charles Williams, Judi Mellman, Thomas A. Gross, Christopher Peskind, Elaine R. Raskind, Murray A. TI Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study SO BIOLOGICAL PSYCHIATRY LA English DT Article DE nightmare; posttraumatic stress disorder; prazosin; rapid eye movement sleep; sleep disturbance ID COMBAT-RELATED PTSD; REM-SLEEP; PHARMACOTHERAPY; NIGHTMARES; VETERANS; METHOXAMINE; DISTURBANCE; ANTAGONISTS; TEGMENTUM; EFFICACY AB Background: Prazosin, a central nervous system (CNS) active alpha-1 adrenoreceptor antagonist, has reduced nightmares and sleep disturbance in placebo-controlled studies of combat-related posttraumatic stress disorder (PTSD). We evaluated objective sleep parameters and PTSD symptoms in a placebo-controlled prazosin trial for civilian trauma-related PTSD. Methods: Thirteen outpatients with chronic civilian trauma PTSD, frequent nightmares, and sleep disturbance participated in a randomized placebo-controlled crossover trial of prazosin. Sleep parameters were quantified at home with the REMView (Respironics, Pittsburgh, Pennsylvania). The PTSD symptoms were quantified with the Clinician Administered PTSD Scale (CAPS) "recurrent distressing dreams" and "disturbed sleep" items, a non-nightmare distressed awakenings scale, the PTSD Dream Rating Scale (PDRS), the PTSD Checklist-Civilian (PCL-C), and the Clinical Global Impression of Improvement (CGI-1). Results: Prazosin compared with placebo significantly increased total sleep time by 94 min; increased rapid eye movement (REM) sleep time and mean REM period duration without altering sleep onset latency; significantly reduced trauma-related nightmares, distressed awakenings, and total PCL scores; significantly improved CGI-I scores; and changed PDRS scores toward normal dreaming. Conclusions: Prazosin reductions of nighttime PTSD symptoms in civilian trauma PTSD are accompanied by increased total sleep time, REM sleep time, and mean REM period duration in the absence of a sedative-like effect on sleep onset latency. C1 [Taylor, Fletcher B.; Gross, Christopher; Peskind, Elaine R.; Raskind, Murray A.] VA Puget Sound Hlth Care Syst, NW Network VISN Mental Illness Res Educ & Clin Ct, Seattle, WA 98108 USA. [Thompson, Charles; Gross, Christopher; Peskind, Elaine R.; Raskind, Murray A.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA. [Taylor, Fletcher B.; Martin, Patti; Williams, Judi] Rainier Associates, Tacoma, WA USA. [Taylor, Fletcher B.; Thompson, Charles; Gross, Christopher; Peskind, Elaine R.; Raskind, Murray A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Mellman, Thomas A.] Howard Univ, Washington, DC 20059 USA. RP Raskind, MA (reprint author), VA Puget Sound Hlth Care Syst, NW Network VISN Mental Illness Res Educ & Clin Ct, 1660 S Columbian Way,S-116, Seattle, WA 98108 USA. EM murray.raskind@va.gov FU NIMH NIH HHS [R01 MH069867-03, MH069867, R01 MH069867] NR 32 TC 134 Z9 139 U1 3 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 2008 VL 63 IS 6 BP 629 EP 632 DI 10.1016/j.biopsych.2007.07.001 PG 4 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 268ZD UT WOS:000253618300014 PM 17868655 ER PT J AU Farmer, MM Bastani, R Kwan, L Belman, M Ganz, PA AF Farmer, Melissa M. Bastani, Roshan Kwan, Lorna Belman, Michael Ganz, Patricia A. TI Predictors of colorectal cancer screening from patients enrolled in a managed care health plan SO CANCER LA English DT Article DE patient survey; colorectal cancer screening; provider influence; patient barriers; managed care ID UNITED-STATES; GUIDELINES; TRIAL; WOMEN; RECOMMENDATIONS; PREVENTION; PHYSICIANS; BEHAVIOR; BARRIERS; PROGRESS AB BACKGROUND. Despite the growing recognition of the importance of colorectal cancer (CRC) screening in reducing cancer mortality, national screening rates are low, indicating a critical need to understand the barriers and remedies for underutilization of CRC screening tests. METHODS. Using results from independent cross-sectional telephone surveys with patients aged >= 50 years performed before (2000; n = 498) and after (2003; n = 482) a quality improvement intervention for CRC screening within a large managed care health plan, the trends and predictors of CRC screening with fecal occult blood test (FOBT) and/or endoscopy (flexible sigmoidoscopy/colonoscopy) were examined from a patient perspective. RESULTS. In 2000, patient reported screening rates within guidelines were 38% for any test, 23% for endoscopy, and 22% for FOBT. In 2003, screening rates increased to 50% for any test, 39% for endoscopy, and 24% for FOBT. Having discussed CRC with a doctor significantly increased the odds of being screened (FOBT: odds ratio [OR], 2.09 [95% confidence interval (95% CI), 1.47-2.96]; endoscopy: OR, 2.33 [95% CI, 1.67-3.26]; and any test: OR, 2.86 [95% CI, 2.06-3.961]), and reporting barriers to CRC in general decreased the odds of being screened (FOBT: OR, 0.76 [95% CI, 0.60-0.95]; endoscopy: OR, 0.74 [95% CI, 0.60-0.92]; and any test: OR, 0.66 [95% CI, 0.54-0.80]). CONCLUSIONS. Although screening rates increased over the 3-year period, evidence was found of ongoing underutilization of CRC screening. The 2 strongest determinants of obtaining CRC screening were provider influence and patient barriers related to CRC screening in general, pointing to the need for multilevel interventions that target both the provider and patient. C1 [Farmer, Melissa M.] Ctr Excellence Study Hlthcare Provider Behav, Greater Los Angeles Hlth Serv Res, Sepulveda, CA USA. [Farmer, Melissa M.] Ctr Excellence Study Hlthcare Provider Behav, Greater Los Angeles Hlth Serv Dev, Sepulveda, CA USA. [Farmer, Melissa M.; Bastani, Roshan; Ganz, Patricia A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Bastani, Roshan; Kwan, Lorna; Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA. [Belman, Michael] Blue Cross Calif, Clin Qual, Woodland Hills, CA USA. [Ganz, Patricia A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Farmer, MM (reprint author), Vet Affairs GLA Hlthcare Syst, 16111 Plummer St, Sepulveda, CA 91343 USA. EM Melissa.Farmer@va.gov FU NCI NIH HHS [R01 CA75544] NR 26 TC 22 Z9 23 U1 2 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD MAR 15 PY 2008 VL 112 IS 6 BP 1230 EP 1238 DI 10.1002/cncr.23290 PG 9 WC Oncology SC Oncology GA 274QP UT WOS:000254016200006 PM 18266204 ER PT J AU Kuritzkes, DR Lalama, CM Ribaudo, HJ Marcial, M Meyer, WA Shikuma, C Johnson, VA Fiscus, SA D'Aquila, RT Schackman, BR Acosta, EP Gulick, RM AF Kuritzkes, Daniel R. Lalama, Christina M. Ribaudo, Heather J. Marcial, Michelle Meyer, William A., III Shikuma, Cecilia Johnson, Victoria A. Fiscus, Susan A. D'Aquila, Richard T. Schackman, Bruce R. Acosta, Edward P. Gulick, Roy M. TI Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 14th Conference on Retroviruses and Opportunistic Infections CY FEB 25-28, 2007 CL Los Angeles, CA ID ANTIRETROVIRAL-DRUG-RESISTANCE; IMMUNODEFICIENCY-VIRUS TYPE-1; INITIAL TREATMENT; HIV-1 INFECTION; THERAPY; MUTATIONS; TRIAL AB A case-cohort study was used to determine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, as assessed by viral genotyping, on the response to efavirenz-containing regimens in AIDS Clinical Trials Group A5095. The sample included a random cohort of efavirenz-treated subjects plus unselected subjects who experienced virologic failure. Of 220 subjects in the random cohort, 57 (26%) had virologic failure. The prevalence of baseline NNRTI resistance was 5%. The risk of virologic failure for subjects with baseline NNRTI resistance was higher than that for subjects without such resistance (hazard ratio 2.27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy. C1 [Kuritzkes, Daniel R.; Marcial, Michelle] Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02138 USA. [Lalama, Christina M.; Ribaudo, Heather J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Meyer, William A., III] Quest Diagnost Inc, Baltimore, MD USA. [Shikuma, Cecilia] Univ Hawaii, Honolulu, HI 96822 USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Johnson, Victoria A.] Univ Alabama, Sch Med, Birmingham, AL USA. [Fiscus, Susan A.] Univ N Carolina, Chapel Hill, NC USA. [D'Aquila, Richard T.] Vanderbilt Univ, Nashville, TN USA. [Gulick, Roy M.] Cornell Univ, Weill Med Coll, New York, NY USA. RP Kuritzkes, DR (reprint author), Brigham & Womens Hosp, Sect Retroviral Tehrapeut, 65 Landsdowne St Rm 449, Cambridge, MA 02139 USA. EM dkuritzkes@partners.org FU NCRR NIH HHS [RR024996]; NIAID NIH HHS [AI027767, AI051966, AI060354, AI06836, AI068636, AI069419, AI069452, AI069472, AI38858] NR 15 TC 101 Z9 101 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2008 VL 197 IS 6 BP 867 EP 870 DI 10.1086/528802 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 271FI UT WOS:000253773900013 PM 18269317 ER PT J AU Shah, T Lampiris, H Vu, M Monto, A Tien, PC AF Shah, Tina Lampiris, Harry Vu, Mai Monto, Alex Tien, Phyllis C. TI Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID PREVALENCE; GENOTYPE-3 C1 [Shah, Tina] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA. [Lampiris, Harry; Vu, Mai; Tien, Phyllis C.] San Francisco VA Med Ctr, Infect Dis Sect, San Francisco, CA USA. [Monto, Alex] San Francisco VA Med Ctr, Gastroenterol Sect, San Francisco, CA USA. [Lampiris, Harry; Monto, Alex; Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Shah, T (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA. FU NIAID NIH HHS [K23 AI066943, K23 AI066943-05] NR 11 TC 2 Z9 2 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2008 VL 197 IS 6 BP 932 EP 933 DI 10.1086/528800 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 271FI UT WOS:000253773900021 PM 18419352 ER PT J AU Kiesewetter, DO Knudson, K Collins, M Srinivasula, S Lim, E Di Mascio, M AF Kiesewetter, Dale O. Knudson, Kathleen Collins, Matt Srinivasula, Sharat Lim, Esther Di Mascio, Michele TI Enantiomeric radiochemical synthesis of R and S (1-(6-amino-9H-purin-9-yl)-3-fluoropropan-2-yloxy)methylphosphonic acid (FPMPA) SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS LA English DT Article; Proceedings Paper CT 17th International Symposium on Radiopharmaceutical Sciences CY APR 30-MAY 04, 2007 CL Aachen, GERMANY DE fluorine-18; Tenofovir; antiretroviral drugs; HAART ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACYCLIC NUCLEOSIDE PHOSPHONATES; ANTIRETROVIRAL AGENTS; DRUG-RESISTANCE; INFECTION; DERIVATIVES; INVITRO; PHARMACOKINETICS; THERAPY; INVIVO AB Therapy for human immunodeficiency virus (HIV)-infected patients requires chronic multidrug administration. The eventual failure of therapy in some patients has brought into question the tissue concentration of the drugs. With an appropriately radiolabeled compound, we could utilize positron emission tomography to provide quantitative time-activity curves for various tissues. We have developed a fluorine-18 labeled analog of Tenofovir, the active metabolite of Tenofovir DF, a commonly prescribed component of multidrug therapy. Because (1-(6-amino-9H-purin-9-yl)-3-fluoropropan-2-yloxy)methylphosphonic acid (FPMPA) has a chiral center, we prepared both enantiomers and confirmed that the S-isomer exhibited significantly higher antiviral activity than the R-Isomer. In viral replication inhibition assays in human MT4 cells infected with SHIV(DJ12R), S-FPMPA had an IC(50) of 1.85 mu M (95% CI 0.8-5.53), while the R-isomer was inactive. An appropriate chiral precursor was prepared to allow the incorporation of fluorine-18. The [(18)F]FPMPA in racemic, R, or S form was prepared in a 50 min synthesis in 38 +/- 5% yield (n = 23, corrected for decay). The product was of high radiochemical and enantiomeric purity. The specific activity of the final product was 4.0 +/- 1.8 Ci/mu mol at EOB (end of bombardment). This product may provide information about drug tissue distribution in animal models under chronic drug treatment. C1 [Kiesewetter, Dale O.; Knudson, Kathleen] NIBIB, NIH, PRG, Positron Emiss Tomog Radiochem Grp, Bethesda, MD 20892 USA. [Collins, Matt] Bioqual, Rockville, MD USA. [Srinivasula, Sharat] NCI Frederick, SAIC Frederick, Biostat Res Branch, Ft Detrick, MD 21702 USA. [Lim, Esther] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Di Mascio, Michele] NIAID, NIH, Biostat Res Branch, Bethesda, MD 20892 USA. RP Kiesewetter, DO (reprint author), NIBIB, NIH, PRG, Positron Emiss Tomog Radiochem Grp, 10 Ctr Dr MSC 1180,10-1C401, Bethesda, MD 20892 USA. EM dk7k@nih.gov FU Intramural NIH HHS [Z01 EB000001-03]; NCI NIH HHS [N01CO12400] NR 32 TC 3 Z9 4 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0362-4803 J9 J LABELLED COMPD RAD JI J. Label. Compd. Radiopharm. PD MAR 15 PY 2008 VL 51 IS 3-4 BP 187 EP 194 DI 10.1002/jlcr.1505 PG 8 WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry, Analytical SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA 299BI UT WOS:000255730400011 PM 19724660 ER PT J AU Shaw, LJ Berman, DS Maron, DJ Mancini, J Hayes, SW Hartigan, PM Weintraub, WS O'Rourke, RA Dada, M Spertus, JA Chaitman, BR Friedman, J Slomka, P Heller, GV Germano, G Gosselin, G Berger, P Kostuk, WJ Schwartz, RG Knudtson, M Veledar, E Bates, ER McCallister, B Teo, KK Boden, WE AF Shaw, Leslee J. Berman, Daniel S. Maron, David J. Mancini, John Hayes, Sean W. Hartigan, Pamela M. Weintraub, William S. O'Rourke, Robert A. Dada, Marcin Spertus, John A. Chaitman, Bernard R. Friedman, John Slomka, Piotr Heller, Gary V. Germano, Guido Gosselin, Gilbert Berger, Peter Kostuk, William J. Schwartz, Ronald G. Knudtson, Merill Veledar, Emir Bates, Eric R. McCallister, Benjamin Teo, Koon K. Boden, William E. CA COURAGE Invest TI Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden - Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy SO CIRCULATION LA English DT Article DE ischemia; perfusion; prevention; prognosis ID EMISSION COMPUTED-TOMOGRAPHY; MYOCARDIAL-PERFUSION SPECT; INCREMENTAL PROGNOSTIC VALUE; ARTERY-DISEASE; EJECTION FRACTION; RISK; STRATIFICATION; QUANTIFICATION; INFARCTION; SEVERITY AB Background-Extent and severity of myocardial ischemia are determinants of risk for patients with coronary artery disease, and ischemia reduction is an important therapeutic goal. The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) nuclear substudy compared the effectiveness of percutaneous coronary intervention (PCI) for ischemia reduction added to optimal medical therapy (OMT) with the use of myocardial perfusion single photon emission computed tomography (MPS). Methods and Results-Of the 2287 COURAGE patients, 314 were enrolled in this substudy of serial rest/stress MPS performed before treatment and 6 to 18 months (mean = 374 +/- 50 days) after randomization using paired exercise (n = 84) or vasodilator stress (n = 230). A blinded core laboratory analyzed quantitative MPS measures of percent ischemic myocardium. Moderate to severe ischemia encumbered >= 10% myocardium. The primary end point was >= 5% reduction in ischemic myocardium at follow-up. Treatment groups had similar baseline characteristics. At follow-up, the reduction in ischemic myocardium was greater with PCI+OMT (-2.7%; 95% confidence interval, -1.7%, -3.8%) than with OMT (-0.5%; 95% confidence interval, -1.6%, 0.6%; P < 0.0001). More PCI+OMT patients exhibited significant ischemia reduction (33% versus 19%; P=0.0004), especially patients with moderate to severe pretreatment ischemia (78% versus 52%; P = 0.007). Patients with ischemia reduction had lower unadjusted risk for death or myocardial infarction (P = 0.037 [risk-adjusted P = 0.26]), particularly if baseline ischemia was moderate to severe (P = 0.001 [risk-adjusted P=0.08]). Death or myocardial infarction rates ranged from 0% to 39% for patients with no residual ischemia to >= 10% residual ischemia on follow- up MPS (P=0.002 [risk-adjusted P=0.09]). Conclusions-In COURAGE patients who underwent serial MPS, adding PCI to OMT resulted in greater reduction in ischemia compared with OMT alone. Our findings suggest a treatment target of >= 5% ischemia reduction with OMT with or without coronary revascularization. C1 [Shaw, Leslee J.; Veledar, Emir] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Berman, Daniel S.; Hayes, Sean W.; Friedman, John; Slomka, Piotr; Germano, Guido] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada. [Hartigan, Pamela M.] Vet Affairs Connecticut Healthcare Syst, Vet Affairs Cooperat Studies Program Coordinating, West Haven, CT USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [O'Rourke, Robert A.; Heller, Gary V.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA. [Spertus, John A.; McCallister, Benjamin] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Chaitman, Bernard R.] St Louis Univ, St Louis, MO 63103 USA. [Gosselin, Gilbert] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Berger, Peter] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA. [Kostuk, William J.] London Hlth Sci Ctr, London, ON, Canada. [Schwartz, Ronald G.] Univ Rochester, Rochester, NY USA. [Knudtson, Merill] Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada. [Bates, Eric R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Teo, Koon K.] McMaster Univ, Hamilton, ON, Canada. [Boden, William E.] SUNY Buffalo, Western New York Vet Affairs Healthcare Network, Buffalo Gen Hosp, Buffalo, NY 14260 USA. RP Shaw, LJ (reprint author), Emory Univ, EPICORE, Suite 1-N,1256 Briarchiff Rd NE, Atlanta, GA 30306 USA. EM leslee.shaw@emory.edu RI Veledar, Emir/K-2808-2012 OI Veledar, Emir/0000-0002-3831-5433 NR 21 TC 687 Z9 720 U1 2 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 11 PY 2008 VL 117 IS 10 BP 1283 EP 1291 DI 10.1161/CIRCULATIONAHA.107.743963 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 272KU UT WOS:000253859100007 PM 18268144 ER PT J AU Saam, T Underhill, HR Chu, BC Takaya, N Cai, JM Polissar, NL Yuan, C Hatsukami, TS AF Saam, Tobias Underhill, Hunter R. Chu, Baocheng Takaya, Norihide Cai, Jianming Polissar, Nayak L. Yuan, Chun Hatsukami, Thomas S. TI Prevalence of American heart association type VI carotid atherosclerotic lesions identified by magnetic resonance imaging for different levels of stenosis as measured by duplex ultrasound SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID RISK-ASSESSMENT STRATEGIES; IN-VIVO; INTRAPLAQUE HEMORRHAGE; VULNERABLE PATIENT; ARTERY STENOSIS; PLAQUE; CLASSIFICATION; ENDARTERECTOMY; MRI; DEFINITIONS AB Objectives Via magnetic resonance imaging (MRI), we sought to determine the prevalence of atherosclerotic American Heart Association type VI lesions (AHA-LT6) (lesions with luminal surface defect, hemorrhage/thrombus, or calcified nodule) in carotid arteries that represented all categories of stenosis as measured by duplex ultrasound. Background Arterial stenosis alone has been shown to be a poor predictor of cardiovascular events. Autopsy studies suggest that features associated with AHA-LT6 lesions, rather than the degree of luminal narrowing, characterize the high-risk plaque. Methods A total of 192 subjects underwent bilateral carotid artery magnetic resonance imaging (MRI) scans at 1.5T after evaluation with ultrasound to determine stenosis. After excluding arteries with a previous endarterectomy, poor image quality, or missing ultrasound data, there were 175 patients with 260 arteries available for analysis. The AHA lesion type was determined by the consensus opinion of 2 experienced carotid MRI reviewers. Results In total, 96 of 260 (37.0%) arteries had >= location with AHA-LT6. Of the arteries with AHA-LT6, 84.4% had hemorrhage, 45.8% had a ruptured fibrous cap, and 14.6% showed other type of complications. Prevalence of AHA-LT6 was an increasing sequence of 8.1% in the 37 arteries with 1% to 15% stenosis, 21.7% in the 60 arteries with 16% to 49% stenosis, 36.8% in the 114 arteries with 50% to 79% stenosis, and 77.6% in the 49 arteries with 80% to 99% stenosis. Conclusions Complicated AHA-LT6 are frequently found in arteries with <= 50% stenosis. These findings indicate that complex lesions develop in a substantial number of arteries in the absence of high-grade stenosis. Ongoing prospective studies will determine the predictive value of vulnerable plaque features, as visualized by MRI, for risk of subsequent ischemic events. C1 [Hatsukami, Thomas S.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Hatsukami, Thomas S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Saam, Tobias] Univ Munich, Dept Clin Radiol, Munich, Germany. [Underhill, Hunter R.; Chu, Baocheng; Takaya, Norihide; Cai, Jianming; Yuan, Chun] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Mt Whisper Light Stat Consulting, Seattle, WA USA. RP Hatsukami, TS (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Surg & Perioperat Care 112,1660 S Columbian Way, Seattle, WA 98195 USA. EM tomhat@u.washington.edu FU NHLBI NIH HHS [P01 HL072262, R01 HL073401, R01 HL61851, R01HL56874, T32 HL07828] NR 24 TC 68 Z9 72 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 BP 1014 EP 1021 DI 10.1016/j.jacc.2007.10.054 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JG UT WOS:000253997000007 PM 18325441 ER PT J AU Bradley, SM Soine, LA Caldwell, JH Goldberg, SL AF Bradley, Steven M. Soine, Laurie A. Caldwell, James H. Goldberg, Steven L. TI Effect of stress myocardial perfusion imaging results on liver transplant eligibility SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 57th Annual Scientific Session of the American-College-of-Cardiology CY MAR 29-APR 01, 2008 CL Chicago, IL SP Amer Coll Cardiol C1 Univ Washington, Seattle, WA 98195 USA. Vet Affairs Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 SU A BP A257 EP A257 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JH UT WOS:000253997102010 ER PT J AU Hakeem, A Bhatti, S Dillie, K Cook, JR Samad, Z Chang, SM AF Hakeem, Abdul Bhatti, Sabha Dillie, Kathryn Cook, Jeffery R. Samad, Zainab Chang, SuMin TI Abnormal myocardial SPECT is a powerful predictor of cardiac death (CD) in patients with chronic kidney disease (CKD) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 57th Annual Scientific Session of the American-College-of-Cardiology CY MAR 29-APR 01, 2008 CL Chicago, IL SP Amer Coll Cardiol C1 Univ Wisconsin, Hosp & Clin, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 SU A BP A167 EP A167 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JH UT WOS:000253997101172 ER PT J AU Haugen, SJ Regensteiner, JG Hiatt, WR Nehler, M Eng, M Rueda, C Strecker, P Bucher-Bartelson, B Casserly, IP AF Haugen, Scott J. Regensteiner, Judith G. Hiatt, William R. Nehler, Mark Eng, Marvin Rueda, Carlos Strecker, Pamela Bucher-Bartelson, Becki Casserly, Ivan P. TI Clinical outcomes in patients with advanced limb ischemia SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 57th Annual Scientific Session of the American-College-of-Cardiology CY MAR 29-APR 01, 2008 CL Chicago, IL SP Amer Coll Cardiol C1 [Haugen, Scott J.; Regensteiner, Judith G.; Hiatt, William R.; Nehler, Mark; Eng, Marvin; Rueda, Carlos; Strecker, Pamela; Bucher-Bartelson, Becki; Casserly, Ivan P.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 SU A BP A337 EP A337 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JH UT WOS:000253997102353 ER PT J AU Ho, PM Peterson, ED Wang, L Magid, DJ Fihn, SD Larsen, GC Jesse, RA Rumsfeld, JS AF Ho, P. Michael Peterson, Eric D. Wang, Li Magid, David J. Fihn, Stephan D. Larsen, Greg C. Jesse, Robert A. Rumsfeld, John S. TI Incidence of death and myocardial infarction associated with stopping clopidogrel after acute coronary syndrome: Evidence supporting a rebound effect SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 57th Annual Scientific Session of the American-College-of-Cardiology CY MAR 29-APR 01, 2008 CL Chicago, IL SP Amer Coll Cardiol C1 [Ho, P. Michael; Peterson, Eric D.; Wang, Li; Magid, David J.; Fihn, Stephan D.; Larsen, Greg C.; Jesse, Robert A.; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Ho, P. Michael; Peterson, Eric D.; Wang, Li; Magid, David J.; Fihn, Stephan D.; Larsen, Greg C.; Jesse, Robert A.; Rumsfeld, John S.] Univ Colorado Hlth Sci Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 SU A BP A250 EP A250 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JH UT WOS:000253997101521 ER PT J AU Hsieh, BPC Whooley, MA Schiller, NB AF Hsieh, Bill Pei-Chin Whooley, Mary A. Schiller, Nelson B. TI The prevalence and prognostic value of cardiac troponin T elevation in ambulatory patients with stable coronary artery disease SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 57th Annual Scientific Session of the American-College-of-Cardiology CY MAR 29-APR 01, 2008 CL Chicago, IL SP Amer Coll Cardiol C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 SU A BP A378 EP A378 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JH UT WOS:000253997102522 ER PT J AU Maddox, TM Ross, C He, PM Masoudi, FA Magid, D Daugherty, S Peterson, P Rumsfeld, JS AF Maddox, Thomas M. Ross, Colleen He, P. Michael Masoudi, Fred A. Magid, David Daugherty, Stacie Peterson, Pam Rumsfeld, John S. TI The prognostic importance of impaired heart rate recovery and chronotropic incompetence in association with the duke treadmill score during exercise stress testing SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 57th Annual Scientific Session of the American-College-of-Cardiology CY MAR 29-APR 01, 2008 CL Chicago, IL SP Amer Coll Cardiol C1 Univ Colorado, Hlth Sci Ctr, Denver VAMC, Denver, CO 80202 USA. Kaiser Permanente, Denver, CO USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 SU A BP A160 EP A160 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JH UT WOS:000253997101140 ER PT J AU Patel, DN Erikson, JM Bailey, SR Valente, AJ Chandrasekar, B AF Patel, Devanci N. Erikson, John M. Bailey, Steven R. Valente, Anthony J. Chandrasekar, Bysani TI Adiponectin blocks IL-18-mediated endothelial cell death through activation of Akt and suppression of NF42B-PTEN signaling SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 57th Annual Scientific Session of the American-College-of-Cardiology CY MAR 29-APR 01, 2008 CL Chicago, IL SP Amer Coll Cardiol C1 S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 SU A BP A298 EP A298 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JH UT WOS:000253997102189 ER PT J AU Zabalgoitia, MR Chilton, R Moody, JM Bailey, SR Chandrasekar, B AF Zabalgoitia, Miguel R. Chilton, Robert Moody, Joe M., Jr. Bailey, Steven R. Chandrasekar, Bysani TI High glucose and advanced glycation end products potentiate IL-17-mediated human coronary artery smooth muscle cell proliferation, and is reversed by resveratrol SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 57th Annual Scientific Session of the American-College-of-Cardiology CY MAR 29-APR 01, 2008 CL Chicago, IL SP Amer Coll Cardiol C1 S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 11 PY 2008 VL 51 IS 10 SU A BP A283 EP A283 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 274JH UT WOS:000253997102122 ER PT J AU Carlson, NE Moore, MM Dame, A Howieson, D Silbert, LC Quinn, JF Kaye, JA AF Carlson, N. E. Moore, M. M. Dame, A. Howieson, D. Silbert, L. C. Quinn, J. F. Kaye, J. A. TI Trajectories of brain loss in aging and the development of cognitive impairment SO NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; TEMPORAL-LOBE; VOLUME LOSS; OLDEST-OLD; ATROPHY; HIPPOCAMPUS; DEMENTIA; DECLINE; RATES; MCI AB Background: The use of volumetric MRI as a biomarker for assessing transitions to dementia presumes that more rapid brain loss marks the clinical transition from benign aging to mild cognitive impairment (MCI). The trajectory of this volume loss relative to the timing of the clinical transition to dementia has not been established. Methods: The authors annually evaluated 79 healthy elderly subjects for up to 15 consecutive years with standardized clinical examinations and volumetric brain MRI assessments of ventricular volume. During the study period, 37 subjects developed MCI. A mixed effects model with a change point modeled the pattern of brain volume loss in healthy aging compared with subjects diagnosed with MCI. Results: The brain loss trajectory of subjects developing MCI during follow-up differed from healthy aging in a two-phase process. First, the annual rate of expansion of ventricular volume decreased with age; however, the annual rates of expansion were greater in those who developed cognitive impairment during follow-up compared with those who did not. Further, subjects who developed MCI had an acceleration of ventricular volume expansion approximately 2.3 years prior to clinical diagnosis of MCI. Conclusions: Ventricular expansion is faster in those developing mild cognitive impairment years prior to clinical symptoms, and eventually a more rapid expansion occurs approximately 24 months prior to the emergence of clinical symptoms. These differential rates of preclinical atrophy suggest that there are specific windows for optimal timing of introduction of dementia prevention therapies in the future. C1 [Carlson, N. E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97239 USA. [Moore, M. M.; Dame, A.; Howieson, D.; Silbert, L. C.; Quinn, J. F.; Kaye, J. A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Kaye, J. A.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA. [Silbert, L. C.; Quinn, J. F.] Portland VA Med Ctr, Portland, OR USA. RP Carlson, NE (reprint author), Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, 3181 SW Sam Jackson Pk Rd,Mail Code CB669, Portland, OR 97239 USA. EM carlsoni@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU NCRR NIH HHS [UL1 RR024140 01]; NIA NIH HHS [AG08017] NR 27 TC 80 Z9 82 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR 11 PY 2008 VL 70 IS 11 BP 828 EP 833 DI 10.1212/01.wnl.0000280577.43413.d9 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 271WU UT WOS:000253820200003 PM 18046010 ER EF